auto B-chronic_disease
- I-chronic_disease
immune I-chronic_disease
disease I-chronic_disease
, O
acute O
stage O
( O
e.g. O
, O
rheumatoid B-chronic_disease
arthritis I-chronic_disease
) O

diagnosed O
epilepsy B-chronic_disease

photosensitivity O
to O
flickering B-allergy_name
lights I-allergy_name

recurrent O
cancer B-cancer
following O
prior O
resection O

non B-pregnancy
- I-pregnancy
pregnant I-pregnancy

women B-gender
of O
childbearing O
potential O
must O
have O
a O
negative B-pregnancy
pregnancy I-pregnancy
test O
to O
participate O
in O
this O
study O

meningeal B-chronic_disease
signs O
are O
present O

non B-language_fluency
- I-language_fluency
english I-language_fluency
speaking I-language_fluency
patient I-language_fluency
or I-language_fluency
parent I-language_fluency
/ I-language_fluency
guardian I-language_fluency
for O
pediatric O
patients O

iq B-clinical_variable
lower O
than O
@NUMBER B-upper_bound

hormonal B-contraception_consent
contraceptive I-contraception_consent
use I-contraception_consent
( O
past B-upper_bound
@NUMBER I-upper_bound
mo I-upper_bound
. I-upper_bound
) O

coronary B-treatment
stent I-treatment
placement I-treatment
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

disseminated B-chronic_disease
intravascular I-chronic_disease
coagulation I-chronic_disease

patient O
and O
parent O
/ O
legal O
guardian O
are O
english B-language_fluency
speaking I-language_fluency

have O
required O
management O
of O
acute B-chronic_disease
or I-chronic_disease
chronic I-chronic_disease
infections I-chronic_disease

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
score I-clinical_variable
of O
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound

cancer B-cancer
diagnosis O

self O
- O
identify O
as O
latino B-ethnicity

active O
diarrhea B-chronic_disease
( O
diarrhea O
is O
defined O
in O
this O
study O
as O
three O
or O
more O
loose O
stools O
per O
day O
for O
two B-upper_bound
consecutive O
days O
) O

allergy O
to O
penicillin B-allergy_name
or O
cephalosporin B-allergy_name
class O
antibiotics O

ceclor B-treatment
( I-treatment
cefaclor I-treatment
) I-treatment

cefadroxil B-treatment

keflex B-treatment
( I-treatment
cephalexin I-treatment
) I-treatment

no O
known O
physical B-chronic_disease
, O
neurological B-chronic_disease
, O
behavioral B-chronic_disease
or O
psychological B-chronic_disease
impairment I-chronic_disease
that O
would O
affect O
their O
ability O
to O
perform O
the O
test O

women B-gender

inr B-clinical_variable
< O
@NUMBER B-upper_bound
times I-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound

patients O
with O
known O
hypersensitivity O
to O
octreotide B-allergy_name
or O
somatostatin B-allergy_name

aniridia B-chronic_disease

glaucoma B-cancer
( O
uncontrolled O
or O
controlled O
with O
medication O
) O

subjects O
who O
have O
a O
contraindication O
( O
e.g O
. O
a O
condition O
, O
medication B-treatment
with O
a O
known O
interaction O
, O
known O
allergy O
) O
to O
only O
one O
or O
two O
of O
the O
three O
pharmacotherapy B-treatment
drugs I-treatment
, O
may O
be O
assigned O
one O
of O
the O
pharmacotherapy O
drugs O
that O
is O
not O
contraindicated O

kidney B-chronic_disease
problems I-chronic_disease

negative B-pregnancy
pregnancy I-pregnancy
test O
in O
women B-gender
of O
child O
- O
bearing O
potential O

child B-language_fluency
understands I-language_fluency
english I-language_fluency
and O
is O
enrolled O
in O
school O
( O
but O
can O
be O
bilingual O
) O

children O
treated O
for O
acute B-cancer
leukemia I-cancer
leukemia B-cancer
( O
e.g O
. O
acute B-cancer
lymphoblastic I-cancer
leukemia I-cancer
[ I-cancer
all I-cancer
] I-cancer
ll B-cancer
] O
, O
acute B-cancer
myeloid I-cancer
leukemia I-cancer
[ I-cancer
aml I-cancer
] I-cancer
) O
, O
ll O
, O
or O
other O
types O
of O
leukemia O
( O
if O
treated O
intensively O
) O
aged B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
and O
their O
parents O
/ O
caregivers O

severe B-chronic_disease
neurodevelopmental I-chronic_disease
disorder I-chronic_disease
in O
child O
( O
e.g O
. O
down B-chronic_disease
's I-chronic_disease
syndrome I-chronic_disease
) O

men B-gender

positive O
tobacco O
use O
in O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

be O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
old O

desire O
to O
quit O
smoking O
but O
not O
be O
engaged O
currently O
in O
cessation B-treatment
treatment I-treatment

ecog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
of O
@NUMBER B-lower_bound
, O
@NUMBER O
or O
@NUMBER B-upper_bound

current O
antibiotic B-treatment
therapy I-treatment

active O
cancer B-cancer

trypanophobia B-chronic_disease

must O
be O
willing B-contraception_consent
to I-contraception_consent
implement I-contraception_consent
contraception I-contraception_consent
throughout O
study O
and O
for O
@NUMBER B-upper_bound
days I-upper_bound
following O
rc O

indication O
for O
radical B-treatment
cystectomy I-treatment
( I-treatment
rc I-treatment
) I-treatment

eclampsia B-chronic_disease

patients O
suffering O
from O
symptomatic B-chronic_disease
knee I-chronic_disease
oa I-chronic_disease
( I-chronic_disease
uni I-chronic_disease
/ I-chronic_disease
bi I-chronic_disease
lateral I-chronic_disease
) I-chronic_disease
for O
at O
least O
six B-lower_bound
months I-lower_bound
, O
fulfilling O
the O
acr O
clinical O
criteria O
for O
oa B-chronic_disease
of I-chronic_disease
the I-chronic_disease
knee I-chronic_disease
, O
and O
having O
radiographically O
assessed O
oa O
of O
the O
knee O
according O
to O
the O
kellgren B-clinical_variable
and I-clinical_variable
lawrence I-clinical_variable
scale I-clinical_variable

patients O
with O
diagnosis O
of O
avascular B-chronic_disease
necrosis I-chronic_disease
of I-chronic_disease
the I-chronic_disease
knee I-chronic_disease

patients O
with O
diagnosis O
of O
neuromuscular B-chronic_disease
disease I-chronic_disease

hba1c B-clinical_variable
of O
greater O
than O
or O
equal O
to O
( O
≥ O
) O
@NUMBER B-lower_bound
percent I-lower_bound
( I-lower_bound
% I-lower_bound
) I-lower_bound
to O
less O
than O
or O
equal O
to O
( O
≤ O
) O
@NUMBER B-upper_bound
% I-upper_bound

on O
diet O
and O
exercise O
alone O
during O
the O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
screening O

ability B-language_fluency
to I-language_fluency
read I-language_fluency
and I-language_fluency
speak I-language_fluency
fluent I-language_fluency
english I-language_fluency

disruptive B-chronic_disease
or I-chronic_disease
violent I-chronic_disease
behavior I-chronic_disease

significant O
chronic B-chronic_disease
organ I-chronic_disease
failure I-chronic_disease

bowel B-chronic_disease
obstruction I-chronic_disease

chronic B-chronic_disease
kidney I-chronic_disease
disease I-chronic_disease
with O
estimated B-clinical_variable
glomerular I-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound
/ I-upper_bound
1.73m2 I-upper_bound

hemoglobin B-clinical_variable
< O
@NUMBER B-upper_bound
gm I-upper_bound
/ I-upper_bound
dl I-upper_bound

hepatic B-chronic_disease
disease I-chronic_disease

with O
htn B-chronic_disease

physical O
evidence O
of O
right B-chronic_disease
sided I-chronic_disease
congestive I-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
and O
echocardiographic O
evidence O
of O
severe O
right B-chronic_disease
ventricular I-chronic_disease
dysfunction I-chronic_disease

body B-bmi
mass I-bmi
index I-bmi
within O
@NUMBER B-upper_bound
% I-upper_bound
of I-upper_bound
normal I-upper_bound

debilitating B-chronic_disease
medical I-chronic_disease
conditions I-chronic_disease

self O
- O
identify O
as O
male B-gender

males B-gender
will O
be O
excluded O

women B-gender
who O
are B-pregnancy
pregnant I-pregnancy
or O
nursing O
a O
child O
may O
not O
take O
part O
in O
this O
study O

diagnosed O
with O
category B-chronic_disease
iii I-chronic_disease
chronic I-chronic_disease
pelvic I-chronic_disease
pain I-chronic_disease
syndrome I-chronic_disease

not O
up O
- O
to O
- O
date O
with O
colorectal B-cancer
cancer I-cancer
screening O

body B-bmi
mass I-bmi
index I-bmi
( I-bmi
bmi I-bmi
) I-bmi
> O
@NUMBER B-lower_bound
, O
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
kg2 I-upper_bound

living O
within O
@NUMBER B-upper_bound
miles I-upper_bound
of O
euh O

planned O
or O
elective O
re O
- O
hospitalization O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
discharge O

age B-age
at O
screening O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
for O
male B-gender
and O
permanently O
sterilized O

patients O
with O
type B-lower_bound
@NUMBER I-lower_bound
or O
type B-upper_bound
@NUMBER I-upper_bound
diabetes B-clinical_variable
mellitus I-clinical_variable
, O
diagnosed O
before O
informed O
consent O
and O
treated O
with O
insulin B-treatment
, O
glucagon B-treatment
- I-treatment
like I-treatment
peptide I-treatment
( I-treatment
glp I-treatment
) I-treatment
@NUMBER I-treatment
agonists I-treatment
and O
/ O
or O
oral B-treatment
antidiabetic I-treatment
medication I-treatment

clinically O
relevant O
arrhythmias B-chronic_disease

coronary B-chronic_disease
heart I-chronic_disease
disease I-chronic_disease
not O
compensated O
by O
medical B-treatment
treatment I-treatment
( O
supine B-clinical_variable
pulse I-clinical_variable
rate I-clinical_variable
> O
@NUMBER B-lower_bound
beats I-lower_bound
per O
minute O
, O
existing O
angina B-chronic_disease
pectoris I-chronic_disease
) O

egfr B-clinical_variable
( O
chronic B-clinical_variable
kidney I-clinical_variable
disease I-clinical_variable
epidemiology I-clinical_variable
collaboration I-clinical_variable
[ I-clinical_variable
ckd I-clinical_variable
- I-clinical_variable
epi I-clinical_variable
] I-clinical_variable
formula I-clinical_variable
) O
≥ O
@NUMBER B-lower_bound
and O
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound
/ I-upper_bound
@NUMBER I-upper_bound
m2 I-upper_bound
at O
visit O
@NUMBER O
measured O
by O
the O
central O
laboratory O
and O
no O
planned O
start O
of O
renal B-treatment
replacement I-treatment
therapy I-treatment
during O
the O
trial O

female B-gender
patients I-gender
and O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
for O
postmenopausal O
female O
patients O

speak B-language_fluency
english I-language_fluency
as O
a O
primary O
a O
language O

head O
, O
neck O
or O
back O
wounds O
that O
would O
prevent O
omt B-treatment
treatment I-treatment

weight O
stable O
( O
have O
not O
lost O
or O
gained O
over O
@NUMBER B-lower_bound
pounds I-lower_bound
of O
body B-clinical_variable
weight I-clinical_variable
in O
the O
past B-lower_bound
@NUMBER I-lower_bound
months I-lower_bound
) O

plan B-pregnancy
to I-pregnancy
become I-pregnancy
pregnant I-pregnancy
in O
the O
next B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

any O
prior B-treatment
radiotherapy I-treatment
to O
the O
neck O

men B-gender
of O
reproductive O
potential O
who O
are O
sexually O
active O
with O
women B-gender
of O
reproductive O
potential O
must O
use B-contraception_consent
any I-contraception_consent
contraceptive I-contraception_consent
method I-contraception_consent
with O
a O
failure O
rate O
of O
less O
than O
@NUMBER B-upper_bound
% I-upper_bound
per I-upper_bound
year I-upper_bound

women B-gender
of O
reproductive O
potential O
should O
have O
a O
negative B-pregnancy
serum I-pregnancy
or I-pregnancy
urine I-pregnancy
pregnancy I-pregnancy
test O
( O
minimum O
sensitivity O
@NUMBER B-lower_bound
iu I-lower_bound
/ I-lower_bound
l I-lower_bound
or O
equivalent O
units O
of O
human B-clinical_variable
chorionic I-clinical_variable
gonadotropin I-clinical_variable
[ I-clinical_variable
hcg I-clinical_variable
] I-clinical_variable
) O
within O
@NUMBER B-upper_bound
hours I-upper_bound
of O
the O
start O
of O
study O
drugs O

in O
the O
investigator O
's O
judgment O
, O
the O
need O
for O
emergent O
valve B-treatment
surgery I-treatment
at O
the O
time O
of O
randomization O
or O
a O
high O
likelihood O
of O
cardiac B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
after O
randomization O

expanded B-clinical_variable
disability I-clinical_variable
status I-clinical_variable
scale I-clinical_variable
( I-clinical_variable
edss I-clinical_variable
) I-clinical_variable
expanded B-lower_bound
disability I-lower_bound
status I-lower_bound
scale I-lower_bound
( I-lower_bound
edss I-lower_bound
) I-lower_bound
@NUMBER I-lower_bound
- I-lower_bound
@NUMBER I-lower_bound
@NUMBER B-upper_bound
: O
ambulatory O
for O
at O
least O
@NUMBER B-lower_bound
meters I-lower_bound
without O
rest O
and O
use O
of O
bilateral O
aids O
( O
canes O
, O
crutches O
, O
walker O
) O
or O
better O

insulin B-chronic_disease
- I-chronic_disease
dependent I-chronic_disease
diabetes I-chronic_disease
diabetes B-chronic_disease
or O
diabetes O
not O
controlled O
on O
oral B-treatment
diabetes I-treatment
medications I-treatment

sarcopenia B-chronic_disease

@NUMBER B-lower_bound
years I-lower_bound
to O
≤ O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

previous O
appendicitis B-chronic_disease

white B-clinical_variable
blood I-clinical_variable
cell I-clinical_variable
count I-clinical_variable
( I-clinical_variable
wbc I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound

females B-gender
of O
child O
bearing O
potential O
should O
agree B-contraception_consent
to I-contraception_consent
practice I-contraception_consent
@NUMBER I-contraception_consent
effective I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
, O
at O
the O
same O
time O
, O
from O
the O
time O
of O
signing O
the O
informed O
consent O
form O
through O
@NUMBER B-upper_bound
days I-upper_bound
after O
the O
last O
dose O
of O
study O
drug O
and O
must O
also O
adhere O
to O
the O
guidelines O
of O
any O
treatment B-treatment
- I-treatment
specific I-treatment
pregnancy I-treatment
prevention O
program O
, O
if O
applicable O
, O
or O
agree B-contraception_consent
to I-contraception_consent
practice I-contraception_consent
true I-contraception_consent
abstinence I-contraception_consent
when O
this O
is O
in O
line O
with O
the O
preferred O
and O
usual O
lifestyle O
of O
the O
subject O

karnofsky B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
> O
@NUMBER B-lower_bound

have O
a O
known O
sensitivity O
to O
any O
of O
the O
constituents O
of O
the O
test O
product O
including O
sensitivities O
to O
sandalwood B-allergy_name
oil I-allergy_name
, O
fragrances B-allergy_name
or O
any O
member O
of O
the O
compositae B-allergy_name
family I-allergy_name
of I-allergy_name
vascular I-allergy_name
plants I-allergy_name
( O
eg O
, O
sunflowers B-allergy_name
, O
daisies B-allergy_name
, O
dahlias B-allergy_name
, O
etc O
. O
) O

have O
evidence O
of O
clinically O
significant O
or O
unstable O
disease O
( O
eg O
, O
stroke B-chronic_disease
, O
heart B-chronic_disease
attack I-chronic_disease
) O

received O
any O
treatment B-treatment
for O
their O
egw B-clinical_variable
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
planned O
study O
enrollment O

diagnosis O
of O
other O
active O
malignancy B-cancer

use O
of O
inhaled B-treatment
antibiotics I-treatment
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

chronic B-chronic_disease
kidney I-chronic_disease
disease I-chronic_disease
stage I-chronic_disease
iv I-chronic_disease
/ I-chronic_disease
v I-chronic_disease

the O
subject O
has O
known O
sensitivity O
to O
dextran B-allergy_name

seeking O
treatment B-treatment
for O
a O
substance B-chronic_disease
use I-chronic_disease
disorder I-chronic_disease

are O
not O
currently O
receiving O
psychotherapy B-treatment
or O
counseling B-treatment

acute B-chronic_disease
hepatitis I-chronic_disease

primary B-cancer
tumors I-cancer
of O
any O
head O
and O
neck O
( O
oral O
cavity O
, O
oropharynx O
, O
hypopharynx O
, O
or O
larynx O
) O
site O
will O
be O
included O

has O
history O
of O
( O
non O
- O
infectious O
) O
pneumonitis B-chronic_disease
that O
required O
steroids B-treatment
, O
history O
or O
evidence O
of O
interstitial B-chronic_disease
lung I-chronic_disease
disease I-chronic_disease
or O
active O
, O
non O
- O
infectious O
pneumonitis O

participation O
in O
simultaneous O
therapeutic O
study O
that O
involves O
an O
investigational O
study O
drug O
or O
agent O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
study O
enrollment O

requirement O
for O
live O
vaccine B-treatment
exposure O
that O
would O
be O
expected O
to O
occur O
during O
the O
time O
frame O
of O
the O
study O

pregnancy B-pregnancy
or O
breastfeeding O

current O
abnormal O
thyroid B-clinical_variable
- I-clinical_variable
stimulating I-clinical_variable
hormone I-clinical_variable
( I-clinical_variable
tsh I-clinical_variable
) I-clinical_variable

laboratory B-clinical_variable
hematocrit I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound
at O
time O
of O
screening O

platelet B-clinical_variable
count I-clinical_variable
< O
@NUMBER B-upper_bound
per I-upper_bound
microliter I-upper_bound

women B-gender
with O
urinary B-clinical_variable
excretion I-clinical_variable
with O
greater O
than O
@NUMBER B-lower_bound
mg I-lower_bound
( I-lower_bound
@NUMBER I-lower_bound
g I-lower_bound
) I-lower_bound
per I-lower_bound
day I-lower_bound
( O
spot B-clinical_variable
urine I-clinical_variable
protein I-clinical_variable
/ I-clinical_variable
creatinine I-clinical_variable
ration I-clinical_variable
@NUMBER O
) O

any O
contraindication O
for O
thoracic B-allergy_name
epidural I-allergy_name
or O
paravertebral B-allergy_name
block I-allergy_name

minor O
anomalies O
such O
as O
polydactyly B-chronic_disease
, O
unilateral B-chronic_disease
hydronephrosis I-chronic_disease

women B-gender
who O
have O
taken O
or O
plan O
to O
take O
progesterone O
beyond O
@NUMBER B-upper_bound
weeks I-upper_bound
gestation O
prior O
to O
study O
enrollment O

diagnosed O
with O
insomnia B-chronic_disease
lasting O
@NUMBER B-upper_bound
months I-upper_bound
by O
the O
pact O
provider O
, O
as O
evidenced O
by O
referral O
by O
the O
provider O
for O
access O
to O
the O
shutitm O
program O

in O
first O
or O
subsequent O
relapse O
or O
refractory O
status O
, O
with O
or O
without O
prior B-treatment
hematopoietic I-treatment
stem I-treatment
cell I-treatment
transplant I-treatment
( I-treatment
hsct I-treatment
) I-treatment

age B-age
≥ O
@NUMBER B-lower_bound
years I-lower_bound

history O
of O
multiple B-chronic_disease
sclerosis I-chronic_disease
or O
other O
demyelinating B-chronic_disease
disease I-chronic_disease

active O
herpetic B-chronic_disease
keratitis I-chronic_disease

bisphosphonate B-treatment
or O
denosumab B-treatment
dosage O
must O
have O
been O
stable O
for O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
before O
day O
@NUMBER O
for O
patients O
receiving O
these O
therapies B-treatment

current O
or O
anticipated O
use O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
first O
dose O
of O
study O
drug O
or O
anticipated O
use O
during O
the O
study O
of O
the O
following O
p O
gp O
inhibitors O
( O
amiodarone B-treatment
, O
carvedilol B-treatment
, O
clarithromycin B-treatment
, O
cobicistat B-treatment
, O
darunavir B-treatment
, O
dronedarone B-treatment
, O
erythromycin B-treatment
, O
indinavir B-treatment
, O
itraconazole B-treatment
, O
ketoconazole B-treatment
, O
lapatinib B-treatment
, O
lopinavir B-treatment
, O
propafenone B-treatment
, O
quinidine B-treatment
, O
ranolazine B-treatment
, O
ritonavir B-treatment
, O
saquinavir B-treatment
, O
telaprevir B-treatment
, O
tipranavir B-treatment
, O
verapamil B-treatment
, O
and O
valspodar B-treatment
) O

documented O
disease O
progression O
( O
either O
radiographic B-treatment
or O
biochemical B-treatment
) O
on O
at O
least O
@NUMBER B-lower_bound
novel B-treatment
hormonal I-treatment
therapy I-treatment
( O
enzalutamide B-treatment
and O
/ O
or O
abiraterone B-treatment
acetate I-treatment
/ O
prednisone B-treatment
) O
for O
the O
treatment B-treatment
of O
metastatic B-cancer
crpc I-cancer
, O
irrespective O
of O
prior B-treatment
nht I-treatment
treatment I-treatment
for O
non O
castrate B-cancer
prostate I-cancer
cancer I-cancer
or O
nonmetastatic B-cancer
( I-cancer
m0 I-cancer
) I-cancer
crpc I-cancer

major B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
before O
day O
@NUMBER O

symptomatic B-chronic_disease
or I-chronic_disease
impending I-chronic_disease
spinal I-chronic_disease
cord I-chronic_disease
compression I-chronic_disease
or O
cauda B-chronic_disease
equina I-chronic_disease
syndrome I-chronic_disease

retained O
hardware O
in O
the O
knee O
that O
requires O
removal O
or O
interferes O
with O
total B-treatment
knee I-treatment
arthroplasty I-treatment
( I-treatment
tka I-treatment
) I-treatment
procedure O

between O
the O
ages B-age
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
old O

living O
more O
than O
@NUMBER B-lower_bound
miles I-lower_bound
from O
the O
hip O
fracture O
participant O

patients O
who O
have O
a O
history O
of O
another O
type O
of O
cancer B-cancer
diagnosed O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound

history O
of O
viral B-chronic_disease
hepatitis I-chronic_disease

total O
bilirubin B-clinical_variable
> O
@NUMBER B-lower_bound
times I-lower_bound
the I-lower_bound
upper I-lower_bound
reference I-lower_bound
range I-lower_bound
without O
a O
reversible O
, O
identifiable O
cause O

measurable O
multiple B-cancer
myeloma I-cancer
that O
is O
relapsed O
or O
refractory O
to O
established O
therapies O
with O
known O
clinical O
benefit O
in O
relapsed O
/ O
refractory O
multiple O
myeloma O

clinically O
significant O
cardiac B-chronic_disease
disease I-chronic_disease

known O
positive O
test O
result O
for O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
or O
acquired B-chronic_disease
immune I-chronic_disease
deficiency I-chronic_disease
syndrome I-chronic_disease
( I-chronic_disease
aids I-chronic_disease
) I-chronic_disease

major B-chronic_disease
trauma I-chronic_disease
or O
major B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
initiation O
of O
amv564 B-treatment
treatment I-treatment

female B-gender
patients I-gender
who O
have O
a O
negative B-pregnancy
serum I-pregnancy
or I-pregnancy
urine I-pregnancy
pregnancy I-pregnancy
test O
before O
enrollment O
and O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
two I-contraception_consent
highly I-contraception_consent
effective I-contraception_consent
forms I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
( O
oral O
, O
injected O
or O
implanted O
hormonal O
contraception O
and O
condom O
; O
intrauterine O
device O
and O
condom O
; O
diaphragm O
with O
spermicidal O
gel O
and O
condom O
) O
during O
the O
trial O
and O
for O
@NUMBER O
days O
afterward O
( O
@NUMBER O
days O
after O
the O
end O
of O
amv564 O
treatment O
) O

within O
the O
ages B-age
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

a O
proteasome B-treatment
inhibitor I-treatment
and O
immunomodulatory B-treatment
imide I-treatment
drugs I-treatment
( I-treatment
imid I-treatment
) I-treatment

prior B-treatment
anti I-treatment
- I-treatment
cancer I-treatment
therapy I-treatment
( O
chemotherapy B-treatment
, O
targeted B-treatment
agents O
, O
radiotherapy B-treatment
, O
and O
immunotherapy B-treatment
) O
within O
the O
prior B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
except O
for O
alkylating B-treatment
agents I-treatment
( O
e.g. O
, O
melphalan B-treatment
) O
within O
the O
prior B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

the O
test O
must O
have O
a O
sensitivity O
of O
at O
least O
@NUMBER B-lower_bound
miu I-lower_bound
/ I-lower_bound
ml I-lower_bound

treatment O
status O
: O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
and O
no O
more O
than O
@NUMBER B-lower_bound
years I-lower_bound
after O
the O
conclusion O
of O
active B-treatment
breast I-treatment
cancer I-treatment
therapy I-treatment
, O
including O
surgery B-treatment
, O
radiation B-treatment
therapy I-treatment
and O
( B-treatment
neo I-treatment
) I-treatment
adjuvant I-treatment
chemotherapy I-treatment
, O
if O
administered O

any O
serious O
or O
uncontrolled O
medical O
disorder O
or O
active B-chronic_disease
infection I-chronic_disease

ecog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
≤ O
@NUMBER B-upper_bound

subjects O
who O
have O
had O
prior B-treatment
systemic I-treatment
therapy I-treatment
for O
lung B-cancer
cancer I-cancer

diagnosis O
of O
cf B-chronic_disease
with O
the O
f508del B-treatment
/ O
f508del B-treatment
genotype I-treatment
on O
record O
, O
along O
with O
clinical O
findings O
consistent O
with O
cf O
such O
as O
chronic O
sinopulmonary B-chronic_disease
disease I-chronic_disease
or O
gastrointestinal B-chronic_disease
/ O
nutritional B-chronic_disease
abnormalities I-chronic_disease

subject O
is O
eligible O
for O
routine B-treatment
chemotherapy I-treatment
and O
routine B-treatment
surgery I-treatment
for O
the O
treatment B-treatment
of O
non B-cancer
- I-cancer
metastatic I-cancer
extremity I-cancer
osteosarcoma I-cancer

current O
and O
past O
history O
of O
hypertension B-chronic_disease

no O
known O
allergy O
to O
ingredients O
of O
banana B-allergy_name
bread I-allergy_name
preparation O
( O
eggs B-allergy_name
, O
almonds B-allergy_name
and O
other O
nuts B-allergy_name
since O
the O
celery B-allergy_name
also O
has O
almond B-allergy_name
powder I-allergy_name
) O

community- O
or O
hospital O
- O
acquired O
pneumonia B-chronic_disease

prior O
bevacizumab B-treatment
therapy I-treatment

small O
intestine O
, O
large O
intestine O
, O
or O
stomach O
previously O
irradiated O
to O
> O
@NUMBER B-lower_bound
gy I-lower_bound

patients O
with O
pleural B-chronic_disease
effusions I-chronic_disease
that O
have O
become O
too O
small O
for O
thoracentesis O
at O
the O
time O
of O
registration O
would O
be O
permitted O
on O
study O
, O
indicating O
a O
significant O
response O
to O
first O
- O
line O
chemotherapy B-treatment

willing B-contraception_consent
and I-contraception_consent
able I-contraception_consent
to I-contraception_consent
use I-contraception_consent
medically I-contraception_consent
acceptable I-contraception_consent
forms I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
during O
the O
trial O
and O
for O
up O
to O
@NUMBER B-upper_bound
days I-upper_bound
after O
completion O
of O
all O
treatment B-treatment
to O
prevent O
pregnancy B-pregnancy
or O
fathering O
a O
child O

has O
acute B-chronic_disease
heart I-chronic_disease
, O
kidney B-chronic_disease
, O
liver B-chronic_disease
, O
respiratory B-chronic_disease
failure I-chronic_disease
or O
trauma B-chronic_disease

primary B-language_fluency
language I-language_fluency
other I-language_fluency
than I-language_fluency
english I-language_fluency

primary O
absssi B-chronic_disease
due O
to O
or O
associated O
with O
any O
of O
the O
following O
: O
diabetic B-chronic_disease
foot I-chronic_disease
infection I-chronic_disease
, O
gangrene B-chronic_disease
, O
or O
perianal B-chronic_disease
abscess I-chronic_disease
; O
concomitant B-chronic_disease
infection I-chronic_disease
at O
another O
site O
; O
infected O
burns O
; O
decubitus B-chronic_disease
, O
chronic O
, O
or O
ischemic B-chronic_disease
ulcer I-chronic_disease
; O
evolving O
necrotizing O
process O
; O
infections O
at O
vascular O
catheter O
sites O
or O
involving O
thrombophlebitis B-chronic_disease

anc B-clinical_variable
> O
@NUMBER B-lower_bound
mm3 I-lower_bound
< O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

due O
to O
the O
typical O
age O
of O
patients O
with O
hf O
, O
all O
women B-gender
will O
be O
postmenopausal O
( O
either O
natural O
or O
surgical O
) O
defined O
as O
a O
cessation O
of O
menses O
for O
at O
least O
@NUMBER B-lower_bound
years I-lower_bound
, O
and O
in O
women O
without O
a O
uterus O
, O
follicle B-clinical_variable
stimulating I-clinical_variable
hormone I-clinical_variable
( I-clinical_variable
fsh I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
iu I-lower_bound
/ I-lower_bound
l I-lower_bound

see O
at O
least O
@NUMBER B-lower_bound
unduplicated O
patients O
/ O
year O
/ O
site O

history O
of O
lung B-chronic_disease
disease I-chronic_disease

interstitial B-chronic_disease
lung I-chronic_disease
disease I-chronic_disease

lung B-cancer
cancer I-cancer

marijuana O
use O
( O
smoking O
or O
ingestion O
of O
marijuana O
) O
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

overall B-clinical_variable
cough I-clinical_variable
visual I-clinical_variable
analog I-clinical_variable
scale I-clinical_variable
( I-clinical_variable
cough I-clinical_variable
- I-clinical_variable
vas I-clinical_variable
) I-clinical_variable
score I-clinical_variable
of O
@NUMBER B-lower_bound
or O
higher O

previous O
treatment B-treatment
with O
tocilizumab B-treatment
or O
other O
cytokine B-treatment
- I-treatment
targeted I-treatment
biologic I-treatment
disease I-treatment
modifying I-treatment
antirheumatic I-treatment
drugs I-treatment
( O
including O
adalimumab B-treatment
, O
certolizumab B-treatment
, O
etanercept B-treatment
, O
golimumab B-treatment
, O
infliximab B-treatment
, O
anakinra B-treatment
) O
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
enrollment O

prior B-treatment
therapy I-treatment
with O
other O
her2 B-treatment
targeted I-treatment
agents I-treatment
( O
tdm-1 B-treatment
, O
pertuzumab B-treatment
, O
lapatinib B-treatment
) O

females B-gender
of O
reproductive O
potential O

must O
use B-contraception_consent
two I-contraception_consent
forms I-contraception_consent
of I-contraception_consent
effective I-contraception_consent
contraception I-contraception_consent
during O
the O
duration O
of O
the O
trial O
and O
for O
minimum O
of O
@NUMBER B-lower_bound
months I-lower_bound
after O
last O
dose O
of O
tocilizumab B-treatment
, O
trastuzumab B-treatment
, O
or O
pertuzumab B-treatment

age B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

recent O
single O
event O
multilevel B-treatment
lower I-treatment
extremity I-treatment
orthopedic I-treatment
surgery I-treatment
or O
selective B-treatment
dorsal I-treatment
rhizotomy I-treatment

have O
no B-technology_access
access I-technology_access
to I-technology_access
a I-technology_access
wifi I-technology_access
/ I-technology_access
or I-technology_access
cellular I-technology_access
data I-technology_access
connection I-technology_access
at O
their O
home O

have O
left B-clinical_variable
ventricular I-clinical_variable
ejection I-clinical_variable
fraction I-clinical_variable
( I-clinical_variable
ef I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound
documented O
by O
an O
echocardiogram B-treatment

participating O
in O
other B-treatment
clinical I-treatment
trials I-treatment

consent O
to O
provide O
archived O
tumor B-treatment
biopsy I-treatment
material O
( O
all O
patients O
) O

having O
received O
a O
solid B-treatment
organ I-treatment
transplantation I-treatment

prior O
treatment B-treatment
with O
immune B-treatment
- I-treatment
modulating I-treatment
agents I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
before O
regn2810 B-treatment

current O
requirement O
, O
or O
likely O
future O
requirement O
, O
of O
diathermy B-treatment
during O
the O
study O
duration O

medical O
or O
mental O
instability O
( O
diagnosis O
of O
personality B-chronic_disease
disorder I-chronic_disease
, O
psychosis B-chronic_disease
, O
or O
substance O
abuse O
) O
that O
would O
prevent O
subject O
from O
meeting O
protocol O
timeline O

current O
or O
lifetime O
diagnosis O
of O
severe O
psychiatric B-chronic_disease
disorder I-chronic_disease
( O
e.g. O
, O
bipolar B-chronic_disease
disorder I-chronic_disease
, O
etc O
. O
) O

meet O
the O
cutoff O
for O
autism B-chronic_disease
on O
the O
ados-2 O

known O
immunodeficiency B-chronic_disease
such O
as O
hiv B-chronic_disease
infection I-chronic_disease

patients O
with O
solitary B-chronic_disease
kidney I-chronic_disease

stent B-treatment
placement I-treatment
prior O
to O
ureteroscopy B-treatment
( O
pre O
- O
stented O
patients O
) O

anemia B-chronic_disease
( O
hgb B-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound
) O

thrombocytopenia B-chronic_disease
( O
platelets B-clinical_variable
< O
@NUMBER B-upper_bound
cells I-upper_bound
/ I-upper_bound
μl I-upper_bound
) O

atrial B-chronic_disease
fibrillation I-chronic_disease

known O
allergy O
to O
midodrine B-allergy_name

two B-lower_bound
or O
more O
blood B-clinical_variable
pressure I-clinical_variable
readings O
taken O
at O
least O
@NUMBER B-lower_bound
minutes I-lower_bound
apart O
with O
mean O
arterial O
pressures O
, O
maps B-clinical_variable
@NUMBER B-upper_bound
or O
less O

active B-chronic_disease
tuberculosis I-chronic_disease

prior B-treatment
exposure I-treatment
to I-treatment
pd-1 I-treatment
or I-treatment
pd I-treatment
- I-treatment
li I-treatment
treatment I-treatment

received O
a O
live B-treatment
vaccine I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
planned O
pd-1 O
start O
date O

unresectable O
or O
metastatic B-cancer
scchn I-cancer

pleural B-chronic_disease
effusion I-chronic_disease
: O
when O
pleural O
fluid O
is O
visible O
on O
both O
ct B-treatment
scan I-treatment
and O
on O
a O
chest B-treatment
x I-treatment
- I-treatment
ray I-treatment
, O
a O
pleuracentesis B-treatment
is O
required O
to O
confirm O
that O
the O
pleural O
fluid O
is O
cytologically O
negative O

pre O
- O
existing O
sensory B-clinical_variable
neuropathy I-clinical_variable
of I-clinical_variable
grade I-clinical_variable
≥ O
@NUMBER B-lower_bound

males B-gender
and I-gender
females I-gender

willing O
to O
receive O
hcv B-treatment
treatment I-treatment
on O
- O
site O
at O
dosa O
clinics O

between O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

evidence O
of O
active O
, O
noninfectious B-chronic_disease
pneumonitis I-chronic_disease
or O
history O
of O
interstitial B-chronic_disease
lung I-chronic_disease
disease I-chronic_disease

malignancies B-cancer
other O
than O
tnbc B-cancer
within O
@NUMBER B-upper_bound
years I-upper_bound
prior I-upper_bound
to O
randomization O

treatment O
with O
investigational B-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
initiation O
of O
study O
treatment O

stroke B-chronic_disease

demonstrate O
ability O
to O
expectorate O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
ml I-upper_bound
of O
native O
oral O
fluid O
over O
a O
5-minute O
period O

enrolled O
in O
another O
clinical O
trial O
or O
have O
received O
any O
drug O
as O
part O
of O
a O
research O
study O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
dosing O

use O
of O
hemp O
seeds O
or O
hemp O
oil O
in O
any O
form O
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

patients O
aged B-age
≥ O
@NUMBER B-lower_bound
years I-lower_bound
with O
newly O
diagnosed O
obstructive B-chronic_disease
sleep I-chronic_disease
apnea I-chronic_disease
( I-chronic_disease
osa I-chronic_disease
) I-chronic_disease
who O
were O
never O
treated O
with O
cpap B-treatment

cariprazine B-treatment

ecog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

patients O
active B-chronic_disease
infection I-chronic_disease
requiring O
intravenous O
systemic B-treatment
therapy I-treatment

patients O
who O
have O
received O
chemotherapy B-treatment
, O
small B-treatment
molecule I-treatment
targeted I-treatment
therapy I-treatment
or O
radiation B-treatment
within O
the O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
first O
dose O
of O
study B-treatment
drugs I-treatment

hepatocellular B-cancer
adenoma I-cancer

history O
of O
stroke B-chronic_disease

neonates O
born O
between O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
and O
@NUMBER B-upper_bound
/ I-upper_bound
@NUMBER I-upper_bound
weeks O
gestational B-clinical_variable
age I-clinical_variable
( I-clinical_variable
ga I-clinical_variable
) I-clinical_variable
at O
birth O
with O
primary B-chronic_disease
pulmonary I-chronic_disease
disease I-chronic_disease
of O
the O
newborn O
including O
transient B-chronic_disease
tachypnea I-chronic_disease
of I-chronic_disease
the I-chronic_disease
newborn I-chronic_disease
( I-chronic_disease
ttn I-chronic_disease
) I-chronic_disease

air B-chronic_disease
leak I-chronic_disease
syndrome I-chronic_disease

secondary B-cancer
cancer I-cancer
diagnosis O
( O
prior O
or O
current O
) O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound

severe O
sleep B-chronic_disease
disorders I-chronic_disease
( O
e.g O
. O
narcolepsy B-chronic_disease
) O

recent O
( O
within O
@NUMBER B-upper_bound
months I-upper_bound
) O
treatment B-treatment
with I-treatment
anabolic I-treatment
steroids I-treatment
, O
systemic B-treatment
corticosteroids I-treatment
or O
estrogen B-treatment

history O
of O
documented O
anaphylaxis B-chronic_disease
or O
contraindication O
to O
any O
of O
the O
study O
medications O

participation O
in O
any O
interventional O
study O
of O
another O
investigational B-treatment
product I-treatment
, O
biologic B-treatment
, O
device O
, O
or O
other O
agent O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
oc5 B-treatment
or O
not O
willing O
to O
forego O
other O
forms O
of O
investigational B-treatment
treatment I-treatment
during O
this O
study O

women B-gender
of O
childbearing O
potential O
who O
are O
not B-contraception_consent
using I-contraception_consent
adequate I-contraception_consent
contraceptive I-contraception_consent
precautions I-contraception_consent

absence O
of O
pancreatic O
fluid O
collection O
( O
defined O
as O
those O
> O
@NUMBER B-lower_bound
cm I-lower_bound
in O
size O
located O
along O
the O
course O
of O
the O
main O
pd O
on O
cross O
- O
sectional O
imaging O
) O
at O
the O
time O
of O
study O
enrollment O

a O
fasting B-clinical_variable
glucose I-clinical_variable
≥ O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
or O
an O
hba1c B-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound
will O
be O
taken O
as O
evidence O
of O
type B-chronic_disease
@NUMBER I-chronic_disease
diabetes I-chronic_disease
and O
therefore O
patients O
will O
be O
deemed O
ineligible O
for O
participation O

active O
, O
severe O
psychiatric B-chronic_disease
disease I-chronic_disease

prior O
use O
of O
glucose B-treatment
lowering I-treatment
medication I-treatment
in O
the O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
screening O

active O
consideration O
of O
pregnancy B-pregnancy
during O
the O
period O
of O
study O
. O
subjects O
will O
be O
discontinued O
if O
they O
become O
pregnant B-pregnancy
during O
the O
study O

age B-age
> O
@NUMBER B-lower_bound

diagnosis O
of O
invasive B-cancer
malignancy I-cancer
of I-cancer
the I-cancer
brain I-cancer
, O
head B-cancer
and I-cancer
neck I-cancer
region I-cancer
, O
lung B-cancer
, O
gastrointestinal B-cancer
tract I-cancer
, O
or O
uterine B-cancer
cervix I-cancer

ecog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

medication O
use O
that O
substantially O
reduces O
seizure O
threshold O
to O
tms B-treatment
( O
olanzapine B-treatment
, O
chlorpromazine B-treatment
, O
lithium B-treatment
) O

diagnosed O
with O
a O
primary O
hnc B-cancer

going O
to O
receive O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
of O
rt B-treatment
with O
at O
least O
@NUMBER B-lower_bound
fractions O

patients O
must O
be O
available O
for O
at O
least O
@NUMBER B-lower_bound
month I-lower_bound
post O
procedure B-treatment

these O
patients O
cover O
a O
transdiagnostic O
range O
of O
severe B-chronic_disease
depression I-chronic_disease
, O
anxiety B-chronic_disease
, O
and O
ptsd B-chronic_disease

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

any O
major O
episode O
of O
infection O
requiring O
treatment O
with O
iv B-treatment
antibiotics I-treatment
or O
hospitalization B-treatment
( O
related O
to O
the O
completion O
of O
the O
course O
of O
antibiotics O
) O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
before O
the O
start O
of O
treatment O

neurological O
diagnosis O
of O
amnestic B-chronic_disease
mild I-chronic_disease
cognitive I-chronic_disease
impairment I-chronic_disease
( I-chronic_disease
amci I-chronic_disease
) I-chronic_disease

mao B-treatment
inhibitors I-treatment

ssri B-treatment
's I-treatment

taking O
chronic O
anti B-treatment
- I-treatment
anxiety I-treatment

anti B-treatment
- I-treatment
insomnia I-treatment
medication I-treatment
on O
a O
regular O
basis O

patients O
that O
transition O
from O
active O
agvhd B-chronic_disease
to O
cgvhd B-chronic_disease
without O
tapering O
off O
corticosteroids B-treatment
± I-treatment
cni I-treatment
and O
any O
systemic O
treatment B-treatment

must O
accept O
to O
be O
treated O
with O
only O
one O
of O
the O
following O
bat O
options O
on O
cycle O
@NUMBER O
day O
@NUMBER O
( O
additions O
and O
changes O
are O
allowed O
during O
the O
course O
of O
the O
study O
, O
but O
only O
with O
bat O
from O
the O
following O
bat O
options O
) O
: O
extracorporeal B-treatment
photopheresis I-treatment
( I-treatment
ecp I-treatment
) I-treatment
, O
low O
- O
dose O
methotrexate B-treatment
( I-treatment
mtx I-treatment
) I-treatment
, O
mycophenolate B-treatment
mofetil I-treatment
( I-treatment
mmf I-treatment
) I-treatment
, O
mtor B-treatment
inhibitors I-treatment
( I-treatment
everolimus I-treatment
or I-treatment
sirolimus I-treatment
) I-treatment
, O
infliximab B-treatment
, O
rituximab B-treatment
, O
pentostatin B-treatment
, O
imatinib B-treatment
, O
ibrutinib B-treatment

known O
current O
or O
a O
history O
of O
hepatitis B-chronic_disease
b I-chronic_disease
or I-chronic_disease
c I-chronic_disease
virus I-chronic_disease
, O
including O
chronic O
and O
dormant O
states O
, O
unless O
disease O
has O
been O
treated O
and O
confirmed O
cleared O

receiving O
any O
other O
investigational B-treatment
agents I-treatment
during O
protocol O
therapy B-treatment
, O
or O
up O
to O
@NUMBER B-upper_bound
days I-upper_bound
or O
@NUMBER B-upper_bound
half I-upper_bound
- I-upper_bound
lives I-upper_bound
( O
whichever O
is O
longer O
) O
prior O
to O
beginning O
protocol O
therapy O

tamoxifen B-treatment
therapy I-treatment
or O
other O
hormonal O
agents O
should O
be O
discontinued O
at O
least O
@NUMBER B-lower_bound
week I-lower_bound
before O
the O
patient O
is O
started O
on O
study O
therapy O

patients O
may O
not O
take O
h2 B-treatment
antihistamines I-treatment
and O
leukotriene B-treatment
receptor I-treatment
antagonists I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
before O
screening O
, O
during O
the O
screening O
, O
run O
- O
in O
, O
or O
treatment O
phases O

bradycardia B-clinical_variable
of O
less O
than O
@NUMBER B-upper_bound
beats I-upper_bound
/ I-upper_bound
min I-upper_bound

has O
aml B-cancer
or O
all B-cancer
and O
failed O
any O
prior B-treatment
induction I-treatment
therapy I-treatment
regimen O
or O
have O
relapsed O
after O
prior B-treatment
therapy I-treatment

any O
other O
invasive B-cancer
cancer I-cancer
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound

recent O
weight B-clinical_variable
change I-clinical_variable
( O
+ O
/ O
- O
@NUMBER B-upper_bound
pounds I-upper_bound
in O
@NUMBER B-upper_bound
year I-upper_bound
) O

renal B-chronic_disease
failure I-chronic_disease

have O
a O
self O
- O
reported O
diagnosis O
of O
cancer B-cancer
with O
short O
life O
expectancy O

known O
heart B-chronic_disease
or I-chronic_disease
pulmonary I-chronic_disease
condition I-chronic_disease

pregnancy B-pregnancy
or O
breast O
feeding O

age B-age
< O
@NUMBER B-upper_bound
years I-upper_bound

known O
severe O
hypersensitivity O
reactions O
to O
monoclonal B-allergy_name
antibodies I-allergy_name
( O
nci B-clinical_variable
ctcae I-clinical_variable
grade I-clinical_variable
≥ O
@NUMBER B-lower_bound
) O

subjects O
receiving O
immunosuppressive B-treatment
agents I-treatment
( O
such O
as O
steroids B-treatment
) O
for O
any O
reason O
should O
be O
tapered O
off O
these O
drugs O
@NUMBER B-upper_bound
days I-upper_bound
before O
initiation O
of O
study O
treatment O

major O
surgery B-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
before O
start O
of O
trial O
treatment O

subjects O
with O
castration B-cancer
- I-cancer
resistant I-cancer
prostate I-cancer
cancer I-cancer
( I-cancer
crpc I-cancer
) I-cancer
, O
who O
may O
remain O
on O
treatment B-treatment
with O
luteinizing B-treatment
hormone I-treatment
- I-treatment
releasing I-treatment
hormone I-treatment
agonists I-treatment
or I-treatment
antagonists I-treatment

unstable B-chronic_disease
angina I-chronic_disease

any O
investigational O
biologic O
or O
other O
agent O
or O
procedure O
within O
minimally O
@NUMBER B-upper_bound
days I-upper_bound
or O
@NUMBER B-upper_bound
half I-upper_bound
- I-upper_bound
lives I-upper_bound
prior I-upper_bound
to O
baseline O
, O
whichever O
is O
longer O

dementia B-chronic_disease

suicidal B-chronic_disease
ideation I-chronic_disease

aged B-age
≥ O
@NUMBER B-lower_bound
and O
≤ O
@NUMBER B-upper_bound
years I-upper_bound

must O
have O
no O
ongoing O
active O
, O
uncontrolled B-chronic_disease
infections I-chronic_disease

must O
not O
have O
an O
active O
second B-cancer
malignancy I-cancer
other O
than O
non B-cancer
- I-cancer
melanoma I-cancer
skin I-cancer
cancer I-cancer
or O
cervical B-cancer
carcinoma I-cancer
in I-cancer
situ I-cancer

prior B-treatment
adjuvant I-treatment
chemotherapy I-treatment
is O
permitted O
provided O
it O
was O
completed O
> O
@NUMBER B-lower_bound
months I-lower_bound
from O
registration O

pending O
neck B-treatment
surgery I-treatment

acute B-chronic_disease
medical I-chronic_disease
illness I-chronic_disease

colonoscopy B-treatment
within O
@NUMBER B-upper_bound
years I-upper_bound

history O
of O
adenomatous B-cancer
polyps I-cancer

any O
joint O
contracture O
or O
severe O
spasticity B-chronic_disease
in O
the O
affected O
upper O
extremity O
, O
as O
measured O
by O
a O
modified B-clinical_variable
ashworth I-clinical_variable
score I-clinical_variable
> O
than O
@NUMBER B-lower_bound
out O
of O
@NUMBER B-upper_bound

no O
planned O
alteration O
in O
upper B-treatment
- I-treatment
extremity I-treatment
therapy I-treatment
or O
medication O
for O
muscle O
tone O
during O
the O
course O
of O
the O
study O

uncontrolled O
epilepsy B-chronic_disease

heavy O
caffeine O
use O
( O
greater O
than O
@NUMBER B-lower_bound
mg I-lower_bound
on O
a O
regular O
, O
daily O
basis O
) O

signs O
or O
symptoms O
consistent O
with O
sexually B-chronic_disease
transmitted I-chronic_disease
infection I-chronic_disease

if O
a O
potential O
participant O
reports O
a O
prior O
history O
of O
ipv B-treatment
, O
s O
/ O
he O
may O
still O
be O
eligible O
for O
participation O
pending O
a O
more O
detailed O
assessment O
completed O
by O
trained O
project O
staff O
using O
the O
danger O
assessment O
scale O
( O
campbell O
, O
@NUMBER O
) O

pregnancy B-pregnancy
is O
the O
mother O
's O
first O
with O
the O
baby O
's O
father O

subjects O
with O
known O
hypersensitivity O
or O
other O
allergic O
reactions O
attributed O
to O
compounds O
of O
similar O
biologic O
composition O
to O
netupitant B-allergy_name
, O
palonosetron B-allergy_name
, O
dexamethasone B-allergy_name
, O
or O
other O
agents O
used O
in O
the O
study O

the O
planned O
dexamethasone B-treatment
during O
conditioning B-treatment
therapy I-treatment

diagnosis O
of O
severe O
or O
poorly O
controlled O
concurrent B-chronic_disease
medical I-chronic_disease
disorders I-chronic_disease
that O
may O
cause O
depression B-chronic_disease
or O
require O
medication O
that O
could O
cause O
depressive O
symptoms O

patients O
must O
be O
candidates O
for O
neoadjuvant B-treatment
paclitaxel I-treatment
chemotherapy I-treatment
by O
their O
treating O
oncologist O

anterior B-treatment
cruciate I-treatment
ligament I-treatment
( I-treatment
acl I-treatment
) I-treatment
reconstruction I-treatment
with I-treatment
concomitant I-treatment
meniscus I-treatment
or I-treatment
cartilage I-treatment
restoration I-treatment
procedures I-treatment

history O
of O
deep B-chronic_disease
vein I-chronic_disease
thrombosis I-chronic_disease
( I-chronic_disease
dvt I-chronic_disease
) I-chronic_disease

pad B-chronic_disease
presumed O
to O
be O
of O
atherosclerotic B-chronic_disease
origin O

patients O
who O
had O
received O
immunosuppressive B-treatment
therapy I-treatment
including O
cyclophosphamide B-treatment
, O
mmf B-treatment
, O
cyclosporine B-treatment
, O
tacrolimus B-treatment
or O
azathioprine B-treatment
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

renal B-treatment
biopsy I-treatment
read O
at O
mayo O
clinic O
confirming O
the O
diagnosis O
of O
pgnmid B-chronic_disease
or O
c3 B-chronic_disease
gn I-chronic_disease

chronic B-treatment
opioid I-treatment
use O

taking O
opioids B-treatment
for O
longer O
than O
@NUMBER B-upper_bound
months I-upper_bound
, O
or O
daily B-clinical_variable
oral I-clinical_variable
morphine I-clinical_variable
equivalent I-clinical_variable
of O
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
day I-lower_bound
for O
one B-upper_bound
month I-upper_bound

pregnant B-pregnancy
or O
breastfeeding O
women B-gender
will O
not O
be O
entered O
into O
this O
study O
due O
to O
risks O
of O
fetal O
and O
teratogenic O
adverse O
events O
as O
seen O
in O
animal O
studies O
. O
pregnancy B-pregnancy
tests O
must O
be O
obtained O
in O
female B-gender
females B-gender
who O
are O
post O
- O
menarchal O
and O
of O
child O
bearing O
potential O
( O
e.g O
. O
female O
that O
has O
not O
been O
amenorrheic O
for O
at O
least O
@NUMBER B-lower_bound
consecutive I-lower_bound
months I-lower_bound
or O
surgically O
sterilized O
) O

subjects O
with O
baseline O
symptoms O
of O
fever O
and O
/ O
or O
cough O
and O
/ O
or O
shortness O
of O
breath O
and O
/ O
or O
wheezing O
and O
/ O
or O
fatigue B-clinical_variable
grade I-clinical_variable
≥ O
@NUMBER B-lower_bound
( O
ctcae O
v4.0 O
) O

uncontrolled O
intercurrent O
illness O
including O
, O
but O
not O
limited O
to O
, O
ongoing O
or O
active B-chronic_disease
infection I-chronic_disease
, O
bradycardia B-chronic_disease
, O
related O
to O
cardiac B-chronic_disease
disease I-chronic_disease
, O
bundle B-chronic_disease
branch I-chronic_disease
block I-chronic_disease
, O
symptomatic B-chronic_disease
congestive I-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease
pectoris I-chronic_disease
, O
cardiac B-chronic_disease
arrhythmia I-chronic_disease
, O
or O
psychiatric B-chronic_disease
illness I-chronic_disease
/ I-chronic_disease
social I-chronic_disease
situations I-chronic_disease
that O
would O
limit O
compliance O
with O
study O
requirements O

unresolved O
toxicities O
from O
prior O
anticancer B-treatment
therapy I-treatment
, O
defined O
as O
having O
not O
resolved O
to O
nci B-clinical_variable
ctcae I-clinical_variable
grade I-clinical_variable
≤ O
@NUMBER B-upper_bound
with O
the O
exception O
of O
alopecia B-chronic_disease
and O
laboratory O
values O
listed O
per O
the O
inclusion O
criteria O
. O
subjects O
with O
irreversible O
toxicity O
that O
is O
not O
reasonably O
expected O
to O
be O
exacerbated O
by O
the O
investigational O
product O
may O
be O
included O
( O
eg O
, O
hearing O
loss O
) O

history O
of O
allergic O
reactions O
attributed O
to O
compounds O
of O
similar O
chemical O
or O
biologic O
composition O
to O
apalutamide B-allergy_name
or O
docetaxel B-allergy_name

psychiatric B-chronic_disease
illness I-chronic_disease
/ O
social B-chronic_disease
situations I-chronic_disease
that O
would O
limit O
compliance O
with O
study O
requirements O

men B-gender
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
adequate I-contraception_consent
contraception I-contraception_consent

performance B-clinical_variable
status I-clinical_variable
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

contraindications O
for O
mri B-allergy_name
or O
gbca B-allergy_name
( O
standard O
of O
care O
) O

history O
of O
previous O
administration O
of O
gbca B-treatment

a O
minimum O
gerd B-clinical_variable
- I-clinical_variable
hrql I-clinical_variable
score I-clinical_variable
while O
on O
ppis B-treatment
of O
@NUMBER O

enrolled O
in O
a O
concurrent B-treatment
clinical I-treatment
trial I-treatment

history O
of O
heartburn B-chronic_disease
- I-chronic_disease
like I-chronic_disease
pain I-chronic_disease
, O
regurgitation B-chronic_disease
, O
or O
both O
prior O
to O
the O
initiation O
of O
proton B-treatment
pump I-treatment
inhibitor I-treatment
( I-treatment
ppis I-treatment
) I-treatment
therapy I-treatment

all O
adults O
over O
the O
age B-age
of O
@NUMBER B-lower_bound

birth B-clinical_variable
weight I-clinical_variable
less O
than O
@NUMBER B-upper_bound
kg I-upper_bound

younger O
than O
@NUMBER B-upper_bound
years I-upper_bound
( O
chronological O
age B-age
) O

pregnant B-pregnancy
or O
breastfeeding O
women B-gender
will O
be O
excluded O
to O
minimize O
the O
risks O
of O
neuromuscular O
electrical O
stimulation O

left B-chronic_disease
bundle I-chronic_disease
branch I-chronic_disease
block I-chronic_disease
( I-chronic_disease
lbbb I-chronic_disease
) I-chronic_disease
with O
qrs B-clinical_variable
duration I-clinical_variable
≥ O
@NUMBER B-lower_bound
ms I-lower_bound
, O
ef B-clinical_variable
≤ O
@NUMBER B-upper_bound
% I-upper_bound
, O
and O
mild B-chronic_disease
( I-chronic_disease
nyha I-chronic_disease
class I-chronic_disease
ii I-chronic_disease
) I-chronic_disease
ischemic I-chronic_disease
or O
nonischemic B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
or O
asymptomatic B-chronic_disease
( I-chronic_disease
nyha I-chronic_disease
class I-chronic_disease
i I-chronic_disease
) I-chronic_disease
ischemic I-chronic_disease
heart I-chronic_disease
failure I-chronic_disease

women B-gender
of O
childbearing O
potential O
who O
are O
or O
plan B-pregnancy
to I-pregnancy
become I-pregnancy
pregnant I-pregnancy
during O
the O
course O
of O
the O
trial O

active O
heart B-treatment
transplant I-treatment
list O
or O
who O
has O
or O
is O
to O
receive O
ventricular B-treatment
assist I-treatment
device I-treatment
( I-treatment
vad I-treatment
) I-treatment

self O
- O
reported O
shortness B-chronic_disease
of I-chronic_disease
breath I-chronic_disease
( O
a O
score O
of O
@NUMBER B-lower_bound
or O
greater O
on O
the O
modified B-clinical_variable
medical I-clinical_variable
research I-clinical_variable
council I-clinical_variable
dyspnea I-clinical_variable
scale I-clinical_variable
) O

corrected O
diffusing O
capacity B-clinical_variable
of I-clinical_variable
lung I-clinical_variable
for I-clinical_variable
carbon I-clinical_variable
monoxide I-clinical_variable
( I-clinical_variable
dlco I-clinical_variable
) I-clinical_variable
at O
@NUMBER B-lower_bound
percent I-lower_bound
of O
predicted O
or O
above O

inability O
to O
perform O
@NUMBER O
minute O
walk O
test O
( O
distance O
< O
@NUMBER B-upper_bound
m I-upper_bound
) O
, O
or O
@NUMBER O
minute O
walk O
test O
> O
@NUMBER B-lower_bound
m I-lower_bound

patient O
is O
on O
the O
cardiac B-treatment
transplant I-treatment
waiting O
list O

presence O
of O
significant O
valve B-chronic_disease
disease I-chronic_disease
defined O
by O
the O
site O
cardiologist O

without O
previously O
documented O
ef B-clinical_variable
< O
@NUMBER B-upper_bound
% I-upper_bound
( O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
) O

patients O
who O
have O
psa O
recurrence O
after O
local O
salvage B-treatment
therapy I-treatment
may O
participate O
in O
this O
study O

have B-technology_access
a I-technology_access
smartphone I-technology_access

exclusions O
are O
major O
congenital O
anomalies O
, O
major B-chronic_disease
cardiac I-chronic_disease
defects I-chronic_disease
( O
other O
than O
patent B-chronic_disease
ductus I-chronic_disease
arteriosus I-chronic_disease
, O
patent B-chronic_disease
foramen I-chronic_disease
ovale I-chronic_disease
, O
small O
atrial B-chronic_disease
septal I-chronic_disease
defect I-chronic_disease
, O
and O
small O
ventricular B-chronic_disease
septal I-chronic_disease
defect I-chronic_disease
) O
, O
and O
intubation B-treatment
in O
the O
delivery O
room O

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
of O
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound

histological O
or O
cytological O
diagnosis O
of O
adenocarcinoma B-cancer
of O
the O
exocrine O
pancreas O
that O
is O
metastatic O
( O
stage O
iv O
) O
and O
not O
amenable O
to O
resection O
with O
curative O
intent O

clinically O
significant O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
( O
known O
lvef B-clinical_variable
≤ O
@NUMBER B-upper_bound
% I-upper_bound
, O
cor B-chronic_disease
pulmonale I-chronic_disease
, O
diastolic B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
etc O

gfr B-clinical_variable
< O
@NUMBER B-upper_bound
estimated O
by O
cockroft O
- O
gault O

subjects O
should O
not O
have O
a O
pulmonary B-treatment
exacerbation I-treatment
or O
changes O
in O
therapy B-treatment
for O
pulmonary B-chronic_disease
disease I-chronic_disease
within O
@NUMBER B-upper_bound
days I-upper_bound
before O
receiving O
the O
first O
dose O
of O
study O
drug O

has O
a O
serum B-clinical_variable
psa I-clinical_variable
concentration I-clinical_variable
at O
the O
screening O
visit O
of O
> O
@NUMBER B-lower_bound
ng I-lower_bound
/ I-lower_bound
ml I-lower_bound
( I-lower_bound
@NUMBER I-lower_bound
μg I-lower_bound
/ I-lower_bound
l I-lower_bound
) I-lower_bound
, O
or O
, O
when O
applicable O
, O
post O
radical B-treatment
prostatectomy I-treatment
of O
> O
@NUMBER B-lower_bound
ng I-lower_bound
/ I-lower_bound
ml I-lower_bound
( I-lower_bound
@NUMBER I-lower_bound
μg I-lower_bound
/ I-lower_bound
l I-lower_bound
) I-lower_bound
or O
post O
radiotherapy B-treatment
, O
cryotherapy B-treatment
, O
or O
high B-treatment
frequency I-treatment
ultrasound I-treatment
> O
@NUMBER O
ng O
/ O
ml O
( O
@NUMBER O
μg O
/ O
l O
) O
above O
the O
post O
interventional O
nadir O

has O
a O
serum B-clinical_variable
testosterone I-clinical_variable
at O
the O
screening O
visit O
of O
≥ O
@NUMBER B-lower_bound
ng I-lower_bound
/ I-lower_bound
dl I-lower_bound
( I-lower_bound
@NUMBER I-lower_bound
nmol I-lower_bound
/ I-lower_bound
l I-lower_bound
) I-lower_bound

pathologically B-clinical_variable
thick I-clinical_variable
wall I-clinical_variable
/ I-clinical_variable
septation I-clinical_variable
( O
> O
@NUMBER B-lower_bound
mm I-lower_bound
) O

who O
have O
previously O
received O
any O
anti B-treatment
- I-treatment
pd-1 I-treatment
/ I-treatment
pd I-treatment
- I-treatment
l1 I-treatment
therapy I-treatment
, O
alone O
or O
in O
combination O

psoriatic O
group O
only O
: O
psoriasis B-chronic_disease
is O
untreated O
( O
as O
defined O
in O
exclusion O
criteria O
@NUMBER O
) O
or O
subject O
has O
been O
on O
a O
stable O
topical O
or O
systemic B-treatment
treatment I-treatment
with O
no O
dose O
alteration O
or O
regimen B-clinical_variable
alteration I-clinical_variable
for O
> O
@NUMBER B-lower_bound
months I-lower_bound

history O
of O
diabetes B-chronic_disease
mellitus I-chronic_disease

ages B-age
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound

have O
maple B-chronic_disease
syrup I-chronic_disease
urine I-chronic_disease
disease I-chronic_disease

hypersensitivity O
to O
l B-allergy_name
- I-allergy_name
leucine I-allergy_name

stable O
doses O
of O
all O
concomitant B-treatment
medications I-treatment
for O
over O
@NUMBER B-lower_bound
weeks I-lower_bound

6-minute B-clinical_variable
walk I-clinical_variable
distance I-clinical_variable
( I-clinical_variable
@NUMBER I-clinical_variable
mwd I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
m I-lower_bound
at O
screening O

arterial B-treatment
catheter I-treatment
present O
for O
continuous O
blood O
pressure O
monitoring O

need O
to O
use O
acetaminophen B-treatment
on O
regular O
basis O
( O
since O
can O
interfere O
with O
cgm O
accuracy O
) O

age B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

hiv B-chronic_disease
negative O

immunomodulators B-treatment
and O
/ O
or O

ages B-age
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound

platelets B-clinical_variable
≥ O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
mm3 I-lower_bound
; O
hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

unstable B-chronic_disease
angina I-chronic_disease
and O
/ O
or O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
requiring O
hospitalization O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

history O
of O
knee B-treatment
replacement I-treatment
surgery I-treatment
, O
as O
these O
may O
have O
contractures O
causing O
unexpected O
changes O
in O
alignment O

severe B-chronic_disease
osteoarthritis I-chronic_disease
of O
the O
hips O
/ O
knees O
/ O
ankles O

women B-gender
with O
hip O
and O
wrist O
fractures O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
presentation O

concurrent O
or O
use O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
drugs O
known O
to O
interact O
with O
dm B-treatment
or O
cyp2d6 B-treatment
or O
drugs O
known O
to O
increase O
the O
risk O
of O
adverse O
effects O
from O
dm O

congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease

developmental B-chronic_disease
disorders I-chronic_disease
e.g O
. O
autism B-chronic_disease

aged B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
old O
in O
our O
partnering O
head O
start O
agency O

inability B-language_fluency
to I-language_fluency
read I-language_fluency
english I-language_fluency

subject O
is O
at O
least O
@NUMBER B-lower_bound
years I-lower_bound
old O
( O
or O
considered O
an O
adult O
per O
state O
law O
) O

patients O
with O
prior O
malignancy B-cancer
will O
be O
excluded O
except O
for O
adequately O
treated O
basal B-cancer
cell I-cancer
or I-cancer
squamous I-cancer
cell I-cancer
skin I-cancer
cancer I-cancer
, O
adequately O
treated O
noninvasive B-cancer
carcinomas I-cancer
, O
or O
other O
cancers B-cancer
from O
which O
the O
patient O
has O
been O
disease O
- O
free O
for O
at O
least O
@NUMBER B-lower_bound
years I-lower_bound

between O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
old O

elbow O
pain O
with O
other O
possible O
etiologies O
( O
e.g. O
, O
degenerative B-chronic_disease
joint I-chronic_disease
disease I-chronic_disease
) O

eastern B-clinical_variable
collaborative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
of O
@NUMBER B-lower_bound
or O
@NUMBER B-upper_bound
at O
screening O

type B-chronic_disease
@NUMBER I-chronic_disease
or I-chronic_disease
type I-chronic_disease
@NUMBER I-chronic_disease
diabetes I-chronic_disease
mellitus I-chronic_disease
requiring O
insulin B-treatment
at O
study O
entry O

asymptomatic B-clinical_variable
carotid I-clinical_variable
disease I-clinical_variable
with O
≥ O
@NUMBER B-lower_bound
% I-lower_bound
carotid B-chronic_disease
artery I-chronic_disease
stenosis I-chronic_disease

current O
or O
planned O
use O
of O
fibrates B-treatment
or O
agents B-treatment
with I-treatment
ppar I-treatment
- I-treatment
α I-treatment
agonist I-treatment
activity I-treatment
( O
eg O
, O
saroglitazar B-treatment
) O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
( I-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
) I-upper_bound
of O
visit O
@NUMBER O
( O
screening O
/ O
enrollment O
visit O
) O

type B-chronic_disease
@NUMBER I-chronic_disease
diabetes I-chronic_disease
diabetes B-chronic_disease
of O
longer O
than O
@NUMBER B-lower_bound
weeks I-lower_bound
duration O
documented O
in O
medical O
records O
, O
for O
example O
: O
local O
laboratory O
evidence O
through O
medical O
record O
review O
of O
elevated O
hba1c B-clinical_variable
( O
≥ O
@NUMBER B-lower_bound
% I-lower_bound
[ I-lower_bound
@NUMBER I-lower_bound
mmol I-lower_bound
/ I-lower_bound
mol I-lower_bound
] I-lower_bound
) O
, O
elevated O
plasma O
glucose O
( O
fasting B-clinical_variable
≥ O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
[ I-lower_bound
@NUMBER I-lower_bound
mmol I-lower_bound
/ I-lower_bound
l I-lower_bound
] I-lower_bound
, O
2-hour B-clinical_variable
≥ O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
[ I-lower_bound
@NUMBER I-lower_bound
mmol I-lower_bound
/ I-lower_bound
l I-lower_bound
] I-lower_bound
during O
oral O
glucose O
tolerance O
testing O
, O
or O
random B-clinical_variable
value I-clinical_variable
≥ O
@NUMBER O
mg O
/ O
dl O
with O
classic O
symptoms O
, O
or O
currently O
taking O
medication O
for O
treatment B-treatment
of O
diabetes O
; O
and O
either O

be O
free O
of O
dementia B-chronic_disease
, O
and O
able O
to O
cognitively O
and O
physically O
give O
informed O
consent O

liver B-chronic_disease
and O
kidney B-chronic_disease
disease I-chronic_disease
: O
active B-chronic_disease
liver I-chronic_disease
disease I-chronic_disease
will O
be O
excluded O

major O
digestive B-chronic_disease
disorders I-chronic_disease
including O
inflammatory B-chronic_disease
bowel I-chronic_disease
diseases I-chronic_disease
, O
irritable B-chronic_disease
bowel I-chronic_disease
syndrome I-chronic_disease
, O
and O
celiac B-chronic_disease
disease I-chronic_disease

those O
subjects O
allergic O
to O
the O
ingredients B-allergy_name
of I-allergy_name
the I-allergy_name
meals I-allergy_name

those O
with O
medical O
conditions O
that O
preclude O
a O
lumbar B-treatment
puncture I-treatment
such O
as O
an O
intracranial B-cancer
tumor I-cancer
, O
lower O
spinal O
hardware O
, O
or O
use O
of O
anticoagulation B-treatment

@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound

cardiovascular B-chronic_disease
, O
respiratory B-chronic_disease
or O
musculoskeletal B-chronic_disease
disease I-chronic_disease
or O
joint B-chronic_disease
problems O
that O
preclude O
moderate O
physical O
activity O

major B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
the O
first O
dose O
of O
study O
drug O

≥ O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

patient O
has O
undergone O
stem B-treatment
cell I-treatment
transplant I-treatment
or O
gene B-treatment
therapy I-treatment
for O
the O
treatment O
of O
i O
nherited B-chronic_disease
eb I-chronic_disease

serum B-clinical_variable
creatinine I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
and O
estimated B-clinical_variable
glomerular I-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
or O
creatinine B-clinical_variable
clearance I-clinical_variable
≥ O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound

women B-gender
of O
childbearing O
potential O
must O
be O
practicing B-contraception_consent
a I-contraception_consent
highly I-contraception_consent
effective I-contraception_consent
method I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
consistent I-contraception_consent
with I-contraception_consent
local I-contraception_consent
regulations I-contraception_consent
regarding I-contraception_consent
the I-contraception_consent
use I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
methods I-contraception_consent
for I-contraception_consent
subjects I-contraception_consent
participating I-contraception_consent
in I-contraception_consent
clinical I-contraception_consent
studies I-contraception_consent
: O
eg O
, O
established B-contraception_consent
use I-contraception_consent
of I-contraception_consent
oral I-contraception_consent
, O
injected B-contraception_consent
or I-contraception_consent
implanted I-contraception_consent
hormonal I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent

subject O
must O
have O
a O
weight O
consistent O
with O
a O
recommended O
weight O
range O
for O
their O
age B-age
at O
the O
time O
of O
screening O

adequate O
renal O
function O
as O
defined O
by O
creatinine B-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

patients O
who O
are O
suitable O
for O
standard O
re O
- O
induction O
chemotherapy B-treatment
or O
hematopoietic B-treatment
stem I-treatment
cell I-treatment
transplantation I-treatment
and O
willing O
to O
receive O
it O

caregiver O
is O
able B-language_fluency
to I-language_fluency
speak I-language_fluency
and I-language_fluency
understand I-language_fluency
either I-language_fluency
english I-language_fluency
or I-language_fluency
spanish I-language_fluency

the O
child O
has O
other O
significant O
medical O
conditions O
, O
such O
as O
congenital B-chronic_disease
heart I-chronic_disease
disease I-chronic_disease
, O
cystic B-chronic_disease
fibrosis I-chronic_disease

≥ O
@NUMBER B-lower_bound
years I-lower_bound
old O
with O
no O
upper O
age O
limit O

requires O
continuous O
intravenous B-treatment
vasopressor I-treatment
infusion I-treatment
for O
blood O
pressure O
support O

has O
access B-technology_access
to I-technology_access
a I-technology_access
computer I-technology_access
connected I-technology_access
to I-technology_access
the I-technology_access
internet I-technology_access
or I-technology_access
a I-technology_access
smartphone I-technology_access
compatible I-technology_access
with I-technology_access
the I-technology_access
fitbit I-technology_access
application I-technology_access

recent O
quitters O
( O
have O
not O
smoked O
in O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
) O

history O
of O
deep B-chronic_disease
vein I-chronic_disease
thrombosis I-chronic_disease
( I-chronic_disease
dvt I-chronic_disease
) I-chronic_disease
or O
pulmonary B-chronic_disease
embolism I-chronic_disease
( I-chronic_disease
pe I-chronic_disease
) I-chronic_disease
within O
the O
last O
year O
or O
history O
or O
recurrent O
dvt O
/ O
pe O

severe B-chronic_disease
hemophilia I-chronic_disease
a I-chronic_disease
( O
past O
evidence O
of O
circulating O
fviii B-clinical_variable
activity I-clinical_variable
of O
< O
@NUMBER B-upper_bound
% I-upper_bound
normal O
) O

treated O
or O
exposed O
to O
fviii B-treatment
concentrates I-treatment
or O
cryoprecipitate B-clinical_variable
for O
at O
least O
@NUMBER B-lower_bound
exposure O
days O

any O
other O
active B-chronic_disease
bacterial I-chronic_disease
infection I-chronic_disease

not O
including O
steroids B-treatment
for O
lung B-chronic_disease
maturity I-chronic_disease

on O
dialysis B-treatment

pulmonary B-chronic_disease
edema I-chronic_disease

subject O
has O
had O
previous O
exposure O
to O
orencia B-treatment
( O
abatacept O
) O

subject O
is O
at O
risk O
for O
tuberculosis B-chronic_disease

liver B-chronic_disease
disease I-chronic_disease

curatively- O
treated O
basal B-cancer
cell I-cancer
carcinoma I-cancer

heart B-chronic_disease
failure I-chronic_disease
patients O

any O
serious O
medical O
condition O
likely O
to O
impede O
successful O
completion O
of O
the O
study O
, O
such O
as O
certain O
mental B-chronic_disease
disorders I-chronic_disease
, O
cardiac B-chronic_disease
arrhythmias I-chronic_disease
, O
and O
uncontrolled O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
or O
respiratory B-chronic_disease
disease I-chronic_disease

evidence O
of O
esophageal B-chronic_disease
and I-chronic_disease
/ I-chronic_disease
or I-chronic_disease
gastric I-chronic_disease
varices I-chronic_disease

patients O
with O
serum B-clinical_variable
platelet I-clinical_variable
count I-clinical_variable
less O
than O
@NUMBER B-upper_bound
× I-upper_bound
@NUMBER I-upper_bound
/ I-upper_bound
l I-upper_bound

physician O
diagnosis O
of O
meniscal B-chronic_disease
tear I-chronic_disease

diagnosis O
of O
borderline B-chronic_disease
personality I-chronic_disease
disorder I-chronic_disease

> O
@NUMBER B-lower_bound
months I-lower_bound
since O
a O
first B-chronic_disease
clinical I-chronic_disease
cortical I-chronic_disease
or I-chronic_disease
subcortical I-chronic_disease
, I-chronic_disease
hemorrhagic I-chronic_disease
or I-chronic_disease
nonhemorrhagic I-chronic_disease
stroke I-chronic_disease

pregnant B-pregnancy
women B-gender
due O
to O
unknown O
risks O
of O
surface O
nmes O
during O
pregnancy B-pregnancy

active B-chronic_disease
cutaneous I-chronic_disease
bacterial I-chronic_disease
or I-chronic_disease
viral I-chronic_disease
infection I-chronic_disease
in O
any O
treatment B-treatment
area O
at O
baseline O
( O
eg O
, O
clinically O
infected O
ad O
) O

age B-age
≥ O
@NUMBER B-lower_bound

use O
of O
antibiotics B-treatment
( O
other O
than O
topical O
formulations O
) O
for O
any O
reason O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
screening O

diabetes B-chronic_disease
( O
poorly O
controlled O
or O
on O
insulin B-treatment
) O

significant O
liver B-chronic_disease
problems I-chronic_disease
or O
renal B-chronic_disease
failure I-chronic_disease

blood B-treatment
transfusion I-treatment
within O
three O
( B-upper_bound
@NUMBER I-upper_bound
) I-upper_bound
months I-upper_bound
prior I-upper_bound
to O
screening O
visit O

history O
of O
gastric B-chronic_disease
or I-chronic_disease
duodenal I-chronic_disease
ulcer I-chronic_disease

positive O
test O
for O
drugs O
of O
abuse O
in O
the O
urine O
any O
relevant O
biochemical O
abnormality O
interfering O
with O
the O
assessments O
of O
gelesis200 B-treatment
anti I-treatment
- I-treatment
obesity I-treatment
medications I-treatment
( O
including O
herbal O
preparations O
) O
within O
one B-upper_bound
( I-upper_bound
@NUMBER I-upper_bound
) I-upper_bound
month I-upper_bound
prior I-upper_bound
to O
screening O
visit O

presence O
of O
active B-chronic_disease
neurological I-chronic_disease
disorder I-chronic_disease
( I-chronic_disease
s I-chronic_disease
) I-chronic_disease

severe O
hypertension B-chronic_disease
with O
systolic B-clinical_variable
> O
@NUMBER B-lower_bound
mmhg I-lower_bound
and O
diastolic B-clinical_variable
> O
@NUMBER B-lower_bound
mmhg I-lower_bound
at O
rest O

at O
suicidal B-chronic_disease
risk O
assessed O
by O
scid O
interview O

visual B-chronic_disease
impairment I-chronic_disease
that O
limits O
walking O
ability O

an O
ankle B-clinical_variable
brachial I-clinical_variable
index I-clinical_variable
( I-clinical_variable
abi I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound
at O
the O
baseline O
study O
visit O
is O
an O
inclusion O
criterion O
for O
pad O

subjects O
with O
a O
fazekas B-clinical_variable
scale I-clinical_variable
> O
@NUMBER B-lower_bound

currently O
trying O
to O
become B-pregnancy
pregnant I-pregnancy

major O
fetal B-chronic_disease
anomalies I-chronic_disease

resident O
in O
the O
area O
and O
willing O
to O
attend O
up O
to O
@NUMBER B-lower_bound
clinic O
visits O
for O
a O
36-month O
period O
at O
the O
virology O
research O
clinic O
( O
vrc O
) O

patients O
ages B-age
@NUMBER B-lower_bound
months I-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound
with O
a O
diagnosis O
of O
ad B-chronic_disease
( O
any O
severity O
) O

treatment B-treatment
for O
a O
communicable O
skin B-chronic_disease
disorder I-chronic_disease
currently O
or O
over O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

known O
hypersensitivity O
to O
edotreotide B-allergy_name
or O
everolimus B-allergy_name

somatostatin B-chronic_disease
receptor I-chronic_disease
positive I-chronic_disease
( I-chronic_disease
sstr+ I-chronic_disease
) I-chronic_disease
disease I-chronic_disease

hepatitis B-chronic_disease
c I-chronic_disease
test O
result O

the O
intent O
to O
undergo O
surgery B-treatment
during O
the O
time O
of O
involvement O
in O
the O
study O

participation O
in O
another O
intervention O
study O
that O
influences O
maternal O
and O
fetal O
morbidity O
and O
mortality O
or O
participation O
in O
this O
trial O
in O
a O
previous O
pregnancy B-pregnancy

patients O
who O
have O
received O
or O
will O
be O
receiving O
neoadjuvant B-treatment
systemic I-treatment
therapy I-treatment
, O
endocrine B-treatment
therapy I-treatment
, O
or O
targeted O
agents O

planning O
breast O
conserving O
surgery O
including O
sentinel B-treatment
node I-treatment
biopsy I-treatment

any O
condition O
that O
may O
adversely O
affect O
bone O
marrow O
such O
as O
malignancy B-cancer
or O
prior O
irradiation O
to O
the O
pelvic O
bone O

expected O
survival O
of O
at O
least O
two B-lower_bound
years I-lower_bound

severe O
copd B-chronic_disease

current O
enrollment O
in O
another B-treatment
therapeutic I-treatment
clinical I-treatment
trial I-treatment
or O
receipt O
of O
an O
investigational O
study O
drug O
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
study O
enrollment O

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
the I-upper_bound
upper I-upper_bound
limits I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
except O
for O
patients O
with O
gilbert B-chronic_disease
's I-chronic_disease
disease I-chronic_disease

uncontrolled O
inter B-chronic_disease
- I-chronic_disease
current I-chronic_disease
illness I-chronic_disease
including O
, O
but O
not O
limited O
to O
, O
ongoing O
or O
active B-chronic_disease
infection I-chronic_disease
, O
symptomatic O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
uncontrolled B-chronic_disease
hypertension I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease
pectoris I-chronic_disease
, O
uncontrolled O
cardiac B-chronic_disease
arrhythmia I-chronic_disease
, O
or O
psychiatric B-chronic_disease
illness I-chronic_disease
/ I-chronic_disease
social I-chronic_disease
situations I-chronic_disease
that O
would O
limit O
compliance O
with O
study O
requirements O

have O
a O
venous B-chronic_disease
ulcer I-chronic_disease
( I-chronic_disease
vu I-chronic_disease
) I-chronic_disease
or O
diabetic B-chronic_disease
ulcer I-chronic_disease
( I-chronic_disease
du I-chronic_disease
) I-chronic_disease
that O
has O
been O
documented O
for O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
without O
complete O
re B-treatment
- I-treatment
epithelialization I-treatment
and O
is O
larger O
than O
@NUMBER B-lower_bound
cm2 I-lower_bound
in O
size O

cranial B-clinical_variable
mri I-clinical_variable
changes O
of O
intracranial B-chronic_disease
hypotension I-chronic_disease

lumbar B-treatment
puncture I-treatment

other O
condition O
requiring O
the O
need O
for O
anxiolysis B-treatment

the O
presence O
of O
orthostatic B-chronic_disease
headache I-chronic_disease

no O
plans O
to O
move O
from O
the O
area O
over O
the O
2-year B-lower_bound
period O

history O
of O
exposure O
to O
antiresorptive B-treatment
medications O
such O
as O
bisphosphonates B-treatment
or O
rank B-treatment
- I-treatment
l I-treatment
inhibitors I-treatment

patients O
with O
known O
hemorrhagic B-chronic_disease
and I-chronic_disease
coagulation I-chronic_disease
disorder I-chronic_disease

diagnosis O
of O
cancer B-cancer

on O
scheduled O
cyp3a4 O
substrates O
with O
narrow O
safety O
range O
at O
the O
time O
of O
study O
enrollment O
( O
alfentanil B-treatment
, O
cyclosporine B-treatment
, O
dihydroergotamine B-treatment
ergotamine B-treatment
, O
ergotamine O
, O
pimozide B-treatment
, O
quinidine B-treatment
, O
sirolimus B-treatment
, O
tacrolimus B-treatment
) O

total B-treatment
( I-treatment
t. I-treatment
) I-treatment
bilirubin I-treatment
, O
albumin B-treatment
, O
prothrombin B-treatment
time I-treatment
, O
and O
serum B-treatment
creatinine I-treatment
tests O
can O
be O
done O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
study O
enrollment O
( O
only O
if O
not O
performed O
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
) O

intend B-pregnancy
to I-pregnancy
become I-pregnancy
pregnant I-pregnancy
during O
the O
participation O
of O
the O
study O

oligoasthenoteratospermia B-chronic_disease
or O
azoospermia B-chronic_disease
on O
semen B-treatment
analysis I-treatment

chronic B-chronic_disease
kidney I-chronic_disease
disease I-chronic_disease
stage I-chronic_disease
iii I-chronic_disease
or O
greater O
( O
egfr B-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound
) O

current O
or O
history O
of O
treatment B-treatment
with O
medications O
that O
may O
cause O
significant O
weight O
gain O
, O
within O
@NUMBER B-upper_bound
month I-upper_bound
prior I-upper_bound
to O
screening O
for O
this O
trial O
, O
including O
systemic B-treatment
corticosteroids I-treatment
( O
except O
for O
a O
short O
course O
of O
treatment O
, O
i.e. O
, O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
days I-upper_bound
) O
, O
tri B-treatment
- I-treatment
cyclic I-treatment
antidepressants I-treatment
, O
atypical B-treatment
antipsychotic I-treatment
and O
mood B-treatment
stabilizers I-treatment
( O
e.g. O
, O
imipramine B-treatment
, O
amitryptiline B-treatment
, O
mirtazapine B-treatment
, O
paroxetine B-treatment
, O
phenelzine B-treatment
, O
clorpromazine B-treatment
, O
thioridazine B-treatment
, O
clozapine B-treatment
, O
olanzapine B-treatment
, O
valproic B-treatment
acid I-treatment
and O
its O
derivatives O
, O
and O
lithium B-treatment
) O

current O
participation O
in O
an O
organized O
weight B-treatment
reduction I-treatment
program I-treatment
or O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
month I-upper_bound
prior I-upper_bound
to O
screening O
for O
this O
trial O

known O
or O
suspected O
hypersensitivity O
to O
trial B-allergy_name
product I-allergy_name
( I-allergy_name
s I-allergy_name
) I-allergy_name
or I-allergy_name
related I-allergy_name
product I-allergy_name
( I-allergy_name
s I-allergy_name
) I-allergy_name

currently O
receiving O
intrathecal B-treatment
baclofen I-treatment

seizure B-chronic_disease
beyond O
age B-age
@NUMBER B-lower_bound

pre B-clinical_variable
- I-clinical_variable
screen I-clinical_variable
moca I-clinical_variable
score I-clinical_variable
of O
< O
@NUMBER B-upper_bound
( O
to O
rule O
out O
dementia B-chronic_disease
) O

race O
/ O
ethnicity O
: O
african B-ethnicity
american I-ethnicity
/ O
black B-ethnicity
or O
latino B-ethnicity
/ O
hispanic B-ethnicity

> O
@NUMBER B-lower_bound
× I-lower_bound
uln I-lower_bound
if O
hepatic B-cancer
metastases I-cancer

pathologically O
documented O
, O
definitively O
diagnosed O
non B-cancer
- I-cancer
resectable I-cancer
advanced I-cancer
solid I-cancer
tumor I-cancer

any O
chronic B-chronic_disease
inflammatory I-chronic_disease
disease I-chronic_disease
that O
is O
not O
adequately O
controlled O
or O
that O
requires O
systemic B-treatment
immunosuppressive I-treatment
or O
immunomodulatory B-treatment
therapy I-treatment

mild B-chronic_disease
cognitive I-chronic_disease
impairment I-chronic_disease
due O
to O
ad B-chronic_disease
or O
mild B-chronic_disease
ad I-chronic_disease
dementia I-chronic_disease

counter O
- O
indication O
for O
mri B-allergy_name
or O
pet B-allergy_name

diagnosis O
of O
t2d B-chronic_disease

subjects O
with O
an O
indication O
for O
hbot B-treatment

patients O
with O
disease O
that O
is O
suitable O
for O
local B-treatment
therapy I-treatment
administered O

history O
of O
prior B-treatment
cytotoxic I-treatment
chemotherapy I-treatment
chemotherapy B-treatment
( O
with O
or O
without O
concomitant O
radiation B-treatment
therapy I-treatment
) O
with O
subsequent O
distant O
( O
metastatic B-cancer
) O
disease O
relapse O
, O
or O
progression O
of O
disease O
while O
on O
chemotherapy O

measurable O
disease O
of O
at O
least O
@NUMBER B-lower_bound
cm I-lower_bound
in O
greatest O
dimension O
at O
least O
@NUMBER B-lower_bound
non O
- O
irradiated O
sites O

planning B-pregnancy
to I-pregnancy
become I-pregnancy
pregnant I-pregnancy
in O
the O
next O
year O

participation O
in O
another O
family O
- O
based O
psychosocial O
intervention O
trial O
six B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
study O

plan O
or O
intent O
on O
the O
columbia B-clinical_variable
suicide I-clinical_variable
severity I-clinical_variable
rating I-clinical_variable
scale I-clinical_variable
( I-clinical_variable
c I-clinical_variable
- I-clinical_variable
ssrs I-clinical_variable
) I-clinical_variable
, O
but O
scoring O
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
on O
the O
c B-clinical_variable
- I-clinical_variable
ssrs I-clinical_variable
behavior I-clinical_variable
scale I-clinical_variable
, O
and O
without O
history O
of O
a O
lethal O
suicide B-chronic_disease
attempt I-chronic_disease
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

infection B-chronic_disease
, O
sepsis B-chronic_disease
, O
and O
osteomyelitis B-chronic_disease

patient O
is O
currently O
participating O
in O
any O
other O
surgical B-treatment
intervention I-treatment
studies O
or O
pain O
management O
studies O

rheumatoid B-chronic_disease
arthritis I-chronic_disease
or O
other O
forms O
of O
inflammatory B-chronic_disease
joint I-chronic_disease
disease I-chronic_disease

current O
prescription O
eye O
drop O
usage O
( O
e.g. O
, O
glaucoma B-treatment
drops I-treatment
, O
corticosteroid B-treatment
drops I-treatment
, O
etc O
. O
) O

time O
interval O
of O
@NUMBER O
weeks O
( O
± O
@NUMBER O
week O
) O
between O
visits O
for O
at O
least O
two B-lower_bound
visits O
immediately O
preceding O
study O
enrollment O

no O
objective O
orthostasis B-chronic_disease
( O
significant O
drop O
in O
blood O
pressure O
when O
standing O
) O

poorly O
controlled O
depression B-chronic_disease

stable B-treatment
dopaminergic I-treatment
medication I-treatment
regimen I-treatment
for O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
screening O

suspected O
bowel B-chronic_disease
obstruction I-chronic_disease
( O
partial O
or O
intermittent O
) O
, O
strangulation B-chronic_disease
, O
peritonitis B-chronic_disease
, O
or O
perforation B-chronic_disease

had O
undergone O
a O
hysterectomy B-treatment

radiculopathy B-chronic_disease

symptomatic B-chronic_disease
, I-chronic_disease
nontraumatic I-chronic_disease
rotator I-chronic_disease
cuff I-chronic_disease
tears I-chronic_disease
as O
confirmed O
on O
mri B-treatment

infraspinatus B-chronic_disease

with O
mri B-clinical_variable
-confirmed O
tendinosis O
of O
the O
rotator O
cuff O

pregnant B-pregnancy
, O
breastfeeding O
, O
or O
unwilling B-contraception_consent
to I-contraception_consent
practice I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
during O
participation O
in O
the O
study O

the O
subject O
has O
been O
diagnosed O
with O
another O
autoimmune B-chronic_disease
disorder I-chronic_disease
, O
other O
than O
autoimmune B-chronic_disease
thyroid I-chronic_disease
conditions I-chronic_disease

post B-chronic_disease
- I-chronic_disease
stroke I-chronic_disease
pain I-chronic_disease

stroke B-chronic_disease
of I-chronic_disease
ischemic I-chronic_disease
etiology I-chronic_disease
only O

anabolic B-treatment
or O
steroid B-treatment
hormonal I-treatment
therapy I-treatment
; O
within O
the O
past O
year O
and O
longer O
than O
six B-lower_bound
months I-lower_bound

motor O
incomplete O
sci B-clinical_variable
[ I-clinical_variable
american I-clinical_variable
spinal I-clinical_variable
injury I-clinical_variable
association I-clinical_variable
impairment I-clinical_variable
scale I-clinical_variable
( I-clinical_variable
ais I-clinical_variable
) I-clinical_variable
grades I-clinical_variable
c I-clinical_variable
and I-clinical_variable
d I-clinical_variable
] I-clinical_variable

bleeding B-chronic_disease
disorders I-chronic_disease

subarachnoid B-chronic_disease
hemorrhage I-chronic_disease
from O
ruptured B-chronic_disease
cerebral I-chronic_disease
aneurysm I-chronic_disease

pre O
- O
existing O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease

botulinum B-treatment
toxin I-treatment
injections I-treatment
in O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

current O
pregnancy B-pregnancy

contraindication O
to O
acthar B-allergy_name
per O
prescribing O
information O

working O
age B-age
adult O
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
yrs I-upper_bound
. O
of O
age O

female B-gender
patients I-gender
who O
tested O
positive O
for O
pregnancy B-pregnancy
during O
pre O
- O
sct O
evaluation O

life B-clinical_variable
expectancy I-clinical_variable
of O
greater O
than O
@NUMBER B-lower_bound
months I-lower_bound

liver B-clinical_variable
enzyme I-clinical_variable
s O
> O
@NUMBER B-lower_bound
x I-lower_bound
the I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound

parkinson B-chronic_disease
's I-chronic_disease
disease I-chronic_disease

prior B-treatment
focal I-treatment
corticosteroid I-treatment
treatment I-treatment
is O
allowed O
, O
as O
long O
as O
the O
study O
eye O
is O
not O
involved O
. O
however O
prior O
( O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
day O
@NUMBER O
) O
or O
current O
systemic B-treatment
corticosteroid I-treatment
therapy I-treatment
( O
oral B-treatment
or I-treatment
intravenous I-treatment
corticosteroid I-treatment
treatment I-treatment
) O
is O
not O
permitted O

the O
study O
eye O
is O
treatment O
naive O
regarding O
treatment B-treatment
of I-treatment
neovascular I-treatment
amd I-treatment

metabolic B-chronic_disease
disorders I-chronic_disease
involving O
impaired O
nitrogen O
utilization O

severe O
chronic B-chronic_disease
liver I-chronic_disease
disease I-chronic_disease
( O
meld B-clinical_variable
score I-clinical_variable
≥ O
@NUMBER B-lower_bound
) O
or O
acute B-chronic_disease
fulminant I-chronic_disease
hepatitis I-chronic_disease

patients O
bridged O
to O
transplant O
with O
ecmo B-treatment

hyperactive O
or O
mixed O
delirium O
with O
rass B-clinical_variable
≥ O
@NUMBER B-lower_bound
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
h O
( O
rass O
≥ O
@NUMBER O
indicates O
any O
degree O
of O
restlessness O

have O
a O
community O
diagnosis O
of O
autism B-chronic_disease
spectrum I-chronic_disease
disorder I-chronic_disease
( O
as O
reported O
by O
parent O
) O

body B-bmi
mass I-bmi
index I-bmi
( I-bmi
bmi I-bmi
) I-bmi
: O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
kg I-upper_bound
/ I-upper_bound
m2 I-upper_bound
@NUMBER B-lower_bound
kg O
/ O
m2 O
for O
the O
obese O
subjects O
< O
@NUMBER B-upper_bound
kg I-upper_bound
/ I-upper_bound
m2 I-upper_bound
for O
the O
non O
- O
obese O
subjects O
weight O
stable O
during O
prior B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
non O
- O
smokers O
ob O
with O
impaired B-chronic_disease
fasting I-chronic_disease
glucose I-chronic_disease
: O
elevated O
elevated O
morning O
fasting B-clinical_variable
glucose I-clinical_variable
levels I-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
for O
@NUMBER O
of O
@NUMBER B-upper_bound
days I-upper_bound
non O
- O
obese O
and O
ob O
subjects O
: O
fasting O
glucose O
levels O
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
- O
@NUMBER O
hr O
ogtt B-clinical_variable
glucose I-clinical_variable
value I-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

bilateral B-treatment
oophorectomy I-treatment

history O
of O
glaucoma B-chronic_disease

tubal B-treatment
ligation I-treatment
or O
are O
less O
than O
two B-upper_bound
years I-upper_bound
postmenopausal O

who O
have O
not O
had O
a O
hysterectomy B-treatment

basal B-chronic_disease
joint I-chronic_disease
arthritis I-chronic_disease
of I-chronic_disease
eaton I-chronic_disease
stage I-chronic_disease
@NUMBER I-chronic_disease

patients O
on O
coumadin B-treatment
/ O
steroids B-treatment
/ O
nsaids B-treatment
/ O
tylenol B-treatment

radiographic B-treatment
evidence I-treatment
of I-treatment
eaton I-treatment
stage I-treatment
@NUMBER I-treatment
and I-treatment
@NUMBER I-treatment
only O

diffusion B-clinical_variable
capacity I-clinical_variable
of I-clinical_variable
the I-clinical_variable
lung I-clinical_variable
for I-clinical_variable
carbon I-clinical_variable
monoxide I-clinical_variable
( I-clinical_variable
dlco I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound

postmenopausal O
women B-gender

expected B-clinical_variable
duration I-clinical_variable
of I-clinical_variable
neutropenia I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
days I-lower_bound

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
old O

diagnostic B-clinical_variable
and I-clinical_variable
statistical I-clinical_variable
manual-5 I-clinical_variable
( I-clinical_variable
dsm-5 I-clinical_variable
) I-clinical_variable
substance O
use O
disorder O

be O
able O
to O
imitate O
at O
least O
@NUMBER B-lower_bound
speech O
sounds O
on O
command O

have O
a O
nonverbal O
mental O
age B-age
over O
@NUMBER B-lower_bound
months I-lower_bound

able O
to O
understand O
the O
ask B-clinical_variable
nasal-12 I-clinical_variable
and O
snot-22 B-clinical_variable
scales O

hepatitis B-chronic_disease

patients O
receiving O
therapeutic O
dose O
of O
gabapentin B-treatment
( O
rather O
than O
continuation O
of O
home O
dose O
) O
prior O
to O
enrollment O

severe B-chronic_disease
renal I-chronic_disease
impairment I-chronic_disease
( O
estimated O
crcl B-clinical_variable
< O
@NUMBER B-upper_bound
) O

adult O
women B-gender

over O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

low B-clinical_variable
platelet I-clinical_variable
count I-clinical_variable
( O
recorded O
measurement O
< O
@NUMBER B-upper_bound
during O
hospital B-treatment
admission I-treatment
) O

adults O
unable O
to O
consent O
, O
infants O
, O
children O
, O
teenagers O
, O
pregnant B-pregnancy
patients O
and O
prisoners O
will O
be O
excluded O

patients O
who O
do O
not O
complete O
the O
duration O
of O
treatment O
of O
negative B-treatment
pressure I-treatment
wound I-treatment
therapy I-treatment
( O
@NUMBER O
days O
) O
, O
or O
patients O
who O
do O
not O
follow O
up O
for O
a O
minimum O
of O
@NUMBER B-lower_bound
days I-lower_bound
from O
the O
date O
of O
surgery B-treatment
will O
be O
excluded O

biochemically B-cancer
recurrent I-cancer
prostate I-cancer
cancer I-cancer
with O
psa B-clinical_variable
doubling I-clinical_variable
time I-clinical_variable
≤ O
@NUMBER B-upper_bound
months I-upper_bound
at O
the O
time O
of O
study O
entry O

with O
a O
minimum O
of O
@NUMBER B-lower_bound
values O
separated O
by O
at O
least O
@NUMBER B-upper_bound
weeks I-upper_bound
apart O

chronic B-chronic_disease
renal I-chronic_disease
disease I-chronic_disease

lymph B-clinical_variable
nodes I-clinical_variable
must O
be O
≥ O
@NUMBER B-lower_bound
mm I-lower_bound
per O
short O
axis O

patient O
must O
consent O
to O
allow O
for O
a O
baseline O
tumor B-cancer
biopsy B-treatment

resting B-clinical_variable
heart I-clinical_variable
rate I-clinical_variable
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
bpm I-upper_bound

have O
a O
known O
hypersensitivity O
to O
any O
of O
the O
ingredients O
or O
excipients O
of O
the O
investigational B-allergy_name
medicinal I-allergy_name
product I-allergy_name
( I-allergy_name
imp I-allergy_name
) I-allergy_name

cutaneous B-cancer
basocellular I-cancer
carcinoma I-cancer

willing B-contraception_consent
to I-contraception_consent
use I-contraception_consent
an I-contraception_consent
acceptable I-contraception_consent
method I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
( O
i.e. O
, O
a O
hormonal B-contraception_consent
contraceptive I-contraception_consent
, O
intra B-contraception_consent
- I-contraception_consent
uterine I-contraception_consent
device I-contraception_consent
, O
diaphragm B-contraception_consent
with I-contraception_consent
spermicide I-contraception_consent
, O
condom B-contraception_consent
with I-contraception_consent
spermicide I-contraception_consent
, O
or O
abstinence B-contraception_consent
) O
for O
the O
duration O
of O
the O
study O
and O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
after O
the O
last O
dose O
of O
brentuximab B-treatment
vedotin I-treatment

subject O
having O
undergone O
surgical B-treatment
revascularization I-treatment
or O
major B-treatment
amputation I-treatment
less O
than O
@NUMBER B-upper_bound
month I-upper_bound
prior I-upper_bound
to O
screening O

subjects O
with O
international B-clinical_variable
normalized I-clinical_variable
ratio I-clinical_variable
( I-clinical_variable
inr I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound

has O
not O
yet O
completed O
a O
period O
of O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
since O
ending O
another O
investigational O
device O
or O
drug O
trial O
( O
s O
) O

age B-age
range O
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound

active O
treatment O
for O
vte B-treatment

pregnant B-pregnancy
or O
breastfeeding O
women B-gender

prior B-treatment
treatment I-treatment
with I-treatment
anti I-treatment
- I-treatment
ctla-4 I-treatment
, O
anti B-treatment
- I-treatment
pd-1 I-treatment
, O
anti B-treatment
- I-treatment
pd I-treatment
- I-treatment
l1 I-treatment
, O
or O
anti B-treatment
pd I-treatment
- I-treatment
l2 I-treatment
, O
or O
with O
ido B-treatment
inhibitor I-treatment

hba1c B-clinical_variable
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
% I-upper_bound

score O
< O
@NUMBER B-upper_bound
on O
the O
mini B-clinical_variable
- I-clinical_variable
mental I-clinical_variable
state I-clinical_variable
exam I-clinical_variable

uncontrolled O
stage B-chronic_disease
ii I-chronic_disease
hypertension I-chronic_disease
( O
blood B-clinical_variable
pressure I-clinical_variable
above O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
mm I-lower_bound
hg I-lower_bound
) O

patients O
must O
have O
a O
platelet B-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
μl I-lower_bound

be O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
or O
older O
at O
some O
point O
during O
study O
participation O

required O
m O
edical B-treatment
or I-treatment
surgical I-treatment
intervention I-treatment
to O
restore O
hemostasis B-treatment

general B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
evaluated I-clinical_variable
by I-clinical_variable
ecog I-clinical_variable
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
scale O

active B-chronic_disease
hepatitis I-chronic_disease
b I-chronic_disease
or I-chronic_disease
c I-chronic_disease
hepatitis B-chronic_disease
b I-chronic_disease
or I-chronic_disease
c I-chronic_disease
, O
and O
hbsag B-chronic_disease
or O
hcv B-chronic_disease
rna O
viral O
load O
positivity O
, O
respectively O
or O
currently O
on O
antiviral B-treatment
therapy I-treatment
for O
hepatitis O
b O
or O
c O

being O
male B-gender

subjects O
who O
have O
previously B-treatment
failed I-treatment
treatment I-treatment
with I-treatment
more I-treatment
than I-treatment
two I-treatment
biologic I-treatment
dmards I-treatment

active B-chronic_disease
sjia I-chronic_disease
disease I-chronic_disease
according O
to O
ilar O
criteria O
for O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
before O
screening O

confirmed O
positive O
test O
results O
for O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease

participant O
has O
unresolved O
adverse O
events O
greater O
than O
grade B-lower_bound
@NUMBER I-lower_bound
from O
prior B-treatment
anticancer I-treatment
therapy I-treatment
except O
for O
alopecia B-chronic_disease

participants O
with O
a O
history O
of O
or O
ongoing O
interstitial B-chronic_disease
lung I-chronic_disease
disease I-chronic_disease

between O
@NUMBER B-lower_bound
and O
@NUMBER B-upper_bound
years I-upper_bound
old O

live O
within O
@NUMBER B-upper_bound
minutes I-upper_bound
driving O
time O
( O
@NUMBER O
hour O
) O
from O
the O
research O
center O

age B-age
≥ O
@NUMBER B-lower_bound
at O
signing O
of O
consent O

long O
term O
adt B-treatment
is O
defined O
as O
> O
@NUMBER B-lower_bound
months I-lower_bound
and O
≤ O
@NUMBER B-upper_bound
months I-upper_bound

participant O
must O
also O
have O
an O
act B-clinical_variable
score I-clinical_variable
of O
@NUMBER B-upper_bound
or O
less O
, O
or O
a O
history O
of O
one B-lower_bound
or O
more O
exacerbations O
in O
the O
past O
year O
that O
required O
patient O
report O
of O
systemic B-treatment
corticosteroid I-treatment
use O

claustrophobia B-chronic_disease
, O
inner B-treatment
ear I-treatment
implants I-treatment
, O
aneurysm B-chronic_disease
or O
other O
surgical O
clips O
, O
metal O
foreign O
bodies O
in O
eye O
, O
pacemaker B-treatment
or O
other O
contraindication O
to O
mr B-treatment
scanning I-treatment

history O
of O
mi B-chronic_disease
, O
stroke B-chronic_disease
and O
/ O
or O
poorly O
controlled O
hypertension B-chronic_disease

patients O
ages B-age
@NUMBER B-lower_bound
years I-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound

patients O
who O
are O
pregnant B-pregnancy

children O
do O
not O
develop O
these O
malignancies B-cancer
and O
therefore O
are O
not O
considered O
candidates O
for O
this O
trial O

a O
history O
of O
serious O
medical O
or O
neurologic B-chronic_disease
neurological B-chronic_disease
illness I-chronic_disease
, O
such O
as O
cardiovascular B-chronic_disease
, O
gastrointestinal B-chronic_disease
, O
hepatic B-chronic_disease
, O
renal B-chronic_disease
, O
neurologic O
or O
other O
systemic B-chronic_disease
illness I-chronic_disease

copd B-chronic_disease
requiring O
home O
oxygen O

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound

patients O
with O
cognitive B-chronic_disease
impairment I-chronic_disease
precluding O
informed O
consent O

botox B-treatment
injection I-treatment
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
starting O
the O
study O

liver B-treatment
transplant I-treatment
, O
including O
hepatocyte B-treatment
cell I-treatment
therapy I-treatment
/ I-treatment
transplant I-treatment

meets O
dsm-5 O
criteria O
for O
current O
alcohol B-chronic_disease
use I-chronic_disease
disorder I-chronic_disease
with O
the O
presence O
of O
@NUMBER B-lower_bound
or O
more O
symptoms O
( O
i.e. O
, O
current O
severity O
of O
severe O
) O

self O
- O
report O
of O
a O
history O
of O
alcohol B-treatment
withdrawal I-treatment
treatment I-treatment

smokes O
≥ O
@NUMBER B-lower_bound
cigarettes I-lower_bound
/ I-lower_bound
day I-lower_bound
for O
≥ O
@NUMBER B-lower_bound
years I-lower_bound

presenting O
for O
pain O
related O
to O
acute B-treatment
cancer I-treatment
therapy I-treatment

pulmonary B-chronic_disease
disease I-chronic_disease
requiring O
home B-treatment
oxygen I-treatment
therapy I-treatment

undergoing O
lumbar B-treatment
fusion I-treatment
surgery I-treatment

a O
change O
in O
anti B-treatment
- I-treatment
vegf I-treatment
agent I-treatment
in O
the O
previous O
two O
administrations O

active B-chronic_disease
ocular I-chronic_disease
or I-chronic_disease
periocular I-chronic_disease
infection I-chronic_disease
or O
intraocular B-chronic_disease
inflammation I-chronic_disease

unstable B-chronic_disease
angina I-chronic_disease

gestational B-clinical_variable
age I-clinical_variable
at O
feto O
procedure O
@NUMBER B-lower_bound
weeks I-lower_bound
@NUMBER I-lower_bound
days I-lower_bound
to O
@NUMBER B-upper_bound
weeks I-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

maternal B-chronic_disease
hiv I-chronic_disease
, O
hepatits B-chronic_disease
b I-chronic_disease
, O
hepatitis B-chronic_disease
c I-chronic_disease

maternal O
contraindications O
to O
fetoscopic B-allergy_name
surgery I-allergy_name
or O
severe B-chronic_disease
maternal I-chronic_disease
condition I-chronic_disease
in O
pregnancy B-pregnancy

patients O
who O
have O
disease O
relapse O
, O
active O
gvhd B-chronic_disease
or O
history O
of O
more O
than O
stage B-lower_bound
@NUMBER I-lower_bound
skin B-chronic_disease
acute I-chronic_disease
gvhd I-chronic_disease
, O
history O
of O
cgvhd B-chronic_disease

recovery O
to O
the O
baseline O
count O
( O
in O
the O
absence O
of O
transfusion O
) O
hgb B-clinical_variable
> O
9.0 B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

> O
@NUMBER B-lower_bound
years I-lower_bound
old O

fluent B-language_fluency
in I-language_fluency
english I-language_fluency
or O
spanish B-language_fluency

history O
of O
allergies O
to O
the O
nicotine B-allergy_name
patches I-allergy_name

prior B-treatment
injection I-treatment
treatment I-treatment
treatment B-treatment
for O
plantar O
fasciitis O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
with O
steroids O
or O
tissue O
engineered O
materials O
just O
in O
the O
site O
seeking O
treatment O

prior B-treatment
surgery I-treatment
on O
the O
affected O
foot O

pregnant B-pregnancy
within O
the O
past B-upper_bound
six I-upper_bound
( I-upper_bound
@NUMBER I-upper_bound
) I-upper_bound
months I-upper_bound

creatinine B-clinical_variable
greater O
than O
1.4 B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound

drug O
or O
alcohol O
abuse O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
( O
excluding O
tobacco O
) O

use O
of O
serotonergic B-treatment
antiemetics I-treatment
( O
i.e O
. O
ondansetron B-treatment
) O
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound

pulmonary B-chronic_disease
venous I-chronic_disease
hypertension I-chronic_disease

only O
subjects O
whose O
body B-clinical_variable
weight I-clinical_variable
has O
been O
stable O
( O
± O
@NUMBER B-lower_bound
lbs I-lower_bound
) O
over O
the O
preceding B-upper_bound
three I-upper_bound
months I-upper_bound

complete O
active B-treatment
treatment I-treatment
( O
surgery B-treatment
, O
chemotherapy B-treatment
, O
and O
/ O
or O
radiotherapy B-treatment
) O
at O
least O
one B-lower_bound
month I-lower_bound
prior I-lower_bound
to O
study O
initiation O
( O
patients O
on O
continued O
hormone B-treatment
treatment I-treatment
will O
not O
be O
excluded O
) O

age B-age
< O
@NUMBER B-upper_bound
years I-upper_bound

forced B-clinical_variable
expiratory I-clinical_variable
volume I-clinical_variable
@NUMBER I-clinical_variable
( I-clinical_variable
fev1 I-clinical_variable
) I-clinical_variable
fev1 B-clinical_variable
) O
/ O
forced B-clinical_variable
vital I-clinical_variable
capacity I-clinical_variable
( I-clinical_variable
fvc I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound
and O
fev1 O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
% I-upper_bound
normal O
) O
undergoing O
whipple O
procedures O
or O
other O
major B-treatment
surgeries I-treatment

patients O
must O
be O
ambulatory O
with O
good O
performance O
status O
( O
ecog B-clinical_variable
@NUMBER B-lower_bound
or O
@NUMBER B-upper_bound
) O

patients O
who O
have O
received O
prior B-treatment
immunotherapy I-treatment
for O
unresectable O
or O
metastatic B-cancer
disease I-cancer

has O
a O
diagnosis O
of O
immunodeficiency B-chronic_disease
or O
is O
receiving O
systemic B-treatment
steroid I-treatment
therapy I-treatment
or O
any O
other O
form O
of O
immunosuppressive B-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
trial O
treatment O

has O
an O
active B-chronic_disease
infection I-chronic_disease
requiring O
systemic B-treatment
therapy I-treatment

individual O
who O
has O
received O
any O
administration O
of O
ketamine B-treatment
in O
the O
current O
episode O
for O
the O
treatment O
of O
depression B-chronic_disease

wbc B-clinical_variable
< O
@NUMBER B-upper_bound
k I-upper_bound
/ I-upper_bound
cumm I-upper_bound

cardiac B-chronic_disease
arrest I-chronic_disease
occurring O
while O
admitted O
to O
the O
hospital O
, O
with O
sustained O
( O
> O
@NUMBER B-lower_bound
minutes I-lower_bound
) O
return B-clinical_variable
of I-clinical_variable
spontaneous I-clinical_variable
circulation I-clinical_variable
( I-clinical_variable
rosc I-clinical_variable
) I-clinical_variable

all O
participants O
who O
have O
a O
fda O
contraindication O
or O
cautions O
for O
nicotine B-allergy_name
lozenge I-allergy_name
use O
( O
pregnancy B-pregnancy
, O
breastfeeding O
, O
recent O
cardiovascular B-chronic_disease
distress I-chronic_disease
, O
or O
phenylketonuria B-chronic_disease
) O

individuals O
@NUMBER B-lower_bound
years I-lower_bound
and O
older O

age B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

history O
of O
hypersensitivity O
or O
adverse O
reaction O
to O
bupivacaine B-allergy_name
or O
narcotics B-allergy_name

agrees O
to O
wear O
a O
head O
mounted O
display O
( O
hmd O
) O
for O
up O
to O
@NUMBER B-upper_bound
minutes I-upper_bound

patients O
with O
uncompensated B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease

history O
of O
chronic B-chronic_disease
pain I-chronic_disease

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age
with O
no O
diseases O
or O
conditions O
that O
would O
affect O
their O
participation O
in O
the O
study O

chronic B-chronic_disease
obstructive I-chronic_disease
pulmonary I-chronic_disease
disease I-chronic_disease
subjects O
: O
patients O
diagnosed O
with O
mild B-chronic_disease
to I-chronic_disease
moderate I-chronic_disease
copd I-chronic_disease

coronary B-treatment
angiography I-treatment
subjects O
: O
patients O
undergoing O
routine O
coronary B-treatment
angiography I-treatment

permanently O
requires O
assistance O
in O
≥ O
@NUMBER B-lower_bound
activities O
of O
daily O
living O

speaks B-language_fluency
english I-language_fluency
or I-language_fluency
spanish I-language_fluency

no O
intake O
of O
opiate B-treatment
medication I-treatment
for O
the O
past B-upper_bound
six I-upper_bound
months I-upper_bound

bupropion B-treatment

chantix B-treatment

other O
tobacco O
use O
besides O
cigarettes O
or O
little O
cigars O
( O
e.g. O
, O
hookah O
, O
cigarillos O
, O
smokeless O
tobacco O
, O
chewing O
tobacco O
, O
pipes O
, O
cigars O
, O
etc O
. O
) O
on O
@NUMBER B-lower_bound
or O
more O
days O
in O
the O
last O
month O

self O
report O
of O
past O
or O
current O
diagnosis O
of O
bi B-chronic_disease
- I-chronic_disease
polar I-chronic_disease
disorder I-chronic_disease

nitroglycerin B-treatment

subjects O
with O
asymptomatic B-cancer
brain I-cancer
metastases I-cancer
or O
spinal B-chronic_disease
cord I-chronic_disease
compression I-chronic_disease
who O
have O
been O
treated O
, O
are O
considered O
stable O
, O
and O
who O
have O
not O
received O
corticosteroids B-treatment
or O
anticonvulsants B-treatment
for O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
prior I-lower_bound
to O
screening O
may O
be O
included O

known O
osa B-chronic_disease
sa B-chronic_disease
will O
be O
defined O
as O
a O
sleep B-chronic_disease
hypopnea I-chronic_disease
study O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
that O
is O
consistent O
with O
osa O

patients O
with O
known O
or O
suspected O
obstructive B-chronic_disease
sleep I-chronic_disease
apnea I-chronic_disease
( I-chronic_disease
osa I-chronic_disease
) I-chronic_disease

suspected O
osa B-chronic_disease
will O
be O
defined O
as O
a O
patient O
with O
a O
screening O
questionnaire O
( B-clinical_variable
stop I-clinical_variable
- I-clinical_variable
bang I-clinical_variable
) I-clinical_variable
score I-clinical_variable
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
( O
a O
score O
consistent O
with O
a O
high O
risk O
of O
osa O
) O

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
( I-clinical_variable
anc I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
x I-lower_bound
10 I-lower_bound
^ I-lower_bound
9 I-lower_bound
/ I-lower_bound
l I-lower_bound

hemoglobin B-clinical_variable
more O
or O
equal O
than O
@NUMBER B-lower_bound
grams I-lower_bound
/ I-lower_bound
dl I-lower_bound
below O
the O
institutional O
level O
of O
normal O

hypercalcemia B-chronic_disease
: O
serum B-clinical_variable
calcium I-clinical_variable
> O
@NUMBER B-lower_bound
mmol I-lower_bound
/ I-lower_bound
l I-lower_bound
( O
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
) O
higher O
than O
the O
upper O
limit O
of O
normal O
or O
> O
@NUMBER B-lower_bound
mmol I-lower_bound
/ I-lower_bound
l I-lower_bound
( O
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
) O

intolerance O
to O
infused O
protein B-allergy_name
products I-allergy_name
, O
sucrose B-allergy_name
, O
histidine B-allergy_name
or O
polysorbate B-allergy_name
@NUMBER I-allergy_name

ages B-age
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound

subjects O
presenting O
chronic B-chronic_disease
degenerative I-chronic_disease
and O
/ O
or O
inflammatory B-chronic_disease
diseases I-chronic_disease

subjects O
with O
( O
a O
history O
of O
) O
metabolic B-chronic_disease
or I-chronic_disease
gastrointestinal I-chronic_disease
diseases I-chronic_disease
including O
hepatic B-chronic_disease
disorders I-chronic_disease

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
old O

diabetes B-chronic_disease
mellitus I-chronic_disease
diagnosis O

females B-gender
of O
child O
- O
bearing O
potential O
must O
use B-contraception_consent
a I-contraception_consent
highly I-contraception_consent
effective I-contraception_consent
method I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
throughout O
the O
entire O
study O
period O
and O
for O
@NUMBER B-upper_bound
days I-upper_bound
after O
study O
drug O
discontinuation O

patients O
with O
other O
serious O
medical O
conditions O
that O
may O
affect O
their O
ability O
to O
self O
- O
monitor O
blood O
pressure O
( O
such O
a O
dementia B-chronic_disease
) O

current O
or O
previously O
treated O
brain B-cancer
or I-cancer
leptomeningeal I-cancer
metastases I-cancer

other O
injectable O
for O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

hiv B-chronic_disease

known O
aortic B-chronic_disease
aneurysm I-chronic_disease

known O
obstructive B-chronic_disease
sleep I-chronic_disease
apnea I-chronic_disease
/ O
high O
likelihood O
of O
obstructive O
sleep O
apnea O

subjects O
with O
mucosal B-chronic_disease
diseases I-chronic_disease
( O
e.g. O
, O
erosive B-chronic_disease
lichen I-chronic_disease
planus I-chronic_disease
) O
in O
the O
localized O
area O
around O
the O
study O
implant O
site O

have O
a O
histologically O
or O
cytologically O
confirmed O
adenocarcinoma B-cancer
or O
poorly O
differentiated O
carcinoma B-cancer
of I-cancer
the I-cancer
prostate I-cancer

molecular O
evidence O
of O
other O
homologous B-chronic_disease
recombination I-chronic_disease
deficiency I-chronic_disease

age B-age
≥ O
@NUMBER B-lower_bound

history O
of O
brain B-cancer
metastases I-cancer

psychiatric B-chronic_disease
illness I-chronic_disease
/ I-chronic_disease
social I-chronic_disease
situations I-chronic_disease
that O
could O
limit O
compliance O
with O
study O
requirements O

participants O
with O
a O
known O
or O
suspected O
allergy O
to O
iodine B-allergy_name

pulmonary B-chronic_disease
infiltrates I-chronic_disease
, O
non O
- O
fixed O

wegener B-chronic_disease
's I-chronic_disease
granulomatosis I-chronic_disease

prior O
treatment O
for O
follicular B-cancer
lymphoma I-cancer

resistance O
to O
anti B-treatment
- I-treatment
pd-1 I-treatment
/ I-treatment
pd I-treatment
- I-treatment
l1 I-treatment
therapy I-treatment
is O
defined O
as O
: O
documented O
progressive O
disease O
occurring O
while O
on O
/ O
or O
within O
@NUMBER B-upper_bound
months I-upper_bound
after O
anti B-treatment
- I-treatment
pd-1 I-treatment
and I-treatment
/ I-treatment
or I-treatment
anti I-treatment
- I-treatment
pd I-treatment
- I-treatment
l1 I-treatment
agent I-treatment
( O
single O
or O
combination O
) O
received O
as O
the O
last B-treatment
therapy I-treatment
prior O
to O
enrollment O

primary B-chronic_disease
aldosteronism I-chronic_disease

having O
completed O
primary B-treatment
treatment I-treatment
( O
surgery B-treatment
, O
chemotherapy B-treatment
, O
or O
radiotherapy B-treatment
) O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

unable B-language_fluency
to I-language_fluency
read I-language_fluency
or I-language_fluency
speak I-language_fluency
chinese I-language_fluency
( I-language_fluency
mandarin I-language_fluency
or I-language_fluency
cantonese I-language_fluency
) I-language_fluency

patients O
positive O
for O
hepatitis B-chronic_disease

biologic B-treatment
( I-treatment
anti I-treatment
- I-treatment
neoplastic I-treatment
agent I-treatment
) I-treatment
: O
@NUMBER O
day O
must O
have O
elapsed O
from O
the O
start O
of O
protocol B-treatment
therapy I-treatment
since O
the O
completion O
of O
therapy B-treatment
with I-treatment
a I-treatment
biologic I-treatment
agent I-treatment

hiv B-chronic_disease
positive O
women B-gender

ambulates B-clinical_variable
at O
< O
@NUMBER B-upper_bound
meters I-upper_bound
/ I-upper_bound
second I-upper_bound
with O
or O
without O
physical O
assistance O
and O
assistance O
device O

born O
at O
our O
institution O
or O
transferred O
from O
another O
institution O
within O
the O
first B-upper_bound
@NUMBER I-upper_bound
hours I-upper_bound
of O
life O
and O
receive O
an O
exclusive O
human O
milk O
protein O
diet O
( O
mother O
's O
milk O
supplemented O
with O
donor O
human O
milk O
and O
donor O
human O
milk O
derived O
fortifier O
) O

major B-chronic_disease
depression I-chronic_disease
with I-chronic_disease
psychotic I-chronic_disease
features I-chronic_disease
( O
@NUMBER O
, O
@NUMBER O
) O

age B-age
< O
@NUMBER B-upper_bound
years I-upper_bound

maternal B-chronic_disease
chorioamnionitis I-chronic_disease

planned B-pregnancy
pregnancy I-pregnancy
continuation O
with O
no O
indication O
for O
delivery O
for O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound

human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease

plasma B-clinical_variable
cell I-clinical_variable
leukemia I-clinical_variable
( O
> O
@NUMBER B-lower_bound
x109 I-lower_bound
/ I-lower_bound
l I-lower_bound
circulating O
plasma O
cells O
by O
standard O
differential O
) O

not B-language_fluency
fluent I-language_fluency
in I-language_fluency
english I-language_fluency

coagulopathy B-treatment
with O
platelets B-clinical_variable
( I-clinical_variable
plt I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound
k I-upper_bound

inability O
to O
perform O
informed O
consent O
due O
to O
any O
medical B-chronic_disease
or I-chronic_disease
psychiatric I-chronic_disease
condition I-chronic_disease

gastric B-treatment
bypass I-treatment

total O
bilirubin B-clinical_variable
< O
@NUMBER B-upper_bound
times I-upper_bound
uln I-upper_bound
for O
age B-age

binge B-chronic_disease
eating I-chronic_disease
disorder I-chronic_disease

pah B-chronic_disease
associated I-chronic_disease
with I-chronic_disease
connective I-chronic_disease
tissue I-chronic_disease
diseases I-chronic_disease
( I-chronic_disease
pah I-chronic_disease
- I-chronic_disease
actd I-chronic_disease
) I-chronic_disease

with O
pulmonary B-chronic_disease
veno I-chronic_disease
- I-chronic_disease
occlusive I-chronic_disease
disease I-chronic_disease

central B-cancer
nervous I-cancer
system I-cancer
tumors I-cancer
will O
be O
evaluated O
by O
rano O
criteria O

serum B-clinical_variable
creatinine I-clinical_variable
> O
@NUMBER B-lower_bound
x I-lower_bound
uln I-lower_bound
for O
age B-age

total B-clinical_variable
bilirubin I-clinical_variable
> O
@NUMBER B-lower_bound
x I-lower_bound
the I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound
( I-lower_bound
uln I-lower_bound
) I-lower_bound
for O
age B-age

≥ O
@NUMBER B-lower_bound

ongoing O
risk O
for O
bleeding O
due O
to O
active B-chronic_disease
peptic I-chronic_disease
ulcer I-chronic_disease
disease I-chronic_disease

dalteparin B-treatment

disabling B-chronic_disease
stroke I-chronic_disease
defined O
as O
a O
baseline O
national B-clinical_variable
institutes I-clinical_variable
of I-clinical_variable
health I-clinical_variable
stroke I-clinical_variable
score I-clinical_variable
( I-clinical_variable
nihss I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
at O
the O
time O
of O
randomization O

subjects O
with O
serum B-clinical_variable
creatinine I-clinical_variable
level I-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
as O
measured O
at O
the O
baseline O
study O
visit O

hiv B-chronic_disease
sexual O
risk O
( O
≥ O
@NUMBER B-lower_bound
act O
of O
condomless O
anal O
with O
a O
male B-gender
partner I-gender
of O
unknown O
status O
or O
hiv+ O
status O
, O
unless O
with O
hiv+ O
partner O
with O
known O
undetectable O
viral O
load O
) O

congenital B-chronic_disease
amegakaryocytic I-chronic_disease
thrombocytopenia I-chronic_disease

current O
unstable O
psychiatric B-chronic_disease
illness I-chronic_disease
as O
assessed O
by O
clinical O
diagnostic O
interview O

one O
prior B-treatment
anti I-treatment
- I-treatment
cancer I-treatment
therap I-treatment
y O
that O
did O
not O
work O

nsclc B-cancer
that O
is O
clinically O
t4 O
by O
virtue O
of O
mediastinal O
organ O
invasion O
or O
stage O
iiib O
by O
virtue O
of O
n3 B-chronic_disease
disease I-chronic_disease

prior B-treatment
treatment I-treatment
with O
anti B-treatment
- I-treatment
pd-1 I-treatment
or O
pd B-treatment
- I-treatment
l1 I-treatment
therapies I-treatment

risk O
of O
poor O
cosmetic O
outcome O
after O
initial O
lumpectomy B-treatment
and O
possible O
additional O
excision O

have O
contraindications O
for O
acupuncture B-allergy_name
or O
mri B-allergy_name

swan B-treatment
- I-treatment
ganz I-treatment
catheter I-treatment

patients O
with O
renal B-chronic_disease
disease I-chronic_disease

platelet B-clinical_variable
count I-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
10 I-upper_bound
^ I-upper_bound
9 I-upper_bound
/ I-upper_bound
l I-upper_bound

history O
of O
schizophrenia B-chronic_disease
, O
delusions B-chronic_disease

medically O
cleared O
for O
surgery B-treatment
and O
anesthesia B-treatment

parkinson B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
per O
uk O
parkinson B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
society O
brain O
bank O
( O
queens O
square O
) O
criteria O

history O
of O
positivity O
for O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease

no O
known O
history O
of O
dihydropyrimidine B-chronic_disease
dehydrogenase I-chronic_disease
deficiency I-chronic_disease

the O
presence O
of O
metastatic B-cancer
pancreatic I-cancer
adenocarcinoma I-cancer

patients O
with O
an O
acute O
medical O
condition O
( O
e.g O
. O
pneumonia B-chronic_disease
, O
sepsis B-chronic_disease
) O
that O
is O
expected O
to O
hinder O
them O
from O
completing O
this O
study O

targeted O
tumor B-cancer
in O
the O
skull O
/ O
spine O

participants O
with O
history O
of O
tbi B-chronic_disease
with O
loss O
of O
consciousness O
for O
more O
than O
@NUMBER B-lower_bound
hours I-lower_bound
or O
post B-chronic_disease
- I-chronic_disease
traumatic I-chronic_disease
amnesia I-chronic_disease
for O
more O
than O
@NUMBER B-lower_bound
days I-lower_bound

recent O
arrest O
or O
release O
from O
jail O
/ O
prison O
/ O
detention O
( O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
( I-clinical_variable
anc I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
mm3 I-lower_bound

other O
reasons O
for O
being O
unable O
or O
unwilling O
to O
participate O
in O
study O
procedures O
( O
e.g. O
, O
contraindications O
to O
mri B-allergy_name
) O

diagnosis O
of O
any O
underlying B-chronic_disease
neurologic I-chronic_disease
disorder I-chronic_disease
that O
would O
potentially O
confound O
interpretation O
of O
the O
study O
results O

renal B-treatment
replacement I-treatment
therapy I-treatment

present O
and O
expected O
to O
visit O
regularly O
( O
minimum O
about O
@NUMBER B-lower_bound
times I-lower_bound
a I-lower_bound
week I-lower_bound
) O
while O
the O
patient O
is O
in O
hospital O

male B-gender
patient I-gender

allergies O
to O
antibiotics B-allergy_name
or O
xylocaine B-allergy_name

autoimmune B-chronic_disease
disease I-chronic_disease

liver B-chronic_disease
, O
kidney B-chronic_disease
, O
or O
urinary B-chronic_disease
disease I-chronic_disease

non B-treatment
- I-treatment
steroidal I-treatment
anti I-treatment
- I-treatment
inflammatories I-treatment

osmolality B-clinical_variable
levels I-clinical_variable
of O
> O
@NUMBER B-lower_bound
mmol I-lower_bound
/ I-lower_bound
kg I-lower_bound

patients O
who O
are O
currently O
taking O
oxt B-treatment
or O
have O
taken O
in B-treatment
- I-treatment
oxt I-treatment
in O
the O
past O
with O
no O
response O

sodium B-clinical_variable
levels I-clinical_variable
of O
> O
@NUMBER B-lower_bound
mmol I-lower_bound
/ I-lower_bound
l I-lower_bound
or O
< O
@NUMBER B-upper_bound
mmol I-upper_bound
/ I-upper_bound
l I-upper_bound

simple O
febrile B-chronic_disease
seizures I-chronic_disease

implanted B-treatment
left I-treatment
ventricular I-treatment
assist I-treatment
device I-treatment
( I-treatment
lvad I-treatment
) I-treatment

diagnosis O
of O
aphasia B-chronic_disease
with O
naming O
deficits O
and O
concurrent O
lexical B-chronic_disease
/ O
semantic B-chronic_disease
impairment I-chronic_disease

female B-gender
sex O

known O
or O
suspected O
allergy O
and O
/ O
or O
hypersensitivity O
to O
travoprost B-allergy_name
or O
any O
prostaglandin B-allergy_name
, O
fluorescein B-allergy_name
, O
or O
to O
any O
component O
of O
the O
study O
products O

acute B-chronic_disease
ischemic I-chronic_disease
symptoms O
compatible O
with O
diagnosis O
of O
mi B-chronic_disease

moderately O
severe O
or O
severe O
depressive O
symptoms O
( O
phq-9 B-clinical_variable
≥ O
@NUMBER B-lower_bound
) O

individuals O
who O
weigh B-clinical_variable
more O
than O
@NUMBER B-lower_bound
kg I-lower_bound

individuals O
with O
preoperative B-chronic_disease
ventricular I-chronic_disease
arrhythmia I-chronic_disease
requiring O
medical O
management O

accreta B-chronic_disease

brain B-cancer
metastasis I-cancer
is O
allowed O
if O
previously O
treated O
, O
stable O
and O
off O
steroids O
for O
a O
minimum O
of O
@NUMBER B-lower_bound
days I-lower_bound

bmi B-bmi
between O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

have O
a O
contralateral O
healthy O
knee O
and O
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
grade O
@NUMBER O
injury O
to O
the O
ipsilateral O
acl O

clcr B-clinical_variable
= O
{ O
[ O
( O
@NUMBER O
age B-age
) O
× O
weight O
) O
] O
/ O
( O
@NUMBER O
x O
scr B-clinical_variable
) O
} O
× O
@NUMBER O
where O
clcr B-clinical_variable
( I-clinical_variable
creatinine I-clinical_variable
clearance I-clinical_variable
) I-clinical_variable
is O
measured O
in O
ml O
/ O
min O
, O
age O
is O
expressed O
in O
years O
, O
weight O
in O
kilograms O
( O
kg O
) O
, O
and O
scr B-clinical_variable
( I-clinical_variable
serum I-clinical_variable
creatinine I-clinical_variable
) I-clinical_variable
in O
mg O
/ O
dl O

each O
lesion B-clinical_variable
must O
be O
≥ O
@NUMBER B-lower_bound
mm I-lower_bound
when O
measured O
by O
ct O
, O
mri O
or O
caliper O
measurement O
by O
clinical O
exam O
; O
or O
≥ O
@NUMBER B-lower_bound
mm I-lower_bound
when O
measured O
by O
chest O
x O
- O
ray O

endometrial B-cancer
cancers I-cancer
that O
are O
mss O
as O
determined O
by O
normal O
immunohistochemical O
nuclear O
expression O
of O
all O
the O
mismatch O
repair O
genes O
msh2 O
, O
msh6 O
, O
mlh1 O
and O
pms2 O

participants O
with O
a O
history O
of O
treatment B-treatment
with I-treatment
an I-treatment
anti I-treatment
- I-treatment
pd-1 I-treatment
, O
anti B-treatment
- I-treatment
pd I-treatment
- I-treatment
l1 I-treatment
, O
anti B-treatment
- I-treatment
ctla-4 I-treatment
or O
other O
investigational O
agents O
that O
target O
immune O
checkpoint O
inhibitors O

this O
test O
is O
now O
done O
routinely O
for O
every O
newly O
diagnosed O
endometrial B-cancer
cancer I-cancer
patient O
in O
most O
centers O
in O
the O
us O

tumors B-cancer
which O
have O
not O
been O
sequenced O
for O
pole O
mutations O
( O
i.e O
. O
their O
pole O
mutations O
status O
is O
unknown O
) O
but O
are O
mss O

history O
of O
cancer B-cancer

coronary B-treatment
artery I-treatment
revascularization I-treatment

major B-chronic_disease
organ I-chronic_disease
system I-chronic_disease
disease I-chronic_disease

significant O
abnormal O
liver O
function O
defined O
as O
aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable

combination B-treatment
treatment I-treatment
( O
e.g. O
, O
androgen O
signaling O
inhibitor O
in O
conjunction O
with O
another O
systemic B-treatment
treatment I-treatment
) O

patients O
with O
rate O
- O
controlled O
atrial B-chronic_disease
fibrillation I-chronic_disease
/ I-chronic_disease
flutter I-chronic_disease

aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
and O
alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
< O
1.5x B-upper_bound
uln I-upper_bound

platelets B-clinical_variable
≥ O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
µl I-lower_bound

patients O
< O
@NUMBER B-upper_bound
years I-upper_bound
old O
with O
an O
extracoelomic O
solid B-cancer
tumor I-cancer
requiring O
sln B-treatment
biopsy I-treatment

patients O
with O
melanoma B-cancer
brain I-cancer
metastases I-cancer
are O
allowed O

women B-gender
of O
childbearing O
potential O
must O
have O
a O
negative B-pregnancy
serum I-pregnancy
or I-pregnancy
urine I-pregnancy
pregnancy I-pregnancy
test O
within O
@NUMBER B-upper_bound
hours I-upper_bound
prior I-upper_bound
to O
the O
start O
of O
nivolumab B-treatment

breastfeeding O
should O
be O
discontinued O
if O
the O
mother O
is O
treated O
with O
nivolumab B-treatment
, O
dabrafenib B-treatment
, O
and O
trametinib B-treatment

history O
of O
major B-chronic_disease
medical I-chronic_disease
disease I-chronic_disease
impacting O
study O

lifetime O
serious O
head B-chronic_disease
injury I-chronic_disease
or O
stroke B-chronic_disease
judged O
to O
impact O
pain O
or O
sleep O

pittsburgh B-clinical_variable
sleep I-clinical_variable
quality I-clinical_variable
index I-clinical_variable
questionnaire I-clinical_variable
score I-clinical_variable
< O
@NUMBER B-upper_bound

does O
not O
self O
- O
identify O
as O
african B-ethnicity
american I-ethnicity
or I-ethnicity
black I-ethnicity

women B-gender
scheduled O
for O
standard O
multiport O
laparoscopic B-treatment

robotic B-treatment
assisted I-treatment
laparoscopic I-treatment
hysterectomy I-treatment

personal B-clinical_variable
health I-clinical_variable
questionnaire I-clinical_variable
depression I-clinical_variable
scale I-clinical_variable
( I-clinical_variable
phq-8 I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound

hemoglobin B-clinical_variable
< O
@NUMBER B-upper_bound

most O
but O
not O
all O
spinal B-treatment
cord I-treatment
stimulators I-treatment
or O
deep B-treatment
brain I-treatment
stimulator I-treatment
, O
ferrous O
- O
containing O
metals O
within O
the O
body O
( O
e.g. O
, O
braces O
, O
aneurysm O
clips O
, O
shrapnel O
/ O
retained O
particles O
) O

pregabalin B-treatment
, O
clonidine B-treatment
, O
selective O
estrogen O
receptor O
modulators O
, O
aromatase B-treatment
inhibitors I-treatment
, O
tissue O
selective O
estrogen O
complexes O

serotonin B-treatment
selective I-treatment
reuptake I-treatment
inhibitors I-treatment
( I-treatment
ssri I-treatment
) I-treatment
( O
@NUMBER O
weeks O
) O

serum B-clinical_variable
potassium I-clinical_variable
( I-clinical_variable
k+ I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
or O
≥ O
@NUMBER B-lower_bound
meq I-lower_bound
/ I-lower_bound
l I-lower_bound
allergic O
reactions O
or O
contraindications O
to O
a O
local B-allergy_name
anesthetic I-allergy_name
or O
contrast B-allergy_name
dye I-allergy_name

women B-gender
of O
childbearing O
potential O
must O
agree O
to O
undergo O
pregnancy O
testing O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
study O
entry O
and O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
adequate I-contraception_consent
contraception I-contraception_consent
( O
barrier O
method O
of O
birth O
control O
, O
abstinence O
, O
not O
hormonal O
) O
prior O
to O
study O
entry O
and O
for O
the O
duration O
of O
study O
participation O
as O
well O
as O
chemical O
lhrh O
agonist O
with O
goserelin O

participating O
in O
another O
clinical B-treatment
trial I-treatment
related O
to O
study O
outcomes O
( O
as O
determined O
by O
the O
pi O
) O

able B-language_fluency
to I-language_fluency
understand I-language_fluency
english I-language_fluency

not O
currently O
using O
chantix B-treatment
or O
wellbutrin B-treatment

recurrent O
non B-cancer
- I-cancer
small I-cancer
cell I-cancer
lung I-cancer
cancer I-cancer

a O
creatinine B-clinical_variable
level I-clinical_variable
of O
less O
than O
@NUMBER B-upper_bound
@NUMBER I-upper_bound
/ I-upper_bound
@NUMBER I-upper_bound
times I-upper_bound
the I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
for O
the O
local O
lab O
test O
, O
or O
, O
a O
creatinine B-clinical_variable
clearance I-clinical_variable
of O
at O
least O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
( I-lower_bound
min*1.73m2 I-lower_bound
) I-lower_bound

hernia B-chronic_disease

post O
- O
op O
pancreatic B-treatment
surgery I-treatment

available O
autologous B-treatment
transduced I-treatment
t I-treatment
cell I-treatment
product I-treatment

hepatic B-chronic_disease
encephalopathy I-chronic_disease

hgb B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

total B-clinical_variable
bilirubin I-clinical_variable
< O
@NUMBER B-upper_bound
times I-upper_bound
uln I-upper_bound
for O
age B-age

have O
a O
contraindication O
to O
the O
use O
of O
metformin B-allergy_name

age B-age
@NUMBER B-lower_bound
years I-lower_bound
or O
older O

history O
of O
tooth O
extraction O
, O
jaw B-treatment
surgery I-treatment
, O
dental O
implants O
, O
or O
other O
dental B-treatment
surgery I-treatment
within O
the O
prior B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

treatment B-treatment
with I-treatment
bisphosphonates I-treatment
in O
the O
preceding O
@NUMBER B-upper_bound
years I-upper_bound

uncontrolled O
hypothyroidism B-chronic_disease

currently O
enrolled O
in O
another B-treatment
experimental I-treatment
hf I-treatment
research I-treatment
study I-treatment

bipolar B-chronic_disease
disorder I-chronic_disease

participant O
has O
another O
active B-chronic_disease
coagulation I-chronic_disease
disorder I-chronic_disease

scheduled O
to O
participate O
in O
another B-treatment
clinical I-treatment
study I-treatment
involving O
an O
investigational O
product O
( O
ip O
) O
or O
investigational O
device O
during O
the O
course O
of O
this O
study O

albumin B-clinical_variable
< O
@NUMBER B-upper_bound

hb B-clinical_variable
level I-clinical_variable
< O
@NUMBER B-upper_bound
gm I-upper_bound
/ I-upper_bound
dl I-upper_bound

should O
a O
woman B-gender
become B-pregnancy
pregnant I-pregnancy
pregnant B-pregnancy
or O
suspect O
she O
is O
pregnant O
while O
participating O
in O
this O
study O
, O
she O
should O
inform O
her O
treating O
physician O
immediately O

patients O
who O
are O
on O
stable O
doses O
of O
a O
pde-5i B-treatment
and O
era B-treatment
combination I-treatment
therapy I-treatment
or O
on O
stable O
pde-5i B-treatment
monotherapy I-treatment
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
and O
at O
randomization O
but O
not O
at O
treatment B-treatment
goal O
( O
tadalafil B-treatment
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
mg I-upper_bound
once O
daily O
or O
sildenafil B-treatment
at O
least O
@NUMBER B-lower_bound
mg I-lower_bound
daily O
dose O
) O

@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound
old O

ability O
to O
participate O
in O
mri B-treatment

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
ul I-lower_bound

referred O
for O
physical B-treatment
therapy I-treatment

postoperative O
patients O
with O
resected O
brain B-cancer
metastases I-cancer
are O
eligible O

history O
of O
cardiovascular B-chronic_disease
disease I-chronic_disease

history O
of O
diabetes B-chronic_disease

obesity B-chronic_disease
( O
bmi B-bmi
> O
@NUMBER B-lower_bound
kg I-lower_bound
/ I-lower_bound
m2 I-lower_bound
) O

fluent B-language_fluency
in I-language_fluency
english I-language_fluency

concurrent O
use O
of O
mao B-treatment
inhibitors I-treatment
, O
or O
use O
in O
the O
last B-upper_bound
two I-upper_bound
weeks I-upper_bound

presence O
of O
signs O
and O
symptoms O
suggestive O
of O
atypical B-chronic_disease
parkinsonism I-chronic_disease

current O
use O
of O
anticholinergics B-treatment
( O
e.g O
. O
nortriptyline B-treatment
, O
amitriptyline B-treatment
, O
hyoscyamine B-treatment
) O

current O
use O
of O
laxatives B-treatment
( O
miralax B-treatment
, O
ex B-treatment
- I-treatment
lax I-treatment
, O
senna B-treatment
, O
herbal B-treatment
supplements I-treatment
) O
, O
linaclotide B-treatment
, O
lubiprostone B-treatment
, O
and O
prucalopride B-treatment
to O
treat O
constipation- O
patients O
using O
these O
medications O
will O
be O
eligible O
to O
participate O
if O
they O
can O
discontinue O
the O
medication O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
( I-lower_bound
@NUMBER I-lower_bound
hrs I-lower_bound
@NUMBER B-lower_bound
days I-lower_bound
( O
@NUMBER O
hrs O
. O
) O
before O
the O
date O
of O
screening O
and O
are O
willing O
to O
stay O
off O
them O
till O
the O
study O
is O
complete O

have O
active O
crohn B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
, O
defined O
as O
a O
baseline O
crohn B-clinical_variable
's I-clinical_variable
disease I-clinical_variable
activity I-clinical_variable
index I-clinical_variable
( I-clinical_variable
cdai I-clinical_variable
) I-clinical_variable
score I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
but O
≤ O
@NUMBER B-upper_bound

primarily O
english B-ethnicity

have O
pathologically O
confirmed O
advanced O
/ O
metastatic B-cancer
cancer I-cancer
prior O
to O
enrollment O

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound

bilirubin B-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound

extensive O
nodal O
involvement O
is O
defined O
as O
metastatic B-cancer
disease I-cancer
involving O
any O
nodal O
region O
outside O
of O
the O
involved O
breast O

individuals O
with O
a O
history O
of O
a O
different O
malignancy B-cancer
are O
ineligible O

should O
a O
woman B-gender
become O
pregnant B-pregnancy
or O
suspect O
she O
is O
pregnant O
while O
participating O
in O
this O
study O
, O
she O
should O
inform O
her O
treating O
physician O
immediately O

preoperative O
non- O
sinus B-chronic_disease
rhythm I-chronic_disease

angina B-chronic_disease

histologically O
or O
cytopathologically O
confirmed O
adenocarcinoma B-cancer
of I-cancer
the I-cancer
pancreas I-cancer

chronic B-chronic_disease
hypertension I-chronic_disease
receiving O
antihypertensive B-treatment
treatment I-treatment

thyroid B-chronic_disease
disease I-chronic_disease

creatinine B-clinical_variable
above O
normal O
limits O

admission O
to O
labor O
and O
delivery O
with O
a O
plan O
for O
delivery O
( O
women B-gender
in O
both O
latent O
and O
active O
labor O
will O
be O
eligible O
) O

intention O
to O
use B-contraception_consent
a I-contraception_consent
contraceptive I-contraception_consent
implant I-contraception_consent
postpartum I-contraception_consent

polycystic B-chronic_disease
ovarian I-chronic_disease
syndrome I-chronic_disease

autoimmune B-chronic_disease
disease I-chronic_disease
, O
such O
as O
systemic B-chronic_disease
lupus I-chronic_disease
erythematosis I-chronic_disease
or O
rheumatoid B-chronic_disease
arthritis I-chronic_disease
, O
that O
is O
active O
and O
requires O
current O
immunosuppressive B-treatment
therapy I-treatment

chemotherapy B-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
trial B-treatment
treatment I-treatment

distant B-cancer
metastasis I-cancer

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
ps I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
( O
appendix O
a O
) O

radiotherapy B-treatment
for O
primary O
hpvoc B-cancer
within O
@NUMBER B-upper_bound
weeks I-upper_bound

carcinoma B-cancer
in I-cancer
situ I-cancer
of O
the O
cervix O
or O
bladder O

level O
of O
radiographic B-clinical_variable
bone I-clinical_variable
level I-clinical_variable
has O
the O
distance O
from O
cej O
to O
interproximal O
crest O
up O
to O
@NUMBER B-upper_bound
mm I-upper_bound

between O
the O
ages B-age
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound

patients O
known O
to O
be O
seropositive O
for O
hiv B-chronic_disease
and O
active O
hepatitis B-chronic_disease
, O
even O
if O
liver O
function O
studies O
are O
in O
the O
normal O
range O

patients O
with O
unsatisfactory O
colposcopy B-treatment

evidence O
of O
endocervical B-cancer
disease I-cancer
defined O
as O
cin B-chronic_disease
@NUMBER O
/ O
@NUMBER O
diagnosed O
on O
endocervical B-treatment
curettage I-treatment

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound
without O
growth O
factor O
use O
≤ O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
treatment B-treatment
( O
cycle O
@NUMBER O
day O
@NUMBER O
, O
c1d1 O
) O

female B-gender
patients I-gender
must O
be O
surgically O
sterile O
or O
be O
postmenopausal O
, O
or O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
effective I-contraception_consent
contraception I-contraception_consent
during O
the O
period O
of O
the O
trial O
and O
for O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
after O
completion O
of O
treatment B-treatment

glaucomatous B-chronic_disease
visual I-chronic_disease
field I-chronic_disease
abnormality I-chronic_disease

participant O
is O
currently O
participating O
in O
or O
has O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
participated O
in O
any O
other O
clinical O
trial O
of O
a O
drug O
by O
ocular O
or O
systemic O
administration O

patient O
has O
a O
history O
of O
multiple B-chronic_disease
sclerosis I-chronic_disease

two O
visual O
field O
tests O
of O
adequate O
quality O
with O
a O
maximum B-clinical_variable
visual I-clinical_variable
field I-clinical_variable
index I-clinical_variable
( I-clinical_variable
vfi I-clinical_variable
) I-clinical_variable
variability I-clinical_variable
of O
± O
@NUMBER O
% O

woman B-gender
of O
child O
- O
bearing O
potential O

adult O
patients O
( O
@NUMBER B-lower_bound
and O
over O
) O

diagnoses O
to O
be O
included O
a O
) O
acute B-cancer
myeloid I-cancer
leukemia I-cancer
; O
b O
) O
acute B-cancer
lymphocytic I-cancer
leukemia I-cancer
; O
c O
) O
chronic B-cancer
myeloid I-cancer
leukemia I-cancer
; O
d O
) O
chronic B-chronic_disease
lymphoproliferative I-chronic_disease
disorder I-chronic_disease
; O
e O
) O
myelodysplastic B-cancer
syndrome I-cancer
; O
f O
) O
myeloproliferative B-cancer
syndromes I-cancer
; O
g O
) O
non B-cancer
- I-cancer
hodgkin I-cancer
's I-cancer
lymphoma I-cancer
; O
h O
) O
hodgkin B-cancer
's I-cancer
lymphoma I-cancer
; O
i O
) O
multiple B-cancer
myeloma I-cancer

patients O
with O
high O
- O
risk O
hematologic B-cancer
malignancies I-cancer
with O
anticipated O
poor O
prognosis O
with O
non B-treatment
transplant I-treatment
therapy I-treatment
, O
including O
those O
in O
remission O
or O
with O
induction O
failure O
and O
after O
treated O
or O
untreated O
relapse O

prior B-treatment
allogeneic I-treatment
transplant I-treatment

uncontrolled B-chronic_disease
infections I-chronic_disease

< O
@NUMBER B-upper_bound
weeks I-upper_bound
gestation B-clinical_variable

outborn O
infants O
who O
received O
enteral O
nutrition O
at O
the O
other O
institution O
prior O
to O
surgical B-treatment
repair I-treatment

≥ O
@NUMBER B-lower_bound
and I-lower_bound
@NUMBER I-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
weeks I-lower_bound
gestational B-clinical_variable
age I-clinical_variable

smoke O
@NUMBER B-age
- O
@NUMBER B-upper_bound
cigarettes O
/ O
day O

fev1 B-clinical_variable
of O
at O
least O
@NUMBER B-lower_bound
% I-lower_bound
of O
predicted O

use O
of O
systemic B-treatment
or I-treatment
inhaled I-treatment
steroids I-treatment

part O
c O
: O
advanced O
, O
unresectable O
cancer B-cancer
( O
dose O
escalation O
) O
and O
advanced O
, O
unresectable O
, O
or O
metastatic B-cancer
non I-cancer
- I-cancer
small I-cancer
cell I-cancer
lung I-cancer
cancer I-cancer
with O
a O
braf O
or O
ras O
mutation O
, O
and O
colorectal B-cancer
cancer I-cancer
with O
a O
ras O
mutation O
and O
advanced O
or O
metastatic B-cancer
cancer I-cancer
with O
an O
activating O
mitogen O
activated O
protein O
kinase O
pathway O
alteration O
( O
dose O
expansion O
) O

patients O
with O
renal B-chronic_disease
insufficiency I-chronic_disease

renal B-chronic_disease
and O
liver B-chronic_disease
failure I-chronic_disease
requiring O
dialysis B-treatment
or O
child B-clinical_variable
- I-clinical_variable
pugh I-clinical_variable
score I-clinical_variable
> O
@NUMBER B-lower_bound

scheduled O
for O
a O
cardiac B-treatment
surgical I-treatment
procedure I-treatment
with O
planned O
post O
- O
operative O
admission O
to O
the O
csicu B-clinical_variable
for O
≥ O
@NUMBER B-lower_bound
hours I-lower_bound

contraindications O
for O
the O
exercise B-allergy_name
treadmill I-allergy_name
test I-allergy_name

scheduled O
for O
arthroscopic B-treatment
labral I-treatment
repair I-treatment
with O
or O
without O
osteoplasty B-treatment
of I-treatment
the I-treatment
hip I-treatment

history O
of O
at O
least O
@NUMBER B-lower_bound
prior I-lower_bound
prbc B-treatment
transfusion I-treatment
( O
preferably O
same O
donor O
) O

patient O
must O
be O
scheduled O
to O
undergo O
allogeneic O
hematopoietic B-treatment
stem I-treatment
cell I-treatment
transplant I-treatment
( I-treatment
hsct I-treatment
) I-treatment
( O
adults O
or O
pediatric O
patients O
) O
or O
autologous B-treatment
hsct I-treatment
( O
pediatric O
patients O
only O
) O

myasthenia B-chronic_disease
gravis I-chronic_disease

has O
received O
an O
oral B-treatment
mtor I-treatment
inhibitor I-treatment
such O
as O
everolimus B-treatment
or O
sirolimus B-treatment

has O
received O
any O
anticonvulsant B-treatment
medication I-treatment
including O
vigabatrin B-treatment
, O
other O
anti B-treatment
- I-treatment
seizure I-treatment
therapeutic I-treatment
agent I-treatment
including O
cannabidiol B-treatment

@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound
old O

cystic B-chronic_disease
periventricular I-chronic_disease
leukomalacia I-chronic_disease
( I-chronic_disease
pvl I-chronic_disease
) I-chronic_disease

intra B-chronic_disease
- I-chronic_disease
uterine I-chronic_disease
growth I-chronic_disease
restriction I-chronic_disease
( I-chronic_disease
iugr I-chronic_disease
) I-chronic_disease
no O
head O
sparing O

hemoglobin B-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound

subjects O
need O
to O
have O
been O
in O
an O
unrestricted O
setting O
for O
at O
least O
@NUMBER B-upper_bound
weeks I-upper_bound
prior O
to O
screening O

age B-age
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound

allergy O
to O
nsaid B-allergy_name
or O
previous O
adverse O
reaction O
( O
ie O
. O
gi B-chronic_disease
bleeding I-chronic_disease
) O

ability O
to O
speak B-language_fluency
and I-language_fluency
understand I-language_fluency
english I-language_fluency

any O
other O
illness O
, O
psychiatric B-chronic_disease
disorder I-chronic_disease
, O
alcohol O
or O
chemical O
dependence O
that O
in O
the O
opinion O
of O
the O
investigator O
would O
render O
a O
patient O
unsuitable O
to O
participate O
in O
the O
study O

current O
medication O
believed O
to O
affect O
cognitive O
/ O
psychomotor O
function O
( O
i.e. O
, O
opioid B-treatment
, O
analgesics B-treatment
, O
anxiolytics B-treatment
or O
antidepressants B-treatment
) O

plan O
to O
start O
any O
motor O
imagery O
or O
physical O
strength O
training O
program O
for O
the O
@NUMBER B-upper_bound
months I-upper_bound
duration O
of O
the O
study O

known O
underlying O
collagen B-chronic_disease
vascular I-chronic_disease
disease I-chronic_disease
or O
intrinsic B-chronic_disease
lung I-chronic_disease
disease I-chronic_disease
that O
could O
complicate O
expected O
sequelae O
of O
radiation O

duration O
of O
psychosis B-chronic_disease
> O
@NUMBER B-lower_bound
years I-lower_bound

confirmed O
diagnosis O
of O
mds B-cancer
, O
cmml B-cancer
, O
or O
aml B-cancer

participants O
with O
cmml B-chronic_disease
must O
have O
been O
treated O
with O
at O
least O
one B-lower_bound
prior I-lower_bound
therapy B-treatment
( O
hydroxyurea B-treatment
or O
a O
hypomethylating B-treatment
agent I-treatment
[ I-treatment
hma I-treatment
] I-treatment
) O

wrist B-clinical_variable
range I-clinical_variable
of O
motion O
of O
at O
least O
@NUMBER B-lower_bound
degrees I-lower_bound

abnormal B-chronic_disease
liver I-chronic_disease
or I-chronic_disease
kidney I-chronic_disease
function I-chronic_disease

self O
- O
reported O
history O
of O
claustrophobia B-chronic_disease

administration O
of O
one O
or O
more O
packed B-treatment
red I-treatment
blood I-treatment
cells I-treatment
( I-treatment
rbcs I-treatment
) I-treatment
transfusion I-treatment
in O
the O
week O
prior O
to O
enrollment O

stable O
treatment B-treatment
is O
defined O
as O
dose O
adjustment O
to O
no O
less O
than O
one B-upper_bound
half I-upper_bound
of O
the O
current O
dosage O
or O
to O
no O
more O
than O
@NUMBER B-upper_bound
times I-upper_bound
the O
current O
dosage O

established O
diagnosis O
of O
diabetic B-chronic_disease
nephropathy I-chronic_disease
as O
the O
underlying O
cause O
of O
renal B-chronic_disease
disease I-chronic_disease

female B-gender
subject I-gender
is O
unwilling B-contraception_consent
to I-contraception_consent
continue I-contraception_consent
using I-contraception_consent
a I-contraception_consent
highly I-contraception_consent
- I-contraception_consent
effective I-contraception_consent
method I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
throughout O
the O
duration O
of O
the O
study O

known O
hiv B-chronic_disease
-infected O
patients O

patients O
receiving O
any O
other O
investigational B-treatment
agents I-treatment
or O
immunotherapy B-treatment

previous O
allo B-treatment
- I-treatment
hsct I-treatment
of O
any O
kind O

prior O
hypomethylating B-treatment
or O
immunomodulatory B-treatment
agents O
for O
mds B-chronic_disease

creatinine B-clinical_variable
( I-clinical_variable
cr I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound
x O
uln O
and O
cr B-clinical_variable
clearance I-clinical_variable
( I-clinical_variable
crcl I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
by O
cockcroft O
and O
gault O

severe B-chronic_disease
renal I-chronic_disease
insufficiency I-chronic_disease

history O
of O
cancer B-cancer
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
, O
with O
the O
exception O
of O
localized O
basal B-cancer
or O
squamous B-cancer
cell I-cancer
carcinoma I-cancer

mmse B-clinical_variable
between O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
( O
inclusive O
) O
at O
time O
of O
enrollment O

abnormal B-chronic_disease
liver I-chronic_disease
function I-chronic_disease
( O
defined O
as O
serum B-clinical_variable
transaminases I-clinical_variable
more O
than O
twice B-lower_bound
the I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound
for O
the O
reference O
laboratory O
) O

defect O
in O
oxidative O
phosphorylation O
( O
such O
as O
a O
confirmed O
mitochondrial B-chronic_disease
myopathy I-chronic_disease
) O

received O
blood B-treatment
product I-treatment
transfusions I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
screening O

positive O
preoperative O
urine O
culture O
within O
@NUMBER B-upper_bound
months I-upper_bound

renal B-chronic_disease
stone I-chronic_disease
of O
any O
size O
for O
which O
pcnl B-treatment
is O
recommended O

bilirubin B-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

neurologic O
function O
: O
neuropathy B-chronic_disease
( O
sensory O
and O
motor O
) O
less O
than O
or O
equal O
to O
ctcae B-clinical_variable
grade B-upper_bound
@NUMBER I-upper_bound

platelet B-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
x I-lower_bound
@NUMBER I-lower_bound
/ I-lower_bound
l I-lower_bound

the O
patient O
can O
undergo O
the O
procedure O
and O
the O
tumor B-cancer
can O
potentially O
be O
completely O
resected O

kps B-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound

markedly O
hypocellular B-chronic_disease

pulmonary B-chronic_disease
disease I-chronic_disease
necessitating O
home B-treatment
oxygen I-treatment
therapy I-treatment

any O
other O
pre O
- O
existing O
laboratory O
abnormality O
, O
medical O
condition O
, O
or O
disease O
that O
, O
in O
the O
opinion O
of O
investigator O
, O
may O
cause O
the O
subject O
to O
be O
unsuitable O
for O
the O
study O
or O
place O
the O
subject O
at O
potential O
risk O
from O
being O
in O
the O
study O
, O
e.g O
. O
a O
malignancy B-cancer
, O
uncontrolled B-chronic_disease
hypertension I-chronic_disease
, O
unstable B-chronic_disease
ischemic I-chronic_disease
heart I-chronic_disease
disease I-chronic_disease
, O
or O
uncontrolled B-chronic_disease
diabetes I-chronic_disease
mellitus I-chronic_disease

irlss B-clinical_variable
score I-clinical_variable
rls B-chronic_disease
s O
score O
≥ O
@NUMBER B-lower_bound
plus O
rls O
symptoms O
for O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
and O
currently O
occurring O
≥ O
@NUMBER B-lower_bound
nights I-lower_bound
per I-lower_bound
week I-lower_bound

secondary B-chronic_disease
rls I-chronic_disease
due O
to O
neurological B-chronic_disease
conditions I-chronic_disease
or O
head B-chronic_disease
trauma I-chronic_disease

have O
a O
counter O
indication O
to O
eeg B-treatment

unstable O
mental B-chronic_disease
illness I-chronic_disease

histologically O
confirmed O
prostate B-cancer
cancer I-cancer

history O
of O
myocardial B-chronic_disease
infarction I-chronic_disease
( I-chronic_disease
mi I-chronic_disease
) I-chronic_disease
, O
stroke B-chronic_disease
and O
/ O
or O
poorly O
controlled O
hypertension B-chronic_disease

active O
heart B-chronic_disease
, O
lung B-chronic_disease
, O
liver B-chronic_disease
, O
gastrointestinal B-chronic_disease
or O
kidney B-chronic_disease
disease I-chronic_disease

history O
of O
glaucoma B-chronic_disease

participants O
who O
will O
not O
consume O
study O
therapy B-treatment
or O
will O
not O
stop O
taking O
natural O
product O
supplements O
of O
their O
own O
selection O

bisphosphonates B-treatment
, O
parathyroid B-clinical_variable
hormone I-clinical_variable
or O
strontium B-clinical_variable
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

systemic O
oral O
or O
transdermal B-treatment
estrogen I-treatment
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

aki B-chronic_disease
is O
defined O
as O
acute B-chronic_disease
kidney I-chronic_disease
injury I-chronic_disease

aki B-chronic_disease
occurring O
in O
the O
setting O
of O
burns O
, O
obstructive B-chronic_disease
uropathy I-chronic_disease
, O
scleroderma B-chronic_disease
renal I-chronic_disease
crisis I-chronic_disease
, O
atheroembolism B-chronic_disease
, O
functional B-treatment
or I-treatment
surgical I-treatment
nephrectomy I-treatment
, O
cyclosporine B-treatment
, O
or O
tacrolimus B-treatment
nephrotoxicity I-treatment

concurrent O
enrollment O
in O
another B-treatment
interventional I-treatment
clinical I-treatment
trial I-treatment
. O
patients O
enrolled O
in O
clinical B-treatment
trials I-treatment
where O
only O
measurements O
and O
/ O
or O
samples O
are O
taken O

threshold B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
of O
@NUMBER O
/ O
@NUMBER O
mmhg O

history O
of O
high O
grade O
( O
ctcae B-clinical_variable
≥ O
grade B-lower_bound
@NUMBER I-lower_bound
) O
immune O
mediated O
adverse O
event O
from O
prior B-treatment
cancer I-treatment
immunotherapy I-treatment

patients O
requiring O
chronic B-treatment
high I-treatment
dose I-treatment
immunosuppressants I-treatment
including O
steroids B-treatment

previously O
infected O
, O
with O
evidence O
of O
immunity O
and O
no O
evidence O
of O
active B-chronic_disease
hepatitis I-chronic_disease

participant O
on O
azathioprine B-treatment
or O
6-mercaptopurine B-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
baseline O

diagnosis O
of O
indeterminate B-chronic_disease
colitis I-chronic_disease
( I-chronic_disease
ic I-chronic_disease
) I-chronic_disease

adults O
( O
ages B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
) O

history O
of O
hearing B-chronic_disease
loss I-chronic_disease

use O
of O
medications B-treatment
that O
strongly O
alter O
cyp3a4 B-clinical_variable
activity O

positive O
pregnancy B-pregnancy
test O

nyha B-chronic_disease
class I-chronic_disease
iv I-chronic_disease
symptomatology O
, O
defined O
as O
chronic B-chronic_disease
dyspnea I-chronic_disease
or O
fatigue O
at O
rest O
or O
on O
minimal O
exertion O
in O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

acute B-chronic_disease
respiratory I-chronic_disease
distress I-chronic_disease

history O
of O
post B-chronic_disease
- I-chronic_disease
traumatic I-chronic_disease
stress I-chronic_disease
disorder I-chronic_disease
( I-chronic_disease
ptsd I-chronic_disease
) I-chronic_disease
, O
bipolar B-chronic_disease
disorder I-chronic_disease
, O
schizophrenia B-chronic_disease
or O
psychotic B-chronic_disease
disorder I-chronic_disease
as O
assessed O
by O
medical O
record O
review O
and O
/ O
or O
self O
- O
reported O

use O
of O
dopaminergic B-treatment
cns I-treatment
stimulants I-treatment
( O
prescription O
, O
over O
- O
the O
counter O
or O
recreational O
drugs O
) O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
screening O
intake O
visit O
, O
as O
assessed O
by O
review O
of O
health O
history O
form O
and O
concomitant O
medication O
review O
at O
screening O
intake O
visit O
( O
from O
medical O
record O
and O
/ O
or O
self O
- O
reported O
) O
that O
are O
deemed O
by O
a O
physician O
investigator O
to O
have O
a O
potential O
influence O
on O
the O
binding O
of O
[ O
@NUMBER O
f O
] O
ftp O

uncontrolled O
intercurrent B-chronic_disease
illness I-chronic_disease
including O
, O
but O
not O
limited O
to O
, O
ongoing O
or O
uncontrolled O
systemic B-chronic_disease
fungal I-chronic_disease
, O
bacterial B-chronic_disease
, O
viral B-chronic_disease

other O
infection B-chronic_disease
, O
symptomatic O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease
pectoris I-chronic_disease
, O
cardiac B-chronic_disease
arrhythmia I-chronic_disease

taking O
estrogen B-treatment
supplements I-treatment

moderate O
to O
severe B-chronic_disease
encephalopathy I-chronic_disease
( O
based O
on O
modified O
sarnat O
exam O
) O
present O
between O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
hours I-upper_bound
after O
birth O

perinatal B-chronic_disease
depression I-chronic_disease
based O
on O
at O
least O
one O
of O
the O
following O

ph B-clinical_variable
< O
@NUMBER B-upper_bound
in O
cord O
gas O
( O
arterial O
or O
venous O
) O
or O
in O
an O
infant O
gas O
( O
arterial O
or O
venous O
) O
obtained O
at O
< O
@NUMBER B-upper_bound
minutes I-upper_bound
of O
age B-age

≥ O
@NUMBER B-lower_bound
weeks I-lower_bound
of O
gestational B-clinical_variable
age I-clinical_variable

has O
documented O
gastrointestinal B-chronic_disease
, O
cerebral B-chronic_disease
, O
or O
other O
hemorrhage B-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound

undergoing O
bilateral B-treatment
hip I-treatment
or I-treatment
knee I-treatment
replacement I-treatment

depression O
as O
part O
of O
bipolar B-chronic_disease
disorder I-chronic_disease
or O
schizophrenia B-chronic_disease
or O
schizoaffective B-chronic_disease
disorder I-chronic_disease

current O
or O
past O
manic B-chronic_disease
/ I-chronic_disease
hypomanic I-chronic_disease
episode I-chronic_disease
or O
psychotic B-chronic_disease
symptoms I-chronic_disease

patient O
with O
relapsed O
or O
refractory O
cd19-positive O
b B-cancer
- I-cancer
acute I-cancer
lymphoblastic I-cancer
leukaemia I-cancer
( I-cancer
b I-cancer
- I-cancer
all I-cancer
) I-cancer
who O
have O
exhausted O
alternative O
treatment O
options O

prior B-treatment
treatment I-treatment
( O
at O
least O
@NUMBER B-lower_bound
full O
treatment O
cycle O
) O
with O
a O
farnesyltransferase B-treatment
inhibitor I-treatment

non B-cancer
- I-cancer
melanoma I-cancer
skin I-cancer
cancer I-cancer

absence O
of O
crt O
with O
class O
i O
indication O
criteria O
for O
biventricular B-treatment
pacing I-treatment
( O
left O
bundle O
branch O
block O
pattern O
and O
q B-clinical_variable
- I-clinical_variable
wave I-clinical_variable
/ I-clinical_variable
r I-clinical_variable
- I-clinical_variable
wave I-clinical_variable
/ I-clinical_variable
s I-clinical_variable
- I-clinical_variable
wave I-clinical_variable
( I-clinical_variable
qrs I-clinical_variable
) I-clinical_variable
duration I-clinical_variable
≥ O
@NUMBER B-lower_bound
milliseconds I-lower_bound
( I-lower_bound
ms I-lower_bound
) I-lower_bound
) O

female B-gender
subjects I-gender
who O
are B-pregnancy
pregnant I-pregnancy

hemodynamic O
instability O
: O
hypotension B-chronic_disease
( O
systolic B-clinical_variable
pressure I-clinical_variable
< O
@NUMBER B-upper_bound
millimeter I-upper_bound
mercury I-upper_bound
( I-upper_bound
mmhg I-upper_bound
) I-upper_bound
) O
or O
requirement O
for O
inotropic O
support O
or O
mechanical O
hemodynamic O
support O

patients O
with O
significant O
organic O
mitral B-chronic_disease
valve I-chronic_disease
pathology I-chronic_disease
( O
e.g O
. O
myxomatous B-chronic_disease
degeneration I-chronic_disease
, O
mitral B-chronic_disease
valve I-chronic_disease
prolapse I-chronic_disease
or O
flail B-chronic_disease
leaflets I-chronic_disease
) O

recent O
laryngeal B-treatment
surgery I-treatment
( O
within O
one B-upper_bound
month I-upper_bound
) O

dependency O
on O
anticoagulants B-treatment
or O
antiplatelet B-treatment
medication I-treatment
due O
to O
high O
risk O
for O
adverse O
events O
if O
these O
medications O
are O
stopped O
for O
a O
prolonged O
period O
of O
time O

able B-language_fluency
to I-language_fluency
conduct I-language_fluency
research I-language_fluency
activities I-language_fluency
in I-language_fluency
english I-language_fluency
or I-language_fluency
spanish I-language_fluency

a O
woman B-gender
that O
is O
pregnant B-pregnancy
or O
nursing O
a O
child O

known O
underlying O
immunodeficiency B-chronic_disease

subjects O
with O
active B-cancer
or I-cancer
symptomatic I-cancer
central I-cancer
nervous I-cancer
system I-cancer
metastases I-cancer

the O
subject O
has O
a O
diagnosis O
of O
melanoma B-cancer
or O
renal B-cancer
cell I-cancer
carcinoma I-cancer

participants O
with O
valid O
prescriptions O
for O
opiates B-treatment
, O
benzodiazepines B-treatment
, O
barbiturates B-treatment
, O
amphetamines B-treatment
or O
methadone B-treatment

neurogenic B-chronic_disease
orthostatic I-chronic_disease
hypotension I-chronic_disease

wellbutrin B-treatment
( I-treatment
bupropion I-treatment
) I-treatment

maximum O
age B-age
@NUMBER B-upper_bound
years I-upper_bound

minimum O
completion O
of O
@NUMBER B-lower_bound
years I-lower_bound
of O
education O

prior B-treatment
therapy I-treatment
with O
a O
pi3k B-treatment
delta I-treatment
inhibitor I-treatment

patients O
with O
active B-chronic_disease
hiv I-chronic_disease

chronic B-chronic_disease
kidney I-chronic_disease
disease I-chronic_disease
stage I-chronic_disease
@NUMBER I-chronic_disease

bmi B-bmi
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
kg I-upper_bound
/ I-upper_bound
m2 I-upper_bound

refraction O
between O
@NUMBER O
and O
@NUMBER O
diopters O
and O
astigmatism B-clinical_variable
≤ O
@NUMBER B-upper_bound
diopters O

patients O
must O
be O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
post O
systemic O
steroids O
prior O
to O
enrollment O

confirmed O
diagnosis O
of O
type B-chronic_disease
@NUMBER I-chronic_disease
diabetes I-chronic_disease
as O
documented O
in O
the O
electronic O
health O
record O

bmi B-bmi
> O
@NUMBER B-lower_bound

polytrauma B-chronic_disease
patients O

available O
prior O
ct O
or O
pet O
/ O
ct O
scan O
done O
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound
for O
comparison O

presence O
of O
palpable O
or O
radiographically O
measurable O
disease O
of O
at O
least O
@NUMBER B-lower_bound
cm I-lower_bound
in O
longest O
dimension O

any O
confirmed O
evidence O
of O
hepatitis B-chronic_disease
b I-chronic_disease
or I-chronic_disease
c I-chronic_disease
infection I-chronic_disease

receipt O
of O
licensed B-treatment
vaccines I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
before O
or O
after O
immunization B-treatment
( O
@NUMBER B-upper_bound
days I-upper_bound
for O
live B-treatment
vaccines I-treatment
) O

female B-gender
who O
intends B-pregnancy
to I-pregnancy
become I-pregnancy
pregnant I-pregnancy
during O
the O
study O
period O

patients O
who O
are O
pregnant B-pregnancy
or O
may B-pregnancy
become I-pregnancy
pregnant I-pregnancy

who O
have O
previously O
received O
solid B-treatment
organ I-treatment
transplantation I-treatment

history O
of O
allergy O
to O
eggs B-allergy_name
, O
egg B-allergy_name
products I-allergy_name
, O
aminoglycoside B-allergy_name
antibiotics I-allergy_name

persons O
with O
vitiligo B-chronic_disease

radiographically O
- O
demonstrable O
metastases B-cancer
at O
any O
time O
prior O
to O
the O
time O
of O
enrollment O

pt3b B-cancer
or O
pt4 B-cancer
primary I-cancer
tumor I-cancer

vaccination O
with O
a O
killed O
vaccine O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
day O
@NUMBER O
of O
prostvac O
- O
v O
/ O
f O

contraindications O
to O
anesthesia B-allergy_name
for O
procedure O

patients O
on O
hemodialysis B-treatment
or O
end B-chronic_disease
stage I-chronic_disease
renal I-chronic_disease
disease I-chronic_disease
( I-chronic_disease
esrd I-chronic_disease
) I-chronic_disease

patients O
with O
acute B-chronic_disease
coronary I-chronic_disease
syndrome I-chronic_disease

able O
to O
complete O
neurocognitive B-treatment
function I-treatment
assessments O
, O
psychological B-treatment
function I-treatment
assessments O
, O
and O
qol B-treatment
assessments O
administered O
at O
screening O
visit O

actinic B-chronic_disease
keratosis I-chronic_disease

history O
of O
seizure B-chronic_disease
activity O

meets O
the O
clinical O
definition O
of O
ad B-chronic_disease
based O
on O
nincds O
- O
adrda O
criteria O
, O
with O
confirmatory O
f-2-dg O
and O
f O
- O
florbetapir O
( O
amyvid O
) O
pet B-treatment
scan I-treatment
findings O

any O
physical O
signs O
that O
would O
suggest O
a O
difficult O
airway O
( O
e.g O
. O
mouth O
opening O
< O
@NUMBER B-upper_bound
cm I-upper_bound
, O
short O
distance O
between O
the O
chin O
and O
neck O
, O
poor O
mandibular O
subluxation O
, O
thick O
neck O
) O

ages B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
old O

age B-age
@NUMBER B-lower_bound
years I-lower_bound
or O
older O

inability B-language_fluency
to I-language_fluency
speak I-language_fluency
and I-language_fluency
read I-language_fluency
english I-language_fluency

infection O
requiring O
intravenous B-treatment
vancomycin I-treatment
and O
admission O
to O
charleston O
area O
medical O
center O
- O
memorial O
hospital O

patients O
who O
have O
completed O
treatment O
but O
are O
within O
five B-upper_bound
years I-upper_bound
of O
treatment O
completion O
( O
primary B-treatment
surgery I-treatment
, O
chemotherapy B-treatment
or O
radiation B-treatment
therapy I-treatment
) O
, O
whichever O
was O
received O
last O
. O
hormonal B-treatment
therapy I-treatment
and O
targeted B-treatment
therapy I-treatment
are O
allowed O

availability O
of O
an O
hla B-clinical_variable
( I-clinical_variable
human I-clinical_variable
leukocyte I-clinical_variable
antigen I-clinical_variable
) I-clinical_variable
matched O
related O
donor O

patients O
with O
pre B-chronic_disease
- I-chronic_disease
gestational I-chronic_disease
or I-chronic_disease
gestational I-chronic_disease
diabetes I-chronic_disease
mellitus I-chronic_disease

glomerular B-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
/ I-lower_bound
1.73m2 I-lower_bound
as O
estimated O
by O
the O
cockcroft O
- O
gault O
formula O
or O
creatinine B-clinical_variable
clearance I-clinical_variable
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
as O
determined O
by O
24-hour O
urine O
collection O

subjects O
with O
known O
hiv B-chronic_disease
, O
active B-chronic_disease
hepatitis I-chronic_disease
b I-chronic_disease
, O
or O
active B-chronic_disease
hepatitis I-chronic_disease
c I-chronic_disease
( O
detectable O
rna O
) O
. O
hiv O
- O
positive O
subjects O
on O
combination O
antiretroviral B-treatment
therapy I-treatment
are O
ineligible O
because O
of O
the O
potential O
for O
pharmacokinetic O
interactions O
with O
durvalumab B-treatment
and O
/ O
or O
tremelimumab B-treatment

patients O
with O
a O
history O
of O
solid B-treatment
organ I-treatment
transplant I-treatment

known O
history O
of O
active B-chronic_disease
tuberculosis I-chronic_disease
( I-chronic_disease
tb I-chronic_disease
) I-chronic_disease

able B-language_fluency
to I-language_fluency
speak I-language_fluency
and I-language_fluency
understand I-language_fluency
english I-language_fluency

received O
antimicrobial B-treatment
therapy I-treatment
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

immunosuppressed B-chronic_disease
patients O

those O
on O
glucocorticoids B-treatment
and O
anticonvulsants B-treatment
will O
be O
allowed O
to O
continue O
in O
the O
study O
because O
their O
use O
is O
common O
in O
this O
population O

history O
of O
prior O
af B-chronic_disease

demonstrated O
ability O
to O
achieve O
> O
@NUMBER B-lower_bound
% I-lower_bound
predicted O
inspiratory O
capacity O
based O
on O
ideal O
body O
weight O
using O
is O
within O
the O
first O
@NUMBER B-upper_bound
hours I-upper_bound
of O
admission O

any O
major O
unstable O
medical O
/ O
psychiatric B-chronic_disease
illness I-chronic_disease
( O
e.g. O
, O
hospitalization O
within O
@NUMBER B-upper_bound
days I-upper_bound
, O
suicide B-chronic_disease
risk I-chronic_disease
, O
etc O
. O
) O

sexually O
active O
women O
of O
childbearing O
potential O
must O
use B-contraception_consent
a I-contraception_consent
reliable I-contraception_consent
method I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
while O
participating O
in O
this O
study O

have O
past O
history O
of O
peripheral B-chronic_disease
vestibular I-chronic_disease
pathology I-chronic_disease
or O
ocular B-chronic_disease
motor I-chronic_disease
deficits I-chronic_disease

oral B-treatment
steroid I-treatment
use O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
surgery B-treatment

chronic B-chronic_disease
rhinosinusitis I-chronic_disease
with I-chronic_disease
polyps I-chronic_disease
( I-chronic_disease
crswnp I-chronic_disease
) I-chronic_disease

current O
diagnosis O
of O
acidosis B-chronic_disease

inappropriate O
anatomy O
for O
femoral O
introduction O
and O
delivery O
of O
the O
sapien B-treatment
@NUMBER I-treatment
thv I-treatment

decreased O
processing O
speed O
( O
defined O
as O
@NUMBER B-lower_bound
sd O
below O
age B-age
-adjusted O
norms O
on O
the O
digit O
symbol O
test O
) O

patients O
scheduled O
for O
open B-treatment
reduction I-treatment
and I-treatment
internal I-treatment
fixation I-treatment
of I-treatment
a I-treatment
distal I-treatment
radius I-treatment
fracture I-treatment

patients O
will O
be O
defined O
to O
have O
chronic O
pain O
if O
they O
are O
using O
regular O
daily O
doses O
of O
systemic B-treatment
narcotics I-treatment
for O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
prior I-upper_bound
to O
the O
surgery B-treatment

metabolic B-chronic_disease
disorders I-chronic_disease

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
status I-clinical_variable
≤ O
@NUMBER B-upper_bound

participation O
in O
any O
other O
trial O
of O
an O
investigational O
agent O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
first O
dose O
of O
study O
drug O

the O
resting O
12-lead B-treatment
electrocardiogram I-treatment
obtained O
during O
screening O
shows O
qtc B-clinical_variable
( I-clinical_variable
fridericia I-clinical_variable
correction I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
ms I-lower_bound
or O
has O
a O
congenital B-chronic_disease
prolonged I-chronic_disease
qt I-chronic_disease
syndrome I-chronic_disease

suspected O
severe O
fetal B-chronic_disease
anemia I-chronic_disease

pregnant B-pregnancy
, O
breastfeeding O
, O
or O
planning B-pregnancy
to I-pregnancy
become I-pregnancy
pregnant I-pregnancy
or O
breastfeed O
during O
the O
study O

contraindications O
for O
mri O
examinations O
( O
e.g. O
, O
pacemakers B-treatment
or O
ferromagnetic B-treatment
vascular I-treatment
clips I-treatment
) O

history O
of O
prior O
cardiovascular B-chronic_disease
disease I-chronic_disease
or O
significant O
risk O
factors O

no O
history O
of O
heart B-chronic_disease
arrhythmia I-chronic_disease

allergic B-chronic_disease
asthma I-chronic_disease
population I-chronic_disease
( I-chronic_disease
aa I-chronic_disease
) I-chronic_disease

cardiac B-chronic_disease
disease I-chronic_disease

fev1 B-clinical_variable
< O
@NUMBER B-upper_bound
% I-upper_bound
predicted O
normal O
pre B-treatment
- I-treatment
bronchodilator I-treatment

ms B-treatment
relapse I-treatment
or O
steroid B-treatment
treatment O
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound

current O
psychotherapy B-treatment
/ I-treatment
behavioral I-treatment
treatments I-treatment
for O
depression B-chronic_disease

very O
severe B-chronic_disease
depression I-chronic_disease
that O
would O
interfere O
with O
the O
ability O
to O
participate O
in O
the O
study O
( O
based O
on O
clinical O
judgment O
by O
the O
physician O
at O
the O
recruitment O
site O
) O

subjects O
who O
have O
received O
a O
primary B-treatment
unilateral I-treatment
tka I-treatment
for O
a O
diagnosis O
of O
osteoarthritis B-chronic_disease

patients O
with O
nsclc B-cancer
diagnosis O
who O
have O
been O
referred O
for O
a O
clinical O
fdg B-treatment
pet I-treatment
/ I-treatment
ct I-treatment
staging I-treatment
scan I-treatment
as O
part O
of O
their O
standard O
of O
care O

aged B-age
@NUMBER B-lower_bound
or O
over O

new B-clinical_variable
york I-clinical_variable
heart I-clinical_variable
association I-clinical_variable
class B-chronic_disease
iii I-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
or O
ejection B-clinical_variable
fraction I-clinical_variable
of O
less O
than O
@NUMBER B-upper_bound
% I-upper_bound
on O
echocardiogram B-treatment
or O
multi B-treatment
gated I-treatment
acquisition I-treatment
scan I-treatment
( I-treatment
muga I-treatment
) I-treatment

patients O
with O
a O
malignancy B-cancer
that O
has O
been O
treated O
with O
surgery B-treatment
alone O
with O
curative O
intent O
will O
also O
be O
excluded O
, O
unless O
the O
malignancy O
has O
been O
in O
documented O
remission O
without O
treatment B-treatment
for O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
prior I-lower_bound
to O
enrollment O

age B-age
aged B-age
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
years I-lower_bound
of O
age O

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
old O

neurodegenerative B-chronic_disease
disorder I-chronic_disease

ability O
to O
successfully O
use O
the O
alivecor O
™ O
heart O
monitor O
, O
capture O
a O
baseline O
ecg B-treatment
, O
and O
transmit O
on O
the O
day O
of O
enrollment O

must O
be O
using B-contraception_consent
effective I-contraception_consent
contraception I-contraception_consent
( O
ie O
, O
oral B-contraception_consent
contraceptives I-contraception_consent
, O
intrauterine B-contraception_consent
device I-contraception_consent
, O
double B-contraception_consent
barrier I-contraception_consent
method I-contraception_consent
of I-contraception_consent
condom I-contraception_consent
and I-contraception_consent
spermicide I-contraception_consent
) O

active O
systemic B-chronic_disease
fungal I-chronic_disease
, O
bacterial O
, O
viral O
, O
or O
other O
infection O
, O
unless O
disease O
is O
under O
treatment B-treatment
with O
anti O
- O
microbials O
and O
/ O
or O
controlled O
or O
stable O
( O
e.g O
. O
if O
specific O
, O
effective O
therapy O
is O
not O
available O
/ O
feasible O
or O
desired O
[ O
e.g O
. O
chronic B-chronic_disease
viral I-chronic_disease
hepatitis I-chronic_disease
, O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
] O
) O

high O
- O
risk O
myeloproliferative B-cancer
neoplasm I-cancer

history O
of O
prior B-treatment
radiation I-treatment
exposure I-treatment
radiation B-treatment
exposure I-treatment
for O
research O
purposes O
within O
the O
past O
year O
such O
that O
participation O
in O
this O
study O
would O
place O
them O
over O
fda O
limits O
for O
annual O
radiation O
exposure O
. O
this O
guideline O
is O
an O
effective O
dose O
of O
@NUMBER O
rem O
received O
per O
year O

absence O
of O
dementia B-chronic_disease

baseline O
dementia B-chronic_disease

current O
psychiatric B-chronic_disease
illness I-chronic_disease

between O
the O
age B-age
of O
@NUMBER B-lower_bound
and O
@NUMBER B-upper_bound

individuals O
between O
the O
age B-age
of O
@NUMBER B-lower_bound
and O
@NUMBER B-upper_bound
who O
have O
a O
history O
of O
frequent O
bacterial O
infections O
and O
are O
being O
evaluated O
for O
humoral B-chronic_disease
immunodeficiency I-chronic_disease

participation O
in O
a O
clinical O
study O
involving O
administration O
of O
either O
an O
investigational O
or O
a O
marketed O
drug O
within O
@NUMBER B-upper_bound
days I-upper_bound
or O
@NUMBER O
terminal O
half O
- O
lives O
before O
screening O

patient O
with O
sarcoidosis B-chronic_disease

women B-gender
of O
childbearing O
potential O
must O
be O
using B-contraception_consent
adequate I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
measures I-contraception_consent
( O
abstinence B-contraception_consent
, O
hormonal B-contraception_consent
contraceptives I-contraception_consent
, O
intrauterine B-contraception_consent
device I-contraception_consent
, O
barrier B-contraception_consent
method I-contraception_consent
with I-contraception_consent
spermicide I-contraception_consent
, O
or O
surgical B-contraception_consent
sterilization I-contraception_consent
) O
and O
must O
agree B-contraception_consent
to I-contraception_consent
continue I-contraception_consent
such I-contraception_consent
precautions I-contraception_consent
, O
and O
not B-pregnancy
become I-pregnancy
pregnant I-pregnancy
or O
plan B-pregnancy
a I-pregnancy
pregnancy I-pregnancy
for O
@NUMBER B-upper_bound
months I-upper_bound
after O
receiving O
their O
last O
treatment B-treatment
with O
study O
agent O

subject O
attains O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
during O
study O
duration O

contraindications O
to O
hepatic B-treatment
artery I-treatment
embolization I-treatment

intolerance O
to O
contrast B-allergy_name
media I-allergy_name

alanine B-clinical_variable
aminotransferase I-clinical_variable
≥ O
@NUMBER B-lower_bound
× I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound
( I-lower_bound
uln I-lower_bound
) I-lower_bound
for O
age B-age

bcr B-cancer
- I-cancer
abl1 I-cancer
-rearranged O
( O
ph+ O
) O
all O

eligible O
ages B-age
in O
australia O
and O
canada O
; O
@NUMBER B-lower_bound
years I-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound

systemic B-treatment
steroid I-treatment
pretreatment I-treatment
without O
presteroid O
wbc O
documentation O

trisomy B-chronic_disease
@NUMBER I-chronic_disease
( I-chronic_disease
down I-chronic_disease
syndrome I-chronic_disease
) I-chronic_disease

uncontrolled B-chronic_disease
hypertension I-chronic_disease
or O
metabolic B-chronic_disease
disorder I-chronic_disease

patient O
must O
have O
proven O
or O
suspected O
non B-cancer
small I-cancer
cell I-cancer
lung I-cancer
cancer I-cancer
( I-cancer
nsclc I-cancer
) I-cancer
cancer B-cancer
( O
nsclc O
) O
and O
be O
clinical O
stage B-lower_bound
i I-lower_bound
or O
iia B-upper_bound
, O
according O
to O
the O
@NUMBER O
th O
edition O
staging O
system O
of O
the O
american O
joint O
commission O
on O
cancer O
for O
lung O
cancer O
( O
t1or O
t2a O
, O
n0 O
or O
n1 O
, O
m0 O
) O

patients O
already O
scheduled O
to O
receive O
conventional B-treatment
radiotherapy I-treatment
, O
chemotherapy B-treatment
, O
biological B-treatment
therapy I-treatment
, O
vaccine B-treatment
therapy I-treatment
, O
or O
surgery B-treatment
as O
treatment O

use O
of O
medications O
that O
interact O
with O
icosapent B-treatment
ethyl I-treatment

clinically O
significant O
, O
symptomatic B-chronic_disease
mitral I-chronic_disease
regurgitation I-chronic_disease

patients O
unable B-language_fluency
to I-language_fluency
understand I-language_fluency
english I-language_fluency

age B-age
≥ O
@NUMBER B-lower_bound

ecog B-clinical_variable
ps I-clinical_variable
of O
@NUMBER O

currently O
be O
receiving O
daily O
treatment B-treatment
with O
a O
prescription O
opioid B-treatment
for O
chronic O
pain O

( O
mmse B-clinical_variable
< O
@NUMBER B-upper_bound
) O

received O
seasonal O
flu O
vaccination O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
first O
trial O
injection O
( O
and O
not O
more O
recently O
) O

active B-chronic_disease
autoimmune I-chronic_disease
disease I-chronic_disease
requiring O
disease B-treatment
- I-treatment
modifying I-treatment
therapy I-treatment

adjuvant B-treatment
ifn I-treatment
- I-treatment
a I-treatment
, O
is O
allowed O
if O
last O
dose O
was O
received O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
of O
starting O
study O
treatment B-treatment

pembrolizumab B-treatment
such O
as O
: O
condom O
, O
diaphragm O
, O
hormonal O
, O
iud O
, O
or O
sponge O
plus O
spermicide O

wbc B-clinical_variable
> O
@NUMBER B-lower_bound
/ I-lower_bound
mm^3 I-lower_bound

history O
of O
heparin B-treatment
induced O
thrombocytopenia B-chronic_disease

known O
diagnosis O
of O
disseminated B-chronic_disease
intravascular I-chronic_disease
coagulation I-chronic_disease

all O
participants O
will O
be O
english B-language_fluency
speaking I-language_fluency

history O
of O
cardiac B-chronic_disease
disease I-chronic_disease
, O
including O
myocardial B-chronic_disease
infarction I-chronic_disease

not O
on O
opiates B-treatment
at O
time O
of O
presentation O
to O
clinic O

the O
patient O
must O
have O
pain O
which O
appears O
to O
be O
related O
to O
the O
radiographically O
documented O
metastasis B-cancer
in O
the O
opinion O
of O
the O
treating O
physician O
, O
and O
the O
decision O
has O
been O
made O
by O
the O
responsible O
clinician O
that O
a O
course O
of O
palliative O
external B-treatment
beam I-treatment
radiation I-treatment
therapy I-treatment
is O
appropriate O
treatment O

english B-language_fluency
- I-language_fluency
speaking I-language_fluency
during O
clinical O
encounters O

> O
@NUMBER B-lower_bound
kg I-lower_bound
/ I-lower_bound
m2 I-lower_bound

excessive O
coffee O
and O
tea O
consumers O
( O
> O
@NUMBER B-lower_bound
cups I-lower_bound
/ I-lower_bound
day I-lower_bound
) O

fasting B-clinical_variable
venous I-clinical_variable
blood I-clinical_variable
glucose I-clinical_variable
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

have O
donated O
blood O
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
the O
screening O
visit O

have O
or O
had O
cancer B-cancer
other O
than O
non B-cancer
- I-cancer
melanoma I-cancer
skin I-cancer
cancer I-cancer
in O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound

smoking B-clinical_variable
cessation I-clinical_variable
> O
@NUMBER B-lower_bound
yrs I-lower_bound

trauma O
related O
intracranial O
neuroimaging B-chronic_disease
abnormalities I-chronic_disease

should O
a O
woman B-gender
become O
pregnant B-pregnancy
or O
suspect O
she O
is O
pregnant O
while O
she O
or O
her O
partner O
is O
participating O
in O
this O
study O
, O
she O
should O
inform O
her O
treating O
physician O
immediately O

patients O
undergoing O
sabr B-treatment
for O
the O
treatment O
of O
a O
lung B-cancer
tumor I-cancer
, O
inclusive O
of O
non B-cancer
- I-cancer
small I-cancer
cell I-cancer
lung I-cancer
cancer I-cancer
or O
lung B-cancer
metastases I-cancer

documented O
sustained O
improvement O
of O
the O
subject O
's O
ipf B-chronic_disease
ipf B-chronic_disease
condition I-chronic_disease
up O
to O
@NUMBER B-upper_bound
months I-upper_bound
before O
study O
entry O
with O
or O
without O
ipf O
- O
specific O
therapy B-treatment

hemoglobin B-clinical_variable
> O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
l I-lower_bound

systolic B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
< O
@NUMBER B-upper_bound
mmhg I-upper_bound

not O
explained O
by O
other O
illnesses O
except O
somatic B-chronic_disease
disorders I-chronic_disease

the O
subject O
will O
be O
observed O
in O
the O
hospital O
for O
at O
least O
@NUMBER B-lower_bound
hours I-lower_bound
after O
the O
study O
drug O
is O
administered O

supratentorial B-chronic_disease
t1-gd I-chronic_disease
enhancing O
lesion O
( O
s O
) O
amenable O
to O
total O
resection O

current O
intent O
to O
commit O
suicide B-chronic_disease

women B-gender
who O
are B-pregnancy
pregnant I-pregnancy
or O
plan B-pregnancy
to I-pregnancy
become I-pregnancy
pregnant I-pregnancy
during O
the O
study O

adequately O
treated O
and O
cured O
basal B-cancer
or I-cancer
squamous I-cancer
cell I-cancer
skin I-cancer
cancer I-cancer
cancer B-cancer
, O
curatively O
treated O
in O
situ B-cancer
disease I-cancer
, O
or O
other O
cancer O
from O
which O
the O
patient O
has O
been O
disease O
- O
free O
for O
@NUMBER B-lower_bound
years I-lower_bound
or O
more O

hepatitis B-chronic_disease
b I-chronic_disease

hepatitis B-chronic_disease
c I-chronic_disease
infection O

women B-gender
with O
laparotomy B-treatment
incisions I-treatment
left O
open O
due O
to O
case O
classification O
as O
contaminated O
or O
dirty O

women B-gender
with O
sensitivity O
to O
silver B-allergy_name

forced B-clinical_variable
expiratory I-clinical_variable
flow I-clinical_variable
at I-clinical_variable
@NUMBER I-clinical_variable
% I-clinical_variable
of I-clinical_variable
predicted I-clinical_variable
( I-clinical_variable
fef25 I-clinical_variable
- I-clinical_variable
75 I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound
of I-lower_bound
predicted I-lower_bound

clinical B-clinical_variable
stage I-clinical_variable
> O
t2b B-lower_bound
or O
evidence O
of O
nodal O

acute B-chronic_disease
coronary I-chronic_disease
syndrome I-chronic_disease
( O
hospitalization O
for O
unstable B-chronic_disease
angina I-chronic_disease
or O
myocardial B-chronic_disease
infarction I-chronic_disease
) O

hypersensitivity O
to O
darbepoetin B-allergy_name

renal B-chronic_disease
insufficiency I-chronic_disease
with O
an O
estimated B-clinical_variable
glomerular I-clinical_variable
filtration I-clinical_variable
( I-clinical_variable
egf I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound

distal B-chronic_disease
femur I-chronic_disease
fractures I-chronic_disease

daily O
smokers O
of O
at O
least O
@NUMBER B-lower_bound
cigarettes I-lower_bound
/ I-lower_bound
day I-lower_bound
who O
are O
classified O
as O
in O
the O
pre O
- O
contemplator O
stage O
of O
change O
( O
i.e O
. O
do O
not O
intend O
to O
quit O
smoking O
in O
the O
next B-upper_bound
6-months I-upper_bound
) O

evidence O
of O
an O
acute B-chronic_disease
myocardial I-chronic_disease
infarction I-chronic_disease
≤ O
@NUMBER B-upper_bound
month I-upper_bound
( O
@NUMBER O
days O
) O
before O
randomization O

use O
of O
probiotics B-treatment
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

have O
a O
medical O
condition O
that O
contradicts O
treatment B-treatment
with I-treatment
escitalopram I-treatment

biologic B-treatment
or O
hormonal B-treatment
therapy I-treatment
for O
cancer B-treatment
treatment I-treatment

ast B-clinical_variable
( I-clinical_variable
sgot I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
uln I-upper_bound

cytotoxic B-treatment
chemotherapy I-treatment

gi B-chronic_disease
obstruction I-chronic_disease

incipient O
toxic B-chronic_disease
megacolon I-chronic_disease

knee B-clinical_variable
flexion I-clinical_variable
range I-clinical_variable
of I-clinical_variable
motion I-clinical_variable
( I-clinical_variable
rom I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound

meets O
diagnostic O
criteria O
for O
full O
or O
subthreshold B-chronic_disease
posttraumatic I-chronic_disease
stress I-chronic_disease
disorder I-chronic_disease

bipolar B-chronic_disease
affective I-chronic_disease
disorder I-chronic_disease
( I-chronic_disease
bpad I-chronic_disease
) I-chronic_disease

increased B-chronic_disease
intracranial I-chronic_disease
pressure I-chronic_disease

subjects O
undergoing O
revision O
total B-treatment
knee I-treatment
arthroplasty I-treatment
or O
revision O
total B-treatment
hip I-treatment
arthroplasty I-treatment

subjects O
with O
known O
allergies O
to O
product O
components O
( O
silicone B-allergy_name
adhesives I-allergy_name
and O
polyurethane B-allergy_name
films I-allergy_name
( O
direct O
contact O
with O
wound O
) O
, O
acrylic B-allergy_name
adhesives I-allergy_name
( O
direct O
contact O
with O
skin O
) O
, O
polyethylene B-allergy_name
fabrics I-allergy_name
and O
super B-allergy_name
- I-allergy_name
absorbent I-allergy_name
powders I-allergy_name
( I-allergy_name
polyacrylates I-allergy_name
) I-allergy_name
( O
within O
the O
dressing O
) O

behavioral B-chronic_disease
disorders I-chronic_disease
that O
would O
prevent O
ability O
to O
follow O
the O
protocol O

not O
engaged O
in O
regularly O
exercise O
for O
approximately O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
enrollment O

predefined O
cardiovascular B-chronic_disease
disease I-chronic_disease

diagnosis O
of O
chronic B-chronic_disease
fatigue I-chronic_disease
syndrome I-chronic_disease

low B-clinical_variable
platelet I-clinical_variable
count I-clinical_variable
on O
screening O
( O
< O
@NUMBER B-upper_bound
/ I-upper_bound
mm3 I-upper_bound

patients O
with O
renal B-chronic_disease
abnormalities I-chronic_disease
, O
such O
as O
pelvic B-treatment
kidney I-treatment
, O
horseshoe B-treatment
kidney I-treatment
, O
or O
renal B-treatment
transplantation I-treatment
, O
that O
would O
require O
modification O
of O
surgical B-treatment
lymph I-treatment
node I-treatment
assessments I-treatment

must O
have O
gog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
@NUMBER B-lower_bound
, O
@NUMBER O
, O
or O
@NUMBER B-upper_bound

bone B-treatment
fracture I-treatment
/ I-treatment
surgery I-treatment
of O
an O
extremity O
during O
the O
preceding B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

brain B-cancer
metastases I-cancer
, O
whether O
resected O
or O
not O
, O
and O
any O
known O
leptomeningeal B-cancer
disease I-cancer
or O
known O
bone B-cancer
metastases I-cancer

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

it O
is O
required O
that O
patients O
with O
stage B-clinical_variable
iiia I-clinical_variable
disease I-clinical_variable
have O
> O
@NUMBER B-lower_bound
mm I-lower_bound
nodal O
involvement O
via O
pathology O
assessment O
of O
the O
resected O
node O

age B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
score I-clinical_variable
of O
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound

positive O
for O
hepatitis B-chronic_disease
c I-chronic_disease
antibody O
, O
hepatitis B-chronic_disease
b I-chronic_disease
surface O
antigen O
, O
or O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
antibody O

subjects O
who O
are O
taking O
warfarin B-treatment

anticipated O
extubation O
within O
@NUMBER B-upper_bound
hours I-upper_bound
of O
enrollment O

expected O
survival O
less O
than O
@NUMBER B-upper_bound
hours I-upper_bound

fasting B-clinical_variable
plasma I-clinical_variable
triglycerides I-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound

who O
have O
had O
prior B-treatment
treatment I-treatment
with O
il-2 B-treatment
, O
interferon B-treatment
, O
anti B-treatment
- I-treatment
pd-1 I-treatment
, O
anti B-treatment
- I-treatment
pd I-treatment
- I-treatment
l1 I-treatment
, O
anti B-treatment
- I-treatment
pd I-treatment
- I-treatment
l2 I-treatment
, O
anti B-treatment
- I-treatment
cd137 I-treatment
, O
anti B-treatment
- I-treatment
ox-40 I-treatment
, O
anti B-treatment
- I-treatment
cd40 I-treatment
, O
or O
anti B-treatment
- I-treatment
ctla-4 I-treatment
antibodies I-treatment

patients O
on O
monoclonal B-treatment
antibody I-treatment
preparations I-treatment
directed I-treatment
to I-treatment
tnfα I-treatment

age B-age
less O
than O
@NUMBER B-upper_bound
years I-upper_bound

concomitant O
, O
non B-chronic_disease
- I-chronic_disease
cardiac I-chronic_disease
disease I-chronic_disease
process O
with O
life B-clinical_variable
expectancy I-clinical_variable
< O
@NUMBER B-upper_bound
year I-upper_bound

histological O
or O
cytological O
documented O
diagnosis O
of O
locally O
advanced O
, O
recurrent O
or O
metastatic B-cancer
( O
stage B-cancer
iiib I-cancer
or O
stage B-cancer
iv I-cancer
) O
nsclc B-cancer

prior B-treatment
therapy I-treatment
with O
mifepristone B-treatment

total O
serum B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
times I-upper_bound
uln I-upper_bound

have O
a O
madrs B-clinical_variable
score I-clinical_variable
of O
at O
least O
@NUMBER B-lower_bound
at O
screening O

availability O
of O
tumor B-cancer
tissue O
at O
study O
enrollment O

body B-clinical_variable
weight I-clinical_variable
must O
be O
≥ O
@NUMBER B-lower_bound
kilograms I-lower_bound
( I-lower_bound
kg I-lower_bound
) I-lower_bound
if O
suspension O
is O
not O
available O

prior B-treatment
allogenic I-treatment
bone I-treatment
marrow I-treatment
transplantation I-treatment
or O
prior B-treatment
solid I-treatment
organ I-treatment
transplantation I-treatment

patients O
who O
did O
not O
enroll O
during O
their O
chemotherapy B-treatment
are O
still O
eligible O
to O
enroll O
during O
subsequent B-treatment
hormonal I-treatment
therapy I-treatment
or O
radiation B-treatment
as O
long O
as O
it O
is O
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
diagnosis O

moderate O
response O
( O
grade O
@NUMBER O
, O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
% I-upper_bound
residual B-clinical_variable
tumor I-clinical_variable
) O

lesions B-clinical_variable
in O
or O
close O
to O
scar O
tissue O
( O
< O
@NUMBER B-upper_bound
cm I-upper_bound
) O

initiation O
of O
treatments B-treatment
that O
could O
impact O
bone O
metabolism O
( O
diuretics O
, O
hormones O
, O
bine O
anabolic O
agents O
) O
in O
the O
prior B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

known O
history O
of O
non B-chronic_disease
- I-chronic_disease
infectious I-chronic_disease
pneumonitis I-chronic_disease

cysts B-chronic_disease

herpes B-chronic_disease
zoster I-chronic_disease
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
or O
any O
infection B-chronic_disease
requiring O
hospitalization O
or O
intravenous B-treatment
or O
intramuscular B-treatment
antibiotics I-treatment
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

therapy O
must O
include O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
of O
mycophenolate B-treatment
or O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
of O
cyclophosphamide B-treatment
followed O
by O
mycophenolate O
or O
azathioprine B-treatment

previously O
untreated O
aml B-cancer
ineligible O
for O
receiving O
standard O
intensive B-treatment
therapy I-treatment

severe B-chronic_disease
autonomic I-chronic_disease
dysreflexia I-chronic_disease

timed B-clinical_variable
up I-clinical_variable
- I-clinical_variable
and I-clinical_variable
- I-clinical_variable
go I-clinical_variable

receiving O
botox B-treatment
therapy I-treatment
currently O
or O
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

patients O
with O
a O
crp B-clinical_variable
greater O
than O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
l I-lower_bound
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
anticipated O
transplant O

clinically O
significant O
pulmonary O
compromise O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
first O
dose O
, O
including O
pneumonia B-chronic_disease
, O
pneumonitis B-chronic_disease
, O
requirement O
for O
supplemental O
oxygen O
) O
. O
use O
to O
maintain O
adequate O
oxygenation O
, O
or O
pleural B-chronic_disease
effusion I-chronic_disease
sufficient O
to O
warrant O
pleurocentesis B-treatment
or O
any O
history O
of O
≥ O
grade B-lower_bound
@NUMBER I-lower_bound
drug O
induced O
or O
radiation B-chronic_disease
pneumonitis I-chronic_disease

gi B-chronic_disease
bleeding I-chronic_disease
or O
acute B-chronic_disease
pancreatitis I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound

known O
history O
of O
hepatitis B-chronic_disease
b I-chronic_disease
or I-chronic_disease
c I-chronic_disease
infection I-chronic_disease
hepatitis B-chronic_disease
b I-chronic_disease
or O
c O
infection O
or O
known O
positive O
test O
for O
hepatitis B-chronic_disease
b I-chronic_disease
surface I-chronic_disease
antigen I-chronic_disease
or I-chronic_disease
core I-chronic_disease
antigen I-chronic_disease
, O
or O
hepatitis B-chronic_disease
c I-chronic_disease
polymerase O
chain O
reaction O
( O
pcr O
) O

average O
pain O
of O
at O
least O
@NUMBER B-lower_bound
on O
a O
numeric O
rating O
scale O
in O
the O
previous O
week O
( O
nrs B-clinical_variable
; O
ranging O
from O
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
) O

unstable O
medical B-chronic_disease
conditions I-chronic_disease
( O
e.g O
. O
uncontrolled B-chronic_disease
diabetes I-chronic_disease
, O
uncompensated B-chronic_disease
cardiac I-chronic_disease
issues I-chronic_disease
, O
heart B-chronic_disease
failure I-chronic_disease
or O
chronic B-chronic_disease
obstructive I-chronic_disease
pulmonary I-chronic_disease
disease I-chronic_disease
) O

≤ O
@NUMBER B-upper_bound
years I-upper_bound

af B-chronic_disease
with I-chronic_disease
hydrops I-chronic_disease

any O
maternal B-chronic_disease
- I-chronic_disease
fetal I-chronic_disease
conditions I-chronic_disease
associated O
with O
high O
odds O
of O
premature O
delivery O
or O
death O

maternal B-clinical_variable
serum I-clinical_variable
potassium I-clinical_variable
level I-clinical_variable
< O
@NUMBER B-upper_bound
mmol I-upper_bound
/ I-upper_bound
l I-upper_bound
/ O
< O
@NUMBER B-upper_bound
meq I-upper_bound
/ I-upper_bound
l I-upper_bound
( O
at O
start O
of O
treatment O
) O

relevant O
preexisting O
maternal O
obstructive B-chronic_disease
airway I-chronic_disease
disease I-chronic_disease

primary O
diagnosis O
of O
ocd B-chronic_disease

sufficient O
severity O
of O
ocd B-chronic_disease
symptoms O

a O
urine O
pregnancy B-pregnancy
test O
will O
be O
performed O
within O
@NUMBER B-upper_bound
hours I-upper_bound
before O
the O
rna B-treatment
cart19 I-treatment
infusion O

patients O
with O
inflammatory B-chronic_disease
bowel I-chronic_disease
disease I-chronic_disease

@NUMBER B-lower_bound
years I-lower_bound
old O
or O
older O

a O
cord O
blood O
/ O
first O
hour O
of O
life O
blood B-treatment
gas I-treatment
with O
ph B-clinical_variable
> O
@NUMBER B-lower_bound
and O
< O
@NUMBER B-upper_bound

continue O
to O
carry O
the O
diagnosis O
of O
parkinson B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
consistent O
with O
uk O
brain O
bank O
criteria O

latino B-ethnicity
: O
self O
- O
report O

acute B-chronic_disease
dermatitis I-chronic_disease
dermatitis B-chronic_disease
outbreak O
or O
dermatitis O
on O
or O
near O
the O
test O
area O
on O
the O
back O

clinically O
significant O
cerebrovascular B-chronic_disease
disease I-chronic_disease
including O
cortical O
infarct O
, O
strategically O
located O
subcortical O
gray O
matter O
or O
extensive O
white O
matter O
abnormalities O

if O
a O
woman B-gender
and O
peri O
- O
menopausal O
and O
unwilling O
to O
maintain O
current O
hormone B-treatment
replacement I-treatment
therapy I-treatment
status O
and O
allowed O
medication B-treatment
usage O
during O
the O
study O

medications O
with O
significant O
effect O
on O
memory O
such O
as O
anticholinergic B-treatment
( O
diphenhydramine B-treatment
, O
tricyclic B-treatment
antidepressants I-treatment
, O
benztropine B-treatment
) O
; O
sedative B-treatment
hypnotics I-treatment
such O
as O
benzodiazepines B-treatment
; O
narcotics B-treatment
; O
and O
antiparkinsonian O
medications O
will O
all O
be O
excluded O

include O
> O
@NUMBER B-lower_bound
mm I-lower_bound
st B-treatment
depression I-treatment
, O
extra O
systole O
, O
chest B-chronic_disease
pain I-chronic_disease
, O
arrhythmias B-chronic_disease
, O
hypotension B-chronic_disease
and O
or O
dizziness O
or O
significant O
st O
segment O
elevation O
during O
the O
treadmill O
test O

persons O
with O
neurological B-chronic_disease
, O
psychiatry B-chronic_disease
or O
other O
clinical O
conditions O
likely O
to O
cause O
dementia B-chronic_disease

less O
than O
@NUMBER B-upper_bound
week I-upper_bound
of O
post B-chronic_disease
- I-chronic_disease
traumatic I-chronic_disease
amnesia I-chronic_disease
( I-chronic_disease
pta I-chronic_disease
) I-chronic_disease

planned B-pregnancy
pregnancy I-pregnancy
during O
the O
follow O
- O
up O
period O
( O
since O
exposure O
to O
an O
insecticide O
is O
involved O
) O

patients O
will O
be O
eligible O
if O
they O
had O
lumbar B-treatment
surgery I-treatment
for O
a O
degenerative O
condition O
and O
their O
surgeon O
deems O
it O
safe O
for O
them O
to O
walk O
more O

participation O
in O
a O
clinical B-treatment
trial I-treatment
evaluating O
another O
preventative O
strategy O
for O
chronic B-chronic_disease
gvhd I-chronic_disease
or O
ongoing O
participation O
in O
a O
clinical O
trial O
for O
therapy B-treatment
of O
acute B-chronic_disease
gvhd I-chronic_disease

prior O
completion O
of O
experimental B-treatment
therapy I-treatment
for O
acute B-chronic_disease
gvhd I-chronic_disease
is O
permissible O
if O
the O
experimental O
agent O
was O
used O
> O
@NUMBER B-lower_bound
days I-lower_bound
prior I-lower_bound
to O
enrollment O

history O
of O
radiation B-treatment
to O
neck O

serious B-chronic_disease
or O
unstable O
medical O
or O
psychological B-chronic_disease
conditions I-chronic_disease
that O
, O
in O
the O
opinion O
of O
the O
investigator O
, O
would O
compromise O
the O
subject O
's O
safety O
or O
successful O
participation O
in O
the O
study O

the O
patient O
's O
tumor B-cancer
has O
been O
evaluated O
and O
prospectively O
identified O
as O
having O
fgfr B-clinical_variable
@NUMBER O
, O
@NUMBER O
, O
@NUMBER O
, O
or O
@NUMBER O
genetic O
alterations O

neurologic B-chronic_disease
disorders I-chronic_disease

active O
autoimmune B-chronic_disease
disease I-chronic_disease
requiring O
systemic B-treatment
therapy I-treatment
in O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
( O
imgn853 B-treatment
and O
pembrolizumab B-treatment
only O
) O

surgery B-treatment
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound

use O
of O
immunomodulatory B-treatment
or O
experimental B-treatment
drugs I-treatment

past O
thrombotic B-chronic_disease
disease I-chronic_disease

patients O
who O
do O
not O
undergo O
chemotherapy B-treatment

current O
use O
of O
systemic B-treatment
immunosuppressant I-treatment
( I-treatment
s I-treatment
) I-treatment
, O
or O
prior B-treatment
anti I-treatment
- I-treatment
cancer I-treatment
therapy I-treatment
to O
include O
: O
lenalidomide B-treatment
, O
fludarabine B-treatment
, O
or O
alemtuzumab B-treatment
within O
@NUMBER B-upper_bound
months I-upper_bound
; O
radioimmunoconjugate B-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
; O
mab B-treatment
or O
antibody B-treatment
- I-treatment
drug I-treatment
conjugate I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
; O
or O
radiotherapy B-treatment
/ O
chemotherapy B-treatment
/ O
hormone B-treatment
therapy I-treatment
/ O
targeted B-treatment
small I-treatment
- I-treatment
molecule I-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
day O
@NUMBER O
of O
cycle O
@NUMBER O

positive O
for O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
or O
hepatitis B-chronic_disease
b I-chronic_disease
or I-chronic_disease
c I-chronic_disease

have O
at O
least O
@NUMBER B-lower_bound
years I-lower_bound
of O
driving O
experience O

adequate O
bone O
marrow O
, O
renal O
function O
, O
cardiac O
, O
and O
pulmonary O
function O
, O
negative B-pregnancy
pregnancy I-pregnancy
test O
( O
for O
women B-gender
) O

uncontrolled O
hepatitis B-chronic_disease
b I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hbv I-chronic_disease
) I-chronic_disease
infection I-chronic_disease
hbv B-chronic_disease
) O
infection O
, O
defined O
as O
plasma O
hbv O
dna O
detectable O
by O
polymerase O
chain O
reaction O
( O
pcr O
) O

anc B-clinical_variable
> O
@NUMBER B-lower_bound

esomeprazole B-treatment
( I-treatment
nexium I-treatment
) I-treatment

cardiogenic B-chronic_disease
shock I-chronic_disease

patients O
older O
than O
age B-age
@NUMBER B-lower_bound
with O
ischemic O
symptoms O
( O
stable B-chronic_disease
or O
unstable B-chronic_disease
angina I-chronic_disease
or O
nstemi B-chronic_disease
without O
thrombosis B-chronic_disease
of O
the O
target O
lesion O
on O
coronary B-treatment
angiography I-treatment
) O
or O
evidence O
of O
myocardial B-chronic_disease
ischemia I-chronic_disease
in O
the O
presence O
of O
≥ O
@NUMBER B-lower_bound
% I-lower_bound
de O
novo O
stenosis O
located O
in O
native O
coronary O
vessels O
( O
max O
. O
@NUMBER B-upper_bound
lesions I-upper_bound
in O
one O
or O
@NUMBER B-upper_bound
separate I-upper_bound
vessels I-upper_bound
) O

not O
recovered O
from O
toxicity O
due O
to O
all O
prior B-treatment
therapies I-treatment

past O
history O
of O
tuberculosis B-chronic_disease
( I-chronic_disease
tb I-chronic_disease
) I-chronic_disease
or O
active B-chronic_disease
infection I-chronic_disease
with I-chronic_disease
tb I-chronic_disease
, O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
, O
hepatitis B-chronic_disease
b I-chronic_disease
or O
hepatitis B-chronic_disease
c I-chronic_disease

history O
of O
myelodysplasia B-cancer
( O
due O
to O
suggested O
cautionary O
use O
of O
colchicine B-treatment
in O
this O
setting O
) O

expected O
geographic O
unavailability O
at O
a O
participating O
hd O
unit O
for O
> O
@NUMBER B-lower_bound
consecutive I-lower_bound
weeks I-lower_bound
or O
> O
@NUMBER B-lower_bound
weeks I-lower_bound
total O
during O
the O
next B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
( O
excluding O
unavailability O
due O
to O
hospitalizations B-treatment
) O

post O
kidney B-treatment
transplantation I-treatment

rrf B-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound
/ I-upper_bound
@NUMBER I-upper_bound
m2 I-upper_bound
as O
determined O
by O
iohexol O
gfr O
measurement O

non B-cancer
- I-cancer
hodgkin I-cancer
lymphoma I-cancer
( I-cancer
nhl I-cancer
) I-cancer

current O
foot B-chronic_disease
ulcer I-chronic_disease

defined O
as O
a O
@NUMBER B-lower_bound
% I-lower_bound
or O
greater O
decline O
in O
egfr O
following O
the O
two O
- O
week O
run O
- O
in O
as O
compared O
to O
baseline O

increase O
in O
angina B-chronic_disease
, O
angina O
at O
rest O

leukocytes B-clinical_variable
: O
≥ O
4 B-lower_bound
* I-lower_bound
10 I-lower_bound
^ I-lower_bound
9 I-lower_bound
/ I-lower_bound
l I-lower_bound

presence O
of O
active B-chronic_disease
infection I-chronic_disease
infection B-chronic_disease
at O
screening O
or O
history O
of O
serious O
infection O
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound

malignant B-cancer
, O
unresectable O
pheochromocytoma B-cancer
or O
paraganglioma B-cancer

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound
absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
( I-clinical_variable
anc I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
× I-lower_bound
@NUMBER I-lower_bound
/ I-lower_bound
l I-lower_bound
( O
> O
@NUMBER B-lower_bound
per I-lower_bound
mm3 I-lower_bound
) O
platelet B-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
× I-lower_bound
@NUMBER I-lower_bound
/ I-lower_bound
l I-lower_bound
( O
> O
@NUMBER B-lower_bound
per I-lower_bound
mm3 I-lower_bound
) O
serum B-clinical_variable
bilirubin I-clinical_variable
≤ O
1.5× B-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
ast B-clinical_variable
< O
@NUMBER B-upper_bound
creatinine B-clinical_variable
clearance I-clinical_variable
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
aspartate B-clinical_variable
transaminase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
and O
alanine B-clinical_variable
transaminase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
× I-upper_bound
uln I-upper_bound
@NUMBER B-upper_bound
× I-upper_bound
uln I-upper_bound
( O
≤ O
@NUMBER O
× O
uln O
if O
documented O
liver B-cancer
metastasis I-cancer
are O
present O
) O

ipss B-clinical_variable
score I-clinical_variable
at O
initial O
evaluation O
should O
be O
greater O
than O
@NUMBER B-lower_bound
, O
and O
uroflowmetry B-clinical_variable
( I-clinical_variable
qmax I-clinical_variable
) I-clinical_variable
of O
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
s I-upper_bound
( I-upper_bound
milliliters I-upper_bound
per I-upper_bound
second I-upper_bound
) I-upper_bound

supine B-chronic_disease
hypertension I-chronic_disease
will O
be O
defined O
as O
systolic B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
> O
@NUMBER B-lower_bound
mmhg I-lower_bound
and O
/ O
or O
diastolic B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
> O
@NUMBER B-lower_bound
mmhg I-lower_bound
while O
lying O
down O

pericardial B-chronic_disease
disease I-chronic_disease

receiving O
chemotherapy B-treatment
during O
study O
period O

men B-gender
because O
osteoporosis B-chronic_disease
is O
less O
common O
in O
men B-gender

age B-age
≥ O
@NUMBER B-lower_bound
years I-lower_bound

initial O
zest O
@NUMBER O
study O
only O
included O
women B-gender

human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
-positive O
patients O
on O
combination B-treatment
antiretroviral I-treatment
therapy I-treatment

leukocytes B-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mcl I-lower_bound

between O
the O
ages B-age
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

english B-language_fluency
and I-language_fluency
spanish I-language_fluency
speaking I-language_fluency
stroke O
patients O
with O
diagnosis O
of O
ischemic B-chronic_disease
stroke I-chronic_disease
, O
hemorrhagic B-chronic_disease
stroke I-chronic_disease
or O
tia B-chronic_disease
who O
are O
discharged O
home O
from O
participating O
hospitals O

subject O
has O
active O
brain B-cancer
metastases I-cancer
or O
leptomeningeal B-cancer
metastases I-cancer
. O
subjects O
with O
prior O
history O
of O
brain B-cancer
metastasis I-cancer
who O
have O
undergone O
local B-treatment
therapy I-treatment
( O
i.e. O
, O
metastatectomy B-treatment
and O
/ O
or O
radiation B-treatment
) O
and O
show O
no O
evidence O
of O
local O
recurrence O
or O
progression O
over O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
prior I-upper_bound
to O
screening O
are O
eligible O

unintended B-clinical_variable
weight I-clinical_variable
loss I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound
in O
@NUMBER B-upper_bound
months I-upper_bound
preceding O
study O
entry O

healthy O
male B-gender
or O
female B-gender

currently O
breast O
feeding O
, O
pregnant B-pregnancy
or O
planning B-pregnancy
to I-pregnancy
conceive I-pregnancy
or O
father O
children O
from O
screening O
through O
@NUMBER B-upper_bound
days I-upper_bound
after I-upper_bound
last O
dose O
of O
study B-treatment
drug I-treatment

patients O
with O
metastatic B-cancer
colorectal I-cancer
cancer I-cancer
with O
no O
available O
therapy B-treatment
options O
that O
are O
known O
to O
provide O
clinical O
benefit O
per O
institutional O
standard O
of O
care O

hypertension B-chronic_disease
included O
in O
problem O
list O

use O
of O
antihypertensive B-treatment
agents I-treatment
except O
thiazide B-treatment
diuretics I-treatment

have O
a O
life B-clinical_variable
expectancy I-clinical_variable
less O
than O
@NUMBER B-upper_bound
year I-upper_bound

planned O
use O
of O
external O
vac B-treatment
dressing O
intra O
- O
operatively O

subject O
is O
determined O
to O
have O
an O
american B-clinical_variable
society I-clinical_variable
of I-clinical_variable
anesthesiologists I-clinical_variable
' I-clinical_variable
( I-clinical_variable
asa I-clinical_variable
) I-clinical_variable
physical I-clinical_variable
clas I-clinical_variable
s O
of O
@NUMBER B-lower_bound
, O
@NUMBER O
, O
or O
@NUMBER B-upper_bound

uncontrolled B-chronic_disease
diabetes I-chronic_disease
( O
i.e O
. O
known O
hba1c B-clinical_variable
value I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound
) O

current O
daily O
smoking O
( O
@NUMBER B-lower_bound
or O
more O
cigarettes O
per O
day O
for O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
or O
longer O
) O

ast B-clinical_variable
and O
alt B-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

not O
willing O
to O
avoid O
grapefruit O
, O
grapefruit O
juices O
, O
grapefruit O
hybrids O
, O
seville O
oranges O
, O
pummelos O
, O
and O
exotic O
citrus O
fruits O
from O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
dose O
of O
study B-treatment
medication I-treatment
, O
throughout O
the O
study O
, O
and O
until O
@NUMBER B-upper_bound
weeks I-upper_bound
after O
the O
last O
dose O
of O
azd1775 O
due O
to O
potential O
cyp3a4 O
interaction O
with O
the O
study O
medication O

pre B-treatment
- I-treatment
treatment I-treatment
swallowing O
evaluation O
by O
speech O
and O
swallowing O
therapist O
, O
to O
included O
a O
modified O
barium O
swallow O
showing O
no O
significant O
impairment O
with O
swallowing O
oral B-treatment
medications I-treatment

recommendation O
to O
undergo O
concurrent B-treatment
crt I-treatment
, O
as O
determined O
by O
the O
treating O
physician O
, O
with O
a O
curative O
goal O

sexually O
active O
males B-gender
unless O
they O
use B-contraception_consent
a I-contraception_consent
condom I-contraception_consent
during O
intercourse O
while O
taking O
drug O
and O
for O
@NUMBER O
months O
after O
stopping O
ceritinib B-treatment
and O
should O
not O
father O
a O
child O
for O
at O
least O
@NUMBER O
months O
after O
the O
last O
dose O
of O
treatment B-treatment

because O
no O
dosing O
or O
adverse O
event O
data O
are O
currently O
available O
on O
the O
use O
of O
plx3397 O
in O
combination O
with O
sirolimus O
in O
patients O
< O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age
, O
children O
are O
excluded O
from O
this O
study O
, O
but O
will O
be O
eligible O
for O
future O
pediatric O
trials O

disease O
site O
/ O
type O
with O
pathologic O
confirmation O
of O
diagnosis O
at O
participating O
cancer B-cancer
site O

hiv B-chronic_disease
-positive O
patients O
on O
combination O
antiretroviral B-treatment
therapy I-treatment
are O
ineligible O
because O
of O
the O
potential O
for O
pharmacokinetic O
interactions O
with O
plx3397 B-treatment

phase O
@NUMBER O
: O
advanced O
, O
unresectable O
sarcoma B-cancer
( O
any O
subtype O
) O

fibrosarcoma B-cancer

myocardial B-chronic_disease
infarction I-chronic_disease
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
, O
or O
stable O
or O
unstable B-chronic_disease
angina I-chronic_disease

patient O
must O
have O
a O
negative B-pregnancy
pregnancy I-pregnancy
test O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
study O
entry O

prior B-treatment
adjuvant I-treatment
chemotherapy I-treatment
with I-treatment
gemcitabine I-treatment
and O
/ O
or O
docetaxel B-treatment
/ O
paclitaxel B-treatment
is O
allowed O

surgery B-treatment
for O
primary O
or O
metastatic B-cancer
disease I-cancer
after O
chemotherapy B-treatment
following O
a O
response O
is O
allowed O

hiv B-chronic_disease
-positive O
individuals O
on O
combination B-treatment
antiretroviral I-treatment
therapy I-treatment

subjects O
may O
have O
previously O
received O
pre B-treatment
- I-treatment
operative I-treatment
radiation I-treatment
therapy I-treatment

subjects O
with O
qtc B-clinical_variable
interval I-clinical_variable
> O
@NUMBER B-lower_bound
ms I-lower_bound

evidence O
of O
leukemia B-cancer
after O
induction B-treatment
therapy I-treatment
which O
, O
in O
the O
opinion O
of O
the O
investigator O
, O
would O
be O
appropriate O
for O
reinduction O
with O
sirolimus B-treatment
/ I-treatment
mec I-treatment
therapy I-treatment

evidence O
of O
leukemia B-cancer
recurrence O
after O
a O
nadir B-treatment
bone I-treatment
marrow I-treatment
biopsy I-treatment
demonstrates O
no O
evidence O
of O
residual B-cancer
leukemia I-cancer

patients O
must O
have O
histologic O
evidence O
of O
high O
risk O
acute B-cancer
myeloid I-cancer
leukemia I-cancer

residual O
leukemia B-cancer
after O
a O
minimum O
of O
@NUMBER B-lower_bound
prior O
courses O
of O
chemotherapy B-treatment
( O
same O
or O
different O
) O

tacrolimus B-treatment
( O
e.g O
. O
prograf B-treatment
) O
subjects O
taking O
fluconozole B-treatment
, O
voriconizole B-treatment
, O
itraconazole B-treatment
, O
posaconazole B-treatment
, O
and O
ketokonazole B-treatment
within O
@NUMBER B-upper_bound
hours I-upper_bound
of O
study O
drug O
starting O

patients O
on O
stable O
dose O
phosphodiesterase B-treatment
inhibitors I-treatment
( O
sildenafil B-treatment
, O
tadalafil B-treatment
or O
vardenafil B-treatment
) O
, O
endothelin B-treatment
antagonists I-treatment
, O
alpha B-treatment
adrenergic I-treatment
antagonists I-treatment
, O
or O
calcium B-treatment
channel I-treatment
blockers I-treatment
defined O
as O
3-months B-upper_bound
with O
no O
change O
in O
dose O

subjects O
currently O
taking O
or O
other O
prostacyclins B-treatment

direct O
breast O
feeding O
≥ O
@NUMBER B-lower_bound
% I-lower_bound
of O
daily O
feeding O
occurrences O

known O
genetic B-chronic_disease
, O
metabolic B-chronic_disease
or O
syndromic B-chronic_disease
disease I-chronic_disease

undergoing O
invasive B-clinical_variable
mechanical I-clinical_variable
ventilation I-clinical_variable
for O
> O
@NUMBER B-lower_bound
hours I-lower_bound
, O
excluding O
any O
time O
during O
which O
the O
patient O
was O
being O
ventilated O
in O
the O
operating O
room O
, O
ct O
or O
ir O
, O
as O
this O
could O
represent O
too O
long O
a O
delay O
in O
instituting O
the O
intervention O
for O
it O
to O
have O
a O
chance O
of O
being O
effective O

any O
current O
or O
past O
history O
of O
clinically O
significant O
arrhythmias B-chronic_disease
, O
including O
treatment B-treatment
with I-treatment
anti I-treatment
- I-treatment
arrhythmics I-treatment

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

history O
( O
within O
prior B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
) O
of O
either O
myocardial B-chronic_disease
infarction I-chronic_disease
or O
unstable B-chronic_disease
or O
poorly B-chronic_disease
controlled I-chronic_disease
angina I-chronic_disease

known O
infection O
with O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
or O
known O
chronic B-chronic_disease
active I-chronic_disease
hepatitis I-chronic_disease
b I-chronic_disease
or O
hepatitis B-chronic_disease
c I-chronic_disease
virus I-chronic_disease
( O
hbv B-chronic_disease
/ O
hcv B-chronic_disease
) O
infection O
, O
unless O
a O
co O
- O
morbidity O
in O
patients O
with O
hepatocellular B-cancer
carcinoma I-cancer
( I-cancer
hcc I-cancer
) I-cancer

patient O
agrees O
and O
is O
willing O
to O
provide O
@NUMBER O
serial B-treatment
tumor I-treatment
biopsy I-treatment
( O
biopsies O
are O
mandatory O
) O
, O
which O
would O
not O
put O
the O
patient O
or O
their O
treatment B-treatment
at O
significant O
risk O

patients O
who O
have O
received O
antibody B-treatment
- I-treatment
based I-treatment
therapies I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
or O
@NUMBER B-upper_bound
half I-upper_bound
- I-upper_bound
lives I-upper_bound
of O
the O
agent O
, O
whichever O
time O
period O
is O
longer O

patients O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

serum B-clinical_variable
creatinine I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

active O
untreated O
systemic O
infection B-chronic_disease
at O
time O
of O
transplantation B-treatment
( O
including O
active B-chronic_disease
infection I-chronic_disease
with O
aspergillus O
or O
other O
mold O
within O
@NUMBER B-upper_bound
days I-upper_bound
) O

sexually O
active O
participants O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
adequate I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
for O
the O
during O
the O
study O
period O
( O
from O
before O
the O
start O
of O
the O
preparative B-treatment
chemotherapy I-treatment
through O
@NUMBER B-upper_bound
year I-upper_bound
post B-treatment
- I-treatment
transplant I-treatment
) O

diagnosis O
of O
immunodeficiency B-chronic_disease
or O
is O
receiving O
systemic B-treatment
steroid I-treatment
therapy I-treatment
or O
any O
other O
form O
of O
immunosuppressive B-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
trial B-treatment
treatment I-treatment

male B-gender
subjects I-gender
should O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
an I-contraception_consent
adequate I-contraception_consent
method I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
starting O
with O
the O
first O
dose O
of O
study O
therapy B-treatment
through O
@NUMBER B-upper_bound
days I-upper_bound
after I-upper_bound
the O
last O
dose O
of O
study O
therapy O

no O
uncontrolled O
, O
inter B-chronic_disease
- I-chronic_disease
current I-chronic_disease
or I-chronic_disease
recent I-chronic_disease
illness I-chronic_disease
that O
in O
the O
investigator O
's O
opinion O
precludes O
participation O
in O
the O
study O
, O
including O
those O
undergoing O
therapy O
for O
a O
separate O
invasive B-cancer
malignancy I-cancer

all O
women B-gender
of O
child O
bearing O
potential O
( O
last O
menstrual O
period O
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
and O
not O
surgically O
sterile O
) O
will O
be O
tested O
for O
pregnancy B-pregnancy
at O
pre O
- O
entry O

subject O
with O
previous O
history O
of O
malignancy B-gender
is O
eligible O
, O
provided O
that O
he O
/ O
she O
has O
been O
disease O
free O
for O
> O
@NUMBER B-lower_bound
years I-lower_bound

cardiovascular B-chronic_disease
disease I-chronic_disease
; O
subjective O
or O
objective O
indicators O
of O
ischemic B-chronic_disease
heart I-chronic_disease
disease I-chronic_disease
( O
e.g. O
, O
angina B-chronic_disease
, O
st B-chronic_disease
segment I-chronic_disease
depression I-chronic_disease
) O
or O
serious O
arrhythmias B-chronic_disease
at O
rest O
or O
during O
the O
graded O
exercise O
test O
( O
gxt O
) O
without O
follow O
- O
up O
evaluation O
will O
be O
cause O
for O
exclusion O
; O
follow O
- O
up O
evaluation O
must O
include O
diagnostic O
testing O
( O
e.g. O
, O
stress O
echocardiogram O
or O
thallium O
stress O
test O
) O
with O
interpretation O
by O
a O
cardiologist O

thyroid B-chronic_disease
dysfunction I-chronic_disease
, O
defined O
as O
an O
ultrasensitive B-clinical_variable
tsh I-clinical_variable
< O
@NUMBER B-upper_bound
or O
> O
@NUMBER B-lower_bound
mu I-lower_bound
/ I-lower_bound
l I-lower_bound
; O
volunteers O
with O
abnormal O
tsh O
values O
will O
be O
re O
- O
considered O
for O
participation O
in O
the O
study O
after O
follow O
- O
up O
evaluation O
by O
the O
pcp O
with O
initiation O
or O
adjustment O
of O
thyroid B-treatment
hormone I-treatment
replacement I-treatment

aged B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
y I-upper_bound

diagnosed O
eating B-chronic_disease
disorder I-chronic_disease
( O
i.e. O
, O
anorexia B-chronic_disease
nervosa I-chronic_disease
, O
bulimia B-chronic_disease
nervosa I-chronic_disease
, O
binge B-chronic_disease
eating I-chronic_disease
disorder I-chronic_disease
) O
in O
either O
parent O
( O
participating O
and O
nonparticipating O
) O
and O
/ O
or O
the O
participating O
child O

anasarca B-chronic_disease

cyanotic B-chronic_disease
congenital I-chronic_disease
heart I-chronic_disease
defect I-chronic_disease

gastroschisis B-chronic_disease

age B-age
greater O
than O
@NUMBER B-lower_bound
years I-lower_bound

patients O
with O
chronic B-chronic_disease
liver I-chronic_disease
disease I-chronic_disease

previous O
allergy O
or O
intolerance O
to O
allopurinol B-allergy_name
or O
febuxostat B-allergy_name

stage B-chronic_disease
@NUMBER I-chronic_disease
or I-chronic_disease
@NUMBER I-chronic_disease
chronic I-chronic_disease
kidney I-chronic_disease
disease I-chronic_disease
( I-chronic_disease
ckd I-chronic_disease
) I-chronic_disease
- O
defined O
as O
egfr B-clinical_variable
of O
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound

fasting B-clinical_variable
ldl I-clinical_variable
cholesterol I-clinical_variable
within O
1.5x B-upper_bound
uln I-upper_bound
per O
institutional O
guidelines O
( O
ie O
, O
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
for O
@NUMBER B-lower_bound
- O
@NUMBER O
years O
of O
age B-age
, O
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
for O
subjects O
> O
@NUMBER O
years O
old O
) O
* O
and O
fasting B-clinical_variable
serum I-clinical_variable
cholesterol I-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
( O
< O
@NUMBER B-upper_bound
mmol I-upper_bound
/ I-upper_bound
l I-upper_bound
) O
* O
and O
fasting B-clinical_variable
triglycerides I-clinical_variable
< O
@NUMBER B-upper_bound
uln I-upper_bound
( O
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
for O
ages B-age
@NUMBER O
- O
@NUMBER O
, O
< O
@NUMBER B-upper_bound
for O
ages O
> O
@NUMBER O
) O
* O

other O
than O
the O
drugs O
used O
in O
this O
protocol O
, O
other B-treatment
drugs I-treatment
drugs B-treatment
targeted I-treatment
to I-treatment
treat I-treatment
progeria I-treatment
progeria B-chronic_disease
are O
excluded O

have O
not O
recovered O
from O
the O
side O
effects O
of O
any O
major B-treatment
surgery I-treatment
( O
defined O
as O
requiring O
general B-treatment
anesthesia I-treatment
but O
excluding O
a O
procedure O
for O
insertion O
of O
central O
venous O
access O
) O

serum B-clinical_variable
albumin I-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

subjects O
receiving O
any O
pro B-treatment
- I-treatment
coagulant I-treatment
agents I-treatment
( O
e.g O
. O
ddavp B-treatment
, O
recombinant B-treatment
factor I-treatment
viia I-treatment
or O
prothrombin B-treatment
complex I-treatment
concentrates I-treatment
( I-treatment
pcc I-treatment
) I-treatment
and O
/ O
or O
an O
antifibrinolytic B-treatment
agent I-treatment
within O
@NUMBER B-upper_bound
hours I-upper_bound
of O
enrollment O
, O
or O
with O
known O
hypercoagulable B-chronic_disease
state O

not O
pregnant B-pregnancy
and O
not O
nursing O

glomerular B-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
( I-clinical_variable
gfr I-clinical_variable
) I-clinical_variable
is O
calculated O
based O
on O
cockcroft O
- O
gault O
method O

subjects O
will O
be O
enrolled O
based O
on O
confirmed O
histology O
diagnosis O
of O
the O
npc B-cancer

treated O
basal B-cancer
cell I-cancer
carcinoma I-cancer

lactate B-clinical_variable
≥ O
@NUMBER B-lower_bound

age B-age
≥ O
@NUMBER B-lower_bound

subject O
has O
active O
uncontrolled O
systemic O
fungal B-chronic_disease
, O
bacterial B-chronic_disease
, O
or O
viral B-chronic_disease
infection I-chronic_disease
infection B-chronic_disease
( O
defined O
as O
ongoing O
signs O
/ O
symptoms O
related O
to O
the O
infection O
without O
improvement O
despite O
appropriate O
antibiotics B-treatment
, O
antiviral B-treatment
therapy I-treatment
, O
and O
/ O
or O
other O
treatment B-treatment
) O

hydroxyurea B-treatment

hydroxyurea B-treatment
should O
not O
be O
given O
within O
@NUMBER B-upper_bound
hours I-upper_bound
prior I-upper_bound
to O
and O
after O
administration O
of O
azacitidine B-treatment

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
( I-clinical_variable
anc I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound
/ I-upper_bound
μl I-upper_bound

concurrent O
administration O
of O
any O
other O
anti B-treatment
- I-treatment
cancer I-treatment
therapy I-treatment

hemoglobin B-clinical_variable
( I-clinical_variable
hgb I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound
( O
may O
be O
achieved O
with O
erythropoietin B-treatment
agents I-treatment
; O
no O
blood B-treatment
transfusions I-treatment
in O
the O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
entry O
) O

hormonal B-treatment
therapy I-treatment
with I-treatment
luteinizing I-treatment
hormone I-treatment
- I-treatment
releasing I-treatment
hormone I-treatment
( I-treatment
lhrh I-treatment
) I-treatment
analogues O
for O
medical O
castration O
in O
patients O
with O
castrate B-cancer
- I-cancer
resistant I-cancer
prostate I-cancer
cancer I-cancer

patients O
unable O
to O
swallow O
orally B-treatment
administered I-treatment
medication I-treatment
and O
patients O
with O
gastrointestinal B-chronic_disease
disorders I-chronic_disease
likely O
to O
interfere O
with O
absorption O
of O
the O
study B-treatment
medication I-treatment

prior O
standard O
of O
care O
cancer B-treatment
chemotherapy I-treatment
, O
immunotherapy B-treatment
, O
or O
radiotherapy B-treatment
< O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
first O
dose O
of O
study B-treatment
agent I-treatment
( I-treatment
s I-treatment
) I-treatment

active O
uncontrolled O
systemic O
bacterial B-chronic_disease
, O
viral B-chronic_disease
, O
or O
fungal B-chronic_disease
infection I-chronic_disease
, O
unstable O
cardiovascular B-chronic_disease
disease I-chronic_disease
, O
or O
other O
systemic B-chronic_disease
disease I-chronic_disease
that O
would O
limit O
compliance O
with O
study O
procedures O

prothrombin B-clinical_variable
time I-clinical_variable
( I-clinical_variable
pt I-clinical_variable
) I-clinical_variable
/ O
international B-clinical_variable
normalized I-clinical_variable
ratio I-clinical_variable
and O
( O
ptt B-clinical_variable
) O
in O
normal O
range O
± B-upper_bound
@NUMBER I-upper_bound
% I-upper_bound

patients O
with O
a O
history O
of O
psychiatric B-chronic_disease
illness I-chronic_disease
must O
be O
judged O
able O
to O
understand O
fully O
the O
investigational O
nature O
of O
the O
study O
and O
the O
risks O
associated O
with O
the O
therapy B-treatment

patients O
with O
squamous B-cancer
cell I-cancer
carcinoma I-cancer
of O
the O
head O
and O
neck O
for O
whom O
treatment B-treatment
with I-treatment
pembrolizumab I-treatment
is O
indicated O

unresolved O
immune O
- O
mediated O
pneumonitis B-chronic_disease
, O
diarrhea B-chronic_disease
, O
elevation O
of O
hepatocellular O
enzymes O
or O
other O
toxicities O
requiring O
greater O
than O
physiological B-treatment
replacement I-treatment
doses I-treatment
of I-treatment
steroids I-treatment

cyp2c8 B-treatment
substrates I-treatment
( O
rosiglitazone B-treatment
, O
pioglitazone B-treatment
, O
rapaglinide B-treatment
) O
and O
cyp2d6 B-treatment
substrates I-treatment
( O
dextromethorphan B-treatment
, O
thioridazine B-treatment
) O
should O
be O
avoided O

currently O
receiving O
any O
other O
anti B-treatment
- I-treatment
cancer I-treatment
agents I-treatment

currently O
receiving O
enzyme O
inducing O
anticonvulsants B-treatment

extracranial O
solid B-cancer
tumors I-cancer
including O
histiocytoses B-chronic_disease

lansky B-clinical_variable
performance I-clinical_variable
level I-clinical_variable
of O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
percent I-lower_bound
for O
participants O
who O
are O
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age
at O
the O
time O
of O
screening O

participants O
with O
any O
of O
the O
following O
tumors B-cancer
who O
have O
experienced O
relapse O
following O
front B-treatment
- I-treatment
line I-treatment
therapy I-treatment

random O
or O
fasting B-clinical_variable
blood I-clinical_variable
glucose I-clinical_variable
within O
the O
upper O
normal O
limits O
for O
age B-age

previous O
tricuspid B-treatment
valve I-treatment
repair I-treatment
or I-treatment
replacement I-treatment

at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
beyond O
prior B-treatment
treatment I-treatment
( O
chemotherapy B-treatment
, O
investigational B-treatment
drugs I-treatment
including O
small B-treatment
molecular I-treatment
inhibitors I-treatment
, O
endocrine B-treatment
therapy I-treatment
, O
immunotherapy B-treatment
and O
/ O
or O
radiation B-treatment
therapy I-treatment
) O
or O
major B-treatment
surgery I-treatment

other O
concurrent O
medical B-chronic_disease
or O
psychiatric B-chronic_disease
conditions I-chronic_disease
that O
, O
in O
the O
investigator O
's O
opinion O
, O
may O
be O
likely O
to O
confound O
study O
interpretation O
or O
prevent O
completion O
of O
study O
procedures O
and O
follow O
- O
up O
examinations O

patients O
with O
active O
≥ O
grade B-lower_bound
@NUMBER I-lower_bound
anorexia B-chronic_disease
, O
nausea O
or O
vomiting O
, O
and O
/ O
or O
signs O
of O
intestinal O
obstruction O

excluding O
sling O
or O
sacrocolpopexy B-treatment
mesh O

asa B-chronic_disease
i I-chronic_disease
& I-chronic_disease
ii I-chronic_disease

known O
to O
be O
hiv B-chronic_disease
-positive O
on O
combination O
antiretroviral B-treatment
therapy I-treatment
because O
of O
the O
potential O
for O
pharmacokinetic O
interactions O
with O
the O
study O
agents O

t2 B-lower_bound
- O
t4 B-upper_bound
primary B-cancer
tumors I-cancer

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

these O
patients O
are O
at O
increased O
risk O
of O
lethal B-chronic_disease
infections I-chronic_disease
when O
treated O
with O
marrow B-treatment
suppressive I-treatment
therapy I-treatment

is O
diagnosed O
with O
a O
clinically O
defined O
neurological B-chronic_disease
disorder I-chronic_disease
including O
, O
but O
not O
limited O
to O
: O
any O
condition O
likely O
to O
be O
associated O
with O
increased B-chronic_disease
intracranial I-chronic_disease
pressure I-chronic_disease
; O
space O
occupying O
brain O
lesion O
; O
history O
of O
stroke B-chronic_disease
, O
transient B-chronic_disease
ischemic I-chronic_disease
attack I-chronic_disease
within O
two B-upper_bound
years I-upper_bound
; O
cerebral B-chronic_disease
aneurysm I-chronic_disease
; O
dementia B-chronic_disease
; O
parkinson B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
; O
huntington B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
; O
multiple B-chronic_disease
sclerosis I-chronic_disease

meets O
diagnostic O
criteria O
for O
a O
current O
dsm-5 O
depressive B-chronic_disease
, O
anxiety B-chronic_disease
, O
obsessive B-chronic_disease
- I-chronic_disease
compulsive I-chronic_disease
, O
somatic B-chronic_disease
, O
personality B-chronic_disease
, O
eating B-chronic_disease
, O
or O
trauma B-chronic_disease
and O
stress B-chronic_disease
- I-chronic_disease
related I-chronic_disease
disorders I-chronic_disease
( O
including O
in O
partial O
remission O
) O

women B-gender
who O
are O
pregnant B-pregnancy
or O
breast O
feeding O

patients O
with O
traditional O
risk O
factors O
for O
ha B-clinical_variable
- I-clinical_variable
mrsa I-clinical_variable
( O
e.g. O
, O
immunodeficiency B-chronic_disease
, O
indwelling O
catheter O
or O
percutaneous B-treatment
medical I-treatment
device I-treatment
, O
undergoing O
dialysis B-treatment
, O
presenting O
with O
a O
surgical B-treatment
site I-treatment
infection I-treatment
, O
or O
residing O
in O
a O
long O
- O
term O
care O
facility O
within O
the O
past O
year O
) O

acute B-chronic_disease
or I-chronic_disease
serious I-chronic_disease
illness I-chronic_disease
requiring O
systemic B-treatment
treatment I-treatment
and O
/ O
or O
hospitalization B-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
entry O

known O
allergy O
/ O
sensitivity O
or O
any O
hypersensitivity O
to O
tesamorelin B-allergy_name

total O
bilirubin B-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
( O
if O
the O
participant O
is O
receiving O
atazanavir B-treatment
, O
a O
total O
bilirubin O
of O
≤ O
@NUMBER O
x O
uln O
is O
acceptable O
) O

active O
or O
planned O
use O
of O
rhgh B-treatment
, O
anabolic B-treatment
steroids I-treatment
( O
other O
than O
replacement O
doses O
of O
testosterone O
) O
, O
anti B-treatment
- I-treatment
tnfa I-treatment
therapy I-treatment
or O
other O
biologic B-treatment
( O
tocilizumab B-treatment
, O
xelijanz B-treatment
, O
etc O
. O
) O

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
months I-upper_bound
of O
age B-age
at O
randomization O

history O
of O
hypoxic B-chronic_disease
seizures I-chronic_disease
during O
a O
wheezing O
episode O

more O
than O
four B-lower_bound
days I-lower_bound
of O
symptoms O
of O
wheezing B-chronic_disease
, O
or O
tightness B-chronic_disease
in I-chronic_disease
the I-chronic_disease
chest I-chronic_disease
or O
cough B-chronic_disease
in O
the O
past B-upper_bound
two I-upper_bound
weeks I-upper_bound
causing O
at O
least O
minimal O
limitation O
of O
activity O

need O
for O
systemic O
corticosteroids O
or O
a O
hospitalization O
for O
respiratory O
symptoms O
within O
four B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
screening O

immunodeficiency B-chronic_disease
( O
primary O
or O
secondary O
) O

positive O
allergy O
to O
aeroallergen B-allergy_name

patients O
who O
received O
csj137 B-treatment
dose O
in O
the O
pas O

pre B-chronic_disease
- I-chronic_disease
diabetic I-chronic_disease
based O
on O
oral B-treatment
glucose I-treatment
tolerance O
test O
with O
@NUMBER O
hour O
values O
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
after O
an O
oral O
glucose O
load O
, O
and O
no O
diagnosis O
of O
diabetes B-chronic_disease
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

total B-clinical_variable
bilirubin I-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

evidence O
of O
concomitant O
infection O
on O
exam O
or O
gram B-treatment
stain I-treatment
( O
i.e O
. O
herpes B-chronic_disease
, O
both O
bacteria O
and O
acanthamoeba O
on O
gram O
stain O
) O

not O
treated O
already O
with O
antimicrobial B-treatment
medications I-treatment
at O
presentation O

ros1-rearranged O
nsclc B-cancer
patients O
presenting O
with O
cns O
- O
only O
progression O

excluding O
approved O
or O
investigational B-treatment
trk I-treatment
, O
ros1 B-treatment
, O
or O
alk B-treatment
inhibitors I-treatment
in O
patients O
who O
have O
tumors B-cancer
that O
harbor O
those O
respective O
gene O
rearrangements O

prior O
treatment O
with O
crizotinib B-treatment
is O
permitted O
only O
in O
alk- O
or O
ros1-rearranged O
nsclc O
patients O
presenting O
with O
cns O
- O
only O
progression O

exclusion O
criteria O
will O
be O
cp O
with O
gross B-clinical_variable
motor I-clinical_variable
function I-clinical_variable
classification I-clinical_variable
score I-clinical_variable
( I-clinical_variable
gmfcs I-clinical_variable
) I-clinical_variable
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
, O
corresponding O
to O
poor O
or O
absent O
mobility O
and O
neck O
control O

suspected B-pregnancy
pregnancy I-pregnancy

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mcl I-lower_bound

patients O
must O
have O
histologically O
or O
cytologically O
confirmed O
head B-cancer
and I-cancer
neck I-cancer
squamous I-cancer
cell I-cancer
cancer I-cancer
( I-cancer
hnscc I-cancer
) I-cancer
including O
paranasal B-cancer
sinus I-cancer
cancers I-cancer

use O
of O
psychopharmacologic B-treatment
treatments I-treatment
for O
anxiety B-chronic_disease
or O
depression B-chronic_disease
is O
allowable O

dementia B-chronic_disease
diagnosed O
by O
baseline O
cognitive O
assessment O

non B-cancer
- I-cancer
hodgkin I-cancer
lymphoma I-cancer

a O
diagnosis O
of O
cmml B-cancer
, O
unless O
in O
morphologic O
cr O

hct B-clinical_variable
- I-clinical_variable
ci I-clinical_variable
/ O
age B-clinical_variable
score I-clinical_variable
≤ O
@NUMBER O
points O
( O
patients O
with O
greater O
than O
@NUMBER O
points O
will O
be O
allowed O
for O
trial O
with O
approval O
of O
the O
pi O
and O
the O
co O
- O
pi O
or O
his O
designee O
. O
this O
is O
an O
adjustment O
to O
account O
for O
healthy O
patients O
who O
meet O
the O
spirit O
of O
this O
protocol O
but O
have O
histories O
that O
result O
in O
higher O
than O
hct O
- O
ci O
@NUMBER O
points O
. O
an O
example O
is O
a O
patient O
with O
a O
solid B-cancer
tumor I-cancer
malignancy I-cancer
malignancy B-cancer
in O
their O
remote O
history O
( O
adds O
@NUMBER O
points O
to O
hct O
- O
ci O
total O
) O
where O
the O
treatment B-treatment
for O
the O
malignancy O
occurred O
years O
to O
decades O
before O
and O
there O
has O
been O
complete O
recovery O
of O
toxicities O

kps B-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound
patients O
older O
than O
@NUMBER O
years O
, O
kps O
≥ O
@NUMBER B-lower_bound
% I-lower_bound
patients O
younger O
than O
@NUMBER O
years O

ra B-chronic_disease
or O
rars B-chronic_disease
or O
isolated O
@NUMBER O
q- O
can O
proceed O
to O
transplant B-treatment
without O
any O
treatment B-treatment

no O
prior O
malignancy B-cancer

other O
adequately O
treated O
malignancy B-cancer
for O
which O
the O
patient O
is O
currently O
disease O
free O
for O
at O
least O
one B-lower_bound
year I-lower_bound

patients O
currently O
receiving O
active O
therapy B-treatment
for O
other O
neoplastic B-chronic_disease
disorders I-chronic_disease

patient O
must O
be O
offered O
and O
made O
aware O
of O
all O
food O
and O
drug O
administration O
( O
fda O
) O
‐approved O
treatment B-treatment
options O
; O
patients O
with O
bone B-chronic_disease
only I-chronic_disease
disease I-chronic_disease
may O
not O
have O
received O
radium-223 B-treatment

benign B-cancer
histology O

absolute O
contraindications O
to O
liver B-treatment
biopsy I-treatment
including O
coagulopathy B-chronic_disease

the O
subjects O
must O
be O
comfortable O
when O
receiving O
tms B-treatment
of O
all O
strengths O

prior O
treatment O
with O
an O
anti B-treatment
- I-treatment
cd20 I-treatment
agent I-treatment
, O
either O
alone O
or O
in O
combination O
, O
is O
allowed O

karnofsky B-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound
@NUMBER B-lower_bound
% O
for O
participants O
> O
@NUMBER O
years O
and O
lansky B-clinical_variable
≥ O
@NUMBER O
for O
participants O
≤ O
@NUMBER O
years O

medically O
cleared O
to O
work O
as O
hyperbaric B-treatment
chamber I-treatment
inside O
attendants O
, O
reporting O
for O
a O
regular O
duty O
day O

unstable O
medical O
conditions O
( O
cancer B-cancer
) O

advanced O
stage O
hcc B-cancer
( O
barcelona B-cancer
clinic I-cancer
liver I-cancer
cancer I-cancer
[ I-cancer
bclc I-cancer
] I-cancer
stage O
c O
or O
b O
per O
american B-chronic_disease
association I-chronic_disease
for I-chronic_disease
the I-chronic_disease
study I-chronic_disease
of I-chronic_disease
liver I-chronic_disease
disease I-chronic_disease
[ I-chronic_disease
aasld I-chronic_disease
] I-chronic_disease
guidelines O
) O

history O
of O
moderate O
or O
severe O
ascites B-chronic_disease

known O
significant O
immunodeficiency B-chronic_disease
due O
to O
underlying O
illness O
( O
e.g. O
, O
hiv B-chronic_disease
/ O
aids B-chronic_disease
) O

pleural B-chronic_disease
effusions I-chronic_disease
related O
to O
liver B-chronic_disease
insufficiency I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
screening O

tumors B-clinical_variable
encompassing I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound
of O
the O
liver O
volume O
and O
/ O
or O
inferior B-treatment
vena I-treatment
cava I-treatment
invasion I-treatment

ct B-treatment
or O
mri B-treatment
without O
contrast O
as O
part O
of O
positron B-treatment
emission I-treatment
tomography I-treatment
[ B-treatment
pet I-treatment
] I-treatment
/ I-treatment
ct I-treatment
or I-treatment
pet I-treatment
/ I-treatment
mri I-treatment

no O
involvement O
, O
or O
< O
180 B-upper_bound
° I-upper_bound
interface O
between O
tumor B-cancer
and O
vessel O
wall O
, O
of O
the O
portal O
vein O
and O
/ O
or O
superior O
mesenteric O
vein O

patients O
must O
have O
measurable B-chronic_disease
disease I-chronic_disease
in O
the O
pancreas O

patients O
must O
not B-pregnancy
be I-pregnancy
pregnant I-pregnancy
or O
nursing O

patients O
with O
uncontrolled O
intercurrent O
illness O
including O
, O
but O
not O
limited O
to O
ongoing O
or O
active B-chronic_disease
infection I-chronic_disease
, O
symptomatic O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease
pectoris O
, O
cardiac B-chronic_disease
arrhythmia I-chronic_disease
, O
or O
psychiatric B-chronic_disease
illness I-chronic_disease
/ O
social O
situations O
that O
would O
limit O
compliance O
with O
study O
requirements O

color O
- O
blindness O
for O
blue O
or O
green O
( O
see O
fmri B-treatment
task I-treatment
) O

currently O
taking O
any O
exclusionary B-treatment
medications I-treatment

history O
of O
inadequate O
response O
/ O
poor O
tolerability O
to O
bupropio B-allergy_name

monoamine B-treatment
oxidase I-treatment
inhibitors I-treatment

any O
history O
of O
seizure B-chronic_disease
disorder I-chronic_disease

adolescent O
females B-gender
of O
childbearing O
potential O
can O
only O
be O
included O
in O
the O
study O
if O
a O
pregnancy B-pregnancy
test O
is O
negative O

in O
patients O
previously O
stabilized O
on O
3,4-dap B-treatment
or I-treatment
amifampridine I-treatment
phosphate I-treatment
, O
history O
of O
meaningful O
improvement O
in O
motor O
function O
( O
in O
opinion O
of O
investigator O
) O

centrally B-clinical_variable
- I-clinical_variable
scored I-clinical_variable
polysomnogram I-clinical_variable
( I-clinical_variable
psg I-clinical_variable
) I-clinical_variable
confirming O
an O
obstructive B-clinical_variable
apnea I-clinical_variable
index I-clinical_variable
( I-clinical_variable
oai I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound
/ I-upper_bound
hour I-upper_bound
and O
apnea B-clinical_variable
- I-clinical_variable
hypopnea I-clinical_variable
index I-clinical_variable
( I-clinical_variable
ahi I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
/ I-upper_bound
hour I-upper_bound
and O
no O
oxygen B-clinical_variable
saturation I-clinical_variable
( I-clinical_variable
spo2 I-clinical_variable
) I-clinical_variable
desaturation I-clinical_variable
< O
@NUMBER B-upper_bound
% I-upper_bound
in O
conjunction O
with O
obstructive O
events O
, O
confirmed O
on O
psg O

known O
genetic O
, O
craniofacial B-chronic_disease
, O
neurological B-chronic_disease
or I-chronic_disease
psychiatric I-chronic_disease
conditions I-chronic_disease
likely O
to O
affect O
the O
airway O
, O
cognition O
or O
behavior O

other O
severe O
chronic O
health O
problems O
such O
as O
diabetes B-chronic_disease
, O
narcolepsy B-chronic_disease
, O
and O
poorly B-chronic_disease
controlled I-chronic_disease
asthma I-chronic_disease

eosinophilia B-chronic_disease
and O
known O
positivity O
for O
the O
fip1l1-pgdfra O
fusion O

history O
of O
a O
seizure B-chronic_disease
disorder O
or O
requirement O
for O
anti B-treatment
- I-treatment
seizure I-treatment
medication I-treatment

myelodysplastic B-cancer
syndrome I-cancer
( I-cancer
mds I-cancer
) I-cancer
that O
is O
very O
high- O
or O
high O
- O
risk O
as O
defined O
by O
the O
international O
prognostic O
scoring O
system O
for O
myelodysplastic B-cancer
syndromes I-cancer
( O
ipss O
- O
r O
) O

participation O
in O
a O
weight O
management O
program O
involving O
diet O
and O
pa O
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
mos I-upper_bound

history O
of O
lens O
abnormalities O
including O
posterior B-chronic_disease
polar I-chronic_disease
cataract I-chronic_disease
and O
zonular B-chronic_disease
weakness I-chronic_disease
precluding O
standard B-treatment
non‐complex I-treatment
cataract I-treatment
surgery I-treatment

retinal B-chronic_disease
or I-chronic_disease
posterior I-chronic_disease
segment I-chronic_disease
disease I-chronic_disease

study O
doctor O
will O
assess O
patient O
findings O
and O
determine O
how O
long O
rgp O
lens O
wear O
must O
be O
discontinued O
prior B-treatment
to I-treatment
surgery I-treatment

subject O
eyes O
will O
lack O
other O
pre‐existing O
ocular O
pathology O
or O
condition O
that O
may O
confound O
treatment B-treatment
effects O
, O
including O
diabetic B-chronic_disease
retinopathy I-chronic_disease
, O
previous O
retinal B-chronic_disease
detachment I-chronic_disease
, O
iris B-chronic_disease
neovascularization I-chronic_disease
, O
amblyopia B-chronic_disease
, O
optic B-chronic_disease
nerve I-chronic_disease
atrophy I-chronic_disease
or O
recurrent O
severe O
anterior O
or O
posterior O
segment O
inflammation O
of O
unknown O
etiology O

estimated B-clinical_variable
creatinine I-clinical_variable
clearance I-clinical_variable
of O
at O
least O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
( O
using O
the O
cockcroft O
- O
gault O
equation O
) O
at O
screening O
only O

patients O
with O
a O
history O
of O
epilepsy B-chronic_disease
, O
subjects O
currently O
prescribed B-treatment
treatments I-treatment
for O
epilepsy O
, O
or O
subjects O
with O
a O
history O
of O
seizure B-chronic_disease
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound

subjects O
with O
known O
barrett B-chronic_disease
's I-chronic_disease
esophagus I-chronic_disease
( I-chronic_disease
be I-chronic_disease
) I-chronic_disease

history O
of O
painful O
or O
hard B-chronic_disease
bowel I-chronic_disease
movements I-chronic_disease
( I-chronic_disease
bms I-chronic_disease
) I-chronic_disease

histologically O
or O
cytologically O
confirmed O
diagnosis O
of O
melanoma B-cancer

uncontrolled O
thyroid B-chronic_disease
disease I-chronic_disease
or O
cystic B-chronic_disease
fibrosis I-chronic_disease

untreated O
or O
clinically O
active O
melanoma O
brain B-cancer
metastases I-cancer

estimated B-clinical_variable
glomerular I-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
( I-clinical_variable
egfr I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
m2 I-lower_bound

history O
of O
schizophrenia B-chronic_disease
, O
schizoaffective B-chronic_disease
disorder I-chronic_disease
or O
any O
psychotic B-chronic_disease
disorder I-chronic_disease
, O
or O
bipolar B-chronic_disease
disorder I-chronic_disease

past O
intolerance O
or O
hypersensitivity O
to O
ketamine O
, O
or O
history O
of O
recreational O
use O
of O
phencyclidine B-treatment
( I-treatment
pcp I-treatment
) I-treatment
or O
ketamine O

appropriate O
candidate O
for O
treatment B-treatment
using O
posterior O
surgical O
approach O

known O
allergy O
to O
titanium B-allergy_name
, O
titanium B-allergy_name
alloys I-allergy_name
, O
or O
mr B-allergy_name
( I-allergy_name
magnetic I-allergy_name
resonance I-allergy_name
) I-allergy_name
contrast I-allergy_name
agents I-allergy_name

moderate O
stenosis B-clinical_variable
is O
defined O
as O
> O
@NUMBER B-lower_bound
% I-lower_bound
reduction O
of O
the O
antero O
- O
posterior O
dimension O
compared O
to O
the O
next O
adjacent O
normal O
level O
, O
with O
nerve O
root O
crowding O
compared O
to O
the O
normal O
level O
, O
as O
determined O
by O
the O
investigator O
on O
computerized B-treatment
tomography I-treatment
( I-treatment
ct I-treatment
) I-treatment
scan I-treatment
or O
mri B-treatment

more O
than O
one B-lower_bound
surgical B-treatment
procedure I-treatment
at O
any O
combination O
of O
lumbar O
levels O

osteopenia B-chronic_disease
: O
a O
screening O
questionnaire O
for O
osteopenia B-chronic_disease
, O
score O
( O
simple O
calculated O
osteoporosis O
risk O
estimation O
) O
, O
will O
be O
used O
to O
screen O
patients O
who O
require O
a O
dexa B-treatment
( I-treatment
dual I-treatment
- I-treatment
energy I-treatment
x I-treatment
- I-treatment
ray I-treatment
absorptiometry I-treatment
) I-treatment
bone O
mineral O
density O
measurement O

patient O
has O
underg O
one B-lower_bound
at O
least O
one O
epidural B-treatment
injection I-treatment
at O
any O
prior O
time O
point O
, O
and O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
of O
prior O
conservative O
care O
without O
adequate O
and O
sustained O
symptom O
relief O

patient O
has O
a O
concurrent O
malignancy B-cancer
or O
malignancy O
within O
@NUMBER B-upper_bound
years I-upper_bound
of O
enrollment O

patient O
is O
currently O
receiving O
warfarin B-treatment
or O
other O
coumarin O
- O
derived O
anticoagulant B-treatment
for O
treatment B-treatment
, O
prophylaxis B-treatment
or O
otherwise O

prior O
exposure O
to O
abiraterone B-treatment
acetate I-treatment
or O
other O
specific O
cyp-17 B-treatment
inhibitors I-treatment

the O
following O
uses O
of O
corticosteroids B-treatment
are O
permitted O
: O
single O
doses O
, O
topical B-treatment
applications I-treatment
( O
e.g. O
, O
for O
rash O
) O
, O
inhaled B-treatment
sprays I-treatment
( O
e.g. O
, O
for O
obstructive B-chronic_disease
airways I-chronic_disease
diseases I-chronic_disease
) O
, O
eye B-treatment
drops I-treatment
or O
local B-treatment
injections I-treatment
( O
e.g. O
, O
intra B-treatment
- I-treatment
articular I-treatment
) O

hemodynamic O
evidence O
of O
ph O
on O
baseline O
right B-treatment
heart I-treatment
catheterization I-treatment
( I-treatment
rhc I-treatment
) I-treatment
by O
the O
thermodilution B-treatment
method I-treatment

severe O
hepatic B-chronic_disease
impairment I-chronic_disease
, O
e.g. O
, O
child B-chronic_disease
- I-chronic_disease
pugh I-chronic_disease
class I-chronic_disease
c I-chronic_disease
liver I-chronic_disease
disease I-chronic_disease

treatment B-treatment
with I-treatment
strong I-treatment
inducers I-treatment
of I-treatment
cytochrome I-treatment
p450 I-treatment
isozyme I-treatment
@NUMBER I-treatment
a4 I-treatment
( I-treatment
cyp3a4 I-treatment
) I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
study O
treatment B-treatment
initiation O
( O
e.g. O
, O
carbamazepine B-treatment
, O
rifampicin B-treatment
, O
rifabutin B-treatment
, O
phenytoin B-treatment
and O
st B-treatment
. I-treatment
john I-treatment
's I-treatment
wort I-treatment
) O

pre B-clinical_variable
- I-clinical_variable
bronchodilator I-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound
fev1 B-clinical_variable
of O
< O
@NUMBER B-upper_bound
% I-upper_bound
of O
the O
predicted O
normal O
value O
for O
the O
patient O
after O
withholding O
bronchodilators B-treatment
at O
both O
visit O
@NUMBER O
and O
@NUMBER O
, O
according O
to O
ats O
/ O
ers O
criteria O

women B-gender
of O
child O
- O
bearing O
potential O
, O
defined O
as O
all O
women B-gender
physiologically O
capable O
of O
becoming B-pregnancy
pregnant I-pregnancy
, O
unless O
they O
are O
using B-contraception_consent
highly I-contraception_consent
effective I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
during O
dosing O
of O
study B-treatment
treatment I-treatment
and O
for O
@NUMBER B-upper_bound
days I-upper_bound
after I-upper_bound
stopping O
of O
study O
treatment O

have O
had O
an O
asthma B-chronic_disease
attack O
/ O
exacerbation O
requiring O
systemic B-treatment
steroids I-treatment
or O
hospitalization B-treatment
or O
emergency O
room O
visit O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
visit O
@NUMBER O
( O
screening O
) O

asthma B-chronic_disease
/ O
allergic B-chronic_disease
rhinitis I-chronic_disease
explains O
symptoms O

immotile B-chronic_disease
cilia I-chronic_disease
syndrome I-chronic_disease

≥ O
@NUMBER B-lower_bound
days I-lower_bound
of O
colored B-clinical_variable
nasal I-clinical_variable
discharge I-clinical_variable
and O
fever B-clinical_variable
≥ O
39 B-lower_bound
° I-lower_bound
c I-lower_bound

complex O
cardiac B-treatment
surgery I-treatment
surgery B-treatment
will O
be O
defined O
as O
surgery O
involving O
more O
than O
one B-lower_bound
heart O
valve O
, O
redo B-treatment
- I-treatment
sternotomy I-treatment
procedures I-treatment
, O
or O
combined O
valvular B-treatment
and I-treatment
cabg I-treatment
procedures I-treatment

pre O
- O
operative O
renal B-chronic_disease
dysfunction I-chronic_disease
including O
a O
baseline O
creatinine B-clinical_variable
equal O
to O
or O
greater O
than O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
or O
requiring O
dialysis O

concurrent O
systemic B-treatment
immunosuppressant I-treatment
therapy I-treatment

low O
- O
risk O
prostate B-cancer
cancer I-cancer
after B-treatment
curative I-treatment
surgery I-treatment

pathologically O
confirmed O
diagnosis O
of O
myelodysplastic B-cancer
syndrome I-cancer

unable O
to O
swallow O
capsules O
or O
malabsorption B-chronic_disease
syndrome I-chronic_disease
, O
disease O
significantly O
affecting O
gastrointestinal O
function O
, O
or O
resection O
of O
the O
stomach O
or O
small O
bowel O
, O
symptomatic O
inflammatory B-chronic_disease
bowel I-chronic_disease
disease I-chronic_disease
or O
ulcerative B-chronic_disease
colitis I-chronic_disease
, O
or O
partial O
or O
complete O
bowel B-chronic_disease
obstruction I-chronic_disease

unresolved O
toxicities O
from O
prior B-treatment
anti I-treatment
- I-treatment
cancer I-treatment
therapy I-treatment
, O
defined O
as O
having O
not O
resolved O
to O
common B-clinical_variable
terminology I-clinical_variable
criteria I-clinical_variable
for I-clinical_variable
adverse I-clinical_variable
event I-clinical_variable
( I-clinical_variable
ctcae I-clinical_variable
, I-clinical_variable
version I-clinical_variable
@NUMBER I-clinical_variable
) I-clinical_variable
, I-clinical_variable
grade I-clinical_variable
≤ O
@NUMBER B-upper_bound
, O
or O
to O
the O
levels O
dictated O
in O
the O
inclusion O
/ O
exclusion O
criteria O

active O
brain B-cancer
metastases I-cancer
or O
leptomeningeal B-cancer
metastases I-cancer

male B-gender
subjects I-gender
who O
are O
unwilling B-contraception_consent
to I-contraception_consent
use I-contraception_consent
contraception I-contraception_consent
during O
the O
treatment B-treatment
and O
for O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
after I-lower_bound
the O
last O
dose O
of O
study B-treatment
treatment I-treatment
( O
@NUMBER O
half O
- O
lives O
of O
study B-treatment
drug I-treatment
plus O
@NUMBER B-upper_bound
days I-upper_bound
duration O
of O
sperm O
turnover O
) O

subjects O
may O
have O
received O
any O
number O
of O
prior B-treatment
lines I-treatment
of I-treatment
therapy I-treatment

subjects O
must O
consent O
to O
allow O
for O
the O
acquisition O
of O
tumor B-cancer
sample O
prior B-treatment
to I-treatment
starting I-treatment
treatment I-treatment
on O
study O
( O
in O
most O
cases O
patients O
will O
require O
a O
tumor B-treatment
biopsy I-treatment
) O

one O
dose O
of O
intrathecal B-treatment
chemotherapy I-treatment

confirmed O
diagnosis O
of O
fd B-chronic_disease
( O
genetic O
testing O
) O

male B-gender
or I-gender
female I-gender
patients I-gender
with O
familial B-chronic_disease
dysautonomia I-chronic_disease
( I-chronic_disease
fd I-chronic_disease
) I-chronic_disease

systolic B-clinical_variable
bp I-clinical_variable
standard I-clinical_variable
deviation I-clinical_variable
> O
@NUMBER B-lower_bound
mmhg I-lower_bound

any O
contraindication O
for O
mri B-allergy_name
, O
including O
metal O
in O
the O
body O
related O
to O
an O
injury O
or O
surgery B-treatment
( O
e.g. O
, O
surgical B-allergy_name
clips I-allergy_name
, O
metal B-allergy_name
fragments I-allergy_name
in I-allergy_name
the I-allergy_name
eyes I-allergy_name
) O
, O
piercings B-allergy_name
that O
can O
not O
be O
removed O
, O
braces B-allergy_name
, O
or O
permanent B-allergy_name
retainers I-allergy_name

pervasive B-chronic_disease
developmental I-chronic_disease
disorder I-chronic_disease

agree B-contraception_consent
to I-contraception_consent
practice I-contraception_consent
effective I-contraception_consent
contraception I-contraception_consent

at O
least O
@NUMBER B-lower_bound
years I-lower_bound
old O

clinically O
significant O
abnormal B-chronic_disease
serum I-chronic_disease
potassium I-chronic_disease
( O
regardless O
of O
potassium B-treatment
agent I-treatment
supplementation I-treatment
) O
; O
serum B-chronic_disease
calcium I-chronic_disease
( O
ionic O
or O
binding O
to O
albumin O
post O
- O
adjusted O
) O
or O
serum B-chronic_disease
magnesium I-chronic_disease
( O
regardless O
of O
magnesium B-treatment
agent I-treatment
supplementation I-treatment
) O

subject O
is O
currently O
receiving O
or O
intending O
to O
receive O
anti B-treatment
- I-treatment
coagulants I-treatment
for O
therapeutic O
purposes O

toxicity O
from O
a O
previous B-treatment
anti I-treatment
- I-treatment
tumor I-treatment
treatment I-treatment
that O
does O
not O
return O
to O
grade O
@NUMBER B-lower_bound
or O
@NUMBER B-upper_bound
( O
except O
for O
alopecia B-chronic_disease
) O

alkaline B-clinical_variable
phosphatase I-clinical_variable
( I-clinical_variable
alp I-clinical_variable
) I-clinical_variable
alp B-clinical_variable
) O
> O
@NUMBER B-lower_bound
uln I-lower_bound
@NUMBER B-lower_bound
uln I-lower_bound
without O
hepatic B-cancer
metastases I-cancer
or O
alt B-clinical_variable
, O
ast B-clinical_variable
or O
alp O
> O
@NUMBER O
uln O
with O
hepatic O
metastases O

female B-gender
patients I-gender
of O
child O
- O
producing O
potential O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
two I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
the I-contraception_consent
following I-contraception_consent
contraceptive I-contraception_consent
: O
condoms B-contraception_consent
, O
intrauterine B-contraception_consent
device I-contraception_consent
( I-contraception_consent
iud I-contraception_consent
) I-contraception_consent
, O
contraceptives B-contraception_consent
( I-contraception_consent
oral I-contraception_consent
or I-contraception_consent
parenteral I-contraception_consent
) I-contraception_consent
, O
implanon B-contraception_consent
, O
injectables B-contraception_consent
during O
the O
study O
and O
up O
to O
@NUMBER B-upper_bound
days I-upper_bound
post O
the O
last B-treatment
day I-treatment
of I-treatment
study I-treatment
treatment I-treatment

locally O
advanced O
or O
metastatic B-cancer
pnet I-cancer
that O
has O
progressed O
on O
everolimus B-treatment
, O
sunitinib B-treatment
or O
both O
, O
during O
the O
expansion O
phase O

platelet B-clinical_variable
count I-clinical_variable
of O
< O
@NUMBER B-upper_bound
×109 I-upper_bound
/ I-upper_bound
l I-upper_bound
, O
or O
hemoglobin B-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound

patients O
with O
either O
symptomatic O
or O
asymptomatic O
aaa B-chronic_disease
as O
defined O
by O
aortic B-clinical_variable
diameter I-clinical_variable
≥ O
1.5x B-lower_bound
normal I-lower_bound
diameter I-lower_bound

obesity B-chronic_disease
( O
bmi B-bmi
≥ O
@NUMBER B-lower_bound
kg I-lower_bound
/ I-lower_bound
m2 I-lower_bound
) O

age B-age
< O
@NUMBER B-upper_bound
yrs I-upper_bound
, O
or O
> O
@NUMBER B-lower_bound
yrs I-lower_bound

chronic O
daily O
use O
of O
high O
- O
dose O
nsaid B-treatment
for O
osteoarthritis B-chronic_disease
, O
rheumatoid B-chronic_disease
arthritis I-chronic_disease
, O
or O
other O
chronic O
inflammatory B-chronic_disease
diseases I-chronic_disease
( O
chronic O
defined O
as O
@NUMBER O
mg O
/ O
day O
for O
> O
@NUMBER B-lower_bound
weeks I-lower_bound
) O

clinically O
significant O
respiratory B-chronic_disease
disorders I-chronic_disease
with O
impaired B-chronic_disease
respiratory I-chronic_disease
effort O
or O
difficulty O
taking O
inhaled O
drugs O

major B-chronic_disease
depressive I-chronic_disease
episode O
, O
as O
described O
in O
the O
diagnostic O
and O
statistical O
manual O
of O
mental O
disorders O
( O
dsm O
- O
iv O
) O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
, O
which O
could O
lead O
to O
difficulty O
complying O
with O
the O
protocol O

all O
study O
participants O
must O
be O
registered O
into O
the O
mandatory O
pomalidomide B-treatment
( I-treatment
pomalyst I-treatment
) I-treatment
risk O
evaluation O
and O
mitigation O
strategy O
( O
rems O
) O
program O
, O
and O
be O
willing O
and O
able O
to O
comply O
with O
the O
requirements O
of O
the O
pomalyst O
rems O
program O

on O
long O
- O
term O
steroid B-treatment
or O
anti B-treatment
- I-treatment
inflammatory I-treatment
drugs I-treatment

a O
projected O
need O
by O
the O
treating O
physician O
for O
continued O
treatment B-treatment
with I-treatment
iv I-treatment
diuretics I-treatment
for O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
with O
the O
goal O
of O
significant O
fluid B-clinical_variable
removal I-clinical_variable
( O
> O
@NUMBER B-lower_bound
l I-lower_bound
net I-lower_bound
fluid I-lower_bound
loss I-lower_bound
/ I-lower_bound
day I-lower_bound
) O

patients O
who O
have O
the O
intention O
to O
receive O
non O
- O
study O
pde5 B-treatment
inhibitors I-treatment
and O
flu B-treatment
vaccination I-treatment
( I-treatment
s I-treatment
) I-treatment
anytime O
during O
the O
study O

salvage B-treatment
surgery I-treatment
is O
not O
recommended O
as O
per O
national O
comprehensive O
cancer O
network O
( O
nccn O
) O
guidelines O
, O
or O
after O
multidisciplinary O
treatment O
evaluation O
, O
including O
those O
with O
surgically O
unresectable O
disease O
at O
primary O
site O
or O
regional O
lymph O
nodes O

sustained O
hypotension B-clinical_variable
( O
< O
@NUMBER B-upper_bound
/ I-upper_bound
@NUMBER I-upper_bound
mmhg I-upper_bound
) O
or O
uncontrolled O
hypertension B-clinical_variable
( O
> O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
mmhg I-lower_bound
) O

therapy B-treatment
with I-treatment
nitrates I-treatment
, O
alpha B-treatment
- I-treatment
blockers I-treatment
, O
or O
cytochrome B-treatment
p450 I-treatment
( I-treatment
cyp3a4 I-treatment
) I-treatment
inhibitors I-treatment
within O
7-days B-upper_bound
prior I-upper_bound
to O
study O
treatment O
initiation O

unstable B-chronic_disease
angina I-chronic_disease
angina B-chronic_disease
or O
angina O
occurring O
during O
sexual O
intercourse O

normal O
mri B-treatment
of I-treatment
the I-treatment
brain I-treatment

use O
of O
cns B-treatment
active I-treatment
drugs I-treatment

for O
participants O
who O
still O
experience O
the O
effects O
of O
their O
suicide B-chronic_disease
attempt I-chronic_disease
, O
i.e O
. O
someone O
who O
overdosed O
is O
significantly O
drowsy O
or O
confused O
, O
the O
consenting O
process O
will O
occur O
after O
the O
patient O
has O
improved O
from O
the O
effects O

pre O
- O
existing O
severe O
gastrointestinal B-chronic_disease
narrowing I-chronic_disease
( I-chronic_disease
pathologic I-chronic_disease
or I-chronic_disease
iatrogenic I-chronic_disease
) I-chronic_disease

between O
@NUMBER B-lower_bound
and O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

patients O
who O
are O
on O
simultaneous O
oral B-treatment
and I-treatment
iv I-treatment
chemotherapeutic I-treatment
regimens I-treatment

for O
patients O
without O
a O
measurable O
serum O
or O
urine O
m O
- O
component O
or O
serum O
free O
light O
chain O
level O
: O
% B-clinical_variable
marrow I-clinical_variable
involvement I-clinical_variable
with O
myeloma B-cancer
( O
absolute O
increase O
must O
be O
≥ O
@NUMBER B-lower_bound
% I-lower_bound
) O

patient O
has O
≥ O
grade B-lower_bound
@NUMBER I-lower_bound
peripheral B-clinical_variable
neuropathy I-clinical_variable
, O
or O
grade B-lower_bound
@NUMBER I-lower_bound
with O
pain O
on O
clinical O
examination O
during O
the O
screening O
period O

serum B-clinical_variable
m I-clinical_variable
- I-clinical_variable
protein I-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

treatment B-treatment
sensitive O
hiv B-chronic_disease
and O
, O
if O
on O
anti B-treatment
- I-treatment
hiv I-treatment
therapy I-treatment
, O
hiv O
viral O
load O
< O
@NUMBER B-upper_bound
copies I-upper_bound
/ I-upper_bound
mm^3 I-upper_bound

the O
modality O
of O
treatment B-treatment
of O
brain B-cancer
metastases I-cancer
can O
include O
surgical B-treatment
resection I-treatment
, O
whole B-treatment
brain I-treatment
radiotherapy I-treatment
, O
stereotactic B-treatment
radiosurgery I-treatment
, O
or O
any O
combination O
of O
the O
above O

patients O
will O
have O
recovered O
from O
toxicities O
from O
prior B-treatment
systemic I-treatment
anticancer I-treatment
treatment I-treatment
or O
local B-treatment
therapies I-treatment

ductal B-cancer
carcinoma I-cancer
in I-cancer
situ I-cancer

aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
( O
serum B-clinical_variable
glutamic I-clinical_variable
oxaloacetic I-clinical_variable
transaminase I-clinical_variable
[ I-clinical_variable
sgot I-clinical_variable
] I-clinical_variable
) O
/ O
alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
( O
serum B-clinical_variable
glutamate I-clinical_variable
pyruvate I-clinical_variable
transaminase I-clinical_variable
[ I-clinical_variable
sgpt I-clinical_variable
] I-clinical_variable
) O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
or O
≤ O
@NUMBER O
x O
uln O
for O
subjects O
with O
liver B-cancer
metastases I-cancer

have O
a O
performance O
status O
of O
@NUMBER B-lower_bound
or O
@NUMBER B-upper_bound
on O
the O
eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
scale I-clinical_variable
( I-clinical_variable
ps I-clinical_variable
) I-clinical_variable

allergies O
to O
lidocaine B-allergy_name
or O
novocain B-allergy_name

hemoglobin B-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound

body B-bmi
mass I-bmi
index I-bmi
of O
@NUMBER B-lower_bound
or O
greater O

chronic O
use O
of O
nsaids B-treatment
( I-treatment
nonsteroidal I-treatment
anti I-treatment
- I-treatment
inflammatory I-treatment
drugs I-treatment
) I-treatment
aspirin I-treatment
or O
omega-3 B-treatment
free I-treatment
fatty I-treatment
acid I-treatment
supplementation I-treatment
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
( O
defined O
as O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
consecutive I-lower_bound
days I-lower_bound
) O

men B-gender
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
a I-contraception_consent
latex I-contraception_consent
condom I-contraception_consent
during I-contraception_consent
sexual I-contraception_consent
contact I-contraception_consent
with O
a O
female B-gender
of O
childbearing O
potential O
even O
if O
they O
have O
had O
a O
successful O
vasectomy B-treatment

refractory O
to O
lenalidomide B-treatment
in O
the O
most O
recent O
line O
of O
therapy B-treatment
, O
as O
defined O
by O
the O
international O
myeloma O
consensus O
panel O
criteria O
[ O
@NUMBER O
] O
- O
as O
failure O
to O
achieve O
minimal O
response O
or O
development O
of O
progressive O
disease O
while O
on O
lenalidomide O
or O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
lenalidomide B-treatment
therapy I-treatment

must O
have O
a O
negative B-pregnancy
serum I-pregnancy
or I-pregnancy
urine I-pregnancy
pregnancy I-pregnancy
test O
with O
a O
sensitivity O
of O
at O
least O
@NUMBER B-lower_bound
miu I-lower_bound
/ I-lower_bound
ml I-lower_bound
within O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
days I-upper_bound
and O
again O
within O
@NUMBER B-upper_bound
hours I-upper_bound
prior I-upper_bound
to O
prescribing O
lenalidomide B-treatment
for O
cycle O
@NUMBER O
( O
prescriptions O
must O
be O
filled O
within O
@NUMBER B-upper_bound
days I-upper_bound
as O
required O
by O
revlimid O
rems O
® O
) O

creatinine B-clinical_variable
≤ O
@NUMBER B-upper_bound
ng I-upper_bound
/ I-upper_bound
ml I-upper_bound

patients O
must O
have O
a O
histologically O
documented O
( O
either O
primary O
or O
metastatic O
site O
) O
diagnosis O
of O
breast B-cancer
cancer I-cancer
that O
is O
her2 O
non O
- O
overexpressing O
by O
immunohistochemistry B-clinical_variable
, O
namely O
@NUMBER B-lower_bound
or O
@NUMBER B-upper_bound

prior B-treatment
treatment I-treatment
with O
immune B-treatment
therapy I-treatment

within O
@NUMBER B-upper_bound
months I-upper_bound
of O
their O
last B-treatment
adjuvant I-treatment
systemic I-treatment
treatment I-treatment

allergy O
to O
arginine B-allergy_name

newly O
started O
on O
hu O
for O
< O
@NUMBER B-upper_bound
months I-upper_bound

insulin B-treatment
resistant O
according O
to O
the O
matsuda O
index O

severe B-chronic_disease
edema I-chronic_disease

@NUMBER O
days O
wash O
out O
for O
palliative B-treatment
radiation I-treatment

renal O
function O
( O
creatinine O
level O
within O
normal O
institutional O
limit O
, O
or O
creatinine B-clinical_variable
clearance I-clinical_variable
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
m2 I-lower_bound
for O
patients O
with O
creatinine O
levels O
above O
institutional O
normal O
, O
calculated O
using O
the O
cockcroft O
- O
gault O
formula O
) O

patients O
with O
a O
prior B-treatment
cumulative I-treatment
cisplatin I-treatment
dose I-treatment
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
m^2 I-lower_bound
( O
pertains O
to O
arm O
a O
only O
) O

patients O
with O
known O
disorders O
associated O
with O
hemolysis B-chronic_disease

tanner B-clinical_variable
stage I-clinical_variable
ii B-lower_bound
- O
v B-upper_bound

syndromic B-chronic_disease
obesity I-chronic_disease
( O
such O
as O
prader B-chronic_disease
willi I-chronic_disease
, O
hypothalamic B-chronic_disease
obesity I-chronic_disease
, O
or O
laurence- B-chronic_disease
moon I-chronic_disease
- I-chronic_disease
biedl I-chronic_disease
) O

resolution O
of O
any O
effects O
of O
prior B-treatment
therapy I-treatment
( O
except O
alopecia B-chronic_disease
) O
to O
nci O
ctcae O
v4.03 O
grade B-clinical_variable
≤ O
@NUMBER B-upper_bound
and O
to O
baseline O
laboratory O
values O
as O
defined O
in O
inclusion O
criteria O
# O
@NUMBER O

known O
obstructive B-chronic_disease
sleep I-chronic_disease
apnea I-chronic_disease

recent O
weight B-clinical_variable
change O
( O
+ B-upper_bound
/ I-upper_bound
- I-upper_bound
@NUMBER I-upper_bound
pounds I-upper_bound
in O
@NUMBER B-upper_bound
year I-upper_bound
) O

current O
or O
prior O
history O
of O
grade O
≥ O
@NUMBER B-lower_bound
peripheral B-chronic_disease
sensory I-chronic_disease
and O
/ O
or O
motor B-chronic_disease
neuropathy I-chronic_disease

at O
least O
three B-lower_bound
weeks I-lower_bound
since O
the O
last O
biological B-treatment
/ O
investigational B-treatment
therapy I-treatment
[ O
excluding O
monoclonal B-clinical_variable
antibodies I-clinical_variable
( I-clinical_variable
mabs I-clinical_variable
) I-clinical_variable
] O

baseline O
imaging O
shows O
suitable O
vascular O
anatomy O
/ O
vessel O
size O
for O
the O
intergraft O
™ O
venous O
connector O
and O
an O
artery O
at O
least O
@NUMBER B-lower_bound
mm I-lower_bound
in O
diameter O
that O
is O
suitable O
for O
creating O
the O
arterial B-treatment
anastomosis I-treatment

diabetes B-chronic_disease
is O
included O
in O
this O
group O
due O
to O
the O
progressive O
changes O
to O
the O
sensation O
and O
circulation O
in O
the O
lower O
extremities O

untreated O
rampant B-chronic_disease
caries I-chronic_disease
and O
uncontrolled O
periodontal B-chronic_disease
disease I-chronic_disease

recipients O
who O
have O
had O
a O
stem B-treatment
cell I-treatment
transplant I-treatment
must O
be O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
after O
stem B-treatment
cell I-treatment
infusion I-treatment

females B-gender
of O
childbearing O
potential O
must O
have O
a O
negative B-pregnancy
serum I-pregnancy
or I-pregnancy
urine I-pregnancy
beta I-pregnancy
human I-pregnancy
chorionic I-pregnancy
gonadotropin I-pregnancy
( I-pregnancy
b I-pregnancy
- I-pregnancy
hcg I-pregnancy
) I-pregnancy
pregnancy I-pregnancy
test O
result O
within O
@NUMBER B-upper_bound
hours I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
treatment B-treatment
and O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
an I-contraception_consent
effective I-contraception_consent
contraception I-contraception_consent
method I-contraception_consent
during O
the O
study O
and O
for O
@NUMBER B-upper_bound
weeks I-upper_bound
after I-upper_bound
the O
last O
dose O
of O
the O
study B-treatment
drug I-treatment

co O
- O
administration O
with O
moderate O
cyp3a4 B-treatment
inhibitors I-treatment
( O
e.g. O
, O
erythromycin B-treatment
, O
fluconazole B-treatment
) O
or O
pgp B-treatment
inhibitors I-treatment
may O
be O
used O
with O
caution O
and O
everolimus B-treatment
dosing O
must O
be O
discussed O
with O
pi O
at O
the O
time O
of O
enrollment O

patients O
with O
a O
known O
hypersensitivity O
to O
everolimus B-allergy_name
or O
other O
rapamycins B-allergy_name
( O
sirolimus B-allergy_name
, O
temsirolimus B-allergy_name
) O
or O
to O
its O
excipients O

uncontrolled O
diabetes B-chronic_disease
as O
defined O
by O
fasting B-clinical_variable
serum I-clinical_variable
glucose I-clinical_variable
> O
@NUMBER B-lower_bound
x I-lower_bound
uln I-lower_bound

brain O
abnormality O
such O
as O
a O
brain B-cancer
tumor I-cancer
, I-cancer
stroke B-chronic_disease
, O
brain O
damage O
from O
head O
trauma O
or O
blood O
vessel O
abnormalities O
, O
on O
an O
mri B-treatment
scan I-treatment

able B-language_fluency
to I-language_fluency
read I-language_fluency
and I-language_fluency
communicate I-language_fluency
in I-language_fluency
english I-language_fluency

psychosis B-chronic_disease
or O
severe B-chronic_disease
depression I-chronic_disease
, O
anxiety B-chronic_disease
, O
substance B-chronic_disease
abuse I-chronic_disease
disorder I-chronic_disease

any O
renal B-chronic_disease
disease I-chronic_disease
( O
egfr B-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound
) O
or O
acute B-chronic_disease
nephritis I-chronic_disease

maintenance O
of O
undetectable B-clinical_variable
plasma I-clinical_variable
hiv-1 I-clinical_variable
rna I-clinical_variable
( O
< O
@NUMBER B-upper_bound
copies I-upper_bound
/ I-upper_bound
ml I-upper_bound
) O
for O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
. O
episodes B-clinical_variable
of I-clinical_variable
single I-clinical_variable
hiv I-clinical_variable
plasma I-clinical_variable
rna I-clinical_variable
hiv B-clinical_variable
plasma I-clinical_variable
rna I-clinical_variable
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
copies.ml I-upper_bound
will O
not O
exclude O
participation O
if O
subsequent O
hiv O
plasma O
rna O
is O
< O
@NUMBER O
copies O
/ O
ml O

any O
major B-treatment
surgery I-treatment
, O
radiotherapy B-treatment
, O
chemotherapy B-treatment
, O
biologic B-treatment
therapy I-treatment
, O
immunotherapy B-treatment
, O
experimental B-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
the O
first B-treatment
dose I-treatment
of I-treatment
the I-treatment
study I-treatment
drugs I-treatment

ecog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
≤ O
@NUMBER B-upper_bound

males B-gender
who O
have O
partners O
of O
childbearing O
potential O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
an I-contraception_consent
effective I-contraception_consent
contraceptive I-contraception_consent
method O
during O
the O
study O
and O
a O
period O
of O
@NUMBER B-upper_bound
weeks I-upper_bound
after I-upper_bound
the O
last B-treatment
dose I-treatment
of I-treatment
investigational I-treatment
drug I-treatment

prior O
treatment B-treatment
with I-treatment
growth I-treatment
factors I-treatment
and O
/ O
or O
lenalidomide B-treatment
is O
allowed O
for O
any O
cohort O

maternal O
contraindication O
to O
fetoscopic B-treatment
surgery I-treatment
or O
severe B-treatment
maternal I-treatment
medical I-treatment
condition I-treatment
in O
pregnancy B-pregnancy

pregnant B-pregnancy
women B-gender
< O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

patients O
with O
known O
central B-cancer
nervous I-cancer
system I-cancer
infiltration I-cancer
with I-cancer
leukemia I-cancer

serum B-clinical_variable
creatinine I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
the I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound

high B-cancer
- I-cancer
risk I-cancer
mds I-cancer
( O
i.e O
. O
refractory B-chronic_disease
anemia I-chronic_disease
with I-chronic_disease
excess I-chronic_disease
blasts I-chronic_disease
[ O
raeb-1 B-chronic_disease
or O
raeb-2 B-chronic_disease
] O
by O
world O
health O
organization O
[ O
who O
] O
classification O
, O
or O
any O
who O
subset O
with O
international B-clinical_variable
prognostic I-clinical_variable
scoring I-clinical_variable
system I-clinical_variable
[ I-clinical_variable
ipss I-clinical_variable
] I-clinical_variable
intermediate-2 O
or O
high O
, O
or O
any O
patients O
that O
has O
failed O
prior B-treatment
therapy I-treatment
with I-treatment
hypomethylating I-treatment
agents I-treatment
) O

expected O
to O
survive O
beyond O
the O
first O
@NUMBER B-upper_bound
days I-upper_bound
after I-upper_bound
enrolment O

major B-chronic_disease
birth I-chronic_disease
defect I-chronic_disease
or O
malformation B-chronic_disease
syndrome I-chronic_disease

patients O
who O
are O
actively O
suicidal B-chronic_disease
or O
evaluated O
as O
being O
a O
high O
suicide O
risk O

subjective B-clinical_variable
total I-clinical_variable
sleep I-clinical_variable
time I-clinical_variable
( I-clinical_variable
stst I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound
hours I-upper_bound
on O
≥ O
@NUMBER B-lower_bound
night O
during O
the O
prior O
week O

subjects O
must O
present O
with O
a O
clinical O
diagnosis O
of O
stable O
( O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
) O
plaque B-chronic_disease
psoriasis I-chronic_disease

subjects O
whose O
results O
from O
the O
screening O
acth B-treatment
stimulation I-treatment
test O
are O
considered O
normal O

use O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
screening O
visit O
of O
any O
product O
containing O
corticosteroids B-treatment

calcitonin B-clinical_variable
equal O
or O
above O
@NUMBER B-lower_bound
ng I-lower_bound
/ I-lower_bound
l I-lower_bound

stable O
body B-clinical_variable
weight I-clinical_variable
during O
the O
previous O
@NUMBER B-upper_bound
days I-upper_bound
before I-upper_bound
screening O
( O
below O
@NUMBER B-upper_bound
kg I-upper_bound
self O
- O
reported O
weight O
change O
) O

patients O
with O
metastatic B-cancer
disease I-cancer
may O
have O
received O
prior B-treatment
nephrectomy I-treatment
and O
/ O
or O
prior B-treatment
systemic I-treatment
therapy I-treatment
( O
no O
limit O
on O
number O
) O
; O
their O
baseline O
pmri O
would O
be O
performed O
prior O
to O
starting O
a O
new O
treatment B-treatment

severe B-chronic_disease
renal I-chronic_disease
function I-chronic_disease
impairment I-chronic_disease
( O
estimated B-clinical_variable
glomerular I-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
[ I-clinical_variable
egfr I-clinical_variable
] I-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound
/ I-upper_bound
@NUMBER I-upper_bound
m^2 I-upper_bound
) O
would O
make O
the O
patient O
inappropriate O
for O
enrollment O
due O
to O
the O
increased O
risk O
of O
nephrogenic B-chronic_disease
systemic I-chronic_disease
fibrosis I-chronic_disease
( I-chronic_disease
nsf I-chronic_disease
) I-chronic_disease
with O
higher O
dose O
of O
iv B-treatment
gadolinium I-treatment
- I-treatment
based I-treatment
contrast I-treatment
agents I-treatment
( I-treatment
gbca I-treatment
) I-treatment
administration O

currently O
receiving O
bmt B-treatment
at O
montefiore O
community O
health O
center O
( O
chc O
) O

@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
or O
older O
at O
the O
time O
of O
screening O

if O
a O
participant O
is O
receiving O
anticoagulant B-treatment
or O
anti B-treatment
- I-treatment
platelet I-treatment
therapy I-treatment
( O
such O
as O
warfarin B-treatment
and O
clopidogrel B-treatment
) O
, O
the O
participant O
is O
unwilling O
to O
or O
unable O
to O
safely O
discontinue O
anticoagulant O
or O
anti O
- O
platelet O
therapy O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
until O
at O
least O
@NUMBER B-lower_bound
hours I-lower_bound
after I-lower_bound
the O
bal B-treatment
procedures I-treatment
. O
an O
exception O
is O
low B-treatment
- I-treatment
dose I-treatment
aspirin I-treatment
alone O
which O
is O
allowed O

screening O
levels O
of O
endogenous B-clinical_variable
plasma I-clinical_variable
( I-clinical_variable
antigenic I-clinical_variable
) I-clinical_variable
a1pi I-clinical_variable
of O
≤ O
@NUMBER B-upper_bound
μm I-upper_bound
may O
be O
collected O
at O
any O
time O
during O
the O
screening O
period O
for O
treatment B-treatment
-naïve O
participants O
, O
or O
following O
a O
@NUMBER B-lower_bound
week I-lower_bound
minimum O
wash O
- O
out O
from O
previous B-treatment
augmentation I-treatment
therapy I-treatment
in O
treatment O
- O
experienced O
participants O

the O
participant O
has O
a O
history O
of O
frequent O
pulmonary B-chronic_disease
exacerbations I-chronic_disease
exacerbations B-chronic_disease
( O
greater O
than O
@NUMBER B-lower_bound
moderate O
or O
severe O
exacerbations O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
screening O

the O
participant O
is O
experiencing O
or O
has O
a O
history O
of O
chronic O
severe O
cor B-chronic_disease
pulmonale I-chronic_disease
( O
resting O
mean O
pulmonary B-clinical_variable
artery I-clinical_variable
pressure I-clinical_variable
≥ O
@NUMBER B-lower_bound
millimeter I-lower_bound
( I-lower_bound
s I-lower_bound
) I-lower_bound
of I-lower_bound
mercury I-lower_bound
( I-lower_bound
mm I-lower_bound
hg I-lower_bound
) I-lower_bound
) O

the O
participant O
is O
receiving O
or O
requires O
long O
- O
term O
( O
> O
@NUMBER B-lower_bound
weeks I-lower_bound
) O
immunosuppressive B-treatment
therapy I-treatment
, O
such O
as O
systemic B-treatment
corticosteroids I-treatment
at O
doses O
greater O
than O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
day I-lower_bound
of O
prednisone B-treatment
( O
or O
its O
equivalent O
) O
, O
mycophenolate B-treatment
mofetil I-treatment
, O
azathioprine B-treatment
, O
cyclophosphamide B-treatment
, O
and O
rituximab B-treatment

cardiac O
: O
left B-clinical_variable
ventricular I-clinical_variable
ejection I-clinical_variable
fraction I-clinical_variable
( I-clinical_variable
lvef I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound

pediatric O
or O
adult O
( O
ages B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
) O
hct B-treatment
recipient O
with O
grade B-lower_bound
ii I-lower_bound
- O
iv B-upper_bound
steroid B-chronic_disease
refractory I-chronic_disease
or O
steroid B-chronic_disease
- I-chronic_disease
dependent I-chronic_disease
acute I-chronic_disease
gvhd I-chronic_disease
, O
defined O
as O
any O
one O
of O
the O
following O

breast O
- O
feeding O
women B-gender
who O
do O
not O
agree O
to O
stop O
breast O
- O
feeding O
during O
and O
for O
@NUMBER O
days O
following O
the O
end O
of O
oral B-treatment
glyburide I-treatment
administration O

unconsciousness O
or O
other O
mental B-chronic_disease
impairment I-chronic_disease
that O
prevents O
neurological O
assessment O
within O
the O
first B-upper_bound
@NUMBER I-upper_bound
hours I-upper_bound

patients O
undergoing O
open B-treatment
elective I-treatment
liver I-treatment
resection I-treatment
for O
primary O
liver O
pathology O
( O
benign O
or O
malignant O
) O
or O
secondary O
metastatic B-cancer
liver I-cancer
disease I-cancer
, O
including O
patients O
undergoing O
concomitant B-treatment
surgical I-treatment
procedures I-treatment
( O
such O
as O
colorectal B-treatment
resection I-treatment
or O
debulking B-treatment
procedures I-treatment
) O
, O
with O
no O
contraindication O
to O
the O
insertion O
of O
an O
epidural B-treatment
catheter I-treatment
( O
localized B-chronic_disease
infection I-chronic_disease
, O
septicemia B-chronic_disease
, O
or O
pre B-treatment
- I-treatment
operative I-treatment
coagulopathy I-treatment
) O

registered O
male B-gender
or O
female B-gender
primary O
liver B-treatment
transplant I-treatment
candidate O

castrate B-clinical_variable
testosterone I-clinical_variable
levels I-clinical_variable
( O
< O
@NUMBER B-upper_bound
ng I-upper_bound
/ I-upper_bound
dl I-upper_bound
) O
achieved O
by O
orchiectomy O
or O
maintenance O
on O
a O
luteinizing B-treatment
hormone I-treatment
- I-treatment
releasing I-treatment
hormone I-treatment
( I-treatment
lhrh I-treatment
) I-treatment
agonist I-treatment
or O
antagonist B-treatment

leukocytes B-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm^3 I-lower_bound

must O
have O
appropriate O
wash O
out O
( O
> O
@NUMBER B-lower_bound
half O
- O
lives O
) O
of O
androgen B-treatment
receptor I-treatment
antagonists I-treatment
, O
@NUMBER O
alpha B-treatment
reductase I-treatment
inhibitors I-treatment
or O
ketoconazole B-treatment
prior O
to O
the O
start O
of O
cycle O
@NUMBER O
; O
if O
the O
agent O
is O
not O
in O
the O
table O
below O
, O
the O
washout O
should O
be O
@NUMBER B-upper_bound
weeks I-upper_bound

uncontrolled O
, O
intercurrent B-chronic_disease
illness I-chronic_disease
including O
, O
but O
not O
limited O
to O
, O
ongoing O
or O
active B-chronic_disease
infection I-chronic_disease
, O
uncontrolled B-chronic_disease
diabetes I-chronic_disease
, O
symptomatic O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease
pectoris I-chronic_disease
, O
cardiac B-chronic_disease
arrhythmia I-chronic_disease
, O
or O
psychiatric B-chronic_disease
illness I-chronic_disease
/ I-chronic_disease
social I-chronic_disease
situations I-chronic_disease
that O
would O
limit O
compliance O
with O
study O
requirements O

life B-clinical_variable
expectancy I-clinical_variable
of O
greater O
than O
@NUMBER B-lower_bound
months I-lower_bound

may O
not O
have O
received O
enzalutamide B-treatment
or O
arn-509 B-treatment
( O
another O
androgen B-treatment
receptor I-treatment
antagonist I-treatment
) O
in O
the O
past O

vasectomy B-treatment
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
prior I-lower_bound
to O
starting O
study B-treatment
treatment I-treatment
period O
and O
those O
whose O
female B-gender
sexual O
partner O
( O
s O
) O
are O
more O
than O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
and O
postmenopausal O
for O
at O
least O
@NUMBER B-lower_bound
years I-lower_bound
or O
surgically O
sterile O
( O
tubal B-contraception_consent
ligation I-contraception_consent
, O
hysterectomy B-contraception_consent
, O
or O
bilateral B-contraception_consent
oophorectomy I-contraception_consent
) O
agree O
to O
use O
at O
least O
a O
condom B-contraception_consent

@NUMBER B-lower_bound
@NUMBER O
to O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

biopsy B-treatment
-proven O
malignant B-cancer
breast I-cancer
lesion I-cancer
including O
by O
not O
limited O
to O
invasive B-cancer
ductal I-cancer
carcinoma I-cancer
, O
invasive B-cancer
lobular I-cancer
carcinoma I-cancer
, O
and O
ductal B-cancer
carcinoma I-cancer
in I-cancer
situ I-cancer

receiving O
neoadjuvant B-treatment
chemotherapy I-treatment

children O
who O
have O
previously O
received O
chemotherapy B-treatment
, O
radiation B-treatment
therapy I-treatment
or O
any O
anti B-treatment
- I-treatment
leukemic I-treatment
therapy I-treatment
are O
not O
eligible O
for O
this O
protocol O
, O
with O
the O
exception O
of O
cytarabine B-treatment
for O
the O
treatment B-treatment
of O
tmd B-chronic_disease

patient O
has O
a O
known O
sensitivity O
to O
device B-allergy_name
materials I-allergy_name

patient O
is O
a O
candidate O
for O
revision O
of O
all O
femoral O
and O
tibial O
components O
of O
a O
total B-treatment
knee I-treatment
replacement I-treatment

patient O
is O
a O
male B-gender
or O
non- O
pregnant B-pregnancy
female B-gender

skeletally O
mature O
and O
age B-age
@NUMBER B-lower_bound
years I-lower_bound
or O
older O
at O
time O
of O
study O
device O
implantation O

history O
of O
allergic O
reactions O
attributed O
to O
compounds O
of O
similar O
chemical O
or O
biologic O
composition O
to O
medi-570 B-allergy_name
or O
history O
of O
anaphylaxis B-chronic_disease
to O
any O
biological B-allergy_name
component I-allergy_name

major B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
or O
during O
the O
study O
period O

receipt O
of O
live O
or O
live O
attenuated B-treatment
vaccine I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
enrollment O

relapsed O
or O
refractory O
post B-treatment
autologous I-treatment
cell I-treatment
transplantation I-treatment
( I-treatment
hct I-treatment
) I-treatment

total B-clinical_variable
bilirubin I-clinical_variable
< O
@NUMBER B-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound

vitiligo B-chronic_disease

corticosteroids B-treatment
prescribed O
for O
the O
management O
of O
brain B-cancer
metastases I-cancer
have O
been O
discontinued O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
prior I-lower_bound
to O
registration O

major B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
starting O
protocol O
treatment B-treatment

patients O
with O
a O
prior O
history O
of O
brain B-cancer
metastases I-cancer

agents O
include O
heparin B-treatment
or O
low O
molecular O
weight O
heparin O
, O
warfarin B-treatment
, O
clopidogrel B-treatment
, O
ibuprofen B-treatment
and O
other O
nonsteroidal B-treatment
anti I-treatment
- I-treatment
inflammatory I-treatment
drug I-treatment
( I-treatment
nsaids I-treatment
) I-treatment
, O
tirofiban B-treatment
, O
and O
other O
anticoagulants B-treatment
, O
drugs B-treatment
, O
or O
herbal B-treatment
supplements I-treatment
that O
affect O
platelet B-clinical_variable
function O

low O
- O
dose O
anticoagulation B-treatment
medications I-treatment
that O
are O
used O
to O
maintain O
the O
patency O
of O
a O
central O
intravenous O
catheter O

must O
have O
recovered O
from O
adverse O
events O
attributable O
to O
previous O
treatment O
to O
≤ O
grade B-upper_bound
@NUMBER I-upper_bound

age B-age
≤ O
@NUMBER B-upper_bound
years I-upper_bound
at O
time O
of O
initial O
qualifying O
solid B-cancer
tumor I-cancer
diagnosis O

histologic O
diagnosis O
of O
solid B-cancer
malignancy I-cancer

no O
therapy B-treatment
planned O

promyelocytic B-cancer
leukemia I-cancer
( I-cancer
apml I-cancer
) I-cancer

have O
a O
peripheral B-clinical_variable
blast I-clinical_variable
count I-clinical_variable
of O
> O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound
( O
may O
use O
hydroxyurea B-treatment
as O
in O
# O
@NUMBER O
above O
) O

received O
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
m2 I-lower_bound
equivalents O
of O
daunorubicin B-treatment

latex B-allergy_name
allergy O

metformin B-treatment
contraindicated O
where O
liver B-clinical_variable
function I-clinical_variable
tests O
> O
three B-lower_bound
times I-lower_bound
the I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound
( O
alanine B-clinical_variable
transaminase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
u I-lower_bound
/ I-lower_bound
l I-lower_bound
, O
aspartate B-clinical_variable
transaminase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
u I-lower_bound
/ I-lower_bound
l I-lower_bound
at O
nsha O
) O

suicide B-chronic_disease
ideation I-chronic_disease
( O
current O
score O
of O
@NUMBER O
on O
the O
suicidal B-chronic_disease
ideation I-chronic_disease
section O
of O
the O
columbia B-clinical_variable
- I-clinical_variable
suicide I-clinical_variable
severity I-clinical_variable
rating I-clinical_variable
scale I-clinical_variable
( I-clinical_variable
c I-clinical_variable
- I-clinical_variable
ssrs I-clinical_variable
) I-clinical_variable

participant O
has O
previously O
received O
an O
allogenic B-treatment
stem I-treatment
cell I-treatment
transplant I-treatment

refractory B-chronic_disease
disease I-chronic_disease
is O
defined O
as O
less O
than O
( O
< O
) O
@NUMBER B-upper_bound
percent I-upper_bound
( I-upper_bound
% I-upper_bound
) I-upper_bound
reduction O
in O
m O
- O
protein O
or O
progression O
of O
disease O
during O
treatment O

within O
@NUMBER B-upper_bound
days I-upper_bound
after O
cessation O
of O
treatment O

hepatic B-chronic_disease
encephalopathy I-chronic_disease
encephalopathy B-chronic_disease
within O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
or O
requirement O
for O
medications B-treatment
to O
prevent O
or O
control O
encephalopathy O

immunotherapy B-treatment
-naïve O

main O
portal B-chronic_disease
vein I-chronic_disease
thrombosis I-chronic_disease
( O
vp4 O
) O
as O
documented O
on O
imaging B-treatment

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
( I-clinical_variable
anc I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
x I-lower_bound
10 I-lower_bound
^ I-lower_bound
9 I-lower_bound
/ I-lower_bound
l I-lower_bound
( O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
first B-treatment
study I-treatment
treatment I-treatment
) O

any O
history O
of O
clinically O
significant O
arrhythmias B-chronic_disease
( O
such O
as O
ventricular B-chronic_disease
tachycardia I-chronic_disease
, O
ventricular B-chronic_disease
fibrillation I-chronic_disease
, O
or O
torsades B-chronic_disease
de I-chronic_disease
pointes I-chronic_disease
) O

any O
positive O
test O
result O
for O
hepatitis B-chronic_disease
b I-chronic_disease
or O
c B-chronic_disease
virus O
indicating O
acute B-chronic_disease
or O
chronic B-chronic_disease
infection I-chronic_disease

aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
and O
alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
( O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
for O
hcc B-cancer
) O
( O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
first B-treatment
study I-treatment
treatment I-treatment
) O

brain B-cancer
metastases I-cancer
, O
leptomeningeal B-cancer
disease I-cancer
or O
bone B-cancer
metastases I-cancer

cardiovascular B-chronic_disease
disease I-chronic_disease
-related O
requirement O
for O
daily O
supplemental O
oxygen O

subjects O
who O
are O
compulsorily B-treatment
detained I-treatment
for O
treatment B-treatment
of O
either O
a O
psychiatric B-chronic_disease
or I-chronic_disease
physical I-chronic_disease
( I-chronic_disease
infection I-chronic_disease
disease I-chronic_disease
) I-chronic_disease
illness I-chronic_disease

uncontrolled B-chronic_disease
angina I-chronic_disease
within O
the O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
consent O

within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
time O
of O
study O
treatment B-treatment

females B-gender
on O
hormone B-treatment
replacement I-treatment
therapy I-treatment
( I-treatment
hrt I-treatment
) I-treatment
hrt B-treatment
) O
and O
whose O
menopausal O
status O
is O
in O
doubt O
will O
be O
required O
to O
use B-contraception_consent
one I-contraception_consent
of I-contraception_consent
the I-contraception_consent
contraception I-contraception_consent
methods I-contraception_consent
if O
they O
wish O
to O
continue O
their O
hrt O
during O
the O
study O
; O
otherwise O
, O
they O
must O
discontinue O
hrt O
to O
allow O
confirmation O
of O
post O
- O
menopausal O
status O
prior O
to O
study O
enrollment O

male B-gender
participants I-gender
must O
be O
willing O
to O
refrain O
from O
sperm O
donation O
during O
this O
time O

patients O
must O
be O
willing O
to O
provide O
tumor B-cancer
samples O
at O
the O
time O
points O
specified O
in O
the O
study O
procedure O
tables O

patients O
with O
cutaneous B-cancer
, O
mucosal B-cancer
, O
acral B-cancer
, O
ocula B-cancer
r O
or O
unknown B-cancer
primary I-cancer
melanomas I-cancer
are O
eligible O
for O
enrollment O

patients O
deemed O
by O
emergency O
physician O
to O
have O
ahf B-chronic_disease
, O
who O
they O
plan O
to O
discharge O
or O
hold O
for O
brief O
ed O
- O
based O
observation O

macroscopic B-treatment
complete I-treatment
salvage I-treatment
surgery I-treatment
surgery B-treatment
with O
curative O
intent O
( O
surgery O
was O
not O
performed O
only O
for O
biopsy B-treatment
or O
palliation B-treatment
) O

have O
a O
positive B-pregnancy
pregnancy I-pregnancy
test O
( O
reproductive O
age O
should O
use B-contraception_consent
effective I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
during O
study O
if O
randomized O
to O
sbrt B-treatment
treatment I-treatment
arm O
) O

female B-gender
subjects I-gender
male B-gender
subjects I-gender
of O
childbearing O
potential O
and O
male O
subjects O
with O
female B-gender
partners I-gender
of O
childbearing O
potential O
must O
be O
willing O
to O
avoid O
pregnancy B-pregnancy

liver O
function O
abnormality O
as O
defined O
by O
total B-clinical_variable
bilirubin I-clinical_variable
> O
@NUMBER B-lower_bound
× I-lower_bound
uln I-lower_bound
@NUMBER B-lower_bound
× I-lower_bound
uln I-lower_bound
or O
aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
/ I-clinical_variable
alanine I-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
× I-lower_bound
uln I-lower_bound
( O
except O
for O
subjects O
with O
liver O
involvement O
, O
who O
can O
have O
ast B-clinical_variable
/ I-clinical_variable
alt I-clinical_variable
> O
@NUMBER O
× O
uln O
) O

phase O
ia O
part O
: O
advanced O
solid B-cancer
tumors I-cancer
or O
metastases B-cancer
including O
lymphoma B-cancer
localized O
in O
the O
head O
and O
neck O
region O
or O
thorax O
with O
an O
indication O
for O
fractionated O
palliative O
rt B-treatment
( O
arm O
a O
) O
; O
or O
treatment B-treatment
-naïve O
scchn B-cancer
eligible O
for O
fractionated O
curatively O
intended O
rt O
with O
concurrent O
cisplatin B-treatment
( O
arm O
b O
) O

subject O
has O
active B-chronic_disease
viral I-chronic_disease
or O
bacterial B-chronic_disease
infections I-chronic_disease
or O
any O
coexisting O
medical O
problem O
that O
would O
significantly O
increase O
the O
risks O
of O
this O
treatment B-treatment
program O

subject O
has O
known O
active O
hepatitis B-chronic_disease
b I-chronic_disease
or O
hepatitis B-chronic_disease
c I-chronic_disease
infection O

subject O
has O
known O
hypersensitivity O
to O
dexamethasone B-allergy_name
, O
clarithromycin B-allergy_name
, O
lenalidomide B-allergy_name
, O
or O
thalidomide B-allergy_name

antibiotics B-treatment
: O
clarithromycin B-treatment
, O
erythromycin B-treatment
, O
telithromycin B-treatment
, O
troleandomycin B-treatment

have O
an O
estimated O
life B-clinical_variable
expectancy I-clinical_variable
> O
@NUMBER B-lower_bound
months I-lower_bound

patients O
who O
require O
frequent O
( O
several O
times O
a O
day O
) O
monitoring O
of O
their O
blood O
glucose O
or O
patients O
who O
have O
recently O
been O
hospitalized B-treatment
for O
glucose O
control O

patients O
also O
will O
have O
an O
anxiety B-chronic_disease
symptom O
severity O
score O
of O
at O
least O
@NUMBER B-lower_bound
on O
the O
hospital B-clinical_variable
anxiety I-clinical_variable
and O
depression B-clinical_variable
- I-clinical_variable
anxiety I-clinical_variable
scale I-clinical_variable
( I-clinical_variable
hads I-clinical_variable
- I-clinical_variable
a I-clinical_variable
) I-clinical_variable
or I-clinical_variable
a I-clinical_variable
dsm-5 O
diagnosis O
of O
an O
anxiety O
disorder O
, O
such O
as O
general B-chronic_disease
anxiety I-chronic_disease
, O
social B-chronic_disease
anxiety I-chronic_disease
, O
or O
panic B-chronic_disease
disorder I-chronic_disease

resting B-clinical_variable
bp I-clinical_variable
> O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
mm I-lower_bound
hg I-lower_bound

history O
of O
allogenic B-treatment
organ I-treatment
transplantation I-treatment
that O
requires O
use O
of O
immunosuppressive B-treatment
agents I-treatment

body B-bmi
mass I-bmi
index I-bmi
> O
@NUMBER B-lower_bound
% I-lower_bound
ile I-lower_bound
for O
age B-age
and O
sex O
by O
standard O
growth O
charts O

received O
a O
new O
or O
ongoing O
prescription O
for O
at O
least O
one B-lower_bound
sga B-treatment
( O
i.e. O
, O
olanzapine B-treatment
, O
clozapine B-treatment
, O
risperidone B-treatment
, O
quetiapine B-treatment
, O
aripiprazole B-treatment
, O
ziprasidone B-treatment
, O
iloperidone B-treatment
, O
lurasidone B-treatment
, O
paliperidone B-treatment
, O
brexpiprazole B-treatment
or O
cariprazine B-treatment
) O
that O
is O
not O
prescribed O
as O
a O
prn B-treatment
medication I-treatment

hiv B-chronic_disease
positive O
patient O

liver O
in O
which O
the O
investigator O
is O
unwilling O
or O
unable O
( O
for O
logistical O
reasons O
) O
to O
perform O
normothermic B-treatment
machine I-treatment
perfusion I-treatment
( I-treatment
nmp I-treatment
) I-treatment
preservation O

patients O
undergoing O
primary B-treatment
liver I-treatment
transplantation I-treatment

age B-age
≥ O
@NUMBER B-lower_bound
years I-lower_bound

any O
radiation B-treatment
therapy I-treatment
( I-treatment
rt I-treatment
) I-treatment
for O
the O
currently O
diagnosed O
breast B-cancer
cancer I-cancer
prior O
to O
study O
enrollment O

history O
of O
ipsilateral O
or O
contralateral B-treatment
breast I-treatment
or O
thoracic B-treatment
rt I-treatment
for O
any O
condition O

unresolved O
post O
- O
surgical O
complications O
( O
eg O
, O
significant O
infection B-chronic_disease
) O
with O
healing O
difficulties O

more O
than O
four B-lower_bound
additional O
diagnosed O
brain B-cancer
metastases I-cancer

anc B-clinical_variable
> O
@NUMBER B-lower_bound
/ I-lower_bound
microl I-lower_bound

currently O
active O
, O
clinically O
significant O
cardiovascular B-chronic_disease
disease I-chronic_disease
such O
as O
uncontrolled O
or O
symptomatic O
arrhythmias B-chronic_disease
, O
class B-chronic_disease
@NUMBER I-chronic_disease
or I-chronic_disease
@NUMBER I-chronic_disease
congestive I-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
as O
defined O
by O
new O
york O
heart O
association O
functional O
classification O
, O
or O
a O
history O
of O
myocardial B-chronic_disease
infarction I-chronic_disease
or O
unstable B-chronic_disease
angina I-chronic_disease
, O
or O
acute B-chronic_disease
coronary I-chronic_disease
syndrome I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
screening O

immunophenotypic B-treatment
profile O
or O
immunohistochemistry B-treatment
read O
by O
an O
expert O
pathologist O
as O
consistent O
with O
cll B-cancer

men B-gender
and O
women B-gender
with O
histologically O
confirmed O
disease O

sll B-cancer
: O
lymphadenopathy B-chronic_disease
with O
the O
tissue O
morphology O
of O
cll B-cancer
but O
that O
are O
not O
leukemic O
, O
< O
@NUMBER B-upper_bound
cells I-upper_bound
/ I-upper_bound
microl I-upper_bound

subjects O
who O
received O
a O
strong O
cytochrome B-treatment
p450 I-treatment
( I-treatment
cyp I-treatment
) I-treatment
@NUMBER I-treatment
a I-treatment
inhibitor I-treatment
within O
@NUMBER B-treatment
days I-treatment
prior I-treatment
to O
the O
first O
dose O
of O
ibrutinib B-treatment
or O
subjects O
who O
require O
continuous O
treatment B-treatment
with O
a O
strong O
cyp3a O
inhibitor O

liver O
enzymes O
( O
ast B-clinical_variable
or O
alt B-clinical_variable
) O
levels O
above O
@NUMBER B-lower_bound
x I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound

subjects O
with O
clinically O
diagnosed O
hepatic B-chronic_disease
disease I-chronic_disease
( O
including O
but O
not O
limited O
to O
auto B-chronic_disease
immune I-chronic_disease
disease I-chronic_disease
, O
hepatitis B-chronic_disease
and O
cirrhosis B-chronic_disease
) O

active O
endocarditis B-chronic_disease

documented O
symptomatic O
carotid B-chronic_disease
disease I-chronic_disease
, O
defined O
as O
> O
@NUMBER B-lower_bound
% I-lower_bound
stenosis B-chronic_disease
or O
> O
@NUMBER B-lower_bound
% I-lower_bound
stenosis O
with O
symptoms O

end B-chronic_disease
stage I-chronic_disease
renal I-chronic_disease
disease I-chronic_disease
( I-chronic_disease
esrd I-chronic_disease
) I-chronic_disease
or O
documented O
history O
of O
renal B-treatment
replacement I-treatment
/ O
dialysis B-treatment

previously O
attempted O
occlusion O
of O
the O
left O
atrial O
appendage O
( O
by O
any O
surgical B-treatment
or O
percutaneous B-treatment
method O
) O

significant O
mitral O
valve O
stenosis O
( O
i.e. O
, O
mitral O
valve O
stenosis O
< O
1.5cm2 B-upper_bound
) O

antisocial B-chronic_disease
personality I-chronic_disease
disorder I-chronic_disease
diagnosis O
as O
assessed O
during O
clinical O
interview O
, O
as O
well O
as O
a O
history O
of O
hospitalization O
and O
/ O
or O
recurrent O
suicidal B-chronic_disease
behavior I-chronic_disease
judged O
to O
be O
directly O
due O
to O
the O
personality O
disorder O

autoimmune B-chronic_disease
or O
inflammatory B-chronic_disease
disorder I-chronic_disease
of O
any O
kind O

embedded B-treatment
metallic I-treatment
objects I-treatment
, O
prosthetics B-treatment
made O
of O
paramagnetic B-treatment
metals I-treatment
, O
aneurysmal B-treatment
clips I-treatment
and O
/ O
or O
a O
history O
of O
claustrophobia B-chronic_disease

history O
of O
the O
following O
: O
schizophrenia B-chronic_disease
, O
schizoaffective B-chronic_disease
disorder I-chronic_disease
, O
other O
( O
non O
mood B-chronic_disease
disorder I-chronic_disease
) O
psychosis B-chronic_disease
, O
depression B-chronic_disease
secondary O
to O
a O
medical O
condition O
, O
mental B-chronic_disease
retardation I-chronic_disease
, O
dementia B-chronic_disease
, O
or O
delirium O

at O
least O
one B-lower_bound
episode I-lower_bound
of O
binge O
substance O
use O
or O
suicidal B-chronic_disease
ideation I-chronic_disease
recorded O
in O
the O
apache O
community O
- O
based O
surveillance O
system O
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

severe O
risk O
for O
suicide O
( O
i.e. O
, O
suicide B-chronic_disease
attempt I-chronic_disease
within O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
) O

at O
least O
@NUMBER B-lower_bound
days I-lower_bound
must O
have O
elapsed O
for O
local O
xrt B-treatment

hgb B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound
- O
can O
be O
transfused O

myelosuppressive B-treatment
therapy I-treatment

patient O
with O
any O
significant O
concurrent B-chronic_disease
illness I-chronic_disease

patient O
with O
illness O
, O
psychiatric B-chronic_disease
disorder I-chronic_disease
or O
social O
issue O
that O
could O
compromise O
patient O
safety O
or O
compliance O
with O
the O
protocol B-treatment
treatment I-treatment
or O
procedures O
, O
or O
interfere O
with O
the O
consent O
, O
study O
participation O
, O
follow O
- O
up O
, O
or O
interpretation O
of O
study O
results O

this O
restriction O
does O
not O
include O
intrathecal B-treatment
chemotherapy I-treatment
, O
which O
is O
permitted O

recent O
stroke B-chronic_disease
, O
cardiac B-chronic_disease
infarction I-chronic_disease
or O
embolism O

active O
hepatitis B-chronic_disease
b I-chronic_disease
, O
either O
active O
carrier O
( O
hbsag B-chronic_disease
+ O
) O
or O
viremic B-chronic_disease
( O
hbv B-clinical_variable
dna I-clinical_variable
≥ O
@NUMBER B-lower_bound
copies I-lower_bound
/ I-lower_bound
ml I-lower_bound
, O
or O
≥ O
@NUMBER B-lower_bound
iu I-lower_bound
/ I-lower_bound
ml I-lower_bound
) O

myocardial B-chronic_disease
infarction I-chronic_disease
within O
@NUMBER B-upper_bound
year I-upper_bound
of O
study O
entry O

uncontrolled B-chronic_disease
hypertension I-chronic_disease
hypertension B-chronic_disease
, O
i.e. O
, O
blood B-clinical_variable
pressure I-clinical_variable
( I-clinical_variable
bp I-clinical_variable
) I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
; O
patients O
who O
have O
a O
history O
of O
hypertension O
controlled O
by O
medication B-treatment
must O
be O
on O
a O
stable O
dose O
and O
meet O
all O
other O
inclusion O
criteria O

women B-gender
who O
are O
willing O
to O
undergo O
a O
complete O
evaluation O
and O
/ O
or O
biopsy B-treatment
procedure O
if O
recommended O
by O
the O
treating O
physician O

women B-gender
with O
a O
bi B-clinical_variable
- I-clinical_variable
rads I-clinical_variable
category O
@NUMBER B-lower_bound
or O
@NUMBER B-upper_bound
designation O
on O
breast O
mri B-clinical_variable

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
≤ O
@NUMBER B-upper_bound
( O
karnofsky B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound

previous O
malignancy B-cancer
, O
other O
than O
basal B-cancer
cell I-cancer
or O
squamous B-cancer
cell I-cancer
carcinoma I-cancer
of I-cancer
the I-cancer
skin I-cancer
or O
in B-cancer
situ I-cancer
carcinoma I-cancer
of O
the O
cervix O
, O
from O
which O
the O
patient O
has O
been O
disease O
free O
for O
less O
than O
@NUMBER B-upper_bound
years I-upper_bound

received O
atg B-treatment
, O
campath B-treatment
or O
other O
t B-treatment
cell I-treatment
immunosuppressive I-treatment
monoclonal I-treatment
antibodies I-treatment
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

received O
prior O
myeloablative B-chronic_disease
or O
non B-treatment
- I-treatment
myeloablative I-treatment
allogeneic I-treatment
hematopoietic I-treatment
stem I-treatment
cell I-treatment
transplant I-treatment
using O
either O
bone O
marrow O
, O
single O
/ O
double O
cord O
blood O
or O
pbsc O

aml B-cancer
evolving O
from O
myelodysplastic B-cancer
syndrome I-cancer
( I-cancer
mds I-cancer
) I-cancer

they O
must O
have O
histologically O
or O
cytologically O
confirmed O
bc B-cancer
, O
crc B-cancer
, O
gec B-cancer
, O
melanoma B-cancer
, O
nsclc B-cancer
, O
or O
rcc B-cancer
with O
liver B-cancer
metastases I-cancer
or O
hcc B-cancer

have O
previous B-treatment
therapy I-treatment
with I-treatment
talimogene I-treatment
laherparepvec I-treatment
, O
oncolyic B-treatment
viruses I-treatment
, O
or O
tumor B-treatment
vaccine I-treatment

toxic O
effects O
of O
the O
most O
recent O
prior B-treatment
chemotherapy I-treatment
not O
resolved O
to O
grade B-upper_bound
@NUMBER I-upper_bound
or O
less O
( O
except O
alopecia B-chronic_disease
) O

@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

an O
active O
ssi B-chronic_disease
at O
the O
time O
of O
surgery B-treatment

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
< O
@NUMBER B-upper_bound
/ I-upper_bound
ml I-upper_bound

total O
bilirubin B-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound

has O
declined O
treatment B-treatment
with I-treatment
sorafenib I-treatment

prothrombin B-clinical_variable
time I-clinical_variable
( I-clinical_variable
pt I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
seconds I-lower_bound
above O
control O

currently O
taking O
corticosteroids B-treatment

hepatitis B-chronic_disease
b I-chronic_disease
surface O
antigen O
( O
hbsag O
) O

hodgkin B-cancer
lymphoma I-cancer
relapsing O
after O
auto B-treatment
- I-treatment
hsct I-treatment

patients O
with O
hematologic B-cancer
malignancy I-cancer
must O
have O
no O
hla B-cancer
identical O
sibling O
or O
suitable O
unrelated O
donor O
or O
time O
needed O
to O
find O
an O
acceptable O
unrelated O
donor O
match O

significant O
serious O
intercurrent B-chronic_disease
illness I-chronic_disease
unrelated O
to O
cancer B-cancer
or O
its O
treatment B-treatment
not O
covered O
by O
other O
exclusion O
criteria O
expected O
to O
significantly O
increase O
the O
risk O
of O
hsct B-clinical_variable

t. B-treatment
cruzi I-treatment
- I-treatment
eia I-treatment
( I-treatment
chagas I-treatment
) I-treatment

enrollment O
in O
other O
studies O
using O
b O
imatoprost B-treatment
sr I-treatment

appropriate O
fixation B-treatment
procedure I-treatment

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

histologically O
confirmed O
low B-cancer
- I-cancer
grade I-cancer
glioma I-cancer
including O
astrocytoma B-cancer
grade I-cancer
@NUMBER I-cancer
, O
oligodendroglioma B-cancer
grade I-cancer
@NUMBER I-cancer
, O
or O
oligoastrocytoma B-cancer
grade I-cancer
@NUMBER I-cancer

implanted B-treatment
electronic I-treatment
medical I-treatment
device I-treatment
in O
the O
brain O
( O
e.g. O
, O
deep B-treatment
brain I-treatment
stimulator I-treatment
, O
vagus B-treatment
nerve I-treatment
stimulator I-treatment
, O
programmable B-treatment
shunt I-treatment
) O

severe O
cardiac B-chronic_disease
insufficiency I-chronic_disease
cardiac B-chronic_disease
insufficiency O
( O
nyha B-clinical_variable
iii B-lower_bound
or O
iv B-upper_bound
) O
, O
with O
uncontrolled O
and O
/ O
or O
unstable O
cardiac O
or O
coronary B-chronic_disease
artery I-chronic_disease
disease I-chronic_disease

tumor B-cancer
is O
supratentorially O
located O
and O
measureable O

has O
been O
diagnosed O
with O
lupus B-chronic_disease

heart B-chronic_disease
disease I-chronic_disease
( O
other O
than O
hypertension B-chronic_disease
) O
, O
heart B-chronic_disease
failure I-chronic_disease
or O
coronary B-chronic_disease
heart I-chronic_disease
disease I-chronic_disease
requiring O
hospitalization O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

multiple B-chronic_disease
sclerosis I-chronic_disease

treated O
diabetes B-chronic_disease

chronic B-chronic_disease
obstructive I-chronic_disease
pulmonary I-chronic_disease
disease I-chronic_disease
( I-chronic_disease
copd I-chronic_disease
) I-chronic_disease
with O
home O
oxygen O
dependence O
or O
@NUMBER O
or O
more O
hospitalizations O
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

ages B-age
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
inclusive O

history O
of O
heart B-chronic_disease
disease I-chronic_disease

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
≤ O
@NUMBER B-upper_bound

fasting B-clinical_variable
plasma I-clinical_variable
glucose I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
( O
or O
@NUMBER B-lower_bound
mmol I-lower_bound
/ I-lower_bound
l I-lower_bound
) O

history O
of O
arrhythmia B-chronic_disease
requiring O
an O
implantable B-treatment
cardiac I-treatment
defibrillator I-treatment

ischemic B-chronic_disease
cerebrovascular I-chronic_disease
event I-chronic_disease
, O
including O
transient B-chronic_disease
ischemic I-chronic_disease
attack I-chronic_disease
and O
artery B-treatment
revascularization I-treatment
procedures I-treatment

women B-gender
more O
than O
@NUMBER B-lower_bound
years I-lower_bound
must O
be O
post O
- O
menopausal O
for O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
following O
the O
end O
of O
all O
exogenous B-treatment
hormonal I-treatment
treatments I-treatment
or O

there O
are O
no O
limits O
on O
prior O
lines O
of O
therapy B-treatment
; O
however O
, O
patients O
must O
have O
recovered O
to O
eligibility O
levels O
from O
prior O
toxicity O
or O
adverse O
events O
as O
a O
result O
of O
previous B-treatment
treatment I-treatment
prior I-treatment
to O
entering O
the O
study O
( O
except O
alopecia B-chronic_disease
) O

any O
unresolved O
toxicity B-clinical_variable
> O
ctcae B-lower_bound
grade I-lower_bound
@NUMBER I-lower_bound
despite O
optimal O
care O
/ O
support O
, O
from O
previous B-treatment
anti I-treatment
- I-treatment
cancer I-treatment
therapy I-treatment
, O
except O
for O
alopecia B-chronic_disease
, O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
cycle O
@NUMBER O
, O
day O
@NUMBER O

histologically O
and O
/ O
or O
cytologically O
confirmed O
, O
non B-cancer
- I-cancer
small I-cancer
cell I-cancer
lung I-cancer
cancer I-cancer
( I-cancer
nsclc I-cancer
) I-cancer
of O
adenocarcinoma B-cancer
histology O
at O
the O
time O
of O
initial O
diagnosis O

males B-gender
of O
child O
bearing O
potential O
must O
agree B-contraception_consent
to I-contraception_consent
practice I-contraception_consent
effective I-contraception_consent
barrier I-contraception_consent
contraception I-contraception_consent
during O
the O
entire O
study O
treatment B-treatment
period O
and O
through O
@NUMBER B-lower_bound
months I-lower_bound
) O
after O
the O
last O
dose O
of O
study O
drug O
, O
( O
includes O
males B-gender
surgically B-treatment
sterilized I-treatment
( O
i.e O
. O
status O
post B-treatment
vasectomy I-treatment
) O

dipg B-cancer
patients O
enrolled O
to O
group O
@NUMBER O
b O
must O
not O
have O
been O
previously O
treated O
with O
radiation B-treatment
or O
any O
medical B-treatment
therapy I-treatment

lansky B-clinical_variable
or O
karnofsky B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
score I-clinical_variable
must O
be O
> O
@NUMBER B-lower_bound
% I-lower_bound

coagulation B-chronic_disease
, O
bleeding B-chronic_disease
or O
blood B-chronic_disease
disorders I-chronic_disease

total B-clinical_variable
cholesterol I-clinical_variable
of O
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

patients O
with O
residual B-cancer
tumor I-cancer
after O
surgery B-treatment
( O
any O
single O
site O
) O
exceeding O
@NUMBER B-lower_bound
cm I-lower_bound
in I-lower_bound
maximum I-lower_bound
dimension I-lower_bound

pelvic B-chronic_disease
lymph I-chronic_disease
node I-chronic_disease
sampling O

patients O
requiring O
a O
primary B-treatment
total I-treatment
knee I-treatment
replacement I-treatment

for O
procedures O
with O
moderate O
or O
significant O
risk O
of O
bleeding B-chronic_disease
, O
long B-treatment
- I-treatment
acting I-treatment
agents I-treatment
such O
as O
aspirin B-treatment
or O
clopidogrel B-treatment
should O
be O
discussed O
with O
the O
medical O
monitor O
and O
may O
need O
to O
be O
discontinued O
before O
g100 B-treatment
therapy I-treatment

has O
had O
an O
allogeneic B-treatment
tissue I-treatment
/ O
solid B-treatment
organ I-treatment
transplant I-treatment

investigational B-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
g100 B-treatment
dosing O

recent O
( O
< O
@NUMBER B-upper_bound
week I-upper_bound
ago O
) O
clinically O
significant O
infection B-chronic_disease
, O
active B-chronic_disease
tuberculosis I-chronic_disease
or O
evidence O
of O
active O
hepatitis B-chronic_disease
b I-chronic_disease
, O
hepatitis B-chronic_disease
c I-chronic_disease
or O
hiv B-chronic_disease
infection I-chronic_disease

significant O
autoimmune B-chronic_disease
disease I-chronic_disease
, O
including O
active O
non O
- O
infectious O
pneumonitis B-chronic_disease
, O
with O
the O
exception O
of O
alopecia B-chronic_disease
, O
vitiligo B-chronic_disease
, O
hypothyroidism B-chronic_disease
or O
other O
conditions O
that O
have O
never O
been O
clinically O
active O
or O
were O
transient O
and O
have O
completely O
resolved O
and O
require O
no O
ongoing O
therapy B-treatment

adequately O
controlled O
blood B-clinical_variable
pressure I-clinical_variable
( I-clinical_variable
bp I-clinical_variable
) I-clinical_variable
bp B-clinical_variable
) O
with O
or O
without O
antihypertensive B-treatment
medications I-treatment
, O
defined O
as O
bp O
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
/ I-upper_bound
@NUMBER I-upper_bound
mmhg I-upper_bound
at O
screening O
and O
no O
change O
in O
antihypertensive O
medications O
within O
@NUMBER B-upper_bound
week I-upper_bound
prior I-upper_bound
to O
the O
cycle O
@NUMBER O
day O
@NUMBER O

for O
the O
non B-chronic_disease
- I-chronic_disease
small I-chronic_disease
cell I-chronic_disease
lung I-chronic_disease
cancer I-chronic_disease
( I-chronic_disease
nsclc I-chronic_disease
) I-chronic_disease
and O
melanoma B-cancer
cohorts O
, O
participants O
must O
have O
progressed O
on O
or O
after O
prior B-treatment
treatment I-treatment
with I-treatment
one I-treatment
anti I-treatment
- I-treatment
pd-1 I-treatment
, O
anti B-treatment
- I-treatment
pd I-treatment
- I-treatment
l1 I-treatment
, O
or O
anti B-treatment
- I-treatment
pdl2 I-treatment
agent I-treatment

has O
a O
diagnosis O
of O
immunodeficiency B-chronic_disease
or O
is O
receiving O
systemic B-treatment
steroid I-treatment
therapy I-treatment
or O
any O
other O
form O
of O
immunosuppressive B-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
study B-treatment
treatment I-treatment

in O
the O
case O
archival O
tissue O
can O
not O
be O
provided O
, O
participants O
with O
inaccessible O
tumors B-cancer
for O
biopsy B-treatment
specimens O
can O
be O
enrolled O
without O
a O
biopsy O
upon O
consultation O
and O
agreement O
by O
the O
sponsor O

no O
active O
autoimmune B-chronic_disease
disease I-chronic_disease
that O
has O
required O
systemic B-treatment
treatment I-treatment
in O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
( O
ie O
, O
with O
use O
of O
disease B-treatment
modifying I-treatment
agents I-treatment
, O
corticosteroids B-treatment
or O
immunosuppressive B-treatment
drugs I-treatment
) O

must O
consent O
to O
complete O
all O
treatment B-treatment
and O
follow O
- O
up O
visits O

prior B-treatment
treatment I-treatment
with I-treatment
chimeric I-treatment
antigen I-treatment
receptor I-treatment
t I-treatment
- I-treatment
cell I-treatment
( I-treatment
car I-treatment
- I-treatment
t I-treatment
) I-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
before O
first O
btct4465a B-treatment
( I-treatment
mosunetuzumab I-treatment
) I-treatment
administration O

at O
least O
@NUMBER B-lower_bound
years I-lower_bound
postmenarche O

hepatitis B-chronic_disease
b I-chronic_disease
( O
hbv O
) O
: O
patients O
with O
positive O
serology O
for O
hepatitis B-chronic_disease
b I-chronic_disease
defined O
as O
positivity O
for O
hepatitis O
b O
surface O
antigen O
( O
hbsag O
) O
or O
hepatitis O
b O
core O
antibody O
( O
anti O
- O
hbc O
) O

karnofsky B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
( I-clinical_variable
kps I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound

known O
active O
bacterial B-chronic_disease
, O
viral B-chronic_disease
, O
fungal B-chronic_disease
, O
mycobacterial B-chronic_disease
, O
or O
other O
infection B-chronic_disease
( O
excluding O
fungal B-chronic_disease
infections I-chronic_disease
of O
nail O
beds O
) O
or O
any O
major O
episode O
of O
infection O
requiring O
treatment B-treatment
with I-treatment
iv I-treatment
antibiotics I-treatment
antibiotics B-treatment
or O
hospitalization B-treatment
( O
related O
to O
the O
completion O
of O
the O
course O
of O
antibiotics O
) O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
study O
enrollment O

known O
infection B-chronic_disease
with O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease

aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
( O
serum B-clinical_variable
glutamic I-clinical_variable
oxaloacetic I-clinical_variable
transaminase I-clinical_variable
[ I-clinical_variable
sgot I-clinical_variable
] I-clinical_variable
) O
/ O
alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
( O
serum B-clinical_variable
glutamate I-clinical_variable
pyruvate I-clinical_variable
transaminase I-clinical_variable
[ I-clinical_variable
sgpt I-clinical_variable
] I-clinical_variable
) O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
uln I-upper_bound

current O
cardiac B-chronic_disease
arrhythmia I-chronic_disease
requiring O
concurrent O
use O
of O
anti B-treatment
- I-treatment
arrhythmic I-treatment
drugs I-treatment

history O
of O
stroke B-chronic_disease
or O
transient B-chronic_disease
ischemic I-chronic_disease
attack I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
registration O

patients O
must O
be O
able O
to O
tolerate O
oral B-treatment
medications I-treatment
and O
not O
have O
gastrointestinal B-chronic_disease
illnesses I-chronic_disease
that O
would O
preclude O
absorption O
of O
cediranib B-treatment
or O
olaparib B-treatment

patients O
with O
untreated O
brain B-cancer
metastases I-cancer
, O
spinal O
cord O
compression O
, O
or O
evidence O
of O
symptomatic O
brain O
metastases O
or O
leptomeningeal B-cancer
disease I-cancer
as O
noted O
on O
computed B-treatment
tomography I-treatment
( I-treatment
ct I-treatment
) I-treatment
or O
magnetic B-treatment
resonance I-treatment
imaging I-treatment
( I-treatment
mri I-treatment
) I-treatment
scans I-treatment
should O
be O
excluded O
from O
this O
clinical O
trial O
, O
since O
neurologic B-chronic_disease
dysfunction I-chronic_disease
may O
confound O
the O
evaluation O
of O
neurologic O
and O
other O
adverse O
events O
( O
aes O
) O

the O
lesions O
have O
improved O
or O
remained O
stable O
radiographically B-treatment
and O
clinically O
for O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
after I-lower_bound
@NUMBER B-lower_bound
weeks I-lower_bound
after O
completion O
of O
brain B-treatment
irradiation I-treatment
or O
stereotactic B-treatment
brain I-treatment
radiosurgery I-treatment
and O
off O
steroids B-treatment
for O
at O
least O
@NUMBER O
weeks O

chest B-treatment
x I-treatment
- I-treatment
ray I-treatment
within O
the O
last B-upper_bound
six I-upper_bound
( I-upper_bound
@NUMBER I-upper_bound
) I-upper_bound
months I-upper_bound

non O
- O
smoker O
for O
at O
least O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
screening O
and O
agrees O
not O
to O
smoke O
during O
the O
study O

sao2 B-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound
on O
room O
air O
at O
screening O
and O
baseline O

use O
of O
an O
investigational B-treatment
drug I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
screening O

unwilling B-contraception_consent
to I-contraception_consent
practice I-contraception_consent
a I-contraception_consent
medically I-contraception_consent
acceptable I-contraception_consent
form I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
from O
screening O
to O
day O
@NUMBER O
( O
acceptable B-contraception_consent
forms I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
: O
abstinence B-contraception_consent
, O
hormonal B-contraception_consent
birth I-contraception_consent
control I-contraception_consent
, O
intrauterine B-contraception_consent
device I-contraception_consent
, O
or O
barrier B-contraception_consent
method I-contraception_consent
plus I-contraception_consent
a I-contraception_consent
spermicidal I-contraception_consent
agent I-contraception_consent
) O

older O
than O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

patients O
with O
untreated O
brain B-cancer
metastases I-cancer
are O
allowed O
provided O
that O
the O
patient O
is O
clinically O
asymptomatic O
and O
stable O

the O
effects O
of O
azd9291 B-treatment
and O
necitumumab B-treatment
on O
the O
developing O
human O
fetus O
are O
unknown O
; O
for O
this O
reason O
and O
because O
egfr B-treatment
inhibitors I-treatment
are O
known O
to O
be O
teratogenic O
, O
pregnant B-pregnancy
women B-gender
are O
excluded O
from O
this O
study O
; O
because O
there O
is O
an O
unknown O
but O
potential O
risk O
for O
adverse O
events O
in O
nursing O
infants O
secondary O
to O
treatment B-treatment
of O
the O
mother O
azd9291 O
and O
necitumumab O
breastfeeding O
should O
be O
discontinued O
if O
the O
mother O
is O
treated O
with O
azd9291 O
and O
necitumumab O
; O
these O
potential O
risks O
may O
also O
apply O
to O
other O
agents O
used O
in O
this O
study O

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
( O
patients O
with O
gilbert B-chronic_disease
's I-chronic_disease
syndrome I-chronic_disease
may O
have O
serum B-clinical_variable
bilirubin I-clinical_variable
> O
@NUMBER B-lower_bound
uln I-lower_bound
) O

women B-gender
will O
be O
considered O
not O
of O
childbearing O
potential O
if O
they O
are O
surgically O
sterile O
( O
bilateral O
oophorectomy O
or O
hysterectomy O
) O
and O
/ O
or O
post O
menopausal O
( O
amenorrheic B-chronic_disease
for O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
) O

clinical O
diagnosis O
of O
bipolar B-chronic_disease
illness I-chronic_disease
, O
schizophrenia B-chronic_disease
, O
conduct B-chronic_disease
disorder I-chronic_disease
, O
and O
/ O
or O
substance O
use O
/ O
abuse O

obesity B-chronic_disease
associated O
with O
genetic B-chronic_disease
disorder I-chronic_disease
( O
monogenetic B-chronic_disease
obesity I-chronic_disease
) O

type B-chronic_disease
@NUMBER I-chronic_disease
or I-chronic_disease
@NUMBER I-chronic_disease
diabetes I-chronic_disease
mellitus I-chronic_disease

unwilling B-contraception_consent
to I-contraception_consent
use I-contraception_consent
@NUMBER I-contraception_consent
or I-contraception_consent
more I-contraception_consent
acceptable I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
when O
engaging O
in O
sexual O
activity O
throughout O
the O
study O

concomitant O
treatment O
with O
any O
of O
the O
following O
drugs O
: O
azathioprine B-treatment
, O
cyclophosphamide B-treatment
, O
cyclosporine B-treatment
, O
pirfenidone B-treatment
, O
full B-treatment
dose I-treatment
anticoagulation I-treatment
( O
vitamin B-treatment
k I-treatment
antagonists I-treatment
, O
dabigatran B-treatment
, O
heparin B-treatment
, O
etc O
. O
) O
, O
fibrinolysis B-treatment
and O
high B-treatment
dose I-treatment
anti I-treatment
- I-treatment
platelet I-treatment
therapy I-treatment
( O
ex O
. O
plavix O
@NUMBER O
mg O
) O
^2 O
myocardial B-chronic_disease
infarction I-chronic_disease
or O
unstable B-chronic_disease
angina I-chronic_disease
within O
@NUMBER B-upper_bound
or O
@NUMBER B-lower_bound
month I-lower_bound
of O
starting O
nintedanib B-treatment
treatment O
, O
respectively O

sexually O
active O
males B-gender
not O
committing O
to O
birth O
control O
during O
the O
course O
of O
the O
study O
( O
except O
if O
their O
partner O
is O
not O
of O
childbearing O
potential O
) O

active B-chronic_disease
gastrointestinal I-chronic_disease
bleeding I-chronic_disease
or O
ulcers O
or O
major O
injuries O
or O
surgery B-treatment

adenocarcinoma B-cancer
of I-cancer
the I-cancer
bladder I-cancer

for O
disease O
specific O
studies O
: O
the O
subject O
has O
had O
evidence O
within O
@NUMBER B-upper_bound
years I-upper_bound
of O
the O
start O
of O
study B-treatment
treatment I-treatment
of O
another O
malignancy B-cancer
which O
required O
systemic B-treatment
treatment I-treatment

in O
addition O
, O
complete O
wound O
healing O
from O
prior B-treatment
surgery I-treatment
surgery B-treatment
must O
be O
confirmed O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
before I-lower_bound
the O
first O
dose O
of O
cabozantinib B-treatment
irrespective O
of O
the O
time O
from O
surgery O

the O
subject O
has O
evidence O
of O
tumor B-cancer
invading O
the O
gastrointestinal O
( O
gi O
) O
tract O
( O
esophagus B-cancer
, O
stomach B-cancer
, O
small B-cancer
or I-cancer
large I-cancer
bowel I-cancer
, O
rectum B-cancer
or O
anus B-cancer
) O
, O
or O
any O
evidence O
of O
endotracheal B-cancer
or O
endobronchial B-cancer
tumor I-cancer
within O
@NUMBER B-upper_bound
days I-upper_bound
before I-upper_bound
the O
first O
dose O
of O
cabozantinib B-treatment

the O
subject O
has O
received O
cytotoxic B-treatment
chemotherapy I-treatment
( O
including O
investigational B-treatment
cytotoxic I-treatment
chemotherapy I-treatment
) O
or O
biologic B-treatment
agents I-treatment
( O
e.g. O
, O
cytokines B-treatment
or O
antibodies B-treatment
) O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
, O
or O
nitrosoureas B-treatment
/ O
mitomycin B-treatment
c I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
before O
the O
first O
dose O
of O
study O
treatment B-treatment

to O
bone O
or O
brain B-cancer
metastasis I-cancer
within O
@NUMBER B-upper_bound
weeks I-upper_bound
before O
the O
first O
dose O
of O
study B-treatment
treatment I-treatment

participation O
in O
another B-treatment
clinical I-treatment
trial I-treatment
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

patients O
with O
documented O
allergy O
to O
egg B-allergy_name
products I-allergy_name

patients O
currently O
taking O
steroids B-treatment
as O
prophylaxis O
against O
seizures B-chronic_disease

bothersome O
idiopathic O
( O
non O
- O
neurologic O
) O
urgency B-clinical_variable
urinary I-clinical_variable
incontinence I-clinical_variable
( I-clinical_variable
uui I-clinical_variable
) I-clinical_variable
who O
recall O
≥ O
@NUMBER B-lower_bound
urgency O
predominant O
urinary O
incontinence O
episodes O
in O
the O
prior O
week O
( O
urgency O
urinary O
incontinence O
or O
mixed O
urinary O
incontinence O
- O
urgency O
predominant O
) O

anti B-treatment
- I-treatment
ige I-treatment
( O
such O
as O
omalizumab B-treatment
) O
within O
the O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
screening O

body B-bmi
mass I-bmi
index I-bmi
( I-bmi
bmi I-bmi
) I-bmi
between O
@NUMBER B-lower_bound
and O
@NUMBER B-upper_bound
, O
inclusive O
, O
for O
patients B-clinical_variable
≥ O
@NUMBER B-lower_bound
years I-lower_bound
old O

have O
received O
any O
investigational B-treatment
treatment I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
( O
or O
within O
@NUMBER B-upper_bound
terminal I-upper_bound
half I-upper_bound
- I-upper_bound
lives I-upper_bound
of O
the O
investigational B-treatment
drug I-treatment
whichever O
is O
longer O
) O
of O
the O
screening O
visit O

patients O
taking O
medication B-treatment
( I-treatment
s I-treatment
) I-treatment
( O
either O
daily O
or O
as O
needed O
) O
with O
the O
potential O
to O
affect O
the O
course O
of O
asthma B-chronic_disease
or O
to O
interact O
with O
sympathomimetic B-treatment
amines I-treatment

patients O
with O
hypersensitivity O
to O
any O
sympathomimetic B-allergy_name
drug I-allergy_name
( O
e.g. O
, O
formoterol B-allergy_name
, O
albuterol B-allergy_name
/ O
salbutamol B-allergy_name
, O
or O
salmeterol B-allergy_name
) O
or O
any O
inhaled B-allergy_name
, O
intranasal B-allergy_name
, O
or O
systemic B-allergy_name
corticosteroid I-allergy_name
therapy I-allergy_name

willing O
to O
discontinue O
asthma B-treatment
medications I-treatment
( O
ics B-treatment
and O
labas B-treatment
) O
during O
the O
run O
- O
in O
period O
and O
for O
the O
remainder O
of O
the O
study O

patients O
should O
be O
able O
to O
withhold O
all O
inhaled O
sabas B-treatment
for O
at O
least O
@NUMBER B-lower_bound
hours I-lower_bound
prior I-lower_bound
to O
lung O
function O
assessments O
on O
study O
visits O

any O
newly O
identified O
breast O
abnormality O
requiring O
surgical B-treatment
excision I-treatment

cytologically O
confirmed O
lcis B-cancer

women B-gender
< O
@NUMBER B-upper_bound
years I-upper_bound
old O
who O
are O
of O
child O
- O
bearing O
potential O
must O
have O
a O
negative B-pregnancy
pregnancy I-pregnancy
test O
( O
urine O
hcg O
or O
serum O
) O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
enrollment O

females B-gender
of O
childbearing O
potential O
( O
fcbp O
) O
may O
participate O

subjects O
received O
oral B-treatment
azacitidine I-treatment
in O
combination O
with O
another O
compound O
during O
a O
parent O
oral O
azacitidine O
study O
( O
subjects O
form O
multi O
- O
arm O
parent O
oral O
azacitidine O
studies O
will O
be O
allowed O
to O
enroll O
into O
the O
rollover O
study O
, O
if O
the O
subject O
is O
receiving O
single B-treatment
- I-treatment
agent I-treatment
oral I-treatment
azacitidine I-treatment
at O
the O
time O
of O
transition O
into O
the O
rollover O
study O
) O

marijuana O
use O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
fmdba O
and O
apwv O
testing O

any O
serious O
, O
unstable O
medical B-chronic_disease
or O
psychiatric B-chronic_disease
condition I-chronic_disease
that O
would O
prevent O
, O
( O
as O
judged O
by O
the O
investigator O
) O
the O
subject O
properly O
providing O
informed O
consent O
or O
any O
condition O
which O
would O
jeopardize O
compliance O
with O
the O
protocol O

patients O
with O
exposure O
to O
other B-treatment
jak I-treatment
- I-treatment
stat I-treatment
inhibitory I-treatment
agents I-treatment

no O
ms B-chronic_disease
exacerbation I-chronic_disease
for O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
screening O

bmi B-bmi
> O
@NUMBER B-lower_bound

known O
allergy O
to O
any O
of O
the O
ingredients O
contained O
in O
sage B-allergy_name
chlorhexidine I-allergy_name
gluconate I-allergy_name
cloths I-allergy_name

history O
of O
spine B-chronic_disease
infections I-chronic_disease

allergy O
to O
lidocaine B-allergy_name
or O
oxymetazoline B-allergy_name
hydrochloride I-allergy_name

participating O
in O
another B-treatment
investigational I-treatment
device I-treatment
or I-treatment
drug I-treatment
study I-treatment
within O
@NUMBER B-upper_bound
year I-upper_bound
of O
treatment B-treatment

patients O
with O
severe O
emphysema B-chronic_disease
, O
pulmonary B-chronic_disease
vasculitis I-chronic_disease
, O
or O
a O
history O
of O
pulmonary B-chronic_disease
emboli I-chronic_disease

patients O
with O
thrombosis B-chronic_disease
within O
the O
hepatic O
, O
portal O
, O
or O
mesenteric O
veins O

for O
patients O
who O
undergo O
mastectomy B-treatment
, O
the O
margins O
must O
be O
free O
of O
residual O
gross O
tumor B-cancer

intrinsic B-chronic_disease
lung I-chronic_disease
disease I-chronic_disease
resulting O
in O
dyspnea B-chronic_disease

patients O
with O
alkaline B-clinical_variable
phosphatase I-clinical_variable
that O
is O
> O
uln O
but O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
or O
unexplained O
bone O
pain O
are O
eligible O
for O
inclusion O
in O
the O
study O
if O
a O
bone B-treatment
scan I-treatment
, O
pet B-treatment
- I-treatment
ct I-treatment
scan I-treatment
, O
or O
pet B-treatment
scan I-treatment
performed O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
randomization O
does O
not O
demonstrate O
metastatic B-cancer
disease I-cancer

psychiatric B-chronic_disease
or O
addictive B-chronic_disease
disorders I-chronic_disease
or O
other O
conditions O
that O
, O
in O
the O
opinion O
of O
the O
investigator O
, O
would O
preclude O
the O
patient O
from O
meeting O
the O
study O
requirements O

sentinel B-treatment
lymphadenectomy I-treatment
alone O

the O
interval O
between O
the O
last O
surgery B-treatment
for O
breast B-cancer
cancer I-cancer
( O
including O
re O
- O
excision O
of O
margins O
) O
and O
randomization O
must O
be O
no O
more O
than O
@NUMBER B-lower_bound
days I-lower_bound

the O
tumor B-cancer
must O
have O
been O
determined O
to O
be O
human B-cancer
epidermal I-cancer
growth I-cancer
factor I-cancer
receptor I-cancer
@NUMBER I-cancer
( I-cancer
her2 I-cancer
) I-cancer
-negative O

total B-clinical_variable
bilirubin I-clinical_variable
must O
be O
≤ O
upper O
limit O
of O
normal O
( O
uln O
) O
for O
the O
laboratory O
( O
lab O
) O
unless O
the O
patient O
has O
a O
bilirubin B-clinical_variable
elevation I-clinical_variable
> O
uln O
to O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
due O
to O
gilbert B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
or O
similar O
syndrome O
involving O
slow O
conjugation O
of O
bilirubin O

english B-language_fluency
or I-language_fluency
spanish I-language_fluency
literate I-language_fluency

pregnant B-pregnancy
with O
a O
singleton O
gestation B-clinical_variable
that O
is O
equal O
to O
or O
greater O
than O
@NUMBER B-lower_bound
weeks I-lower_bound

because O
no O
dosing O
adverse O
event O
data O
are O
currently O
available O
on O
the O
use O
of O
topotecan B-treatment
in I-treatment
combination I-treatment
with I-treatment
vx-970 I-treatment
in O
subjects O
less O
than O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age
, O
children O
are O
excluded O
from O
this O
study O
, O
but O
will O
be O
eligible O
for O
future O
pediatrics O
trials O

creatinine B-clinical_variable
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
or O
creatinine B-clinical_variable
clearance I-clinical_variable
by O
cockcroft O
- O
gault O
formula O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound

subjects O
must O
not O
have O
received O
chemotherapy B-treatment
, O
or O
undergone O
major B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
and O
radiotherapy B-treatment
within O
@NUMBER B-upper_bound
hours I-upper_bound
prior I-upper_bound
to O
enrollment O

subjects O
with O
evidence O
of O
severe O
or O
uncontrolled B-chronic_disease
systemic I-chronic_disease
disease I-chronic_disease
, O
or O
any O
concurrent O
condition O
, O
which O
could O
compromise O
participation O
in O
the O
study O
, O
including O
, O
but O
not O
limited O
to O
, O
active O
or O
uncontrolled O
infection O
, O
immune B-chronic_disease
deficiencies I-chronic_disease
, O
hepatitis B-chronic_disease
b I-chronic_disease
, O
hepatitis B-chronic_disease
c I-chronic_disease
, O
uncontrolled B-chronic_disease
diabetes I-chronic_disease
, O
uncontrolled B-chronic_disease
hypertension I-chronic_disease
, O
symptomatic B-chronic_disease
congestive I-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease
pectoris I-chronic_disease
, O
myocardial B-chronic_disease
infarction I-chronic_disease
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
, O
uncontrolled B-chronic_disease
cardiac I-chronic_disease
arrhythmia I-chronic_disease
, O
stroke B-chronic_disease
/ I-chronic_disease
cerebrovascular I-chronic_disease
accident I-chronic_disease
within O
the O
past O
@NUMBER O
months O
, O
or O
psychiatric B-chronic_disease
illness I-chronic_disease
/ I-chronic_disease
social I-chronic_disease
situations I-chronic_disease
which O
would O
jeopardize O
compliance O
with O
the O
protocol O

subjects O
with O
histologically O
confirmed O
sclc B-cancer
, O
nsclc B-cancer
, O
ovarian B-cancer
cancer I-cancer
, O
cervical B-cancer
cancer I-cancer
, O
and O
neuroendocrine B-cancer
cancers I-cancer

subjects O
who O
have O
had O
treatment B-treatment
for O
their O
brain B-cancer
metastasis I-cancer
and O
whose O
brain B-chronic_disease
disease I-chronic_disease
is O
stable O
without O
steroid B-treatment
therapy I-treatment
for O
@NUMBER B-upper_bound
week I-upper_bound
or O
on O
physiologic O
doses O
of O
steroids B-treatment
may O
be O
enrolled O

abnormal O
electroencephalogram B-clinical_variable
in O
the O
past O
month O

renal B-chronic_disease
or O
hepatic B-chronic_disease
dysfunction I-chronic_disease
( O
abnormal O
blood O
urea O
nitrogen O
/ O
creatinine O
or O
@NUMBER O
times O
elevated O
liver O
transaminases O
) O

pt B-clinical_variable
/ O
inr B-clinical_variable
, O
pt O
below O
or O
equal O
to O
the O
upper O
limit O
of O
normal O
of O
@NUMBER O
seconds O
; O
inr O
within O
normal O
reference O
range O
of O
less O
than O
@NUMBER B-upper_bound
( O
normal O
range O
for O
non O
- O
anti O
- O
coagulated O
patients O
) O

a O
history O
of O
guillain B-chronic_disease
- I-chronic_disease
barre I-chronic_disease
syndrome I-chronic_disease

who O
have O
not O
received O
seasonal O
flu B-treatment
vaccine I-treatment
for O
the O
current O
year O
( O
september O
- O
june O
) O

current O
migraine B-chronic_disease
has O
a O
greater O
than O
@NUMBER B-lower_bound
hours I-lower_bound
duration O
with O
a O
current O
pain B-clinical_variable
score I-clinical_variable
of O
@NUMBER B-lower_bound
or O
greater O
on O
a O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
numeric B-clinical_variable
pain I-clinical_variable
rating I-clinical_variable
scale I-clinical_variable

revision B-treatment
surgery I-treatment

clinically O
significant O
peripheral B-chronic_disease
vascular I-chronic_disease
disease I-chronic_disease
vascular B-chronic_disease
disease I-chronic_disease
or O
vascular O
disease O
, O
including O
rapidly O
growing O
aortic B-chronic_disease
aneurysm I-chronic_disease
or O
abdominal B-chronic_disease
aortic I-chronic_disease
aneurysm I-chronic_disease

patients O
are O
allowed O
to O
have O
received O
prior O
parpi B-treatment
, O
and O
/ O
or O
anti B-treatment
- I-treatment
angiogenesis I-treatment
therapy I-treatment
including O
but O
not O
limited O
to O
thalidomide B-treatment
, O
bevacizumab B-treatment
, O
sunitinib B-treatment
, O
sorafenib B-treatment
, O
or O
other O
anti B-treatment
- I-treatment
angiogenics I-treatment

patients O
must O
have O
histologically O
or O
cytologically O
confirmed O
persistent O
or O
recurrent O
ovarian B-cancer
, O
fallopian B-cancer
tube I-cancer
, O
or O
primary B-cancer
peritoneal I-cancer
cancer I-cancer

patients O
must O
have O
received O
prior B-treatment
treatment I-treatment
with I-treatment
enzalutamide I-treatment
and I-treatment
/ I-treatment
or I-treatment
abiraterone I-treatment

patients O
who O
were O
previously B-treatment
treated I-treatment
with I-treatment
cediranib I-treatment
are O
ineligible O

patients O
with O
any O
cardiac O
history O
of O
the O
following O
conditions O
within O
@NUMBER B-upper_bound
year I-upper_bound
prior I-upper_bound
to O
study O
enrollment O

patients O
must O
not O
have O
received O
other O
anti B-treatment
- I-treatment
angiogenesis I-treatment
therap I-treatment
( I-treatment
ies I-treatment
) I-treatment
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
study O
enrollment O

liver B-chronic_disease
disease I-chronic_disease
or O
elevation O
of O
liver O
enzymes O

abdominal B-chronic_disease
pain I-chronic_disease
of O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
duration O
and O
fulfilling O
symptom O
- O
based O
criteria O
for O
functional B-chronic_disease
dyspepsia I-chronic_disease
( O
@NUMBER O
) O

previous B-treatment
treatment I-treatment
with I-treatment
ketotifen I-treatment

regnant B-pregnancy
/ O
planning B-pregnancy
to I-pregnancy
become I-pregnancy
pregnant I-pregnancy

psychiatric B-chronic_disease
condition I-chronic_disease
preventing O
successful O
engagement O
in O
cbt B-treatment

white B-clinical_variable
blood I-clinical_variable
cells I-clinical_variable
( I-clinical_variable
wbc I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
, O
hemoglobin B-clinical_variable
( I-clinical_variable
hgb I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
, O
platelets B-clinical_variable
> O
@NUMBER B-lower_bound
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
consent O

behavioral O
problems O
of O
sufficient O
magnitude O
to O
preclude O
participation O
in O
the O
study O
. O
these O
include O
anxiety B-chronic_disease
, O
obsessive B-chronic_disease
compulsive I-chronic_disease
behaviors I-chronic_disease
, O
attention B-chronic_disease
problems I-chronic_disease
, O
agitation B-chronic_disease
, O
o O
ppositional B-chronic_disease
behavio I-chronic_disease
r O

no O
previous O
or O
current O
medical O
history O
of O
epilepsy B-chronic_disease
, O
neurologic B-chronic_disease
, O
heart B-chronic_disease
, O
endocrinologic B-chronic_disease
, O
renal B-chronic_disease
, O
chronic B-chronic_disease
infectious I-chronic_disease
, O
metabolic B-chronic_disease
, O
psychiatric B-chronic_disease
disease I-chronic_disease
or O
cancer B-cancer

diagnosis O
of O
psychotic B-chronic_disease
disorder I-chronic_disease

able B-language_fluency
to I-language_fluency
read I-language_fluency
and I-language_fluency
speak I-language_fluency
english I-language_fluency

diagnosed O
with O
a O
primary O
glioma B-cancer
and O
going O
to O
receive O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
of O
radiotherapy B-treatment
with O
at O
least O
@NUMBER B-lower_bound
fractions O

agree B-contraception_consent
to I-contraception_consent
practice I-contraception_consent
effective I-contraception_consent
barrier I-contraception_consent
contraception I-contraception_consent
during O
the O
entire O
study O
treatment B-treatment
period O
and O
through O
@NUMBER B-upper_bound
days I-upper_bound
after I-upper_bound
the O
last O
dose O
of O
study B-treatment
drug I-treatment

burkitt B-cancer
lymphoma I-cancer

patients O
who O
have O
a O
clinically O
active O
hepatitis B-chronic_disease
b I-chronic_disease
or I-chronic_disease
c I-chronic_disease
virus I-chronic_disease
infection O

patients O
who O
have O
an O
infection B-chronic_disease
requiring O
systemic B-treatment
antibiotic I-treatment
therapy I-treatment
or O
other O
serious O
infection O
within O
@NUMBER B-upper_bound
days I-upper_bound
before I-upper_bound
study O
enrollment O

patients O
who O
have O
been O
diagnosed O
or O
treated O
for O
another O
malignancy B-cancer
within O
@NUMBER B-upper_bound
years I-upper_bound
before I-upper_bound
study O
enrollment O

bipolar B-chronic_disease
nos I-chronic_disease
, O

history O
of O
significant O
treatment B-treatment
non O
- O
adherence O
or O
situations O
where O
the O
subjects O
is O
unlikely O
to O
adhere O
to O
treatment O
, O
in O
the O
opinion O
of O
the O
investigator O

substance O
use O
disorders O
, O
including O
alcohol O
, O
active O
within O
the O
@NUMBER B-upper_bound
months I-upper_bound

previous B-treatment
kyphoplasty I-treatment
in O
the O
same O
area O

subject O
with O
a O
history O
of O
substance O
abuse O
including O
alcoholism O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
( O
except O
nicotine O
and O
caffeine O
) O

subjects O
with O
a O
significant O
neurological B-chronic_disease
disorder I-chronic_disease
or O
insult O

patients O
who O
are O
currently O
receiving O
treatment B-treatment
with I-treatment
cidofovir I-treatment
, I-treatment
leflunomide I-treatment
, I-treatment
or I-treatment
other I-treatment
antiviral I-treatment
therapy I-treatment
with O
no O
response O
, O
will O
be O
eligible O
for O
ctl B-treatment
infusion I-treatment

patients O
with O
any O
type O
of O
malignancies B-cancer

participants O
must O
be O
@NUMBER B-lower_bound
years I-lower_bound
or O
older O

daily O
smokers O
with O
carbon O
monoxide O
readings O
less O
than O
@NUMBER B-upper_bound
ppm I-upper_bound

does O
not O
fit O
into O
@NUMBER O
xe O
vest O
coil O
used O
for O
mri B-treatment

patient O
scheduled O
to O
undergo O
thoracic B-treatment
rt I-treatment
at O
duke O
university O
to O
a O
dose O
of O
at O
least O
@NUMBER B-lower_bound
gy I-lower_bound

respiratory B-chronic_disease
illness I-chronic_disease
of O
a O
bacterial O
or O
viral O
etiology O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
mri O

subject O
has O
any O
form O
of O
known O
cardiac B-chronic_disease
arrhythmia I-chronic_disease

subject O
meets O
all O
criteria O
above O
but O
does O
not O
have O
a O
clinical O
diagnosis O
of O
respiratory B-chronic_disease
disease I-chronic_disease

≥ O
@NUMBER B-lower_bound
month I-lower_bound
( O
ie O
, O
@NUMBER O
weeks O
after O
full O
term O
[ O
@NUMBER O
weeks O
gestational O
age B-age
] O
) O
to O
< O
@NUMBER B-upper_bound
years I-upper_bound
of O
age O

subject O
has O
a O
clinically O
relevant O
ecg O
abnormality O
, O
in O
the O
opinion O
of O
the O
investigator O
( O
eg O
, O
second O
or O
third O
degree O
heart O
block O
at O
rest O
or O
a O
corrected O
qt B-clinical_variable
interval I-clinical_variable
[ I-clinical_variable
qtc I-clinical_variable
] I-clinical_variable
≥ O
@NUMBER B-lower_bound
ms I-lower_bound
) O

subject O
has O
a O
diagnosis O
of O
epilepsy B-chronic_disease
with O
partial B-chronic_disease
- I-chronic_disease
onset I-chronic_disease
seizures I-chronic_disease

subject O
has O
a O
hemodynamically O
significant O
congenital B-chronic_disease
heart I-chronic_disease
disease I-chronic_disease

subject O
has O
an O
acute B-chronic_disease
or I-chronic_disease
subacutely I-chronic_disease
progressive I-chronic_disease
central I-chronic_disease
nervous I-chronic_disease
system I-chronic_disease
disease I-chronic_disease

the O
dosage O
regimen O
of O
concomitant O
aed B-treatment
therapy I-treatment
aed B-treatment
therapy O
must O
be O
kept O
constant O
for O
a O
period O
of O
≥ O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
visit O
@NUMBER O
a O
stable O
daily O
dosage O
regimen O
of O
a O
concomitant O
benzodiazepine B-treatment
( I-treatment
bzd I-treatment
) I-treatment
will O
be O
considered O
as O
a O
concomitant O
aed O

the O
results O
of O
≥ O
@NUMBER B-lower_bound
@NUMBER B-lower_bound
prior I-lower_bound
eeg B-treatment
and O
≥ O
@NUMBER O
magnetic B-treatment
resonance I-treatment
imaging I-treatment
/ O
computerized B-treatment
tomography I-treatment
scan I-treatment
should O
be O
consistent O
with O
this O
diagnosis O

any O
positive O
test O
for O
hepatitis B-chronic_disease
b I-chronic_disease
virus I-chronic_disease
or O
hepatitis B-chronic_disease
c I-chronic_disease
virus I-chronic_disease
or O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
indicating O
acute B-chronic_disease
or I-chronic_disease
chronic I-chronic_disease
infection I-chronic_disease

measurable O
disease O
by O
ct B-treatment
or O
mri B-treatment
per O
response O
evaluation O
criteria O
in O
solid B-cancer
tumors I-cancer
version O
@NUMBER O
( O
recist O
@NUMBER O
) O
criteria O

seizures B-chronic_disease

patients O
undergoing O
cervicography B-treatment
or O
colposcopy B-treatment
or O
via B-chronic_disease
or O
patients O
undergoing O
leep B-treatment
for O
the O
treatment B-treatment
of O
cervical B-cancer
cancer I-cancer

hemodynamically O
significant O
arrhythmias B-chronic_disease

severe O
stenotic O
valvular B-chronic_disease
disease I-chronic_disease
amendable O
to O
surgical B-treatment
treatment I-treatment

any O
leukemia B-cancer
-specific O
marker O
( O
such O
as O
t O
( O
@NUMBER O
; O
@NUMBER O
) O
; O
t O
( O
@NUMBER O
; O
@NUMBER O
) O
or O
t O
( O
@NUMBER O
; O
@NUMBER O
) O
) O
documented O
in O
the O
patient O
's O
leukemia O
cells O
pre B-treatment
- I-treatment
transplant I-treatment
on O
a O
post B-treatment
- I-treatment
transplant I-treatment
evaluation O

patients O
receiving O
a O
donor B-treatment
lymphocyte I-treatment
infusion I-treatment
( I-treatment
dli I-treatment
) I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
planned O
t B-treatment
cell I-treatment
infusion I-treatment

treatment B-treatment
for O
relapsed O
/ O
residual O
all B-cancer
disease O

direct O
contraindications O
or O
previous O
intolerances O
to O
any O
component O
of O
the O
standard O
of O
care O
regimen O
including O
plex B-clinical_variable
, O
@NUMBER B-upper_bound
% I-upper_bound
human B-clinical_variable
albumin I-clinical_variable
, O
@NUMBER O
% O
gammagard B-clinical_variable
s I-clinical_variable
/ I-clinical_variable
d I-clinical_variable
or O
@NUMBER B-upper_bound
% I-upper_bound
gammagard B-clinical_variable
liquid I-clinical_variable

concurrent O
sepsis B-chronic_disease
or O
active B-chronic_disease
bacterial I-chronic_disease
infection I-chronic_disease

female B-gender
who O
is O
breastfeeding O

male B-gender
patients I-gender
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
condoms I-contraception_consent
or O
other O
suitable O
means O
of O
pregnancy B-pregnancy
prevention O
such O
as O
abstinence B-contraception_consent
during O
the O
initial O
30-day B-lower_bound
study O
period O

recipient O
of O
an O
abo B-treatment
- I-treatment
incompatible I-treatment
kidney I-treatment

requires O
treatment B-treatment
with I-treatment
the I-treatment
cyp1a2 I-treatment
inhibitors I-treatment
, O
ciprofloxacin B-treatment
and O
/ O
or O
fluvoxamine B-treatment

cohort O
@NUMBER O
( O
patients O
with O
metastatic B-cancer
disease I-cancer
with O
targetable O
lesions O
within O
the O
head O
and O
neck O
) O

uncontrolled O
intercurrent O
illness O
including O
but O
not O
limited O
to O
ongoing O
or O
active B-chronic_disease
infection I-chronic_disease
, O
symptomatic O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease
pectoris I-chronic_disease
, O
cardiac B-chronic_disease
arrhythmia I-chronic_disease
, O
or O
psychiatric B-chronic_disease
illness I-chronic_disease
/ I-chronic_disease
social I-chronic_disease
situations I-chronic_disease
that O
would O
limit O
compliance O
with O
study O
requirements O

any O
vaccination B-treatment
given O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
treg O
collection O
for O
treg O
production O

history O
of O
malignancy B-cancer
within O
@NUMBER B-upper_bound
years I-upper_bound
of O
enrollment O

participation O
in O
any O
other O
studies O
that O
involved O
investigational B-treatment
drugs I-treatment
or O
regimens O
in O
the O
preceding O
year O

stable O
liver O
tests O
, O
defined O
as O
alt B-clinical_variable
and O
either O
alkaline B-clinical_variable
phosphatase I-clinical_variable
or O
ggt B-clinical_variable
either O
within O
normal O
limits O
or O
< O
\\ O
= B-upper_bound
@NUMBER I-upper_bound
. I-upper_bound
@NUMBER O
x O
baseline O

systemic B-chronic_disease
illness I-chronic_disease
requiring O
or O
likely O
to O
require O
recurrent O
or O
chronic O
immunosuppression B-treatment
( I-treatment
is I-treatment
) I-treatment
drug I-treatment
use O

participants O
with O
reproductive O
potential O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
effective I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
for O
the O
duration O
of O
the O
study O

primary B-chronic_disease
sclerosing I-chronic_disease
cholangitis I-chronic_disease

measurable O
disease O
is O
defined O
as O
at O
least O
one B-lower_bound
lesion O
that O
can O
be O
accurately O
measured O
in O
at O
least O
one O
dimension O
( O
longest O
diameter B-clinical_variable
to O
be O
recorded O
for O
non- O
nodal B-clinical_variable
lesions I-clinical_variable
and O
short O
axis O
for O
nodal O
lesions O
) O
as O
≥ O
@NUMBER B-lower_bound
mm I-lower_bound
( O
≥ O
@NUMBER B-lower_bound
cm I-lower_bound
) O
with O
conventional O
techniques O
or O
as O
≥ O
@NUMBER B-lower_bound
mm I-lower_bound
( O
≥ O
@NUMBER B-lower_bound
cm I-lower_bound
) O
with O
spiral B-treatment
computed I-treatment
tomography I-treatment
( I-treatment
ct I-treatment
) I-treatment
scan I-treatment
, O
magnetic B-treatment
resonance I-treatment
imaging I-treatment
( I-treatment
mri I-treatment
) I-treatment
, O
or O
calipers B-treatment
by O
clinical O
exam O

subjects O
with O
a O
history O
of O
pulmonary B-chronic_disease
embolism I-chronic_disease
is O
excluded O

female B-gender
and O
is O
unwilling B-contraception_consent
to I-contraception_consent
use I-contraception_consent
effective I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
between O
the O
time O
of O
screening O
and O
study O
procedure O

has O
a O
clinically O
significant O
abnormal B-chronic_disease
ekg I-chronic_disease
[ O
assessment O
by O
pi O
or O
delegate O
] O

allergy O
to O
morphine B-allergy_name

metal B-treatment
implants I-treatment
, O
pacemaker B-treatment
, O
metal B-treatment
prostheses I-treatment
, O
metal B-treatment
orthodontic I-treatment
appliances I-treatment
or O
shrapnel B-treatment
in O
the O
body O

participation O
in O
nuclear B-treatment
medicine I-treatment
protocols I-treatment
in O
the O
last O
year O

sex O
: O
pink B-chronic_disease
eye I-chronic_disease
{ I-chronic_disease
adenoviral I-chronic_disease
conjunctivitis I-chronic_disease
( I-chronic_disease
ad I-chronic_disease
- I-chronic_disease
cs I-chronic_disease
) I-chronic_disease
} I-chronic_disease
occurs O
with O
equal O
prevalence O
in O
males B-gender
and I-gender
females I-gender
, O
therefore O
we O
will O
recruit O
both O
genders O

patients O
must O
have O
received O
at O
least O
two B-lower_bound
cycles O
of O
anthracycline B-treatment
based I-treatment
chemotherapy I-treatment
administered I-treatment
with I-treatment
curative I-treatment
intent I-treatment

diabetes B-chronic_disease
types I-chronic_disease
i I-chronic_disease
and I-chronic_disease
ii I-chronic_disease

history O
of O
malignancy B-cancer
of O
any O
organ O
system O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound

presence O
of O
a O
bacterial B-chronic_disease
, O
fungal B-chronic_disease
, O
viral B-chronic_disease
or O
protozoal B-chronic_disease
infection I-chronic_disease
requiring O
systemic B-treatment
anti I-treatment
- I-treatment
infective I-treatment
therapy I-treatment

vaccinated O
for O
pneumococcal B-chronic_disease
disease I-chronic_disease
within O
last B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound

negative O
hcv B-chronic_disease
pcr O
if O
anti O
- O
hcv O
antibodies O
are O
positive O

scleroderma B-chronic_disease

liver B-chronic_disease
dysfunction I-chronic_disease
{ O
childs B-clinical_variable
- I-clinical_variable
pugh I-clinical_variable
class I-clinical_variable
c I-clinical_variable
} O

patient O
who O
has O
been O
operated O
at O
least O
once B-lower_bound
for O
the O
current O
nsti B-chronic_disease
infection I-chronic_disease
and O
had O
a O
curative O
deep O
tissue O
debridement O

patients O
with O
cardiac B-chronic_disease
arrest I-chronic_disease
requiring O
cardiopulmonary B-treatment
resuscitation I-treatment
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

patients O
with O
overt O
peripheral B-chronic_disease
vascular I-chronic_disease
disease I-chronic_disease
in O
the O
involved O
area O

recent O
cerebrovascular B-chronic_disease
accident I-chronic_disease
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

patient O
has O
a O
current O
major B-chronic_disease
infection I-chronic_disease
distant O
from O
the O
operative O
site O

patient O
is O
mentally B-chronic_disease
incompetent I-chronic_disease
or O
unable O
to O
understand O
what O
participation O
in O
the O
study O
entails O

defined O
as O
a O
total B-clinical_variable
iq I-clinical_variable
score I-clinical_variable
less O
than O
@NUMBER B-upper_bound
as O
measured O
by O
the O
wechsler O
test O
of O
adult O
reading O
or O
as O
indicated O
by O
chart O
review O

hemodynamically O
unstable O
mi B-chronic_disease
with O
elevated O
cardiac B-clinical_variable
biomarker I-clinical_variable
( O
creatinine B-clinical_variable
kinase I-clinical_variable
- I-clinical_variable
mb I-clinical_variable
( I-clinical_variable
ck I-clinical_variable
- I-clinical_variable
mb I-clinical_variable
) I-clinical_variable
or O
troponin B-clinical_variable
> O
@NUMBER B-lower_bound
@NUMBER B-lower_bound
x I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound
( I-lower_bound
uln I-lower_bound
) I-lower_bound
) O
and O
no O
evidence O
of O
at O
least O
@NUMBER O
consecutive O
ckmb B-treatment
or O
troponin O
value O
trending O
downward O
from O
previous O
value O
( O
at O
least O
@NUMBER B-lower_bound
hours I-lower_bound
apart O
) O

severe O
peripheral B-chronic_disease
vascular I-chronic_disease
disease I-chronic_disease
that O
will O
preclude O
the O
use O
of O
a O
@NUMBER B-treatment
f I-treatment
access I-treatment
sheath I-treatment
, O
which O
is O
required O
for O
the O
insertion O
of O
the O
heartmate B-treatment
php I-treatment
catheter I-treatment

subject O
has O
a O
vascular B-chronic_disease
( I-chronic_disease
blood I-chronic_disease
vessels I-chronic_disease
) I-chronic_disease
and O
skin B-chronic_disease
disorders I-chronic_disease
or O
erythematous O
scars O
or O
erythematous O
striae O
or O
wishes O
to O
improve O
skin O
laxity O
or O
skin O
firmness O

radiographic O
findings O
consistent O
with O
non B-cancer
- I-cancer
small I-cancer
cell I-cancer
lung I-cancer
cancer I-cancer
, O
including O
lesions O
with O
ground O
glass O
opacities O
with O
a O
solid O
component O
of O
@NUMBER B-lower_bound
% I-lower_bound
or O
greater O

evidence O
of O
distant O
metastases B-cancer

ckd B-clinical_variable
stages I-clinical_variable
@NUMBER B-lower_bound
and O
@NUMBER B-upper_bound
( O
estimated B-clinical_variable
crcl I-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound
) O

diagnosis O
of O
type B-chronic_disease
@NUMBER I-chronic_disease
diabetes I-chronic_disease
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
using O
criteria O
of O
the O
american O
diabetes O
association O

previous O
cardiovascular B-chronic_disease
or O
cerebrovascular B-chronic_disease
event O
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
screening O
or O
active O
or O
clinically O
significant O
coronary O
and O
/ O
or O
peripheral B-chronic_disease
vascular I-chronic_disease
disease I-chronic_disease
( I-chronic_disease
pvd I-chronic_disease
) I-chronic_disease

post O
- O
menopausal O
women B-gender
who O
are O
on O
hormone B-treatment
replacement I-treatment
therapy I-treatment

patient O
does O
not O
have O
uncontrolled B-chronic_disease
diabetes I-chronic_disease
mellitus I-chronic_disease
( O
i.e. O
, O
fasting B-clinical_variable
blood I-clinical_variable
glucose I-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
) O

the O
presence O
or O
absence O
of O
para‐aortic B-cancer
lymph I-cancer
node I-cancer
metastasis I-cancer
will O
be O
based O
on O
pre B-treatment
- I-treatment
therapy I-treatment
@NUMBER I-treatment
f‐fdg I-treatment
pet I-treatment
/ I-treatment
ct I-treatment

have O
wee B-clinical_variable
prnt80 I-clinical_variable
< O
1:40 B-upper_bound
for O
booster O
series O

eligible O
individuals O
will O
have O
an O
established O
cognitive O
deficit O
as O
measured O
by O
one O
or O
more O
of O
these O
tests O
, O
scoring O
below O
the O
@NUMBER B-upper_bound
th I-upper_bound
percentile I-upper_bound
, O
using O
comparative O
norms O
according O
to O
age B-age
, O
gender O
, O
and O
education O

individuals O
with O
tardive B-chronic_disease
dyskinesia I-chronic_disease

montgomery B-clinical_variable
asberg I-clinical_variable
depression I-clinical_variable
rating I-clinical_variable
scale I-clinical_variable
< O
@NUMBER B-upper_bound

alanine B-clinical_variable
aminotransferase I-clinical_variable
& I-clinical_variable
asparate I-clinical_variable
aminotransferase I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
or I-upper_bound
normal I-upper_bound

any O
hemorrhage B-clinical_variable
or O
bleeding B-clinical_variable
event I-clinical_variable
≥ O
grade B-lower_bound
@NUMBER I-lower_bound
within O
@NUMBER B-upper_bound
weeks I-upper_bound

evidence O
or O
history O
of O
bleeding B-chronic_disease
diathesis I-chronic_disease
or O
coagulopathy B-chronic_disease

persistent B-clinical_variable
proteinuria I-clinical_variable
≥ O
grade B-lower_bound
@NUMBER I-lower_bound
interstitial B-chronic_disease
lung I-chronic_disease
disease I-chronic_disease
with O
ongoing O
signs O
and O
symptoms O
at O
the O
time O
of O
informed O
consent O

sedentary O
lifestyle O
, O
as O
engaging O
in O
less O
than O
@NUMBER B-upper_bound
minutes I-upper_bound
structured O
aerobic O
walking O

history O
& O
physical O
with O
neurologic O
examination O
prior O
to O
initiation O
of O
adjuvant B-treatment
tmz I-treatment

patients O
treated O
on O
any O
other B-treatment
therapeutic I-treatment
clinical I-treatment
protocols I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
study O
entry O

women B-gender
of O
childbearing O
potential O
and O
male B-gender
participants I-gender
must O
be O
willing B-contraception_consent
to I-contraception_consent
practice I-contraception_consent
adequate I-contraception_consent
contraception I-contraception_consent
throughout O
the O
study O
and O
for O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
after I-lower_bound
the O
last O
dose O
of O
study B-treatment
drug I-treatment

aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
( O
serum B-clinical_variable
glutamic I-clinical_variable
oxaloacetic I-clinical_variable
transaminase I-clinical_variable
[ I-clinical_variable
sgot I-clinical_variable
] I-clinical_variable
) O
/ O
alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
( O
serum B-clinical_variable
glutamate I-clinical_variable
pyruvate I-clinical_variable
transaminase I-clinical_variable
[ I-clinical_variable
sgpt I-clinical_variable
] I-clinical_variable
) O

no O
factors O
that O
increase O
the O
risk O
of O
qtc O
prolongation O
or O
risk O
of O
arrhythmic O
events O
such O
as O
heart B-chronic_disease
failure I-chronic_disease
, O
congenital O
long B-chronic_disease
qt I-chronic_disease
syndrome I-chronic_disease
, O
family O
history O
of O
long O
qt O
syndrome O
or O
unexplained B-chronic_disease
sudden I-chronic_disease
death I-chronic_disease

patient O
must O
not O
have O
hypokalemia B-chronic_disease
( O
value O
< O
institutional O
lower O
limit O
of O
normal O
) O

resting B-clinical_variable
corrected I-clinical_variable
qt I-clinical_variable
interval I-clinical_variable
( I-clinical_variable
qtc I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
msec I-upper_bound

stable O
dose O
of O
replacement O
steroid B-treatment
for O
adrenal B-chronic_disease
insufficiency I-chronic_disease
or O
low O
doses O
for O
non O
- O
malignant O
disease O

total B-clinical_variable
bilirubin I-clinical_variable
bilirubin B-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
( O
unless O
documented O
gilbert B-chronic_disease
's I-chronic_disease
syndrome I-chronic_disease
, O
for O
which O
bilirubin O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
uln I-upper_bound
is O
permitted O
) O

it O
is O
recommended O
that O
there O
are O
10-minute O
( O
+ O
/ O
- O
@NUMBER O
minutes O
) O
breaks O
between O
the O
ecgs B-treatment

under O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

within O
@NUMBER B-upper_bound
weeks I-upper_bound
following O
notification O
of O
treatment B-treatment
assignment O

concurrent O
participation O
in O
another O
study O
involving O
investigational B-treatment
drugs I-treatment
or O
investigational B-treatment
medical I-treatment
devices I-treatment

a O
kidney B-treatment
transplant I-treatment
patient O
with O
type B-chronic_disease
@NUMBER I-chronic_disease
diabetes I-chronic_disease
who O
has O
an O
hba1c B-clinical_variable
< O
@NUMBER B-upper_bound
and O
no O
history O
of O
severe B-chronic_disease
hypoglycemia I-chronic_disease

any O
coagulopathy B-chronic_disease
or O
medical O
condition O
requiring O
long O
- O
term O
anticoagulant B-treatment
therapy I-treatment
( O
e.g O
. O
warfarin B-treatment
) O
after O
islet B-treatment
transplantatio I-treatment
n O
( O
low B-treatment
- I-treatment
dose I-treatment
aspirin I-treatment
treatment I-treatment
[ O
@NUMBER O
mg O
po O
] O
is O
allowed O
) O

any O
history O
of O
malignancy B-cancer
except O
for O
completely O
r O
esected B-cancer
squamous I-cancer
or O
basal B-cancer
cell I-cancer
carcinoma I-cancer
of I-cancer
the I-cancer
skin I-cancer

atrial B-chronic_disease
fibrillation I-chronic_disease
with O
rapid O
ventricular O
response O

clinical O
evidence O
of O
left B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
as O
the O
main O
etiology O
for O
respiratory O
compromise O

medically O
fit O
enough O
to O
undertake O
surgery B-treatment
which O
may O
require O
general B-treatment
anesthesia I-treatment

positive O
stool O
test O
for O
clostridium B-chronic_disease
difficile I-chronic_disease
, O
ova O
and O
parasites O
, O
or O
routine O
stool O
culture O

use O
of O
over O
- O
the O
- O
counter O
herbal O
or O
dietary O
supplements O
( O
excluding O
vitamin O
and O
minerals O
) O
two B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
or O
during O
the O
study O
period O

stated O
desire O
to O
become B-pregnancy
pregnant I-pregnancy
during O
the O
study O
period O

current O
use O
of O
antipsychotic B-treatment
, O
anticonvulsant B-treatment
, O
anxiolytic B-treatment
, O
anticoagulant B-treatment
or O
sedative B-treatment
medications I-treatment

recent O
severe B-chronic_disease
head I-chronic_disease
injury I-chronic_disease
( O
within O
the O
last O
year O
) O
with O
loss B-clinical_variable
of I-clinical_variable
consciousness I-clinical_variable
> O
@NUMBER B-lower_bound
minutes I-lower_bound
or O
with O
permanent B-chronic_disease
neurologic I-chronic_disease
sequelae I-chronic_disease

opioid B-treatment
use O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
study O
medication O
( O
injectable B-treatment
naltrexone I-treatment
) O
or O
risks O
for O
opioid B-treatment
use O
during O
the O
study O

@NUMBER B-upper_bound
weeks I-upper_bound
must O
have O
passed O
since O
the O
last O
procedure O
and O
protocol O
therapy B-treatment

bmi B-bmi
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound

homa B-clinical_variable
- I-clinical_variable
ir I-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound

individuals O
with O
significant O
cardiovascular B-chronic_disease
, O
hepatic B-chronic_disease
or O
renal B-chronic_disease
disease I-chronic_disease
, O
uncontrolled B-chronic_disease
hypertension I-chronic_disease
, O
and O
chronic B-chronic_disease
pulmonary I-chronic_disease
disease I-chronic_disease
( O
eg O
, O
asthma B-chronic_disease
, O
copd B-chronic_disease
) O

presence O
of O
chronic B-chronic_disease
low I-chronic_disease
back I-chronic_disease
pain I-chronic_disease
( I-chronic_disease
clbp I-chronic_disease
) I-chronic_disease

be O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
or O
older O

known O
history O
of O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
infection O
or O
current O
chronic O
or O
active O
hepatitis B-chronic_disease
b I-chronic_disease
or I-chronic_disease
c I-chronic_disease
infection O
requiring O
treatment B-treatment
with O
antiviral B-treatment
therapy I-treatment

known O
to O
be O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
positive I-chronic_disease
( I-chronic_disease
hiv+ I-chronic_disease
) I-chronic_disease

monoclonal B-treatment
antibodies I-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
before I-upper_bound
study O
entry O

concurrent B-treatment
therapy I-treatment
with O
any O
drug O
active O
against O
hsv B-chronic_disease
( O
acyclovir B-treatment
, O
valaciclovir B-treatment
, O
penciclovir B-treatment
, O
famciclovir B-treatment
, O
gancyclovir B-treatment
, O
foscarnet B-treatment
, O
cidofovir B-treatment
) O
or O
any O
immunosuppressive B-treatment
drug I-treatment
therapy I-treatment
( O
except O
dexamethasone B-treatment
or O
prednisone B-treatment
) O

investigational B-treatment
/ O
biologic B-treatment
agents I-treatment
: O
patients O
must O
have O
recovered O
from O
any O
acute O
toxicities O
potentially O
related O
to O
the O
agent O
and O
received O
last O
dose O
≥ O
@NUMBER B-lower_bound
days I-lower_bound
prior I-lower_bound
@NUMBER B-lower_bound
days I-lower_bound
prior O
to O
entering O
this O
study O
( O
this O
period O
must O
be O
extended O
beyond O
the O
time O
during O
which O
adverse O
events O
are O
known O
to O
occur O
for O
agents O
with O
known O
adverse O
events O
≥ O
@NUMBER O
days O
) O

prior O
history O
of O
encephalitis B-chronic_disease
, O
multiple B-chronic_disease
sclerosis I-chronic_disease
, O
or O
other O
central B-chronic_disease
nervous I-chronic_disease
system I-chronic_disease
( I-chronic_disease
cns I-chronic_disease
) I-chronic_disease
infection I-chronic_disease

tumor B-cancer
involvement O
which O
would O
require O
ventricular O
, O
cerebellar O
or O
brainstem O
inoculation O
or O
would O
require O
access O
through O
a O
ventricle O
in O
order O
to O
deliver O
treatment B-treatment

willingness O
to O
spend O
1-h B-upper_bound
in O
a O
scanner O

portal B-chronic_disease
systemic I-chronic_disease
encephalopathy I-chronic_disease

patients O
who O
have O
any O
severe O
and O
/ O
or O
uncontrolled O
medical O
conditions O
such O
as O
: O
a O
. O
serious B-chronic_disease
uncontrolled I-chronic_disease
cardiac I-chronic_disease
arrhythmia I-chronic_disease
, O
or O
any O
other O
clinically O
significant O
cardiac B-chronic_disease
disease I-chronic_disease
b O
. O
active B-chronic_disease
( I-chronic_disease
acute I-chronic_disease
or I-chronic_disease
chronic I-chronic_disease
) I-chronic_disease
or I-chronic_disease
uncontrolled I-chronic_disease
severe I-chronic_disease
infection I-chronic_disease
, O
liver B-chronic_disease
disease I-chronic_disease
such O
as O
cirrhosis B-chronic_disease
, O
decompensated B-chronic_disease
liver I-chronic_disease
disease I-chronic_disease
, O
and O
active B-chronic_disease
and I-chronic_disease
chronic I-chronic_disease
hepatitis I-chronic_disease
( O
i.e O
. O
quantifiable O
hepatitis B-chronic_disease
b I-chronic_disease
virus I-chronic_disease
[ I-chronic_disease
hbv I-chronic_disease
] I-chronic_disease
-deoxyribonucleic O
acid O
[ O
dna O
] O
and O
/ O
or O
positive O
surface O
antigen O
of O
the O
hepatitis B-chronic_disease
b I-chronic_disease
virus I-chronic_disease
[ I-chronic_disease
hbsag I-chronic_disease
] I-chronic_disease
, O
quantifiable O
hepatitis B-chronic_disease
c I-chronic_disease
virus I-chronic_disease
[ I-chronic_disease
hcv I-chronic_disease
] I-chronic_disease
-ribonucleic O
acid O
[ O
rna O
] O
) O
, O
c. O
known O
severely B-chronic_disease
impaired I-chronic_disease
lung I-chronic_disease
function I-chronic_disease
( O
spirometry O
and O
diffusing B-clinical_variable
capacity I-clinical_variable
of I-clinical_variable
the I-clinical_variable
lungs I-clinical_variable
for I-clinical_variable
carbon I-clinical_variable
monoxide I-clinical_variable
[ I-clinical_variable
dlco I-clinical_variable
] I-clinical_variable
@NUMBER B-upper_bound
% I-upper_bound
or O
less O
of O
normal O
and O
oxygen B-clinical_variable
( I-clinical_variable
o2 I-clinical_variable
) I-clinical_variable
saturation I-clinical_variable
@NUMBER B-upper_bound
% I-upper_bound
or O
less O
at O
rest O
on O
room O
air O
) O
, O
d. O
active O
, O
bleeding B-chronic_disease
diathesis I-chronic_disease
; O
e O
. O
moderate B-chronic_disease
or I-chronic_disease
severe I-chronic_disease
hepatic I-chronic_disease
impairment I-chronic_disease
( O
child O
- O
pugh O
b O
or O
c O
) O

confirmed O
diagnosis O
of O
autism B-chronic_disease
spectrum I-chronic_disease
disorder I-chronic_disease

english B-language_fluency
speakers I-language_fluency

patient O
is O
starting O
one O
of O
the O
following O
ms B-treatment
therapies I-treatment
: O
injectable O
( O
subcutaneous B-treatment
interferon I-treatment
beta I-treatment
or O
glatiramer B-treatment
acetate I-treatment
) O
or O
oral O
( O
fingolimod B-treatment
, O
teriflunomide B-treatment
, O
or O
dimethyl B-treatment
fumarate I-treatment
) O
therapies O

body B-bmi
mass I-bmi
index I-bmi
( I-bmi
bmi I-bmi
) I-bmi
≥ O
@NUMBER B-lower_bound
kg I-lower_bound
/ I-lower_bound
m^2 I-lower_bound

histologically O
confirmed O
adenocarcinoma B-cancer
of I-cancer
the I-cancer
prostate I-cancer
, O
clinically O
localized O
, O
low O
or O
low O
- O
intermediate O
risk O
disease O
( O
t1c B-clinical_variable
/ O
t2a B-clinical_variable
, O
gleason B-clinical_variable
≤ O
@NUMBER B-upper_bound
[ O
3 O
+ O
4 O
] O
, O
prostate B-clinical_variable
- I-clinical_variable
specific I-clinical_variable
antigen I-clinical_variable
[ I-clinical_variable
psa I-clinical_variable
] I-clinical_variable
< O
@NUMBER B-upper_bound
) O

primary B-treatment
treatment I-treatment
is O
active B-treatment
surveillance I-treatment
( I-treatment
as I-treatment
) I-treatment
with I-treatment
planned I-treatment
annual I-treatment
surveillance I-treatment
biopsies I-treatment

at O
least O
one B-lower_bound
measurable O
disease O
site O
that O
meets O
target O
lesion O
requirements O

history O
of O
intracranial O
hemorrhage O
, O
neoplasm B-cancer
, O
arteriovenous B-chronic_disease
malformation I-chronic_disease
, O
or O
aneurysm B-chronic_disease

major B-treatment
surgery I-treatment
or O
other O
serious O
trauma O
during O
preceding B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

sickle B-chronic_disease
cell I-chronic_disease
disease I-chronic_disease

age B-age
of O
≥ O
@NUMBER B-lower_bound
years I-lower_bound

females B-gender
of O
childbearing O
potential O
should O
have O
a O
negative B-pregnancy
serum I-pregnancy
beta I-pregnancy
- I-pregnancy
hcg I-pregnancy
test O
within O
@NUMBER B-upper_bound
hours I-upper_bound
of O
beginning O
dli O
and O
/ O
or O
duk O
- O
cpg-01 O
unless O
contraception B-contraception_consent
is O
used O
after O
initial O
testing O

patients O
with O
treated O
acute O
gvhd B-chronic_disease
must O
be O
on O
a O
stable O
dose O
of O
therapy B-treatment
( O
no O
increase O
in O
immunosuppressive B-treatment
therapy I-treatment
for O
the O
@NUMBER B-upper_bound
weeks I-upper_bound
before I-upper_bound
planned O
nk O
cell O
- O
enriched O
dlis O
) O

have O
either O
a O
dvd B-technology_access
player I-technology_access
or O
internet B-technology_access
access I-technology_access
through I-technology_access
computer I-technology_access
or I-technology_access
phone I-technology_access

provide O
at O
least O
@NUMBER B-lower_bound
meals O
/ O
snacks O
to O
the O
children O

dlco B-clinical_variable
/ I-clinical_variable
va I-clinical_variable
and O
fev1 B-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound
of O
predicted O
on O
pfts O

pregnancy B-pregnancy
as O
detected O
by O
a O
urine O
test O

ability O
to O
take O
oral B-treatment
medication I-treatment

have O
measurable B-chronic_disease
disease I-chronic_disease

must O
have O
had O
prior B-treatment
abiraterone I-treatment
treatment I-treatment

surgically O
resectable O
disease O
( O
r0 O
or O
r1 O
) O
by O
spiral B-treatment
ct I-treatment
scan I-treatment

≤ O
@NUMBER B-upper_bound
lines O
of O
prior B-treatment
systemic I-treatment
therapy I-treatment
for I-treatment
patients I-treatment
with I-treatment
progressive I-treatment
locally I-treatment
- I-treatment
advanced I-treatment
disease I-treatment

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
gm I-lower_bound
/ I-lower_bound
dl I-lower_bound

history O
of O
bone B-treatment
marrow I-treatment
transplant I-treatment
and O
stem B-treatment
cell I-treatment
rescue I-treatment

known O
active O
hepatitis B-chronic_disease
b I-chronic_disease
infection I-chronic_disease
( O
defined O
as O
presence O
of O
hepatitis B-chronic_disease
b I-chronic_disease
[ I-chronic_disease
hepb I-chronic_disease
] I-chronic_disease
surface O
antigen O
[ O
sag O
] O
and O
/ O
or O
hep O
b O
deoxyribonucleic O
acid O
[ O
dna O
] O
) O
, O
known O
active O
hepatitis B-chronic_disease
c I-chronic_disease
infection I-chronic_disease
( O
defined O
as O
presence O
of O
hepatitis B-chronic_disease
c I-chronic_disease
[ I-chronic_disease
hep I-chronic_disease
c I-chronic_disease
] I-chronic_disease
ribonucleic O
acid O
[ O
rna O
] O
) O
and O
/ O
or O
known O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
carrier O

measurable B-chronic_disease
disease I-chronic_disease
according O
to O
response O
evaluation O
criteria O
in O
solid O
tumors O
( O
recist O
) O
version O
( O
v O
) O
@NUMBER O

untreated O
or O
symptomatic O
brain B-cancer
metastases I-cancer
requiring O
corticosteroid B-treatment
corticosteroid B-treatment
therapy I-treatment
( O
no O
corticosteroid O
use O
for O
this O
purpose O
in O
the O
preceding O
@NUMBER B-upper_bound
weeks I-upper_bound
) O

there O
should O
be O
a O
repeat O
serum O
hcg O
test O
( O
with O
a O
non O
- O
rising O
result O
) O
to O
rule O
out O
pregnancy B-pregnancy

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
mm I-upper_bound
breslow B-clinical_variable
depth I-clinical_variable

any O
vaccination B-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
gm B-treatment
- I-treatment
csf I-treatment
administration O

scheduled O
for O
sentinel B-treatment
lymph I-treatment
node I-treatment
biopsy I-treatment
as O
part O
of O
their O
standard O
surgical O
management O

must O
be O
using B-contraception_consent
an I-contraception_consent
adequate I-contraception_consent
method I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
to O
avoid O
pregnancy B-pregnancy
throughout O
the O
study O
and O
for O
up O
to O
@NUMBER B-upper_bound
weeks I-upper_bound
after O
the O
study O
in O
such O
a O
manner O
that O
the O
risk O
of O
pregnancy O
is O
minimized O

average B-clinical_variable
normal I-clinical_variable
sleep I-clinical_variable
duration I-clinical_variable
≤ O
@NUMBER B-upper_bound
hours I-upper_bound

sleep B-chronic_disease
disorders I-chronic_disease

< O
@NUMBER B-upper_bound
% I-upper_bound
must O
be O
on O
a O
stable O
medical O
regimen O

ctcae B-clinical_variable
gr I-clinical_variable
≥ O
@NUMBER B-lower_bound
neuropathy B-chronic_disease

clinically O
significant O
active O
infection O
or O
uncontrolled O
medical B-chronic_disease
condition I-chronic_disease

within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
cycle O
@NUMBER O
, O
day O
@NUMBER O
, O
or O
anticipated O
requirement O
for O
systemic B-treatment
immunosuppressive I-treatment
medications I-treatment
during O
the O
trial O

atypical B-cancer
teratoid I-cancer
rhabdoid I-cancer
tumor I-cancer
( I-cancer
atrt I-cancer
) I-cancer

ependymoma B-cancer

grade B-cancer
i I-cancer
or I-cancer
ii I-cancer
glioma I-cancer

subependymal B-cancer
giant I-cancer
cell I-cancer
astrocytoma I-cancer
( I-cancer
sega I-cancer
) I-cancer

blunt B-chronic_disease
or O
penetrating B-chronic_disease
trauma I-chronic_disease

subjects O
must O
have O
a O
clinical O
diagnosis O
of O
ctcl B-cancer
( I-cancer
mycosis I-cancer
fungoides I-cancer
) I-cancer
, O
stage O
ia O
, O
stage O
ib O
, O
or O
stage O
iia O

patients O
must O
have O
undergone O
curative B-treatment
resection I-treatment
and O
have O
no O
evidence O
of O
residual B-chronic_disease
or I-chronic_disease
metastatic I-chronic_disease
disease I-chronic_disease

starting O
with O
the O
pre O
- O
screening O
or O
screening O
visit O
through O
@NUMBER B-upper_bound
days I-upper_bound
after I-upper_bound
the O
last O
dose O
of O
trial B-treatment
treatment I-treatment

exclusion O
criteria O
for O
individuals O
with O
sci B-chronic_disease
and O
healthy O
controls O

between O
ages B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound

creatinine B-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

pathological O
diagnosis O
of O
pancreatic B-cancer
adenocarcinoma I-cancer
adequately O
treated O
with O
induction B-treatment
chemotherapy I-treatment
for O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound

sgot B-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound

have O
a O
karnofsky B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
score I-clinical_variable
of O
@NUMBER B-lower_bound
or O
above O

regular O
yoga O
practice O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

have O
borderline B-cancer
resectable I-cancer
or O
unresectable O
locally O
advanced O
disease O
or O
metastatic B-cancer
disease I-cancer

have O
histologically O
confirmed O
adenocarcinoma B-cancer
of I-cancer
the I-cancer
pancreas I-cancer

receiving O
@NUMBER B-treatment
rd I-treatment
- I-treatment
line I-treatment
palliative I-treatment
chemotherapy I-treatment

dexamethasone B-treatment
up O
to O
a O
total O
dose O
of O
@NUMBER B-upper_bound
mg I-upper_bound
per I-upper_bound
day I-upper_bound
will O
be O
allowed O
if O
medically O
indicated O

steroid O
dose O
of O
dexamethasone B-treatment
greater O
than O
@NUMBER B-lower_bound
mg I-lower_bound
per O
day O
( O
or O
equivalent O
) O

wherein O
grades O
are O
defines O
as O
: O
grade O
@NUMBER O
: O
no O
staining O
; O
grade O
@NUMBER B-lower_bound
: O
@NUMBER O
@NUMBER B-upper_bound
% I-upper_bound
; O
grade O
@NUMBER O
: O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
% I-upper_bound
and O
grade O
@NUMBER O
: O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
% I-upper_bound
of O
cell O
staining O
for O
her2 B-cancer
and O
intensity O
scores O
are O
: O
negative O
; O
1 O
+ O
; O
2 O
+ O
and O
3 O
+ O
using O
breast B-treatment
cancer I-treatment
standard I-treatment
arrays I-treatment
as O
a O
guide O
for O
intensity O

scheduled O
for O
surgery B-treatment
at O
brigham O
and O
women O
's O
hospital O
for O
known O
or O
highly O
suspected O
stage B-cancer
iii I-cancer
or I-cancer
iv I-cancer
ovarian I-cancer
cancer I-cancer
( O
i.e O
. O
elevated B-clinical_variable
ca-125 I-clinical_variable
with O
a O
pelvic B-chronic_disease
mass I-chronic_disease
, O
ascites B-chronic_disease
, O
and O
carcinomatosis B-cancer
) O

atrial B-clinical_variable
fibrillation I-clinical_variable
or O
flutter B-clinical_variable
burden I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound
of O
the O
time O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

inotrope O
dependent O
heart B-chronic_disease
failure I-chronic_disease
condition O

any O
additional O
medical B-chronic_disease
condition I-chronic_disease
, O
serious O
intercurrent B-chronic_disease
illness I-chronic_disease
, O
or O
other O
extenuating O
circumstance O
that O
, O
in O
the O
opinion O
of O
the O
investigator O
, O
may O
significantly O
interfere O
with O
study O
compliance O

if O
a O
false O
pregnancy B-pregnancy
test O
is O
suspected O
, O
e.g. O
, O
perimenopausal O
condition O
, O
an O
obstetrician O
will O
be O
consulted O
to O
determine O
if O
she O
is O
/ O
is O
not O
capable O
of O
becoming B-pregnancy
pregnant I-pregnancy

≥ O
@NUMBER B-lower_bound
years I-lower_bound
old O
, O
or O
of O
childbearing O
potential O
for O
whom O
a O
pregnancy B-pregnancy
test O
( O
with O
the O
results O
known O
prior O
to O
investigational B-treatment
product I-treatment
administration O
) O
is O
negative O

abnormalities B-chronic_disease
of I-chronic_disease
the I-chronic_disease
esophagus I-chronic_disease
which O
delay O
esophageal O
emptying O
such O
as O
stricture B-chronic_disease
or O
achalasia B-chronic_disease

current B-treatment
treatment I-treatment
with O
medicines O
containing O
digoxin B-treatment
or O
warfarin B-treatment

participation O
in O
a O
study O
of O
an O
investigational O
drug O
during O
the O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

any O
condition O
requiring O
concurrent O
systemic B-treatment
immunosuppressive I-treatment
therapy I-treatment

arm O
@NUMBER O
: O
received O
at O
least O
one O
prior O
line O
of O
therapy B-treatment
for O
incurable O
or O
metastatic B-cancer
nsclc I-cancer

central B-cancer
nervous I-cancer
system I-cancer
( I-cancer
cns I-cancer
) I-cancer
metastases I-cancer
may O
be O
permitted O
but O
must O
be O
treated O
and O
neurologically O
stable O

refractory O
to O
prior B-treatment
immunotherapy I-treatment
immunotherapy B-treatment
( O
clinical B-treatment
or I-treatment
radiographic I-treatment
progression I-treatment
after B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound
or O
less O
of O
immunotherapy O
) O

up O
to O
one O
prior O
line O
of O
checkpoint B-treatment
inhibitor I-treatment
therapy I-treatment
is O
permitted O
( O
must O
have O
received O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
of O
treatment B-treatment
) O

patients O
must O
have O
adequate O
hematologic O
reserve O
with O
wbc B-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound
, O
absolute B-clinical_variable
neutrophils I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound
and O
platelets B-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound
. O
patients O
who O
are O
on O
coumadin O
must O
have O
a O
platelet B-clinical_variable
count I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound

pre O
- O
existing O
cardiac B-chronic_disease
or O
respiratory B-chronic_disease
disorders I-chronic_disease

all O
women B-gender
of O
childbearing O
potential O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
a I-contraception_consent
reliable I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
method I-contraception_consent
( O
oral B-contraception_consent
contraceptive I-contraception_consent
pills I-contraception_consent
, O
intrauterine B-contraception_consent
device I-contraception_consent
, O
nexplanon B-contraception_consent
, O
depoprovera B-contraception_consent
, O
or O
permanent B-contraception_consent
sterilization I-contraception_consent
, O
etc O
. O
, O
or O
another O
acceptable O
method O
as O
determined O
by O
the O
investigator O
) O
during O
the O
entire O
period O
of O
the O
trial O
( O
@NUMBER B-upper_bound
years I-upper_bound
) O
, O
and O
must O
not O
intend O
to O
become B-pregnancy
pregnant I-pregnancy
during O
study O
participation O
and O
for O
@NUMBER B-upper_bound
months I-upper_bound
after I-upper_bound
treatment B-treatment
is O
discontinued O

patients O
must O
be O
able O
to O
swallow O
oral B-treatment
medication I-treatment

subjects O
with O
concomitant O
malignancy B-cancer
or O
a O
previous O
malignancy O
within O
the O
past B-upper_bound
three I-upper_bound
years I-upper_bound

age B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
( O
inclusive O
) O

no O
evidence O
of O
suicidal B-chronic_disease
intentions I-chronic_disease
or I-chronic_disease
behaviors I-chronic_disease
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

age B-age
of O
onset O
before O
@NUMBER B-upper_bound
years I-upper_bound

has O
a O
known O
additional O
malignancy B-cancer
that O
is O
progressing O
or O
requires O
active O
treatment B-treatment
; O
exceptions O
include O
basal B-cancer
cell I-cancer
carcinoma I-cancer
of I-cancer
the I-cancer
skin I-cancer
, O
squamous B-cancer
cell I-cancer
carcinoma I-cancer
of I-cancer
the I-cancer
skin I-cancer
, O
or O
in B-cancer
situ I-cancer
cervical I-cancer
cancer I-cancer
that O
has O
undergone O
potentially O
curative B-treatment
therapy I-treatment
; O
free O
of O
disease O
for O
more O
than O
@NUMBER B-lower_bound
years I-lower_bound

has O
known O
hypersensitivity O
to O
mk-3475 O
( O
pembrolizumab B-allergy_name
) O
or O
any O
of O
its O
incipients O

is O
currently O
participating O
in O
or O
has O
participated O
in O
a O
study O
of O
an O
investigational B-treatment
agent I-treatment
or O
using O
an O
investigational B-treatment
device I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
the O
first O
dose O
of O
treatment B-treatment

patients O
with O
a O
known O
hypersensitivity O
to O
gemcitabine B-treatment
( O
arm O
b O
only O
) O

als B-chronic_disease
diagnosed O
as O
probable O
, O
laboratory O
- O
supported O
probable O
or O
definite O
according O
to O
the O
world O
federation O
of O
neurology O
el O
escorial O
revised O
criteria32 O
as O
determined O
by O
a O
neurologist O
with O
neuromuscular O
subspecialty O
training O

estimated B-clinical_variable
glomerular I-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

competent O
caregiver O
who O
can O
and O
will O
be O
responsible O
for O
administering O
study B-treatment
drug I-treatment

must O
not B-pregnancy
be I-pregnancy
able I-pregnancy
to I-pregnancy
become I-pregnancy
pregnant I-pregnancy
( O
e.g. O
, O
post O
- O
menopausal O
for O
at O
least O
one B-lower_bound
year I-lower_bound
, O
surgically O
sterile O
, O
or O
using B-contraception_consent
adequate I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
) O
or O
breastfeed O
for O
the O
duration O
of O
the O
study O
. O
adequate O
methods O
of O
contraception O
include O
: O
implanted O
contraception O
, O
intrauterine O
device O
in O
place O
for O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound
, O
or O
barrier O
method O
in O
conjunction O
with O
spermicide O

able B-language_fluency
to I-language_fluency
communicate I-language_fluency
and I-language_fluency
provide I-language_fluency
consent I-language_fluency
in I-language_fluency
english I-language_fluency
or I-language_fluency
spanish I-language_fluency

history O
of O
uveitis B-chronic_disease
or O
unknown O
macular B-chronic_disease
edema I-chronic_disease

aged B-age
@NUMBER B-lower_bound
to O
< O
@NUMBER B-upper_bound
years I-upper_bound
( O
at O
screening O
) O

children O
will O
be O
selected O
by O
purposive O
sampling O
and O
will O
include O
those O
who O
are O
scheduled O
to O
have O
an O
ace B-treatment
stoma I-treatment
and O
will O
require O
regular O
antegrade B-treatment
enema I-treatment
administration I-treatment
to O
maintain O
continence O

asthma B-chronic_disease
-related O
hospitalization O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

daily O
use O
of O
ppi B-treatment
's I-treatment
( I-treatment
proton I-treatment
pump I-treatment
inhibitor I-treatment
) I-treatment
or O
h2 B-treatment
blockers I-treatment
for O
gerd B-chronic_disease
( O
it O
is O
permitted O
to O
take O
on O
an O
occasional O
basis- O
no O
more O
than O
@NUMBER B-upper_bound
x I-upper_bound
per O
week O

use O
of O
biologics B-treatment
for O
asthma B-chronic_disease
/ I-chronic_disease
allergies I-chronic_disease
unless O
there O
is O
a O
@NUMBER B-upper_bound
month I-upper_bound
washout I-upper_bound
prior I-upper_bound
to O
enrollment O
( O
the O
washout O
for O
biologics O
is O
done O
for O
clinical O
reasons O
and O
not O
specifically O
for O
inclusion O
for O
the O
study O
) O

use O
of O
mouthwash O
containing O
chlorhexidine B-treatment
( O
lowers O
no O
) O
within O
@NUMBER B-upper_bound
week I-upper_bound
prior I-upper_bound
to O
screening O
and O
throughout O
the O
study O

partial B-clinical_variable
thromboplastin I-clinical_variable
time I-clinical_variable
( I-clinical_variable
ptt I-clinical_variable
) I-clinical_variable
within O
1.5x B-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound

creatinine B-clinical_variable
ratio I-clinical_variable
( I-clinical_variable
upc I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound

stable O
on O
hemodialysis B-treatment
for O
more O
than O
@NUMBER B-lower_bound
months I-lower_bound

documented O
diagnosis O
of O
scd B-chronic_disease

history O
of O
vaginal B-treatment
irradiation I-treatment

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

alcohol O
intake O
of O
less O
than O
@NUMBER B-upper_bound
g I-upper_bound
per O
day O
in O
females B-gender
males B-gender
and O
@NUMBER O
g O
per O
day O
in O
males O

hematocrit B-clinical_variable
of O
less O
than O
@NUMBER B-upper_bound
% I-upper_bound

significant O
motor B-chronic_disease
impairment I-chronic_disease

background B-treatment
therapies I-treatment
allowed O
: O
antimalarials B-treatment
( O
dose B-clinical_variable
constant I-clinical_variable
for O
≥ O
one B-lower_bound
month I-lower_bound
before I-lower_bound
study O
entry O
and O
during O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
trial O
) O
, O
methotrexate B-treatment
( O
same O
criteria O
as O
for O
antimalarials O
) O
, O
azathioprine B-treatment
( O
same O
criteria O
) O
, O
mycophenolate B-treatment
( O
same O
criteria O
) O
, O
leflunomide B-treatment
( O
same O
criteria O
) O

subjects O
with O
bilag B-clinical_variable
a O
in O
any O
system O
outside O
the O
musculoskeletal O
system O

subjects O
with O
active O
glomerulonephritis B-chronic_disease
( O
> O
@NUMBER B-lower_bound
g I-lower_bound
protein O
/ O
@NUMBER O
h O
and O
/ O
or O
active O
urine O
sediment O
) O

gerd B-chronic_disease
symptoms O
, O
in O
absence O
of O
ppi B-treatment
therapy I-treatment
( O
minimum O
@NUMBER B-lower_bound
days I-lower_bound
) O

orthostatic B-chronic_disease
hypotension I-chronic_disease
will O
be O
defined O
as O
≥ O
@NUMBER B-lower_bound
mmhg I-lower_bound
decrease O
in O
systolic B-clinical_variable
bp I-clinical_variable
or O
≥ O
@NUMBER B-lower_bound
mmhg I-lower_bound
of O
diastolic B-clinical_variable
bp I-clinical_variable
within O
@NUMBER B-upper_bound
minutes I-upper_bound
on O
standing O
associated O
with O
impaired O
autonomic O
reflexes O
determined O
by O
autonomic O
testing O
in O
the O
absence O
of O
other O
identifiable O
causes O
( O
freeman O
et O
al O
. O
, O
@NUMBER O
) O

participants O
with O
a O
heart B-clinical_variable
rate I-clinical_variable
of O
less O
than O
@NUMBER B-upper_bound
or O
a O
systolic B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
of O
less O
than O
@NUMBER B-upper_bound
at O
the O
outset O
of O
the O
study O

women B-gender
men B-gender
of O
child O
- O
bearing O
potential O
and O
men O
must O
be O
willing B-contraception_consent
to I-contraception_consent
use I-contraception_consent
adequate I-contraception_consent
contraception I-contraception_consent
during O
the O
entire O
study O
and O
for O
@NUMBER B-upper_bound
weeks I-upper_bound
following O
completion O
of O
all O
chemotherapy B-treatment
on O
study O
; O
this O
includes O
hormonal B-contraception_consent
or O
barrier B-contraception_consent
method I-contraception_consent
, O
or O
abstinence B-contraception_consent

women B-gender
of O
reproductive O
potential O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
adequate I-contraception_consent
contraception I-contraception_consent
( O
hormonal B-contraception_consent
or O
barrier B-contraception_consent
method I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
; O
abstinence B-contraception_consent
) O
prior O
to O
study O
entry O
and O
for O
the O
duration O
of O
study O
participation O

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound

a O
history O
of O
ischemic B-chronic_disease
heart I-chronic_disease
disease I-chronic_disease
, O
heart B-treatment
transplant I-treatment
, O
cardiovascular B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
year I-upper_bound

anticipated O
initiation O
, O
change O
, O
or O
discontinuation O
of O
a O
hormonal O
contraceptive O
within O
the O
next B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

history O
of O
hypercholesterolemia B-clinical_variable
( O
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
) O
or O
hypertriglyceridemia B-clinical_variable
( O
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
) O

current O
smokers O
or O
history O
of O
heavy B-clinical_variable
smoking I-clinical_variable
( O
> O
@NUMBER B-lower_bound
packs I-lower_bound
/ I-lower_bound
day I-lower_bound
) O

subjects O
with O
any O
chronic B-chronic_disease
disease I-chronic_disease

patients O
must O
be O
on O
single B-treatment
immune I-treatment
suppression I-treatment
therapy I-treatment
with I-treatment
either I-treatment
tacrolimus I-treatment
or I-treatment
cyclosporine I-treatment
at O
the O
time O
of O
cd8 B-treatment
+ I-treatment
memory I-treatment
t I-treatment
- I-treatment
cell I-treatment
infusion I-treatment

total B-clinical_variable
bilirubin I-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound

diagnosed O
> O
@NUMBER O
years O
ago O
without O
evidence O
of O
disease O
, O
or O
treated O
≤ O
@NUMBER O
years O
ago O
but O
have O
a O
greater O
than O
@NUMBER B-lower_bound
% I-lower_bound
chance O
of O
life B-clinical_variable
expectancy I-clinical_variable
of O
≥ O
@NUMBER O
years O
for O
that O
malignancy B-cancer

patient O
with O
primary O
liver B-cancer
tumor I-cancer
or O
metastasis B-cancer
scheduled O
for O
stereotactic B-treatment
ablative I-treatment
radiotherapy I-treatment
( I-treatment
sabr I-treatment
) I-treatment

head B-cancer
and I-cancer
neck I-cancer
cancer I-cancer
patients O
with O
tumor B-cancer
invading O
major O
blood O
vessels O
for O
whom O
there O
may O
be O
a O
risk O
of O
blockage O
or O
bleeding O
if O
inflammation O
or O
edema B-chronic_disease
is O
transiently O
increased O
by O
hiltonol B-treatment
injections I-treatment

in O
the O
opinion O
of O
the O
local O
pi O
: O
head B-cancer
and I-cancer
neck I-cancer
cancer I-cancer
patients O
with O
airway O
tumor B-cancer
recurrence O
that O
may O
compromise O
breathing O
or O
swallowing O
if O
inflammation O
or O
edema B-chronic_disease
is O
transiently O
aggravated O
by O
hiltonol O
injection O

persistent O
toxicity O
from O
recent B-treatment
therapy I-treatment
that O
has O
not O
sufficiently O
resolved O
in O
the O
judgment O
of O
the O
study O
physician O

history O
of O
suicide B-chronic_disease
suicide B-chronic_disease
attempts I-chronic_disease
or O
inpatient O
hospitalization O
for O
risk O
of O
suicide O
in O
the O
past B-upper_bound
six I-upper_bound
month I-upper_bound

for O
diagnosis O
of O
gbm B-cancer
: O
has O
undergone O
maximal O
safe O
surgical B-treatment
resection I-treatment
, O
a O
course O
of O
postoperative B-treatment
radiation I-treatment
therapy I-treatment
with O
concurrent B-treatment
temozolomide I-treatment
, O
and O
maintenance B-treatment
temozolomide I-treatment

prior O
participation O
in O
a O
blinded B-treatment
afatinib I-treatment
clinical I-treatment
study I-treatment
, O
even O
if O
not O
assigned O
to O
afatinib B-treatment
treatment I-treatment

active O
diabetes B-chronic_disease
insipidus I-chronic_disease

concurrent B-treatment
or O
planned B-treatment
systemic I-treatment
chemotherapy I-treatment
, O
radiotherapy B-treatment
, O
new B-treatment
hormonal I-treatment
or O
anti B-treatment
- I-treatment
her2 I-treatment
directed I-treatment
therapy I-treatment
directed O
at O
management O
of O
breast B-cancer
cancer I-cancer

her2-positive B-cancer
is O
defined O
as O
her2 B-clinical_variable
ihc I-clinical_variable
3 O
+ O
, O
ish B-clinical_variable
≥ O
@NUMBER B-lower_bound
, O
or O
average O
her2 B-clinical_variable
copy I-clinical_variable
number I-clinical_variable
≥ O
@NUMBER B-lower_bound
signals O

prior B-treatment
treatment I-treatment
with O
any O
methotrexate B-treatment
containing O
systemic B-treatment
regimen I-treatment
within O
@NUMBER B-upper_bound
year I-upper_bound

triple B-cancer
negative I-cancer
( O
er B-cancer
- I-cancer
negative I-cancer
, O
pr B-cancer
- I-cancer
negative I-cancer
, O
and O
her2-negative B-cancer
disease O
) O

whole O
brain B-treatment
radiotherapy I-treatment
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
or O
partial O
brain O
radiotherapy O
exceeding O
greater O
than O
@NUMBER B-lower_bound
% I-lower_bound
of O
total B-clinical_variable
brain I-clinical_variable
volume I-clinical_variable
in O
the O
last O
@NUMBER O
months O

brain B-cancer
or O
metastatic B-cancer
cancer I-cancer

will O
be O
matched O
for O
age B-age
, O
gender O
, O
height O
and O
weight O
and O
will O
have O
no O
history O
of O
cardiovascular B-chronic_disease
related I-chronic_disease
abnormalities I-chronic_disease

active O
suicidal B-chronic_disease
ideation I-chronic_disease

hormone B-treatment
deprivation I-treatment
therapy I-treatment

known O
cns O
lymphoma B-cancer

known O
active O
hepatitis B-chronic_disease
b I-chronic_disease
or O
hepatitis B-chronic_disease
c I-chronic_disease

subject O
has O
malabsorption B-chronic_disease
syndrome I-chronic_disease
or O
other O
condition O
which O
may O
affect O
an O
enteral O
route O
of O
administration O

alanine B-clinical_variable
transaminase I-clinical_variable
( I-clinical_variable
alanine I-clinical_variable
aminotransferase I-clinical_variable
[ I-clinical_variable
alt I-clinical_variable
] I-clinical_variable
) I-clinical_variable
alt B-clinical_variable
] O
) O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
normal I-upper_bound
limit I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
( O
in O
the O
expansion O
cohort O
, O
patients O
with O
known O
liver O
involvement O
may O
have O
alt O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
) O

clinically O
stable O
with O
respect O
to O
the O
cns B-cancer
tumor I-cancer
at O
the O
time O
of O
study O
entry O

evidence O
of O
complete O
or O
partial O
bowel B-chronic_disease
obstruction I-chronic_disease

must O
have O
failed O
prior B-treatment
standard I-treatment
curative I-treatment
chemotherapy I-treatment
for O
their O
disease O

chemotherapy B-treatment

polymyalgia B-chronic_disease

maintained O
on O
modern B-treatment
therapeutic I-treatment
regimens I-treatment
utilizing I-treatment
non I-treatment
- I-treatment
cyp I-treatment
- I-treatment
interactive I-treatment
agents I-treatment

patients O
previously O
treated O
with O
an O
mammalian B-treatment
tor I-treatment
( I-treatment
mtor I-treatment
) I-treatment
or O
pi3k B-treatment
inhibitor I-treatment

patients O
with O
controlled O
diabetes B-chronic_disease
are O
allowed O
on O
study O
; O
controlled O
diabetes O
is O
defined O
as O
fetal B-clinical_variable
bovine I-clinical_variable
serum I-clinical_variable
( I-clinical_variable
fbs I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
in O
the O
context O
of O
this O
study O

the O
effects O
of O
mln0128 O
( O
tak-228 O
) O
on O
the O
developing O
human O
fetus O
are O
unknown O
; O
for O
this O
reason O
women B-gender
men B-gender
of O
child O
- O
bearing O
potential O
and O
men O
must O
agree B-contraception_consent
to I-contraception_consent
practice I-contraception_consent
@NUMBER I-contraception_consent
highly I-contraception_consent
effective I-contraception_consent
method I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
and O
@NUMBER B-contraception_consent
additional I-contraception_consent
effective I-contraception_consent
( I-contraception_consent
barrier I-contraception_consent
) I-contraception_consent
method I-contraception_consent
, O
at O
the O
same O
time O
, O
prior O
to O
study O
through O
@NUMBER B-upper_bound
days I-upper_bound
( O
or O
longer O
, O
as O
mandated O
by O
local O
labeling O
[ O
eg O
, O
uspi O
, O
smpc O
, O
etc O
; O
] O
) O
after O
the O
last O
dose O
of O
study B-treatment
drug I-treatment

class B-lower_bound
iii I-lower_bound
or O
iv B-upper_bound
heart B-chronic_disease
failure I-chronic_disease

strong O
motivation O
to O
proceed O
with O
transplantation B-treatment

karnofsky B-clinical_variable
status I-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound

oral B-treatment
corticosteroid I-treatment
use O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
the O
screening O
visit O

subjects O
with O
no O
airflow O
obstruction O
by O
spirometry B-treatment
but O
with O
a O
decrease O
in O
diffusing O
capacity O
of O
lung O
for O
carbon O
monoxide O
( O
dlco O
) O
possibly O
indicating O
emphysema B-chronic_disease

age B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound

dementia B-chronic_disease
( O
mini B-clinical_variable
mental I-clinical_variable
state I-clinical_variable
examination I-clinical_variable
[ I-clinical_variable
mmse I-clinical_variable
] I-clinical_variable
scores I-clinical_variable
≤ O
@NUMBER B-upper_bound
) O

patient O
has O
stage O
@NUMBER B-cancer
b I-cancer
or I-cancer
@NUMBER I-cancer
nslc I-cancer
or O
extensive O
stage O
sclc B-cancer
and O
is O
within O
one B-upper_bound
month I-upper_bound
of O
treatment B-treatment
initiation O

current B-pregnancy
pregnancy I-pregnancy

prior B-treatment
immunotherapy I-treatment
with I-treatment
checkpoint I-treatment
blockade I-treatment
( O
i.e O
. O
pd1 B-treatment
inhibitor I-treatment
, O
pdl1 B-treatment
inhibitor I-treatment
or O
ctl4-antagonist B-treatment
or O
similar O
agent O
) O
must O
have O
been O
completed O
more O
than O
@NUMBER B-lower_bound
month I-lower_bound
prior I-lower_bound
to O
the O
t B-treatment
cell I-treatment
infusion I-treatment

cohort O
@NUMBER O
: O
treatment B-treatment
-naïve O
patients O
with O
cmet B-treatment
mutations I-treatment
regardless O
of O
cmet O
gcn O

impairment B-chronic_disease
of I-chronic_disease
gi I-chronic_disease
function I-chronic_disease
or I-chronic_disease
gi I-chronic_disease
disease I-chronic_disease
that O
may O
significantly O
alter O
the O
absorption O
of O
inc280 B-treatment

stage B-lower_bound
iiib I-lower_bound
or O
iv B-upper_bound
nsclc B-cancer
( O
any O
histology O
) O
at O
the O
time O
of O
study O
entry O

initiation O
of O
high O
dose O
vitamin B-treatment
e I-treatment
( O
> O
@NUMBER B-lower_bound
iu I-lower_bound
per O
day O
) O
or O
other O
medications B-treatment
which O
could O
alter O
nash O
histology O
at O
any O
time O
after O
baseline B-treatment
liver I-treatment
biopsy I-treatment
or O
during O
the O
trial O

liver B-treatment
biopsy I-treatment
for O
clinical O
indication O
to O
evaluate O
for O
nash O
within O
@NUMBER B-upper_bound
year I-upper_bound
of O
enrollment O

weight B-clinical_variable
reduction I-clinical_variable
of O
> O
@NUMBER B-lower_bound
% I-lower_bound
between O
baseline O
liver B-treatment
biopsy I-treatment
and O
enrollment O
, O
as O
weight B-clinical_variable
loss I-clinical_variable
> O
@NUMBER O
% O
may O
change O
nash O
severity O

hemoglobin B-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound
; O
white B-clinical_variable
blood I-clinical_variable
cell I-clinical_variable
count I-clinical_variable
< O
@NUMBER B-upper_bound
cells I-upper_bound
/ I-upper_bound
mm3 I-upper_bound
, O
platelet B-clinical_variable
count I-clinical_variable
< O
@NUMBER B-upper_bound
cells I-upper_bound
/ I-upper_bound
mm3 I-upper_bound
of I-upper_bound
blood I-upper_bound
, O
direct B-clinical_variable
bilirubin I-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
, O
total B-clinical_variable
bilirubin I-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
, O
albumin B-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound
, O
international B-clinical_variable
normalized I-clinical_variable
ratio I-clinical_variable
( I-clinical_variable
inr I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound

minimum O
bmi B-bmi
per O
current O
guidelines O
for O
wls B-chronic_disease
in O
adolescents O

any O
serious B-chronic_disease
systemic I-chronic_disease
disease I-chronic_disease
that O
might O
influence O
survival O

metabolic B-chronic_disease
alkalosis I-chronic_disease
( O
serum B-clinical_variable
bicarbonate I-clinical_variable
> O
@NUMBER B-lower_bound
meq I-lower_bound
/ I-lower_bound
l I-lower_bound
) O

symptomatic B-chronic_disease
heart I-chronic_disease
disease I-chronic_disease
determined O
by O
prior B-treatment
electrocardiogram I-treatment
, O
stress O
test O
, O
and O
/ O
or O
history O

has O
a O
diagnosis O
of O
immunodeficiency B-chronic_disease
or O
is O
receiving O
systemic B-treatment
steroid I-treatment
therapy I-treatment
or O
any O
other O
form O
of O
immunosuppressive B-treatment
therapy I-treatment

have O
received O
a O
live B-treatment
vaccine I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
trial B-treatment
treatment I-treatment

intrauterine B-contraception_consent
devices I-contraception_consent
( I-contraception_consent
iuds I-contraception_consent
) I-contraception_consent

is O
her2 O
normal O
, O
defined O
as O
her2 O
@NUMBER O
or O
1 O
+ O
by O
immunohistochemistry B-treatment
( I-treatment
ihc I-treatment
) I-treatment
ihc B-treatment
) O
and O
negative O
by O
fluorescence B-treatment
in I-treatment
situ I-treatment
hybridization I-treatment
( I-treatment
fish I-treatment
) I-treatment
fish B-treatment
) O
if O
performed O
; O
or O
her2 O
is O
2 O
+ O
by O
ihc O
and O
negative O
by O
fish O
; O
or O
her2 B-cancer
negative I-cancer
by O
fish O
if O
ihc O
is O
not O
performed O

american B-clinical_variable
society I-clinical_variable
of I-clinical_variable
anesthesiologists I-clinical_variable
( I-clinical_variable
asa I-clinical_variable
) I-clinical_variable
physical I-clinical_variable
status I-clinical_variable
classification I-clinical_variable
@NUMBER B-lower_bound
or O
@NUMBER B-upper_bound
, O
who O
will O
be O
receiving O
sedation B-treatment
for O
an O
emergency O
department O
procedure O

individuals O
reporting O
current O
enrollment O
in O
a O
substance B-treatment
abuse I-treatment
treatment I-treatment
program I-treatment

mandated O
to O
substance O
abuse O
treatment B-treatment
by O
a O
court O
order O

acute B-chronic_disease
myocardial I-chronic_disease
infarction I-chronic_disease

admitted O
for O
initial O
management O
of O
a O
thermal O
burn O
injury O
( O
flame O
, O
scald O
, O
contact O
) O
with O
> O
@NUMBER B-lower_bound
% I-lower_bound
total B-clinical_variable
body I-clinical_variable
surface I-clinical_variable
area I-clinical_variable

for O
stratum O
@NUMBER O
: O
cd4 B-clinical_variable
+ I-clinical_variable
cell I-clinical_variable
count I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
mm^3 I-lower_bound
obtained O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
enrollment O
at O
any O
united O
states O
( O
u.s O
. O
) O
laboratory O
that O
has O
a O
clinical O
laboratory O
improvement O
amendments O
( O
clia O
) O
certification O
or O
its O
equivalent O

participants O
must O
receive O
appropriate O
care O
and O
treatment B-treatment
for O
hiv B-chronic_disease
hiv B-chronic_disease
infection I-chronic_disease
, O
including O
antiretroviral B-treatment
medications I-treatment
when O
clinically O
indicated O
, O
and O
should O
be O
under O
the O
care O
of O
a O
physician O
experienced O
in O
hiv O
management O

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
for O
subjects O
with O
gilbert B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
or O
with O
atazanavir B-treatment
- O
or O
indinavir B-treatment
-induced O
unconjugated O
hyperbilirubinemia B-chronic_disease
without O
aspartate O
aminotransferase O
( O
ast O
) O
or O
alanine O
aminotransferase O
( O
alt O
) O
elevation O
and O
must O
have O
a O
total B-clinical_variable
bilirubin I-clinical_variable
less O
than O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
( O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
enrollment O
) O

total B-clinical_variable
bilirubin I-clinical_variable
: O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
, O
or O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
for O
participants O
with O
gilbert B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
or O
with O
atazanavir B-treatment
- O
or O
indinavir B-treatment
-induced O
unconjugated B-treatment
hyperbilirubinemia I-treatment
without O
ast B-clinical_variable
or O
alt B-clinical_variable
elevation O
, O
and O
must O
have O
a O
total B-clinical_variable
bilirubin I-clinical_variable
less O
than O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
) O
( O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
enrollment O
) O
( O
participants O
may O
receive O
gcsf O
and O
transfusions O
to O
meet O
these O
parameters O
) O

the O
result O
must O
be O
obtained O
within O
@NUMBER O
weeks O
prior O
to O
enrollment O
; O
ppd B-chronic_disease
positive O
( O
or O
quantiferon O
assay O
positive O
) O
participants O
are O
permitted O
if O
prophylaxis B-treatment
has O
been O
completed O
prior O
to O
enrollment O

any O
combination O
of O
oral B-treatment
antidiabetic I-treatment
agents I-treatment

positive O
pregnancy B-pregnancy
screen O
during O
screening O

measured O
or O
calculated O
creatinine B-clinical_variable
* I-clinical_variable
* I-clinical_variable
clearance I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound

active B-chronic_disease
infection I-chronic_disease
requiring O
systemic B-treatment
therapy I-treatment

at O
least O
one O
site O
of O
disease O
that O
is O
considered O
potentially O
suitable O
for O
treatment B-treatment
with O
sbrt B-treatment

history O
of O
( O
non O
- O
infectious O
) O
pneumonitis B-chronic_disease
that O
required O
steroids B-treatment
, O
current O
pneumonitis O
or O
evidence O
of O
interstitial B-chronic_disease
lung I-chronic_disease
disease I-chronic_disease

gcs B-clinical_variable
of O
@NUMBER O
with O
mid O
- O
position O
and O
non O
- O
reactive O
pupils O
bilaterally O
( O
@NUMBER O
mm O
) O

@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound
old O
with O
a O
bmi B-bmi
of O
@NUMBER B-lower_bound
kg I-lower_bound
/ I-lower_bound
m2 I-lower_bound
or O
greater O
who O
will O
be O
undergoing O
bariatric B-treatment
surgery I-treatment
( O
vsg B-treatment
and O
rygb B-treatment
) O

combined O
p B-treatment
- I-treatment
glycoprotein I-treatment
and O
moderate B-treatment
cyp I-treatment
@NUMBER I-treatment
a4 I-treatment
inhibitor I-treatment

bilateral O
disease O
( O
diagnosed O
cancer B-cancer
in I-cancer
both I-cancer
breasts I-cancer
) O

greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
years I-lower_bound
old O

history O
of O
a O
low O
absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable

there O
are O
cases O
of O
ben O
in O
individuals O
of O
middle B-ethnicity
eastern I-ethnicity
, O
caucasian B-ethnicity
, O
and O
other O
ethnicity O

subject O
has O
a O
history O
of O
hospitalization B-treatment
for O
acute B-chronic_disease
illness I-chronic_disease
in O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

age B-age
> O
@NUMBER B-lower_bound
years I-lower_bound
at O
time O
of O
study O
entry O

concurrent O
administration O
of O
strong B-treatment
inhibitors I-treatment
or I-treatment
moderate I-treatment
inducers I-treatment
of I-treatment
cyp1a2 I-treatment
is O
not O
permitted O
; O
administration O
must O
be O
discontinued O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
prior I-lower_bound
to O
initiating O
study B-treatment
drug I-treatment
administration O

patients O
must O
have O
histologic O
or O
cytologic O
diagnosis O
of O
advanced B-cancer
/ I-cancer
metastatic I-cancer
nsclc I-cancer
. O
for O
those O
with O
mixed O
histology O
, O
there O
must O
be O
a O
predominant O
histology O

patients O
with O
vitiligo B-chronic_disease
, O
grave B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
, O
or O
psoriasis B-chronic_disease
not O
requiring O
systemic B-treatment
treatment I-treatment
( O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
) O

between O
@NUMBER B-lower_bound
and O
@NUMBER B-upper_bound
years I-upper_bound
old O

concurrent O
participation O
in O
psychotherapy B-treatment
or O
et B-cancer
for O
hd B-chronic_disease

hoarding B-chronic_disease
disorder I-chronic_disease
diagnosis O
outlined O
by O
the O
diagnostic O
and O
statistical O
manual O
of O
mental O
disorders O

veterans O
age B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

substance B-chronic_disease
abuse I-chronic_disease
disorder I-chronic_disease
as O
measured O
by O
the O
mini O
- O
international O
neuropsychiatric O
interview O

meet O
current O
criteria O
for O
dependence O
on O
any O
psychoactive B-treatment
substance I-treatment
, O
including O
nicotine B-treatment
and O
caffeine B-treatment

histologically O
- O
confirmed O
metastatic B-cancer
or O
recurrent O
her2 B-cancer
-negative O
( O
via O
ihc B-treatment
or O
fish B-treatment
) O
breast B-cancer
cancer I-cancer
or O
other O
histologically O
- O
confirmed O
metastatic B-cancer
solid I-cancer
tumor I-cancer

it O
is O
required O
that O
the O
subjects O
undergoing O
bronchoscopy B-treatment
are O
not O
on O
any O
anti O
- O
platelets O
( O
such O
as O
aspirin B-treatment
, O
clopidogrel B-treatment
, O
etc O
. O
) O
or O
anticoagulants B-treatment
( O
such O
as O
coumadin B-treatment
, O
heparin B-treatment
, O
xarelto B-treatment
® I-treatment
, O
etc O
. O
) O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
prior I-lower_bound
to O
the O
bronchoscopy O

history O
of O
treatment B-treatment
with I-treatment
any I-treatment
ppi I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
( I-upper_bound
@NUMBER I-upper_bound
hours I-upper_bound
) I-upper_bound
before I-upper_bound
investigational B-treatment
product I-treatment
dosing O
on O
day O
@NUMBER O

steroid B-treatment
inhalers I-treatment
and O
topical B-treatment
steroids I-treatment
may O
be O
used O

women B-gender
who O
exhibit O
serious B-chronic_disease
psychiatric I-chronic_disease
symptoms O
determined O
by O
cno O
trained O
staff O

patients O
must O
meet O
the O
diagnostic O
criteria O
for O
hps B-chronic_disease

lactating O
females B-gender
must O
discontinue O
breast O
feeding O

soluble B-clinical_variable
il-2 I-clinical_variable
receptor I-clinical_variable
( I-clinical_variable
cd25 I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
u I-lower_bound
/ I-lower_bound
ml I-lower_bound

first B-treatment
allogeneic I-treatment
hematopoietic I-treatment
stem I-treatment
cell I-treatment
transplantation I-treatment
( I-treatment
hsct I-treatment
) I-treatment
using O
myeloablative B-treatment
conditioning I-treatment
( I-treatment
mac I-treatment
) I-treatment
, O
non B-treatment
- I-treatment
myeloablative I-treatment
( I-treatment
nma I-treatment
) I-treatment
, O
or O
reduced B-treatment
- I-treatment
intensity I-treatment
conditioning I-treatment
( I-treatment
ric I-treatment
) I-treatment
preparative I-treatment
regimens I-treatment

serum B-clinical_variable
creatinine I-clinical_variable
≤ O
@NUMBER B-upper_bound
× I-upper_bound
uln I-upper_bound
or O
creatinine B-clinical_variable
clearance I-clinical_variable
≥ O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
m2 I-lower_bound
for O
subjects O
with O
creatinine O
levels O
above O
institutional O
normal O

women B-gender
of O
childbearing O
potential O
is O
defined O
as O
a O
sexually O
active O
mature O
woman B-gender
who O
has O
not O
undergone O
a O
hysterectomy B-treatment
or O
who O
has O
had O
menses O
at O
any O
time O
in O
the O
preceding B-upper_bound
@NUMBER I-upper_bound
consecutive I-upper_bound
months I-upper_bound

patient O
is O
not O
now O
, O
and O
never O
has O
received O
adjuvant B-treatment
endocrine I-treatment
therapy I-treatment
or O
patient O
is O
currently O
receiving O
or O
has O
received O
adjuvant O
endocrine O
therapy O
in O
the O
past O

age B-age
≤ O
@NUMBER B-upper_bound
year I-upper_bound

females B-gender
who O
are O
pregnant B-pregnancy
( O
positive O
hcg B-treatment
) O

patients O
who O
have O
any O
severe O
and O
/ O
or O
uncontrolled O
medical O
conditions O
such O
as O
: O
a O
) O
unstable B-chronic_disease
angina I-chronic_disease
pectoris I-chronic_disease
, O
symptomatic O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
myocardial B-chronic_disease
infarction I-chronic_disease
≤ O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
start O
of O
everolimus B-treatment
, O
serious O
uncontrolled O
cardiac B-chronic_disease
arrhythmia I-chronic_disease
, O
or O
any O
other O
clinically O
significant O
cardiac B-chronic_disease
disease I-chronic_disease
; O
b O
) O
symptomatic O
congestive O
heart O
failure O
of O
new B-clinical_variable
york I-clinical_variable
heart I-clinical_variable
association I-clinical_variable
class I-clinical_variable
iii B-lower_bound
or O
iv B-upper_bound
; O
c O
) O
active B-chronic_disease
( O
acute O
or O
chronic O
) O
or O
uncontrolled B-chronic_disease
severe I-chronic_disease
infection I-chronic_disease
( O
not O
responding O
to O
antibiotics B-treatment
) O
, O
liver B-chronic_disease
disease I-chronic_disease
such O
as O
cirrhosis B-chronic_disease
, O
decompensated O
liver O
disease O
, O
and O
active O
and O
chronic O
hepatitis O
( O
i.e O
. O
quantifiable O
hepatitis B-chronic_disease
b I-chronic_disease
virus O
- O
deoxyribonucleic O
acid O
[ O
hbv O
- O
dna O
] O
and O
/ O
or O
positive O
hepatitis O
b O
surface O
antigen O
[ O
hbsag O
] O
, O
quantifiable O
hepatitis B-chronic_disease
c I-chronic_disease
virus I-chronic_disease
-ribonucleic O
acid O
[ O
hcv O
- O
rna O
] O
) O
; O
d O
) O
known O
severely O
impaired B-chronic_disease
lung I-chronic_disease
function I-chronic_disease
( O
spirometry O
and O
diffusing B-clinical_variable
capacity I-clinical_variable
of I-clinical_variable
the I-clinical_variable
lung I-clinical_variable
for I-clinical_variable
carbon I-clinical_variable
monoxide I-clinical_variable
[ I-clinical_variable
dlco I-clinical_variable
] I-clinical_variable
@NUMBER B-upper_bound
% I-upper_bound
or O
less O
of O
normal O
and O
oxygen B-clinical_variable
[ I-clinical_variable
o2 I-clinical_variable
] I-clinical_variable
saturation I-clinical_variable
@NUMBER B-upper_bound
% I-upper_bound
or O
less O
at O
rest O
on O
room O
air O
) O
; O
e O
) O
active O
, O
bleeding B-chronic_disease
diathesis I-chronic_disease

women B-gender
who O
are B-pregnancy
pregnant I-pregnancy
or O
nursing O
( O
lactating O
) O
women B-gender

planning B-pregnancy
on I-pregnancy
becoming I-pregnancy
pregnant I-pregnancy
within O
@NUMBER B-upper_bound
months I-upper_bound

free O
from O
benzodiazepines B-treatment
and O
betablockers B-treatment
within O
@NUMBER B-upper_bound
hours I-upper_bound
of O
evaluations O

high B-clinical_variable
scores I-clinical_variable
on I-clinical_variable
rumination I-clinical_variable
; I-clinical_variable
response I-clinical_variable
style I-clinical_variable
questionnaire I-clinical_variable
( O
rsq B-clinical_variable
≥ O
@NUMBER B-lower_bound
) O

native B-language_fluency
english I-language_fluency
speakers I-language_fluency

negative O
serum O
or O
urine O
beta O
- O
human O
chorionic O
gonadotropin O
( O
hcg O
) O
pregnancy B-pregnancy
test O
at O
screening O
for O
female B-gender
patients I-gender
of O
childbearing O
potential O

patients O
taking O
sorivudine B-treatment
or O
brivudine B-treatment
must O
be O
off O
of O
these O
drugs O
for O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
starting O
capecitabine B-treatment

creatinine B-clinical_variable
clearance I-clinical_variable
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
( O
estimated O
as O
calculated O
with O
cockcroft O
- O
gault O
equation O
) O

if O
patient O
is O
currently O
receiving O
allopurinol B-treatment
, O
must O
discuss O
with O
principal O
investigator O
( O
pi O
) O
to O
see O
of O
another O
agent O
may O
substitute O
for O
it O

malabsorption B-chronic_disease
syndrome I-chronic_disease

patients O
can O
have O
tumor B-cancer
which O
is O
locally O
advanced O
or O
borderline O
resectable O

a O
history O
of O
, O
or O
current O
conditions O
affecting O
the O
digestive O
tract O
, O
such O
as O
ulcerative B-chronic_disease
colitis I-chronic_disease
, O
indeterminate B-chronic_disease
colitis I-chronic_disease
, O
fistulizing B-chronic_disease
disease I-chronic_disease
, O
abdominal B-chronic_disease
or I-chronic_disease
perianal I-chronic_disease
abscess I-chronic_disease
, O
adenomatous B-chronic_disease
colonic I-chronic_disease
polyps I-chronic_disease
not O
excised O
, O
colonic B-chronic_disease
mucosal I-chronic_disease
dysplasia I-chronic_disease
, O
and O
short B-chronic_disease
bowel I-chronic_disease
syndrome I-chronic_disease

oral B-clinical_variable
antibiotics I-clinical_variable
≤ O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
screening O

af B-clinical_variable
> O
@NUMBER B-lower_bound
years I-lower_bound

cad B-chronic_disease
requiring O
intervention O
( O
either O
surgical O
, O
i.e O
. O
cabg B-treatment
, O
or O
catheter B-treatment
) O

documented O
history O
of O
previous B-treatment
catheter I-treatment
ablation I-treatment
with I-treatment
perforation I-treatment
, O
history O
of O
pericarditis B-chronic_disease
, O
pericardial B-chronic_disease
effusion I-chronic_disease
, O
or O
tamponade B-chronic_disease

ep B-treatment
catheter I-treatment
ablation I-treatment
procedure O
to O
treat O
atrial B-chronic_disease
fibrillation I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound

structural B-chronic_disease
heart I-chronic_disease
disease I-chronic_disease
requiring O
surgical B-treatment
treatment I-treatment

valve B-chronic_disease
disease I-chronic_disease
requiring O
repair O
or O
replacement O
within O
@NUMBER B-upper_bound
months I-upper_bound
following O
surgical B-treatment
ablation I-treatment
procedure I-treatment

< O
@NUMBER B-upper_bound
% I-upper_bound
by O
multi B-clinical_variable
gated I-clinical_variable
acquisition I-clinical_variable
scan I-clinical_variable
( I-clinical_variable
muga I-clinical_variable
) I-clinical_variable

histologically O
proven O
tnbc B-cancer

no O
limit O
to O
prior B-treatment
therapy I-treatment
for O
metastatic B-cancer
breast I-cancer
cancer I-cancer

subject O
has O
known O
history O
of O
testing O
positive O
for O
hiv B-chronic_disease
or O
aids B-chronic_disease

subject O
has O
received O
any O
anti B-treatment
- I-treatment
cancer I-treatment
therapy I-treatment
including O
chemotherapy B-treatment
, O
immunotherapy B-treatment
, O
biologic B-treatment
, O
targeted B-treatment
therapy I-treatment
, O
or O
any O
investigational B-treatment
therapy I-treatment

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
iuln I-upper_bound
with O
direct B-clinical_variable
bilirubin I-clinical_variable
within O
normal O
range O
in O
subjects O
with O
gilbert B-chronic_disease
's I-chronic_disease
syndrome I-chronic_disease

≥ O
@NUMBER B-lower_bound
cm I-lower_bound
on O
spiral B-treatment
ct I-treatment

current O
treatment B-treatment
or O
recent O
cessation O
( O
< O
@NUMBER B-upper_bound
mo I-upper_bound
) O
of O
hormone B-treatment
replacement I-treatment
therapy I-treatment

regular O
vigorous O
aerobic O
/ O
endurance O
exercise O
( O
> O
@NUMBER B-lower_bound
vigorous I-lower_bound
bouts I-lower_bound
/ I-lower_bound
week I-lower_bound
) O

a O
serum B-clinical_variable
thyroglobulin I-clinical_variable
of O
@NUMBER B-lower_bound
ng I-lower_bound
/ I-lower_bound
ml I-lower_bound
or O
greater O
in O
the O
context O
of O
suppressed O
thyroid O
- O
stimulating O
hormone O
( O
tsh B-clinical_variable
) O
( O
tsh O
≤ O
@NUMBER B-upper_bound
mcu I-upper_bound
/ I-upper_bound
ml I-upper_bound
) O
≤ O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
study O
registration O
; O
use O
of O
any O
thyroglobulin B-treatment
assay I-treatment
is O
allowed O
, O
though O
all O
serum O
thyroglobulin O
measurements O
for O
study O
purposes O
must O
be O
conducted O
with O
the O
same O
thyroglobulin O
assay O

diagnosis O
of O
recurrent B-cancer
and O
/ O
or O
metastatic B-cancer
thyroid I-cancer
cancer I-cancer

non B-cancer
- I-cancer
melanotic I-cancer
skin I-cancer
cancer I-cancer
cancer B-cancer
or O
carcinoma B-cancer
- I-cancer
in I-cancer
- I-cancer
situ I-cancer
of I-cancer
the I-cancer
cervix I-cancer
; O
note O
: O
if O
there O
is O
a O
history O
of O
prior O
malignancy B-cancer
, O
patients O
must O
not O
be O
receiving O
other O
specific B-treatment
treatment I-treatment
( O
chemotherapy B-treatment
, O
hormonal B-treatment
therapy I-treatment
, O
radiation B-treatment
) O
for O
their O
cancer O

burkitt B-cancer
lymphoma I-cancer

history O
of O
grade O
@NUMBER O
anaphylactic O
reactions O
to O
humanized B-allergy_name
or O
murine B-allergy_name
monoclonal I-allergy_name
antibodies I-allergy_name

patients O
may O
have O
received O
prior B-treatment
steroid I-treatment
treatment I-treatment
, O
but O
not O
started O
greater O
than O
@NUMBER B-lower_bound
days I-lower_bound
prior I-lower_bound
prior B-treatment
to I-treatment
initiation I-treatment
of I-treatment
protocol I-treatment
therapy I-treatment

primary B-cancer
mediastinal I-cancer
b I-cancer
- I-cancer
cell I-cancer
lymphoma I-cancer
( I-cancer
pmbl I-cancer
) I-cancer

radiation B-treatment
therapy I-treatment
( I-treatment
xrt I-treatment
) I-treatment

bmi B-bmi
= O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
and O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
kg I-upper_bound
/ I-upper_bound
m² I-upper_bound

for O
arm O
e O
, O
in O
addition O
to O
patients O
with O
relapsed B-cancer
or I-cancer
refractory I-cancer
acute I-cancer
leukemias I-cancer
acute B-cancer
leukemias I-cancer
or O
high B-cancer
- I-cancer
risk I-cancer
mds I-cancer
, O
patients O
with O
untreated O
high O
- O
risk O
mds O
or O
acute O
leukemias O

sexually O
active O
men B-gender
must O
also O
use B-contraception_consent
acceptable I-contraception_consent
contraceptive I-contraception_consent
methods O
for O
the O
duration O
of O
time O
on O
study O
and O
for O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
after I-lower_bound
the O
last O
dose O
of O
study B-treatment
drug I-treatment

aids B-chronic_disease
or O
aids O
- O
defining O
illness O

adult O
patients O
> O
@NUMBER B-lower_bound
years I-lower_bound
old O

overall O
life B-clinical_variable
expectancy I-clinical_variable
< O
@NUMBER B-upper_bound
year I-upper_bound

phase O
i O
: O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
and O
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

there O
are O
no O
limits O
on O
number O
of O
prior B-treatment
therapeutic I-treatment
regimens I-treatment

the O
patient O
is O
to O
undergo O
treatment B-treatment
with O
electrocautery B-treatment
in O
the O
operating O
room O
under O
endoscopic O
visualization O

agree B-contraception_consent
to I-contraception_consent
practice I-contraception_consent
effective I-contraception_consent
barrier I-contraception_consent
contraception I-contraception_consent
during O
the O
entire O
study B-treatment
treatment I-treatment
period O
and O
through B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
after O
the O
last O
dose O
of O
study B-treatment
drug I-treatment

evidence O
of O
current O
uncontrolled O
cardiovascular B-treatment
conditions I-treatment
, O
including O
uncontrolled O
cardiac B-treatment
conditions I-treatment
such O
as O
hypertension B-treatment
, O
or O
cardiac B-chronic_disease
arrhythmias I-chronic_disease
, O
or O
new B-clinical_variable
york I-clinical_variable
heart I-clinical_variable
association I-clinical_variable
stage I-clinical_variable
iii B-lower_bound
and O
iv B-upper_bound
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
or O
unstable B-chronic_disease
angina I-chronic_disease
or O
myocardial B-chronic_disease
infarction I-chronic_disease
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

history O
of O
allergy O
to O
mannitol B-allergy_name

participation O
in O
other B-treatment
clinical I-treatment
trials I-treatment
, O
including O
those O
with O
other O
investigational B-treatment
agents I-treatment
not O
included O
in O
this O
trial O
, O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
the O
start O
of O
this O
trial O
and O
throughout O
the O
duration O
of O
this O
trial O

patients O
who O
completed O
induction B-treatment
treatment I-treatment
followed O
by O
autologous B-treatment
stem I-treatment
cell I-treatment
transplant I-treatment
as O
initial B-treatment
therapy I-treatment
for O
symptomatic O
myeloma B-cancer
as O
per O
imwg O
criteria O
and O
initiated O
revlimid B-treatment
( O
lenalidomide B-treatment
) O
maintenance O

dsm O
- O
iv O
criteria O
for O
major B-chronic_disease
depressive I-chronic_disease
disorder I-chronic_disease

renal B-chronic_disease
insufficiency I-chronic_disease

category O
i B-treatment
drugs I-treatment
that O
are O
generally O
accepted O
to O
have O
a O
risk O
of O
causing O
torsades O
de O
pointes O
including O
: O
( O
patients O
must O
discontinue O
drug O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
prior I-lower_bound
to O
starting O
dasatinib B-treatment
) O

must O
not O
have O
received O
bevacizumab B-treatment
or O
other O
monoclonal B-treatment
antibody I-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
study O
the O
entry O

stem B-treatment
cell I-treatment
transplant I-treatment
( I-treatment
sct I-treatment
) I-treatment
: O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
following O
autologous B-treatment
sct I-treatment
and O
@NUMBER B-upper_bound
weeks I-upper_bound
for O
allogeneic B-treatment
sct I-treatment

patients O
must O
not O
be O
receiving O
any O
anti B-treatment
- I-treatment
thrombotic I-treatment
or O
anti B-treatment
- I-treatment
platelet I-treatment
agents I-treatment
; O
patient O
can O
not O
be O
on O
drugs O
that O
cause O
significant O
prolonged B-chronic_disease
qt I-chronic_disease
( O
category O
i O
drug O
) O

lower B-treatment
extremity I-treatment
vascular I-treatment
surgery I-treatment

no O
more O
than O
@NUMBER B-lower_bound
discontiguous O
vertebral B-clinical_variable
body I-clinical_variable
levels I-clinical_variable
treated O

any O
serious O
/ O
and O
or O
unstable O
pre O
- O
existing O
medical B-chronic_disease
disorder I-chronic_disease
( O
aside O
from O
malignancy B-cancer
exception O
above O
) O
, O
psychiatric B-chronic_disease
disorder I-chronic_disease
, O
or O
other O
conditions O
that O
could O
interfere O
with O
subject O
's O
safety O
, O
obtaining O
informed O
consent O
or O
compliance O
to O
the O
study O
procedures O

male B-gender
patients I-gender
with O
female B-gender
partners I-gender
who O
are O
of O
childbearing O
potential O

patients O
must O
be O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

adrenal B-treatment
replacement I-treatment
steroid I-treatment
doses I-treatment
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
daily O
prednisone B-treatment
equivalent O
are O
permitted O
in O
the O
absence O
of O
active O
autoimmune B-chronic_disease
disease I-chronic_disease

no O
active B-chronic_disease
systemic I-chronic_disease
infection I-chronic_disease
requiring O
parenteral B-treatment
antibiotic I-treatment
therapy I-treatment

at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
since O
the O
last B-treatment
systemic I-treatment
therapy I-treatment
or O
radiotherapy B-treatment
regimen I-treatment
prior O
to O
enrolment O

prior O
treatment B-treatment
with O
an O
ftase B-treatment
inhibitor I-treatment

has O
relapsed O
or O
is O
refractory O
to O
prior B-treatment
therapy I-treatment

creatinine B-clinical_variable
up O
to O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

speaks B-language_fluency
either I-language_fluency
english I-language_fluency
or I-language_fluency
spanish I-language_fluency
, O
living O
in O
or O
near O
newark O
with O
no O
plans O
to O
move O
in O
the O
next O
year O
, O
able O
to O
sign O
consent O
and O
complete O
questionnaires O
with O
aid O
of O
trained O
personnel O

use O
of O
an O
investigational B-treatment
drug I-treatment
in O
the O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
screening O
and O
must O
agree O
to O
not O
participate O
in O
any O
drug O
or O
device O
study O
while O
enrolled O
in O
this O
study O

duration O
of O
sever O
to O
profound O
hearing B-chronic_disease
loss I-chronic_disease
of O
@NUMBER B-lower_bound
years I-lower_bound
or O
greater O

prior O
hcc B-cancer

meet O
criteria O
for O
current O
or O
lifetime O
mdd B-chronic_disease
without O
psychotic O
features O

previous O
allergic O
reaction O
to O
varenicline B-allergy_name

systolic B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
> O
@NUMBER B-lower_bound
mmhg I-lower_bound
or O
diastolic B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
> O
@NUMBER B-lower_bound
mmhg I-lower_bound
after O
two O
readings O
or O
symptomatic B-chronic_disease
uncontrolled I-chronic_disease
stage I-chronic_disease
ii I-chronic_disease
hypertension I-chronic_disease

patients O
with O
curative B-treatment
treatment I-treatment
options O

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
old I-upper_bound

consent O
to O
be O
randomized O
to O
active O
or O
sham B-treatment
tns I-treatment
treatment I-treatment

evidence O
of O
receiving O
psychosocial B-treatment
or I-treatment
medication I-treatment
treatment I-treatment
through O
a O
clinic O
or O
facility O
other O
than O
the O
va O
gla O
ptsd O
clinic O

report O
of O
severe O
tbi B-chronic_disease
with O
coma B-clinical_variable
duration I-clinical_variable
( O
@NUMBER B-lower_bound
minutes I-lower_bound
or O
more O
) O
during O
the O
screening O
interview O
and O
/ O
or O
duration O
of O
post O

more O
than O
@NUMBER B-lower_bound
-level O
acdf B-treatment
surgeries I-treatment

acetabular B-treatment
repair I-treatment
with O
instrumentation O

complicating O
medical O
conditions O
that O
may O
influence O
the O
outcome O
of O
neuropsychological O
assessment O
or O
functional O
imaging O
( O
e.g. O
, O
hiv B-chronic_disease
, O
brain B-cancer
tumor I-cancer
, O
etc O
. O
) O

the O
primary O
language O
of O
the O
subjects O
must O
be O
english B-language_fluency

are O
more O
than O
@NUMBER B-lower_bound
months I-lower_bound
from O
transplant B-treatment
( O
@NUMBER B-upper_bound
months I-upper_bound
at O
infusion B-treatment
) O

no O
non B-treatment
- I-treatment
biologic I-treatment
dmard I-treatment
s O
in O
preceding O
two B-upper_bound
month I-upper_bound
s O
( O
other O
than O
mtx B-treatment
and O
hcq B-treatment
) O

macular B-chronic_disease
disease I-chronic_disease

ra B-chronic_disease

tumors B-cancer

paediatric O
patients O
aged B-age
@NUMBER B-lower_bound
year I-lower_bound
to O
< O
@NUMBER B-upper_bound
years I-upper_bound
at O
the O
time O
of O
informed O
consent O

psychotic B-chronic_disease
or O
bipolar B-chronic_disease
spectrum I-chronic_disease
disorder I-chronic_disease
( O
as O
assessed O
at O
screening O
) O

anc B-clinical_variable
> O
@NUMBER B-lower_bound

having O
experienced O
a O
traumatic O
event O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound

known O
diffuse O
alveolar B-chronic_disease
hemorrhage I-chronic_disease
from I-chronic_disease
vasculitis I-chronic_disease

known O
significant O
valvular B-chronic_disease
heart I-chronic_disease
disease I-chronic_disease

research O
- O
protected O
populations O
( O
pregnant B-pregnancy
women B-gender
, O
prisoners O
, O
intellectually O
disabled O
) O

open B-treatment
biopsy I-treatment
is O
considered O
a O
major B-treatment
surgery I-treatment

ast B-clinical_variable
( O
sgot B-clinical_variable
) O
/ O
alt B-clinical_variable
( O
sgpt B-clinical_variable
) O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
, O
alkaline B-clinical_variable
phosphatase I-clinical_variable
≤ O
@NUMBER O
x O
uln O
, O
unless O
bone B-cancer
metastasis I-cancer
is O
present O
in O
the O
absence O
of O
liver B-cancer
metastasis I-cancer

currently O
receiving O
any O
other O
investigational B-treatment
agents I-treatment

ability O
to O
be O
followed O
in O
bhp O
clinic O
for O
art O
for O
up O
to O
@NUMBER B-upper_bound
weeks I-upper_bound
after I-upper_bound
enrollment O

birth B-clinical_variable
weight I-clinical_variable
≥ O
@NUMBER B-lower_bound
grams I-lower_bound

at O
least O
one B-lower_bound
site O
of O
measurable O
disease O
in O
subjects O
with O
solid B-cancer
tumors I-cancer
and O
nhl B-cancer

high B-cancer
grade I-cancer
lymphomas I-cancer
( O
burkitts B-cancer
or O
lymphoblastic B-cancer
) O
, O
plasma B-cancer
cell I-cancer
leukemia I-cancer

histologically O
confirmed O
diagnosis O
of O
indolent B-cancer
non I-cancer
- I-cancer
hodgkin I-cancer
's I-cancer
lymphoma I-cancer
( I-cancer
inhl I-cancer
) I-cancer
in O
cd20 B-cancer
positive O
patients O
, O
with O
histological O
subtype O
limited O
to O

prior B-treatment
treatment I-treatment
with O
copanlisib B-treatment

known O
history O
of O
venous B-chronic_disease
( I-chronic_disease
thromboembolism I-chronic_disease
) I-chronic_disease
vte I-chronic_disease
prior O
to O
diagnosis O
( O
dvt B-chronic_disease
or O
pulmonary B-chronic_disease
embolism I-chronic_disease
( I-chronic_disease
pe I-chronic_disease
) I-chronic_disease
) O
due O
to O
increased O
underlying O
risk O
of O
new O
event O

protein B-chronic_disease
c I-chronic_disease
deficiency I-chronic_disease
( O
increased O
risk O
of O
skin B-chronic_disease
necrosis I-chronic_disease
do O
those O
on O
injectable B-treatment
anticoagulation I-treatment
) O

endometrial B-cancer
/ O
uterine B-cancer

mass O
that O
is O
non O
- O
gynecologic O
in O
origin O
( O
mass O
/ O
tumor B-cancer
of O
origin O
other O
than O
reproductive O
organ O
such O
as O
rectal O
, O
abdominal O
, O
breast O
) O

recent O
stroke B-chronic_disease

thrombocytopenia B-chronic_disease

creatinine B-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound

eligible O
for O
surgery B-treatment
with I-treatment
curative I-treatment
intent I-treatment

have O
mri B-treatment
or O
tms B-treatment
contraindications O
such O
as O
pre O
- O
injury O
claustrophobia B-chronic_disease
, O
metal O
in O
eyes O
/ O
face O
or O
brain O

receiving O
central B-treatment
nervous I-treatment
system I-treatment
( I-treatment
cns I-treatment
) I-treatment
stimulants I-treatment
that O
can O
not O
be O
safely O
discontinued O
via O
titration B-treatment

healthy O
adults O
between O
@NUMBER B-lower_bound
and O
@NUMBER B-upper_bound
years I-upper_bound
old O

has O
a O
known O
additional O
malignancy B-cancer
that O
is O
progressing O
or O
required O
treatment B-treatment
≤ O
@NUMBER B-upper_bound
months I-upper_bound
of O
study O
registration O

minimum O
guidance O
on O
surgical O
intent O
includes O
subjects O
who O
do O
not O
have O
significant O
cardiovascular B-chronic_disease
disease I-chronic_disease
such O
as O
nhya O
class B-chronic_disease
iii I-chronic_disease
or I-chronic_disease
iv I-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
unstable B-chronic_disease
arrhythmias I-chronic_disease
or O
angina B-chronic_disease
, O
active B-chronic_disease
cad I-chronic_disease
, O
and O
/ O
or O
ef B-clinical_variable
< O
@NUMBER B-upper_bound
% I-upper_bound

subject O
has O
an O
intramural B-chronic_disease
hematoma I-chronic_disease
of O
the O
descending O
thoracic O
aorta O

subject O
has O
had O
a O
myocardial B-chronic_disease
infarction I-chronic_disease
( I-chronic_disease
mi I-chronic_disease
) I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound

subject O
has O
had O
previous B-treatment
endovascular I-treatment
repair I-treatment
of O
the O
ascending O
and O
/ O
or O
descending O
thoracic O
aorta O
< O
@NUMBER B-upper_bound
days I-upper_bound
of O
implantation B-treatment
of O
investigational O
device O
or O
previous O
repair O
was O
a O
non O
- O
medtronic O
device O

plasma B-clinical_variable
aldosterone I-clinical_variable
≥ O
@NUMBER B-lower_bound
ng I-lower_bound
/ I-lower_bound
dl I-lower_bound

type B-chronic_disease
ii I-chronic_disease
diabetes I-chronic_disease
, O
as O
defined O
by O
ada O
criteria O

subject O
has O
a O
diagnosis O
of O
schizophrenia B-chronic_disease
as O
determined O
by O
a O
review O
of O
medical O
records O
, O
discussion O
with O
referring O
psychiatrist O
as O
well O
as O
the O
structured O
clinical O
interview O
for O
dsm O
- O
iv O
( O
scid O
- O
iv O
) O

unstable O
psycho B-chronic_disease
- I-chronic_disease
social I-chronic_disease
condition I-chronic_disease
including O
housing O
and O
poor O
support O

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
( I-clinical_variable
anc I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound

at O
least O
one B-lower_bound
measurable O
target O
lesion O
, O
as O
defined O
by O
recist O
v1.1 O

bilateral O
tubal B-treatment
occlusion I-treatment

patients O
must O
have O
an O
eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
of O
@NUMBER B-lower_bound
or O
@NUMBER B-upper_bound
and O
an O
estimated O
life B-clinical_variable
expectancy I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
months I-lower_bound

patients O
who O
are O
on O
chronic B-treatment
systemic I-treatment
steroid I-treatment
therapy I-treatment
for O
any O
reason O

patients O
with O
gilbert B-chronic_disease
's I-chronic_disease
syndrome I-chronic_disease
must O
have O
a O
total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

dermatological O
skin B-chronic_disease
disease I-chronic_disease
of O
the O
scalp O

history O
of O
hydrocephalus B-chronic_disease

non B-chronic_disease
- I-chronic_disease
alzheimer I-chronic_disease
dementia I-chronic_disease

diagnosed O
with O
a O
neuromuscular B-chronic_disease
disease I-chronic_disease

other O
treatments B-treatment
known O
to O
affect O
the O
growth O
of O
the O
neural O
and O
vascular O
system O

subjects O
must O
be O
enrolled O
before O
starting O
chemoradiation B-treatment
, O
either O
pre B-treatment
-or I-treatment
post I-treatment
- I-treatment
surgery I-treatment

who O
suspect O
they O
might O
be O
pregnant B-pregnancy

surgical B-treatment
procedure I-treatment
: O
tonsillectomy B-treatment
with I-treatment
monopolar I-treatment
cautery I-treatment
, O
hemostasis B-treatment
with I-treatment
monopolar I-treatment
cautery I-treatment
and I-treatment
/ I-treatment
or I-treatment
suction I-treatment
cautery I-treatment

hla B-clinical_variable
- I-clinical_variable
a2 I-clinical_variable
positive O
based O
on O
flow O
cytometry O

patients O
may O
have O
tumor B-cancer
spread I-cancer
within I-cancer
the I-cancer
cns I-cancer

patients O
who O
have O
received O
prior B-treatment
immunotherapy I-treatment

has O
> O
stage B-chronic_disease
ii I-chronic_disease
pelvic I-chronic_disease
organ I-chronic_disease
prolapse I-chronic_disease

presence O
of O
a O
life O
- O
threatening O
disease O
such O
as O
cancer B-cancer

patients O
with O
an O
active O
foot B-chronic_disease
ulcer I-chronic_disease

prior B-treatment
foot I-treatment
amputation I-treatment

has O
an O
ecog B-clinical_variable
ps I-clinical_variable
of O
@NUMBER B-lower_bound
, O
@NUMBER O
, O
or O
@NUMBER B-upper_bound

willingness O
to O
donate O
blood O
for O
biomarker O
studies O
related O
to O
the O
type O
of O
therapies O
used O
in O
this O
trial O
and O
the O
tumor B-cancer
types O
being O
treated O

use O
of O
other O
psychotropic O
medications O
( O
e.g. O
, O
ssris B-treatment
) O
will O
be O
allowed O
provided O
the O
dose O
has O
been O
stable O
for O
> O
@NUMBER B-lower_bound
weeks I-lower_bound

women B-gender
of O
childbearing O
a O
pregnancy B-pregnancy
test O
( O
to O
be O
ruled O
out O
by O
urine B-clinical_variable
β I-clinical_variable
- I-clinical_variable
hcg I-clinical_variable
) O
will O
be O
conducted O
prior O
to O
study O

taking O
medications B-treatment
( O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
baseline O
visit O
) O
that O
have O
the O
potential O
to O
prolong O
the O
qt B-clinical_variable
interval I-clinical_variable
, O
as O
judged O
by O
a O
study O
physician O
, O
or O
may O
require O
such O
medications O
during O
the O
course O
of O
the O
study O

willingness O
to O
participate O
in O
behavioral O
and O
medicinal O
treatments B-treatment
for O
alcohol O
use O
disorder O

current O
history O
of O
arrhythmias B-chronic_disease

current O
or O
past O
history O
of O
clinically O
significant O
qt O
prolongation O
, O
including O
: O
qtcf B-clinical_variable
> O
@NUMBER B-lower_bound
ms I-lower_bound
( O
average O
of O
@NUMBER B-lower_bound
12-lead B-clinical_variable
measurements I-clinical_variable
) O

clinically O
eligible O
for O
rectal B-treatment
spacer I-treatment
insertion I-treatment
( O
e.g O
. O
duraseal B-treatment
, O
spaceoar B-treatment
, O
or O
equivalent O
product O
) O
per O
physician O
evaluation O

no O
known O
allergies O
to O
spacer B-allergy_name
material I-allergy_name
: O
polyethylene B-allergy_name
glycol I-allergy_name
( I-allergy_name
peg I-allergy_name
) I-allergy_name
hydrogel I-allergy_name

positive B-cancer
lymph I-cancer
nodes I-cancer
or O
metastatic B-cancer
disease I-cancer
from O
prostate B-cancer
cancer I-cancer
by O
imaging O
studies O
( O
ct B-treatment
or O
mri B-treatment
) O
, O
unless O
biopsy B-treatment
proven O
to O
be O
negative O

cytogenetic B-chronic_disease
clonal I-chronic_disease
evolution I-chronic_disease

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
@NUMBER B-lower_bound
@NUMBER O
, O
or O
@NUMBER B-upper_bound

history O
of O
another O
active O
malignancy B-cancer
within O
@NUMBER B-upper_bound
years I-upper_bound
prior I-upper_bound
to O
study O
entry O

subject O
has O
received O
ucc B-clinical_variable
care I-clinical_variable
for O
≥ O
@NUMBER B-lower_bound
weeks I-lower_bound
at O
treating O
wound O
clinic O

patient O
may O
not O
be O
concurrently O
enrolled O
in O
another O
investigational B-treatment
drug I-treatment
treatment I-treatment
study O

patients O
may B-pregnancy
not I-pregnancy
be I-pregnancy
pregnant I-pregnancy
or O
breast O
feeding O

patients O
must O
with O
eligible O
for O
surgical B-treatment
resection I-treatment
of O
their O
breast B-cancer
cancer I-cancer
or O
repeat O
biopsy B-treatment
after O
completing O
@NUMBER B-upper_bound
days I-upper_bound
of O
treatment O

hypersensitivity O
to O
any O
botulinum B-allergy_name
toxin I-allergy_name
preparation O
or O
to O
any O
of O
the O
components O
in O
the O
formulation O

patients O
with O
episodic B-chronic_disease
migraines I-chronic_disease

history O
of O
allergy O
to O
study B-allergy_name
drug I-allergy_name
components O
or O
history O
of O
severe O
hypersensitivity O
reaction O
of O
any O
monoclonal B-allergy_name
antibody I-allergy_name

platelet B-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
ul I-lower_bound

previously O
treated O
with O
no O
more O
than O
two B-lower_bound
lines O
of O
prior B-treatment
systemic I-treatment
therapy I-treatment
for O
advanced O
stage O
lung B-cancer
cancer I-cancer

recurrent B-cancer
or I-cancer
primary I-cancer
gastrointestinal I-cancer
cancer I-cancer
, O
with O
regional O
spread O
confined O
to O
the O
peritoneal O
cavity O

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
more O
than O
or O
equal O
to O
@NUMBER B-lower_bound
and O
platelet B-clinical_variable
count I-clinical_variable
more O
than O
or O
equal O
to O
@NUMBER B-lower_bound
renal O
function O
: O
creatinine B-clinical_variable
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
hepatic O
function O
: O
bilirubin B-clinical_variable
less O
than O
or O
equal O
1.5times B-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
, O
sgot B-clinical_variable
and O
alkaline B-clinical_variable
phosphatase I-clinical_variable
less O
than O
or O
equal O
@NUMBER B-upper_bound
times I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
range O
patients O
must O
have O
signed O
an O
informed O
consent O

arterial B-chronic_disease
thrombotic I-chronic_disease

international B-clinical_variable
normalized I-clinical_variable
ratio I-clinical_variable
( I-clinical_variable
inr I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound

known O
or O
presumed O
intolerance O
of O
gemcitabine B-treatment
, O
vorinostat B-treatment
or O
sorafenib B-treatment

platelets B-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm^3 I-lower_bound
( O
may O
not O
be O
transfused O
to O
meet O
this O
level O
for O
enrollment O
) O

qt B-clinical_variable
( I-clinical_variable
c I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
ms I-lower_bound
( O
≥ O
grade B-lower_bound
@NUMBER I-lower_bound
) O
on O
electrocardiogram B-treatment
( I-treatment
ecg I-treatment
) I-treatment
prior O
to O
initiation O
of O
treatment B-treatment

alcohol B-clinical_variable
consumption I-clinical_variable
> O
@NUMBER B-lower_bound
oz I-lower_bound
. I-lower_bound
liquor I-lower_bound
, I-lower_bound
@NUMBER I-lower_bound
x I-lower_bound
@NUMBER I-lower_bound
oz I-lower_bound
. I-lower_bound
glasses I-lower_bound
of I-lower_bound
wine I-lower_bound
, I-lower_bound
or I-lower_bound
@NUMBER I-lower_bound
x I-lower_bound
@NUMBER I-lower_bound
oz I-lower_bound
beers I-lower_bound
/ I-lower_bound
day I-lower_bound
, O
by O
self O
report O

have O
a O
significant O
igg B-chronic_disease
deficiency I-chronic_disease
( O
igg B-clinical_variable
level I-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
) O
have O
an O
iga B-chronic_disease
deficiency I-chronic_disease
( O
iga B-clinical_variable
level I-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
) O

have O
a O
stable O
immunosuppressive B-treatment
therapy I-treatment
( O
is O
) O
( O
azathioprine B-treatment
, O
mycophenolate B-treatment
mofetil B-treatment
, O
tacrolimus B-treatment
, O
cyclosporine B-treatment
for O
> O
@NUMBER B-lower_bound
months I-lower_bound
prior I-lower_bound
to O
screening O

have O
received O
a O
biologic B-treatment
investigational I-treatment
agent I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
screening O

have O
received O
treatment B-treatment
with I-treatment
belimumab I-treatment
at O
any O
time O
prior O
to O
screening O

initiated O
ivig B-clinical_variable
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
screening O

presence O
of O
positive O
autoantibody B-clinical_variable
( O
ana B-clinical_variable
> O
1:80 B-lower_bound
or O
rnp B-clinical_variable
or O
ssa B-clinical_variable
/ O
ssb B-clinical_variable
or O
any O
of O
the O
myositis B-chronic_disease
specific O
autoantibody O
: O
antisynthetase B-clinical_variable
autoantibodies I-clinical_variable
( O
anti B-clinical_variable
- I-clinical_variable
jo-1 I-clinical_variable
, O
pl-7 B-clinical_variable
, O
pl-12 B-clinical_variable
, O
ej B-clinical_variable
, O
oj B-clinical_variable
, O
ks B-clinical_variable
) O
, O
anti B-clinical_variable
- I-clinical_variable
srp I-clinical_variable
, O
anti B-clinical_variable
- I-clinical_variable
mi-2 I-clinical_variable
, O
anti B-clinical_variable
- I-clinical_variable
p140 I-clinical_variable
) O

overweight O
/ O
obese B-chronic_disease
adults O

certified O
or O
master O
's O
level O
social O
worker O
, O
a O
nurse O
with O
an O
rn O
and O
at O
least O
two B-lower_bound
years I-lower_bound
' O
experience O
working O
with O
older O
adults O
and O
their O
family O
members O
evaluated O
on O
an O
individual O
basis O
by O
the O
pis O
) O

caregivers O
who O
participate O
must O
be O
spouses O
or O
partners O
of O
people O
with O
dementia B-chronic_disease
living O
with O
them O
at O
home O
when O
they O
enter O
the O
study O

not B-language_fluency
fluent I-language_fluency
in I-language_fluency
spoken I-language_fluency
and I-language_fluency
written I-language_fluency
english I-language_fluency

not O
having O
a O
family O
member O
with O
whom O
they O
are O
in O
communication O
about O
the O
person O
with O
dementia B-chronic_disease

history O
of O
severe B-chronic_disease
av I-chronic_disease
node I-chronic_disease
dysfunction I-chronic_disease
unless O
an O
electronic O
pacemaker O
is O
present O

adult O
patient O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
old O
presenting O
to O
the O
emergency O
department O
with O
complaint O
of O
distal O
radius O
fracture O

high B-chronic_disease
acuity I-chronic_disease
/ I-chronic_disease
distress I-chronic_disease
per O
the O
attending O
ed O
physician O

hemoglobin B-clinical_variable
( I-clinical_variable
hgb I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound
( O
please O
note O
: O
it O
is O
acceptable O
from O
the O
standpoint O
of O
study O
eligibility O
to O
undergo O
transfusion O
in O
order O
to O
achieve O
hemoglobin B-clinical_variable
≥ O
@NUMBER O
g O
/ O
dl O
) O

platelet B-clinical_variable
( I-clinical_variable
plt I-clinical_variable
) I-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound

regular O
use O
of O
analgesic B-treatment
medication I-treatment
for O
cancer B-cancer
- I-cancer
related I-cancer
bone I-cancer
pain I-cancer
cancer B-cancer
-related O
bone O
pain O
( O
≥ O
level B-lower_bound
@NUMBER I-lower_bound
; O
who O
ladder O
for O
cancer O
pain O
) O

chronic B-chronic_disease
obstructive I-chronic_disease
pulmonary I-chronic_disease
disease I-chronic_disease
exacerbation O
or O
other O
respiratory O
illness O
requiring O
hospitalization O
or O
precluding O
study O
therapy B-treatment
at O
the O
time O
of O
registration O

history O
of O
rectal B-chronic_disease
fistula I-chronic_disease

a O
medication B-treatment
for O
apathy O
is O
appropriate O
, O
in O
the O
opinion O
of O
the O
study O
physician O

closed B-chronic_disease
angle I-chronic_disease
glaucoma I-chronic_disease
or O
pheochromocytoma B-cancer

lack O
of O
appetite O
that O
results O
in O
significant O
unintentional O
weight O
loss O
as O
determined O
by O
the O
study O
physician O
in O
the O
last B-upper_bound
three I-upper_bound
months I-upper_bound

possible O
or O
probable O
alzheimer B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
( O
national O
institute O
of O
neurological O
and O
communicative O
disorders O
and O
stroke O
- O
alzheimer O
's O
disease O
and O
related O
disorders O
association O
( O
nincds O
- O
adrda O
) O
criteria O
) O
, O
with O
mini B-clinical_variable
- I-clinical_variable
mental I-clinical_variable
state I-clinical_variable
exam I-clinical_variable
( I-clinical_variable
mmse I-clinical_variable
) I-clinical_variable
score I-clinical_variable
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
inclusive O

patients O
receiving O
any O
other O
investigational B-treatment
agents I-treatment
( O
imaging B-treatment
agents I-treatment
are O
acceptable O
) O

tolerate O
one O
test O
dose O
( O
@NUMBER B-upper_bound
g I-upper_bound
) O
of O
ascorbate B-treatment

uncontrolled O
intercurrent B-chronic_disease
illness I-chronic_disease
including O
, O
but O
not O
limited O
to O
, O
ongoing O
or O
active B-chronic_disease
infection I-chronic_disease
that O
would O
result O
in O
a O
hospital O
stay O
or O
delay O
of O
treatment B-treatment
, O
symptomatic O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease
pectoris I-chronic_disease
, O
cardiac B-chronic_disease
arrhythmia I-chronic_disease
, O
or O
psychiatric B-chronic_disease
illness I-chronic_disease
/ O
social O
situations O
that O
would O
limit O
compliance O
with O
study O
requirements O
or O
impact O
patient O
safety O

able O
to O
start O
bevacizumab B-treatment
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
but O
no O
more O
than O
@NUMBER B-upper_bound
weeks I-upper_bound
from O
date O
of O
biopsy O

at O
least O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

history O
of O
myocardial B-chronic_disease
infarction I-chronic_disease
or O
unstable B-chronic_disease
angina I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
study O
enrollment O

known O
hypersensitivity O
to O
any O
component O
of O
bevacizumab B-allergy_name

major B-treatment
surgical I-treatment
procedure O
or O
significant O
traumatic O
injury O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
@NUMBER O
st O
bevacizumab B-treatment
infusion O
or O
anticipation O
of O
need O
for O
major B-treatment
surgical I-treatment
procedure O
during O
the O
course O
of O
the O
study O

significant O
liver B-chronic_disease
function I-chronic_disease
impairment I-chronic_disease

total O
bilirubin B-clinical_variable
> O
@NUMBER B-lower_bound
times I-lower_bound
the I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound

creatinine B-clinical_variable
( I-clinical_variable
upc I-clinical_variable
) I-clinical_variable
ratio I-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
at O
screening O

documented O
clinically O
significant O
arrhythmias B-chronic_disease

> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
for O
srd B-clinical_variable
arm I-clinical_variable

active O
plasma B-cancer
cell I-cancer
leukemia I-cancer

adequate O
hematopoietic O
function O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
c1 O
d1 O

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
of O
≤ O
@NUMBER B-upper_bound

prior B-treatment
autologous I-treatment
stem I-treatment
cell I-treatment
transplantation I-treatment
< O
@NUMBER B-upper_bound
month I-upper_bound
, O
or O
allogeneic B-treatment
stem I-treatment
cell I-treatment
transplantation I-treatment
< O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
c1d1 O

smoldering B-cancer
mm I-cancer

≥ O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
for O
svd O
, O
spvd O
, O
and O
sdd O
arms O

individuals O
being O
treated O
with O
@NUMBER O
or O
more O
antihypertensive B-treatment
medications I-treatment
, O
including O
a O
diuretic O
if O
tolerated O
, O
with O
sbp B-clinical_variable
≥ O
@NUMBER B-lower_bound
or O
dbp B-clinical_variable
≥ O
@NUMBER B-lower_bound
mm I-lower_bound
hg I-lower_bound
will O
also O
be O
eligible O

bone O
marrow O
( O
bm O
) O
harvest O
required O
to O
reach O
adequate O
cell O
dose O
for O
transplant B-treatment

recovery O
from O
non O
- O
hematologic O
toxicities O
of O
salvage B-treatment
cytoreductive I-treatment
chemotherapy I-treatment
to O
≤ O
grade B-upper_bound
@NUMBER I-upper_bound
( O
common B-clinical_variable
terminology I-clinical_variable
criteria I-clinical_variable
for I-clinical_variable
adverse I-clinical_variable
events I-clinical_variable
[ I-clinical_variable
ctcae I-clinical_variable
] I-clinical_variable
version I-clinical_variable
@NUMBER I-clinical_variable
[ O
v4 O
] O
) O

self O
identify O
as O
african B-ethnicity
american I-ethnicity

significant O
psychiatric O
history O
; O
a O
diagnosis O
of O
schizophrenia B-chronic_disease
, O
bipolar B-chronic_disease
disorder I-chronic_disease
, O
or O
severe B-chronic_disease
depression I-chronic_disease

must O
have O
a O
body B-bmi
mass I-bmi
index I-bmi
less O
than O
@NUMBER B-upper_bound

surgery B-treatment
in O
the O
past B-upper_bound
six I-upper_bound
months I-upper_bound

person O
with O
lidocaine B-allergy_name
sensitivity O

active O
, O
uncontrolled O
bacterial B-chronic_disease
, O
viral O
, O
or O
fungal B-chronic_disease
infections I-chronic_disease
, O
requiring O
systemic B-treatment
therapy I-treatment

have O
a O
history O
of O
hypersensitivity O
reaction O
to O
any O
of O
the O
components O
of O
temozolomide B-allergy_name

males B-gender
not O
naturally O
or O
surgically O
sterile O
, O
who O
have O
a O
female B-gender
partner I-gender
of O
childbearing O
potential O
, O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
two I-contraception_consent
reliable I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
from O
screening O
and O
up O
to O
@NUMBER B-upper_bound
days I-upper_bound
after I-upper_bound
discontinuation O
of O
study O
treatment B-treatment

positive O
results O
from O
hiv B-chronic_disease
serology O
testing O
, O
if O
any O
available O

women B-gender
of O
childbearing O
potential O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
two I-contraception_consent
reliable I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
from O
screening O
and O
up O
to O
@NUMBER B-upper_bound
days I-upper_bound
after O
discontinuation O
of O
study B-treatment
treatment I-treatment

@NUMBER O
ajcc O
clinical O
cancer B-cancer
stage O
as O
determined O
by O
either O
urologist O
or O
radiation O
oncologist O
must O
be O
t1c B-lower_bound
- O
t2b B-upper_bound
, O
n0 O
, O
m0 O

current O
medical B-chronic_disease
or O
psychiatric B-chronic_disease
illness I-chronic_disease
that O
may O
interfere O
with O
treatment B-treatment
completion O
and O
followup O

prior B-treatment
turp I-treatment

disease O
: O
fl B-cancer
; O
criteria O
for O
diagnosis O
: O
histopathologic O
confirmation O

in O
patients O
with O
cll B-cancer
, O
circulating O
lymphocytes B-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm^3 I-lower_bound

known O
ongoing O
or O
known O
active O
systemic B-chronic_disease
infection I-chronic_disease
, O
known O
active O
hepatitis B-chronic_disease
b I-chronic_disease
or O
c B-chronic_disease
virus B-chronic_disease
infection I-chronic_disease
, O
or O
known O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
positive O

prior B-treatment
treatment I-treatment
of O
b B-cancer
- I-cancer
nhl I-cancer
with O
radiation B-treatment
therapy I-treatment
, O
non B-treatment
- I-treatment
standard I-treatment
systemic I-treatment
therapy I-treatment
, O
or O
antibiotics B-treatment
( O
in O
cases O
of O
mzl B-cancer
) O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
the O
first O
dose O
of O
ixazomib B-treatment

inability O
to O
tolerate O
mri B-treatment
or O
tms B-treatment

prior B-treatment
brain I-treatment
surgery I-treatment
or O
exposure O
to O
transcranial B-treatment
magnetic I-treatment
stimulation I-treatment

stable O
medical O
condition O
without O
cardiopulmonary B-chronic_disease
disease I-chronic_disease

known O
hypersensitivity O
to O
tzds B-allergy_name

patients O
with O
diabetes B-chronic_disease
are O
excluded O
because O
diabetes O
by O
itself O
will O
induce O
profound O
changes O
in O
endothelial O
function O
and O
we O
want O
to O
assess O
the O
effects O
of O
ppar B-treatment
agonists I-treatment
in O
vascular O
risk O
beyond O
changes O
in O
insulin O
resistance O

postmenopausal O
women B-gender
who O
have O
undergone O
a O
dexa B-treatment
scan I-treatment
during O
the O
last O
year O
and O
have O
a O
t B-clinical_variable
score I-clinical_variable
better O
than O
@NUMBER B-lower_bound
will O
be O
included O
without O
repeating O
the O
dexa O
scan O
prior O
to O
enrollment O

patients O
with O
the O
indication O
of O
angioplasty B-treatment
or O
another O
procedure O
in O
addition O
to O
cabg B-treatment

with O
the O
indication O
of O
myocardial B-treatment
revascularization I-treatment
with O
≥ O
@NUMBER B-lower_bound
criteria O
of O
frailty O
by O
fried O
frailty O
criteria O
, O
and O
suitable O
to O
undergo O
either O
off O
- O
pump O
or O
on O
- O
pump O
cabg O

myeloproliferative B-chronic_disease
disorder I-chronic_disease

at O
least O
one B-lower_bound
extracranial O
measurable O
lesion O
as O
defined O
by O
recist O
@NUMBER O

patient O
has O
other O
severe O
, O
acute O
, O
or O
chronic O
medical B-chronic_disease
conditions I-chronic_disease
including O
uncontrolled B-chronic_disease
diabetes I-chronic_disease
mellitus I-chronic_disease
or O
psychiatric B-chronic_disease
conditions I-chronic_disease
or O
laboratory O
abnormalities O
that O
in O
the O
opinion O
of O
the O
investigator O
may O
increase O
the O
risk O
associated O
with O
study O
participation O
, O
or O
that O
may O
interfere O
with O
the O
interpretation O
of O
study O
results O

patient O
with O
a O
concurrent O
malignancy B-cancer
or O
history O
of O
a O
malignant B-cancer
disease I-cancer
other O
than O
nsclc B-cancer
that O
has O
been O
diagnosed O
and O
/ O
or O
required O
therapy B-treatment
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound

patients O
must O
wait O
for O
the O
central O
laboratory O
result O
of O
the O
alk O
rearrangement O
status O
before O
initiating O
treatment B-treatment
with I-treatment
ceritinib I-treatment

patients O
with O
any O
grade O
of O
alopecia B-chronic_disease
are O
allowed O
to O
enter O
the O
study O

have B-technology_access
a I-technology_access
smart I-technology_access
phone I-technology_access

creatinine B-clinical_variable
clearance I-clinical_variable
less O
than O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound
/ I-upper_bound
1.73m2 I-upper_bound
( O
calculated O
by O
the O
schwartz O
formula O
) O

liver B-clinical_variable
transaminases I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
times I-lower_bound
the I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound

received O
more O
than O
@NUMBER B-lower_bound
hours I-lower_bound
of O
iv B-treatment
antibiotics I-treatment
prior I-treatment
to O
enrollment O

participants O
who O
enroll O
in O
a O
preoperative B-treatment
therapy I-treatment
trial O
or O
who O
have O
been O
treated O
with O
neoadjuvant B-treatment
chemotherapy I-treatment

has O
had O
extensive O
prior B-treatment
surgery I-treatment
or O
sclerotherapy B-treatment
to O
treat O
lm B-chronic_disease
such O
that O
scarring O
may O
interfere O
with O
evaluation O
and O
treatment B-treatment
effect O
of O
sildenafil B-treatment

have O
a O
required O
mri B-treatment
examination O
to O
confirm O
that O
the O
lymphatic B-cancer
malformation I-cancer
is O
present O
and O
is O
greater O
than O
@NUMBER B-lower_bound
cm I-lower_bound
in O
diameter B-clinical_variable
in O
order O
for O
the O
subjects O
to O
receive O
medication B-treatment
, O
which O
happens O
during O
the O
initial O
screening O
evaluation O
portion O
of O
the O
trial O

between O
the O
ages B-age
age B-age
s O
of O
@NUMBER B-lower_bound
months I-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
of O
age O
at O
the O
time O
of O
entry O
into O
the O
study O

co O
- O
administering O
alpha B-treatment
- I-treatment
blockers I-treatment
with O
revatio B-treatment
because O
of O
additive O
blood O
pressure O
- O
lowering O
effects O

both O
partners O
within O
the O
couple O
report O
known O
, O
positive O
hiv O
status O
or O
one O
or O
both O
partners O
reports O
having O
tested O
negative O
for O
hiv O
within O
@NUMBER B-upper_bound
months I-upper_bound

disease O
free O
of O
prior O
malignancies B-cancer
for O
> O
@NUMBER B-lower_bound
years I-lower_bound
with O
exception O
of O
currently O
treated O
basal B-cancer
cell I-cancer
carcinoma I-cancer
, O
squamous B-cancer
cell I-cancer
carcinoma I-cancer
of I-cancer
the I-cancer
skin I-cancer
, O
or O
carcinoma B-cancer
in I-cancer
situ I-cancer
of I-cancer
the I-cancer
cervix I-cancer
or I-cancer
breast I-cancer

patients O
had O
prior B-treatment
autologous I-treatment
or O
allogeneic B-treatment
stem I-treatment
cell I-treatment
transplant I-treatment

the O
development O
of O
erythema B-chronic_disease
nodosum I-chronic_disease
if O
characterized O
by O
a O
desquamating O
rash O
while O
taking O
thalidomide B-treatment
or O
similar O
drugs O

lactating O
females B-gender
must O
agree O
not O
to O
breast O
feed O
while O
taking O
lenalidomide B-treatment

anticipating O
a O
move O
outside O
of O
the O
region O
within O
@NUMBER B-upper_bound
months I-upper_bound

enrollment O
post O
partum O
with O
an O
anticipated O
next O
pregnancy B-pregnancy
within O
@NUMBER B-upper_bound
months I-upper_bound

post O
partum O
and O
not O
anticipating O
another O
pregnancy B-pregnancy
within O
@NUMBER B-upper_bound
months I-upper_bound

cytomegalovirus B-chronic_disease
( I-chronic_disease
cmv I-chronic_disease
) I-chronic_disease
status O

serum B-clinical_variable
creatinine I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
or O
creatinine B-clinical_variable
clearance I-clinical_variable
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound

acute B-cancer
myeloid I-cancer
leukemia I-cancer
( I-cancer
aml I-cancer
) I-cancer
and O
high O
risk O
myelodysplastic B-cancer
syndrome I-cancer
( I-cancer
mds I-cancer
) I-cancer
undergoing O
second O
allogeneic B-treatment
( I-treatment
allo I-treatment
) I-treatment
-stem I-treatment
cell I-treatment
transplant I-treatment
( I-treatment
sct I-treatment
) I-treatment
using O
the O
same O
donor O
or O
different O
donor O
for O
disease O
relapse O

ambulatory O
outpatients O
with O
breast O
( O
including O
ductal B-cancer
carcinoma I-cancer
in I-cancer
situ I-cancer
[ I-cancer
dcis I-cancer
] I-cancer
) O
cancer B-cancer

fatigue O
brought O
on O
by O
conditions O
other O
than O
cancer B-cancer

patients O
to O
be O
treated O
with O
rt B-treatment
for O
curative O
intent O

chronic B-chronic_disease
obstructive I-chronic_disease
pulmonary I-chronic_disease
disease I-chronic_disease
requiring O
oxygen O
replacement O

platelets B-clinical_variable
< O
@NUMBER B-upper_bound

gastro B-chronic_disease
- I-chronic_disease
intestinal I-chronic_disease
abnormalities I-chronic_disease
, O
including O
bowel B-chronic_disease
obstruction I-chronic_disease

serum O
flc O
assay O
: O
involved O
flc B-clinical_variable
level I-clinical_variable
≥ O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
( O
≥ O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
l I-lower_bound
) O

abnormal B-clinical_variable
serum I-clinical_variable
free I-clinical_variable
light I-clinical_variable
chain I-clinical_variable
ratio I-clinical_variable
( O
< O
@NUMBER B-upper_bound
or O
> O
@NUMBER B-lower_bound
) O

prior B-treatment
surgical I-treatment
procedures O

histologically- O
or O
cytologically O
- O
documented O
, O
locally O
- O
advanced O
, O
or O
metastatic B-cancer
solid I-cancer
malignancy I-cancer
or O
lymphoma B-cancer
that O
is O
incurable O

severe O
hypersensitivity O
( O
≥ O
grade B-lower_bound
@NUMBER I-lower_bound
) O
to O
pembrolizumab B-allergy_name
and O
/ O
or O
any O
of O
its O
excipients B-allergy_name

cataracts B-chronic_disease
due O
to O
rubella B-chronic_disease

corneal B-chronic_disease
disease I-chronic_disease

flat B-chronic_disease
anterior I-chronic_disease
chamber I-chronic_disease

optic B-chronic_disease
atrophy I-chronic_disease

vitritis B-chronic_disease

a O
failed O
therapeutic O
trial O
of O
escitalopram B-treatment
in O
the O
current O
depressive O
episode O
( O
defined O
as O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
of O
treatment B-treatment
at O
a O
daily O
dose O
of O
@NUMBER B-lower_bound
mg I-lower_bound
or O
higher O
) O

current O
diagnosis O
of O
major B-chronic_disease
depressive I-chronic_disease
disorder I-chronic_disease
( O
dsm O
- O
iv O
- O
tr O
) O
, O
single O
episode O
, O
recurrent O
or O
chronic O
, O
without O
psychotic O
features O
, O
as O
detected O
by O
mini O
and O
clinical O
exam O

history O
of O
alcohol O
or O
drug O
dependence O
or O
abuse O
in O
the O
last B-upper_bound
three I-upper_bound
years I-upper_bound

medically O
stable O
- O
cleared O
for O
surgery B-treatment

expected O
survival O
of O
less O
than O
@NUMBER B-upper_bound
month I-upper_bound

venous B-chronic_disease
thromboembolism I-chronic_disease
, O
myocardial B-chronic_disease
infarction I-chronic_disease
, O
disseminated B-chronic_disease
intravascular I-chronic_disease
coagulation I-chronic_disease
( I-chronic_disease
dic I-chronic_disease
) I-chronic_disease
, O
cerebral O
vascular O
accident O
, O
transient B-chronic_disease
ischemic I-chronic_disease
attack I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease
pectoris I-chronic_disease
hospitalization O
or O
severe O
peripheral B-chronic_disease
vascular I-chronic_disease
disease I-chronic_disease
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
screening O

scheduled O
to O
begin O
an O
appropriate O
adjuvant B-treatment
or I-treatment
neoadjuvant I-treatment
chemotherapy I-treatment
regimen I-treatment
as O
defined O
by O
nccn O
guidelines O
( O
www.nccn.org O
) O

active B-chronic_disease
corneal I-chronic_disease
inflammation I-chronic_disease

magnesium B-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
( O
< O
@NUMBER B-upper_bound
mmol I-upper_bound
/ I-upper_bound
l I-upper_bound
) O
or O
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
( O
> O
@NUMBER B-lower_bound
mmol I-lower_bound
/ I-lower_bound
l I-lower_bound
) O
despite O
intervention O
to O
normalize O
levels O

recurrent O
/ O
persistent O
disease O
despite O
@NUMBER O
induction O
intravesical O
therapy O
courses O
given O
within O
@NUMBER B-upper_bound
months I-upper_bound
( O
with O
bcg B-treatment
being O
one O
of O
them O
) O
, O
or O
despite O
one O
induction O
bcg B-treatment
treatment I-treatment
in O
addition O
to O
at O
least O
one O
maintenance O
course O
of O
bcg B-treatment
@NUMBER I-treatment

history O
of O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
( O
hiv B-clinical_variable
@NUMBER I-clinical_variable
/ I-clinical_variable
@NUMBER I-clinical_variable
antibodies I-clinical_variable
) O

received O
a O
live B-treatment
vaccine I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound

receiving O
systemic B-treatment
steroid I-treatment
therapy I-treatment

targeted O
small B-treatment
molecule I-treatment
therapy I-treatment

female B-gender
of O
@NUMBER B-lower_bound
years I-lower_bound
and O
older O
of O
any O
race O

scheduled O
for O
neoadjuvant B-treatment
chemotherapy I-treatment
( I-treatment
nac I-treatment
) I-treatment

age B-age
@NUMBER B-lower_bound
and O
@NUMBER B-upper_bound
years I-upper_bound
( O
the O
latter O
to O
reduce O
likelihood O
of O
heart B-chronic_disease
disease I-chronic_disease
) O

undergoing O
concurrent O
physical B-treatment
therapy I-treatment

myelosuppressive B-treatment
chemotherapy I-treatment
: O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
after I-lower_bound
the O
last O
dose O
of O
myelosuppressive B-treatment
chemotherapy I-treatment
( O
@NUMBER B-lower_bound
days I-lower_bound
if O
prior O
nitrosourea B-treatment
) O

patient O
? O
s O
current O
disease O
state O
must O
be O
one O
for O
which O
there O
is O
no O
known O
curative B-treatment
therapy I-treatment
therapy B-treatment
or O
therapy O
proven O
to O
prolong O
survival O
with O
an O
acceptable O
quality O
of O
life O

serum B-clinical_variable
glutamate I-clinical_variable
pyruvate I-clinical_variable
transaminase I-clinical_variable
( I-clinical_variable
sgpt I-clinical_variable
) I-clinical_variable
( O
alanine B-clinical_variable
aminotransferase I-clinical_variable
[ I-clinical_variable
alt I-clinical_variable
] I-clinical_variable
) O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
= O
@NUMBER B-upper_bound
u I-upper_bound
/ I-upper_bound
l I-upper_bound

free O
rupture O
of O
the O
aneurysm B-chronic_disease

known O
sensitivities O
or O
allergies O
to O
stainless B-allergy_name
steel I-allergy_name
, O
nitinol B-allergy_name
, O
polyester B-allergy_name
, O
solder B-allergy_name
( I-allergy_name
tin I-allergy_name
, I-allergy_name
silver I-allergy_name
) I-allergy_name
, O
polypropylene B-allergy_name
, O
urethane B-allergy_name
or O
gold B-allergy_name

men B-gender
with O
taaa B-clinical_variable
larger O
than O
@NUMBER B-lower_bound
cm I-lower_bound
in O
diameter B-clinical_variable
and O
enlarging O
at O
a O
rate O
of O
more O
than O
@NUMBER B-lower_bound
mm I-lower_bound
/ I-lower_bound
year I-lower_bound

suitable O
arterial O
anatomy O
for O
endovascular B-treatment
taaa I-treatment
repair I-treatment
with I-treatment
taaa I-treatment
device I-treatment

women B-gender
with O
taaa B-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
cm I-lower_bound
in I-lower_bound
diameter I-lower_bound

life B-clinical_variable
expectancy I-clinical_variable
of O
greater O
than O
or O
equal O
to O
( O
≥ O
) O
@NUMBER B-lower_bound
weeks I-lower_bound

prior B-treatment
corticosteroids I-treatment
as O
anti B-treatment
- I-treatment
cancer I-treatment
therapy I-treatment
within O
a O
minimum O
of O
@NUMBER B-lower_bound
days I-lower_bound
of O
first O
receipt O
of O
study B-treatment
drug I-treatment

measured O
or O
calculated O
creatinine B-clinical_variable
clearance I-clinical_variable
< O
@NUMBER B-upper_bound
% I-upper_bound
lln I-upper_bound

positive O
test O
for O
hepatitis B-chronic_disease
b I-chronic_disease
virus I-chronic_disease
or O
hepatitis B-chronic_disease
c I-chronic_disease
virus I-chronic_disease
indicating O
acute O
or O
chronic B-chronic_disease
infection I-chronic_disease

sinus B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
screening O
visit O

women B-gender
currently O
breastfeeding O

stage B-cancer
iii I-cancer
/ I-cancer
iv I-cancer
high I-cancer
grade I-cancer
epithelial I-cancer
ovarian I-cancer
cancer I-cancer
diagnosed O
at O
least O
@NUMBER B-lower_bound
years I-lower_bound
ago O

known O
history O
of O
hiv B-chronic_disease
seropositivity O

medications B-treatment
with I-treatment
a I-treatment
low I-treatment
therapeutic I-treatment
index I-treatment
that O
are O
primarily O
metabolized O
by O
cyp3a4 O
/ O
@NUMBER O
, O
cyp2c8 O
and O
/ O
or O
cyp2c9 O

patients O
who O
have O
received O
prior O
everolimus B-treatment
or O
ceritinib B-treatment

women B-gender
are O
considered O
post O
- O
menopausal O
and O
not O
of O
child O
bearing O
potential O
if O
they O
have O
had O
@NUMBER B-upper_bound
months I-upper_bound
of O
natural O
( O
spontaneous O
) O
amenorrhea B-chronic_disease
with O
an O
appropriate O
clinical O
profile O
( O
e.g. O
, O
age B-age
appropriate O
, O
history O
of O
vasomotor O
symptoms O
) O
or O
have O
had O
surgical B-treatment
bilateral I-treatment
oophorectomy I-treatment
( O
with O
or O
without O
hysterectomy B-treatment
) O
or O
tubal B-treatment
ligation I-treatment
at O
least O
six B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
screening O

where O
pregnancy B-pregnancy
is O
defined O
as O
the O
state O
of O
a O
female B-gender
after O
conception O
and O
until O
the O
termination O
of O
gestation O
, O
confirmed O
by O
a O
positive O
hcg O
laboratory O
test O

marrow B-clinical_variable
cellularity I-clinical_variable
≤ O
@NUMBER B-lower_bound
% I-lower_bound

of O
childbearing O
potential O
who O
are O
unwilling B-contraception_consent
to I-contraception_consent
employ I-contraception_consent
adequate I-contraception_consent
contraception I-contraception_consent
for O
at O
least O
three B-lower_bound
months I-lower_bound
after O
completing O
study O
treatment B-treatment

patients O
who O
received O
corticosteroids B-treatment
for O
diseases O
other O
than O
lymphoma B-cancer
are O
eligible O
as O
long O
as O
prednisone B-treatment
dose O
is O
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
day I-upper_bound

had O
major B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
study O
drug O
treatment B-treatment

has O
a O
concomitant O
medical B-chronic_disease
condition I-chronic_disease
that O
would O
increase O
the O
risk O
of O
toxicity O

has O
a O
diagnosis O
of O
acute B-cancer
promyelocytic I-cancer
leukemia I-cancer

has O
a O
diagnosis O
of O
refractory B-cancer
or I-cancer
relapsed I-cancer
aml I-cancer
or O
high O
risk O
mds B-chronic_disease
for O
inclusion O
in O
part O
@NUMBER O
, O
part O
@NUMBER O
a O
, O
and O
part O
@NUMBER O
( O
cohorts O
@NUMBER O
and O
@NUMBER O
) O

has O
prolongation O
of O
corrected O
qt B-clinical_variable
interval I-clinical_variable
using O
fridericia O
's O
method O
( O
qtcf O
) O
at O
rest O
, O
where O
the O
mean O
qtcf B-clinical_variable
interval I-clinical_variable
is O
> O
@NUMBER B-lower_bound
ms I-lower_bound
for O
males B-gender
or O
> O
@NUMBER B-lower_bound
ms I-lower_bound
for O
females B-gender
based O
on O
triplicate O
electrocardiograms B-treatment
( I-treatment
ecgs I-treatment
) I-treatment

is O
willing O
to O
undergo O
malignancy B-treatment
genotyping I-treatment
for O
tp53 O
mutation O
, O
insertion O
, O
or O
deletion O
at O
screening O

received O
any O
therapies B-treatment
intended O
to O
treat O
malignancy B-cancer
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
first O
receipt O
of O
ds-3032b O
[ O
except O
for O
hydroxyurea B-treatment
, O
which O
must O
be O
discontinued O
at O
least O
@NUMBER B-lower_bound
hours I-lower_bound
( I-lower_bound
day I-lower_bound
@NUMBER I-lower_bound
) I-lower_bound
prior I-lower_bound
to O
study O
treatment B-treatment
] O

for O
investigational B-treatment
, O
chemotherapy B-treatment
, O
or O
biologic B-treatment
therapy I-treatment

patients O
must O
have O
< O
grade B-upper_bound
@NUMBER I-upper_bound
pre B-treatment
- I-treatment
existing I-treatment
peripheral I-treatment
neuropathy I-treatment
( O
per O
national O
cancer O
institute O
common O
terminology O
criteria O
for O
adverse O
events O
[ O
nci O
ctcae O
] O
v O
@NUMBER O
) O

patients O
in O
whom O
the O
preferred O
treatment B-treatment
is O
cabg B-treatment
( I-treatment
coronary I-treatment
artery I-treatment
bypass I-treatment
grafting I-treatment
) I-treatment

reference O
vessel B-clinical_variable
diameter I-clinical_variable
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

symptomatic O
or O
asymptomatic O
coronary B-chronic_disease
artery I-chronic_disease
disease I-chronic_disease
patients O

tcfa B-chronic_disease
( I-chronic_disease
thin I-chronic_disease
- I-chronic_disease
cap I-chronic_disease
fibroatheroma I-chronic_disease
) I-chronic_disease
defined O
by O
oct O
( O
fibrous B-clinical_variable
cap I-clinical_variable
thickness I-clinical_variable
< O
65 B-upper_bound
µm I-upper_bound
and O
arc B-clinical_variable
> O
90 B-lower_bound
° I-lower_bound
) O

currently O
taking O
any O
psychotropic B-treatment
medications I-treatment

schizophrenia B-chronic_disease
or O
schizoaffective B-chronic_disease
disorder I-chronic_disease

willing O
to O
abstain O
from O
alcohol O
completely O
for O
@NUMBER B-upper_bound
hours I-upper_bound
on O
@NUMBER O
separate O
occasions O

non B-pregnancy
- I-pregnancy
pregnant I-pregnancy
female B-gender

ast B-clinical_variable
( I-clinical_variable
sgot I-clinical_variable
) I-clinical_variable
/ O
alt B-clinical_variable
( I-clinical_variable
sgpt I-clinical_variable
) I-clinical_variable

appropriate O
studies O
will O
beundertaken O
in O
patients O
receiving O
combination O
antiretroviral B-treatment
therapy I-treatment
in O
the O
future O
should O
study O
results O
indicate O
effectiveness O

normal B-clinical_variable
creatininecreatinine I-clinical_variable
level I-clinical_variable
< O
the O
maximum O
for O
age B-age

other O
anti B-treatment
- I-treatment
neoplastic I-treatment
investigational I-treatment
agents I-treatment
, O
or O
antibody O
based O
therapies B-treatment
currently O
or O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
apheresis O

second B-cancer
malignancy I-cancer
other O
than O
in O
situ B-cancer
carcinoma I-cancer
of I-cancer
the I-cancer
cervix I-cancer
, O
unless O
the O
tumor B-cancer
was O
treated O
with O
curative O
intent O
at O
least O
two B-lower_bound
years I-lower_bound
previously O
and O
subject O
is O
in O
remission O

computed B-treatment
tomography I-treatment
of O
the O
chest O
, O
abdomen O
, O
and O
pelvis O
( O
ct B-treatment
cap I-treatment
) O
and O
bone O
scan O
performed O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
study O
entry O
and O
does O
not O
demonstrate O
metastatic B-cancer
disease I-cancer

prior O
anthracycline B-treatment
, O
platinum O
salt O
, O
or O
taxane B-treatment
for O
any O
malignancy B-cancer

serious O
concomitant B-chronic_disease
systemic I-chronic_disease
disorders I-chronic_disease
( O
including O
active B-chronic_disease
infections I-chronic_disease
or O
chronic B-chronic_disease
infection I-chronic_disease
requiring O
suppressive B-treatment
antibiotics I-treatment
) O
that O
would O
compromise O
the O
safety O
of O
the O
patient O
or O
compromise O
the O
patient O
's O
ability O
to O
complete O
the O
study O
, O
at O
the O
discretion O
of O
the O
investigator O

women B-gender
with O
previously O
untreated O
, O
unilateral O
stage B-lower_bound
ii I-lower_bound
- O
iii B-upper_bound
breast B-cancer
cancer I-cancer
, O
er B-clinical_variable
/ O
pgr B-clinical_variable
/ O
her2 B-clinical_variable
negative O
( O
er O
≤ O
@NUMBER B-upper_bound
% I-upper_bound
, O
pgr O
≤ O
@NUMBER O
% O
, O
her2 O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
+ O
by O
immunohistochemistry B-treatment
[ I-treatment
ihc I-treatment
] I-treatment
or O
fluorescence B-treatment
in I-treatment
situ I-treatment
hybridization I-treatment
[ I-treatment
fish I-treatment
] I-treatment
≤ O
@NUMBER B-upper_bound
) O
; O
if O
clinically O
negative O
lymph O
nodes O
, O
tumor B-cancer
size O
should O
be O
minimum O
@NUMBER B-lower_bound
cm I-lower_bound
and O
identifiable O
under O
office O
- O
based O
ultrasound B-treatment
guidance O

imaging O
must O
have O
been O
performed O
no O
greater O
than O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
initiation O
of O
chemotherapy B-treatment

patients O
who O
have O
received O
corneal B-treatment
transplants I-treatment
, O
cadaver B-treatment
skin I-treatment
, O
or O
bone B-treatment
transplants I-treatment
are O
eligible O

patients O
must O
not O
have O
core B-treatment
biopsy I-treatment
or O
other O
minor B-treatment
surgical I-treatment
procedure I-treatment
, O
excluding O
placement B-treatment
of I-treatment
a I-treatment
vascular I-treatment
access I-treatment
device I-treatment
, O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
bevacizumab B-treatment

patients O
must O
not O
have O
history O
of O
myocardial B-chronic_disease
infarction I-chronic_disease
or O
unstable B-chronic_disease
angina I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
study O
enrollment O

multiple B-chronic_disease
sclerosis I-chronic_disease
, O
stroke B-chronic_disease
, O
cerebral B-chronic_disease
palsy I-chronic_disease
, O
amyotrophic B-chronic_disease
lateral I-chronic_disease
sclerosis I-chronic_disease
, O
traumatic B-chronic_disease
brain I-chronic_disease
injury I-chronic_disease
, O
spina B-chronic_disease
bifida I-chronic_disease
, O
parkinson B-chronic_disease
's I-chronic_disease
disease I-chronic_disease

severe O
spasticity B-chronic_disease
( O
defined O
by O
an O
ashworth B-clinical_variable
score I-clinical_variable
of O
> O
@NUMBER B-lower_bound
or O
clinical O
impression O
of O
the O
study O
physician O
or O
physical O
therapist O
) O

systemic B-chronic_disease
or I-chronic_disease
peripheral I-chronic_disease
infection I-chronic_disease

foot B-chronic_disease
ulcer I-chronic_disease

if O
acute B-chronic_disease
osteomyelitis I-chronic_disease
has O
been O
diagnosed O
, O
patient O
may O
be O
enrolled O
only O
after O
the O
infection B-chronic_disease
has O
been O
controlled O

ulcer B-chronic_disease
present O
by O
history O
> O
@NUMBER B-lower_bound
weeks I-lower_bound
at O
time O
of O
enrollment O

greater O
than O
@NUMBER B-lower_bound
% I-lower_bound
reduction B-clinical_variable
in I-clinical_variable
wound I-clinical_variable
size I-clinical_variable
during O
the O
first O
two O
weeks O
of O
observation O
and O
treatment B-treatment
by O
the O
investigator O

presence O
of O
additional O
abnormal O
lab O
values O
obtained O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
day O
@NUMBER O
visit O
determined O
to O
be O
clinically O
significant O
by O
the O
investigator O
including O
: O
wbc B-clinical_variable
> O
@NUMBER B-lower_bound
/ I-lower_bound
cm3 I-lower_bound
or O
< O
@NUMBER B-upper_bound
, I-upper_bound
@NUMBER I-upper_bound
cm3 I-upper_bound
, O
or O
electrolytes O
that O
are O
outside O
the O
host O
institution O
's O
range O
of O
normal O

wagner O
@NUMBER O
, O
@NUMBER O
, O
@NUMBER O
dfu B-chronic_disease

gross O
clinical O
infection O
at O
the O
study O
ulcer B-chronic_disease
site O
including O
cellulitis B-chronic_disease
and O
osteomyelitis B-chronic_disease

three O
or O
fewer O
ulcers B-chronic_disease
that O
are O
separated O
by O
> O
@NUMBER B-lower_bound
cm I-lower_bound
distance I-lower_bound

hiv B-chronic_disease
severe O
liver B-chronic_disease
disease I-chronic_disease

known O
allergy O
tor O
sensitivity O
to O
eclipse B-allergy_name
prp I-allergy_name
kit I-allergy_name
components I-allergy_name
( O
calcium B-allergy_name
chloride I-allergy_name
, O
c O
alcium B-allergy_name
gluconate I-allergy_name
or O
acid B-allergy_name
citrate I-allergy_name
dextrose I-allergy_name
solution I-allergy_name
a I-allergy_name
( I-allergy_name
acda I-allergy_name
) I-allergy_name
) O

ulcer B-chronic_disease
not O
of O
vlu B-chronic_disease
pathophysiology O
( O
e.g. O
, O
pure O
diabetic B-chronic_disease
, O
vasculitic B-chronic_disease
, O
radiation B-treatment
, O
rheumatoid B-chronic_disease
, O
collagen B-chronic_disease
vascular I-chronic_disease
disease I-chronic_disease
, O
pressure B-chronic_disease
, O
or O
arterial B-chronic_disease
etiology O
) O

immunocompromised O
patients O
and O
patients O
known O
to O
be O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
positive O
and O
currently O
receiving O
antiretroviral B-treatment
therapy I-treatment

prior B-treatment
treatmen I-treatment
t O
with O
doxil B-treatment
, O
topotecan B-treatment
, O
gemzar B-treatment
or O
taxol B-treatment
chemotherapy I-treatment
for O
platinum O
- O
resistant O
cancer B-cancer

patients O
may O
have O
cns B-cancer
intracranial I-cancer
tumor I-cancer

patients O
should O
not O
be O
vaccinated O
with O
live B-treatment
attenuated I-treatment
vaccines I-treatment
within O
@NUMBER B-upper_bound
month I-upper_bound
of O
starting O
tremelimumab B-treatment
and O
medi4736 B-treatment
treatment I-treatment

platelets B-clinical_variable
- O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
/ I-lower_bound
mc I-lower_bound

dose O
escalation O
phase O
: O
no O
known O
central B-cancer
nervous I-cancer
system I-cancer
( I-cancer
cns I-cancer
) I-cancer
metastases I-cancer
or O
neurological O
symptoms O
possibly O
related O
to O
active O
cns B-cancer
metastasis I-cancer
in O
dose O
escalation O
phase O

histologically O
or O
cytologically O
confirmed O
diagnosis O
of O
globo B-cancer
h I-cancer
- I-cancer
positive I-cancer
nsclc I-cancer

cochlear B-chronic_disease
nerve I-chronic_disease
deficiency I-chronic_disease

involvement O
in O
a O
rehabilitation B-treatment
program I-treatment
that O
emphasizes O
development O
of O
auditory O
skills O
with O
or O
without O
the O
use O
of O
supplementary O
visual O
communication O

brainstem O
or O
cortical O
anomaly O
that O
makes O
implantation B-treatment
unfeasible O

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
of O
@NUMBER B-lower_bound
or O
@NUMBER B-upper_bound
and O
minimum O
life B-clinical_variable
expectancy I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
months I-lower_bound

having O
side O
effects O
of O
a O
prior O
study O
drug O
that O
are O
not O
recovered O
to O
grade O
≤ O
@NUMBER B-upper_bound
or O
baseline O

patient O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

ecog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
of O
≤ O
@NUMBER B-upper_bound
at O
study O
entry O

females B-gender
of O
childbearing O
potential O
( O
fcbp O
) O
† O
must O
have O
a O
negative B-pregnancy
serum I-pregnancy
pregnancy I-pregnancy
test O
and O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
appropriate I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent

pathology O
confirmed O
relapsed O
or O
refractory O
t B-cancer
- I-cancer
cell I-cancer
lymphoma I-cancer
( O
ptcl B-cancer
and O
stage O
> O
ibctcl O
) O
at O
treating O
institution O

allogeneic B-treatment
stem I-treatment
cell I-treatment
transplantation I-treatment
is O
not O
considered O
a O
standard B-treatment
curative I-treatment
option O

between O
the O
ages B-age
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
old O

androgen B-treatment
deprivation I-treatment
therapy I-treatment
( I-treatment
adt I-treatment
) I-treatment
is O
at O
the O
discretion O
of O
the O
treating O
physician O

prostate B-clinical_variable
- I-clinical_variable
specific I-clinical_variable
antigen I-clinical_variable
( I-clinical_variable
psa I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
ng I-upper_bound
/ I-upper_bound
ml I-upper_bound
within O
( O
+ O
/ O
- O
) O
@NUMBER B-upper_bound
months I-upper_bound
of O
signing O
of O
consent O

t1 B-lower_bound
- O
t3 B-upper_bound
disease O
based O
on O
digital O
rectal O
exam O

zubrod B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
≤ O
@NUMBER B-upper_bound

clinically O
significant O
underlying O
pulmonary B-chronic_disease
disease I-chronic_disease
as O
measured O
by O
pulmonary B-treatment
function I-treatment
tests I-treatment

age B-age
@NUMBER B-lower_bound
to O
< O
@NUMBER B-upper_bound
years I-upper_bound
: O
@NUMBER O
for O
males B-gender
and O
@NUMBER O
for O
females B-gender

age B-age
@NUMBER B-lower_bound
to O
< O
@NUMBER B-upper_bound
years I-upper_bound
: O
@NUMBER B-upper_bound
for O
males B-gender
and O
females B-gender

anti B-treatment
- I-treatment
cancer I-treatment
agents I-treatment
not O
known O
to O
be O
myelosuppressive B-cancer
( O
e.g O
. O
not O
associated O
with O
reduced O
platelet O
or O
absolute O
neutrophil O
count O
[ O
anc O
] O
counts O
) O
: O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
after O
the O
last O
dose O
of O
agent O

for O
patients O
with O
solid B-cancer
tumors I-cancer
without O
known O
bone O
marrow O
involvement O

part O
b2 O
: O
patients O
with O
relapsed O
or O
refractory O
osteosarcoma B-cancer

patients O
with O
a O
history O
of O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
( I-chronic_disease
chf I-chronic_disease
) I-chronic_disease
or O
are O
at O
risk O
because O
of O
underlying O
cardiovascular B-chronic_disease
disease I-chronic_disease
or O
exposure O
to O
cardiotoxic B-treatment
drugs I-treatment
must O
have O
adequate O
cardiac O
function O
as O
clinically O
indicated O

stem B-treatment
cell I-treatment
infusion I-treatment

known O
hiv B-chronic_disease
or O
hepatitis B-chronic_disease
c I-chronic_disease

patients O
who O
received O
platinum B-treatment
- I-treatment
based I-treatment
chemotherapy I-treatment
chemotherapy B-treatment
for O
localized O
lung B-cancer
cancer I-cancer
cancer B-cancer
( O
either O
adjuvant B-treatment
chemotherapy I-treatment
following O
surgery B-treatment
or O
chemotherapy O
given O
in O
conjunction O
with O
definitive B-treatment
radiation I-treatment
) O
are O
eligible O
if O
their O
cancer O
has O
recurred O
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
platinum O
- O
based O
chemotherapy O

patients O
with O
egfr B-clinical_variable
or O
eml4-alk O
mutations O

a O
malignancy B-clinical_variable
diagnosed O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
ago O
if O
the O
subject O
has O
had O
no O
evidence O
of O
disease O
for O
@NUMBER O
years O
prior O
to O
screening O

astrocytoma B-cancer
grade I-cancer
@NUMBER I-cancer
( O
glioblastoma B-cancer
multiforme I-cancer
, O
gbm B-cancer
, O
histologically O
confirmed O
, O
who O
criteria O
) O

sitting B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
> O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
mmhg I-lower_bound
, O
with O
measurements O
recorded O
on O
at O
least O
@NUMBER B-lower_bound
occasions O

evidence O
of O
residual B-cancer
disease I-cancer
after O
surgery B-treatment
and O
soc O
adjuvant B-treatment
therapies I-treatment

for O
women B-gender
of O
child O
- O
bearing O
potential O
, O
agreement B-contraception_consent
to I-contraception_consent
use I-contraception_consent
adequate I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
( O
abstinence B-contraception_consent
, O
hysterectomy B-contraception_consent
, O
bilateral B-contraception_consent
oophorectomy I-contraception_consent
, O
bilateral B-contraception_consent
tubal I-contraception_consent
ligation I-contraception_consent
, O
oral B-contraception_consent
contraception I-contraception_consent
, O
iud B-contraception_consent
, O
or O
use B-contraception_consent
of I-contraception_consent
condoms I-contraception_consent
or I-contraception_consent
diaphragms I-contraception_consent
) O

vaccinations B-treatment
initiated O
between O
@NUMBER B-lower_bound
weeks I-lower_bound
and O
@NUMBER B-upper_bound
months I-upper_bound
from O
completion O
of O
soc O
multi O
- O
modality O
cancer O
care O

current O
use O
of O
antipsychotics B-treatment
or O
anticonvulsant B-treatment
medications I-treatment

diagnosis O
of O
multiple B-chronic_disease
sclerosis I-chronic_disease

certain O
serious B-chronic_disease
illnesses I-chronic_disease
or I-chronic_disease
medical I-chronic_disease
condition I-chronic_disease
( I-chronic_disease
s I-chronic_disease
) I-chronic_disease

has O
had O
certain O
other O
recent O
treatment B-treatment
e.g O
. O
major B-treatment
surgery I-treatment
, O
anticancer B-treatment
therapy I-treatment
, O
extended B-treatment
field I-treatment
radiation I-treatment
, O
received O
investigational B-treatment
agent I-treatment
, O
within O
the O
specified O
time O
frames O
prior O
to O
study O
drug O
administration O

chronic B-chronic_disease
kidney I-chronic_disease
disease I-chronic_disease
- O
including O
baseline O
proteinuria B-clinical_variable
( O
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
24-hr I-lower_bound
, O
p B-clinical_variable
/ I-clinical_variable
c I-clinical_variable
ratio I-clinical_variable
> O
@NUMBER B-lower_bound
, O
or O
persistent O
1 O
+ O
proteinuria O
* O
) O
or O
creatinine B-clinical_variable
> O
@NUMBER B-lower_bound

ast B-clinical_variable
( I-clinical_variable
sgot I-clinical_variable
) I-clinical_variable
/ O
alt B-clinical_variable
( I-clinical_variable
sgpt I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
iuln I-upper_bound
@NUMBER B-upper_bound
x I-upper_bound
iuln I-upper_bound
( O
or O
≤ O
@NUMBER O
x O
iuln O
for O
patients O
with O
liver B-cancer
metastases I-cancer
) O

has O
a O
diagnosis O
of O
immunodeficiency B-chronic_disease
or O
is O
receiving O
systemic B-treatment
steroid I-treatment
therapy I-treatment
( O
in O
dosing O
exceeding O
@NUMBER B-lower_bound
mg I-lower_bound
daily O
of O
prednisone B-treatment
equivalent O
) O
or O
any O
other O
form O
of O
immunosuppressive B-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
mk-3475 B-treatment

patients O
with O
sinonasal B-cancer
sccas O

known O
sero O
- O
positive O
for O
active O
viral B-chronic_disease
infection I-chronic_disease
with O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
, O
hepatitis B-chronic_disease
b I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hbv I-chronic_disease
) I-chronic_disease
or O
hepatitis B-chronic_disease
c I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hcv I-chronic_disease
) I-chronic_disease

patients O
who O
are O
sero O
- O
positive O
because O
of O
hepatitis B-chronic_disease
b I-chronic_disease
virus I-chronic_disease
vaccine B-treatment
are O
eligible O

american B-clinical_variable
society I-clinical_variable
of I-clinical_variable
anesthesiologists I-clinical_variable
( I-clinical_variable
asa I-clinical_variable
) I-clinical_variable
classification I-clinical_variable
of O
> O
@NUMBER B-lower_bound

end B-chronic_disease
stage I-chronic_disease
liver I-chronic_disease
diseas I-chronic_disease
e O

determined O
to O
be O
in O
need O
of O
substance O
use O
treatment B-treatment
by O
the O
court O
intake O
worker O
, O
probation O
officer O
, O
presiding O
judge O
or O
magistrate O
, O
and O
/ O
or O
school O
counselor O

patients O
who O
are O
part O
of O
another B-treatment
trial I-treatment
testing O
other O
investigational B-treatment
agents I-treatment

the O
targeted O
facet B-clinical_variable
joint I-clinical_variable
must O
be O
deeper O
than O
@NUMBER B-lower_bound
mm I-lower_bound
from O
the O
skin O

hgb B-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
( O
transfusions O
allowed O
) O

patients O
with O
active O
hiv B-chronic_disease
infection I-chronic_disease
at O
time O
of O
procurement O
( O
can O
be O
pending O
at O
the O
time O
of O
blood O
draw O
) O

children O
who O
are O
known O
to O
be O
resistant O
to O
steroid B-treatment
therapy I-treatment
, O
immunomodulators B-treatment
and O
biologics B-treatment
, O
or O
on O
a O
steroid B-treatment
dose I-treatment
greater O
than O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
kg I-lower_bound
/ I-lower_bound
day I-lower_bound
( O
maximum O
@NUMBER B-upper_bound
mg I-upper_bound
) O

have O
received O
probiotic B-treatment
preparations I-treatment
≤ O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
randomization O

have O
documented O
cd20 O
+ O
b O
- O
cell O
malignancy B-cancer
, O
with O
active O
disease O
not O
responsive O
to O
prior B-treatment
therapy I-treatment
, O
for O
whom O
no O
standard O
of O
care O
options O
exists O
, O
and O
for O
whom O
treatment B-treatment
with O
an O
anti B-treatment
- I-treatment
cd20 I-treatment
antibody I-treatment

history O
of O
hypersensitivity O
to O
any O
compound O
in O
the O
tetracycline B-allergy_name
antibiotics O
group O

cardiac B-treatment
surgical I-treatment
procedure O
, O
such O
as O
coronary B-treatment
artery I-treatment
bypass I-treatment
graft I-treatment
or O
valve B-treatment
surgery I-treatment
that O
is O
planned O
to O
occur O
within O
@NUMBER B-upper_bound
months I-upper_bound
after O
implant O
or O
ablation B-treatment
that O
is O
planned O
to O
occur O
within O
@NUMBER B-upper_bound
days I-upper_bound
after O
implant O

patient O
is O
able O
and O
willing O
to O
complete O
all O
routine O
study O
visits O
at O
the O
investigational O
site O
through O
@NUMBER B-upper_bound
years I-upper_bound
of O
follow O
- O
up O

presence O
of O
another O
life O
- O
threatening O
, O
underlying O
illness O
separate O
from O
their O
cardiac B-chronic_disease
disorder I-chronic_disease

known O
hypersensitivity O
to O
thalidomide B-allergy_name
or O
lenalidomide B-allergy_name

normal B-clinical_variable
prothrombin I-clinical_variable
( I-clinical_variable
pt I-clinical_variable
) I-clinical_variable
and O
activated B-clinical_variable
partial I-clinical_variable
thromboplastin I-clinical_variable
time I-clinical_variable
( I-clinical_variable
aptt I-clinical_variable
) I-clinical_variable

life B-clinical_variable
expectancy I-clinical_variable
< O
@NUMBER B-upper_bound
months I-upper_bound

patients O
must O
have O
one O
of O
the O
following O
: O
somatic O
mutations O
or O
deletions O
in O
brca1 O
or O
brca2 O
; O
genomic O
alterations O
in O
other O
brca O
pathway O
genes O
( O
subcohorts O
: O
a. O
atm O
, O
b. O
palb2 O
, O
c. O
other O
genes O
, O
e.g O
. O
fanconi B-chronic_disease
anemia I-chronic_disease
genes O
, O
arid1a O
, O
mer11 O
, O
rad50 O
, O
nbs1 O
, O
atr O
; O
amplification O
of O
emsy O
) O
; O
or O
germline O
mutation O
in O
brca1 O
or O
brca O
@NUMBER O
( O
not O
breast B-cancer
or O
ovarian B-cancer
cancer I-cancer
) O

women B-gender
of O
child O
- O
bearing O
potential O
must O
have O
a O
negative B-pregnancy
serum I-pregnancy
or I-pregnancy
urine I-pregnancy
human I-pregnancy
chorionic I-pregnancy
gonadotropin I-pregnancy
( I-pregnancy
hcg I-pregnancy
) I-pregnancy
test O
unless O
prior B-treatment
tubal I-treatment
ligation I-treatment
( O
≥ O
@NUMBER B-lower_bound
year I-lower_bound
before O
screening O
) O
, O
total B-treatment
hysterectomy I-treatment
or O
menopause O
( O
defined O
as O
@NUMBER O
consecutive O
months O
of O
amenorrhea B-chronic_disease
) O
; O
patients O
should O
not B-pregnancy
become I-pregnancy
pregnant I-pregnancy
or O
breastfeed O
while O
on O
this O
study O
; O
sexually O
active O
patients O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
dual I-contraception_consent
contraception I-contraception_consent
for O
the O
duration O
of O
study O
participation O
and O
for O
@NUMBER B-upper_bound
days I-upper_bound
after O
the O
last O
dose O
of O
talazoparib B-treatment

an O
acquired B-chronic_disease
immunodeficiency I-chronic_disease
syndrome I-chronic_disease
( I-chronic_disease
aids I-chronic_disease
) I-chronic_disease
- O
indicator O
condition O
with O
onset O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
screening O

hiv-1 B-chronic_disease
infected O

advanced O
cancer B-cancer
not O
candidate O
for O
treatment B-treatment
with I-treatment
modality I-treatment
or O
agents O
that O
are O
approved O
or O
have O
established O
efficacy O

candidates O
who O
can O
not O
tolerate O
standard B-treatment
treatment I-treatment
or O
whose O
cancers B-cancer
have O
progressed O
on O
current O
standard O
of O
care O

child B-clinical_variable
- I-clinical_variable
pugh I-clinical_variable
score I-clinical_variable
of I-clinical_variable
b I-clinical_variable
and I-clinical_variable
c I-clinical_variable
( O
see O
appendix O
@NUMBER O
) O

prior B-treatment
treatment I-treatment
with I-treatment
arginine I-treatment
depleting I-treatment
agent I-treatment

undergoing O
pneumonectomy B-treatment

an O
existing O
diagnosis O
of O
hiv B-chronic_disease
, O
hepatitis B-chronic_disease
b I-chronic_disease
, O
hepatitis B-chronic_disease
c I-chronic_disease
, O
or O
any O
current O
laboratory O
findings O
or O
clinical O
signs O
and O
symptoms O
that O
suggest O
these O
conditions O

any O
concomitant O
serious O
physical O
illness O
other O
than O
cancer B-cancer
( O
i.e. O
, O
immune B-chronic_disease
deficiency I-chronic_disease
disease I-chronic_disease
, O
bleeding B-chronic_disease
disorder I-chronic_disease
, O
etc O
. O
) O
within O
@NUMBER B-upper_bound
year I-upper_bound
prior I-upper_bound
to O
dosing O

histologically O
confirmed O
unresectable O
solid B-cancer
tumor I-cancer
malignancy B-cancer
with O
at O
least O
@NUMBER B-lower_bound
measurable O
lesion O

platelets B-clinical_variable
( I-clinical_variable
plts I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
μl I-lower_bound

previously O
treated O
for O
advanced O
cancer B-cancer
with O
no O
additional O
therapy B-treatment
options O
available O
known O
to O
prolong O
survival O

calcific B-chronic_disease
uremic I-chronic_disease
arteriolopathy I-chronic_disease
( O
a.k.a O
. O
calciphylaxis B-chronic_disease
) O

@NUMBER O
% O
increase O
in O
serum O
m O
- O
protein O
from O
lowest O
response O
value O
during O
( O
or O
after O
) O
last O
therapy B-treatment

any O
other O
concomitant O
serious B-chronic_disease
illness I-chronic_disease
or O
organ B-chronic_disease
system I-chronic_disease
dysfunction I-chronic_disease
in O
opinion O
of O
investigator O
would O
either O
compromise O
subject O
safety O
or O
interfere O
with O
test O
drug O
safety O
evaluation O

hemoglobin B-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound

absolute B-clinical_variable
bone I-clinical_variable
marrow I-clinical_variable
plasma I-clinical_variable
cell I-clinical_variable
percentage I-clinical_variable
must O
be O
> O
or O
equal O
to O
@NUMBER B-lower_bound
% I-lower_bound
unless O
prior O
complete O
response O
when O
absolute O
bone O
marrow O
plasma O
cell O
percentage O
must O
be O
> O
or O
equal O
to O
@NUMBER B-lower_bound
% I-lower_bound

previous O
coronary B-treatment
artery I-treatment
bypass I-treatment
graft I-treatment
( I-treatment
cabg I-treatment
) O

leukocytes B-clinical_variable
> O
@NUMBER B-lower_bound
/ I-lower_bound
mcl I-lower_bound

prior O
history O
of O
invasive B-cancer
cancer I-cancer
within O
@NUMBER B-upper_bound
years I-upper_bound
of O
study O
entry O
or O
history O
of O
metastatic B-cancer
cancer I-cancer
; O
exceptions O
include O
non O
- O
metastatic O
, O
curatively O
treated O
basal B-cancer
and O
squamous B-cancer
cell I-cancer
carcinoma I-cancer
of I-cancer
the I-cancer
skin I-cancer

clinical O
or O
radiologic O
primary O
tumor B-cancer
size O
is O
at O
least O
@NUMBER B-lower_bound
cm I-lower_bound
diameter I-lower_bound

investigators O
must O
assure O
themselves O
the O
patients O
randomized O
on O
this O
trial O
will O
be O
available O
for O
complete O
documentation O
of O
the O
treatment B-treatment
, O
adverse O
events O
, O
and O
follow O
- O
up O

women B-gender
of O
childbearing O
potential O
must O
have O
a O
urine O
pregnancy B-pregnancy
test O
proven O
negative O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
randomization O

known O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
infection I-chronic_disease
( O
positive O
hiv B-chronic_disease
antibodies O
) O

known O
pneumonitis B-chronic_disease
or O
pulmonary B-chronic_disease
fibrosis I-chronic_disease
with O
clinically O
significant O
impairment O
of O
pulmonary O
function O

other O
malignancies B-cancer
curatively O
treated O
with O
no O
evidence O
of O
disease O
for O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
following O
the O
end O
of O
treatment B-treatment
and O
which O
, O
in O
the O
opinion O
of O
the O
treating O
physician O
, O
do O
not O
have O
a O
substantial O
risk O
of O
recurrence O
of O
the O
prior O
malignancy B-cancer

any O
prior B-treatment
treatment I-treatment
with O
erlotinib B-treatment
or O
other O
agent O
whose O
primary O
mechanism O
of O
action O
is O
known O
to O
inhibit O
egfr O

not B-pregnancy
pregnant I-pregnancy
or O
breast O
feeding O

participants O
with O
a O
known O
diagnosis O
of O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease

platelets B-clinical_variable
≥ O
@NUMBER B-lower_bound
b I-lower_bound
/ I-lower_bound
l I-lower_bound
( I-lower_bound
10 I-lower_bound
^ I-lower_bound
9 I-lower_bound
/ I-lower_bound
l I-lower_bound
) I-lower_bound

receiving O
any O
other O
investigational B-treatment
agents I-treatment
≤ O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
registration O

patients O
on O
medications B-treatment
known O
to O
be O
associated O
with O
torsades B-chronic_disease
de I-chronic_disease
pointes I-chronic_disease

patients O
with O
any O
history O
of O
arterial B-chronic_disease
thromboembolic I-chronic_disease
disease I-chronic_disease

patients O
with O
solid B-cancer
tumors I-cancer
must O
have O
measurable B-chronic_disease
disease I-chronic_disease
( O
response O
evaluation O
criteria O
in O
solid O
tumors O
[ O
recist O
] O
@NUMBER O
) O

known O
neurological B-chronic_disease
disorders I-chronic_disease

vas B-clinical_variable
< O
@NUMBER B-upper_bound

comorbidities O
that O
would O
make O
lap O
band O
surgery O
contraindicated O
( O
severe O
cardiopulmonary B-chronic_disease
diseases I-chronic_disease
, O
severe O
esophagitis B-chronic_disease
, O
stomach B-chronic_disease
or O
duodenal B-chronic_disease
ulcers I-chronic_disease
, O
esophageal B-cancer
or O
gastric B-chronic_disease
varices I-chronic_disease
, O
inflammatory B-chronic_disease
bowel I-chronic_disease
disease I-chronic_disease
, O
liver O
cirrhosis B-chronic_disease
, O
chronic B-chronic_disease
pancreatitis I-chronic_disease
, O
alcohol O
or O
drug O
addiction O
, O
on O
chronic O
steroid B-treatment
treatment I-treatment
, O
or O
active B-chronic_disease
infections I-chronic_disease
) O

history O
of O
uncontrolled O
asthma B-chronic_disease
defined O
for O
this O
study O
as O
requiring O
use O
of O
rescue B-treatment
inhaler I-treatment
≥ O
@NUMBER B-lower_bound
times I-lower_bound
in O
past O
month O

pregnant B-pregnancy
, O
breast O
- O
feeding O
or O
of O
childbearing O
potential O
and O
is O
not O
protected O
by O
a O
medically O
acceptable O
, O
effective O
method O
of O
birth O
control O
while O
enrolled O
in O
the O
study O
; O
medically O
acceptable O
contraceptives O

smoking O
@NUMBER O
or O
more O
cigarettes O
, O
little O
cigars O
and O
/ O
or O
cigarillos O
per O
day O
, O
on O
average O
, O
within O
the O
@NUMBER B-upper_bound
months I-upper_bound
preceding O
the O
screening O
visit O
and O
expired O
carbon B-clinical_variable
monoxide I-clinical_variable
( I-clinical_variable
co I-clinical_variable
) I-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
parts I-lower_bound
per I-lower_bound
million I-lower_bound
( I-lower_bound
ppm I-lower_bound
) I-lower_bound
( O
if O
less O
than O
or O
equal O
to O
@NUMBER O
, O
then O
positive O
cotinine O
test O
) O

certain O
medications B-treatment
to O
treat O
depression B-chronic_disease
( O
last B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
) O
, O
i.e O
. O
monoamine B-treatment
oxidase I-treatment
inhibitors I-treatment
( I-treatment
maois I-treatment
) I-treatment
and O
elavil B-treatment
( I-treatment
amitriptyline I-treatment
) I-treatment

extensive O
disease O
, O
disease O
location O
, O
and O
/ O
or O
co O
- O
morbid O
condition O
that O
the O
pi O
or O
designee O
considers O
unsafe O
for O
surgical O
intervention O
of O
nk B-treatment
cell I-treatment
infusion I-treatment

presence O
of O
or O
determined O
by O
neurosurgery B-treatment
to O
be O
a O
candidate O
for O
an O
implanted O
catheter O
in O
the O
ventricles O
to O
receive O
nk B-treatment
cell I-treatment
infusion I-treatment

cancer B-cancer
within O
@NUMBER B-upper_bound
years I-upper_bound
( O
except O
for O
completely O
excised O
cervical B-cancer
carcinoma I-cancer
in I-cancer
situ I-cancer
or O
excised O
non B-cancer
- I-cancer
melanoma I-cancer
skin I-cancer
cancer I-cancer
) O

lymphocyte B-clinical_variable
count I-clinical_variable
less O
than O
@NUMBER B-upper_bound

sleep B-chronic_disease
disorders I-chronic_disease
identified O
by O
the O
scid B-treatment
and O
the O
duke B-treatment
structured I-treatment
interview I-treatment
for I-treatment
sleep I-treatment
disorders I-treatment
( I-treatment
dsisd I-treatment
) I-treatment

to O
be O
aged B-age
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound

a O
member O
of O
the O
patient O
's O
surgical O
team O
must O
indicate O
equipoise O
for O
the O
benefit O
of O
the O
surgical B-treatment
treatment I-treatment
for O
mbo B-cancer
; O
the O
surgeon O
must O
respond O
yes O
to O
each O
of O
the O
following O
questions O
and O
sign O
the O
s1316 O
surgical O
equipoise O
documentation O
form O
for O
the O
patient O
to O
be O
eligible O

any O
hormonal B-treatment
therapy I-treatment
directed O
at O
the O
malignant B-cancer
tumor I-cancer
must O
be O
discontinued O
at O
least O
one B-upper_bound
week I-upper_bound
prior I-upper_bound
to O
study O
treatment B-treatment
initiation O

ecog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
of O
≤ O
@NUMBER B-upper_bound
at O
study O
entry O

unstable B-chronic_disease
thyroid I-chronic_disease
function I-chronic_disease
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
prior I-upper_bound
to O
study O
start O
to O
exclude O
thyroid B-chronic_disease
- I-chronic_disease
related I-chronic_disease
neuropathy I-chronic_disease
( O
duyff O
et O
al O
, O
@NUMBER O
) O

use O
of O
oral B-treatment
neuromodulatory I-treatment
agents I-treatment
for O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
study O
start O

patients O
with O
a O
past O
cancer B-cancer
history O
( O
within O
@NUMBER B-upper_bound
years I-upper_bound
of O
entry O
) O
and O
/ O
or O
ongoing O
active O
malignancy B-cancer
or O
substantial O
potential O
for O
recurrence O
must O
be O
discussed O
with O
the O
sponsor O
before O
study O
entry O

serum B-clinical_variable
albumin I-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound
( O
or O
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
l I-lower_bound
) O
in O
the O
absence O
of O
receipt O
of O
( B-treatment
iv I-treatment
) I-treatment
albumin I-treatment
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
hours I-upper_bound

serum B-clinical_variable
creatinine I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
( O
or O
≤ O
@NUMBER B-upper_bound
µmol I-upper_bound
/ I-upper_bound
l I-upper_bound
) O

patients O
must O
have O
a O
calculated B-clinical_variable
creatinine I-clinical_variable
clearance I-clinical_variable
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound

with O
weight B-clinical_variable
less O
than O
@NUMBER B-upper_bound
kg I-upper_bound

pregnant B-pregnancy
, O
or O
plans B-pregnancy
to I-pregnancy
become I-pregnancy
pregnant I-pregnancy
in O
the O
next B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
, O
less O
than O
@NUMBER B-upper_bound
months I-upper_bound
postpartum B-clinical_variable
, O
or O
nursing O
or O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
having O
completed O
nursing O

for O
adhd B-chronic_disease
groups O
: O
t B-clinical_variable
- I-clinical_variable
score I-clinical_variable
> O
@NUMBER B-lower_bound
on O
one O
of O
the O
dsm O
- O
iv O
relevant O
scales O

has O
a O
primary O
diagnosis O
of O
any O
other O
axis B-chronic_disease
i I-chronic_disease
disorder I-chronic_disease
( O
determined O
by O
the O
structured O
diagnostic O
interview O
for O
dsm O
; O
scid O
) O
that O
is O
significantly O
impairing O
and O
would O
contraindicate O
participation O
in O
the O
present O
study O

major B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
initiation O
of O
study B-treatment
drug I-treatment

previous O
malignancy B-chronic_disease

receipt O
of O
more O
than O
@NUMBER B-lower_bound
prior B-treatment
regimens I-treatment
of I-treatment
cytotoxic I-treatment
chemotherapy I-treatment
for O
metastatic B-cancer
disease I-cancer
unless O
prior O
approval O
is O
granted O
by O
the O
sponsor O

receipt O
of O
radiotherapy B-treatment
to O
> O
@NUMBER B-lower_bound
% I-lower_bound
of O
bone O
marrow O

corticosteroids B-treatment
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
day I-lower_bound
prednisone B-treatment
or O
equivalent O
, O
or O
growth B-treatment
factor I-treatment
treatment I-treatment
treatment B-treatment
( O
e.g. O
, O
erythropoietin B-treatment
) O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
initiation O
of O
study B-treatment
drug I-treatment

female B-gender
participants I-gender
must O
agree O
to O
abstain O
from O
sexual O
relations O
that O
could O
result O
in O
pregnancy B-pregnancy
or O
use O
a O
reliable O
form O
of O
birth O
control O
during O
the O
study O

patients O
must O
have O
been O
treated O
with O
at O
least O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
day I-lower_bound
of O
prednisone B-treatment
or O
equivalent O
or O
one O
or O
more O
immunomodulating O
agents O
( O
hydroxychloroquine B-treatment
, O
methotrexate B-treatment
, O
azathioprine B-treatment
, O
leflunomide B-treatment
) O
for O
> O
@NUMBER B-lower_bound
months I-lower_bound
before O
screening O

active O
cardiac B-chronic_disease
or O
central B-chronic_disease
nervous I-chronic_disease
system I-chronic_disease
disease I-chronic_disease

between O
the O
ages B-age
of O
@NUMBER B-lower_bound
and O
@NUMBER B-upper_bound
years I-upper_bound

no O
previous O
treatment B-treatment
with O
parp B-treatment
inhibitor I-treatment

subject O
has O
no O
residual B-chronic_disease
neurological I-chronic_disease
dysfunction I-chronic_disease
and O
has O
been O
off O
corticosteroids B-treatment
for O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
prior I-lower_bound
to O
registration O

have O
a O
history O
of O
claustrophobia B-chronic_disease

have O
a O
history O
of O
not O
tolerating O
previous O
mri B-treatment
scans O
without O
medication B-treatment

hba1c B-clinical_variable
reduction I-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
% I-lower_bound

caregivers O
must O
also O
be O
proficient B-language_fluency
in I-language_fluency
english I-language_fluency
to O
complete O
standard O
questionnaires O

an O
unchanged O
antipsychotic B-treatment
medication I-treatment
regimen I-treatment
for O
at O
least O
eight B-lower_bound
( I-lower_bound
@NUMBER I-lower_bound
) I-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
screening O
into O
the O
study O
and O
expected O
to O
remain O
unchanged O
during O
the O
study O
( O
longer O
for O
depot O
or O
long O
- O
acting O
antipsychotics B-treatment
: O
ten O
( O
@NUMBER O
) O
months O
for O
aripiprazole B-treatment
and O
paliperidone B-treatment

current O
substance O
abuse O
, O
or O
history O
of O
meeting O
criteria O
for O
moderate O
or O
severe O
substance O
abuse O
( O
including O
alcohol O
, O
but O
excluding O
nicotine O
and O
caffeine O
) O
in O
the O
past B-upper_bound
six I-upper_bound
( I-upper_bound
@NUMBER I-upper_bound
) I-upper_bound
months I-upper_bound
prior I-upper_bound
to O
screening O

time O
of O
enrollment O
≤ O
@NUMBER B-upper_bound
hours I-upper_bound
from O
initiation O
of O
targeted O
temperature O
management O

ast B-clinical_variable
( I-clinical_variable
sgot I-clinical_variable
) I-clinical_variable
, O
alt B-clinical_variable
( I-clinical_variable
sgpt I-clinical_variable
) I-clinical_variable
, O
and O
alkaline B-clinical_variable
phosphatase I-clinical_variable
≤ O
@NUMBER B-upper_bound
times I-upper_bound
the I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound

administration O
of O
chemotherapy B-treatment
or O
any O
other O
cancer B-treatment
therapy I-treatment
in O
the O
pre O
- O
operative O
period O

history O
of O
allergy O
to O
study B-allergy_name
drug I-allergy_name
components I-allergy_name

if O
ruptured O
aneurysm B-chronic_disease
: O
hunt B-clinical_variable
and I-clinical_variable
hess I-clinical_variable
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

prior O
treatment B-treatment
( O
surgical O
or O
endovascular O
) O
of O
the O
target O
aneurysm B-chronic_disease

use O
( O
current O
or O
prior O
) O
of O
liquid B-treatment
embolic I-treatment
material I-treatment
in O
the O
treatment B-treatment
of O
the O
target O
aneurysm B-chronic_disease

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

cerebral B-chronic_disease
palsy I-chronic_disease
diagnosis O

cancer B-cancer

current O
≥ O
class B-lower_bound
ii I-lower_bound
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
as O
defined O
by O
new B-clinical_variable
york I-clinical_variable
heart I-clinical_variable
association I-clinical_variable

history O
of O
malignancy B-cancer
with O
confirmed O
activating O
ras O
mutation O
at O
any O
time O

patients O
must O
have O
discontinued O
active O
immunotherapy B-treatment
( O
il-2 B-treatment
, O
interferon B-treatment
, O
ctla-4 B-treatment
, O
etc O
. O
) O
or O
chemotherapy B-treatment
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
entering O
the O
study O
and O
oral B-treatment
targeted I-treatment
therapy I-treatment
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
entering O
the O
study O

patients O
must O
not O
receive O
any O
other O
investigational B-treatment
anticancer I-treatment
therapy I-treatment
during O
the O
period O
on O
study O
or O
the O
four B-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
entry O

any O
coexisting O
medical B-chronic_disease
condition I-chronic_disease
that O
in O
the O
judgment O
of O
the O
treating O
physician O
is O
likely O
to O
interfere O
with O
study O
procedures O
or O
results O
including O
uncontrolled O
severe O
infections O
, O
as O
well O
as O
uncontrolled O
cardiac B-chronic_disease
disease I-chronic_disease
, O
or O
other O
organ B-chronic_disease
dysfunction I-chronic_disease

performance B-clinical_variable
status I-clinical_variable
≤ O
@NUMBER B-upper_bound
, O
unless O
directly O
related O
to O
disease O
process O
as O
determined O
by O
the O
principal O
investigator O

temporary O
prior O
measures O
to O
control O
blood B-clinical_variable
counts I-clinical_variable
, O
such O
as O
apheresis B-treatment
or O
hydrea B-treatment
are O
allowed O

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
: O
for O
infants O
less O
than O
or O
equal O
to O
@NUMBER O
hours O
old O
, O
less O
than O
@NUMBER B-upper_bound
cells I-upper_bound
/ I-upper_bound
mm^3 I-upper_bound
; O
for O
infants O
greater O
than O
@NUMBER O
hours O
old O
, O
less O
than O
@NUMBER B-upper_bound
cells I-upper_bound
/ I-upper_bound
mm^3 I-upper_bound

documented O
or O
suspected O
serious O
medical B-chronic_disease
illness I-chronic_disease
, O
serious B-chronic_disease
congenital I-chronic_disease
anomaly I-chronic_disease
, O
or O
immediate O
life B-chronic_disease
- I-chronic_disease
threatening I-chronic_disease
condition I-chronic_disease
in O
the O
infant O
that O
may O
interfere O
with O
the O
ability O
to O
complete O
study O
requirements O
, O
as O
judged O
by O
the O
examining O
clinician O

mother O
received O
no O
antiretroviral B-treatment
therapy I-treatment
( I-treatment
art I-treatment
) I-treatment
during O
pregnancy B-pregnancy

platelet B-clinical_variable
count I-clinical_variable
less O
than O
@NUMBER B-upper_bound
cells I-upper_bound
/ I-upper_bound
mm^3 I-upper_bound

prior O
participation O
in O
any O
hiv-1 B-treatment
vaccine I-treatment
trial I-treatment

patient O
qualifies O
for O
primary O
total O
knee B-treatment
arthroplasty I-treatment
based O
on O
physical O
exam O
and O
medical O
history O

patients O
must O
have O
neurologic O
evidence O
of O
their O
disease O
, O
either O
clinically O
or O
via O
neuroimaging B-treatment
or O
neurophysiological B-treatment
testing I-treatment

receiving O
concurrent O
radiotherapy B-treatment
, O
immunosuppressive B-treatment
medications I-treatment
, O
or O
cytotoxic B-treatment
chemotherapy I-treatment

subjects O
who O
have O
rece O
iv B-treatment
ed O
iv O
or O
oral B-treatment
contrast I-treatment
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound

active O
hepatitis B-chronic_disease
a I-chronic_disease
, I-chronic_disease
b I-chronic_disease
or I-chronic_disease
c I-chronic_disease
virus B-chronic_disease
infection I-chronic_disease
, O
or O
known O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
positive O

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
and O
/ O
or O
other O
performance O
status O
@NUMBER O
, O
@NUMBER O
, O
or O

known O
gi B-chronic_disease
disease I-chronic_disease
or O
gi B-treatment
procedure I-treatment
that O
could O
interfere O
with O
the O
oral O
absorption O
or O
tolerance O
of O
ixazomib B-treatment

secondary B-chronic_disease
amyloidosis I-chronic_disease

active O
lung B-cancer
cancer I-cancer
or O
history O
of O
lung O
cancer O
if O
it O
has O
been O
less O
than O
@NUMBER B-upper_bound
years I-upper_bound
since O
lung B-treatment
resection I-treatment
or O
other B-treatment
treatment I-treatment

active B-chronic_disease
oral I-chronic_disease
infection I-chronic_disease
being O
treated O
by O
health O
care O
professional O

fev1 B-clinical_variable
( O
post O
bronchodilator O
) O
≤ O
@NUMBER B-upper_bound
% I-upper_bound

emergent O
laminectomy B-treatment

history O
of O
metformin B-treatment
use O
or O
any O
insulin B-treatment
sensitizer I-treatment
or O
any O
drug O
for O
the O
treatment B-treatment
of O
metabolic B-chronic_disease
syndrome I-chronic_disease
over O
the O
last B-lower_bound
one I-lower_bound
year I-lower_bound

presence O
or O
history O
of O
diabetes B-chronic_disease
mellitus I-chronic_disease
type I-chronic_disease
i I-chronic_disease
or I-chronic_disease
ii I-chronic_disease

decompensated O
liver O
cirrhosis B-chronic_disease
( O
child B-clinical_variable
- I-clinical_variable
pugh I-clinical_variable
score I-clinical_variable
> O
@NUMBER B-lower_bound
) O

multiple B-chronic_disease
endocrine I-chronic_disease
neoplasia I-chronic_disease
syndrome I-chronic_disease
type I-chronic_disease
@NUMBER I-chronic_disease
( I-chronic_disease
men I-chronic_disease
@NUMBER I-chronic_disease
) I-chronic_disease

planning O
to O
quit O
smoking O
in O
the O
next O
@NUMBER B-upper_bound
days I-upper_bound

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
l I-lower_bound

received O
ips B-clinical_variable
within O
@NUMBER B-upper_bound
days I-upper_bound
or O
@NUMBER B-lower_bound
half I-lower_bound
- I-lower_bound
lives I-lower_bound
of O
the O
first O
study O
dosing O
day O
, O
whichever O
is O
longer O

patients O
with O
any O
concurrent O
medical O
or O
psychiatric B-chronic_disease
condition I-chronic_disease
or O
disease O
which O
, O
in O
the O
investigator O
's O
judgment O
, O
would O
make O
them O
inappropriate O
candidates O
for O
entry O
into O
this O
study O

patients O
with O
gross O
residual B-cancer
tumor I-cancer
after O
surgical B-treatment
resection I-treatment

although O
not O
mandatory O
, O
patients O
with O
evidence O
of O
current O
or O
previous O
active O
myositis B-chronic_disease

ivig B-treatment

patients O
with O
uncontrolled O
diabetes B-chronic_disease

methotrexate B-treatment

cardiovascular B-chronic_disease
conditions I-chronic_disease
: O
coronary B-chronic_disease
artery I-chronic_disease
disease I-chronic_disease
, O
stroke B-chronic_disease
, O
angina B-chronic_disease
, O
uncontrolled O
hypertension B-chronic_disease
, O
a O
clinically O
significant O
electrocardiogram B-treatment
( I-treatment
ecg I-treatment
) I-treatment
abnormality O
( O
e.g. O
, O
symptomatic B-chronic_disease
atrial I-chronic_disease
fibrillation I-chronic_disease
) O
, O
or O
transient B-chronic_disease
ischemic I-chronic_disease
attack I-chronic_disease
( I-chronic_disease
tia I-chronic_disease
) I-chronic_disease
in O
the O
past B-upper_bound
year I-upper_bound

epilepsy B-chronic_disease
with O
history O
of O
seizures B-chronic_disease

has O
a O
psychiatric B-chronic_disease
condition I-chronic_disease
judged O
to O
be O
incompatible O
with O
establishment O
of O
rapport O
or O
safe O
exposure O
to O
psilocybin O

patients O
with O
a O
history O
of O
seizures B-chronic_disease

age B-age
> O
@NUMBER B-lower_bound
years I-lower_bound

body B-bmi
mass I-bmi
index I-bmi
( I-bmi
bmi I-bmi
) I-bmi
over O
@NUMBER B-lower_bound
kg I-lower_bound
/ I-lower_bound
m2 I-lower_bound

current O
or O
untreated O
substance O
use O
disorder O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

patient O
is O
currently O
taking O
serotonergic B-treatment
psychiatric I-treatment
medication I-treatment

participants O
must O
have O
either O
sputum O
cytologic O
atypia O
of O
mild O
dysplasia O
or O
greater O
or O
a O
history O
of O
bronchial B-treatment
biopsy I-treatment
with O
mild B-cancer
or I-cancer
greater I-cancer
dysplasia I-cancer
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

participants O
must O
not O
have O
a O
current O
or O
prior O
invasive B-cancer
malignancy I-cancer
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

participants O
must O
not O
have O
a O
history O
of O
allergic O
reactions O
attributed O
to O
compounds O
of O
similar O
chemical O
or O
biologic O
composition O
of O
iloprost B-allergy_name

participants O
receiving O
long O
- O
term O
adjuvant B-treatment
hormonal I-treatment
therapy I-treatment
( O
such O
as O
tamoxifen B-treatment
or O
aromatase B-treatment
inhibitors I-treatment
for O
breast B-cancer
cancer I-cancer
) O

be O
able B-language_fluency
to I-language_fluency
read I-language_fluency
and I-language_fluency
speak I-language_fluency
english I-language_fluency

emergency B-treatment
treatment I-treatment
for O
hyperleukocytosis B-chronic_disease
with O
hydroxyurea B-treatment
for O
≤ O
@NUMBER B-upper_bound
days I-upper_bound

subject O
has O
hypokalemia B-chronic_disease
and O
hypomagnesemia B-chronic_disease
at O
screening O
( O
defined O
as O
values O
below O
institutional O
lower O
limit O
of O
normal O
[ O
lln O
] O
) O

subject O
requires O
treatment B-treatment
with O
concomitant B-treatment
drugs I-treatment
that O
are O
strong O
inhibitors O
or O
inducers O
of O
p O
glycoprotein O
( O
p O
- O
gp O
) O
with O
the O
exception O
of O
drugs O
that O
are O
considered O
absolutely O
essential O
for O
the O
care O
of O
the O
subject O

documented O
surgically O
sterile O
or O
status O
post O
hysterectomy B-treatment
( O
at O
least O
@NUMBER B-lower_bound
month I-lower_bound
prior I-lower_bound
to O
screening O
) O

conditions O
that O
would O
prohibit O
intermittent O
administration O
of O
corticosteroids B-treatment
for O
t O
- O
dm1 O
premedication O

other O
disease O
or O
condition O
significantly O
affecting O
gastrointestinal B-chronic_disease
function I-chronic_disease

> O
@NUMBER B-lower_bound
months I-lower_bound
of O
age B-age

contraindication O
for O
leukapheresis B-treatment
or O
bone O
marrow O
harvest O
( O
anemia B-clinical_variable
hb I-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound
, O
cardiovascular B-chronic_disease
instability I-chronic_disease
, O
severe O
coagulopathy B-chronic_disease
) O

cytogenetic B-chronic_disease
abnormalities I-chronic_disease
known O
to O
be O
associated O
with O
hematopoietic B-chronic_disease
defect I-chronic_disease
on O
peripheral O
blood O
or O
bone O
marrow O

expected B-clinical_variable
survival I-clinical_variable
< O
@NUMBER B-upper_bound
months I-upper_bound

molecular O
diagnosis O
confirmed O
by O
dna B-clinical_variable
sequencing O
and O
supported O
by O
laboratory O
evidence O
for O
absent O
or O
reduction O
> O
@NUMBER B-lower_bound
% I-lower_bound
of O
the O
biochemical O
activity O
of O
the O
nadph O
- O
oxidase O

participation O
in O
another B-treatment
experimental I-treatment
therapeutic I-treatment
protocol I-treatment
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
baseline O
and O
during O
the O
study O
period O

written O
informed O
consent O
for O
adult O
patient O
, O
and O
assent O
for O
pediatric O
subjects O
seven B-lower_bound
years I-lower_bound
or O
older O

non B-treatment
- I-treatment
stimulant I-treatment
psychoactive I-treatment
medications I-treatment
( O
e.g. O
, O
atomoxetine B-treatment
, O
clonidine B-treatment
, O
tricyclic B-treatment
antidepressants I-treatment
, O
selective B-treatment
serotonin I-treatment
re I-treatment
- I-treatment
uptake I-treatment
inhibitors I-treatment
) O

subject O
is O
unable O
to O
comply O
with O
treatment B-treatment
, O
home O
care O
or O
follow O
- O
up O
visits O

can O
not O
lie O
comfortably O
flat O
on O
your O
back O
for O
up O
to O
@NUMBER B-upper_bound
hours I-upper_bound
in O
the O
pet B-treatment
and O
mri B-treatment
scanners I-treatment
( O
self O
- O
report O
) O

must O
have O
had O
the O
last O
drinking O
episode O
( O
females B-gender
males B-gender
@NUMBER B-lower_bound
or O
more O
drinks O
; O
and O
males O
@NUMBER B-lower_bound
or O
more O
drinks O
) O
within O
@NUMBER B-upper_bound
week I-upper_bound
of O
baseline O
pet B-treatment
scan I-treatment
( O
self O
- O
report O
) O

participants O
seeking O
treatment B-treatment
for O
their O
ad B-chronic_disease
as O
well O
as O
those O
not O
seeking O
treatment O
for O
their O
ad O
will O
be O
included O

antifungal B-treatment
agents I-treatment
( I-treatment
systemic I-treatment
) I-treatment

antihistamines B-treatment
( O
sedating O
) O

antiobesity B-treatment

either O
serum B-clinical_variable
iron I-clinical_variable
< O
@NUMBER B-upper_bound
mcg I-upper_bound
/ I-upper_bound
dl I-upper_bound
( O
regardless O
of O
phosphate O
or O
intact O
fgf23 O
concentration O
) O

anaplastic B-cancer
large I-cancer
cell I-cancer
lymphoma I-cancer

extranodal B-cancer
natural I-cancer
killer I-cancer
( I-cancer
nk I-cancer
) I-cancer
/ I-cancer
t I-cancer
- I-cancer
cell I-cancer
lymphoma I-cancer
, I-cancer
nasal I-cancer
type I-cancer

hepatosplenic B-cancer
gamma I-cancer
- I-cancer
delta I-cancer
t I-cancer
- I-cancer
cell I-cancer
lymphoma I-cancer

psychiatric B-chronic_disease
illness I-chronic_disease
/ O
social O
situations O
that O
would O
limit O
compliance O
with O
study O
requirements O

acute B-clinical_variable
traumatic I-clinical_variable
sci I-clinical_variable
> O
@NUMBER B-lower_bound
hours I-lower_bound
old O

@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
or O
older O

self O
- O
reported O
race O
of O
african B-ethnicity
american I-ethnicity
or O
caucasian B-ethnicity
american I-ethnicity

patients O
must O
be O
anticipated O
to O
complete O
@NUMBER O
cycles O
of O
chemotherapy B-treatment

patients O
must O
have O
primary O
refractory O
or O
first O
relapse O
of O
cluster O
of O
differentiation O
@NUMBER O
( O
cd30 O
) O
+ O
hodgkin B-cancer
lymphoma I-cancer

patients O
with O
evidence O
of O
active O
central B-cancer
nervous I-cancer
system I-cancer
lymphoma I-cancer

serum B-clinical_variable
creatinine I-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
or O
creatinine B-clinical_variable
clearance I-clinical_variable
( I-clinical_variable
crcl I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
, O
performed O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

end B-chronic_disease
- I-chronic_disease
stage I-chronic_disease
renal I-chronic_disease
disease I-chronic_disease
( O
estimated B-clinical_variable
gfr I-clinical_variable
clearance I-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound
/ I-upper_bound
@NUMBER I-upper_bound
m2 I-upper_bound
) O

kidney B-treatment
biopsy I-treatment
documentation O
of O
international B-clinical_variable
society I-clinical_variable
of I-clinical_variable
nephrology I-clinical_variable
/ I-clinical_variable
renal I-clinical_variable
pathology I-clinical_variable
society I-clinical_variable
( I-clinical_variable
isn I-clinical_variable
/ I-clinical_variable
rps I-clinical_variable
) I-clinical_variable
class B-lower_bound
iii I-lower_bound
or O
class B-upper_bound
iv I-upper_bound
proliferative O
nephritis B-chronic_disease
( O
including O
class O
v O
occurring O
in O
combination O
with O
class O
iii O
or O
iv O
) O
within O
@NUMBER B-lower_bound
@NUMBER B-upper_bound
months I-upper_bound
and O
a O
urine B-clinical_variable
protein I-clinical_variable
/ I-clinical_variable
creatinine I-clinical_variable
ratio I-clinical_variable
> O
@NUMBER O
at O
time O
of O
entry O
to O
study O

neutropenia B-clinical_variable
( O
< O
@NUMBER B-upper_bound
/ I-upper_bound
mm3 I-upper_bound
) O

medical B-chronic_disease
condition I-chronic_disease
that O
may O
affect O
the O
cervical O
spine O
neurological O
exam O
and O
/ O
or O
pain O
assessment O
( O
e.g O
. O
peripheral B-chronic_disease
neuropathy I-chronic_disease
) O

diabetes B-chronic_disease
( O
type B-lower_bound
i I-lower_bound
or O
type B-upper_bound
ii I-upper_bound
) O

subject O
with O
a O
bleeding B-chronic_disease
disorder I-chronic_disease

subject O
with O
symptomatic O
postural B-chronic_disease
hypotension I-chronic_disease
( O
severe O
dizziness O
or O
fainting O

had O
eculizumab B-treatment
therapy I-treatment
within O
three B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
screening O

history O
of O
a O
significant O
cardiovascular B-chronic_disease
illness I-chronic_disease

metastatic O
or O
unresectable O
solid B-cancer
tumor I-cancer
malignancy I-cancer

morbid B-chronic_disease
obesity I-chronic_disease
( O
body B-bmi
mass I-bmi
index I-bmi
> O
@NUMBER B-lower_bound
) O

thyroid B-chronic_disease
disease I-chronic_disease
or O
other O
metabolic B-chronic_disease
disorder I-chronic_disease

for O
patients O
with O
non B-treatment
- I-treatment
castrate I-treatment
levels O
of O
circulating O
androgen B-treatment
levels O
( O
testosterone B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound
) O

post B-treatment
- I-treatment
primary I-treatment
androgen I-treatment
- I-treatment
deprivation I-treatment
therapy I-treatment

uncontrolled O
hypertension B-chronic_disease
despite O
appropriate O
medical B-treatment
therapy I-treatment
( O
blood B-clinical_variable
pressure I-clinical_variable
[ I-clinical_variable
bp I-clinical_variable
] I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
mmhg I-lower_bound
systolic O
and O
@NUMBER B-lower_bound
mmhg I-lower_bound
diastolic O
at O
@NUMBER B-upper_bound
separate O
measurements O
no O
more O
than O
@NUMBER B-upper_bound
minutes I-upper_bound
apart O
during O
the O
screening O
visit O
) O

contraindications O
to O
magnetic B-treatment
resonance I-treatment
imaging I-treatment
( I-treatment
mri I-treatment
) I-treatment

use O
of O
any O
medications O
prescribed O
to O
treat O
hyperglycemia B-chronic_disease

undergoing O
hip B-treatment
and I-treatment
knee I-treatment
revisions I-treatment

ast B-clinical_variable
and I-clinical_variable
alt I-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
, O
and O
total B-clinical_variable
bilirubin I-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

to O
define O
dhl B-cancer
, O
patients O
must O
have O
evidence O
of O
c O
- O
myc O
[ O
defined O
as O
: O
cytogenetic O
evidence O
( O
fish O
or O
karyotype O
) O
of O
c O
- O
myc O
breaks O
( O
increased O
copy O
number O
in O
itself O
is O
not O
considered O
positivity O
for O
c O
- O
myc O
) O
or O
positive O
ihc B-clinical_variable
defined O
as O
> O
@NUMBER B-lower_bound
% I-lower_bound
of O
the O
lymphoma B-cancer
cells O
staining O
for O
c O
- O
myc O
] O

currently O
taking O
a O
medication O
( O
e.g. O
, O
antibiotic B-treatment
, O
anti B-treatment
- I-treatment
inflammatory I-treatment
agents I-treatment
, O
glucocorticoids B-treatment
or O
other O
immune B-treatment
modulating I-treatment
medications I-treatment
) O

patient O
must O
be O
> O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

patients O
with O
ajcc O
@NUMBER O
th O
edition O
clinical O
stage B-cancer
iib I-cancer
- O
iiic B-cancer

cardiac B-clinical_variable
ejection I-clinical_variable
fraction I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound
( O
for O
her2 B-clinical_variable
+ O
patients O
) O
as O
assessed O
by O
echocardiogram B-treatment
, O
muga B-treatment
scan I-treatment
, O
or O
cardiac B-treatment
mri I-treatment

patients O
who O
have O
started O
first B-treatment
line I-treatment
mfolfox6 I-treatment
therapy I-treatment
therapy B-treatment
( O
+ O
/ O
- O
trastuzumab B-treatment
for O
her2 B-cancer
amplified I-cancer
tumors I-cancer
) O
may O
be O
considered O
for O
trial O
participation O
if O
they O
have O
received O
no O
more O
than O
@NUMBER B-upper_bound
doses I-upper_bound
of O
therapy O
at O
the O
time O
of O
consent O
and O
screening O

no O
recent O
mi B-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound

ebv B-chronic_disease
seropositive O

rejection O
on O
@NUMBER O
month O
post- O
transplant B-treatment
screening O
biopsy B-treatment

current O
ct B-treatment
scan I-treatment
within O
the O
90-day B-upper_bound
pre O
- O
operative O
period O

clinical O
status O
at O
enrollment O
to O
allow O
tapering O
of O
steroids B-treatment
equal O
to O
or O
less O
than O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
kg I-upper_bound
/ I-upper_bound
day I-upper_bound
of O
prednisone B-treatment

patients O
with O
ongoing O
viral B-chronic_disease
infections I-chronic_disease

albumin B-clinical_variable
> O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

history O
of O
severe O
liver B-chronic_disease
disease I-chronic_disease

not O
using O
phosphate B-treatment
binders I-treatment

research O
participant O
does O
not O
have O
uncontrolled O
seizure B-chronic_disease
activity O
following O
surgery B-treatment
prior O
to O
starting O
the O
first O
t O
cell O
dose O

research O
participant O
must O
not O
require O
more O
than O
@NUMBER B-upper_bound
mg I-upper_bound
tid O
of O
dexamethasone B-treatment
on O
the O
day O
of O
pbmc O
collection O

research O
participants O
being O
treated O
for O
severe O
infection O
or O
who O
are O
recovering O
from O
major B-treatment
surgery I-treatment

women B-gender
men B-gender
of O
child O
- O
bearing O
potential O
and O
men O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
adequate I-contraception_consent
contraception I-contraception_consent
( O
hormonal O
or O
barrier O
method O
of O
birth O
control O
or O
abstinence O
) O
prior O
to O
study O
entry O
and O
for O
six B-upper_bound
months I-upper_bound
following O
duration O
of O
study O
participation O
; O
should O
a O
woman B-gender
become O
pregnant B-pregnancy
or O
suspect B-pregnancy
that I-pregnancy
she I-pregnancy
is I-pregnancy
pregnant I-pregnancy
while O
participating O
on O
the O
trial O
, O
she O
should O
inform O
her O
treating O
physician O
immediately O

melanoma B-cancer
in I-cancer
situ I-cancer

patients O
must O
sign O
an O
informed O
consent O
document O
that O
indicates O
they O
are O
aware O
of O
the O
investigational O
nature O
of O
the O
treatment B-treatment
in O
this O
protocol O
as O
well O
as O
the O
potential O
risks O
and O
benefits O

patients O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
old O

platelet B-clinical_variable
count I-clinical_variable
≤ O
@NUMBER B-upper_bound
per I-upper_bound
mm3 I-upper_bound

serum O
pregnancy B-pregnancy
testing O
will O
be O
required O
for O
women B-gender
of O
childbearing O
potential O

active B-treatment
cognitive I-treatment
/ I-treatment
behavioral I-treatment
therapy I-treatment
initiated O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
@NUMBER B-lower_bound
months I-lower_bound
( O
continuation O
of O
established O
maintenance B-treatment
therapy I-treatment
that O
has O
been O
going O
on O
for O
longer O
than O
@NUMBER O
months O
will O
not O
be O
grounds O
for O
exclusion O
) O

any O
psychotropic B-treatment
medication I-treatment
other O
than O
a O
selective B-treatment
serotonin I-treatment
reuptake I-treatment
inhibitor I-treatment
( I-treatment
ssri I-treatment
) I-treatment
antidepressant I-treatment

any O
chronic O
or O
active O
neurologic B-chronic_disease
disorder I-chronic_disease
, O
including O
seizures B-chronic_disease
and O
epilepsy B-chronic_disease

known O
metastatic B-chronic_disease
disease I-chronic_disease

if O
the O
product O
is O
procured O
from O
the O
recipient O
either O
in O
the O
autologous O
( O
arm O
b O
) O
or O
allogeneic O
( O
arm O
a O
) O
setting O
, O
the O
absolute O
lymphocyte B-clinical_variable
count I-clinical_variable
should O
be O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
for O
procurement O

concurrent O
use O
of O
other O
antiandrogens B-treatment
, O
estrogen B-treatment
- I-treatment
like I-treatment
agents I-treatment
, O
or O
@NUMBER B-treatment
a I-treatment
- I-treatment
reductase I-treatment
inhibitors I-treatment

male B-gender
patient I-gender
and O
his O
female B-gender
partner O
who O
is O
of O
childbearing O
potential O
must O
use B-contraception_consent
@NUMBER I-contraception_consent
acceptable I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
( O
@NUMBER O
of O
which O
must O
include O
a O
condom B-contraception_consent
as I-contraception_consent
a I-contraception_consent
barrier I-contraception_consent
method I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
) O
starting O
at O
screening O
and O
continuing O
throughout O
the O
study O
period O
and O
for O
@NUMBER B-upper_bound
months I-upper_bound
after I-upper_bound
final O
study B-treatment
drug I-treatment
administration O
or O
per O
local O
guidelines O
where O
these O
require O
additional O
description O
of O
contraceptive O
methods O

reported O
diagnosis O
of O
major B-chronic_disease
depression I-chronic_disease
or O
anxiety B-chronic_disease
disorder I-chronic_disease
prior O
to O
breast B-cancer
cancer I-cancer
( I-cancer
bc I-cancer
) I-cancer
diagnosis O

patients O
enrolling O
in O
the O
sporadic O
high B-cancer
grade I-cancer
serous I-cancer
epithelial I-cancer
or O
high B-cancer
grade I-cancer
endometrioid I-cancer
ovarian I-cancer
cancer I-cancer
group O
, O
cohort O
@NUMBER O
, O
must O
have O
a O
negative O
family O
history O
of O
hereditary B-cancer
breast I-cancer
ovarian I-cancer
cancer I-cancer
( I-cancer
hboc I-cancer
) I-cancer
syndrome I-cancer
, O
or O
negative O
gbrca1 O
/ O
@NUMBER O
m O
mutation O
test O

patients O
must O
be O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
from O
previous B-treatment
therapy I-treatment
( O
chemotherapy B-treatment
, O
hormonal B-treatment
therapy I-treatment
, O
and O
radiation B-treatment
therapy I-treatment
, O
or O
investigational B-treatment
agents I-treatment
; O
@NUMBER B-lower_bound
weeks I-lower_bound
for O
mitomycin B-treatment
c I-treatment
) O

hemoglobin B-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound

subject O
must O
be O
over O
@NUMBER B-lower_bound
years I-lower_bound
for O
healthy O
volunteers O

prior O
to O
randomization O
patients O
with O
any O
non O
- O
hematologic O
toxicity O
from O
surgery B-treatment
, O
chemotherapy B-treatment
, O
or O
radiation B-treatment
must O
have O
recovered O
to O
grade O
≤ O
@NUMBER B-upper_bound
with O
the O
exception O
of O
alopecia B-chronic_disease
and O
the O
criteria O
outlined O

patients O
with O
allergies O
to O
the O
stent B-allergy_name
graft I-allergy_name
material I-allergy_name
; O

patients O
with O
expected B-clinical_variable
survival I-clinical_variable
less O
than O
one B-upper_bound
year I-upper_bound

allergy O
to O
any O
component B-allergy_name
of I-allergy_name
the I-allergy_name
study I-allergy_name
drug I-allergy_name

men B-gender
and O
women B-gender
of O
reproductive O
potential O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
an I-contraception_consent
acceptable I-contraception_consent
method I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
during O
treatment B-treatment
and O
for O
six B-upper_bound
months I-upper_bound
after I-upper_bound
completion O
of O
treatment O

unspecified O
( O
ibd B-chronic_disease
- I-chronic_disease
u I-chronic_disease
, O
a O
diagnostic O
classification O
formerly O
termed O
indeterminate B-chronic_disease
colitis I-chronic_disease

no O
arrhythmia B-chronic_disease
requiring O
treatment B-treatment

patients O
taking O
anti B-treatment
- I-treatment
thrombotic I-treatment
agents I-treatment
including O
clopidogrel B-treatment
, O
ticlopidine B-treatment
, O
coumadin B-treatment
, O
heparin B-treatment
, O
enoxaparin B-treatment
, O
and O
direct B-treatment
ii I-treatment
or O
xa B-treatment
inhibitors I-treatment

adhf B-chronic_disease
will O
be O
confirmed O
by O
the O
study O
physician O
, O
and O
will O
be O
defined O
according O
to O
the O
food O
and O
drug O
administration O
definition O
of O
hospitalized B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
as O
a O
combination O
of O
symptoms O
, O
signs O
, O
and O
hf B-treatment
- I-treatment
specific I-treatment
medical I-treatment
treatments I-treatment

minimum O
age B-age
@NUMBER B-lower_bound
years I-lower_bound

completely O
resected O
nsclc B-cancer
with O
negative O
margins O
( O
r0 O
) O

no O
patients O
known O
to O
be O
pregnant B-pregnancy
or O
lactating O

able O
to O
read B-language_fluency
and I-language_fluency
write I-language_fluency
english I-language_fluency

female B-gender
and I-gender
male I-gender
biological O
and O
non O
- O
biological O
family O
members O
of O
brca B-cancer
-positive O
individuals O
or O
lynch B-cancer
syndrome I-cancer
positive O
individuals O

have B-technology_access
a I-technology_access
cellular I-technology_access
telephone I-technology_access
and I-technology_access
are I-technology_access
able I-technology_access
and I-technology_access
willing I-technology_access
to I-technology_access
send I-technology_access
and I-technology_access
receive I-technology_access
text I-technology_access
messages I-technology_access

women B-gender
who O
are B-pregnancy
pregnant I-pregnancy
( O
by O
self O
- O
report O
) O

any O
history O
of O
eyelid B-treatment
surgery I-treatment
or O
ocular B-treatment
surgery I-treatment
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

between O
the O
ages B-age
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

patients O
with O
alt B-clinical_variable
( I-clinical_variable
sgpt I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
x I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound

patients O
with O
a O
creatinine B-clinical_variable
clearance I-clinical_variable
of O
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound

≥ O
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

currently O
in O
a O
treatment B-treatment
program I-treatment
treatment B-treatment
program O
for O
alcohol O
or O
drug O
abuse O
, O
or O
currently O
on O
methadone B-treatment
or O
buprenorphine B-treatment
( O
i.e O
. O
suboxone B-treatment
, O
subutex B-treatment
) O
for O
treatment O
of O
addiction O
, O
or O
currently O
prescribed B-treatment
stimulants I-treatment
for O
treatment O
of O
adhd B-chronic_disease

@NUMBER B-upper_bound
weeks I-upper_bound
from O
nitrosourea B-treatment
- I-treatment
containing I-treatment
chemotherapy I-treatment

based O
on O
the O
neurosurgeon O
's O
judgment O
, O
there O
is O
no O
anticipated O
physical O
connection O
between O
the O
post B-treatment
- I-treatment
resection I-treatment
tumor I-treatment
cavity I-treatment
and O
the O
cerebral O
ventricles O

use O
of O
moderate O
to O
strong O
cyp3a4 B-treatment
inhibitors I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
start O
of O
study B-treatment
treatment I-treatment

diagnosis O
of O
stage B-lower_bound
ii I-lower_bound
- O
iii B-upper_bound
colon B-cancer
or I-cancer
rectal I-cancer
cancer I-cancer
planned O
for O
treatment B-treatment
with I-treatment
adjuvant I-treatment
chemotherapy I-treatment
treatment B-treatment
with O
adjuvant O
chemotherapy O
scheduled O
as O
part O
of O
standard O
treatment O

systolic B-clinical_variable
pressure I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
millimeters I-lower_bound
of I-lower_bound
mercury I-lower_bound
( I-lower_bound
mmhg I-lower_bound
) I-lower_bound
, O
diastolic B-clinical_variable
pressure I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
mmhg I-lower_bound
, O
not O
adequately O
controlled O
by O
anti B-treatment
- I-treatment
hypertensive I-treatment
therapy I-treatment
at O
the O
time O
of O
procedure O
) O

preoperative O
audiometric O
conductive O
overlay O
of O
@NUMBER O
db O
or O
greater O
at O
two B-lower_bound
frequencies I-lower_bound
or O
more O
in O
range O
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
hz I-upper_bound
in O
the O
ear O
to O
be O
implanted O

unilaterally O
implanted O
with O
hires90k B-treatment
™ I-treatment
advantage I-treatment
cochlear I-treatment
implant I-treatment
with O
hifocus B-treatment
™ I-treatment
mid I-treatment
- I-treatment
scala I-treatment
electrode I-treatment
and O
fit O
with O
an O
ear O
- O
level O
sound O
processor O
( O
i.e O
. O
naída B-treatment
family I-treatment
device I-treatment
) O

one O
line O
of O
prior B-treatment
chemotherapy I-treatment
for O
advanced B-cancer
/ O
metastatic B-cancer
disease I-cancer
is O
permissible O

women B-gender
≥ O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
with O
clinical O
stage O
iv O
er+ B-clinical_variable
/ O
her2 B-clinical_variable
- O
breast B-cancer
cancer I-cancer
, O
or O
with O
locally O
recurrent O
er+ O
/ O
her2- O
disease O
not O
amenable O
to O
therapy B-treatment
for O
curative B-treatment
intent I-treatment

renal B-chronic_disease
failure I-chronic_disease
, O
liver B-chronic_disease
failure I-chronic_disease
, O
or O
both O
statin B-treatment
and O
angiotension B-treatment
drug I-treatment
contraindications O

non O
- O
resolution O
of O
toxicities O
induced O
by O
these O
anticancer B-treatment
therapies I-treatment

current O
dependence O
on O
prescription O
opioids B-treatment
as O
evidenced O
by O
documented O
prior B-treatment
treatment I-treatment
for I-treatment
opioid I-treatment
dependence O
, O
signs O
of O
opiate O
withdrawal O
as O
evidenced O
by O
a O
cows B-clinical_variable
score I-clinical_variable
of O
@NUMBER B-lower_bound
or O
greater O
, O
self O
- O
reported O
history O
of O
opioid O
dependence O
, O
and O
a O
positive O
urine O
toxicology O
for O
opiates O

requirement O
for O
current O
ongoing O
opioid B-treatment
treatment I-treatment
for O
adequate O
pain O
management O

serious B-chronic_disease
psychiatric I-chronic_disease
illness I-chronic_disease
including O
psychosis B-chronic_disease
, O
bipolar B-chronic_disease
disorder I-chronic_disease
with I-chronic_disease
psychosis I-chronic_disease

adequate O
cardiac B-chronic_disease
function I-chronic_disease
, O
defined O
as O
left B-clinical_variable
ventricular I-clinical_variable
ejection I-clinical_variable
fraction I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
percent I-lower_bound

adequate O
renal O
function O
: O
defined O
as O
a O
cystatin B-chronic_disease
c I-chronic_disease
egfr I-chronic_disease
or O
creatinine B-chronic_disease
clearance I-chronic_disease
egfr I-chronic_disease
greater O
than O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
sq I-lower_bound
- I-lower_bound
m I-lower_bound

all O
participants O
of O
reproductive O
potential O
must O
agree B-contraception_consent
to I-contraception_consent
a I-contraception_consent
contraceptive I-contraception_consent
method I-contraception_consent
for O
a O
period O
of O
no O
less O
than O
one B-upper_bound
year I-upper_bound
post O
gene B-treatment
transfer I-treatment

any O
condition O
or O
chronic B-chronic_disease
physical I-chronic_disease
or O
mental B-chronic_disease
illness I-chronic_disease
, O
which O
in O
the O
opinion O
of O
the O
investigator O
makes O
participation O
ill O
advised O

frequent O
painful O
vaso B-chronic_disease
- I-chronic_disease
occlusive I-chronic_disease
episodes I-chronic_disease
which O
significantly O
interfere O
with O
normal O
life O
activities O
, O
defined O
as O
a O
history O
of O
@NUMBER B-lower_bound
or O
more O
severe O
acute O
sickle B-chronic_disease
pain I-chronic_disease
events I-chronic_disease
per O
year O
requiring O
additional B-treatment
treatment I-treatment
at O
a O
medical O
facility O
outside O
of O
home O
pain O
management O
over O
the O
preceding B-upper_bound
two I-upper_bound
year I-upper_bound
period O
prior O
to O
study O
enrollment O
, O
or O
which O
necessitate O
chronic B-treatment
transfusion I-treatment
therapy I-treatment

patients O
with O
evidence O
of O
uncontrolled O
bacterial B-chronic_disease
, O
viral B-chronic_disease
, O
or O
fungal B-chronic_disease
infections I-chronic_disease
currently O
taking O
medication B-treatment
and O
progression O
of O
clinical O
symptoms O
within O
one B-upper_bound
month I-upper_bound
prior I-upper_bound
to O
starting O
the O
conditioning O
regimen O

the O
first O
six O
subjects O
, O
at O
minimum O
, O
will O
be O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age
accrual O
in O
this O
age O
range O
will O
continue O
until O
six O
subjects O
are O
evaluable O
and O
permission O
from O
the O
irb O
and O
fda O
to O
enroll O
pediatric O
patients O
has O
been O
given O

are O
over O
age B-age
@NUMBER B-lower_bound
years I-lower_bound

na B-clinical_variable
< O
@NUMBER B-upper_bound
meq I-upper_bound
/ I-upper_bound
l I-upper_bound
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

prior B-treatment
fusion I-treatment
surgery I-treatment
or O
another O
spinal B-treatment
device I-treatment
implanted O
in O
the O
thoracic O
, O
lumbar O
or O
sacral O
spine O

aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
( I-clinical_variable
serum I-clinical_variable
glutamic I-clinical_variable
oxaloacetic I-clinical_variable
transaminase I-clinical_variable
[ I-clinical_variable
sgot I-clinical_variable
] I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
x I-lower_bound
institutional I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound

monosomal B-cancer
karyotype I-cancer

≤ O
@NUMBER B-upper_bound
% I-upper_bound
blasts I-upper_bound
in O
the O
marrow O
and O
/ O
or O

patients O
with O
a O
diagnosis O
of O
bos B-chronic_disease
using O
at O
least O
two B-lower_bound
laboratory O
based O
fev1 B-clinical_variable
values O
obtained O
at O
least O
three B-lower_bound
weeks O
apart O
that O
are O
both O
at O
least O
@NUMBER B-lower_bound
% I-lower_bound
lower O
than O
baseline O
fev1 O
using O
the O
international O
society O
for O
heart O
and O
lung O
transplantation O
( O
ishlt O
) O
definition O
( O
the O
average O
of O
the O
two O
highest O
fev1 O
measurements O
obtained O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
apart O
after O
transplantation B-treatment
) O

current O
involvement O
in O
a O
meditation B-treatment
or O
acupuncture O
group O

currently O
manic B-chronic_disease

histologically O
confirmed O
adenocarcinoma B-cancer
of O
the O
pancreas O
that O
has O
been O
documented O
to O
be O
resectable O
by O
standardized O
radiographic O
criteria O
by O
a O
pancreatic O
surgeon O

inability O
to O
receive O
a O
port O
or O
picc B-treatment
line I-treatment

patients O
are O
not O
permitted O
to O
participate O
in O
another B-treatment
investigational I-treatment
drug I-treatment
study I-treatment
while O
being O
treated O
on O
this O
protocol O

patients O
must O
to O
have O
tumor B-cancer
tissue O
collected O
prior O
to O
enrolling O
on O
this O
trial O

adequately O
treated O
cervical B-cancer
or O
vulvar B-cancer
carcinoma I-cancer
in I-cancer
situ I-cancer
, O
treated O
basal B-cancer
cell I-cancer
or O
squamous B-cancer
carcinoma I-cancer
of I-cancer
the I-cancer
skin I-cancer
, O
superficial B-cancer
bladder I-cancer
tumors I-cancer
( O
ta O
, O
tis O
& O
t1 O
) O
, O
ductal B-cancer
carcinoma I-cancer
in I-cancer
situ I-cancer
( I-cancer
dcis I-cancer
) I-cancer
of I-cancer
the I-cancer
breast I-cancer
and O
low O
grade O
prostate B-cancer
cancer I-cancer

chronic B-chronic_disease
renal I-chronic_disease
insufficiency I-chronic_disease
, O
as O
defined O
by O
serum B-clinical_variable
creatinine I-clinical_variable
of O
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
or O
estimated B-clinical_variable
creatinine I-clinical_variable
clearance I-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound
or O
the O
requirement O
for O
dialysis B-treatment

history O
of O
syncope B-chronic_disease

known O
concomitant O
life O
- O
threatening O
disease O
with O
a O
life B-clinical_variable
expectancy I-clinical_variable
< O
@NUMBER B-upper_bound
months I-upper_bound

systemic O
hypotension B-chronic_disease
with O
systolic B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
< O
@NUMBER B-upper_bound
mmhg I-upper_bound

patients O
with O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
infection O
are O
not O
automatically O
excluded O
, O
but O
must O
meet O
the O
following O
criteria O

cluster B-clinical_variable
of I-clinical_variable
differentiation I-clinical_variable
( I-clinical_variable
cd I-clinical_variable
) I-clinical_variable
@NUMBER I-clinical_variable
count I-clinical_variable
is O
> O
@NUMBER B-lower_bound
/ I-lower_bound
cu I-lower_bound
mm I-lower_bound
and O
their O
viral B-clinical_variable
load I-clinical_variable
is O
< O
@NUMBER B-upper_bound
copies I-upper_bound
/ I-upper_bound
ml I-upper_bound

ast B-clinical_variable
& I-clinical_variable
alt I-clinical_variable
> O
@NUMBER B-lower_bound
x I-lower_bound
iuln I-lower_bound

histologically O
proven O
bladder B-cancer
cancer I-cancer

if O
alkaline B-clinical_variable
phosphatase I-clinical_variable
is O
above O
the O
treating O
institution O
's O
upper B-clinical_variable
limit I-clinical_variable
of I-clinical_variable
normal I-clinical_variable
( I-clinical_variable
uln I-clinical_variable
) I-clinical_variable
, O
presence O
of O
suspicious O
bone O
pain O

renal O
function O
, O
calculated O
creatinine B-clinical_variable
clearance I-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound

stage B-lower_bound
ct2 I-lower_bound
- O
t4a B-upper_bound
n0 B-cancer
m0 B-cancer
disease I-cancer

history O
of O
prior B-treatment
chemotherapy I-treatment

< O
@NUMBER B-upper_bound
months I-upper_bound
of O
age B-age
with O
a O
non B-clinical_variable
- I-clinical_variable
adrenal I-clinical_variable
primary I-clinical_variable
site I-clinical_variable
< O
@NUMBER B-upper_bound
cm I-upper_bound
in I-upper_bound
greatest I-upper_bound
diameter I-upper_bound

clinical B-cancer
stage I-cancer
t2c I-cancer
or O
less O

taken O
finasteride B-treatment
or O
dutasteride B-treatment
during O
the O
prior B-upper_bound
year I-upper_bound

gonadotropin B-treatment
- I-treatment
releasing I-treatment
hormone I-treatment
analogue I-treatment
therapy I-treatment

@NUMBER B-lower_bound
or O
more O
standard O
drink O
on O
@NUMBER B-lower_bound
or O
more O
occasions O
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

ability B-language_fluency
to I-language_fluency
read I-language_fluency
and I-language_fluency
speak I-language_fluency
english I-language_fluency

currently O
receiving O
a O
therapy B-treatment
not O
permitted O
during O
the O
study O

serum B-clinical_variable
creatinine I-clinical_variable
> O
@NUMBER B-lower_bound
x I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound
, O
alanine B-clinical_variable
aminotransferase I-clinical_variable
or O
aspartate B-clinical_variable
aminotransferase I-clinical_variable
> O
@NUMBER B-lower_bound
x I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound
at O
screening O
( O
if O
specified O
) O

history O
of O
prior O
or O
synchronous B-cancer
malignancy I-cancer

participants O
who O
have O
had O
chemotherapy B-treatment
or O
radiotherapy B-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
( O
@NUMBER B-upper_bound
weeks I-upper_bound
for O
bevacizumab B-treatment
) O
of O
liver B-treatment
resection I-treatment

pregnant B-pregnancy
and O
nursing O
women B-gender
are O
excluded O
from O
this O
study O
because O
there O
is O
an O
unknown O
but O
potential O
risk O
of O
adverse O
events O
related O
to O
higher O
- O
dose O
vitamin B-treatment
d3 I-treatment
and O
colon O
or O
liver B-treatment
surgery I-treatment
( O
and O
associated O
perioperative B-treatment
medications I-treatment
and O
anesthesia O
) O
on O
the O
human O
fetus O

a O
history O
of O
or O
current O
conditions O
and O
diseases O
affecting O
the O
digestive O
tract O
, O
such O
as O
indeterminate B-chronic_disease
colitis I-chronic_disease
, O
suspicion O
of O
ischemic B-chronic_disease
, O
radiation B-chronic_disease
or O
microscopic B-chronic_disease
colitis I-chronic_disease
, O
crohn O
's O
disease O
, O
fistulas B-chronic_disease
or O
abdominal B-chronic_disease
abscesses I-chronic_disease
, O
colonic B-chronic_disease
mucosal I-chronic_disease
dysplasia I-chronic_disease
, O
stricture B-chronic_disease
( I-chronic_disease
stenosis I-chronic_disease
) I-chronic_disease
of I-chronic_disease
the I-chronic_disease
colon I-chronic_disease
, O
toxic B-chronic_disease
megacolon I-chronic_disease
, O
or O
unremoved O
adenomatous B-chronic_disease
colonic I-chronic_disease
polyps I-chronic_disease

have O
received O
a O
colonoscopy B-treatment
within O
the O
past O
year O
or O
be O
willing O
to O
undergo O
a O
colonoscopy O
in O
lieu O
of O
a O
flexible B-treatment
sigmoidoscopy I-treatment
at O
screening O

coa B-chronic_disease
- I-chronic_disease
oxidase I-chronic_disease
deficiency I-chronic_disease

d B-chronic_disease
- I-chronic_disease
bifunctional I-chronic_disease
enzyme I-chronic_disease
deficiency I-chronic_disease

mps B-chronic_disease
vi I-chronic_disease
( I-chronic_disease
maroteaux I-chronic_disease
- I-chronic_disease
lamy I-chronic_disease
syndrome I-chronic_disease
) I-chronic_disease

no O
major O
cardioembolic B-chronic_disease
source O
requiring O
anticoagulation B-treatment
or O
other O
specific O
therapy B-treatment

concurrent O
potentially O
life O
threatening O
arrhythmia B-chronic_disease
or O
symptomatic B-chronic_disease
arrhythmia I-chronic_disease

gfr B-clinical_variable
( I-clinical_variable
mdrd I-clinical_variable
) I-clinical_variable
of O
< O
@NUMBER B-upper_bound
at O
visit O
@NUMBER O
( O
screening O
) O

females B-gender
must O
be O
either O
post O
- O
menopausal O
for O
one O
year O
, O
surgically O
sterile O
, O
or O
using O
effective O
contraception O

contraindication O
to O
heparin B-treatment

prior O
stroke B-chronic_disease
or O
transient B-chronic_disease
ischemic I-chronic_disease
attack I-chronic_disease
( O
@NUMBER O
points O
) O

acute B-cancer
myelogeneous I-cancer
leukemia I-cancer
in O
high O
risk O
cr1 B-clinical_variable

greater O
than O
@NUMBER O
cycle O
of O
induction B-treatment
therapy I-treatment
required O
to O
achieve O
remission O
preceding O
myelodysplastic B-cancer
syndrome I-cancer
( I-cancer
mds I-cancer
) I-cancer
presence O
of O
flt3 O
abnormalities O
fab B-cancer
m6 I-cancer
or O
m7 O
leukemia B-cancer

hepatic O
: O
bilirubin B-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
; O
and O
alt B-clinical_variable
, O
ast B-clinical_variable
, O
and O
alkaline B-clinical_variable
phosphatase I-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

positive O
anti O
- O
donor O
hla B-clinical_variable
antibody O

weight B-clinical_variable
≥ O
@NUMBER B-lower_bound
kg I-lower_bound

insult O
to O
the O
central O
nervous O
system O
that O
caused O
the O
motor O
dysfunction O
must O
have O
occurred O
during O
gestation O
or O
within O
one B-upper_bound
year I-upper_bound
after O
birth O
independent O
of O
gestational B-clinical_variable
age I-clinical_variable

bladder B-chronic_disease
atonia I-chronic_disease

patient O
has O
experienced O
an O
irregular O
voiding O
pattern O
despite O
medical O
management O
with O
a O
stable O
5-alpha B-treatment
reductase I-treatment
inhibitor I-treatment
dosage O
for O
@NUMBER B-lower_bound
months I-lower_bound
or O
longer O

life B-clinical_variable
expectancy I-clinical_variable
> O
@NUMBER B-lower_bound
months I-lower_bound

tumor B-cancer
expression O
of O
ny O
- O
eso-1 O
or O
lage-1 O
by O
immunohistochemistry B-treatment
( I-treatment
ihc I-treatment
) I-treatment
and O
/ O
or O
reverse O
transcriptase O
polymerase O
chain O
reaction O
( O
rtpcr O
) O

pancreatic B-cancer
cancer I-cancer
or O
cholangiocarcinoma B-cancer
unsuitable O
for O
surgical B-treatment
resection I-treatment

patient O
unstable O
for O
ercp B-treatment
or O
has O
failed O
ercp B-treatment
( I-treatment
endoscopic I-treatment
retrograde I-treatment
cholangiopancreatography I-treatment
) I-treatment

active B-chronic_disease
hepatitis I-chronic_disease

liver O
function O
: O
direct O
( O
conjugated O
) O
bilirubin B-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
the I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
and O
alt B-clinical_variable
/ I-clinical_variable
ast I-clinical_variable
< O
2.5x B-upper_bound
the I-upper_bound
upper I-upper_bound
normal I-upper_bound
limit I-upper_bound

ongoing O
chronic B-clinical_variable
red I-clinical_variable
cell I-clinical_variable
transfusion I-clinical_variable
> O
@NUMBER B-lower_bound
months I-lower_bound

denies O
drinking O
any O
alcohol O
after O
learning O
about O
current B-pregnancy
pregnancy I-pregnancy

felt O
by O
the O
patient O
's O
obstetrician O
or O
emergency O
room O
attending O
physician O
not O
to O
have O
other O
medical O
problems O
such O
as O
bowel B-chronic_disease
obstruction I-chronic_disease
, O
pancreatitis B-chronic_disease
, O
biliary B-chronic_disease
colic I-chronic_disease
, O
or O
peptic B-chronic_disease
ulcer I-chronic_disease
disease I-chronic_disease
that O
could O
be O
contributing O
to O
the O
patient O
's O
symptoms O

have O
received O
at O
least O
@NUMBER B-lower_bound
administrations O
of O
intravenous B-treatment
( I-treatment
iv I-treatment
) I-treatment
hydration I-treatment
separated O
by O
at O
least O
@NUMBER B-lower_bound
week I-lower_bound
or O
daily O
emesis B-clinical_variable
for O
at O
least O
the O
last B-lower_bound
@NUMBER I-lower_bound
days I-lower_bound
and O
@NUMBER O
administration O
of O
iv B-treatment
hydration I-treatment

use O
of O
dutasteride B-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

have O
a O
histological O
evaluation O
of O
the O
prostate B-treatment
biopsy I-treatment
biopsy B-treatment
with O
assignment O
of O
a O
gleason B-clinical_variable
score I-clinical_variable
to O
the O
biopsy O
material O

have O
a O
histologically O
confirmed O
diagnosis O
of O
adenocarcinoma B-cancer
of I-cancer
the I-cancer
prostate I-cancer

participant O
does O
not O
qualify O
for O
an O
allogeneic B-treatment
transplant I-treatment
due O
to O
medical O
screening O
, O
underlying O
disease O
, O
or O
lack O
of O
alternative O
donors O

aged B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound

pregnant B-pregnancy
or O
nursing O
women B-gender
or O
unwillingness B-contraception_consent
for I-contraception_consent
subject I-contraception_consent
with I-contraception_consent
childbearing I-contraception_consent
potential I-contraception_consent
to I-contraception_consent
use I-contraception_consent
contraception I-contraception_consent
during O
the O
first O
year O
of O
the O
study O

previous B-treatment
eye I-treatment
surgery I-treatment
in O
the O
eye O
selected O
for O
injection O

medication O
regimen O
includes O
narcotics B-treatment

surgery B-treatment
in I-treatment
the I-treatment
thorax I-treatment
or I-treatment
upper I-treatment
abdomen I-treatment

alt B-clinical_variable
and I-clinical_variable
ast I-clinical_variable
≤ O
@NUMBER B-upper_bound
times I-upper_bound
the I-upper_bound
institutional I-upper_bound
upper I-upper_bound
limits I-upper_bound
of I-upper_bound
normal I-upper_bound

ejection B-clinical_variable
fraction I-clinical_variable
measured O
by O
echocardiogram B-treatment
( I-treatment
echo I-treatment
) I-treatment
or O
multi B-treatment
gated I-treatment
acquisition I-treatment
scan I-treatment
( I-treatment
muga I-treatment
) I-treatment
≥ O
@NUMBER B-lower_bound
% I-lower_bound

related O
donor O
selection O
will O
be O
conducted O
in O
accordance O
with O
city O
of O
hope O
's O
department O
of O
hematology O
& O
hematopoietic B-treatment
cell I-treatment
transplantation I-treatment
criteria O
and O
, O
in O
the O
case O
of O
unrelated O
donor O
from O
a O
transplant O
center O
, O
will O
comply O
with O
the O
national O
marrow O
donor O
program O
's O
( O
nmdp O
) O
donor O
selection O
standards O

research O
participants O
must O
have O
bone O
marrow O
and O
/ O
or O
peripheral O
blood O
samples O
available O
for O
confirmation O
of O
diagnosis O
of O
aml B-cancer
or O
bpdcn B-cancer

lymphodepleting B-treatment
regimens I-treatment
, O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
prior I-lower_bound
to O
car B-treatment
t I-treatment
cell I-treatment
infusion I-treatment

age B-age
between O
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound

diagnosis O
of O
cirrhosis B-chronic_disease

serum B-clinical_variable
b12 I-clinical_variable
or O
folate B-clinical_variable
below O
the O
lower O
limits O
of O
normal O

( O
defined O
as O
an O
average O
of O
≥ O
@NUMBER B-lower_bound
units I-lower_bound
of O
rbc B-treatment
transfusions I-treatment
per O
month O
over O
the O
@NUMBER B-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
enrollment O
) O

monotherapy O
arm O
( O
arm O
@NUMBER O
) O
: O
previously O
treated O
with O
a O
jak B-treatment
inhibitor I-treatment
and O
be O
intolerant O
, O
resistant O
, O
refractory O
or O
lost O
response O
to O
the O
jak O
inhibitor O

palpable B-clinical_variable
spleen I-clinical_variable
≥ O
@NUMBER B-lower_bound
cm I-lower_bound
that O
is O
below O
the O
costal O
margin O
on O
physical O
examination O

platelet B-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
x I-lower_bound
10 I-lower_bound
^ I-lower_bound
9 I-lower_bound
/ I-lower_bound
l I-lower_bound
without O
the O
assistance O
of O
thrombopoietic O
factors O
or O
transfusions B-treatment
for O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound

negative B-pregnancy
pregnancy I-pregnancy
test O
within O
@NUMBER B-upper_bound
hrs I-upper_bound
of O
transplant B-treatment
for O
women B-gender
of O
childbearing O
age B-age
and O
who O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
a I-contraception_consent
reliable I-contraception_consent
form I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
for O
one B-upper_bound
year I-upper_bound
following O
transplant O

seen O
previously O
in O
the O
clinics O
at O
nova O
southeastern O
university O
's O
the O
eye O
care O
institute O
with O
a O
diagnosis O
for O
glaucoma B-chronic_disease
suspect O
or O
optic B-chronic_disease
nerve I-chronic_disease
abnormalities I-chronic_disease

history O
of O
severe B-chronic_disease
mental I-chronic_disease
illness I-chronic_disease

have O
a O
psychotic B-chronic_disease
disorder I-chronic_disease
( O
at O
study O
entry O
) O
and O
/ O
or O
have O
exhibited O
serious O
self O
- O
harm O
behaviors O

@NUMBER B-upper_bound
% I-upper_bound
< O
fev1 B-clinical_variable
< O
@NUMBER B-upper_bound
% I-upper_bound
predicted O

patients O
who O
have O
a O
white B-clinical_variable
count I-clinical_variable
less O
than O
@NUMBER B-upper_bound
per I-upper_bound
cubic I-upper_bound
mm I-upper_bound
or O
platelets B-clinical_variable
less O
than O
@NUMBER B-upper_bound
/ I-upper_bound
cubic I-upper_bound
mm I-upper_bound

a O
radioiodine B-treatment
-avid O
metastatic B-cancer
lesion I-cancer
which O
remained O
stable O
in O
size O
or O
progressed O
despite O
radioiodine B-treatment
treatment I-treatment
@NUMBER B-lower_bound
months I-lower_bound
or O
more O
prior O
to O
entry O
in O
the O
study O
; O
there O
are O
no O
size O
limitations O
for O
the O
index O
lesion O
used O
to O
satisfy O
this O
entry O
criterion O

aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
and O
alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
uln I-upper_bound

history O
or O
evidence O
of O
current O
≥ O
class O
ii O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
as O
defined O
by O
the O
new B-clinical_variable
york I-clinical_variable
heart I-clinical_variable
association I-clinical_variable
( I-clinical_variable
nyha I-clinical_variable
) I-clinical_variable
functional O
classification O
system O

patients O
unable O
to O
follow O
a O
low O
iodine O
diet O
or O
requiring O
medication B-treatment
with O
high O
content O
in O
iodide O
( O
amiodarone B-treatment
) O

the O
goal O
will O
be O
to O
have O
a O
minimum O
of O
@NUMBER B-lower_bound
patients O
from O
cohort O
a O
and O
@NUMBER O
patients O
from O
cohort O
b O
attempt O
to O
have O
one O
or O
both O
of O
these O
research B-treatment
biopsies I-treatment
biopsies B-treatment
done O
( O
for O
a O
total O
of O
@NUMBER O
patients O
total O
) O
; O
accrual O
may O
be O
limited O
only O
to O
subjects O
for O
whom O
tumor B-cancer
is O
accessible O
for O
biopsy B-treatment
and O
attempt O
at O
biopsy O
is O
considered O
safe O
if O
continued O
enrollment O
of O
those O
who O
are O
not O
candidates O
for O
biopsy O
make O
it O
impossible O
to O
reach O
the O
accrual O
goals O
for O
research O
biopsies O
described O
above O
( O
e.g. O
, O
if O
@NUMBER O
[ O
of O
@NUMBER O
] O
patients O
are O
accrued O
to O
cohort O
a O
without O
any O
biopsies O
having O
been O
obtained O
within O
the O
cohort O
, O
then O
all O
further O
subjects O
who O
are O
registered O
to O
that O
cohort O
must O
qualify O
for O
attempted O
research B-treatment
biopsy I-treatment
in O
order O
to O
be O
enrolled O
into O
the O
study O

grade O
@NUMBER O
prior B-treatment
treatment I-treatment
related O
toxicities O
may O
be O
allowed O
after O
discussion O
with O
the O
principal O
investigator O

subjects O
who O
would O
have O
been O
excluded O
from O
having O
biopsies B-treatment
done O
due O
to O
the O
above O
reasons O

second B-cancer
primary I-cancer
malignancy I-cancer
that O
requires O
active B-treatment
therapy I-treatment

patients O
with O
relapsed O
disease O
after O
flotetuzumab B-treatment
treatment I-treatment

patients O
with O
a O
previous O
malignancy B-cancer
( O
other O
than O
the O
patients O
' O
known O
cancer B-cancer
) O
that O
were O
treated O
successfully O
and O
are O
disease O
- O
free O
for O
at O
least O
@NUMBER B-lower_bound
years I-lower_bound

the O
patient O
has O
concurrent O
severe O
and O
/ O
or O
uncontrolled O
medical B-chronic_disease
disease I-chronic_disease
that O
could O
compromise O
participation O
in O
the O
study O
( O
i.e. O
, O
uncontrolled O
diabetes O
, O
severe O
infection B-chronic_disease
requiring O
active B-treatment
treatment I-treatment
, I-treatment
severe O
malnutrition B-chronic_disease
, O
chronic O
severe O
liver B-chronic_disease
or O
renal B-chronic_disease
disease I-chronic_disease
) O

the O
patient O
has O
received O
chemotherapy B-treatment
, O
surgery B-treatment
, O
or O
radiotherapy B-treatment
( O
for O
therapeutic O
purposes O
) O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
initiating O
study O
treatment B-treatment
( O
@NUMBER O
weeks O
for O
bevacizumab B-treatment
or O
investigational B-treatment
drugs I-treatment
) O

atrial B-chronic_disease
fibrillation I-chronic_disease
with O
heart B-clinical_variable
rate I-clinical_variable
> O
@NUMBER B-lower_bound
beats I-lower_bound
per I-lower_bound
minute I-lower_bound
( I-lower_bound
bpm I-lower_bound
) I-lower_bound

subjects O
who O
have O
been O
offered O
a O
non B-treatment
- I-treatment
dominant I-treatment
anterior I-treatment
- I-treatment
mesial I-treatment
temporal I-treatment
lobe I-treatment
resection I-treatment
as O
treatment B-treatment
for O
medication B-treatment
refractory B-chronic_disease
epilepsy I-chronic_disease

subjects O
who O
have O
seizures B-chronic_disease
secondary O
to O
drugs O
, O
alcohol O
, O
metabolic B-chronic_disease
illness I-chronic_disease
or O
progressive O
degenerative B-chronic_disease
disease I-chronic_disease

inorganic B-clinical_variable
phosphorus I-clinical_variable
outside O
of O
normal O
limits O

patients O
must O
have O
received O
at O
least O
one B-lower_bound
prior I-lower_bound
regimen O
containing O
gemcitabine B-treatment
with O
or O
without O
cisplatin B-treatment
for O
advanced O
/ O
metastatic B-cancer
disease O

participants O
may O
not O
have O
any O
other O
chronic B-chronic_disease
lung I-chronic_disease
disease I-chronic_disease
; O
e.g O
. O
chronic B-chronic_disease
lung I-chronic_disease
disease I-chronic_disease
of I-chronic_disease
prematurity I-chronic_disease
( I-chronic_disease
cldp I-chronic_disease
) I-chronic_disease
or O
cystic B-chronic_disease
fibrosis I-chronic_disease

physician O
- O
diagnosed O
asthma B-chronic_disease
in O
a O
blood O
sibling O
aged B-age
@NUMBER B-lower_bound
years I-lower_bound
or O
more O

recurrent O
seizures B-chronic_disease

no O
history O
of O
previous B-treatment
back I-treatment
surgery I-treatment
at O
the O
intended O
treatment B-treatment
levels O

patients O
who O
have O
other O
specific O
etiology O
of O
low O
back O
pain O
( O
e.g O
. O
significant O
spinal B-chronic_disease
canal I-chronic_disease
stenosis I-chronic_disease
or O
grade B-chronic_disease
@NUMBER I-chronic_disease
or I-chronic_disease
@NUMBER I-chronic_disease
spondylolisthesis I-chronic_disease
) O

life B-clinical_variable
expectancy I-clinical_variable
≥ O
@NUMBER B-lower_bound
weeks I-lower_bound
at O
time O
of O
enrollment O

negative B-pregnancy
serum I-pregnancy
pregnancy I-pregnancy
test O
for O
women B-gender
of O
childbearing O
potential O

research O
participant O
has O
undergone O
lymphodepletion B-treatment

research O
participant O
? O
s O
absolute B-clinical_variable
leukemic I-clinical_variable
blast I-clinical_variable
count I-clinical_variable
does O
not O
exceed O
@NUMBER B-upper_bound
cells I-upper_bound
/ I-upper_bound
ul I-upper_bound

he O
/ O
she O
must O
have O
a O
pretreatment O
calculated B-clinical_variable
creatinine I-clinical_variable
clearance I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
minute I-lower_bound

preservation O
of O
renal O
function O
, O
serum B-clinical_variable
creatinine I-clinical_variable
did O
not O
increase O
by O
more O
than O
@NUMBER B-lower_bound
fold O
above O
the O
normal O
reference O
range O

research O
participants O
with O
any O
signs O
or O
symptoms O
of O
active B-chronic_disease
infection I-chronic_disease
, O
positive B-treatment
blood I-treatment
cultures I-treatment
or O
radiological O
evidence O
of O
infections B-chronic_disease

chronic O
stable B-chronic_disease
exertional I-chronic_disease
angina I-chronic_disease

pr B-clinical_variable
interval I-clinical_variable
> O
@NUMBER B-lower_bound
msec I-lower_bound

pre B-clinical_variable
- I-clinical_variable
dialysis I-clinical_variable
serum I-clinical_variable
sodium I-clinical_variable
≤ O
@NUMBER B-upper_bound
mmol I-upper_bound
/ I-upper_bound
l I-upper_bound
or O
> O
@NUMBER B-lower_bound
mmol I-lower_bound
/ I-lower_bound
l I-lower_bound

active B-chronic_disease
uncontrolled I-chronic_disease
viral I-chronic_disease
, O
bacterial B-chronic_disease
or O
fungal B-chronic_disease
infection I-chronic_disease

donors O
will O
be O
either O
human B-clinical_variable
leukocyte I-clinical_variable
antigen I-clinical_variable
( I-clinical_variable
hla I-clinical_variable
) I-clinical_variable
hla B-clinical_variable
) O
compatible O
unrelated O
or O
hla O
- O
genotypically O
matched O
related O
donors O
( O
no O
fully O
matched O
sibling O
donor O
) O

hepatic B-clinical_variable
: O
< O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
alanine B-clinical_variable
transaminase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
and O
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
total B-clinical_variable
serum I-clinical_variable
bilirubin I-clinical_variable

grade B-chronic_disease
@NUMBER I-chronic_disease
or I-chronic_disease
@NUMBER I-chronic_disease
peripheral I-chronic_disease
ischemia I-chronic_disease

myocardial B-chronic_disease
infarction I-chronic_disease
or O
unstable B-chronic_disease
angina I-chronic_disease

a O
negative B-pregnancy
serum I-pregnancy
pregnancy I-pregnancy
test O
done O
≤ O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

pre O
- O
menopausal O
females B-gender
and O
females O
< O
@NUMBER B-upper_bound
years I-upper_bound
after O
the O
onset O
of O
menopause O
should O
have O
a O
negative B-pregnancy
pregnancy I-pregnancy
test O
at O
screening O

avoidance O
of O
pregnancy B-pregnancy
measures O

refusing B-contraception_consent
double I-contraception_consent
barrier I-contraception_consent
contraception I-contraception_consent

growth O
of O
renal B-clinical_variable
mass I-clinical_variable
> O
@NUMBER B-lower_bound
mm I-lower_bound
in O
radiographic B-clinical_variable
scans I-clinical_variable
or O
> O
@NUMBER B-lower_bound
mm I-lower_bound
in O
two O
different O
scans O
must O
be O
demonstrated O
within O
a O
one B-upper_bound
year I-upper_bound
period O

participation O
in O
another B-treatment
clinical I-treatment
study I-treatment
with I-treatment
an I-treatment
investigational I-treatment
drug I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
screening O

confirmed O
hiv B-chronic_disease
infection O
defined O
as O
positive O
results O
from O
two O
samples O
collected O
at O
different O
time O
points O

caregiver O
lives O
with O
the O
child O
full O
time O
for O
the O
past B-upper_bound
three I-upper_bound
months I-upper_bound
and O
plans O
to O
continue O
for O
at O
least O
@NUMBER B-lower_bound
more I-lower_bound
months I-lower_bound

age B-age
> O
@NUMBER B-lower_bound
, O
and O
< O
@NUMBER B-upper_bound
years I-upper_bound

recurrent B-chronic_disease
corneal I-chronic_disease
erosion I-chronic_disease
syndrome I-chronic_disease

core B-treatment
biopsy I-treatment
or O
other O
minor B-treatment
surgical I-treatment
procedure I-treatment

suspicion O
of O
papillary B-cancer
thyroid I-cancer
cancer I-cancer
, O
usually O
by O
fine B-treatment
needle I-treatment
aspiration I-treatment
( I-treatment
fna I-treatment
) I-treatment

alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
( O
serum B-clinical_variable
glutamate I-clinical_variable
pyruvate I-clinical_variable
transaminase I-clinical_variable
[ I-clinical_variable
sgpt I-clinical_variable
] I-clinical_variable
) O
and O
/ O
or O
aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
( O
serum B-clinical_variable
glutamic I-clinical_variable
oxaloacetic I-clinical_variable
transaminase I-clinical_variable
[ I-clinical_variable
sgot I-clinical_variable
] I-clinical_variable
) O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
or O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
if O
related O
to O
disease O

cardiac B-clinical_variable
ejection I-clinical_variable
fraction I-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound
( O
by O
either O
cardiac B-treatment
echocardiogram I-treatment
[ I-treatment
echo I-treatment
] I-treatment
or O
multi B-treatment
gated I-treatment
acquisition I-treatment
[ I-treatment
muga I-treatment
] I-treatment
scan I-treatment
) O

serum B-clinical_variable
creatinine I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
score I-clinical_variable
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

prior B-treatment
treatment I-treatment
with O
intrapleural B-treatment
fibrinolytic I-treatment
agents O

platelet B-clinical_variable
count I-clinical_variable
≥ O
100×109 B-lower_bound
l I-lower_bound

clinically O
significant O
atrioventricular B-chronic_disease
( I-chronic_disease
av I-chronic_disease
) I-chronic_disease
conduction I-chronic_disease
disturbances O
and O
/ O
or O
arrhythmias B-chronic_disease
( O
e.g O
. O
@NUMBER O
nd O
or O
@NUMBER O
rd O
degree O
av O
block O
) O

office O
systolic B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
( I-clinical_variable
sbp I-clinical_variable
) I-clinical_variable
of O
greater O
than O
@NUMBER B-lower_bound
mmhg I-lower_bound
based O
on O
an O
average O
of O
@NUMBER O
blood O
pressure O
readings O
measured O
at O
both O
initial O
screening O
visit O

reduction O
of O
sbp B-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
mmhg I-lower_bound
of O
diastolic B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
( I-clinical_variable
dbp I-clinical_variable
) I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
mmhg I-lower_bound
within O
@NUMBER B-upper_bound
minutes I-upper_bound
of O
standing O

known O
sensitivity O
or O
listed O
contraindication O
to O
progesterone B-allergy_name
( O
known O
allergy O
or O
hypersensitivity O
to O
progesterone O
, O
severe B-allergy_name
hepatic I-allergy_name
dysfunction I-allergy_name
, O
undiagnosed B-allergy_name
vaginal I-allergy_name
bleeding I-allergy_name
, O
mammary B-allergy_name
or O
genital B-allergy_name
tract I-allergy_name
carcinoma I-allergy_name
, O
thrombophlebitis B-allergy_name
, O
thromboembolic B-allergy_name
disorders I-allergy_name
, O
cerebral B-allergy_name
hemorrhage I-allergy_name
, O
porphyria B-allergy_name
) O

greater O
than O
@NUMBER B-lower_bound
invasive B-treatment
thoracic I-treatment
procedures I-treatment

hemoglobin B-clinical_variable
greater O
than O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

more O
than O
four B-lower_bound
weeks I-lower_bound
must O
have O
elapsed O
since O
any O
prior B-treatment
systemic I-treatment
therapy I-treatment
at O
the O
time O
the O
patient O
receives O
the O
preparative B-treatment
regimen I-treatment
, O
and O
patients O
toxicities O
must O
have O
recovered O
to O
a O
grade B-upper_bound
@NUMBER I-upper_bound
or O
less O

seronegative O
for O
active O
hepatitis B-chronic_disease
b I-chronic_disease
, O
and O
seronegative O
for O
hepatitis B-chronic_disease
c I-chronic_disease
antibody O

abdominal O
fistula B-chronic_disease

for O
this O
reason O
women B-gender
men B-gender
of O
child O
- O
bearing O
potential O
and O
men O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
adequate I-contraception_consent
contraception I-contraception_consent
( I-contraception_consent
hormonal I-contraception_consent
or I-contraception_consent
barrier I-contraception_consent
method I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
; I-contraception_consent
abstinence I-contraception_consent
) I-contraception_consent
prior O
to O
study O
entry O
and O
for O
@NUMBER B-upper_bound
months I-upper_bound
after I-upper_bound
the O
last O
dose O
of O
study B-treatment
drug I-treatment
, O
even O
if O
oral O
contraceptives O
are O
used O

karnofsky B-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound

patients O
must O
have O
tumor B-cancer
tissue O
available O
for O
submission O
that O
is O
sufficient O
to O
complete O
c O
- O
met O
fluorescence B-treatment
in I-treatment
situ I-treatment
hybridization I-treatment
( I-treatment
fish I-treatment
) I-treatment
studies O
as O
well O
as O
routine O
molecular O
profiling O
at O
the O
upmc O

patients O
who O
have O
undergone O
treatment B-treatment
for O
their O
brain B-treatment
metastases I-treatment
with O
whole B-treatment
brain I-treatment
radiotherapy I-treatment
, O
stereotactic B-treatment
radiosurgery I-treatment
, O
or O
surgical B-treatment
resection I-treatment
must O
be O
clinically O
stable O
and O
recovered O
from O
all O
procedures O
at O
the O
time O
of O
study O
enrollment O

serum B-clinical_variable
phosphorus I-clinical_variable
, O
calcium B-clinical_variable
, O
magnesium B-clinical_variable
and O
potassium B-clinical_variable
≥ O
lln O

the O
subject O
has O
received B-treatment
enzyme I-treatment
- I-treatment
inducing I-treatment
anti I-treatment
- I-treatment
epileptic I-treatment
agents I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
before O
the O
first O
dose O
of O
cabozantinib B-treatment
( O
e.g. O
, O
carbamazepine B-treatment
, O
phenytoin B-treatment
, O
phenobarbital B-treatment
, O
primidone B-treatment
) O

candidate O
ear O
( O
study O
ear O
) O
: O
minimal O
residual O
hearing O
based O
on O
the O
pure B-clinical_variable
tone I-clinical_variable
average I-clinical_variable
of O
@NUMBER B-lower_bound
, O
@NUMBER O
, O
@NUMBER O
, O
and O
@NUMBER B-upper_bound
khz I-upper_bound
thresholds O
of O
≤ O
@NUMBER B-upper_bound
db I-upper_bound
hl I-upper_bound

mri B-treatment
scan I-treatment
within O
@NUMBER B-upper_bound
months I-upper_bound
or O
at O
screening O
to O
confirm O
suitability O
for O
inner O
ear B-treatment
surgery I-treatment

bcc B-cancer
/ I-cancer
scc I-cancer
that O
was O
previously O
treated O
( O
ie O
, O
recurrent O
bcc O
/ O
scc O
) O

histopathologic O
diagnosis O
of O
basal B-cancer
or O
squamous B-cancer
cell I-cancer
carcinoma I-cancer

≥ O
@NUMBER B-lower_bound
years I-lower_bound
old O
with O
estimated O
life B-clinical_variable
expectancy I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
years I-lower_bound

off O
chemotherapy B-treatment
therapy B-treatment
for O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
entering O
this O
study O
with O
no O
toxic O
effects O
of O
that O
therapy O
, O
unless O
there O
is O
evidence O
of O
rapidly O
progressive B-chronic_disease
disease I-chronic_disease

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
year I-upper_bound
old O
male B-gender
and I-gender
female I-gender
patients I-gender
with O
primary B-chronic_disease
cervical I-chronic_disease
dystonia I-chronic_disease

barbiturates B-treatment

efavirenz B-treatment

nevirapine B-treatment

has O
hip B-chronic_disease
joint I-chronic_disease
disease I-chronic_disease
related O
to O
one O
or O
more O

infection O
, O
or O
history O
of O
infection O
, O
acute O
or O
chronic O
, O
in O
the O
hip O
joint O
, O
or O
acute O
or O
chronic O
unresolved O
systemic B-chronic_disease
infection I-chronic_disease

is O
obese B-chronic_disease
: O
( O
defined O
for O
this O
study O
as O
having O
a O
bmi B-bmi
> O
@NUMBER B-lower_bound
) O

secondary B-chronic_disease
hypertension I-chronic_disease

treatment B-treatment
with I-treatment
antihypertensive I-treatment
medications I-treatment
for O
a O
minimum O
of O
@NUMBER B-lower_bound
months I-lower_bound

have O
consensus O
criteria O
for O
severe B-chronic_disease
sepsis I-chronic_disease
( O
two B-lower_bound
of O
four B-upper_bound
systemic B-chronic_disease
inflammatory I-chronic_disease
response I-chronic_disease
syndrome I-chronic_disease
[ I-chronic_disease
sirs I-chronic_disease
] I-chronic_disease
signs O
[ O
tachycardia B-chronic_disease
, O
tachypnea B-chronic_disease
, O
fever O
or O
hypothermia B-chronic_disease
, O
leukocytosis B-chronic_disease
or O
leukopenia B-chronic_disease
] O
) O
and O
a O
known O
or O
suspected O
infection O
resulting O
in O
an O
organ O
failure O
( O
i.e O
. O
respiratory B-chronic_disease
failure I-chronic_disease
, O
renal B-chronic_disease
failure I-chronic_disease
, O
etc O
. O
) O

receipt O
of O
any O
aerosolized O
experimental O
or O
investigational B-treatment
drugs I-treatment
within O
@NUMBER B-upper_bound
month I-upper_bound
of O
enrollment O

nasal B-chronic_disease
bleeding I-chronic_disease
, O
or O
nasal B-chronic_disease
polyps I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
study O

diagnosis O
of O
possible O
or O
probable O
ad B-chronic_disease
by O
standard O
nia O
criteria O
( O
mckahnn O
et O
al O
, O
@NUMBER O
; O
mckhann O
et O
all O
, O
@NUMBER O
) O

biopsy B-treatment
sampling O
of O
primary B-cancer
tumor I-cancer
with O
pathology O
report O
documenting O
diagnostic O
tissue O
type O
is O
required O

diagnostic O
primary B-cancer
tumor I-cancer
tissue I-cancer
must O
be O
available O
for O
ercc1 B-treatment
staining I-treatment

patients O
with O
a O
second O
hnscc B-cancer
primary B-cancer
tumor I-cancer
tumor B-cancer
are O
eligible O
for O
this O
study O
, O
provided O
more O
than O
@NUMBER B-lower_bound
years I-lower_bound
have O
elapsed O
since O
the O
first O
diagnosis O
of O
hnscc O
, O
the O
original O
tumor O
was O
managed O
with O
surgery B-treatment
only O
( O
no O
a O
djuvant B-treatment
chemotherapy I-treatment
/ O
radiotherapy B-treatment
) O
, O
and O
has O
not O
recurred O

written O
informed O
consent O
must O
be O
obtained O
from O
all O
patients O
prior O
to O
beginning O
therapy B-treatment

no O
cerebrovascular B-chronic_disease
ischemia I-chronic_disease
or O
stroke B-chronic_disease
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

with O
the O
exception O
of O
patients O
with O
bilateral B-cancer
tonsil I-cancer
cancers I-cancer

prior B-treatment
mesh I-treatment
hernia I-treatment
repair I-treatment

participants O
must O
have O
high O
- O
risk O
disease O
, O
as O
defined O
by O
gep70 B-clinical_variable
risk I-clinical_variable
score I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound

patients O
must O
have O
adequate B-clinical_variable
pulmonary I-clinical_variable
function I-clinical_variable
studies I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound
of O
predicted O
on O
mechanical O
aspects O
( O
fev1 B-clinical_variable
, O
fvc B-clinical_variable
, O
etc O
) O
and O
diffusion B-clinical_variable
capacity I-clinical_variable
( I-clinical_variable
dlco I-clinical_variable
) I-clinical_variable
> O
@NUMBER O
% O
of O
predicted O

patients O
must O
have O
signed O
an O
irb O
- O
approved O
informed O
consent O
indicating O
their O
understanding O
of O
the O
proposed O
treatment B-treatment
and O
understanding O
that O
the O
protocol O
has O
been O
approved O
by O
the O
irb O

adequately O
treated O
basal B-cancer
cell I-cancer
or O
squamous B-cancer
cell I-cancer
skin I-cancer
cancer I-cancer

a O
history O
of O
other O
malignancy B-clinical_variable
≤ O
@NUMBER B-upper_bound
years I-upper_bound
previous I-upper_bound

ast B-clinical_variable
( I-clinical_variable
sgot I-clinical_variable
) I-clinical_variable
/ O
alt B-clinical_variable
( I-clinical_variable
sgpt I-clinical_variable
) I-clinical_variable
within O
( O
or O
under O
) O
normal O
limits O

er O
less O
than O
allred B-clinical_variable
score I-clinical_variable
of O
@NUMBER O
or O
less O
than O
@NUMBER B-upper_bound
% I-upper_bound
positive O
staining O
cells O
in O
the O
invasive O
component O
of O
the O
tumor B-cancer

for O
subjects O
with O
solid B-cancer
tumors I-cancer
that O
are O
not O
primary O
central B-cancer
nervous I-cancer
system I-cancer
( I-cancer
cns I-cancer
) I-cancer
tumors I-cancer
or O
nf-1 O
associated O
plexiform B-cancer
neurofibromas I-cancer
subjects O
with O
symptomatic O
or O
untreated O
leptomeningeal B-cancer
or O
brain B-cancer
metastases I-cancer
or O
spinal B-chronic_disease
cord I-chronic_disease
compression I-chronic_disease

history O
of O
another O
malignancy B-cancer
including O
resected O
non O
- O
melanomatous O
skin O
cancer O

part O
b O
, O
part O
c O
and O
part O
d O
only O
: O
previous B-treatment
treatment I-treatment
with I-treatment
dabrafenib I-treatment
or O
any O
braf B-treatment
inhibitor I-treatment
, O
trametinib B-treatment
or O
another O
mek B-treatment
inhibitor I-treatment
, O
or O
and O
extracellular B-treatment
signal I-treatment
- I-treatment
regulated I-treatment
kinase I-treatment
inhibitor I-treatment

solid B-cancer
tumor I-cancer
cohort O
( O
b1 O
) O
specific O
criteria O

subjects O
with O
moderate B-chronic_disease
valvular I-chronic_disease
thickening I-chronic_disease
should O
not O
be O
entered O
on O
study O

tumors B-cancer
that O
have O
been O
documented O
by O
clia O
or O
equivalent O
certified O
laboratory O
test O
to O
harbor O
braf O
v600 O
mutation O
at O
diagnosis O
or O
relapse O

active B-chronic_disease
and I-chronic_disease
uncontrolled I-chronic_disease
infections I-chronic_disease
will O
cause O
patients O
to O
be O
excluded O

pregnant B-pregnancy
females B-gender
are O
excluded O

gestational B-age
age I-age
: O
@NUMBER O
weeks O
, O
@NUMBER B-lower_bound
days I-lower_bound
to O
@NUMBER B-upper_bound
weeks I-upper_bound
, O
@NUMBER O
days O

subjects O
receiving O
neoadjuvant B-treatment
chemotherapy I-treatment
therapy B-treatment
for O
whom O
interval B-treatment
debulking I-treatment
surgery I-treatment
( O
assuming O
adequate O
response O
to O
therapy O
) O
is O
not O
planned O

subjects O
with O
comorbidities O
which O
would O
lead O
to O
a O
clinical O
expectation O
that O
they O
will O
not O
survive O
two B-lower_bound
years I-lower_bound
for O
reasons O
other O
than O
ovarian B-cancer
cancer I-cancer

these O
patients O
may O
be O
optimally O
debulked O
( O
less O
than O
@NUMBER B-upper_bound
cm I-upper_bound
residual B-clinical_variable
disease I-clinical_variable
) O
but O
must O
have O
grossly O
visible O
macroscopic O
residual O
disease O
or O
be O
suboptimally O
debulked O

all O
patients O
must O
have O
received O
a O
prior B-treatment
platinum I-treatment
- I-treatment
based I-treatment
chemotherapy I-treatment
regimen I-treatment
for I-treatment
treatment I-treatment
platinum B-treatment
- I-treatment
based I-treatment
chemotherapy I-treatment
regimen O
for O
treatment O
of O
urothelial B-cancer
cancer I-cancer
and O
must O
now O
be O
considered O
refractory O
to O
platinum O
- O
based O
chemotherapy O
; O
patients O
may O
have O
received O
the O
platinum B-treatment
- I-treatment
containing I-treatment
regimen I-treatment
either O
in O
the O
peri B-treatment
- I-treatment
operative I-treatment
or O
metastatic B-treatment
setting I-treatment

calculated B-clinical_variable
creatinine I-clinical_variable
clearance I-clinical_variable
≥ O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
by O
the O
modified O
cockcroft O
and O
gault O
formula O
or O
glomerular B-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
≥ O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
/ I-lower_bound
body I-lower_bound
surface I-lower_bound
area I-lower_bound
( I-lower_bound
bsa I-lower_bound
) I-lower_bound
by O
modification O
of O
diet O
in O
renal O
disease O
or O
chronic O
kidney O
disease O
epidemiology O
collaboration O
( O
ckd O
- O
epi O
) O
formula O

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
iuln I-upper_bound
) I-upper_bound

karnofsky B-clinical_variable
performance I-clinical_variable
score I-clinical_variable
< O
@NUMBER B-upper_bound

patient O
must O
be O
able O
to O
lie O
still O
in O
full O
body O
cast O
for O
@NUMBER B-upper_bound
minutes I-upper_bound

if O
remission O
bone O
marrow O
is O
available O
beyond B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
a O
new O
bone O
marrow O
evaluation O
is O
required O
to O
assess O
remission O
status O

receive O
oxytocin B-treatment

an O
mi B-chronic_disease
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound

bilirubin B-clinical_variable
< O
@NUMBER B-upper_bound
times I-upper_bound
the I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
( O
except O
patients O
with O
gilbert B-chronic_disease
's I-chronic_disease
syndrome I-chronic_disease
who O
must O
have O
a O
total B-clinical_variable
bilirubin I-clinical_variable
of O
< O
@NUMBER B-upper_bound
times I-upper_bound
uln I-upper_bound
) O

congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
( I-chronic_disease
chf I-chronic_disease
) I-chronic_disease
of O
new B-clinical_variable
york I-clinical_variable
heart I-clinical_variable
association I-clinical_variable
( I-clinical_variable
nyha I-clinical_variable
) I-clinical_variable
class I-clinical_variable
≥ O
@NUMBER B-lower_bound

major B-treatment
surgery I-treatment
within O
four B-upper_bound
weeks I-upper_bound
before O
initiation O
of O
therapy B-treatment

heterotopic B-chronic_disease
ossification I-chronic_disease

incomplete B-chronic_disease
sci I-chronic_disease

a O
negative B-pregnancy
urine I-pregnancy
pregnancy I-pregnancy
test O
is O
required O
within O
@NUMBER B-upper_bound
week I-upper_bound
for O
all O
women B-gender
of O
childbearing O
potential O
prior O
to O
enrolling O
on O
this O
trial O

for O
frontline O
cohort O
: O
no O
prior B-treatment
potentially I-treatment
- I-treatment
curative I-treatment
therapy I-treatment
for O
leukemia B-treatment
. O
prior B-treatment
therapy I-treatment
with O
hydroxyurea B-treatment
, O
hematopoietic B-treatment
growth I-treatment
factors I-treatment
, O
azacytidine B-treatment
, O
decitabine B-treatment
, O
atra B-treatment
, O
or O
a O
total O
dose O
of O
cytarabine B-clinical_variable
up O
to O
@NUMBER B-upper_bound
g I-upper_bound
( O
for O
emergency O
use O
for O
stabilization O
) O
is O
allowed O
. O
patients O
with O
secondary B-cancer
aml I-cancer
who O
have O
been O
treated O
for O
their O
antecedent B-cancer
myeloid I-cancer
neoplasm I-cancer
will O
be O
enrolled O
into O
the O
separate O
secondary B-cancer
aml I-cancer
cohort O

biologic B-treatment
( I-treatment
anti I-treatment
- I-treatment
neoplastic I-treatment
agent I-treatment
) I-treatment
: O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
must O
have O
elapsed O
since O
completion O
of O
therapy B-treatment
with I-treatment
a I-treatment
biologic I-treatment
agent I-treatment

female B-gender
participants I-gender
of O
childbearing O
potential O
can B-pregnancy
not I-pregnancy
be I-pregnancy
pregnant I-pregnancy
or O
breast O
- O
feeding O

known O
history O
of O
uncontrolled O
sleep B-chronic_disease
apnea I-chronic_disease
syndrome I-chronic_disease
or O
other O
conditions O
that O
could O
result O
in O
excessive O
daytime O
sleepiness O
, O
such O
as O
severe O
chronic B-chronic_disease
obstructive I-chronic_disease
pulmonary I-chronic_disease
disease I-chronic_disease
or O
a O
requirement O
for O
supplemental O
oxygen O

live B-clinical_variable
expectancy I-clinical_variable
> O
@NUMBER B-lower_bound
weeks I-lower_bound

at O
least O
10-years B-lower_bound
-old O

active O
heart B-chronic_disease
disease I-chronic_disease
including O
myocardial B-chronic_disease
infarction I-chronic_disease
within O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
, O
symptomatic B-chronic_disease
coronary I-chronic_disease
artery I-chronic_disease
disease I-chronic_disease
or O
heart B-chronic_disease
block I-chronic_disease
, O
or O
uncontrolled O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease

aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
ast B-clinical_variable
) O
/ O
alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
alt B-clinical_variable
) O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
; O
ast O
/ O
alt O
≤ O
@NUMBER O
x O
uln O
if O
liver B-cancer
metastasis I-cancer
is O
present O

life B-clinical_variable
expectancy I-clinical_variable
of O
greater O
than O
@NUMBER B-lower_bound
months I-lower_bound
by O
physician O
assessment O

patients O
must O
not O
have O
received O
prior B-treatment
chemotherapy I-treatment
or O
radiation B-treatment
for O
< O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
start O
of O
study O
treatment B-treatment

history O
of O
any O
cardiac B-chronic_disease
events I-chronic_disease
including O
coronary B-treatment
revascularization I-treatment
or O
ischemic O
symptoms O

uncorrectable O
coagulopathy B-chronic_disease
prohibiting O
biopsy B-treatment
. O
( O
inr B-clinical_variable
> O
@NUMBER B-lower_bound
and O
/ O
or O
platelets B-clinical_variable
< O
@NUMBER B-upper_bound
) O

active O
second O
malignancy B-cancer
that O
in O
the O
opinion O
of O
the O
pi O
may O
interfere O
with O
or O
be O
adversely O
affected O
by O
this O
treatment B-treatment

adequate O
renal O
function O
with O
creatinine B-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

known O
or O
suspected O
drug O
sensitivity O
to O
cytarabine B-allergy_name
or O
the O
investigational O
agent O
ficlatuzumab B-allergy_name

persistent B-treatment
aml I-treatment
documented O
by O
bone B-treatment
marrow I-treatment
biopsy I-treatment
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
after O
day O
@NUMBER O
of O
the O
first O
induction O
cycle O
of O
cytotoxic B-treatment
chemotherapy I-treatment

patients O
with O
hepatitis B-chronic_disease
b I-chronic_disease
on O
antivirals O
and O
low O
viral O
load O

granulomatous O
inflammation O
on O
biopsy B-treatment
, O
defined O
as O
histologic O
changes O
showing O
granulomatous O
inflammation O
within O
the O
wall O
of O
an O
artery O
or O
in O
the O
perivascular O
or O
extravascular O
area O
( O
artery O
or O
arteriole O
) O

initiation O
or O
dose O
increase O
of O
the O
maintenance B-treatment
immunosuppressive I-treatment
agent I-treatment
( O
mtx B-treatment
, O
aza B-treatment
, O
ma B-treatment
) O
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
screening O

willing O
and O
able O
to O
comply O
with O
treatment B-treatment
and O
follow O
- O
up O
procedures O

participants O
may O
not O
have O
received O
more O
than O
@NUMBER B-lower_bound
line O
of O
endocrine B-treatment
therapy I-treatment
or O
any O
prior B-treatment
chemotherapy I-treatment
for O
metastatic B-cancer
disease I-cancer

for O
the O
endocrine O
naïve O
cohort O
: O
must O
not O
have O
received O
prior O
endocrine B-treatment
therapy I-treatment
in O
current O
or O
prior O
disease O
setting O

known O
to O
be O
hiv B-chronic_disease
positive O

histologically O
confirmed O
diagnosis O
of O
melanoma B-cancer
, O
breast B-cancer
cancer I-cancer
or O
colorectal B-cancer
cancer I-cancer
at O
mskcc O

medical O
illness O
unrelated O
to O
the O
tumor B-cancer
which O
in O
the O
opinion O
of O
the O
attending O
physician O
and O
principal O
investigator O
will O
preclude O
administration O
of O
the O
agent O

newly O
diagnosed O
patients O
with O
previous O
excisional B-treatment
biopsy I-treatment

hepatomegaly B-clinical_variable
of O
greater O
than O
@NUMBER B-lower_bound
cm I-lower_bound
below O
the O
costochondral O
margin O

patients O
with O
known O
severe O
allergy O
to O
antithymocyte B-allergy_name
globulin I-allergy_name
or O
rabbits B-allergy_name

having O
a O
family O
member O
with O
psychosis B-chronic_disease

pregnancy B-pregnancy
or O
lactation O

females B-gender
of O
childbearing O
potential O
( O
fcbp O
) O
must O
have O
a O
negative B-pregnancy
serum I-pregnancy
or O
urine B-pregnancy
pregnancy I-pregnancy
test O
with O
a O
sensitivity O
of O
at O
least O
@NUMBER B-lower_bound
miu I-lower_bound
/ I-lower_bound
ml I-lower_bound
prior B-treatment
to I-treatment
starting I-treatment
therapy I-treatment
and O
prior O
to O
beginning O
another O
cycle O

patients O
must O
have O
been O
previously O
treated O
with O
an O
immunomodulatory B-treatment
drug I-treatment
( I-treatment
imid I-treatment
) I-treatment
and O
proteasome B-treatment
inhibitor I-treatment
, O
must O
be O
refractory O
to O
carfilzomib B-treatment
defined O
as O
progression O
on O
or O
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
a O
carfilzomib B-treatment
- I-treatment
containing I-treatment
therapy I-treatment
, O
and O
must O
be O
progressing O

patients O
must O
have O
a O
performance O
status O
corresponding O
to O
eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
scores I-clinical_variable
of O
@NUMBER B-lower_bound
, O
@NUMBER O
, O
or O
@NUMBER B-upper_bound

patients O
with O
t B-cancer
- I-cancer
lymphoblastic I-cancer
leukemia I-cancer
( I-cancer
t I-cancer
- I-cancer
all I-cancer
) I-cancer
/ O
lymphoblastic B-cancer
lymphoma I-cancer
( I-cancer
t I-cancer
- I-cancer
ll I-cancer
) I-cancer

patients O
with O
known O
human O
immunodeficiency B-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
infection O

sexually O
active O
patients O
of O
reproductive O
potential O
who O
have O
not B-contraception_consent
agreed I-contraception_consent
to I-contraception_consent
use I-contraception_consent
an I-contraception_consent
effective I-contraception_consent
contraceptive I-contraception_consent
method I-contraception_consent
for O
the O
duration O
of O
their O
study O
participation O

active O
optic B-chronic_disease
glioma I-chronic_disease
or O
other O
low O
- O
grade O
glioma O
requiring O
treatment B-treatment
with O
chemotherapy B-treatment
or O
radiation B-treatment
therapy I-treatment

at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
since O
receiving O
any O
investigational B-treatment
drug I-treatment

concomitant B-treatment
treatment I-treatment
of I-treatment
strong I-treatment
cyp3a4 I-treatment
inducers I-treatment
or I-treatment
inhibitors I-treatment

fully O
recovered O
from O
acute O
toxic O
effects O
of O
all O
prior B-treatment
chemotherapy I-treatment
or O
radiotherapy B-treatment

other O
disorders O
associated O
with O
a O
high O
risk O
of O
fistula B-chronic_disease
formation O
including O
peg B-treatment
tube I-treatment
placement I-treatment
within O
@NUMBER B-upper_bound
months I-upper_bound
before I-upper_bound
the O
first O
dose O
of O
study O
therapy B-treatment

subject O
has O
not O
recovered O
to O
baseline O
or O
ctcae B-clinical_variable
≤ O
grade B-upper_bound
@NUMBER I-upper_bound
from O
toxicity O
due O
to O
all O
prior B-treatment
therapies I-treatment
except O
alopecia B-chronic_disease
and O
other O
non O
- O
clinically O
significant O
aes O

clinically O
- O
significant O
cardiac B-chronic_disease
arrhythmias I-chronic_disease

food O
or O
drugs O
that O
are O
known O
to O
be O
cyp3a4 B-treatment
inhibitors I-treatment
( O
e.g O
. O
grapefruit O
juice O
, O
verapamil B-treatment
, O
ketoconazole B-treatment
, O
miconazole B-treatment
, O
itraconazole B-treatment
, O
erythromycin B-treatment
, O
clarithromycin B-treatment
, O
telithromycin B-treatment
, O
indinavir B-treatment
, O
ritonavir B-treatment
, O
nelfinavir B-treatment
, O
atazanavir B-treatment
, O
amprenavir B-treatment
, O
nefazodone B-treatment
, O
diltiazem B-treatment
, O
and O
delavirdine B-treatment
) O
or O
inducers O
( O
i.e O
. O
dexamethasone B-treatment
, O
glucocorticoids B-treatment
, O
progesterone B-treatment
, O
rifampin B-treatment
, O
phenobarbital B-treatment
, O
st B-treatment
. I-treatment
john I-treatment
's I-treatment
wort I-treatment
) O

minimum O
of O
@NUMBER B-upper_bound
days I-upper_bound
elapsed O
since O
the O
end O
of O
any O
prior B-treatment
therapy I-treatment

any O
disease O
, O
diagnosis O
, O
or O
condition O
( O
medical O
or O
surgical O
) O
that O
, O
in O
the O
opinion O
of O
the O
principal O
investigator O
, O
would O
place O
the O
subject O
at O
increased O
risk O
( O
active O
gynecologic B-chronic_disease
disease I-chronic_disease
in O
which O
increased O
tone O
would O
be O
detrimental O
e.g. O
, O
uterine B-chronic_disease
fibroids I-chronic_disease
with O
ongoing O
bleeding O
) O
, O
compromise O
the O
subject O
's O
compliance O
with O
study O
procedures O
, O
or O
compromise O
the O
quality O
of O
the O
dat O

children O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
who O
have O
not O
provided O
informed O
assent O
in O
the O
presence O
of O
a O
parent O
and O
an O
attending O
physician O
who O
is O
not O
a O
member O
of O
the O
recipient O
's O
care O
team O

osteosarcoma B-cancer
: O
must O
have O
progressed O
or O
recurred O
after O
standard B-treatment
frontline I-treatment
therapy I-treatment

requirement O
for O
other O
cardiac B-treatment
or I-treatment
non I-treatment
- I-treatment
cardiac I-treatment
surgical I-treatment
procedure I-treatment
( O
e.g. O
, O
valve B-treatment
replacement I-treatment
, O
carotid B-treatment
revascularization I-treatment
) O

with O
angina B-chronic_disease
and O
/ O
or O
evidence O
of O
myocardial B-chronic_disease
ischemia I-chronic_disease

subject O
has O
had O
major B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
abbv-399 B-treatment

subject O
has O
history O
of O
major O
immunologic O
reaction O
to O
any O
immunoglobulin B-treatment
g I-treatment
( I-treatment
igg I-treatment
) I-treatment
containing I-treatment
agent I-treatment

subjects O
with O
brain B-chronic_disease
metastases I-chronic_disease
may O
be O
eligible O
@NUMBER B-lower_bound
weeks I-lower_bound
after I-lower_bound
definitive O
therapy B-treatment
to O
all O
known O
sites O
of O
cns B-chronic_disease
disease I-chronic_disease
provided O
they O
are O
asymptomatic O
and O
either O
off O
or O
on O
a O
non O
- O
increasing O
dose O
( O
in O
last B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound
) O
of O
systemic B-treatment
steroids I-treatment
and O
not O
on O
anticonvulsants O
for O
seizure B-chronic_disease
activity O
directly O
related O
to O
progressive O
cns B-cancer
metastases I-cancer

anatomy O
requiring O
coronary B-treatment
artery I-treatment
bypass I-treatment
surgery I-treatment
( I-treatment
cabg I-treatment
) I-treatment

allergies O
to O
clinically O
utilized O
anti B-allergy_name
- I-allergy_name
thrombotic I-allergy_name
or O
anti B-allergy_name
- I-allergy_name
platelet I-allergy_name
agents I-allergy_name

pregnant B-pregnancy
or O
breast O
feeding O
( O
lactating O
) O
women B-gender
, O
where O
pregnancy B-pregnancy
is O
defined O
as O
the O
state O
of O
a O
female B-gender
after O
conception O
and O
until O
the O
termination O
of O
gestation O
, O
confirmed O
by O
a O
positive O
beta B-treatment
- I-treatment
human I-treatment
chorionic I-treatment
gonadotropin I-treatment
( I-treatment
hcg I-treatment
) I-treatment
laboratory O
test O

no O
contraindications O
to O
getting O
contrast O
enhanced O
mri B-treatment
examinations O

plans O
during O
the O
trial O
to O
receive O
any O
other O
( O
non O
- O
trial O
) O
investigational B-treatment
agents I-treatment
, O
or O
concurrent O
biological O
, O
chemotherapy B-treatment
, O
or O
radiation B-treatment
therapy I-treatment

disseminated B-chronic_disease
disease I-chronic_disease
( O
e.g O
. O
lepto B-cancer
- I-cancer
meningeal I-cancer
spread O
, O
tumor B-cancer
metastases I-cancer
) O

hepatic O
, O
biliary O
, O
cardiac O
, O
or O
bone O
marrow O
function O
inadequate O
for O
chemotherapy B-treatment
as O
per O
patient O
's O
treatment B-treatment
regimen I-treatment

females B-gender
who O
are O
pregnant B-pregnancy
or O
breastfeeding O
, O
and O
males B-gender
and I-gender
females I-gender
who O
can O
not O
comply O
with O
requirements O
to O
avoid O
fathering O
a O
child O
or O
becoming B-pregnancy
pregnant I-pregnancy

subjects O
must O
be O
able O
to O
discontinue O
any O
drug B-treatment
treatment I-treatment
aimed O
at O
lowering O
disease O
burden O
in O
cnl B-cancer
or O
acml B-cancer

cardiac B-chronic_disease
dysfunction I-chronic_disease

hemorrhagic B-chronic_disease
strokes I-chronic_disease

any O
anticancer B-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
study O
drug O

dose O
escalation O
, O
renal B-chronic_disease
insufficiency I-chronic_disease
, O
nsclc B-cancer
and O
cpi B-treatment
-treated O
expansion O
cohorts O

histologic O
or O
cytologic O
diagnosis O
of O
nsclc B-cancer
( O
squamous B-cancer
or I-cancer
non I-cancer
- I-cancer
squamous I-cancer
or I-cancer
nsclc I-cancer
-not O
specified O
) O

monocularity B-chronic_disease

negative B-pregnancy
pregnancy I-pregnancy
test O
( O
women B-gender
of O
childbearing O
potential O
) O

uncontrolled O
central B-cancer
nervous I-cancer
system I-cancer
metastases I-cancer

uncontrolled O
or O
evolving O
retinopathy B-chronic_disease
, O
wet B-chronic_disease
macular I-chronic_disease
degeneration I-chronic_disease
, O
uveitis B-chronic_disease
, O
papilledema B-chronic_disease
, O
or O
optic B-chronic_disease
disc I-chronic_disease
disorder I-chronic_disease

creatinine B-clinical_variable
clearance I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
by O
the O
cockcroft B-clinical_variable
- I-clinical_variable
gault I-clinical_variable
equation I-clinical_variable
or O
as O
measured O
by O
@NUMBER O
hour O
urine O
collection O

any O
significant O
cardiovascular B-chronic_disease
events I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
study O
entry O

life B-clinical_variable
expectancy I-clinical_variable
greater O
than O
or O
equal O
to O
( O
≥ O
) O
@NUMBER B-lower_bound
weeks I-lower_bound

measurable B-chronic_disease
disease I-chronic_disease
by O
recist O
v1.1 O

molecular O
testing O
results O
from O
clia O
- O
certified O
laboratories O
( O
using O
tissue O
) O
demonstrating O
elevated O
tissue O
tumor O
mutational O
burden O
( O
ttmb B-clinical_variable
≥ O
@NUMBER B-lower_bound
mutations O
/ O
megabase B-clinical_variable
[ I-clinical_variable
mb I-clinical_variable
] I-clinical_variable
) O

participants O
with O
hematologic B-cancer
malignancies I-cancer

previous O
treatment B-treatment
with O
any O
her2 B-cancer
-targeted O
therapy B-treatment

refractory O
nausea B-chronic_disease
and O
vomiting B-chronic_disease
, O
malabsorption B-chronic_disease
, O
external O
biliary O
shunt O
, O
or O
significant O
bowel O
resection O
that O
would O
preclude O
absorption O
of O
erlotinib B-treatment

uncontrolled O
or O
symptomatic O
hypercalcemia B-chronic_disease

aneurysm B-clinical_variable
with O
a O
history O
of O
growth O
≥ O
@NUMBER B-lower_bound
cm I-lower_bound
per I-lower_bound
year I-lower_bound

diameter B-clinical_variable
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
mm I-upper_bound

diameter B-clinical_variable
: O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
mm I-upper_bound

examples O
include O
remote O
( O
> O
@NUMBER B-lower_bound
days I-lower_bound
) O
participation B-treatment
in I-treatment
a I-treatment
thoracic I-treatment
, I-treatment
abdominal I-treatment
or I-treatment
iliac I-treatment
branch I-treatment
device I-treatment
trial I-treatment
, O
or O
participation B-treatment
in I-treatment
a I-treatment
percutaneous I-treatment
aortic I-treatment
valve I-treatment
trial I-treatment

prior B-treatment
open I-treatment
surgical I-treatment
or I-treatment
interventional I-treatment
procedure I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
the O
anticipated O
date O
of O
the O
fenestrated B-treatment
- I-treatment
branched I-treatment
procedure I-treatment
, O
with O
the O
exception O
of O
planned O
staged O
procedures O
to O
provide O
access O
for O
repair O
( O
e.g O
. O
staged B-treatment
iliac I-treatment
conduit I-treatment
, O
cervical B-treatment
debranching I-treatment
, O
elephant B-treatment
trunk I-treatment
repair I-treatment
) O
, O
to O
facilitate O
the O
procedure O
by O
allowing O
open B-treatment
revascularization I-treatment
of I-treatment
a I-treatment
target I-treatment
artery I-treatment
not I-treatment
amenable I-treatment
to I-treatment
revascularization I-treatment
with I-treatment
the I-treatment
investigational I-treatment
device I-treatment
, O
such O
as O
an O
internal B-treatment
iliac I-treatment
artery I-treatment
, O
subclavian B-treatment
artery I-treatment
or O
visceral B-treatment
artery I-treatment
with O
early O
bifurcation O
, O
tortuosity O
or O
occlusive B-chronic_disease
disease I-chronic_disease
preventing O
successful O
placement O
of O
alignment O
side O
stents O

supra B-chronic_disease
- I-chronic_disease
aortic I-chronic_disease
trunk I-chronic_disease
( I-chronic_disease
brachiocephalic I-chronic_disease
) I-chronic_disease
vessels I-chronic_disease

the O
repair O
may O
be O
coupled O
with O
a O
thoracoabdominal B-treatment
branched I-treatment
device I-treatment
, O
infrarenal B-treatment
device I-treatment
, O
and O
/ O
or O
internal B-treatment
iliac I-treatment
branch I-treatment
device I-treatment

visceral O
vessel O
anatomy O
not O
compatible O
with O
zenith O
t O
- O
branch O
or O
patient O
- O
specific O
stent O
- O
graft O
due O
to O
excessive O
occlusive B-chronic_disease
disease I-chronic_disease
or O
small O
size O
not O
amenable O
to O
stent B-treatment
graft I-treatment
placement I-treatment

cabg B-treatment

patient O
has O
hyperparathyroidism B-chronic_disease

currently O
taking O
or O
intending O
to O
take O
during O
the O
study O
duration O
any O
medication B-treatment
known O
to O
affect O
glycemic O
parameters O
, O
such O
as O
glucocorticoids B-treatment
, O
growth B-treatment
hormone I-treatment
, O
or O
fluoroquinolones B-treatment

traumatic B-clinical_variable
arrest I-clinical_variable
with O
> O
@NUMBER B-lower_bound
minutes I-lower_bound
cpr B-treatment
without O
return O
of O
vital O
signs O

self O
- O
reported O
frequent O
snoring O
( O
≥ O
@NUMBER B-lower_bound
x I-lower_bound
/ I-lower_bound
week I-lower_bound
over O
past O
month O
) O
or O
self O
- O
reported O
non O
- O
snorer O

participants O
with O
tumors B-cancer
involving O
the O
optic O
chiasm O
, O
brain O
, O
or O
spinal O
cord O

tumors B-cancer
that O
are O
not O
clearly O
seen O
by O
mri B-treatment
but O
showing O
on O
pet B-treatment
/ O
ct B-treatment
will O
be O
ablated O
with O
pet O
/ O
ct O
guidance O

may O
not O
be O
receiving O
any O
other O
study B-treatment
agents I-treatment

metastatic B-cancer
advanced O
disease O

patients O
with O
pathology O
or O
cytology O
showing O
carcinoma B-cancer
of I-cancer
pancreas I-cancer
or O
adenosquamous B-cancer
of I-cancer
the I-cancer
pancreas I-cancer

corrected O
dlco B-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound

myelosuppressive B-treatment
chemotherapy I-treatment

may O
receive O
transfusions B-treatment

allergy O
to O
@NUMBER B-allergy_name
- I-allergy_name
aminolevulinic I-allergy_name
acid I-allergy_name
( I-allergy_name
ala I-allergy_name
) I-allergy_name
or O
any O
component B-allergy_name
of I-allergy_name
the I-allergy_name
vehicle I-allergy_name

history O
of O
disorder B-chronic_disease
of I-chronic_disease
porphyrin I-chronic_disease
metabolism I-chronic_disease

clinically O
significant O
fractures O
as O
defined O
by O
iscd O
( O
a O
long O
bone O
fracture O
of O
the O
lower O
extremities O
, O
vertebral O
compression O
fracture O
, O
or O
two O
or O
more O
long O
bone O
fractures O
of O
the O
upper O
extremities O
) O
( O
@NUMBER O
) O
indicated O
by O
a O
cast O
or O
a O
spine O
x B-treatment
- I-treatment
ray I-treatment
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound

patients O
with O
severe O
aplastic B-chronic_disease
anemia I-chronic_disease
are O
eligible O
regardless O
of O
conditioning B-treatment
regimen I-treatment

subjects O
who O
turn O
@NUMBER B-upper_bound
during O
the O
course O
of O
the O
study O
will O
be O
consented O
at O
that O
time O
of O
their O
next O
visit O
by O
a O
member O
of O
the O
research O
staff O

expected O
chronic B-chronic_disease
thrombocytopenia I-chronic_disease
in O
patients O
with O
newly O
diagnosed O
marrow B-chronic_disease
failure I-chronic_disease
syndromes I-chronic_disease
, O
myelodysplastic B-cancer
syndromes I-cancer
, O
aplastic B-chronic_disease
anemia I-chronic_disease
, O
chronic B-cancer
myelomonocytic I-cancer
leukemia I-cancer
or O
myelofibrosis B-cancer

patient O
receiving O
anticoagulation B-treatment

untreated O
coagulopathy B-chronic_disease

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

evidence O
of O
pulmonary B-chronic_disease
insufficiency I-chronic_disease

severe O
peripheral B-chronic_disease
vascular I-chronic_disease
disease I-chronic_disease
that O
would O
preclude O
catheterization B-treatment

stage O
@NUMBER O
, O
@NUMBER O
, O
@NUMBER O
or O
early O
and O
intermediate O
stage O
iva O
( O
t1n0 O
- O
2b O
, O
t2n0 O
- O
2b O
) O
( O
level O
@NUMBER O
, O
non O
- O
matted O
) O
disease O
without O
evidence O
distant O
metastases B-cancer
or O
extracapsular O
extension O
. O
primary O
site O
must O
be O
lateralized O
for O
a O
functional B-treatment
dissection I-treatment

all O
patients O
must O
have O
completed O
any O
prior B-treatment
chemotherapy I-treatment
, O
targeted B-treatment
therapy I-treatment
, O
radiotherapy B-treatment
( O
unless O
palliative O
doses O
which O
must O
be O
discussed O
with O
study O
principal O
investigator O
) O
, O
surgery B-treatment
, O
anti B-treatment
- I-treatment
angiogenic I-treatment
therapy I-treatment
or O
interferon B-treatment
≥ O
@NUMBER B-lower_bound
days I-lower_bound
before I-lower_bound
study O
entry O

history O
or O
current O
evidence O
/ O
risk O
of O
retinal B-chronic_disease
vein I-chronic_disease
occlusion I-chronic_disease
( I-chronic_disease
rvo I-chronic_disease
) I-chronic_disease

international B-clinical_variable
normalized I-clinical_variable
ratio I-clinical_variable
( I-clinical_variable
inr I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
uln I-upper_bound

patients O
with O
pancreatic B-cancer
cancer I-cancer
, O
colorectal B-cancer
cancer I-cancer
, O
and O
braf O
v600e O
melanoma B-cancer
patients O
who O
have O
failed O
braf B-treatment
inhibitors I-treatment
are O
allowed O
to O
enroll O
in O
the O
moderate O
and O
severe O
cohorts O
provided O
the O
patients O
: O
@NUMBER O
) O
sign O
a O
separate O
consent O
form O
which O
outlines O
the O
extremely O
limited O
activity O
observed O
in O
prior O
studies O
, O
and O
@NUMBER O
) O
are O
consented O
to O
the O
study O
by O
a O
protocol O
- O
specified O
designee O
who O
is O
not O
their O
longitudinal O
oncologist O

any O
prior O
malignancy B-cancer

post O
- O
menopausal O
women B-gender
will O
not O
be O
included O
due O
to O
changes O
in O
the O
hpa O
axis O
expression O
and O
hormonal O
effects O
on O
cognition O
. O
in O
women O
over O
the O
age B-age
of O
@NUMBER B-lower_bound
, O
menopausal O
status O
will O
be O
evaluated O
clinically O

other O
dental O
health O
problems O
that O
might O
interfere O
with O
the O
assessment O
, O
installation O
, O
or O
wearing O
of O
orthotic B-treatment
device I-treatment

history O
of O
gallbladder B-chronic_disease
problems I-chronic_disease
or O
gallstones B-chronic_disease
, O
or O
biliary B-chronic_disease
obstruction I-chronic_disease

hormone B-treatment
therapy I-treatment
before O
surgery B-treatment

no O
plan O
to O
receive O
adjuvant B-treatment
hormone I-treatment
or O
radiation B-treatment
therapy I-treatment

concurrent O
participation O
in O
other B-treatment
therapeutic I-treatment
trials I-treatment

have O
self O
- O
reported O
fm B-chronic_disease
symptoms O
for O
at O
least O
one B-lower_bound
year I-lower_bound
and O
also O
meet O
the O
wolfe O
et O
al O
@NUMBER O
criteria O
for O
fibromyalgia B-chronic_disease

willing O
to O
limit O
the O
introduction O
of O
any O
new O
medications B-treatment
or O
treatment B-treatment
modalities O
for O
control O
of O
fm B-chronic_disease
symptoms O
during O
the O
study O

complete B-clinical_variable
blood I-clinical_variable
count I-clinical_variable
( I-clinical_variable
cbc I-clinical_variable
) I-clinical_variable
/ O
differential O
obtained O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
( O
@NUMBER B-upper_bound
days I-upper_bound
) O
prior O
to O
registration O
on O
study O
, O
with O
adequate O
bone O
marrow O
function O

previous O
or O
concurrent O
cytotoxic B-treatment
chemotherapy I-treatment
for O
prostate B-cancer
cancer I-cancer

use O
of O
dutasteride B-treatment
or O
dutasteride O
/ O
tamsulosin B-treatment
( O
jalyn B-treatment
) O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

for O
dose O
escalation O
and O
dose O
expansion O
in O
combination O
with O
bms-936558 O
: O
hl O
and O
dlbcl B-cancer

current O
non O
- O
medical O
use O
of O
cocaine O
, O
psychostimulants O
, O
or O
opioids O
( O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
) O

partial O
response O
of O
> O
@NUMBER B-lower_bound
% I-lower_bound
reduction B-clinical_variable
in I-clinical_variable
bidirectional I-clinical_variable
area I-clinical_variable
of I-clinical_variable
masses I-clinical_variable
and O
suv B-clinical_variable
reduction I-clinical_variable
to O
< O
@NUMBER B-upper_bound
in O
pet B-treatment
avid O
areas O
subjects O
must O
have O
evaluable O
disease O

subjects O
may O
not O
be O
receiving O
any B-treatment
other I-treatment
investigational I-treatment
agents I-treatment
( O
defined O
as O
non O
fda O
- O
approved O
agents O
) O
at O
the O
time O
of O
initiating O
bendamustine B-treatment
regimen I-treatment

have O
experienced O
a O
myocardial B-chronic_disease
infarction I-chronic_disease
or O
unstable B-chronic_disease
angina I-chronic_disease

non O
- O
cardiac O
condition O
limiting O
life B-clinical_variable
expectancy I-clinical_variable
to O
less O
than O
one B-upper_bound
year I-upper_bound
, O
per O
physician O
judgment O

patients O
taking O
alpha B-treatment
antagonists I-treatment
or O
cytochrome B-treatment
p450 I-treatment
@NUMBER I-treatment
a4 I-treatment
inhibitors I-treatment
( O
ketoconazole B-treatment
, O
itraconazole B-treatment
, O
erythromycin B-treatment
, O
saquinavir B-treatment
, O
cimetidine B-treatment
or O
serum B-treatment
proteases I-treatment
inhibitors I-treatment
for O
hiv B-chronic_disease
) O
who O
can O
not O
be O
taken O
off O
these O
medications B-treatment
for O
the O
duration O
of O
the O
study O

silodosin B-treatment

tamsulosin B-treatment

ventricular B-chronic_disease
fibrillation I-chronic_disease
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
screening O

for O
part O
g O
, O
h O
, O
and O
i O
: O
have O
measureable B-chronic_disease
disease I-chronic_disease
as O
defined O
by O
recist O
@NUMBER O

for O
part O
h O
: O
( O
abemaciclib B-treatment
+ O
trastuzumab B-treatment
+ O
pertuzumab B-treatment
) O
: O
the O
participant O
must O
have O
received O
at O
least O
@NUMBER B-lower_bound
chemotherapy B-treatment
regimen I-treatment
for O
metastatic B-cancer
disease I-cancer

have O
a O
diagnosis O
of O
hormone B-cancer
receptor I-cancer
positive I-cancer
( I-cancer
hr+ I-cancer
) I-cancer
, O
human B-cancer
epidermal I-cancer
growth I-cancer
factor I-cancer
receptor I-cancer
@NUMBER I-cancer
( I-cancer
her2 I-cancer
) I-cancer
negative O
metastatic B-cancer
breast I-cancer
cancer I-cancer
for O
parts O
a O
to O
e O
, O
g O
, O
and O
i O

have O
a O
diagnosis O
of O
human O
epidermal O
growth O
factor O
receptor O
@NUMBER O
( O
her2 B-clinical_variable
) O
positive O
metastatic B-cancer
breast I-cancer
cancer I-cancer
for O
parts O
f O
and O
h O

the O
participant O
must O
have O
an O
estimated O
left B-clinical_variable
ventricular I-clinical_variable
ejection I-clinical_variable
fraction I-clinical_variable
within O
the O
normal O
range O
by O
either O
echocardiogram B-treatment
or O
multigated O
acquisition O
( O
muga O
) O
scan O

the O
participant O
should O
remain O
on O
the O
current O
endocrine B-treatment
therapy I-treatment
while O
receiving O
abemaciclib B-treatment

multiple O
failed O
medication B-treatment
treatments B-treatment
of O
inadequate O
dose O
or O
duration O

presence O
of O
psychotic B-chronic_disease
features O

severe O
medical O
co O
- O
morbidity O
including O
cardiovascular B-chronic_disease
disorder I-chronic_disease
, O
lung B-chronic_disease
disorder I-chronic_disease
, O
kidney B-chronic_disease
disease I-chronic_disease
, O
chronic O
neurological B-chronic_disease
disease I-chronic_disease
, O
hematological B-chronic_disease
disease I-chronic_disease
, O
or O
frailty O
that O
impacts O
tolerability O
of O
the O
surgery B-treatment
as O
judged O
by O
the O
screening O
physicians O

ts O
must O
be O
medication B-treatment
refractory O
. O
criteria O
to O
determine O
if O
medication O
refractory O
is O
the O
exact O
criteria O
stated O
by O
mink O
et O
. O
al O
tsa O
dbs O
guidelines O
published O
in O
@NUMBER B-lower_bound
@NUMBER O
: O
subjects O
must O
have O
been O
treated O
by O
a O
psychiatrist O
or O
neurologist O
experienced O
in O
ts O
with O
therapeutic O
doses O
of O
either O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
day I-upper_bound
of O
haloperidol B-treatment
or O
@NUMBER O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
day I-upper_bound
of O
pimozide B-treatment
, O
risperidone B-treatment
( O
@NUMBER O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
day I-upper_bound
) O
, O
and O
aripiprazole B-treatment
( O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
day I-upper_bound
) O

active B-chronic_disease
or I-chronic_disease
suspected I-chronic_disease
infection I-chronic_disease

sickle B-chronic_disease
cell I-chronic_disease
anemia I-chronic_disease

history O
of O
chronic O
pain O
or O
ongoing O
treatment B-treatment
for O
chronic O
pain O

serum B-clinical_variable
creatinine I-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
( O
need O
for O
contrast O
with O
ct B-treatment
coronary I-treatment
angiogram I-treatment
) O

documented O
severe O
hemophilia B-chronic_disease
b I-chronic_disease
( O
fix B-clinical_variable
activity I-clinical_variable
of O
≤ O
@NUMBER B-upper_bound
% I-upper_bound
) O
, O
or O
confirmed O
at O
screening O
by O
the O
central O
laboratory O

known O
hypersensitivity O
( O
ie O
, O
allergic O
reaction O
or O
anaphylaxis O
) O
to O
any O
fix B-allergy_name
product I-allergy_name
or O
hamster B-allergy_name
protein I-allergy_name

known O
kidney B-chronic_disease
or O
liver B-chronic_disease
dysfunction I-chronic_disease
or O
any O
condition O
which O
, O
in O
the O
investigator O
's O
opinion O
, O
place O
the O
patient O
at O
unjustifiable O
risk O

chronic B-treatment
systemic I-treatment
corticosteroid I-treatment
treatment I-treatment

impaired B-chronic_disease
renal I-chronic_disease
function I-chronic_disease
or O
creatinine B-clinical_variable
clearance I-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound

women B-gender
on O
hormonal O
contraceptives O

causes O
of O
ph B-chronic_disease
other O
than O
that O
of O
heart B-chronic_disease
failure I-chronic_disease
, O
such O
as O
: O
chronic B-chronic_disease
thromboembolic I-chronic_disease
ph I-chronic_disease
, O
sickle B-chronic_disease
- I-chronic_disease
cell I-chronic_disease
disease I-chronic_disease
, O
or O
sarcoidosis B-chronic_disease

group O
a O
: O
cd19 O
+ O
b B-cancer
- I-cancer
all I-cancer
undergoing O
allogeneic O
hsct B-treatment
or O
group O
b O
: O
cd19 O
+ O
b B-cancer
cell I-cancer
cll I-cancer
or O
nhl B-cancer
undergoing O
allogeneic O
hsct O

residual B-cancer
disease I-cancer
at O
the O
time O
of O
transplant B-treatment
( O
bulky O
or O
minimal O
) O
or O
post B-treatment
transplant I-treatment
relapse O
as O
evidenced O
by O
pcr O
positivity O
, O
specific O
cytogenetic O
abnormalities O
, O
an O
abnormal O
population O
on O
flow B-treatment
cytometry I-treatment
or O
increased O
blasts O
on O
bone B-treatment
marrow I-treatment
biopsy I-treatment
or O
in O
the O
peripheral O
blood O

severe O
intercurrent O
infection B-chronic_disease

previous B-treatment
abdominal I-treatment
surgery I-treatment

previous B-treatment
left I-treatment
- I-treatment
sided I-treatment
thoracotomy I-treatment
( O
if O
the O
proposed O
open B-treatment
repair I-treatment
would O
require O
dissection B-treatment
of I-treatment
the I-treatment
thoracic I-treatment
aorta I-treatment
) O

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
> O
@NUMBER B-lower_bound
/ I-lower_bound
mm^3 I-lower_bound

platelet B-clinical_variable
count I-clinical_variable
> O
@NUMBER B-lower_bound
/ I-lower_bound
mm^3 I-lower_bound

pleural B-chronic_disease
effusion I-chronic_disease
or O
ascites B-chronic_disease
that O
causes O
respiratory O
compromise O
( O
≥ O
grade B-lower_bound
@NUMBER I-lower_bound
dyspnea B-clinical_variable
) O

post O
- O
menopausal O
women B-gender
( O
defined O
as O
age B-age
≥ O
@NUMBER B-lower_bound
years I-lower_bound
and O
no O
menses O
for O
at O
least O
@NUMBER B-lower_bound
year I-lower_bound
) O

surgically O
sterilized O
women B-gender
are O
not O
required O
to O
undergo O
a O
pregnancy O
test O

up O
to O
@NUMBER B-upper_bound
prior B-treatment
therapies I-treatment
are O
allowed O

all O
acute O
toxic O
effects O
of O
any O
prior B-treatment
treatment I-treatment
have O
resolved O
to O
nci- O
ctcae B-clinical_variable
v I-clinical_variable
@NUMBER I-clinical_variable
grade I-clinical_variable
@NUMBER B-upper_bound
or O
less O
( O
except O
alopecia B-chronic_disease
) O
at O
the O
time O
of O
signing O
the O
informed O
consent O
form O
( O
icf O
) O

known O
or O
suspected O
allergy O
or O
hypersensitivity O
to O
regorafenib B-allergy_name
, O
or O
excipients O
of O
the O
formulations O
given O
during O
the O
course O
of O
this O
trial O

history O
of O
cardiovascular B-chronic_disease
disease I-chronic_disease
( I-chronic_disease
cvd I-chronic_disease
) I-chronic_disease
, O
diabetes B-chronic_disease
mellitus I-chronic_disease
, O
uncontrolled B-chronic_disease
hypertension I-chronic_disease
, O
untreated O
thyroid B-chronic_disease
disease I-chronic_disease
, O
renal B-chronic_disease
disease I-chronic_disease
, O
hepatic B-chronic_disease
disease I-chronic_disease
, O
or O
any O
other O
medical O
condition O
affecting O
weight O
or O
energy O
metabolism O

estimated O
glomerular B-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
( I-clinical_variable
gfr I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound

no O
significant O
cardiac B-chronic_disease
disease I-chronic_disease
, O
including O
the O
following O
: O
unstable B-chronic_disease
angina I-chronic_disease
, O
new B-clinical_variable
york I-clinical_variable
heart I-clinical_variable
association I-clinical_variable
class I-clinical_variable
ii B-lower_bound
- O
iv B-upper_bound
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
myocardial B-chronic_disease
infarction I-chronic_disease
within O
six B-treatment
months I-treatment
prior I-treatment
to O
study O
enrollment O

resectable B-cancer
pancreatic I-cancer
adenocarcinoma I-cancer
disease I-cancer

basal B-cancer
cell I-cancer
carcinoma I-cancer
of I-cancer
the I-cancer
skin I-cancer
, O
cervical B-cancer
carcinoma I-cancer
in I-cancer
situ I-cancer
, O
or O
non B-cancer
- I-cancer
metastatic I-cancer
prostate I-cancer
cancer I-cancer

any O
clinically O
significant O
abnormality O
on O
preoperative O
magnetic B-treatment
resonance I-treatment
imaging I-treatment
( I-treatment
mri I-treatment
) I-treatment

any O
surgical O
contraindications O
to O
undergoing O
dbs B-treatment
, O
including O
labeled O
contraindications O
for O
dbs O
and O
/ O
or O
inability O
to O
undergo O
presurgical B-treatment
mri I-treatment
( O
cardiac B-treatment
pacemaker I-treatment
, O
implantable B-treatment
defibrillator I-treatment
or O
other O
implantable B-treatment
stimulator I-treatment
, O
pregnancy B-pregnancy
, O
metal O
in O
body O
, O
severe O
claustrophobia B-chronic_disease
) O
, O
infection B-chronic_disease
, O
coagulopathy B-chronic_disease
, O
inability O
to O
undergo O
an O
awake O
operation O
, O
significant O
cardiac O
or O
other O
medical O
risk O
factors O
for O
surgery B-treatment

major O
impairment O
in O
functioning O
or O
potentially O
severe O
medical O
outcomes O
( O
repeated O
hospitalizations B-treatment
, O
serious O
suicidal B-chronic_disease
or O
other O
self O
- O
injurious O
behavior O
) O

presence O
of O
a O
condition O
requiring O
diathermy B-treatment

@NUMBER B-upper_bound
month I-upper_bound
washout O
for O
leflunomide B-treatment
, O
ivig B-treatment
or O
cyclophosphamide B-treatment

absolute B-clinical_variable
lymphocyte I-clinical_variable
count I-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
@NUMBER I-upper_bound
/ I-upper_bound
l I-upper_bound
( I-upper_bound
@NUMBER I-upper_bound
/ I-upper_bound
mm3 I-upper_bound
) I-upper_bound

ivig B-treatment
will O
also O
be O
allowed O
as O
an O
immunomodulatory B-treatment
agent I-treatment

known O
active O
current O
or O
history O
of O
recurrent B-chronic_disease
bacterial I-chronic_disease
, O
viral B-chronic_disease
, O
fungal B-chronic_disease
, O
mycobacterial B-chronic_disease
or O
other O
infections B-chronic_disease
( O
including O
but O
not O
limited O
to O
tuberculosis B-chronic_disease
and O
atypical B-chronic_disease
mycobacterial I-chronic_disease
disease I-chronic_disease
, O
hepatitis B-chronic_disease
b I-chronic_disease
and I-chronic_disease
c I-chronic_disease
, O
and O
herpes B-chronic_disease
zoster I-chronic_disease

requires O
non O
- O
emergent O
operation O
to O
create O
an O
intestinal B-treatment
anastomosis I-treatment
for O
maintenance O
of O
intestinal O
continuity O
in O
which O
the O
magnamosis O
device O
can O
be O
used O
instead O
of O
sutures O
or O
staples O

documented O
clinical B-chronic_disease
stroke I-chronic_disease
or O
transient B-chronic_disease
ischemic I-chronic_disease
attack I-chronic_disease
( I-chronic_disease
tia I-chronic_disease
) I-chronic_disease

erythrocyte B-treatment
transfusion I-treatment
within O
the O
prior B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

evidence O
of O
distant B-cancer
metastases I-cancer
of O
stage B-lower_bound
iv I-lower_bound

known O
history O
of O
contrast B-allergy_name
allergy I-allergy_name
that O
can O
not O
be O
medically O
managed O

bone B-treatment
scan I-treatment
is O
not O
required O
for O
patients O
enrolled O
with O
a O
single O
intermediate O
risk O
factor O
only O
, O
but O
this O
scan O
may O
be O
obtained O
at O
the O
discretion O
of O
the O
treating O
physician O

platelets B-clinical_variable
≥ O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
mm3 I-lower_bound

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
ul I-lower_bound

patients O
who O
are O
receiving O
any O
other O
concurrent O
investigational B-treatment
therapy I-treatment
, O
or O
who O
have O
received O
investigational O
therapy O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
the O
first O
scheduled O
day O
of O
protocol B-treatment
treatment I-treatment
treatment B-treatment
( O
investigational O
therapy O
as O
defined O
as O
treatment O
for O
which O
there O
is O
currently O
no O
regulatory O
authority O
approved O
indication O
) O
will O
not O
be O
eligible O

patients O
with O
any O
other O
medical B-chronic_disease
condition I-chronic_disease
, O
including O
mental B-treatment
illness I-treatment
or O
substance O
abuse O
, O
deemed O
by O
the O
investigator O
to O
be O
likely O
to O
interfere O
with O
the O
patient O
's O
ability O
to O
sign O
informed O
consent O
, O
cooperate O
and O
participate O
in O
the O
study O
, O
or O
interfere O
with O
the O
interpretation O
of O
the O
results O
, O
will O
not O
be O
eligible O

patients O
with O
evidence O
of O
clinical B-cancer
t4b I-cancer
( O
unresectable O
) O

platelet B-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
ul I-lower_bound

pregnant B-pregnancy
patients O
are O
ineligible O

patients O
must O
be O
> O
@NUMBER B-lower_bound
months I-lower_bound
and O
< O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age
when O
registered O
on O
study O

patients O
must O
have O
evidence O
of O
mibg B-treatment
uptake O
into O
tumor B-cancer
at O
≥ O
one O
site O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
entry O
on O
study O
and O
subsequent O
to O
any O
intervening O
therapy O

patients O
who O
have O
bone B-chronic_disease
marrow I-chronic_disease
disease I-chronic_disease
must O
still O
have O
adequate O
bone O
marrow O
function O
to O
enter O
the O
study O

they O
have O
a O
history O
of O
a O
venous B-chronic_disease
or I-chronic_disease
arterial I-chronic_disease
thrombosis I-chronic_disease
that O
was O
not O
associated O
to O
a O
central O
line O

high O
risk O
for O
surgical B-treatment
intervention I-treatment
because O
of O
comorbidities O

presenting O
for O
breast B-treatment
cancer I-treatment
treatment I-treatment

hpv B-chronic_disease
( O
‐ O
) O
( O
human B-chronic_disease
papillomavirus I-chronic_disease
) O
or O
p16 O
( O
- O
) O
locally O
/ O
regionally O
advanced O
( B-cancer
t3‐4 I-cancer
or I-cancer
n2‐3 I-cancer
) I-cancer
oropharyngeal I-cancer
cancer I-cancer

patients O
are O
adults O
( O
age B-age
> O
@NUMBER B-lower_bound
) O

referred O
for O
definitive B-treatment
chemo‐rt I-treatment

any O
physical B-chronic_disease
or I-chronic_disease
mental I-chronic_disease
impairment I-chronic_disease
which O
would O
preclude O
participation O
in O
any O
of O
the O
examinations O
, O
such O
as O
inability O
to O
give O
verbal O
responses O
to O
eye O
charts O

hard O
contact O
lens O
users O
( O
pmma O
or O
rigid O
gas O
permeable O
lenses O
) O
must O
have O
removed O
their O
lenses O
at O
least O
four B-lower_bound
( I-lower_bound
@NUMBER I-lower_bound
) I-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
baseline O
measurements O

patients O
who O
are O
older O
than O
@NUMBER B-lower_bound
years I-lower_bound
will O
not O
be O
enrolled O

cardiogenic B-chronic_disease
shock I-chronic_disease
or O
heart B-chronic_disease
failure I-chronic_disease
requiring O
inotropic B-treatment
agents I-treatment
or O
intubation B-treatment

nursing O
mothers O
who O
are O
unwilling O
to O
discontinue O
breastfeeding O
their O
infant O
for O
@NUMBER B-upper_bound
hours I-upper_bound
after O
fluorodopa B-treatment
f I-treatment
@NUMBER I-treatment
injection I-treatment

patients O
who O
do O
not O
have O
a O
diagnosis O
of O
hi B-chronic_disease

subject O
has O
taken O
systemic B-treatment
steroids I-treatment
( O
within O
the O
last O
month O
) O
, O
immunosuppressive B-treatment
or O
immunomodulatory B-treatment
treatment I-treatment
( O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
) O

for O
gynecologic B-cancer
cancer I-cancer
cohort O
only O
recurrent O
or O
progressive B-chronic_disease
disease I-chronic_disease
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
the O
last O
dose O
of O
weekly O
paclitaxel B-treatment
or O
nab B-treatment
- I-treatment
paclitaxel I-treatment

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound
( O
patients O
may O
be O
transfused O
to O
meet O
hemoglobin B-treatment
[ I-treatment
hgb I-treatment
] I-treatment
requirement O
) O

prior B-treatment
therapy I-treatment
with O
an O
angiogenesis B-treatment
inhibitor I-treatment

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
or O
direct B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

physically O
inactive O
( O
no O
participation O
in O
a O
structured O
exercise O
program O
as O
defined O
as O
more O
than O
@NUMBER B-lower_bound
@NUMBER B-lower_bound
minutes I-lower_bound
of O
exercise O
@NUMBER O
or O
more O
days O
a O
week O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
) O

≤ O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound

current O
or O
prior O
diagnosis O
of O
aml B-cancer

myelodysplastic B-cancer
syndrome I-cancer
with O
isolated O
del O
( O
@NUMBER O
q O
) O
( O
@NUMBER B-chronic_disease
q I-chronic_disease
- I-chronic_disease
syndrome I-chronic_disease
) O

patients O
must O
have O
fewer O
than O
@NUMBER B-upper_bound
% I-upper_bound
marrow I-upper_bound
blasts I-upper_bound
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
consent O

prior B-treatment
autologous I-treatment

allogeneic B-treatment
hct I-treatment

exclusion O
for O
dent B-chronic_disease
disease I-chronic_disease
include O
: O
primary O
or O
secondary O
hyperparathyroidism B-chronic_disease
, O
hyperthyroidism B-chronic_disease
, O
chronic B-chronic_disease
diarrhea I-chronic_disease
states I-chronic_disease
; O
intake O
of O
thiazide B-treatment
diuretics I-treatment
, O
glucocorticoids B-treatment
, O
or O
estrogens B-treatment
within O
one B-upper_bound
month I-upper_bound
of O
the O
study O

defect O
and O
/ O
or O
soft O
tissue O
status O
ineligible O
for O
surgical B-treatment
reconstruction I-treatment

patients O
using O
narcotics B-treatment
, O
abusing O
prescription O
drugs O
( O
within O
last B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
) O

presence O
of O
an O
extremity O
long O
b O
one B-lower_bound
( O
femur O
, O
tibia O
, O
humerus O
, O
ulna O
, O
radius O
) O
segmental O
defect O
requiring O
surgical B-treatment
reconstruction I-treatment
with O
at O
least O
one O
of O
the O
following O
etiologies O

acquired O
bony B-chronic_disease
nonunion I-chronic_disease
( O
not O
congenital O
) O
treatable O
by O
segmental B-treatment
resection I-treatment
and O
reconstruction B-treatment

history O
of O
allergic O
reactions O
attributed O
to O
compounds O
of O
similar O
chemical O
or O
biologic O
composition O
to O
propranolol B-treatment

inr B-clinical_variable
< O
or O
= O
@NUMBER B-upper_bound

parameters O
for O
the O
hcc B-cancer
cohort O

patients O
with O
brain B-cancer
metastases I-cancer
may O
participate O
in O
this O
clinical B-treatment
study I-treatment
provided O
that O
symptoms O
have O
been O
controlled O
with O
standard O
therapies B-treatment
and O
/ O
or O
appropriate O
medications B-treatment

patients O
with O
significant O
lung B-chronic_disease
disease I-chronic_disease
, O
an O
ejection B-clinical_variable
fraction I-clinical_variable
less O
than O
@NUMBER B-upper_bound
% I-upper_bound
, O
or O
a O
resting B-clinical_variable
heart I-clinical_variable
rate I-clinical_variable
less O
than O
@NUMBER B-upper_bound
/ I-upper_bound
min I-upper_bound
will O
not O
be O
enrolled O

known O
hypersensitivity O
to O
any O
of O
the O
components O
of O
mm-398 B-allergy_name
or O
other O
liposomal B-allergy_name
products I-allergy_name

active O
autoimmune B-chronic_disease
disease I-chronic_disease
that O
has O
required O
systemic B-treatment
treatment I-treatment
in O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
( O
i.e O
. O
with O
use O
of O
disease O
modifying O
agents O
, O
corticosteroids B-treatment
or O
immunosuppressive B-treatment
drugs I-treatment
) O

for O
men B-gender
and O
women B-gender
of O
child O
- O
producing O
potential O
, O
the B-contraception_consent
use I-contraception_consent
of I-contraception_consent
effective I-contraception_consent
contraceptive I-contraception_consent
methods I-contraception_consent
during O
the O
study O
and O
for O
@NUMBER B-upper_bound
months I-upper_bound
following O
the O
last O
dose O
of O
study O
drug O

new B-clinical_variable
york I-clinical_variable
heart I-clinical_variable
association I-clinical_variable
class I-clinical_variable
iii B-lower_bound
or O
iv B-upper_bound
, O
cardiac B-chronic_disease
disease I-chronic_disease
, O
myocardial B-chronic_disease
infarction I-chronic_disease
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
, O
unstable O
arrhythmia B-chronic_disease

previously B-treatment
treated I-treatment
with I-treatment
an I-treatment
anti I-treatment
- I-treatment
dkk-1 I-treatment
therapy I-treatment

concurrent B-treatment
therapy I-treatment
with I-treatment
strong I-treatment
inhibitors I-treatment
or O
inducers O
of O
cytochrome B-treatment
p450 I-treatment
family I-treatment
@NUMBER I-treatment
, O
subfamily B-treatment
a I-treatment
, O
polypeptide B-treatment
@NUMBER I-treatment
( I-treatment
cyp3a4 I-treatment
) I-treatment
or O
cytochrome B-treatment
p450 I-treatment
family I-treatment
@NUMBER I-treatment
, O
subfamily B-treatment
c I-treatment
, O
polypeptide B-treatment
@NUMBER I-treatment
( I-treatment
cyp2c8 I-treatment
) I-treatment
due O
to O
concerning O
possible O
drug O
- O
drug O
interactions O

inability O
to O
swallow O
capsules O
or O
known O
gastrointestinal O
malabsorption B-chronic_disease

psa B-clinical_variable
≤ O
@NUMBER B-upper_bound
times I-upper_bound
the O
psa O
at O
start O
of O
enzalutamide B-treatment

other O
anticancer B-treatment
or O
experimental B-treatment
therapy I-treatment

patients O
who O
have O
received O
prior B-treatment
pelvic I-treatment
radiotherapy I-treatment

primary O
unresectable O
rectal B-cancer
cancer I-cancer

recurrent B-cancer
rectal I-cancer
cancer I-cancer

fever B-clinical_variable
of O
at O
least O
38.5º B-lower_bound
celsius I-lower_bound
at O
minimum O
of O
once O
every O
@NUMBER O
hours O
for O
at O
least O
@NUMBER B-lower_bound
hours I-lower_bound

known O
history O
of O
tuberculosis B-chronic_disease

atrial B-chronic_disease
fibrillation I-chronic_disease

recent O
cardiac B-treatment
revascularization I-treatment
( O
ptca B-treatment
, O
stent B-treatment
or O
cabg B-treatment
) O
in O
the O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
enrollment O
or O
planned O
for O
the O
@NUMBER B-upper_bound
months I-upper_bound
following O

+ O
hcv B-chronic_disease
rna O

ast B-clinical_variable
and O
alt B-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limits I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound

g B-treatment
- I-treatment
csf I-treatment
and O
platelet B-treatment
transfusions I-treatment
can O
not O
be O
used O
to O
increase O
counts O
to O
meet O
eligibility O
criteria O

must O
have O
a O
negative B-pregnancy
serum I-pregnancy
or I-pregnancy
urine I-pregnancy
pregnancy I-pregnancy
test O
with O
a O
sensitivity O
of O
at O
least O
@NUMBER B-lower_bound
mlu I-lower_bound
/ I-lower_bound
ml I-lower_bound
no O
more O
than O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O
and O
must O
agree O
to O
repeat O
this O
test O
within O
@NUMBER B-upper_bound
hours I-upper_bound
of O
starting O
pomalidomide B-treatment

no O
strong O
inducers O
of O
cytochrome B-treatment
p450 I-treatment
( I-treatment
cyp I-treatment
) I-treatment
@NUMBER I-treatment
a4 I-treatment
or O
cyp1a2 B-treatment
or O
strong O
inhibitors O
of O
cyp3a4 B-treatment
or O
cyp1a2 O

proteasome B-treatment
inhibitor I-treatment
naive O
or O
sensitive B-chronic_disease
disease I-chronic_disease
; O

has O
no O
evidence O
of O
active O
graft B-chronic_disease
versus I-chronic_disease
host I-chronic_disease
disease I-chronic_disease
, O
and O
no O
evidence O
of O
active B-chronic_disease
infection I-chronic_disease

known O
history O
of O
malignant B-chronic_disease
hypertension I-chronic_disease

subjects O
being O
actively O
treated O
for O
a O
secondary B-cancer
malignancy I-cancer
malignancy B-cancer
or O
any O
malignancy O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
, O
with O
the O
exception O
of O
non B-cancer
- I-cancer
melanomatous I-cancer
skin I-cancer
cancer I-cancer
or O
localized O
, O
definitively O
treated O
cervical B-cancer
cancer I-cancer
. O
men B-gender
under O
observation O
for O
local O
prostate B-cancer
cancer I-cancer
are O
also O
eligible O
if O
they O
have O
had O
stable O
disease O
for O
at O
least O
@NUMBER B-lower_bound
year I-lower_bound

non B-pregnancy
- I-pregnancy
pregnant I-pregnancy
female B-gender

any O
significant O
medical B-chronic_disease
complications I-chronic_disease
related O
to O
therapy B-treatment
must O
have O
resolved O

patients O
must O
be O
considered O
reliable O
enough O
to O
comply O
with O
the O
medication B-treatment
regimen O
and O
follow O
- O
up O
, O
and O
have O
social O
support O
necessary O
to O
allow O
this O
compliance O

a O
known O
hypersensitivity O
or O
contraindication O
to O
aspirin B-allergy_name
, O
heparin B-allergy_name
, O
ticlopidine B-allergy_name
( I-allergy_name
ticlid I-allergy_name
) I-allergy_name
, O
or O
clopidogrel B-allergy_name
( I-allergy_name
plavix I-allergy_name
) I-allergy_name
, O
or O
sensitivity O
to O
contrast B-allergy_name
media I-allergy_name
which O
can O
not O
be O
adequately O
premedicated O

use O
of O
anticoagulant B-treatment
other O
than O
low B-treatment
- I-treatment
molecular I-treatment
weight I-treatment
heparin I-treatment

blood B-clinical_variable
pressure I-clinical_variable
averaging I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
mmhg I-lower_bound

estimated B-clinical_variable
glomerular I-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
( I-clinical_variable
egfr I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound
/ I-upper_bound
1.73m2 I-upper_bound

amlodipine B-treatment
or O
eplerenone B-treatment

treatment O
initiated O
with O
an O
empiric B-treatment
antimicrobial I-treatment
to O
which O
the O
organism O
isolated O
in O
the O
urine O
culture O
is O
non O
- O
susceptible O
based O
on O
standard O
laboratory O
criteria O

active B-chronic_disease
infection I-chronic_disease
requiring O
systemic B-treatment
treatment I-treatment

prior B-treatment
therapy I-treatment
with I-treatment
syk I-treatment
inhibitors I-treatment

chronic B-chronic_disease
obstructive I-chronic_disease
pulmonary I-chronic_disease
disease I-chronic_disease
exacerbation O
or O
other O
respiratory B-chronic_disease
illness I-chronic_disease
other O
than O
the O
diagnosed O
lung B-cancer
cancer I-cancer
requiring O
hospitalization O
or O
precluding O
study B-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
before O
registration O

history O
/ O
physical O
examination O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O
including O
resting B-clinical_variable
heart I-clinical_variable
rate I-clinical_variable

patients O
who O
meet O
the O
criterion O
above O
without O
oxygen O
( O
o2 O
) O
, O
but O
who O
need O
acute O
( O
started O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O
) O
supplemental O
oxygen O
due O
to O
tumor B-cancer
-caused O
obstruction O
/ O
hypoxia B-chronic_disease
are O
eligible O
, O
provided O
the O
amount O
of O
the O
o2 O
needed O
has O
been O
stable O

prior O
invasive O
malignancy B-cancer
unless O
disease O
free O
for O
a O
minimum O
of O
@NUMBER B-lower_bound
years I-lower_bound

skin B-cancer
cancer I-cancer
and O
in B-cancer
situ I-cancer
carcinomas I-cancer
of I-cancer
the I-cancer
breast I-cancer
, O
oral B-cancer
cavity I-cancer
, O
cervix B-cancer
, O
and O
other O
organs O
and O
are O
permissible O

active O
systemic B-chronic_disease
infections I-chronic_disease
, O
( O
e.g O
. O
: O
requiring O
anti B-treatment
- I-treatment
infective I-treatment
treatment I-treatment
) O
, O
coagulation B-chronic_disease
disorders I-chronic_disease
or O
any O
other O
active O
major O
medical B-chronic_disease
illnesses I-chronic_disease

patients O
who O
are O
receiving O
other O
investigational B-treatment
agents I-treatment

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
( I-clinical_variable
anc I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
x I-lower_bound
@NUMBER I-lower_bound
/ I-lower_bound
l I-lower_bound

archived B-cancer
tumor I-cancer
tissue I-cancer
from O
a O
primary B-treatment
biopsy I-treatment
or O
metastatic B-cancer
lesion O
for O
centralized O
determination O
of O
ar O
expression O
is O
mandatory O

patients O
receiving O
chronic O
bisphosphonate B-treatment
or O
denosumab B-treatment
therapy I-treatment

this O
group O
of O
patients O
may O
be O
pre O
- O
menopausal O
with O
ovarian B-treatment
suppression I-treatment
or O
post O
- O
menopausal O

abnormal B-clinical_variable
cardiac I-clinical_variable
valve I-clinical_variable
morphology I-clinical_variable
( O
≥ O
grade B-lower_bound
@NUMBER I-lower_bound
) O
documented O
by O
echocardiogram B-treatment
( O
subjects O
with O
grade O
@NUMBER O
abnormalities O
[ O
i.e. O
, O
mild O
regurgitation B-chronic_disease
/ O
stenosis B-chronic_disease
] O
can O
be O
entered O
on O
study O
) O
; O
subjects O
with O
moderate O
valvular O
thickening O
should O
not O
be O
entered O
on O
study O

because O
the O
composition O
, O
pharmacokinetics O
( O
pk O
) O
, O
and O
metabolism O
of O
many O
herbal B-treatment
supplements I-treatment
are O
unknown O
, O
the O
concurrent O
use O
of O
all O
herbal O
supplements O
is O
prohibited O
during O
the O
study O
( O
including O
, O
but O
not O
limited O
to O
, O
st B-treatment
. I-treatment
john I-treatment
's I-treatment
wort I-treatment
, O
kava B-treatment
, O
ephedra B-treatment
[ I-treatment
ma I-treatment
huang I-treatment
] I-treatment
, O
ginkgo B-treatment
biloba I-treatment
, O
dehydroepiandrosterone B-treatment
[ I-treatment
dhea I-treatment
] I-treatment
, O
yohimbe B-treatment
, O
saw B-treatment
palmetto I-treatment
, O
or O
ginseng B-treatment
) O

miscellaneous O
: O
bosentan B-treatment
, O
st B-treatment
. I-treatment
john I-treatment
's I-treatment
wort I-treatment

patients O
must O
have O
measurable O
disease O
, O
defined O
as O
at O
least O
one B-lower_bound
lesion O
that O
can O
be O
accurately O
measured O
in O
at O
least O
one O
dimension O
( O
longest O
diameter O
to O
be O
recorded O
for O
non O
- O
nodal O
lesions O
and O
short O
axis O
for O
nodal O
lesions O
) O
as O
≥ O
@NUMBER B-lower_bound
mm I-lower_bound
with O
conventional B-clinical_variable
techniques I-clinical_variable
or O
as O
≥ O
@NUMBER B-lower_bound
mm I-lower_bound
with O
spiral O
computed B-treatment
tomography I-treatment
( I-treatment
ct I-treatment
) I-treatment
scan I-treatment
, O
magnetic B-treatment
resonance I-treatment
imaging I-treatment
( I-treatment
mri I-treatment
) I-treatment
, O
or O
calipers B-treatment
by O
clinical O
exam O

patients O
who O
have O
had O
immunotherapy B-treatment
, O
chemotherapy B-treatment
or O
radiotherapy B-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
navitoclax B-treatment
, O
or O
prior B-treatment
systemic I-treatment
anti I-treatment
- I-treatment
cancer I-treatment
therapy I-treatment
( O
chemotherapy O
with O
delayed O
toxicity O
, O
extensive B-treatment
radiation I-treatment
therapy I-treatment
, O
immunotherapy O
, O
biologic B-treatment
therapy I-treatment
, O
or O
vaccine B-treatment
therapy I-treatment
) O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
first O
dose O
of O
dabrafenib B-treatment
and O
/ O
or O
trametinib B-treatment
; O
chemotherapy B-treatment
regimens I-treatment
without O
delayed O
toxicity O
within O
the O
last B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound
preceding O
the O
first O
dose O
of O
study O
treatment B-treatment
; O
biologics B-treatment
will O
not O
be O
allowed O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
, O
or O
during O
, O
navitoclax O
administration O

total O
bilirubin B-clinical_variable
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
times I-upper_bound
institutional B-clinical_variable
upper I-clinical_variable
limit I-clinical_variable
of I-clinical_variable
normal I-clinical_variable

zero O
breath O
alcohol O
, O
negative O
urine O
drug O
tests O
and O
a O
self O
- O
report O
of O
no O
drug O
use O
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
on O
day O
of O
informed O
consent O

active O
proliferative B-chronic_disease
diabetic I-chronic_disease
retinopathy I-chronic_disease
in I-chronic_disease
the I-chronic_disease
study I-chronic_disease
eye I-chronic_disease

patients O
who O
have O
received O
corneal B-treatment
transplants I-treatment
in O
the O
study O
eye O

normal B-clinical_variable
thyroid I-clinical_variable
stimulating I-clinical_variable
hormone I-clinical_variable
and O
hematocrit B-clinical_variable
value I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
% I-lower_bound
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

age B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
, O
both O
men B-gender
and I-gender
women I-gender

currently O
being O
prescribed O
psychotropic B-treatment
medication I-treatment
by O
another O
physician O

individuals O
with O
a O
history O
of O
other O
malignancies B-cancer
are O
eligible O
if O
they O
have O
been O
disease O
- O
free O
for O
at O
least O
@NUMBER B-lower_bound
years I-lower_bound
and O
are O
deemed O
by O
the O
investigator O
to O
be O
at O
low O
risk O
for O
recurrence O
of O
that O
malignancy B-cancer

individuals O
with O
the O
following O
cancers B-cancer
are O
eligible O
if O
diagnosed O
and O
treated O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
: O
cervical B-cancer
cancer I-cancer
in I-cancer
situ I-cancer
, O
and O
basal B-cancer
cell I-cancer
or O
squamous B-cancer
cell I-cancer
carcinoma I-cancer
of I-cancer
the I-cancer
skin I-cancer

history O
of O
chronic B-chronic_disease
alcohol I-chronic_disease
abuse I-chronic_disease

any O
surgery B-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
screening O

recent O
flu O
- O
like O
symptoms O
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound

serious O
neurologic B-chronic_disease
disorders I-chronic_disease
including O
seizures B-chronic_disease

taking O
chronic B-treatment
non I-treatment
- I-treatment
steroidal I-treatment
anti I-treatment
- I-treatment
inflammatory I-treatment
drugs I-treatment
( I-treatment
nsaids I-treatment
) I-treatment
such O
as O
aspirin B-treatment
, O
indomethacin B-treatment
, O
naproxen B-treatment
, O
acetaminophen B-treatment
( I-treatment
tylenol I-treatment
) I-treatment
, O
ibuprofen B-treatment
( O
advil B-treatment
, O
motrin B-treatment
) O
and O
not O
able O
or O
willing O
to O
go O
off O
of O
for O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
and O
during O
the O
study O

taking O
diabetic O
medications O
( O
metformin B-treatment
, O
glyburide B-treatment
, O
insulin B-treatment
, O
etc O
. O
) O
, O
thiazolidinediones B-treatment
( O
avandia B-treatment
, O
rezulin B-treatment
, O
actos B-treatment
) O

hepatic B-clinical_variable
enzyme I-clinical_variable
( O
alt B-clinical_variable
/ I-clinical_variable
ast I-clinical_variable
) O
concentrations O
> O
@NUMBER B-lower_bound
times I-lower_bound
the I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound

currently O
on O
medication O
for O
diabetes B-chronic_disease
or O
hypercholesterolemia B-chronic_disease

≥ O
@NUMBER B-lower_bound
mm I-lower_bound
by O
imaging O
/ O
pathology O
of O
core O
to O
ensure O
enough O
pre- O
and O
post O
- O
treatment O
tissue O
for O
analysis O

gfr B-clinical_variable
< O
@NUMBER B-upper_bound

patients O
must O
have O
at O
least O
one B-lower_bound
site O
of O
disease O
that O
is O
accessible O
for O
intratumoral B-treatment
injection I-treatment
percutaneously O
( O
e.g O
. O
inguinal O
, O
axillary O
, O
cervical O
, O
or O
subcutaneous O
) O

history O
of O
ossicular B-treatment
reconstruction I-treatment

rb B-treatment
( I-treatment
retinoblastoma I-treatment
protein I-treatment
) I-treatment
-proficiency O
is O
determined O
by O
tumor B-treatment
biopsy I-treatment
demonstrating O
rb O
normal O
and O
p16in4a O
low O
by O
immunohistochemistry O

subjects O
must O
be O
willing B-contraception_consent
to I-contraception_consent
use I-contraception_consent
an I-contraception_consent
approved I-contraception_consent
form I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
while O
on O
this O
study O
and O
for O
@NUMBER B-upper_bound
days I-upper_bound
after O
completion O

history O
of O
chronic B-treatment
opioid I-treatment
use O

currently O
followed O
by O
a O
pcp B-treatment
( O
had O
an O
eval O
in O
last B-upper_bound
6-months I-upper_bound
) O

hrsd B-clinical_variable
> O
@NUMBER B-lower_bound
and O
a O
dsm B-chronic_disease
- I-chronic_disease
iv I-chronic_disease
depressive I-chronic_disease
disorder I-chronic_disease
( O
e.g O
. O
mdd B-chronic_disease
, O
dysthymia B-chronic_disease
) O

mini B-clinical_variable
mental I-clinical_variable
exam I-clinical_variable
< O
@NUMBER B-upper_bound
or O
a O
diagnosis O
of O
dementia B-chronic_disease

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
( I-clinical_variable
anc I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
mm3 I-lower_bound

any O
unresolved O
bowel B-chronic_disease
or O
bile B-chronic_disease
duct I-chronic_disease
obstruction I-chronic_disease

participation O
in O
another O
clinical O
treatment B-treatment
trial O
while O
on O
study O

subjects O
who O
have O
participated O
in O
a O
clinical O
study O
more O
recently O
than O
one B-lower_bound
month I-lower_bound
before O
the O
current O
study O

active O
or O
suspected O
neoplasia B-chronic_disease

hepatic B-chronic_disease
insufficiency I-chronic_disease

patients O
with O
comorbid O
conditions O
deemed O
too O
medically O
compromised O
to O
tolerate O
the O
risk O
of O
experimental O
treatment B-treatment
with I-treatment
igf-1 I-treatment

patients O
undergoing O
any O
resection B-treatment
requiring I-treatment
an I-treatment
anastomosis I-treatment
to I-treatment
the I-treatment
esophagus I-treatment
for I-treatment
palliative I-treatment
intent I-treatment

combination O
arm O
: O
hypersensitivity O
to O
trastuzumab B-allergy_name

anticoagulant B-treatment
medical I-treatment
therapy I-treatment

family O
history O
of O
type B-chronic_disease
@NUMBER I-chronic_disease
diabetes I-chronic_disease
mellitus I-chronic_disease

patients O
who O
have O
decreased O
immunecompetence O
may O
be O
less O
responsive O
to O
the O
experimental B-treatment
treatment I-treatment
and O
more O
susceptible O
to O
its O
toxicities O

patients O
with O
@NUMBER B-upper_bound
or O
fewer O
brain B-cancer
metastases I-cancer
that O
are O
less O
than O
@NUMBER B-upper_bound
cm I-upper_bound
in O
diameter B-clinical_variable
and O
asymptomatic O
are O
eligible O

patients O
with O
surgically O
resected O
brain B-cancer
metastases I-cancer
are O
eligible O

seronegative O
for O
hiv B-treatment
antibody I-treatment

with O
clinically O
significant O
atrial B-chronic_disease
an I-chronic_disease
d O
/ O
or O
ventricular B-chronic_disease
arrhythmias I-chronic_disease
, O
including O
but O
not O
limited O
to O
: O
atrial B-chronic_disease
fibrillation I-chronic_disease
, O
ventricular B-chronic_disease
tachycardia I-chronic_disease
, O
second- B-chronic_disease
or I-chronic_disease
third I-chronic_disease
- I-chronic_disease
degree I-chronic_disease
heart I-chronic_disease
block I-chronic_disease
or O
have O
a O
history O
of O
ischemic O
heart O
disease O
and O
/ O
or O
chest B-chronic_disease
pain I-chronic_disease

for O
flumist B-treatment
participants O
: O
current O
illness O
that O
limits O
delivery O
to O
nasal O
airway O

unable O
to O
continue O
participation O
for O
@NUMBER B-upper_bound
weeks I-upper_bound

the O
following O
additional O
exclusion O
criteria O
for O
patients O
with O
sickle B-chronic_disease
cell I-chronic_disease
anemia I-chronic_disease
the O
following O
exclusion O
criteria O
also O
apply O

unrelated O
donor O
: O
an O
@NUMBER O
/ O
@NUMBER O
, O
@NUMBER O
/ O
@NUMBER O
or O
@NUMBER O
/ O
@NUMBER O
matched B-clinical_variable
unrelated I-clinical_variable
adult I-clinical_variable
donor I-clinical_variable
( I-clinical_variable
mud I-clinical_variable
) I-clinical_variable
will O
be O
required O
for O
study O
entry O

a O
diagnosis O
of O
uncontrolled B-chronic_disease
diabetes I-chronic_disease

having O
received O
any O
investigational B-treatment
drug I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
study O
entry O

subjects O
allergic O
to O
penicillin B-allergy_name
, O
streptomycin B-allergy_name
, O
amphotericin B-allergy_name

positive O
symptoms O
of O
psychosis B-chronic_disease
( O
> O
@NUMBER B-lower_bound
[ O
moderate O
] O
) O
on O
any O
item O
of O
the O
positive B-clinical_variable
and I-clinical_variable
negative I-clinical_variable
syndrome I-clinical_variable
scale I-clinical_variable
psychosis O
subscale O
( O
once O
abstinent O
) O
except O
for O
the O
hallucination O
item O

chronic O
oral O
or O
intravenous O
use O
of O
steroids B-treatment
or O
immunosuppressive B-treatment
therapy I-treatment

life B-clinical_variable
expectancy I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
months I-lower_bound

one B-lower_bound
or O
more O
episodes B-clinical_variable
of I-clinical_variable
acute I-clinical_variable
chest I-clinical_variable
syndrome I-clinical_variable

other O
primary O
immune O
defects O
where O
hematopoietic B-treatment
stem I-treatment
cell I-treatment
transplantation I-treatment
may O
be O
beneficial O

priapism B-chronic_disease

primary B-chronic_disease
immunodeficiency I-chronic_disease
syndromes O

wiskott B-chronic_disease
- I-chronic_disease
aldrich I-chronic_disease
syndrome I-chronic_disease

patients O
with O
sickle B-chronic_disease
disease I-chronic_disease

age B-age
@NUMBER B-lower_bound
years I-lower_bound
and O
above O

agreement O
to O
not O
drink O
caffeine O
for O
@NUMBER B-upper_bound
hours I-upper_bound
before O
each O
eeg O
assessment O
( O
cp O
only O
) O
visit O
because O
it O
can O
modify O
brain O
activity O

less O
than O
2-years B-upper_bound
disease O
free O
from O
another O
primary B-cancer
malignancy I-cancer
( O
other O
than O
squamous B-cancer
or O
basal B-cancer
cell I-cancer
carcinoma I-cancer
of O
the O
skin O
, O
in B-cancer
- I-cancer
situ I-cancer
carcinoma I-cancer
of O
the O
cervix O
or O
breast O
, O
superficial O
bladder B-cancer
carcinoma I-cancer
, O
or O
previously O
treated O
localized O
prostate B-cancer
cancer I-cancer
with O
normal O
prostate B-clinical_variable
- I-clinical_variable
specific I-clinical_variable
antigen I-clinical_variable
[ I-clinical_variable
psa I-clinical_variable
] I-clinical_variable
levels I-clinical_variable
) O

platelet B-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
x I-lower_bound
10 I-lower_bound
^ I-lower_bound
9 I-lower_bound
/ I-lower_bound
l I-lower_bound
( O
≥ O
@NUMBER B-lower_bound
x I-lower_bound
10 I-lower_bound
^ I-lower_bound
9 I-lower_bound
/ I-lower_bound
l I-lower_bound
if O
lymphoma B-cancer
involvement O
in O
the O
pretreatment B-treatment
bone I-treatment
marrow I-treatment
is O
found O
) O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
starting O
therapy B-treatment

patients O
with O
grade B-lower_bound
@NUMBER I-lower_bound
or O
higher O
( O
nci- O
common B-clinical_variable
toxicity I-clinical_variable
criteria I-clinical_variable
[ I-clinical_variable
ctc I-clinical_variable
] I-clinical_variable
) O
neuropathy O

use O
of O
st B-treatment
. I-treatment
john I-treatment
's I-treatment
wort I-treatment
is O
prohibited O
from O
@NUMBER B-upper_bound
days I-upper_bound
before O
dosing O
until O
@NUMBER B-upper_bound
days I-upper_bound
after O
dosing O

patients O
with O
gvhd B-chronic_disease
> O
grade B-lower_bound
ii I-lower_bound

history O
of O
smoking O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
cigarettes O
daily O
for O
the O
past O
year O

currently O
receiving O
any O
other O
investigational B-treatment
agents I-treatment
that O
are O
intended O
as O
treatments B-treatment
of O
recurrent O
gbm B-cancer

history O
of O
hypersensitivity O
to O
hydrogel B-clinical_variable

patients O
must O
agree O
to O
forgo O
any O
other O
treatment B-treatment
treatments B-treatment
, O
including O
but O
not O
limited O
to O
cytotoxic B-treatment
or O
biologic B-treatment
chemotherapies I-treatment
, O
that O
are O
intended O
to O
treat O
the O
recurrent O
gbm B-cancer
while O
receiving O
treatment O
with O
novottf B-treatment
therapy I-treatment

received O
radiotherapy B-treatment
of O
at O
least O
@NUMBER B-lower_bound
gy B-treatment
and O
temozolomide B-treatment
chemotherapy I-treatment
as O
initial O
treatment B-treatment
for O
gbm O

there O
must O
be O
an O
interval O
of O
at O
least O
@NUMBER O
weeks O
from O
the O
completion O
of O
radiotherapy B-treatment
to O
start O
of O
device O
treatment O
. O
when O
the O
interval O
is O
less O
than O
@NUMBER O
weeks O
from O
the O
completion O
of O
radiotherapy O
, O
the O
histological O
confirmation O
of O
progression O
must O
be O
unequivocal O
per O
rano O
criteria O
. O
the O
use O
of O
pet B-treatment
scan I-treatment
, O
perfusion B-treatment
imaging I-treatment
, O
and O
mrspectroscopy B-treatment
to O
differentiate O
between O
true O
early O
progression O
and O
pseudoprogression O
prior B-treatment
to I-treatment
biopsy I-treatment
or O
resection O
of O
probable O
recurrent O
tumor B-cancer
is O
per O
standard O
of O
care O

uncontrolled O
intercurrent O
illness O
including O
, O
but O
not O
limited O
to O
, O
ongoing O
or O
active B-chronic_disease
infection I-chronic_disease
, O
symptomatic O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease
pectoris I-chronic_disease
, O
cardiac B-chronic_disease
arrhythmia I-chronic_disease
, O
recent O
heart B-chronic_disease
attack I-chronic_disease
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
or O
severe O
heart O
problems O
, O
or O
psychiatric B-chronic_disease
illness I-chronic_disease
/ I-chronic_disease
social I-chronic_disease
situations I-chronic_disease
that O
would O
limit O
compliance O
with O
study O
requirements O

have O
uncontrolled O
severe B-chronic_disease
hypertension I-chronic_disease

patients O
being O
treated O
with O
full O
dose O
warfarin B-treatment

sexually O
active O
patients O
must O
be O
willing B-contraception_consent
to I-contraception_consent
utilize I-contraception_consent
one I-contraception_consent
of I-contraception_consent
the I-contraception_consent
more I-contraception_consent
effective I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
methods I-contraception_consent
for O
@NUMBER B-upper_bound
months I-upper_bound
after O
the O
ctl B-treatment
infusion I-treatment

patients O
requiring O
concomitant B-treatment
use I-treatment
of I-treatment
or I-treatment
treatment I-treatment
with I-treatment
immunosuppressive I-treatment
agents I-treatment

patients O
who O
have O
undergone O
any O
prior B-treatment
transplant I-treatment

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

< O
@NUMBER B-upper_bound
ng I-upper_bound
/ I-upper_bound
ml I-upper_bound
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

previous B-treatment
prostatectomy I-treatment
, O
cryosurgery B-treatment
, O
or O
high B-treatment
intensity I-treatment
focused I-treatment
ultrasound I-treatment
( I-treatment
hifu I-treatment
) I-treatment
for O
prostate B-cancer
cancer I-cancer

osteoporosis B-chronic_disease
, O
defined O
as O
pre O
- O
existing O
diagnosis O
or O
t B-clinical_variable
- I-clinical_variable
score I-clinical_variable
on O
dual B-treatment
- I-treatment
energy I-treatment
x I-treatment
- I-treatment
ray I-treatment
absorptiometry I-treatment
( I-treatment
dexa I-treatment
) I-treatment
scan I-treatment
of O
≤ O
- O
@NUMBER B-upper_bound

spms B-chronic_disease
, O
ppms B-chronic_disease
, O
or O
prms B-chronic_disease
phenotype O
, O
according O
to O
lublin O
and O
reingold O
criteria O

age B-age
between O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound

untreated O
depression B-chronic_disease
that O
may O
affect O
motivation O
to O
participate O
in O
the O
study O

ejection B-clinical_variable
fraction I-clinical_variable
below O
@NUMBER B-upper_bound
% I-upper_bound

central B-cancer
nervous I-cancer
system I-cancer
metastases I-cancer
, O
including O
lymphomatous B-cancer
meningitis I-cancer

subject O
must O
have O
advanced O
solid B-cancer
tumor I-cancer
that O
is O
not O
amenable O
to O
surgical B-treatment
resection I-treatment
or O
other O
approved O
therapeutic O
options O
that O
have O
demonstrated O
clinical O
benefit O

early O
treatment B-treatment
for O
single B-chronic_disease
or I-chronic_disease
multiple I-chronic_disease
infections I-chronic_disease
infection B-chronic_disease
s O
. O
multiple B-chronic_disease
infections I-chronic_disease
with O
one O
reactivation O
and O
one O
controlled O
infection O
are O
eligible O
to O
enroll O

unable O
to O
wean O
steroids B-treatment
to O
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
kg I-upper_bound
/ I-upper_bound
day I-upper_bound
prednisone B-treatment

any O
serious O
and O
/ O
or O
unstable O
pre O
- O
existing O
medical O
( O
aside O
from O
malignancy B-cancer
exception O
above O
) O
, O
psychiatric B-chronic_disease
disorder I-chronic_disease
, O
or O
other O
conditions O
that O
could O
interfere O
with O
subject O
's O
safety O
, O
obtaining O
informed O
consent O
or O
compliance O
to O
the O
study O
procedures O
, O
in O
the O
opinion O
of O
the O
investigator O

at O
least O
@NUMBER B-lower_bound
months I-lower_bound
has O
elapsed O
from O
the O
time O
of O
transplant B-treatment

clinically O
significant O
conduction B-chronic_disease
abnormalities I-chronic_disease
or O
arrhythmias B-chronic_disease
, O
subjects O
with O
bundle B-chronic_disease
branch I-chronic_disease
block I-chronic_disease

male B-gender
subjects I-gender
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
one I-contraception_consent
of I-contraception_consent
the I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
specified I-contraception_consent

negative B-pregnancy
serum I-pregnancy
pregnancy I-pregnancy
test O
≤ O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
first O
study O
drug O
dose O

any O
subject O
who O
is O
expected O
to O
require O
a O
qt B-clinical_variable
prolonging O
medication B-treatment
while O
on O
trial O
should O
not O
be O
enrolled O

the O
subject O
has O
recovered O
from O
transplant B-treatment
-associated O
toxicities O
prior O
to O
the O
first O
dose O
of O
gsk525762 O
, O
and O
for O
subjects O
with O
a O
prior O
history O
of O
allogeneic B-treatment
transplant I-treatment

must O
not O
have O
any O
known O
history O
of O
allergy O
to O
captisol B-allergy_name
® I-allergy_name
( O
a O
cyclodextrin B-allergy_name
derivative O
used O
to O
solubilize O
carfilzomib B-allergy_name
) O

must O
not O
have O
any O
known O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
infection I-chronic_disease

patients O
must O
have O
a O
serum B-clinical_variable
creatinine I-clinical_variable
≤ O
the O
institutional O
upper O
limit O
of O
normal O
or O
a O
creatinine B-clinical_variable
clearance I-clinical_variable
≥ O
@NUMBER B-lower_bound
cc I-lower_bound
/ I-lower_bound
min I-lower_bound
, O
measured O
or O
calculated O
( O
cockcroft B-clinical_variable
- I-clinical_variable
gault I-clinical_variable
formula I-clinical_variable
) O
, O
obtained O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior O
to O
registration O

prior B-treatment
irinotecan I-treatment

evidence O
of O
clinically O
significant O
neurologic B-chronic_disease
, O
cardiac B-chronic_disease
, O
pulmonary B-chronic_disease
, O
hepatic B-chronic_disease
, O
rheumatologic B-chronic_disease
, O
autoimmune B-chronic_disease
, O
diabetes B-chronic_disease
, O
or O
renal B-chronic_disease
disease I-chronic_disease
by O
history O
, O
physical O
examination O
, O
and O
/ O
or O
laboratory O
studies O

history O
of O
iron B-chronic_disease
deficiency I-chronic_disease
anemia I-chronic_disease

laboratory O
evidence O
of O
hematologic B-chronic_disease
disease I-chronic_disease
( O
hemoglobin B-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound
[ O
females B-gender
males B-gender
] O
or O
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound
[ O
males O
] O
; O
absolute B-clinical_variable
leukocyte I-clinical_variable
count I-clinical_variable
< O
@NUMBER B-upper_bound
or O
> O
@NUMBER B-lower_bound
x I-lower_bound
@NUMBER I-lower_bound
/ I-lower_bound
mm3 I-lower_bound
@NUMBER B-upper_bound
x I-upper_bound
@NUMBER I-upper_bound
/ I-upper_bound
mm3 I-upper_bound
; O
absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
[ I-clinical_variable
anc I-clinical_variable
] I-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
@NUMBER I-upper_bound
/ I-upper_bound
mm3 I-upper_bound
; O
absolute B-clinical_variable
lymphocyte I-clinical_variable
count I-clinical_variable
< O
@NUMBER O
x O
@NUMBER O
/ O
mm3 O
; O
or O
platelet B-clinical_variable
count I-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
@NUMBER I-upper_bound
/ I-upper_bound
mm3 I-upper_bound
) O

receipt O
of O
a O
live B-treatment
vaccine I-treatment
vaccine B-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
or O
a O
killed O
vaccine O
within O
@NUMBER B-treatment
weeks I-treatment
prior I-treatment
to O
the O
volunteer O
's O
expected O
day O
@NUMBER O
of O
the O
study O

serum B-clinical_variable
glucose I-clinical_variable
( O
random O
) O
greater O
than O
1.2-times B-lower_bound
the I-lower_bound
upper I-lower_bound
reference I-lower_bound
limit I-lower_bound

prednisone B-treatment
dose O
at O
time O
of O
enrollment O
of O
≥ O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
day I-lower_bound
and O
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
day I-upper_bound

pao2 B-clinical_variable
/ I-clinical_variable
fio2 I-clinical_variable
≤ O
@NUMBER B-upper_bound

mmse B-clinical_variable
< O
@NUMBER B-upper_bound

medicare O
recipients O
and O
were O
hospitalized O
at O
least O
one B-lower_bound
time O
in O
the O
past O
year O

because O
there O
is O
an O
unknown O
but O
potential O
risk O
for O
adverse O
events O
in O
nursing O
infants O
secondary O
to O
treatment B-treatment
of O
the O
mother O
with O
entinostat B-treatment
, O
azacitidine B-treatment
, O
or O
nivolumab B-treatment
breastfeeding O
should O
be O
discontinued O
if O
the O
mother O
is O
treated O
on O
this O
protocol O

men B-gender
who O
are O
sexually O
active O
with O
women B-gender
of O
childbearing O
potential O
must O
also O
use B-contraception_consent
an I-contraception_consent
adequate I-contraception_consent
contraceptive I-contraception_consent
method I-contraception_consent
for O
up O
to O
@NUMBER B-upper_bound
weeks I-upper_bound
after O
fhe O
last O
dose O
of O
nivolumab B-treatment

patients O
who O
are O
receiving O
any O
other O
anticancer B-treatment
therapy I-treatment

patients O
who O
received O
adjuvant B-treatment
or I-treatment
neoadjuvant I-treatment
platinum I-treatment
- I-treatment
doublet I-treatment
chemotherapy I-treatment
therapy B-treatment
( O
after B-treatment
surgery I-treatment
and O
/ O
or O
radiation B-treatment
therapy I-treatment
) O
and O
developed O
recurrent O
or O
metastatic B-cancer
disease I-cancer
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
completing O
therapy O
are O
eligible O
and O
the O
adjuvant B-treatment
or I-treatment
neoadjuvant I-treatment
chemotherapy I-treatment
will O
count O
as O
a O
line O
of O
therapy O
as O
above O

patients O
with O
a O
history O
of O
carcinomatous B-cancer
meningitis I-cancer
are O
not O
eligible O

the O
effects O
of O
entinostat B-treatment
, O
azacitidine B-treatment
, O
and O
nivolumab B-treatment
, O
on O
the O
developing O
human O
fetus O
are O
unknown O

subject O
who O
received O
a O
tyrosine B-treatment
kinase I-treatment
inhibitor I-treatment
after O
failure O
of O
a O
prior B-treatment
platinum I-treatment
- I-treatment
based I-treatment
therapy I-treatment
therapy B-treatment
, O
that O
tyrosine B-treatment
kinase I-treatment
inhibitor I-treatment
therapy I-treatment
would O
count O
as O
an O
additional O
line O
of O
therapy O

any O
significant O
hemorrhage O
defined O
as O
> O
@NUMBER B-lower_bound
cm I-lower_bound
diameter I-lower_bound
of O
blood O
seen O
on O
the O
mri B-treatment
or O
ct B-treatment
scan I-treatment

history O
of O
standard O
dose O
cns B-treatment
radiotherapy I-treatment
: O
radiation B-treatment
of O
@NUMBER O
gy O
in O
@NUMBER O
fractions O
or O
@NUMBER O
gy O
in O
@NUMBER O
gy O
fractions O
, O
or O
equivalent O
or O
lower O
doses O

no O
active B-chronic_disease
bleeding I-chronic_disease
or O
pathological O
condition O
that O
carries O
a O
high O
risk O
of O
bleeding O
( O
e.g. O
, O
tumor O
involving O
major O
vessels O
or O
known O
varices O
) O

patients O
with O
history O
of O
prior O
invasive B-cancer
malignancy I-cancer
( O
except O
non B-cancer
- I-cancer
melanomatous I-cancer
skin I-cancer
cancer I-cancer
) O
must O
have O
been O
disease O
free O
for O
a O
minimum O
of O
@NUMBER B-lower_bound
year I-lower_bound

patients O
taking O
concurrent B-treatment
medication I-treatment
that O
is O
metabolized O
by O
the O
cyp3a4 B-treatment
isoenzyme I-treatment

patients O
who O
are O
unwilling B-contraception_consent
, I-contraception_consent
or I-contraception_consent
unable I-contraception_consent
, I-contraception_consent
to I-contraception_consent
practice I-contraception_consent
an I-contraception_consent
acceptable I-contraception_consent
form I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
( O
e.g O
. O
intrauterine B-contraception_consent
device I-contraception_consent
, O
contraceptive B-contraception_consent
pills I-contraception_consent
, O
diaphragm B-contraception_consent
, O
condoms B-contraception_consent
) O
. O
for O
those O
women B-gender
who O
choose O
to O
use B-contraception_consent
oral I-contraception_consent
contraceptive I-contraception_consent
pills I-contraception_consent
, O
they O
will O
be O
encouraged O
to O
use B-contraception_consent
a I-contraception_consent
second I-contraception_consent
form I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
, O
such O
as O
condoms O
, O
because O
of O
the O
potential O
for O
altered O
serum O
levels O
of O
oral O
contraceptives O

patients O
with O
a O
chronic O
or O
acute B-chronic_disease
renal I-chronic_disease
, O
or O
hepatic B-chronic_disease
disorder I-chronic_disease
, O
a O
significant O
bleeding B-chronic_disease
disorder I-chronic_disease
, O
or O
any O
other O
condition O
which O
in O
the O
investigator O
's O
opinion O
might O
preclude O
study O
participation O
for O
the O
duration O
of O
the O
trial O

fda O
- O
approved O
tkis O
may O
also O
be O
administered O
until O
@NUMBER O
day O
prior O
to O
start O
of O
study O
therapy B-treatment
( O
c1 O
, O
d1 O
) O

patients O
must O
be O
refractory O
or O
have O
relapsed O
following O
prior B-treatment
induction I-treatment
therapy I-treatment

patients O
must O
not O
have O
a O
screening O
corrected O
qt O
using O
fridericia O
's O
formula O
( B-clinical_variable
qtcf I-clinical_variable
) I-clinical_variable
interval I-clinical_variable
> O
@NUMBER B-lower_bound
milliseconds I-lower_bound
( O
by O
fridericia O
calculation O
) O
based O
on O
the O
average O
of O
triplicate B-treatment
electrocardiogram I-treatment
( I-treatment
ekg I-treatment
) I-treatment
performed O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O
; O
note O
that O
triplicate B-treatment
ekg I-treatment
is O
required O
at O
other O
timepoints O

patients O
must O
not O
have O
received O
prior B-treatment
treatment I-treatment
with O
inotuzumab B-treatment
ozogamicin I-treatment

the O
patient O
must O
not O
have O
≥ O
grade B-lower_bound
@NUMBER I-lower_bound
acute O
graft B-chronic_disease
versus I-chronic_disease
host I-chronic_disease
disease I-chronic_disease
( I-chronic_disease
gvhd I-chronic_disease
) I-chronic_disease
or O
either O
moderate O
or O
severe O
limited O
chronic B-chronic_disease
gvhd I-chronic_disease
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

the O
lumbar B-treatment
puncture I-treatment
must O
be O
completed O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

acute O
medical O
complication O
: O
cardiac B-chronic_disease
abnormalities I-chronic_disease
, O
skin B-chronic_disease
breakdowns I-chronic_disease
, O
uncontrolled B-chronic_disease
seizures I-chronic_disease
, O
or O
immunological B-chronic_disease
, O
pulmonary B-chronic_disease
/ I-chronic_disease
renal I-chronic_disease
/ I-chronic_disease
circulatory I-chronic_disease
compromise I-chronic_disease
, O
auto B-chronic_disease
- I-chronic_disease
immune I-chronic_disease
deficiencies I-chronic_disease
, O
sepsis B-chronic_disease
, O
active B-chronic_disease
infection I-chronic_disease
, O
dental B-chronic_disease
caries I-chronic_disease

bmi B-bmi
within O
normal O
range O

age B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound

patients O
known O
to O
have O
philadelphia B-cancer
( I-cancer
ph I-cancer
) I-cancer
+ I-cancer
all I-cancer
are O
not O
eligible O

active O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
( O
new O
york O
heart O
association O
[ O
nyha O
] O
class O
iii O
to O
iv O
) O

known O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
seropositive O

no O
active B-chronic_disease
infection I-chronic_disease

patients O
with O
other O
known O
malignancies B-cancer
within O
the O
past B-upper_bound
three I-upper_bound
years I-upper_bound

contraindication O
to O
both O
contrast O
enhanced O
mri O
and O
contrast O
enhanced O
ct O
( O
i.e O
. O
unable O
to O
undergo O
follow O
- O
up O
imaging O
or O
sbrt B-treatment
treatment I-treatment
planning O
) O

prior B-treatment
radiotherapy I-treatment
to I-treatment
the I-treatment
upper I-treatment
abdomen I-treatment
or O
radioembolization B-treatment
of I-treatment
the I-treatment
liver I-treatment

women O
who O
are B-pregnancy
pregnant I-pregnancy

subjects O
unable O
to O
maintain O
blood B-clinical_variable
glucose I-clinical_variable
less O
than O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

appropriately O
treated O
in O
- O
situ O
/ O
early O
stage O
cervical B-cancer
/ O
endometrial B-cancer
cancer I-cancer

patients O
with O
dilation O
of O
the O
right O
or O
left O
anterior O
descending O
coronary O
artery O
beyond O
a O
z B-clinical_variable
- I-clinical_variable
score I-clinical_variable
of O
+ O
@NUMBER B-lower_bound
during O
the O
acute O
febrile O
phase O
of O
kd B-chronic_disease

receiving O
drugs O
acting O
primarily O
on O
the O
central O
nervous O
system O
, O
which O
lower O
the O
seizure B-chronic_disease
threshold O
( O
see O
appendix O
@NUMBER O
) O

no O
major O
medical O
or O
psychiatric B-chronic_disease
illness I-chronic_disease

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound

patients O
must O
not O
be O
taking O
any O
contraindicated O
medications B-treatment
listed O
on O
the O
duloxetine B-treatment
package O
insert O
including O
the O
following O
: O
phenothiazines B-treatment
, O
propafenone B-treatment
, O
flecanide B-treatment
, O
linezolid B-treatment
, O
or O
anticoagulation B-treatment
medication I-treatment
( O
e.g. O
, O
heparin B-treatment
, O
warfarin B-treatment
, O
or O
direct B-treatment
oral I-treatment
anticoagulants I-treatment
) O
; O
treatment B-treatment
with I-treatment
mao I-treatment
inhibitor I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

active O
herpes B-chronic_disease
simplex I-chronic_disease
or O
zoster B-chronic_disease
at O
the O
time O
of O
treatment O
or O
having O
experienced O
more O
than O
three B-lower_bound
episodes O
of O
herpes O
simplex O
/ O
zoster B-chronic_disease
eruption I-chronic_disease
within O
a O
year O
of O
study O
enrollment O

aitl B-cancer

primary B-cancer
cutaneous I-cancer
anaplastic I-cancer
large I-cancer
cell I-cancer
lymphoma I-cancer

symptomatic O
coronary B-chronic_disease
artery I-chronic_disease
disease I-chronic_disease
( I-chronic_disease
cad I-chronic_disease
) I-chronic_disease
, O
e.g. O
, O
angina B-chronic_disease
canadian B-ethnicity
class B-lower_bound
ii I-lower_bound
- O
iv B-upper_bound
( O
see O
appendix O
@NUMBER O
) O

patients O
who O
have O
a O
history O
of O
hypertension B-chronic_disease
controlled O
by O
medication B-treatment
must O
be O
on O
a O
stable O
dose O
( O
for O
at O
least O
one B-lower_bound
month I-lower_bound
) O
and O
meet O
all O
other O
inclusion O
criteria O

histologically O
confirmed O
glioblastoma B-cancer

progression O
following O
both O
standard O
combined B-treatment
modality I-treatment
treatment I-treatment
with I-treatment
radiation I-treatment
and I-treatment
temozolomide I-treatment
chemotherapy I-treatment
, O
as O
well O
as O
anti B-treatment
- I-treatment
angiogenic I-treatment
therapy I-treatment
( O
ie O
, O
bevacizumab B-treatment
; O
patients O
not O
eligible O
for O
or O
refusing O
antiangiogenic B-treatment
therapy I-treatment
will O
also O
be O
allowed O
) O

the O
subject O
is O
unable O
to O
undergo O
mri B-treatment
scan O
( O
eg O
, O
has O
pacemaker B-treatment
) O

at O
least O
two B-lower_bound
episodes O
of O
severe O
cdi B-chronic_disease
resulting O
in O
hospitalization O
and O
associated O
with O
significant O
morbidity O

must B-pregnancy
be I-pregnancy
non I-pregnancy
- I-pregnancy
pregnant I-pregnancy

women B-gender
who O
have O
a O
core B-treatment
biopsy I-treatment
or O
excisional B-treatment
biopsy I-treatment
containing O
invasive B-cancer
cancer I-cancer

patients O
with O
myelodysplastic B-cancer
syndromes I-cancer
( I-cancer
mds I-cancer
) I-cancer
mds B-cancer
) O
: O
a. O
de O
novo O
mds O
with O
intermediate O
or O
high O
- O
risk O
international O
prognostic O
scoring O
system O
( O
ipss O
) O
scores O
; O
patients O
with O
intermediate-1 O
features O
should O
have O
failed O
to O
respond O
to O
hypomethylating B-treatment
agent I-treatment
therapy I-treatment
, O
or O
b. O
patients O
with O
treatment O
- O
related O
mds O

performance B-clinical_variable
score I-clinical_variable
of O
at O
least O
@NUMBER B-lower_bound
% I-lower_bound
@NUMBER B-lower_bound
% O
by O
karnofsky B-clinical_variable
or O
@NUMBER O
to O
@NUMBER B-upper_bound
by O
eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
( O
age B-age
≥ O
@NUMBER B-lower_bound
years I-lower_bound
) O

acute B-cancer
myeloid I-cancer
leukemia I-cancer
( I-cancer
aml I-cancer
) I-cancer
aml B-cancer
) O
: O
a. O
first O
complete O
remission O
with O
high O
- O
risk O
features O
defined O
as O
: O
( O
i O
) O
greater O
than O
@NUMBER B-lower_bound
cycle I-lower_bound
of O
induction B-treatment
therapy I-treatment
therapy B-treatment
required O
to O
achieve O
remission O
; O
( O
ii O
) O
preceding O
myelodysplastic B-cancer
syndrome I-cancer
( I-cancer
mds I-cancer
) I-cancer
; O
( O
iii O
) O
presence O
of O
flt3 B-cancer
mutations I-cancer
@NUMBER B-lower_bound
mutations O
or O
internal O
tandem O
duplication O
or O
other O
mutations O
associated O
with O
poor O
- O
risk O
aml O
( O
e.g O
. O
dnmt3a O
, O
tet2 O
) O
; O
( O
iv O
) O
french B-clinical_variable
- I-clinical_variable
american I-clinical_variable
- I-clinical_variable
british I-clinical_variable
classification I-clinical_variable
( I-clinical_variable
fab I-clinical_variable
) I-clinical_variable
m6 B-lower_bound
or O
m7 B-upper_bound
classification O
; O
( O
v O
) O
adverse O
cytogenetics O
: O
@NUMBER O
, O
deletion O
( O
del O
) O
@NUMBER O
q O
, O
@NUMBER O
, O
del7q O
, O
abnormalities O
involving O
@NUMBER O
q O
, O
@NUMBER O
q O
, O
@NUMBER O
q O
, O
@NUMBER O
q O
, O
@NUMBER O
q O
, O
@NUMBER O
, O
@NUMBER O
or O
complex B-clinical_variable
karyotype I-clinical_variable
( O
> O
@NUMBER O
abnormalities O
) O
; O
( O
vi O
) O
treatment B-cancer
- I-cancer
related I-cancer
aml I-cancer
, O
or O
b. O
second O
or O
greater O
remission O
; O
patients O
beyond O
second O
remission O
have O
to O
be O
in O
complete O
remission O
( O
cr O
) O
at O
transplant O
to O
be O
eligible O
, O
or O
c. O
primary O
induction O
failure O
with O
partial O
response O
to O
therapy O
who O
achieve O
adequate B-treatment
cytoreduction I-treatment

history O
of O
abdominal B-chronic_disease
fistula I-chronic_disease
, O
gastrointestinal B-chronic_disease
perforation I-chronic_disease
, O
or O
intra B-chronic_disease
- I-chronic_disease
abdominal I-chronic_disease
abscess I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
day O
@NUMBER O

men B-gender
refusing O
to O
exercise O
a O
reliable O
form O
of O
contraception O

presence O
of O
diffuse O
leptomeningeal B-chronic_disease
disease I-chronic_disease

presence O
of O
punctate B-cancer
hemorrhage I-cancer
in I-cancer
the I-cancer
tumor I-cancer

malignancy B-cancer
currently O
undergoing O
treatment B-treatment
or O
history O
of O
cancer B-treatment
treatment I-treatment
within O
@NUMBER B-upper_bound
years I-upper_bound

have O
diagnosed O
with O
multiple B-cancer
or I-cancer
sessile I-cancer
papilloma I-cancer
by O
ultrasound B-treatment
, O
mammography B-treatment
and O
/ O
or O
ductoscopy B-treatment

have O
received O
chemotherapy B-treatment
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

ages B-age
of O
@NUMBER B-lower_bound
and O
@NUMBER B-upper_bound

cns B-treatment
therapy I-treatment
( O
chemotherapy B-treatment
or O
radiation B-treatment
) O
should O
continue O
as O
medically O
indicated O
during O
the O
study O
treatment B-treatment

new O
progressive O
pulmonary O
infiltrates O
on O
screening O
chest B-treatment
x I-treatment
- I-treatment
ray I-treatment
or O
chest B-treatment
ct I-treatment
scan I-treatment
that O
have O
not O
been O
evaluated O
with O
bronchoscopy B-treatment

received O
any O
investigational B-treatment
drugs I-treatment
within O
the O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
first O
dose O
of O
fludarabine B-treatment

refractory O
aml B-cancer
without O
cr O
after O
induction B-treatment
therapy I-treatment
( O
primary O
induction O
failure O
) O
or O
relapsed O
aml O
after O
obtaining O
a O
cr O

immobility B-treatment
casts I-treatment
or O
splints B-treatment
within O
the O
last O
@NUMBER B-upper_bound
months I-upper_bound
for O
tennis O
elbow O

patients O
may O
have O
received O
prior B-treatment
brentuximab I-treatment
vedotin I-treatment
brentuximab B-treatment
vedotin I-treatment
, O
but O
must O
not O
have O
received O
brentuximab O
vedotin O

patients O
must O
have O
pathologically O
confirmed O
relapsed O
or O
refractory O
classical B-cancer
hodgkin I-cancer
lymphoma I-cancer
( I-cancer
chl I-cancer
) I-cancer

patients O
must O
not O
have O
autoimmune B-chronic_disease
disorders I-chronic_disease
or O
conditions O
of O
immunosuppression B-treatment
that O
require O
current O
ongoing B-treatment
treatment I-treatment
with I-treatment
systemic I-treatment
corticosteroids I-treatment
( O
or O
other O
systemic B-treatment
immunosuppressants I-treatment
) O
, O
including O
oral B-treatment
steroids I-treatment
( O
i.e. O
, O
prednisone B-treatment
, O
dexamethasone B-treatment
) O

has O
not O
been O
naturally O
postmenopausal O
for O
at O
least O
@NUMBER B-lower_bound
consecutive I-lower_bound
months I-lower_bound

must O
not O
have O
relapsed O
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
receiving O
previous O
brentuximab B-treatment
vedotin I-treatment

patients O
in O
the O
nivolumab B-treatment
/ O
brentuximab B-treatment
cohorts O
only O
( O
d O
, O
e O
, O
f O
, O
y O
) O
may O
have O
received O
prior B-treatment
ipilimumab I-treatment

patients O
may O
not O
have O
received O
prior B-treatment
nivolumab I-treatment
or O
pd1 B-treatment
/ O
pdl1 B-treatment
axis I-treatment
agents I-treatment

vaccines O
are O
not O
prohibited O
on O
study O
, O
but O
must O
be O
given O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
after O
cycle O
@NUMBER O
and O
not O
within O
@NUMBER B-lower_bound
days I-lower_bound
of O
treatment B-treatment

cd4 B-clinical_variable
count I-clinical_variable
nadir I-clinical_variable
≥ O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
mm3 I-lower_bound

subject O
requires O
or O
is O
anticipated O
to O
require O
any O
of O
the O
prohibited O
medications B-treatment
noted O
in O
the O
protocol O

at O
least O
one B-lower_bound
documented O
saccular O
intracranial B-chronic_disease
cerebral I-chronic_disease
aneurysm I-chronic_disease
detected O
via O
catheter B-treatment
angiography I-treatment
, O
magnetic B-treatment
resonance I-treatment
angiography I-treatment
or O
computed B-treatment
tomography I-treatment
angiography I-treatment

subjects O
with O
a O
heart B-treatment
valve I-treatment
prosthesis I-treatment
requiring O
anticoagulation B-treatment

thrombocytopenia B-chronic_disease
( O
platelet B-clinical_variable
count I-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
@NUMBER I-upper_bound
/ I-upper_bound
l I-upper_bound
) O
at O
screening O

with O
body B-clinical_variable
weight I-clinical_variable
lower O
than O
the O
@NUMBER B-upper_bound
rd I-upper_bound
percentile I-upper_bound

@NUMBER B-lower_bound
weeks I-lower_bound
must O
have O
elapsed O
since O
the O
completion O
of O
a O
non B-treatment
- I-treatment
nitrosourea I-treatment
- I-treatment
containing I-treatment
chemotherapy I-treatment
regimen I-treatment

minimum O
interval O
since O
completion O
of O
radiation B-treatment
treatment I-treatment
is O
@NUMBER B-lower_bound
weeks I-lower_bound

attends O
day O
care O
with O
infants O
less O
than O
@NUMBER B-upper_bound
months I-upper_bound
of O
age B-age

myocardial B-chronic_disease
infarction I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
registration O

symptomatic O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease

life B-chronic_disease
- I-chronic_disease
threatening I-chronic_disease
illness I-chronic_disease
as O
determined O
by O
attending O
clinician O

prior O
whole B-treatment
brain I-treatment
radiotherapy I-treatment

patients O
must O
have O
adequate O
hematologic O
reserve O
with O
absolute B-clinical_variable
neutrophils I-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound
and O
platelets B-clinical_variable
greater O
than O
or O
equal O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound

oligodendroglioma B-cancer

mother O
's O
serology O
test O
results O
are O
negative O
for O
hiv B-chronic_disease
, O
hepatitis B-chronic_disease
b I-chronic_disease
, O
and O
hepatitis B-chronic_disease
c I-chronic_disease

other O
clinical O
concerns O
as O
documented O
by O
a O
site O
investigator O
that O
would O
predict O
( O
more O
likely O
to O
happen O
than O
not O
to O
happen O
) O
a O
risk O
of O
severe B-chronic_disease
complications I-chronic_disease
or O
very O
poor O
outcome O
during O
or O
after O
stage B-treatment
ii I-treatment
surgical I-treatment
repair I-treatment

anaerobic B-chronic_disease
bacterial I-chronic_disease
growth O
after O
@NUMBER B-lower_bound
days I-lower_bound

diagnosis O
of O
autism B-chronic_disease
based O
on O
dsm O
- O
iv O
- O
tr O
criteria O

medically O
unstable O
( O
e.g. O
, O
more O
than O
one B-lower_bound
seizure B-chronic_disease
a O
month O
) O

newly O
diagnosed O
mcl B-cancer
: O
age B-age
> O
@NUMBER B-lower_bound
years I-lower_bound
at O
the O
time O
of O
signing O
the O
informed O
consent O

newly O
diagnosed O
mcl B-cancer
: O
history O
of O
stroke B-chronic_disease
or O
intracranial B-chronic_disease
hemorrhage I-chronic_disease
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
signing O
the O
consent O

newly O
diagnosed O
mcl B-cancer
: O
significant O
screening O
electrocardiogram B-treatment
( I-treatment
ecg I-treatment
) I-treatment
abnormalities O
including O
left B-chronic_disease
bundle I-chronic_disease
branch I-chronic_disease
block I-chronic_disease
, O
@NUMBER B-chronic_disease
nd I-chronic_disease
degree I-chronic_disease
av I-chronic_disease
block I-chronic_disease
type I-chronic_disease
ii I-chronic_disease
, O
@NUMBER B-chronic_disease
rd I-chronic_disease
degree I-chronic_disease
block I-chronic_disease
, O
bradycardia B-chronic_disease
( O
< O
@NUMBER B-upper_bound
bpm I-upper_bound
) O
, O
or O
qtc B-clinical_variable
> O
@NUMBER B-lower_bound
msec I-lower_bound

newly O
diagnosed O
mcl B-cancer
: O
willing O
and O
able O
to O
participate O
in O
all O
study O
related O
procedures O
and O
therapy B-treatment
including O
swallowing O
capsules O
without O
difficulty O

relapsed B-cancer
/ I-cancer
refractory I-cancer
mcl I-cancer
: O
serum B-clinical_variable
bilirubin I-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

age B-age
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
years I-lower_bound
and O
less O
than O
@NUMBER O
years O
of O
age B-age
at O
the O
time O
of O
diagnosis O
( O
may O
enroll O
on O
strata O
w O
, O
s O
or O
n O
) O
, O
or O
( O
@NUMBER O
) O
age O
is O
greater O
than O
or O
equal O
to O
@NUMBER O
years O
and O
less O
than O
@NUMBER B-upper_bound
years I-upper_bound
and O
patient O
has O
shh B-cancer
medulloblastoma I-cancer
( O
must O
enroll O
on O
stratum O
s O
) O

completed O
protocol O
- O
directed O
radiation B-treatment
therapy I-treatment

english B-language_fluency
as I-language_fluency
primary I-language_fluency
language I-language_fluency
and O
training O
aide O
who O
speaks B-language_fluency
english I-language_fluency
available O
to O
participate O
in O
required O
sessions O

sgot B-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
≤ O
2.5x B-upper_bound
the I-upper_bound
institutional I-upper_bound
uln I-upper_bound

≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

had O
an O
autologous B-treatment
transplant I-treatment
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
starting O
study B-treatment
drug I-treatment
treatment I-treatment

has O
an O
eastern B-clinical_variable
cooperative I-clinical_variable
oncology I-clinical_variable
group I-clinical_variable
( I-clinical_variable
ecog I-clinical_variable
) I-clinical_variable
performance I-clinical_variable
status I-clinical_variable
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

is O
willing O
to O
undergo O
tumor B-treatment
genotyping I-treatment
for O
tp53 O
mutation O
, O
insertion O
, O
or O
deletion O
at O
screening O

prolongation O
of O
corrected B-clinical_variable
qt I-clinical_variable
interval I-clinical_variable
by I-clinical_variable
fridericia I-clinical_variable
's I-clinical_variable
method I-clinical_variable
( I-clinical_variable
qtcf I-clinical_variable
) I-clinical_variable
at O
rest O
, O
where O
the O
mean O
qtcf B-clinical_variable
interval I-clinical_variable
is O
> O
@NUMBER B-lower_bound
milliseconds I-lower_bound
( I-lower_bound
ms I-lower_bound
) I-lower_bound
for O
males B-gender

must O
use B-contraception_consent
acceptable I-contraception_consent
form I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
through O
the O
study O
and O
for O
@NUMBER B-upper_bound
days I-upper_bound
after I-upper_bound
final O
dose O
of O
study O
drug O

patients O
with O
history O
of O
allogeneic B-treatment
hematopoeitic I-treatment
stem I-treatment
cell I-treatment
transplant I-treatment

diagnosis O
of O
colorectal B-cancer
or O
head B-cancer
and I-cancer
neck I-cancer
cancer I-cancer

infant O
with O
one O
or O
more O
superficial O
hemangiomas B-cancer
in O
the O
preproliferative O
phase O
or O
very O
early O
proliferative O
growth O
phase O

infants O
with O
hemangiomas B-cancer
that O
threaten O
vital O
functions O
( O
e.g O
. O
obstructing O
the O
airway O
or O
impairing O
hearing O
or O
vision O
) O

aged B-age
less O
than O
@NUMBER B-upper_bound
months I-upper_bound

axillary B-treatment
node I-treatment
dissection I-treatment

patients O
with O
histologically O
positive B-cancer
axillary I-cancer
nodes I-cancer
post B-treatment
neoadjuvant I-treatment
therapy I-treatment

there O
is O
residual O
invasive B-cancer
carcinoma I-cancer
in O
the O
surgical B-treatment
breast I-treatment
specimen O
or O
whether O
there O
is O
evidence O
of O
pathologic O
complete O
response O

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

high O
- O
risk O
: O
embryonal B-cancer
, O
botryoid B-cancer
, O
spindle B-cancer
cell I-cancer
, O
alveolar B-cancer
, O
undifferentiated B-cancer
, O
or O
anaplastic B-cancer
rms I-cancer
with O
metastatic B-cancer
disease I-cancer
at O
diagnosis O
( O
stage O
@NUMBER O
) O

serum B-chronic_disease
creatinine I-chronic_disease
based O
on O
age B-age
and O
gender O

undergoing O
upfront O
surgical B-treatment
resection I-treatment
of O
the O
primary O
tumor B-cancer

histopathologic O
diagnosis O
of O
ctcl B-cancer
( O
mycosis B-chronic_disease
fungoides I-chronic_disease
[ I-chronic_disease
mf I-chronic_disease
] I-chronic_disease
or O
sezary B-chronic_disease
syndrome I-chronic_disease
[ I-chronic_disease
ss I-chronic_disease
] I-chronic_disease
) O
, O
confirmed O
by O
skin B-treatment
biopsy I-treatment
, O
or O
lymph O
node O
, O
or O
blood O
assessment O
, O
of O
current O
disease O

history O
of O
uncontrolled O
seizure B-chronic_disease
disorder I-chronic_disease
or O
active O
central B-chronic_disease
nervous I-chronic_disease
system I-chronic_disease
disease I-chronic_disease

participants O
must O
have O
recovered O
from O
any O
adverse O
effects O
from O
any O
previous B-treatment
ctcl I-treatment
therapy I-treatment
to O
common B-clinical_variable
terminology I-clinical_variable
criteria I-clinical_variable
for I-clinical_variable
adverse I-clinical_variable
events I-clinical_variable
( I-clinical_variable
ctcae I-clinical_variable
) I-clinical_variable
grade O
< O
@NUMBER B-upper_bound
before O
starting O
study O
drug O

a O
reasonable O
attempt O
should O
be O
made O
to O
make O
a O
pathologic O
diagnosis O
of O
malignancy B-cancer
( O
ie O
. O
bronchoscopy B-treatment
, O
ct B-treatment
guided I-treatment
lung I-treatment
biopsy I-treatment
) O

pulmonary B-clinical_variable
function I-clinical_variable
test I-clinical_variable
( I-clinical_variable
pfts I-clinical_variable
) I-clinical_variable
, O
including O
diffusion O
capacity O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
registration O

head B-chronic_disease
injury I-chronic_disease

cyclosporin B-treatment
e.g O
. O
( O
neoral B-treatment
or O
sandimmune B-treatment
) O

a O
malignancy B-cancer
diagnosed O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
ago O
if O
the O
subject O
has O
had O
no O
evidence O
of O
disease O
for O
@NUMBER B-upper_bound
years I-upper_bound
prior I-upper_bound
to O
screening O

measurable O
contrast O
- O
enhancing O
progressive O
or O
recurrent O
gbm B-cancer
by O
mri B-clinical_variable
imaging O
≤ O
two B-upper_bound
weeks I-upper_bound
before O
screening O

small B-treatment
- I-treatment
molecule I-treatment
kinase I-treatment
inhibitor I-treatment

patients O
treated O
before O
with O
any O
biological B-treatment
or O
small B-treatment
molecule I-treatment
or O
medication B-treatment
under O
investigation O
for O
the O
treatment B-treatment
of O
ra B-chronic_disease

patients O
with O
serious B-chronic_disease
or I-chronic_disease
chronic I-chronic_disease
infections I-chronic_disease
within O
the O
previous O
@NUMBER B-upper_bound
months I-upper_bound

≥ O
@NUMBER B-lower_bound
swollen O
and O
/ O
or O
tender O
joints O
of O
the O
hands O

ast B-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
the I-upper_bound
uln I-upper_bound

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
the I-upper_bound
uln I-upper_bound

creatinine B-clinical_variable
: O
adult O
patients O
: O
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
and O
creatinine B-clinical_variable
clearance I-clinical_variable
creatinine B-clinical_variable
clearance O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
; O
pediatric O
patients O
( O
< O
@NUMBER B-upper_bound
years I-upper_bound
old O
) O
creatinine O
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
and O
a O
creatinine O
clearance O
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
/ I-lower_bound
1.73 I-lower_bound
m I-lower_bound
( I-lower_bound
@NUMBER I-lower_bound
) I-lower_bound

haploidentical B-treatment
related O
donors O
for O
pediatric O
recipients O
must O
be O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
or O
older O

history O
of O
psychiatric B-chronic_disease
disorder I-chronic_disease
which O
in O
the O
opinion O
of O
the O
pi O
may O
compromise O
compliance O
with O
transplant B-treatment
protocol O
, O
or O
does O
not O
allow O
for O
appropriate O
informed O
consent O

no O
mutation O
in O
gata2 O
, O
or O
in O
the O
case O
where O
the O
mutation O
in O
gata2 O
has O
not O
been O
identified O
, O
but O
the O
recipient O
has O
the O
clinical O
syndrome O
of O
monomac B-cancer
, O
the O
donor O
is O
required O
to O
have O
no O
clinical O
evidence O
of O
monomac O

diffuse B-cancer
large I-cancer
cell I-cancer
lymphoma I-cancer

males B-gender
or O
females B-gender
of O
reproductive O
potential O
may O
not O
participate O
unless O
they O
have O
agreed B-contraception_consent
to I-contraception_consent
use I-contraception_consent
an I-contraception_consent
effective I-contraception_consent
contraceptive I-contraception_consent
method I-contraception_consent

patients O
with O
serious O
( O
sepsis B-chronic_disease
, O
pneumonia B-chronic_disease
, O
etc O
.. O
) O
proven O
or O
suspected O
infections O
at O
diagnosis O

uncontrolled O
seizures B-chronic_disease

patient O
has O
received O
intra B-treatment
- I-treatment
articular I-treatment
gdca I-treatment
or O
per O
any O
other O
non B-treatment
- I-treatment
i.v I-treatment
. I-treatment
route I-treatment

medical O
co O
- O
morbidities O
that O
are O
not O
cf O
- O
related O
or O
are O
unstable O
per O
investigator O
opinion O
( O
i.e O
. O
history O
of O
bleeding B-chronic_disease
disorders I-chronic_disease
, O
immunodeficiency B-chronic_disease
) O

ast B-clinical_variable
( I-clinical_variable
sgot I-clinical_variable
) I-clinical_variable
/ O
alt B-clinical_variable
( I-clinical_variable
sgpt I-clinical_variable
) I-clinical_variable
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
; O
@NUMBER O
x O
uln O
in O
cases O
of O
liver B-cancer
metastases I-cancer

patients O
who O
are O
actively O
receiving O
any O
other O
investigational B-treatment
agents I-treatment

phase O
ii O
only O
: O
patients O
with O
colorectal B-cancer
cancer I-cancer
with O
known O
msi B-chronic_disease
- I-chronic_disease
high I-chronic_disease
disease I-chronic_disease
who O
have O
not O
previously O
been O
treated O
with O
immunotherapy B-treatment
or O
who O
have O
refused O
treatment B-treatment
with I-treatment
immunotherapy I-treatment

currently O
taking O
anticoagulant B-treatment
or O
immunosuppressive B-treatment
medication I-treatment

fulfills O
diagnosis O
of O
autism B-chronic_disease
spectrum I-chronic_disease
disorders I-chronic_disease
by O
meeting O
dsm O
- O
iv O
- O
tr O
pdd O
diagnostic O
criteria O
of O
autistic B-chronic_disease
disorder I-chronic_disease
, O
asperger B-chronic_disease
's I-chronic_disease
disorder I-chronic_disease
, O
or O
pdd B-chronic_disease
- I-chronic_disease
nos I-chronic_disease

history O
of O
substance O
use O
( O
except O
nicotine O
or O
caffeine O
) O
within O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
or O
urine O
drug O
screen O
positive O
for O
substances O
of O
abuse O

participants O
with O
a O
score O
of O
≥ O
@NUMBER B-lower_bound
or O
more O
on O
the O
anxiety B-clinical_variable
/ I-clinical_variable
depression I-clinical_variable
subscale I-clinical_variable
of I-clinical_variable
cbcl I-clinical_variable
and O
cgi B-clinical_variable
- I-clinical_variable
anxiety I-clinical_variable
severity I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound

childhood B-chronic_disease
disintegrative I-chronic_disease
disorder I-chronic_disease

enzyme B-treatment
- I-treatment
inducing I-treatment
anti I-treatment
- I-treatment
epileptic I-treatment
drugs I-treatment
( I-treatment
eiaed I-treatment
) I-treatment
are O
not O
eligible O
for O
treatment B-treatment
on O
this O
protocol O

going O
on O
arm O
@NUMBER O
must O
have O
received O
planned O
treatment B-treatment
with I-treatment
radiation I-treatment
therapy I-treatment
treatment B-treatment
with O
radiation O
therapy O
and O
concomitant O
temozolomide B-treatment
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
but O
no O
more O
than O
@NUMBER B-lower_bound
days I-lower_bound
prior I-lower_bound
to O
starting O
treatment O
on O
this O
study O

have O
prior O
histologically O
proven O
glioblastoma B-cancer
that O
is O
progressive O
or O
recurrent O
following O
radiation B-treatment
therapy I-treatment
+ O
/ O
- O
chemotherapy B-treatment

histologically O
proven O
glioblastoma B-cancer

liver B-clinical_variable
function I-clinical_variable
tests I-clinical_variable
( I-clinical_variable
lft I-clinical_variable
) I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
times I-lower_bound
normal I-lower_bound

unable O
to O
perform O
treadmill O
testing O
due O
to O
reasons O
such O
as O
orthopedic O
problems O
, O
moderate O
to O
severe O
aortic B-chronic_disease
stenosis I-chronic_disease
as O
found O
on O
echocardiogram B-treatment
at O
screeningvisit O
, O
history O
of O
myocardial B-chronic_disease
infarction I-chronic_disease
in O
the O
last B-upper_bound
three I-upper_bound
months I-upper_bound
or O
angina B-chronic_disease
( O
under O
treatment B-treatment
) O

grade B-chronic_disease
iii I-chronic_disease
/ I-chronic_disease
iv I-chronic_disease
acute I-chronic_disease
gvhd I-chronic_disease

azole B-treatment
antifungals I-treatment

english B-language_fluency
or I-language_fluency
spanish I-language_fluency
speaker I-language_fluency

diabetes B-chronic_disease
or O
metabolic B-chronic_disease
syndrome I-chronic_disease

< O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound

concurrent O
non O
- O
protocol O
- O
specified O
anti B-treatment
- I-treatment
tumor I-treatment
therapy I-treatment
( O
e.g. O
, O
chemotherapy B-treatment
, O
other O
targeted B-treatment
therapy I-treatment
, O
topical B-treatment
therapy I-treatment
such O
as O
5-fluorouracil B-treatment
or O
imiquimod B-treatment
, O
radiation B-treatment
therapy I-treatment
, O
surgery B-treatment
, O
or O
photodynamic B-treatment
therapy I-treatment

life B-clinical_variable
expectancy I-clinical_variable
of O
< O
@NUMBER B-upper_bound
year I-upper_bound

medical O
contraindication O
to O
surgery B-treatment

patients O
who O
are O
unable O
or O
are O
unwilling B-contraception_consent
to I-contraception_consent
adhere I-contraception_consent
to I-contraception_consent
the I-contraception_consent
required I-contraception_consent
contraceptive I-contraception_consent
methods I-contraception_consent
are O
excluded O
from O
the O
study O

the O
patient O
should O
be O
considered O
a O
candidate O
for O
radiotherapy B-treatment
and O
should O
not O
have O
medical O
contraindications O
to O
receipt O
of O
radiation B-treatment
therapy I-treatment

women B-gender
of O
reproductive O
potential O
are O
required O
to O
use B-contraception_consent
two I-contraception_consent
forms I-contraception_consent
of I-contraception_consent
acceptable I-contraception_consent
contraception I-contraception_consent
( O
including O
one O
acceptable O
barrier B-contraception_consent
method I-contraception_consent
with I-contraception_consent
spermicide I-contraception_consent
) O
during O
therapy B-treatment
and O
for O
@NUMBER B-upper_bound
months I-upper_bound
after I-upper_bound
completing O
therapy O

greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
mm3 I-lower_bound
platelets B-clinical_variable

contraindication O
to O
use O
of O
rituximab B-treatment
or O
prednisone B-treatment

enrollment O
in O
a O
phase B-treatment
i I-treatment
trial I-treatment

indolent O
histology O
with O
one O
of O
the O
following O
markers O
of O
large O
tumor B-cancer
burden O
( O
@NUMBER O
) O

patients O
being O
treated O
with O
a O
single B-treatment
agent I-treatment
monoclonal I-treatment
antibody I-treatment

barrier B-contraception_consent
methods I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
: O
condom B-contraception_consent
or I-contraception_consent
occlusive I-contraception_consent
cap I-contraception_consent
( I-contraception_consent
diaphragm I-contraception_consent
or I-contraception_consent
cervical I-contraception_consent
/ I-contraception_consent
vault I-contraception_consent
caps I-contraception_consent
) I-contraception_consent
with I-contraception_consent
spermicidal I-contraception_consent
foam I-contraception_consent
/ I-contraception_consent
gel I-contraception_consent
/ I-contraception_consent
film I-contraception_consent
/ I-contraception_consent
cream I-contraception_consent
/ I-contraception_consent
vaginal I-contraception_consent
suppository I-contraception_consent

patients O
with O
a O
history O
of O
seizures B-chronic_disease

patients O
with O
treatment B-treatment
-related O
acute B-cancer
myeloid I-cancer
leukemia I-cancer
( I-cancer
aml I-cancer
) I-cancer
( I-cancer
t I-cancer
- I-cancer
aml I-cancer
) I-cancer
aml B-cancer
) O
( O
t O
- O
aml O
) O
/ O
myelodysplastic B-cancer
syndrome I-cancer
( I-cancer
mds I-cancer
) I-cancer
mds B-cancer
) O
, O
or O
with O
features O
suggestive O
of O
aml O
/ O
mds O
, O
or O
who O
have O
had O
prior B-treatment
allogeneic I-treatment
bone I-treatment
marrow I-treatment
transplant I-treatment
or O
double B-treatment
umbilical I-treatment
cord I-treatment
blood I-treatment
transplantation I-treatment

agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
highly I-contraception_consent
effective I-contraception_consent
contraception I-contraception_consent
prior O
to O
study O
entry O
, O
for O
the O
duration O
of O
study O
participation O
, O
and O
for O
@NUMBER B-upper_bound
months I-upper_bound
after O
completion O
of O
study O

breastfeeding O
should O
be O
discontinued O
while O
the O
patient O
is O
on O
this O
trial O
and O
for O
@NUMBER B-lower_bound
days I-lower_bound
following O
last O
dose O
of O
study O
drug O

patients O
who O
have O
a O
history O
of O
seizures B-chronic_disease

patients O
with O
prostate B-cancer
cancer I-cancer
may O
continue O
lhrh B-treatment
agonists I-treatment
or O
antagonists B-treatment

radiofrequency B-clinical_variable
ablation I-clinical_variable
( I-clinical_variable
rfa I-clinical_variable
) I-clinical_variable
of O
localized O
lesions O
should O
have O
been O
performed O
≥ O
@NUMBER B-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
treatment B-treatment

patients O
must O
have O
less O
than O
@NUMBER B-upper_bound
% I-upper_bound
bone O
marrow O
or O
peripheral O
blood O
blasts O

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mcl I-lower_bound
( O
within O
@NUMBER B-upper_bound
week I-upper_bound
of O
study O
entry O
) O

any O
of O
the O
following O
within O
@NUMBER B-upper_bound
days I-upper_bound
before O
the O
first O
dose O
of O
study O
treatment B-treatment

hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound
( O
within O
@NUMBER B-upper_bound
week I-upper_bound
of O
study O
entry O
) O

the O
participant O
has O
a O
corrected O
qt O
interval O
calculated O
by O
the O
fridericia B-clinical_variable
formula I-clinical_variable
( I-clinical_variable
qtcf I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
ms I-lower_bound
within O
@NUMBER B-upper_bound
days I-upper_bound
before I-upper_bound
randomization O

dlco B-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound

performance B-clinical_variable
status I-clinical_variable
≥ O
@NUMBER B-lower_bound

ingestion O
of O
buspirone B-treatment
during O
the O
month O
prior O
to O
enrollment O

no O
change O
in O
therapies O
or O
medications O
planned O
during O
the O
91-day B-upper_bound
participation O

major B-treatment
surgery I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
the O
start O
of O
study O
treatment B-treatment
, O
or O
ongoing O
complications O
from O
surgeries B-treatment
performed O
previously O

prior B-treatment
bevacizumab I-treatment
or O
tyrosine B-treatment
- I-treatment
kinase I-treatment
inhibitor I-treatment

women B-gender
men B-gender
of O
childbearing O
potential O
and O
men O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
a I-contraception_consent
medically I-contraception_consent
accepted I-contraception_consent
form I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
for O
the O
duration O
of O
study O
participation O
and O
for O
@NUMBER B-upper_bound
months I-upper_bound
following O
completion O
of O
study O
treatment O

no O
manual O
read O
of O
qt B-clinical_variable

mild O
to O
moderate O
alzheimer B-chronic_disease
's I-chronic_disease
disease I-chronic_disease
and I-chronic_disease
related I-chronic_disease
dementia I-chronic_disease
( I-chronic_disease
adrd I-chronic_disease
) I-chronic_disease
based O
on O
national O
institute O
of O
neurological O
and O
communicative O
disorders O
and O
stroke O
and O
the O
alzheimer O
's O
disease O
and O
related O
disorders O
association O
( O
nincds O
- O
adrda O
) O
criteria O

irreversible O
elevation O
in O
inr B-clinical_variable
> O
@NUMBER B-lower_bound

new O
york O
heart O
association O
( O
nyha O
) O
class O
ii O
or O
higher O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease

patients O
with O
known O
floxuridine B-allergy_name
, O
leucovorin B-allergy_name
, O
or O
mitomycin B-allergy_name
allergy O

subjects O
with O
a O
history O
of O
coronary B-chronic_disease
artery I-chronic_disease
disease I-chronic_disease
may O
be O
included O
if O
they O
have O
had O
a O
normal O
stress O
test O
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
enrollment O
and O
/ O
or O
were O
cleared O
by O
msk O
cardiology O

subjects O
with O
other O
concurrent O
severe O
medical O
problems O
unrelated O
to O
the O
malignancy B-cancer
that O
would O
significantly O
limit O
full O
compliance O
with O
the O
study O
, O
or O
places O
them O
at O
an O
unacceptable O
risk O
for O
participation O
in O
the O
study O

patients O
of O
any O
age B-age
; O
unless O
waived O
by O
local O
irb O
assent O
of O
the O
patient O
and O
in O
all O
cases O
consent O
of O
parent O
or O
legally O
authorized O
representative O
is O
required O
if O
a O
patient O
is O
under O
the O
age O
of O
majority O
and O
not O
legally O
emancipated O

patients O
who O
require O
tricuspid B-treatment
or O
pulmonic B-treatment
valve I-treatment
replacement I-treatment

patients O
with O
acute B-chronic_disease
preoperative I-chronic_disease
neurological I-chronic_disease
deficit I-chronic_disease
, O
myocardial B-chronic_disease
infarction I-chronic_disease
, O
or O
cardiac O
event O
who O
have O
not O
returned O
to O
baseline O
for O
at O
least O
30-days B-lower_bound
prior I-lower_bound
to O
enrollment O

women B-gender
men B-gender
of O
childbearing O
potential O
and O
fertile O
men O
who O
decline B-contraception_consent
to I-contraception_consent
use I-contraception_consent
effective I-contraception_consent
contraception I-contraception_consent
during O
and O
for O
a O
period O
of O
three B-upper_bound
months I-upper_bound
after O
the O
treatment O
period O

failure O
to O
obtain O
insurance O
/ O
payment O
authorization O
for O
zevalin B-treatment
, O
unless O
the O
subject O
agrees O
to O
cover O
the O
cost O

patients O
who O
had O
anything O
less O
than O
a O
cr B-chronic_disease
( O
pr B-chronic_disease
, O
sd B-chronic_disease
or O
progressive B-chronic_disease
disease I-chronic_disease
) O
to O
their O
last O
salvage O
regimen O

rituxan O
alone O
does O
not O
count O
as O
a O
regimen O
; O
however O
, O
bexxar B-treatment
or O
zevalin B-treatment
( O
ib B-treatment
ritumomab O
tiuxetan O
) O
do O
and O
patients O
must O
have O
completed O
radioimmunotherapy B-clinical_variable
( I-clinical_variable
rit I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
enrollment O

left B-clinical_variable
ventricular I-clinical_variable
ejection I-clinical_variable
fraction I-clinical_variable
ejection B-clinical_variable
fraction I-clinical_variable
is O
not O
required O
to O
be O
measured O
, O
however O
if O
it O
is O
measured O
, O
patient O
is O
excluded O
if O
ejection O
fraction O
is O
< O
@NUMBER B-upper_bound
% I-upper_bound

other O
neurological B-chronic_disease
dysfunction I-chronic_disease
should O
be O
excluded O
from O
this O
clinical O
trial O
because O
of O
their O
poor O
prognosis O

radiotherapy B-treatment
must O
have O
been O
completed O
at O
least O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
entry O
into O
the O
study O

poorly O
controlled O
hypertension B-clinical_variable
( O
> O
@NUMBER B-lower_bound
/ O
> O
@NUMBER B-lower_bound
) O

severe O
renal B-chronic_disease
failure I-chronic_disease
with O
estimated O
glomerular B-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
< O
@NUMBER B-upper_bound
ml I-upper_bound
/ I-upper_bound
min I-upper_bound

age B-age
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
years I-upper_bound

if O
prior O
cns B-cancer
leukemia I-cancer
, O
it O
must O
be O
treated O
and O
in O
cns O
cr O

either O
having O
a O
t3 B-cancer
( O
the O
cancer B-cancer
has O
grown O
through O
the O
muscularis O
propria O
and O
into O
the O
outermost O
layers O
of O
the O
colon O
or O
rectum O
but O
not O
through O
them O
) O
or O
higher O
, O
node O
positivity O
or O
metastatic B-cancer
lesion I-cancer
in O
the O
context O
of O
rectal B-cancer
cancer I-cancer
or O
being O
studied O
for O
colorectal B-cancer
cancer I-cancer
follow O
up O
, O
independent O
of O
the O
renal O
function O

subjects O
who O
suffer O
from O
claustrophobia B-chronic_disease

blast B-clinical_variable
count I-clinical_variable
≤ O
@NUMBER B-upper_bound

> O
@NUMBER B-lower_bound
months I-lower_bound
must O
have O
elapsed O
from O
start O
of O
last B-treatment
bmt I-treatment

failure O
to O
achieve O
at O
least O
a O
pr O
after O
induction B-treatment
therapy I-treatment
with I-treatment
cog I-treatment
anbl0532 I-treatment
or O
standard B-treatment
chemotherapy I-treatment

for O
cmv B-chronic_disease
seronegative O
recipients O
, O
a O
cmv O
seronegative O
donor O

minor O
abo B-chronic_disease
incompatibility I-chronic_disease

patients O
who O
relapse O
after O
either O
single O
or O
tandem O
autologous B-treatment
bmt I-treatment
are O
eligible O

patients O
with O
high O
risk O
disease O
as O
defined O
in O
appendix O
@NUMBER O
who O
do O
not O
meet O
eligibility O
requirements O
/ O
organ O
function O
requirements O
for O
myeloablative B-chronic_disease
conditioning O

the O
donor O
and O
recipient O
must O
be O
identical O
at O
at O
least O
one B-lower_bound
allele O
of O
each O
of O
the O
following O
genetic O
loci O
: O
hla O
- O
a O
, O
hla O
- O
b O
, O
hla O
- O
cw O
, O
hla O
- O
drb1 O
, O
and O
hla O
- O
dqb1 O

adequately O
treated O
stage B-cancer
i I-cancer
or I-cancer
ii I-cancer
cancer I-cancer
from O
which O
the O
patient O
is O
currently O
in O
complete O
remission B-treatment

at O
least O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
or O
older O

current O
treatment B-treatment
with I-treatment
systemic I-treatment
steroid I-treatment
therapy I-treatment

lhrh B-treatment
agonist I-treatment

neoadjuvant B-treatment
chemotherapy I-treatment
chemotherapy B-treatment
, O
because O
of O
the O
potential O
effect O
of O
chemotherapy O
on O
the O
immune O
system O

be O
willing O
to O
provide O
a O
tumor B-treatment
biopsy I-treatment
sample O
for O
the O
study O

histologically O
confirmed O
breast B-cancer
cancer I-cancer
for O
which O
chemotherapy B-treatment
with I-treatment
ac I-treatment
( O
doxorubicin B-treatment
plus O
cyclophosphamide B-treatment
) O
is O
being O
utilized O
in O
the O
neoadjuvant O
or O
adjuvant O
setting O
or O
metastatic O
prostate B-cancer
adenocarcinoma I-cancer
for O
which O
docetaxel O
will O
be O
administered O

brain B-cancer
tumor I-cancer

history O
of O
seizures B-chronic_disease
within O
last O
@NUMBER B-upper_bound
years I-upper_bound

treating O
surgeon O
has O
recommended O
surgical O
repair O
of O
the O
aneurysm B-chronic_disease

age B-age
@NUMBER B-lower_bound
years I-lower_bound
or O
over O

status- O
post B-treatment
lung I-treatment
or O
kidney B-treatment
transplantation I-treatment

diagnosis O
of O
tsc B-chronic_disease
associated O
with O
cystic O
lung O
lesions O

tumor B-cancer
between O
@NUMBER B-lower_bound
cm I-lower_bound
and O
@NUMBER B-upper_bound
cm I-upper_bound

agreement B-contraception_consent
to I-contraception_consent
utilize I-contraception_consent
effective I-contraception_consent
contraceptive I-contraception_consent
methods O
during O
the O
study O
( O
for O
one O
year O
) O

mds O
: O
bone B-clinical_variable
marrow I-clinical_variable
with O
≤ O
@NUMBER B-upper_bound
percent I-upper_bound
myeloblasts I-upper_bound
with O
normal O
maturation O
of O
all O
cell O
lines O
; O
peripheral O
blood O
demonstrates O
hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound
, O
platelets B-clinical_variable
≥ O
@NUMBER B-lower_bound
x I-lower_bound
10 I-lower_bound
^ I-lower_bound
9 I-lower_bound
/ I-lower_bound
l I-lower_bound
, O
neutrophils B-clinical_variable
≥ O
@NUMBER B-lower_bound
x I-lower_bound
10 I-lower_bound
^ I-lower_bound
9 I-lower_bound
/ I-lower_bound
l I-lower_bound
, O
and O
no O
circulating O
blasts O

female B-gender
patients I-gender
who O
are O
post O
- O
menarchal O
must O
have O
a O
documented O
negative B-pregnancy
pregnancy I-pregnancy
test O

patients O
with O
a O
known O
immune B-chronic_disease
deficiency I-chronic_disease

must O
be O
off O
concurrent O
treatment B-treatment
or O
medications O
for O
at O
least O
@NUMBER B-lower_bound
week I-lower_bound
including O
: O
interferon B-treatment
( O
e.g O
. O
intron B-treatment
- I-treatment
a I-treatment
® I-treatment
) O
, O
allergy O
desensitization O
injetions O
, O
growth O
factors O
( O
e.g O
. O
pricrut B-treatment
® I-treatment
, O
aranesp B-treatment
® I-treatment
, O
neulasta B-treatment
® I-treatment
) O
, O
interleukins B-treatment
( O
e.g O
. O
proleukin B-treatment
® I-treatment
) O
, O
and O
any O
investigational O
therapeutic O
medication O

must O
not O
have O
a O
history O
of O
any O
immune B-chronic_disease
system I-chronic_disease
disorder I-chronic_disease
or O
laboratory O
abnormality O
or O
any O
condition O
that O
could O
potentially O
alter O
immune O
function O

in O
case O
of O
oophorectomy B-treatment
alone O
, O
only O
when O
the O
reproductive O
status O
of O
the O
woman B-gender
has O
been O
confirmed O
by O
follow O
up O
hormone O
level O
assessment O

in O
case O
of O
use O
of O
oral B-contraception_consent
contraception I-contraception_consent
women B-gender
should O
have O
been O
stable O
on O
the O
same O
pill O
for O
a O
minimum O
of O
@NUMBER B-lower_bound
months I-lower_bound
before O
taking O
study O
treatment B-treatment

chronic B-chronic_disease
or I-chronic_disease
acute I-chronic_disease
pain I-chronic_disease
requiring O
prescription O
medication O
( O
s O
) O

treated O
currently O
with O
golimumab B-treatment
or O
certolizumab B-treatment

thrombocytopenia B-chronic_disease
( O
platelet B-clinical_variable
count I-clinical_variable
< O
@NUMBER B-lower_bound
) O
or O
coagulopathy B-chronic_disease

ability O
to O
lay O
in O
supine O
or O
elevated O
position O
for O
@NUMBER B-upper_bound
hours I-upper_bound

age B-age
@NUMBER B-lower_bound
years I-lower_bound
or O
older O
( O
older O
control O
group O
) O

diagnosis O
of O
moderate O
to O
very O
severe O
chronic B-chronic_disease
airflow I-chronic_disease
limitation I-chronic_disease
and O
compliant O

history O
of O
untreated O
metabolic B-chronic_disease
diseases I-chronic_disease
including O
hepatic B-chronic_disease
or O
renal B-chronic_disease
disorder I-chronic_disease

direct B-clinical_variable
bilirubin I-clinical_variable
of O
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

for O
the O
mf B-chronic_disease
and O
mds B-chronic_disease
/ I-chronic_disease
mpn I-chronic_disease
- I-chronic_disease
u I-chronic_disease
arms O
( O
arms O
@NUMBER O
& O
@NUMBER O
) O
, O
use O
of O
any O
other O
standard B-treatment
drug I-treatment
( O
except O
hydroxyurea B-treatment
, O
anagrelide B-treatment
, O
growth B-treatment
factors I-treatment
, O
revlimid B-treatment
, O
clofarabine B-treatment
, O
etc O
) O
or O
experimental B-treatment
drug I-treatment
or O
therapy B-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
starting O
study O
therapy O

subjects O
of O
childbearing O
potential O
who O
are O
unwilling O
to O
take O
appropriate O
precautions O
( O
from O
screening O
through O
follow O
- O
up O
) O
to O
avoid B-pregnancy
becoming I-pregnancy
pregnant I-pregnancy
or O
fathering O
a O
child O

females B-gender
of O
non O
- O
childbearing O
potential O
are O
defined O
as O
women B-gender
who O
a O
) O
are O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
with O
history O
of O
amenorrhea B-chronic_disease
for O
@NUMBER B-upper_bound
year I-upper_bound
or O
b O
) O
are O
surgically O
sterile O
for O
at O
least O
@NUMBER B-lower_bound
months I-lower_bound

patient O
is O
permitted O
to O
participate O
in O
any O
other O
therapeutic B-treatment
therapy I-treatment
for O
their O
disease O
as O
long O
as O
it O
does O
not O
concern O
vitamin O
d O

previous O
diagnosis O
of O
bleeding B-chronic_disease
disorder I-chronic_disease
( I-chronic_disease
s I-chronic_disease
) I-chronic_disease
or O
current O
use O
of O
blood B-treatment
thinners I-treatment
/ I-treatment
anticoagulants I-treatment

participants O
must O
have O
an O
adequate O
liver O
function O
, O
as O
defined O
by O
bilirubin B-clinical_variable
≤ O
to O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound
, O
and O
sgot B-clinical_variable
and O
sgpt B-clinical_variable
≤ O
to O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

be O
willing O
to O
use O
nicotine B-treatment
replacement I-treatment
therapy I-treatment
( I-treatment
nrt I-treatment
) I-treatment
and O
the O
e O
- O
cigarette O
for O
a O
period O
of O
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
weeks I-upper_bound

history O
of O
propylene B-allergy_name
glycol I-allergy_name
sensitivity O
/ O
allergy O

pass O
an O
mri B-treatment
safety O
screen O
and O
meet O
inclusion O
criteria O
for O
mri B-treatment
scans I-treatment

report O
smoking O
cigarettes O
daily O
in O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

acute O
lupus B-chronic_disease
nephritis I-chronic_disease
nephritis B-chronic_disease
defined O
as O
class B-lower_bound
ii I-lower_bound
, O
i O
v B-upper_bound
or O
v O
nephritis O
diagnosed O
within O
@NUMBER B-upper_bound
months I-upper_bound
or O
prot B-clinical_variable
/ I-clinical_variable
creat I-clinical_variable
> O
@NUMBER B-lower_bound
gm I-lower_bound
/ I-lower_bound
gm I-lower_bound
due O
to O
active O
lupus O
or O
in O
process O
of O
receiving O
induction O
therapy O
for O
nephritis O

leukopenia B-cancer
( O
wbc B-clinical_variable
< O
@NUMBER B-upper_bound
/ I-upper_bound
mm3 I-upper_bound
) O
or O
lymhopenia B-chronic_disease
( O
lymphocytes B-clinical_variable
< O
@NUMBER B-upper_bound
/ I-upper_bound
mm3 I-upper_bound
) O

severe O
chronic B-chronic_disease
pain I-chronic_disease
syndrome I-chronic_disease
on O
admission O

traumatic B-chronic_disease
brain I-chronic_disease
injury I-chronic_disease
, O
multiple B-chronic_disease
limb I-chronic_disease
fractures I-chronic_disease
, O
pelvic B-chronic_disease
fractures I-chronic_disease

you O
will O
need O
to O
participate O
in O
four O
physician O
visits O
and O
blood B-treatment
draws I-treatment

neoadjuvant B-treatment
chemotherapy I-treatment
for O
current O
malignancy B-cancer

surgery B-treatment
intent O
within O
@NUMBER B-upper_bound
weeks I-upper_bound

between O
the O
ages B-age
age B-age
s O
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
at O
the O
time O
of O
enrollment O
in O
tn01 O
and O
age O
≥ O
@NUMBER B-lower_bound
at O
time O
of O
randomization O
in O
this O
trial O

insulin B-treatment
autoantibodies I-treatment
( I-treatment
miaa I-treatment
) I-treatment

normal O
glucose O
tolerance O
by O
ogtt O
confirmed O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
( O
no O
more O
than O
@NUMBER B-upper_bound
days I-upper_bound
) O
of O
baseline O
( O
visit O
@NUMBER O
) O

current O
treatment O
with O
systemic B-treatment
antibiotic I-treatment
therapy I-treatment

history O
of O
skin O
sensitivity O
or O
reaction O
to O
white B-allergy_name
petrolatum I-allergy_name

will O
not O
be O
returning O
to O
the O
dermatology O
clinic O
in O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
days I-upper_bound
for O
suture B-treatment
removal I-treatment

hla B-clinical_variable
@NUMBER B-upper_bound
/ I-upper_bound
@NUMBER I-upper_bound
or O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
matched O
related O
or O
unrelated O
donor O
available O

breasts O
technically O
unsatisfactory O
for O
radiation B-treatment
treatment I-treatment
upon O
the O
discretion O
of O
the O
treating O
physician O

must O
have O
pathology O
proven O
invasive B-cancer
ductal I-cancer
carcinoma I-cancer

tumor B-cancer
malignancies I-cancer
must O
meet O
certain O
criteria O
to O
be O
eligible O

patients O
with O
evidence O
of O
another O
malignancy B-cancer
, O
exclusive O
of O
a O
skin B-cancer
cancer I-cancer
that O
requires O
only O
local B-treatment
treatment I-treatment
, O
should O
not O
be O
enrolled O
on O
this O
protocol O

chronic O
hepatitis B-chronic_disease
b I-chronic_disease
or O
hepatitis B-chronic_disease
c I-chronic_disease
infection O

subjects O
are O
not O
eligible O
if O
there O
is O
a O
prior O
history O
or O
current O
evidence O
of O
central B-chronic_disease
nervous I-chronic_disease
system I-chronic_disease
or O
leptomeningeal B-chronic_disease
involvement O

subjects O
must O
have O
adequate O
renal O
function O
with O
a O
creatinine B-clinical_variable
clearance I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
as O
determined O
by O
the O
cockcroft B-clinical_variable
- I-clinical_variable
gault I-clinical_variable
calculation I-clinical_variable

at O
least O
@NUMBER B-lower_bound
days I-lower_bound
before O
she O
starts O
taking O
lenalidomide B-treatment

@NUMBER O
hr O
urine B-clinical_variable
calcium I-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
d I-lower_bound
in O
women B-gender

discoid B-chronic_disease
/ O
meniscal O
tear O

currently O
taking O
metformin B-treatment
, O
sulfonylureas B-treatment
, O
thiazolidinediones B-treatment
or O
insulin B-treatment
for O
any O
reason O

hgba1c B-clinical_variable
> O
@NUMBER B-lower_bound

history O
of O
metabolic B-chronic_disease
acidosis I-chronic_disease

known O
alcoholism O
or O
ingestion O
of O
more O
than O
@NUMBER B-lower_bound
alcoholic O
beverages O
per O
day O

known O
diabetes B-chronic_disease
( I-chronic_disease
type I-chronic_disease
@NUMBER I-chronic_disease
or I-chronic_disease
@NUMBER I-chronic_disease
) I-chronic_disease

age B-age
must O
be O
> O
@NUMBER B-lower_bound
years I-lower_bound

alternative O
diagnosis O
for O
cause O
of O
dyspnea B-chronic_disease
, O
increased B-chronic_disease
sputum I-chronic_disease
or O
cough B-chronic_disease

smoking B-clinical_variable
history I-clinical_variable
≥ O
@NUMBER B-lower_bound
pack I-lower_bound
- I-lower_bound
years I-lower_bound

patient O
has O
participated O
in O
a O
novartis O
sponsored O
combination O
trial O
where O
imatinib B-treatment
was O
dispensed O
in O
combination O
with O
another O
study O
medication B-treatment
and O
patient O
is O
still O
receiving O
combination B-treatment
therapy I-treatment

placement O
of O
an O
intrauterine B-treatment
device I-treatment
( I-treatment
iud I-treatment
) I-treatment
or O
intrauterine B-chronic_disease
system I-chronic_disease
( I-chronic_disease
ius I-chronic_disease
) I-chronic_disease

pittsburgh B-clinical_variable
sleep I-clinical_variable
quality I-clinical_variable
index I-clinical_variable
( I-clinical_variable
psqi I-clinical_variable
) I-clinical_variable
score I-clinical_variable
> O
@NUMBER O
in O
group O
@NUMBER O
, O
and O
≤ O
@NUMBER O
in O
group O
@NUMBER O

use O
of O
hypno B-treatment
- I-treatment
sedative I-treatment
drugs I-treatment
for O
sleep O
or O
stimulants O

concurrent O
sleep O
disorders O
( O
insomnia B-chronic_disease
, O
narcolepsy B-chronic_disease
, O
central B-chronic_disease
sleep I-chronic_disease
apnea I-chronic_disease
or O
parasomnia B-chronic_disease
) O

unable O
to O
discontinue O
use O
of O
potent O
cytochrome B-treatment
p450 I-treatment
, O
family B-treatment
@NUMBER I-treatment
, O
subfamily B-treatment
a I-treatment
, O
polypeptide B-treatment
@NUMBER I-treatment
( I-treatment
cyp3a4 I-treatment
) I-treatment
inhibitors I-treatment
/ I-treatment
inducers I-treatment

ejection B-clinical_variable
fraction I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound

impairment O
of O
gastrointestinal O
function O
or O
gastrointestinal B-chronic_disease
disease I-chronic_disease
that O
may O
significantly O
alter O
the O
absorption O
of O
everolimus B-treatment
( O
e.g. O
, O
ulcerative B-chronic_disease
disease I-chronic_disease
, O
uncontrolled O
nausea B-chronic_disease
, O
vomiting B-chronic_disease
, O
diarrhea B-chronic_disease
, O
malabsorption B-chronic_disease
syndrome I-chronic_disease
or O
small B-treatment
bowel I-treatment
resection I-treatment

life B-clinical_variable
expectancy I-clinical_variable
of O
greater O
than O
@NUMBER B-lower_bound
weeks I-lower_bound

patient O
must O
have O
a O
karnofsky B-clinical_variable
( O
if O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
) O

the O
patient O
can O
only O
be O
included O
after O
initiation O
of O
appropriate O
lipid B-treatment
lowering I-treatment
medication I-treatment
and O
documentation O
of O
cholesterol B-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
and O
triglycerides B-clinical_variable
< O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
before O
start O
of O
therapy B-treatment

direct O
tumor B-cancer
extension O
into O
the O
stomach B-cancer
, O
duodenum B-cancer
, O
small B-cancer
bowel I-cancer
or O
large B-cancer
bowel I-cancer

prior B-treatment
radiotherapy I-treatment
to O
the O
region O
of O
the O
liver O
that O
would O
result O
in O
overlap O
of O
radiation B-treatment
therapy I-treatment
fields O

serum B-clinical_variable
creatinine I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
or O
creatinine B-clinical_variable
clearance I-clinical_variable
≥ O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound

benign O
non O
- O
enhancing O
periportal O
lymphadenopathy B-cancer
is O
not O
unusual O
in O
the O
presence O
of O
hepatitis B-chronic_disease
and O
is O
permitted O
, O
even O
if O
the O
sum B-clinical_variable
of I-clinical_variable
enlarged I-clinical_variable
nodes I-clinical_variable
is O
> O
@NUMBER B-lower_bound
cm I-lower_bound

body B-bmi
mass I-bmi
index I-bmi
> O
@NUMBER B-lower_bound

clinically O
significant O
cardiac B-chronic_disease
dysfunction I-chronic_disease
defined O
as O
a O
history O
of O
≥ O
nyha B-clinical_variable
class I-clinical_variable
ii I-clinical_variable
symptoms O
, O
angina B-chronic_disease
, O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
, O
myocardial B-chronic_disease
infarction I-chronic_disease
, O
arrhythmias B-chronic_disease
or O
cardiac O
dysfunction O
requiring O
treatment B-treatment
or O
discontinuation O
of O
chemotherapy B-treatment

hematologic O
parameters O
: O
anc B-clinical_variable
≥ O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
mm^3 I-lower_bound
, O
alc B-clinical_variable
≥ O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
mm^3 I-lower_bound
, O
hemoglobin B-clinical_variable
≥ O
@NUMBER B-lower_bound
gm I-lower_bound
/ I-lower_bound
dl I-lower_bound
, O
wbc B-clinical_variable
≥ O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
mm^3 I-lower_bound
, O
platelet B-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm^3 I-lower_bound
, O
pt B-clinical_variable
/ O
ptt B-clinical_variable
less O
than O
or O
equla O
to1.5x B-upper_bound
the I-upper_bound
upper I-upper_bound
limits I-upper_bound
of I-upper_bound
normal I-upper_bound

may O
or O
may O
not O
have O
received O
adjuvant B-treatment
radiotherapy I-treatment
or O
chemotherapy B-treatment
based O
on O
pathologic O
risk O
per O
nccn O
guidelines O

recurrent O
or O
progressive O
metastatic B-cancer
disease I-cancer
after O
standard O
of O
care O
her2 B-clinical_variable
- O
targeted B-treatment
therapies I-treatment

stable O
, O
concurrent O
use O
of O
tamoxifen B-treatment
or O
aromatase B-treatment
inhibitors I-treatment
for O
hormone B-cancer
receptor I-cancer
positive I-cancer
breast I-cancer
cancer I-cancer

with O
her2 B-cancer
+ O
bladder B-cancer
cancer I-cancer
in O
the O
adjuvant O
setting O
( O
adjuvant O
bladder O
cancer O
patients O
) O

with O
malignant O
soft O
tissue O
and O
bone B-cancer
tumors I-cancer
and O
recurrent O
or O
progressive O
, O
metastatic B-cancer
solid B-cancer
tumors I-cancer
who O
have O
progressed O
on O
standard B-treatment
therapies I-treatment
with O
known O
benefit O
but O
for O
whom O
anti B-treatment
- I-treatment
her2 I-treatment
therapy I-treatment
is O
not O
clinically O
indicated O

most O
caudal O
renal O
artery O
to O
aortoiliac B-clinical_variable
bifurcation I-clinical_variable
length I-clinical_variable
≥ O
@NUMBER B-lower_bound
mm I-lower_bound

length B-clinical_variable
≥ O
@NUMBER B-lower_bound
mm I-lower_bound

bmi B-bmi
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
kg I-upper_bound
/ I-upper_bound
m2 I-upper_bound

coronary O
event O
or O
procedure O
( O
myocardial B-chronic_disease
infarction I-chronic_disease
, O
unstable B-chronic_disease
angina I-chronic_disease
, O
coronary B-treatment
artery I-treatment
bypass I-treatment
, O
surgery B-treatment
or O
coronary B-treatment
angioplasty I-treatment
) O
in O
the O
previous B-upper_bound
four I-upper_bound
weeks I-upper_bound

known O
hepatitis O
c O
on O
immunomodulators O
( O
i.e O
. O
interferon B-treatment
) O

mild O
- O
moderate O
erectile B-chronic_disease
dysfunction I-chronic_disease
based O
on O
international B-clinical_variable
index I-clinical_variable
of I-clinical_variable
erectile I-clinical_variable
function I-clinical_variable
( I-clinical_variable
iief I-clinical_variable
) I-clinical_variable
erectile I-clinical_variable
function I-clinical_variable
score I-clinical_variable
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

current O
or O
recent O
( O
within O
@NUMBER B-upper_bound
months I-upper_bound
of O
study O
drug O
administration O
) O
gastrointestinal B-chronic_disease
disease I-chronic_disease
or O
gastrointestinal B-treatment
surgery I-treatment
that O
, O
in O
the O
opinion O
of O
the O
investigator O
and O
the O
bms O
medical O
monitor O
, O
could O
impact O
the O
absorption O
of O
the O
study O
drug O

subjects O
with O
any O
functional O
cvad B-treatment
( I-treatment
central I-treatment
venous I-treatment
access I-treatment
device I-treatment
) I-treatment
in O
the O
upper O
or O
lower O
venous O
system O

subjects O
with O
any O
stable O
disease O
that O
are O
at O
risk O
for O
a O
venous B-chronic_disease
or I-chronic_disease
arterial I-chronic_disease
thrombotic I-chronic_disease
disorder I-chronic_disease

active O
gastrointestinal B-chronic_disease
blood I-chronic_disease
loss O

intolerance O
to O
brentuximab B-treatment
vedotin I-treatment

radioimmunotherapy B-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound

resolution O
of O
all O
non B-cancer
- I-cancer
hematologic I-cancer
brentuximab B-treatment
vedotin B-treatment
-related O
adverse B-clinical_variable
events I-clinical_variable
( I-clinical_variable
aes I-clinical_variable
) I-clinical_variable
to O
< O
grade B-upper_bound
@NUMBER I-upper_bound

current O
untreated O
major O
depression O
defined O
by O
geriatric B-clinical_variable
depression I-clinical_variable
scale I-clinical_variable
> O
@NUMBER B-lower_bound

significant O
neuropsychiatric B-chronic_disease
illnesses I-chronic_disease
such O
as O
bipolar B-chronic_disease
disorder I-chronic_disease
, O
schizophrenia B-chronic_disease
, O
moderate B-chronic_disease
- I-chronic_disease
severe I-chronic_disease
anxiety I-chronic_disease
, O
vascular B-chronic_disease
dementia I-chronic_disease
dementia B-chronic_disease
, O
creutzfeldt B-chronic_disease
- I-chronic_disease
jakob I-chronic_disease
dementia I-chronic_disease
, O
hiv B-chronic_disease
dementia I-chronic_disease
, O
and O
dementia O
in O
other O
specified O
diseases O

patients O
with O
refractory B-chronic_disease
b I-chronic_disease
- I-chronic_disease
cell I-chronic_disease
or O
t B-cancer
- I-cancer
cell I-cancer
non I-cancer
- I-cancer
hodgkin I-cancer
's I-cancer
lymphoma I-cancer
hodgkin B-cancer
's I-cancer
lymphoma I-cancer
or O
hodgkin O
's O
lymphoma O
who O
are O
eligible O
for O
allogeneic B-treatment
transplantation I-treatment

no O
active O
skin B-chronic_disease
infection I-chronic_disease

weight B-clinical_variable
< O
@NUMBER B-upper_bound
lbs I-upper_bound
( O
patient O
bed O
max O
weight B-clinical_variable
) O

age B-age
between O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

inability O
or O
refusal O
to O
have O
at O
least O
one B-lower_bound
peripheral O
intravenous O
line O
for O
intravenous O
access O
( O
as O
applicable O
to O
the O
day O
of O
[ B-treatment
@NUMBER I-treatment
f I-treatment
] I-treatment
4-l I-treatment
- I-treatment
fluoroglutamine I-treatment
( I-treatment
@NUMBER I-treatment
s,4r I-treatment
) I-treatment
injection I-treatment
and I-treatment
blood I-treatment
draws I-treatment
. O
) O

teres B-chronic_disease
minor I-chronic_disease
dysfunction I-chronic_disease

active B-chronic_disease
liver I-chronic_disease
infection I-chronic_disease

cns B-cancer
metastases I-cancer

chemotherapy B-treatment
and O
/ O
or O
targeted O
agent B-treatment
therapy I-treatment
must O
be O
completed O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
radiation B-treatment
and O
started O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
after O
completion O
of O
sbpt O
women B-gender
of O
childbearing O
potential O
and O
male B-gender
participants I-gender
must O
practice B-contraception_consent
adequate I-contraception_consent
contraception I-contraception_consent

tense O
ascites O
requiring O
frequent O
paracentesis B-treatment

a O
screening O
qtc B-clinical_variable
≥ O
@NUMBER B-lower_bound
msec I-lower_bound
, O
hypertriglyceridemia B-chronic_disease
requiring O
therapy B-treatment

patients O
with O
her2 B-cancer
/ I-cancer
neu I-cancer
positive I-cancer
breast I-cancer
cancer I-cancer
are O
not O
eligible O

squamous B-cancer
cell I-cancer
carcinoma I-cancer
of O
the O
skin O
, O
carcinoma B-cancer
in I-cancer
situ I-cancer
of O
the O
cervix O
( O
for O
phase O
ii O
only O
) O

tamoxifen B-treatment
therapy I-treatment
or O
other O
hormonal O
agents O
should O
be O
discontinued O
at O
least O
@NUMBER B-lower_bound
week I-lower_bound
before O
the O
patient O
is O
enrolled O
on O
this O
study O

gi B-chronic_disease
hemorrhage I-chronic_disease
or O
obstruction O
experienced O
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound

patient O
has O
signed O
the O
informed O
consent O
document O
agreeing O
to O
the O
use O
of O
the O
study O
drug O
, O
d O
omperidone B-treatment

stable O
hemoglobin B-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

requiring O
adenotonsillectomy B-treatment
for O
obstructive B-chronic_disease
sleep I-chronic_disease
apnea I-chronic_disease
or O
chronic B-chronic_disease
tonsillitis I-chronic_disease
between O
the O
ages B-age
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound

a O
serum B-clinical_variable
creatinine I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
% I-upper_bound
obtained O
≤ O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
entry O

history O
of O
allergic O
reactions O
attributed O
to O
compounds O
of O
similar O
chemical O
or O
biologic O
composition O
to O
tcn B-allergy_name
- I-allergy_name
pm I-allergy_name

prior O
tcn B-treatment
- I-treatment
pm I-treatment
therapy I-treatment

multicentricity B-cancer

able O
to O
overtly O
name O
more O
than O
an O
average O
of O
@NUMBER O
out O
of O
@NUMBER O
items O
during O
the O
pre B-treatment
- I-treatment
treatment I-treatment
picture O
naming O
test O
( O
philadelphia O
naming O
test O
) O
during O
visits O
@NUMBER O
or O
@NUMBER O

patients O
must O
be O
mri B-treatment
-compatible O
( O
e.g. O
, O
no O
metal O
implants O
, O
not O
claustrophobic B-chronic_disease
, O
etc O
. O
) O

patients O
must O
be O
native B-language_fluency
english I-language_fluency
speakers I-language_fluency

seizures B-chronic_disease
during O
the O
previous O
@NUMBER B-upper_bound
months I-upper_bound

patients O
with O
cervical B-cancer
esophageal I-cancer
carcinoma I-cancer

prior O
invasive O
malignancy B-cancer
( O
except O
non B-cancer
- I-cancer
melanomatous I-cancer
skin I-cancer
cancer I-cancer
) O
, O
unless O
disease O
free O
for O
a O
minimum O
of O
@NUMBER B-lower_bound
years I-lower_bound
( O
e.g O
. O
carcinoma B-cancer
in I-cancer
situ I-cancer
of I-cancer
breast I-cancer
, O
oral B-cancer
cavity I-cancer
, O
or O
cervix B-cancer
are O
permissible O
) O

alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
and O
aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
≤ O
uln O

history O
of O
any O
of O
the O
following O
cardio B-chronic_disease
- I-chronic_disease
vascular I-chronic_disease
condition I-chronic_disease

comorbid B-chronic_disease
psychiatric I-chronic_disease
disease I-chronic_disease
such O
as O
schizophrenia B-chronic_disease
, O
or O
active O
substance O
abusers O
( O
except O
nicotine O
) O

has O
received O
a O
live B-treatment
vaccine I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
planned O
start O
of O
study O
therapy B-treatment

patient O
has O
a O
diagnosis O
of O
immunodeficiency B-chronic_disease
or O
is O
receiving O
ongoing O
immunosuppressive B-treatment
therapy I-treatment
, O
including O
systemic B-treatment
or I-treatment
enteric I-treatment
corticosteroids I-treatment
except O
for O
non B-treatment
- I-treatment
systemically I-treatment
absorbed I-treatment
treatments I-treatment
( O
such O
as O
inhaled O
or O
topical O
steroid B-treatment
therapy I-treatment
for O
asthma B-chronic_disease
, O
chronic B-chronic_disease
obstructive I-chronic_disease
pulmonary I-chronic_disease
disease I-chronic_disease
, O
allergic B-chronic_disease
rhinitis I-chronic_disease
) O
. O
patient O
must O
be O
off O
systemic B-treatment
steroid I-treatment
or O
any O
other O
form O
of O
immunosuppressive O
therapy O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
first O
dose O
of O
trial B-treatment
treatment I-treatment

serum B-clinical_variable
ldh I-clinical_variable
> O
1.5x B-lower_bound
institutional I-lower_bound
uln I-lower_bound

serum B-clinical_variable
creatinine I-clinical_variable
or O
calculated B-clinical_variable
creatinine I-clinical_variable
clearance I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound

known O
active B-chronic_disease
infection I-chronic_disease
with O
hiv B-chronic_disease

non O
adenocarcinoma B-cancer
histology O

acute B-chronic_disease
illnesses I-chronic_disease
such O
as O
acute B-chronic_disease
pancreatitis I-chronic_disease
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
weeks I-upper_bound

fasting B-clinical_variable
serum I-clinical_variable
triglyceride I-clinical_variable
levels O
of O
greater O
than O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound

er B-clinical_variable
and O
/ O
or O
pr B-clinical_variable
positivity O
by O
institutional O
standard O
is O
required O
on O
pathology O
from O
the O
most O
recent O
tumor B-cancer
specimen O
unless O
the O
tissue O
source O
( O
for O
example O
, O
pleural O
effusion O
or O
ascites O
or O
bone B-treatment
biopsy I-treatment
) O
may O
yield O
false O
negative O
er O
and O
/ O
or O
pr O
result O
, O
in O
which O
case O
the O
pathology O
from O
an O
earlier O
time O
point O
could O
be O
used O
and O
a O
discussion O
with O
the O
study O
chair O
is O
required O

to O
be O
eligible O
for O
the O
part O
ii O
fulvestrant B-treatment
-treated O
er+ O
cohort O
, O
prior O
disease O
progression O
on O
fulvestrant O
is O
required O

neurologic B-chronic_disease
conditions I-chronic_disease
other O
than O
stroke B-chronic_disease

child O
bearing O
potential O
terminated O
by O
surgery B-treatment
, O
radiation B-treatment
, O
menopause O
or O
current O
use B-contraception_consent
of I-contraception_consent
two I-contraception_consent
approved I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent

hepatic B-chronic_disease
dysfunction I-chronic_disease

diagnosis O
of O
any O
disease O
for O
which O
a O
second O
or O
greater O
hematopoietic B-treatment
stem I-treatment
cell I-treatment
transplant I-treatment
is O
needed O
due O
to O
insufficient O
donor O
chimerism O
following O
hematopoietic O
recovery O
after O
previous B-treatment
hsct I-treatment

patients O
considered O
for O
transplantation B-treatment
must O
have O
a O
sufficient O
graft O
as O
based O
on O
current O
criteria O
of O
the O
university O
of O
minnesota O
blood B-treatment
and I-treatment
marrow I-treatment
transplantation I-treatment
program I-treatment

previous O
irradiation O
that O
precludes O
the O
safe O
administration O
of O
an O
additional O
dose O
of O
@NUMBER O
cgy O
of O
total B-clinical_variable
body I-clinical_variable
irradiation I-clinical_variable
( I-clinical_variable
tbi I-clinical_variable
) I-clinical_variable

which O
are O
below O
the O
median O
values O
for O
normal O
premenopausal O
women B-gender
( O
endocrine O
sciences O
, O
calabasas O
hills O
, O
calif O
. O
) O

cardiac B-clinical_variable
ejection I-clinical_variable
fraction I-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound

hiv B-chronic_disease
@NUMBER I-chronic_disease
and O
hiv B-chronic_disease
@NUMBER I-chronic_disease
ab I-chronic_disease
( I-chronic_disease
antibody I-chronic_disease
) I-chronic_disease

have O
completed O
effective O
antibiotic B-treatment
therapy I-treatment
to O
treat O
syphilis B-chronic_disease

lung B-clinical_variable
diffusion I-clinical_variable
capacity I-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound

non- O
hodgkin B-cancer
lymphoma I-cancer
with O
poor O
risk O
features O
not O
suitable O
for O
autologous O
hct O

minimal B-chronic_disease
residual I-chronic_disease
disease I-chronic_disease
( I-chronic_disease
mrd I-chronic_disease
) I-chronic_disease
positivity O

individuals O
who O
are O
willing O
and O
able O
to O
complete O
the O
hip B-clinical_variable
outcomes I-clinical_variable
questionnaire I-clinical_variable
and O
sf-12 B-clinical_variable
health I-clinical_variable
survey I-clinical_variable
as O
specified O
by O
the O
study O
protocol O

acute B-chronic_disease
renal I-chronic_disease
dysfunction I-chronic_disease
due O
to O
the O
hepato B-chronic_disease
- I-chronic_disease
renal I-chronic_disease
syndrome I-chronic_disease

patients O
with O
intermediate O
to O
high O
grade O
prostate B-cancer
cancer I-cancer

langerhans B-cancer
cell I-cancer
histiocytosis I-cancer
( I-cancer
lch I-cancer
) I-cancer

other O
severe O
combined B-chronic_disease
immune I-chronic_disease
deficiencies I-chronic_disease
( I-chronic_disease
cid I-chronic_disease
) I-chronic_disease

x B-chronic_disease
- I-chronic_disease
linked I-chronic_disease
lymphoproliferative I-chronic_disease
disease I-chronic_disease
( I-chronic_disease
xlp I-chronic_disease
) I-chronic_disease

unevaluated O
abnormal B-chronic_disease
vaginal I-chronic_disease
bleeding I-chronic_disease
or O
abnormal B-chronic_disease
pap I-chronic_disease
smear I-chronic_disease
in O
the O
previous O
year O

patients O
with O
liver B-chronic_disease
- I-chronic_disease
dominant I-chronic_disease
disease I-chronic_disease
defined O
as O
≥ O
@NUMBER B-lower_bound
% I-lower_bound
tumor B-clinical_variable
burden I-clinical_variable
confined O
to O
the O
liver O

creatinine B-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

that O
would O
place O
the O
patient O
at O
undue O
risk O
and O
that O
would O
preclude O
the O
safe O
use O
of O
chemoembolization B-treatment
or O
would O
interfere O
with O
study O
participation O

who O
have O
histologic O
and O
radiologic O
evidence O
of O
intrahepatic B-cancer
cholangiocarcinoma I-cancer

patients O
are O
excluded O
if O
there O
is O
radiographic O
or O
cerebrospinal O
fluid O
( O
csf O
) O
evidence O
of O
leptomeningeal B-cancer
disease I-cancer

patients O
are O
excluded O
if O
they O
are O
unable O
to O
obtain O
a O
magnetic B-treatment
resonance I-treatment
imaging I-treatment
( I-treatment
mri I-treatment
) I-treatment
scan I-treatment
for O
any O
other O
reason O

patients O
must O
be O
eligible O
to O
have O
all O
lesions B-chronic_disease
treated O
as O
determined O
by O
the O
study O
radiation O
oncologist O

patient O
at O
least O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
and O
aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable

group O
a O
: O
kif5b B-clinical_variable
/ I-clinical_variable
ret I-clinical_variable
or O
related O
variant O
ret O
fusions O

postmenopause O
is O
defined O
as O
amenorrhea B-clinical_variable
≥ O
@NUMBER B-lower_bound
consecutive I-lower_bound
months I-lower_bound

the O
subject O
has O
a O
pathologic O
diagnosis O
of O
non B-cancer
- I-cancer
small I-cancer
cell I-cancer
lung I-cancer
carcinoma I-cancer
that O
is O
metastatic O
or O
unresectable O

active O
peptic B-chronic_disease
ulcer I-chronic_disease
disease I-chronic_disease

serious O
non O
- O
healing O
wound O
/ O
ulcer B-chronic_disease
/ O
bone O
fracture O
within O
@NUMBER B-upper_bound
days I-upper_bound
before I-upper_bound
the O
first O
dose O
of O
study B-treatment
treatment I-treatment

stroke B-chronic_disease
( O
including O
tia B-chronic_disease
, O
or O
other O
ischemic B-chronic_disease
event O
) O
myocardial B-chronic_disease
infarction I-chronic_disease

hiv B-chronic_disease
seropositiviy O

history O
of O
ad B-chronic_disease
and O
asthma B-chronic_disease

known O
allergic O
reaction O
to O
sulfa B-allergy_name
, O
beta B-allergy_name
- I-allergy_name
lactam I-allergy_name
, O
or O
tetracycline B-allergy_name
class I-allergy_name
drugs I-allergy_name
; O
or O
lidocaine B-allergy_name
or O
epinephrine B-allergy_name

subjects O
receiving O
or O
planning O
to O
receive O
an O
ind B-treatment
agent I-treatment
, I-treatment
ultraviolet B-treatment
light I-treatment
therapy I-treatment
, O
monoclonal B-treatment
antibodies I-treatment
, O
or O
systemic B-treatment
immunosuppressants I-treatment

use O
of O
swimming O
pools O
, O
hot O
tubs O
, O
or O
whirlpools O
in O
@NUMBER B-upper_bound
days I-upper_bound
preceding I-upper_bound
baseline O
sampling O

use O
of O
topical O
or O
oral O
complementary B-treatment
/ I-treatment
alternative I-treatment
medicine I-treatment
( I-treatment
cam I-treatment
) I-treatment
agents O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
initiation O
of O
treatment B-treatment

hypersensitivity O
to O
perflutren B-allergy_name

bsa B-clinical_variable
> O
@NUMBER B-lower_bound
m2 I-lower_bound
and O
< O
@NUMBER B-upper_bound
m2 I-upper_bound

chronic O
immunosuppression B-chronic_disease

in O
the O
judgment O
of O
the O
hf O
specialist O
investigator O
at O
the O
site O
, O
the O
subject O
has O
been O
adequately O
treated O
per O
applicable O
standards O
, O
including O
for O
coronary B-chronic_disease
artery I-chronic_disease
disease I-chronic_disease
, O
left B-chronic_disease
ventricular I-chronic_disease
dysfunction I-chronic_disease
, O
mitral B-chronic_disease
regurgitation I-chronic_disease
and O
heart B-chronic_disease
failure I-chronic_disease
( O
e.g. O
, O
with O
cardiac B-treatment
resynchronization I-treatment
therapy I-treatment
, O
revascularization B-treatment
, O
and O
/ O
or O
gdmt B-treatment
) O

leaflet B-clinical_variable
mobility I-clinical_variable
length I-clinical_variable
< O
@NUMBER B-upper_bound
cm I-upper_bound

life B-clinical_variable
expectancy I-clinical_variable
< O
@NUMBER B-upper_bound
months I-upper_bound
due O
to O
non B-chronic_disease
- I-chronic_disease
cardiac I-chronic_disease
conditions I-chronic_disease

the O
local O
site O
heart O
team O
( O
ct O
surgeon O
and O
hf O
specialist O
investigators O
) O
and O
the O
central O
eligibility O
committee O
concur O
that O
surgery O
will O
not O
be O
offered O
as O
a O
treatment B-treatment
option O
and O
that O
medical B-treatment
therapy I-treatment
therapy B-treatment
is O
the O
intended O
therapy O
for O
the O
subject O
, O
even O
if O
the O
subject O
is O
randomized O
to O
the O
control O
group O

the O
subject O
or O
the O
subject O
's O
legal O
representative O
understands O
and O
agrees O
that O
should O
he O
/ O
she O
be O
assigned O
to O
the O
control O
group O
, O
he O
/ O
she O
will O
be O
treated O
with O
medical B-treatment
therapy I-treatment
and O
conservative O
management O
without O
surgery B-treatment
and O
without O
the O
mitraclip B-treatment
, O
either O
domestically O
or O
abroad O

history O
of O
hyperlipidemia B-chronic_disease

pregnant B-pregnancy
females B-gender
as O
determined O
by O
positive O
serum O
or O
urine O
hcg O
test O
( O
from O
the O
first O
urine O
of O
the O
day O
) O
at O
screening O
or O
prior O
to O
dosing O

subject O
has O
pronounced O
dehydration B-chronic_disease

history O
of O
recurrent O
syncope B-chronic_disease
in O
the O
last O
@NUMBER B-upper_bound
months I-upper_bound

a O
minimum O
of O
@NUMBER B-lower_bound
days I-lower_bound
between O
treatment B-treatment
and O
x-396 B-treatment
and O
@NUMBER B-lower_bound
days I-lower_bound
between O
alk B-treatment
tki I-treatment
and O
x-396 O

dextran B-treatment

patients O
must O
be O
willing O
to O
undergo O
@NUMBER O
tumor B-cancer
biopsies B-treatment

prophylactic B-treatment
anticoagulation I-treatment
( O
i.e O
. O
intralumenal B-treatment
heparin I-treatment
) O
for O
venous O
or O
arterial O
access O
devices O

subjects O
with O
known O
liver O
cirrhosis B-chronic_disease
in O
severity O
that O
would O
preclude O
tolerability O
of O
cyclosporine B-treatment
and O
eltrombopag B-treatment
as O
evidenced O
by O
albumin B-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
l I-upper_bound

karnofsky B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
≥ O
@NUMBER B-lower_bound
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
study O
entry O

aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

persons O
of O
reproductive O
potential O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
an I-contraception_consent
adequate I-contraception_consent
method I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
throughout O
treatment B-treatment

for O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
after O
study O
drug O
is O
stopped O

multiple B-cancer
myeloma I-cancer
: O
stage B-lower_bound
ii I-lower_bound
or O
iii B-upper_bound
, O
symptomatic B-chronic_disease
, O
secretory B-clinical_variable
multiple I-clinical_variable
myeloma I-clinical_variable
requiring O
treatment B-treatment

non B-cancer
- I-cancer
hodgkin I-cancer
's I-cancer
lymphoma I-cancer
( I-cancer
nhl I-cancer
) I-cancer
in O
second O
or O
third O
complete O
remission B-treatment
, O
refractory B-cancer
nhl I-cancer
, O
or O
relapsed B-cancer
nhl I-cancer
( O
including O
relapse O
post B-treatment
autologous I-treatment
hematopoietic I-treatment
stem I-treatment
cell I-treatment
transplant I-treatment
) O
; O
double B-cancer
hit I-cancer
lymphomas I-cancer
in O
first O
remission O
or O
more O
advanced B-cancer
disease I-cancer

patients O
must O
have O
two O
cb O
units O
available O
which O
are O
matched O
with O
the O
patient O
at O
@NUMBER B-lower_bound
, O
@NUMBER O
, O
or O
@NUMBER B-upper_bound
/ O
@NUMBER O
human B-clinical_variable
leukocyte I-clinical_variable
antigen I-clinical_variable
( I-clinical_variable
hla I-clinical_variable
) I-clinical_variable
class I-clinical_variable
i I-clinical_variable
( I-clinical_variable
serological I-clinical_variable
) I-clinical_variable
and I-clinical_variable
ii I-clinical_variable
( I-clinical_variable
molecular I-clinical_variable
) I-clinical_variable
antigens I-clinical_variable
; O
each O
cord O
must O
contain O
at O
least O
@NUMBER B-lower_bound
x I-lower_bound
10 I-lower_bound
^ I-lower_bound
7 I-lower_bound
total B-clinical_variable
nucleated I-clinical_variable
cells I-clinical_variable
/ I-clinical_variable
kg I-clinical_variable
recipient O
body O
weight O
( O
pre O
- O
thaw O
) O
; O
cord O
blood O
units O
will O
be O
procured O
through O
the O
national O
marrow O
donor O
program O
( O
nmdp O
) O

patients O
with O
known O
history O
of O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease
/ O
acquired B-chronic_disease
immune I-chronic_disease
deficiency I-chronic_disease
syndrome I-chronic_disease
( I-chronic_disease
aids I-chronic_disease
) I-chronic_disease

any O
other O
illness O
condition O
( O
s O
) O
that O
could O
exacerbate O
potential O
toxicities O
, O
confound O
safety O
assessments O
, O
require O
excluded O
therapy B-treatment
for O
management O
, O
or O
limit O
compliance O
with O
study O
requirements O

bilirubin B-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
( O
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
with O
liver B-cancer
metastasis I-cancer
) O

platelet B-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound

serum B-clinical_variable
glutamic I-clinical_variable
- I-clinical_variable
pyruvic I-clinical_variable
transaminase I-clinical_variable
( I-clinical_variable
sgpt I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
× I-upper_bound
uln I-upper_bound
( O
≤ O
@NUMBER B-upper_bound
× I-upper_bound
uln I-upper_bound
with O
liver B-cancer
metastasis I-cancer
) O
uln B-clinical_variable
= I-clinical_variable
upper I-clinical_variable
normal I-clinical_variable
limit I-clinical_variable
of I-clinical_variable
institution I-clinical_variable
's I-clinical_variable
normal I-clinical_variable
range I-clinical_variable

women B-gender
of O
child O
- O
bearing O
potential O
must O
also O
have O
a O
negative B-pregnancy
pregnancy I-pregnancy
test O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
start O
of O
protocol O
therapy B-treatment
( O
radiation B-treatment
and O
veliparib B-treatment
) O

distant B-cancer
metastases I-cancer
, O
or O
clinically O
or O
pathologically O
involved O
lymph O
nodes O
confirmed O
by O
a O
ct B-treatment
scan I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
study O
entry O

subjects O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age
with O
histological O
diagnosis O
of O
incurable O
cancer B-cancer
( O
solid B-cancer
tumor I-cancer
) O

hematopoietic B-treatment
growth I-treatment
factors I-treatment
: O
at O
least O
@NUMBER B-lower_bound
days I-lower_bound
after O
the O
last O
dose O
of O
a O
long B-treatment
- I-treatment
acting I-treatment
growth I-treatment
factor I-treatment
( O
e.g O
. O
neulasta B-treatment
) O
or O
@NUMBER B-lower_bound
days I-lower_bound
for O
short B-treatment
- I-treatment
acting I-treatment
growth I-treatment
factor I-treatment

if O
the O
initial O
blood B-clinical_variable
glucose I-clinical_variable
is O
non O
- O
fasting O
and O
above O
normal O
limits O
a O
fasting B-clinical_variable
glucose I-clinical_variable
can O
be O
obtained O
and O
must O
be O
within O
the O
upper O
limits O
of O
normal O
for O
age B-age

karnofsky B-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
@NUMBER B-lower_bound
% I-lower_bound
for O
patients O
> O
@NUMBER O
years O
of O
age B-age
and O
lansky B-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER O
for O
patients O
≤ O
@NUMBER O
years O
of O
age O

no O
evidence O
of O
dyspnea B-chronic_disease
at O
rest O
and O
no O
exercise O
intolerance O

patients O
must O
be O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
months I-lower_bound
and O
≤ O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age
at O
the O
time O
of O
study O
enrollment O

patients O
presenting O
with O
visual O
disturbances O
by O
history O
or O
physical O
exam O
should O
have O
an O
ophthalmological O
exam O
and O
, O
if O
indicated O
, O
an O
mri B-treatment
to O
determine O
optic O
nerve O
or O
retinal O
involvement O

refractory O
bone O
marrow O
involvement O
defined O
as O
mrd B-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound
blasts O
done O
at O
a O
cog O
- O
approved O
mrd O
testing O
lab O
after O
most O
recent O
treatment B-treatment
regimen I-treatment
. O
in O
the O
bone O
marrow O
( O
m23 O
) O
and O
any O
cns O
status O

platelet B-clinical_variable
count I-clinical_variable
must O
be O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound
to O
initiate O
therap B-treatment

carcinosarcoma B-cancer

acquired B-treatment
immune I-treatment
deficiency I-treatment
syndrome I-treatment
( I-treatment
aids I-treatment
) I-treatment
or O
aids B-chronic_disease
- I-chronic_disease
related I-chronic_disease
complex I-chronic_disease

active B-chronic_disease
liver I-chronic_disease
disease I-chronic_disease
or O
clinical O
jaundice B-chronic_disease

isncsci B-clinical_variable
isncsci B-clinical_variable
impairment I-clinical_variable
scale I-clinical_variable
grade O
a O
, O
b O
or O
c O
based O
upon O
first O
isncsci O
evaluation O
after O
arrival O
to O
the O
hospital O

injury O
arising O
from O
penetrating B-chronic_disease
mechanism I-chronic_disease

liver B-clinical_variable
enzymes I-clinical_variable
( O
alt B-clinical_variable
/ O
sgpt B-clinical_variable
or O
ast B-clinical_variable
/ O
sgot B-treatment
) O
@NUMBER O
times O
the O
upper O
limit O
of O
normal O
( O
uln O
) O
at O
screening O
visit O

a O
child O
taking O
antibiotic B-treatment
prophylaxis I-treatment
for O
any O
reason O

a O
child O
with O
known O
grade B-lower_bound
iii I-lower_bound
- O
v B-upper_bound
vur B-chronic_disease

fever O
( O
a O
documented O
temperature O
of O
at O
least O
@NUMBER B-lower_bound
degrees I-lower_bound
fahrenheit I-lower_bound
or O
@NUMBER B-lower_bound
degrees I-lower_bound
celsius I-lower_bound
measured O
anywhere O
on O
the O
body O
) O

absolute B-clinical_variable
neutrophil I-clinical_variable
count I-clinical_variable
( I-clinical_variable
anc I-clinical_variable
) I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mcl I-lower_bound

current O
diagnosis O
of O
acute B-chronic_disease
or I-chronic_disease
chronic I-chronic_disease
prostatitis I-chronic_disease
( O
which O
may O
cause O
luts B-chronic_disease
that O
mimic O
bph B-chronic_disease
) O

episode O
of O
unstable B-chronic_disease
angina I-chronic_disease
pectoris I-chronic_disease
, O
myocardial B-chronic_disease
infarction I-chronic_disease
, O
transient B-chronic_disease
ischemic I-chronic_disease
attack I-chronic_disease
, O
or O
cerebrovascular B-chronic_disease
accident I-chronic_disease
( I-chronic_disease
stroke I-chronic_disease
) I-chronic_disease
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

serum O
prostate B-clinical_variable
specific I-clinical_variable
antigen I-clinical_variable
( I-clinical_variable
psa I-clinical_variable
) I-clinical_variable
level I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
ng I-lower_bound
/ I-lower_bound
ml I-lower_bound
( O
hybritech B-treatment
) O

this O
decision O
can O
be O
based O
on O
psa B-clinical_variable
velocity I-clinical_variable
, O
previous B-treatment
trus I-treatment
( I-treatment
transrectal I-treatment
ultrasound I-treatment
) I-treatment
biopsy I-treatment
, O
percent O
free O
psa O
, O
or O
other O
clinical O
estimations O
in O
keeping O
with O
sound O
urologic O
care O

known O
sensitivity O
to O
etidronate B-treatment

subjects O
must O
be O
diagnosed O
with O
acdc B-chronic_disease
based O
on O
genetic O
tests O
confirming O
mutation O
( O
s O
) O
in O
nt5e O
and O
evidence O
of O
lower O
extremity O
arterial O
calcifications O

current O
vision B-treatment
therapy I-treatment
or O
orthoptics B-treatment

creatinine B-clinical_variable
less O
or O
equal O
to O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( I-upper_bound
uln I-upper_bound
) I-upper_bound

low O
risk O
: O
gleason B-clinical_variable
< O
or O
= O
@NUMBER B-upper_bound
& O
psa B-clinical_variable
< O
or O
= O
@NUMBER B-upper_bound
& O
clinical O
stage O
t1b B-lower_bound
- O
t2a B-upper_bound
, O
nx B-cancer
or O
n0 O
, O
mx B-cancer
or O
m0 B-cancer

have O
a O
clinical O
diagnosis O
of O
idiopathic B-chronic_disease
pd I-chronic_disease

history O
of O
appropriate O
response O
to O
dopaminergic B-treatment
medication I-treatment
, O
with O
at O
least O
a O
@NUMBER B-lower_bound
% I-lower_bound
improvement O
in O
motor B-clinical_variable
updrs I-clinical_variable
pd B-chronic_disease
rs O
with O
l B-treatment
- I-treatment
dopa I-treatment
by O
history O
or O
in O
- O
clinic O
testing O
, O
for O
the O
pd O
patients O

mr B-treatment
- I-treatment
imaging I-treatment
with O
evidence O
indicative O
of O
secondary O
disease O
such O
as O
iron B-chronic_disease
deposits I-chronic_disease
in I-chronic_disease
putamen I-chronic_disease
, O
tumor B-cancer
, O
or O
stroke B-chronic_disease
, O
which O
could O
cause O
the O
movement B-chronic_disease
disorder I-chronic_disease

patients O
with O
tremor B-chronic_disease
- I-chronic_disease
dominant I-chronic_disease
pd I-chronic_disease
that O
do O
not O
respond O
to O
dopaminergic B-treatment
therapy I-treatment
and O
that O
exhibit O
a O
tremor B-clinical_variable
score I-clinical_variable
of O
at O
least O
@NUMBER B-lower_bound
for O
tremor B-clinical_variable
severity I-clinical_variable
on O
at O
least O
one B-lower_bound
side O
of O
the O
body O
on O
the O
motor O
updrs O
examination O

intractable O
symptoms O
of O
et B-cancer
or O
dystonia B-chronic_disease
impacting O
at O
least O
@NUMBER B-lower_bound
activities O
of O
daily O
living O

good O
general O
health O
with O
no O
known O
major B-chronic_disease
medical I-chronic_disease
conditions I-chronic_disease

clinically O
relevant O
anemia B-chronic_disease
as O
defined O
as O
hemoglobin B-clinical_variable
concentration I-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound
for O
males B-gender
and O
hemoglobin O
concentration O
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound
for O
females B-gender

salicylic B-treatment
acid I-treatment
, O
acetaminophen B-treatment
, O
ibuprofen B-treatment
, O
naproxen B-treatment
, O
mefenamic B-treatment
acid I-treatment
, O
diclofenac B-treatment
, O
gliclazide B-treatment
carbamazepine I-treatment
, O
valproic B-treatment
acid I-treatment
, O
cimetidine B-treatment
, O
sulfasalazine B-treatment
, O
amoxicillin B-treatment
and O
erythromycin B-treatment

creatinine B-clinical_variable
clearance I-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound

hemoglobin B-clinical_variable
> O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound

patients O
undergoing O
primary B-treatment
systemic I-treatment
treatment I-treatment
treatment B-treatment
( O
hormones B-treatment
or O
chemotherapy B-treatment
) O
as O
initial O
treatment O
with O
neoadjuvant O
reducing O
tumor B-cancer
size O

cervical B-treatment
foraminotomy I-treatment

patients O
with O
history O
of O
allergy O
or O
sensitivity O
to O
tamsulosin B-allergy_name
or O
other O
alpha B-allergy_name
- I-allergy_name
antagonist I-allergy_name
( O
alfuzosin B-allergy_name
, O
doxazosin B-allergy_name
, O
prazosin B-allergy_name
, O
terazosin B-allergy_name
, O
tamsulosin O
, O
and O
phenoxybenzamine B-allergy_name
) O

≥ O
@NUMBER B-lower_bound
years I-lower_bound

a O
co O
- O
existent O
diagnosis O
of O
primary O
hyperparathyroidism B-chronic_disease
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

already O
taking O
vitamin B-treatment
d I-treatment
supplements I-treatment
> O
@NUMBER B-lower_bound
iu I-lower_bound
/ I-lower_bound
day I-lower_bound

currently O
consuming O
digoxin B-treatment
, O
as O
usage O
increases O
risk O
of O
hypercalcemia B-chronic_disease

moderate O
to O
severe O
myopathic B-chronic_disease
pain I-chronic_disease
while O
on O
simvastatin B-treatment

recent O
therapy B-treatment
with O
corticosteroids B-treatment
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

chest B-chronic_disease
pain I-chronic_disease
with O
a O
non B-chronic_disease
- I-chronic_disease
ischemic I-chronic_disease
etiology I-chronic_disease

contraindication O
to O
dobutamine B-treatment

women B-gender
with O
coronary B-clinical_variable
stenosis I-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound
in O
any O
epicardial O
coronary O
artery O
, O
assessed O
visually O
at O
the O
time O
of O
angiography O

significant O
aortic B-chronic_disease
valve I-chronic_disease
stenosis I-chronic_disease

known O
cardiac B-chronic_disease
valvular I-chronic_disease
disease I-chronic_disease
( O
e.g O
. O
bicuspid B-chronic_disease
aortic I-chronic_disease
valve I-chronic_disease
) O
or O
arterial B-chronic_disease
aneurysm I-chronic_disease
( O
s O
) O
that O
may O
allow O
a O
nidus B-chronic_disease
of I-chronic_disease
infection I-chronic_disease

patients O
must O
have O
disease O
that O
is O
no O
longer O
considered O
responsive O
to O
available O
conventional O
modalities O
or O
treatments B-treatment
( O
failed O
any O
known O
standard O
curative O
or O
effective O
therapy B-treatment
for O
that O
disease O
) O

patients O
must O
have O
measurable O
or O
evaluable O
advanced O
and O
/ O
or O
metastatic B-cancer
disease I-cancer
by O
recist O
@NUMBER O

patients O
who O
have O
not O
fully O
recovered O
from O
toxicities B-chronic_disease
of O
any O
prior B-treatment
treatment I-treatment
treatment B-treatment
with O
cytotoxic B-treatment
drugs I-treatment
, O
radiotherapy B-treatment
or O
other O
anti B-treatment
- I-treatment
cancer I-treatment
modalities I-treatment
( O
returned O
to O
baseline O
status O
as O
noted O
before O
most O
recent O
treatment O
) O

patients O
with O
advanced O
and O
/ O
or O
metastatic O
, O
histologically O
documented O
solid B-cancer
tumors I-cancer

patients O
with O
indwelling B-treatment
catheters I-treatment
( O
other O
than O
portacath B-treatment
, O
hickman B-treatment
or O
picc B-treatment
lines I-treatment
) O

cerebrovascular B-chronic_disease
accident I-chronic_disease
, O
including O
transient B-chronic_disease
ischemic I-chronic_disease
attacks I-chronic_disease
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

estimated O
creatinine B-clinical_variable
clearance I-clinical_variable
≥ O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
m2 I-lower_bound

radiotherapy B-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
treatment B-treatment
with O
aps001f B-treatment
( O
intensive B-treatment
radiotherapy I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
or O
palliative B-treatment
radiotherapy I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
) O

unstable B-chronic_disease
angina I-chronic_disease
( O
anginal O
symptoms O
at O
rest O
) O

patients O
who O
have O
not O
received O
medical O
clearance O
from O
their O
physicians O
to O
undergo O
surgery B-treatment

examination O
under O
anesthesia B-treatment
( O
if O
indicated O
) O

prior O
systemic B-treatment
chemotherapy I-treatment
within O
the O
last O
three B-upper_bound
years I-upper_bound

sgot B-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
< O
@NUMBER B-upper_bound
x I-upper_bound
upper B-clinical_variable
limit I-clinical_variable
of I-clinical_variable
normal I-clinical_variable
( I-clinical_variable
uln I-clinical_variable
) I-clinical_variable
for O
age B-age

concomitant O
use O
of O
bisphosphonates B-treatment

patient O
must O
have O
performance B-clinical_variable
status I-clinical_variable
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
on O
the O
ecog B-clinical_variable
performance I-clinical_variable
scale I-clinical_variable
and O
life B-clinical_variable
expectancy I-clinical_variable
> O
@NUMBER B-lower_bound
months I-lower_bound

patients O
with O
known O
hypersensitivity O
to O
the O
components O
of O
study B-allergy_name
drug I-allergy_name
or O
its O
analogs O

qtc B-clinical_variable
prolongation I-clinical_variable
> O
@NUMBER B-lower_bound
msec I-lower_bound
( O
bazett O
's O
formula O
) O
or O
congenitally O
long O
qt B-chronic_disease
syndrome I-chronic_disease

have O
lung B-cancer
cancer I-cancer
harboring I-cancer
an I-cancer
egfr I-cancer
mutation I-cancer

known O
hypersensitivity O
to O
afatinib B-allergy_name
, O
cisplatin B-allergy_name
, O
or O
pemetrexed B-allergy_name

evaluated O
by O
a O
medical O
oncologist O
, O
radiation O
oncologist O
and O
thoracic O
surgeon O
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
enrollment O
into O
study O
to O
document O
that O
they O
are O
a O
candidate O
for O
chemoradiation B-treatment
and O
for O
consideration O
of O
surgical B-treatment
resection I-treatment
( O
not O
required O
to O
be O
a O
surgical O
candidate O

history O
of O
hepatitis B-chronic_disease
or O
injection B-treatment
drug I-treatment
use O

ast B-clinical_variable
( I-clinical_variable
sgot I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
( O
iuln B-clinical_variable
) O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
iuln I-upper_bound
for O
patients O
with O
liver B-cancer
metastases I-cancer

all O
patients O
must O
have O
measurable O
disease O
documented O
by O
ct B-treatment
, O
mri B-treatment
, O
or O
non O
- O
measurable O
disease O
documented O
by O
physical O
exam O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

concomitant O
use O
of O
the O
following O
drugs O
( O
see O
concomitant O
medications O
, O
section O
@NUMBER O
) O
: O
antioxidants B-treatment
; O
herbal B-treatment
or I-treatment
other I-treatment
alternative I-treatment
therapy I-treatment
medications I-treatment
; O
vitamin B-treatment
supplements I-treatment
( O
especially O
vitamins B-treatment
a I-treatment
, I-treatment
c I-treatment
, I-treatment
and I-treatment
e I-treatment
) O
other O
than O
a O
standard O
dose O
multivitamin B-treatment
, O
acetaminophen B-treatment
, O
cyclosporine B-treatment
a I-treatment
or O
analogue O
; O
verapamil B-treatment
; O
tamoxifen B-treatment
or O
analogue O
, O
ketoconazole B-treatment
, O
chlorpromazine B-treatment
; O
ru486 B-treatment
; O
indomethacin B-treatment
; O
or O
sulfinpyrazone B-treatment
, O
tetracycline B-treatment
, O
nalidixic B-treatment
acid I-treatment
, O
nitrofurantoin B-treatment
, O
phenytoin B-treatment
, O
sulfonamides B-treatment
, O
lithium B-treatment
, O
ceftriaxone B-treatment
, O
and O
amiodarone B-treatment

ecog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
of O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
and O
estimated O
survival O
of O
at O
least O
@NUMBER B-upper_bound
months I-upper_bound

known O
allergy O
to O
egg B-allergy_name
products I-allergy_name
or O
soy B-allergy_name
bean I-allergy_name
oil I-allergy_name

poorly O
- O
controlled O
diabetes B-chronic_disease
mellitus I-chronic_disease
, O
as O
defined O
as O
fasting B-clinical_variable
serum I-clinical_variable
glucose I-clinical_variable
concentration I-clinical_variable
over O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
or O
a O
hemoglobin B-clinical_variable
a1c I-clinical_variable
over O
@NUMBER B-lower_bound
% I-lower_bound

serum B-clinical_variable
creatinine I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
the I-upper_bound
upper I-upper_bound
limits I-upper_bound
of I-upper_bound
institutional I-upper_bound
normal I-upper_bound
( I-upper_bound
iuln I-upper_bound
) I-upper_bound

total O
bilirubin B-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
institutional B-clinical_variable
upper I-clinical_variable
limit I-clinical_variable
of I-clinical_variable
normal I-clinical_variable
( I-clinical_variable
iuln I-clinical_variable
) I-clinical_variable

≤ O
@NUMBER B-upper_bound
x I-upper_bound
iuln I-upper_bound
for O
patients O
with O
liver B-cancer
metastases I-cancer

patients O
with O
a O
retinal B-chronic_disease
detachment I-chronic_disease
or O
a O
family O
history O
of O
retinal O
detachment O

male B-gender
subjects O
whose O
female B-gender
partners O
are O
not O
post O
- O
menopausal O

scheduled O
for O
or O
completed O
a O
@NUMBER B-treatment
f I-treatment
- I-treatment
fdg I-treatment
- I-treatment
pet I-treatment
or I-treatment
@NUMBER I-treatment
f I-treatment
- I-treatment
fdg I-treatment
- I-treatment
pet I-treatment
/ I-treatment
ct I-treatment
tumor I-treatment
staging I-treatment
procedure I-treatment

acromegaly B-chronic_disease
patients O
on O
combination B-treatment
therapy I-treatment
with O
maximum O
doses O
of O
srl B-treatment
and O
pegvisomant B-treatment
( O
daily O
or O
weekly O

the O
patient O
had O
radiotherapy B-treatment
within O
@NUMBER B-upper_bound
months I-upper_bound
prior I-upper_bound
to O
study O
entry O

( O
fasting O
blood B-clinical_variable
sugar I-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
) O

alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
and O
aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

any O
serious O
and O
/ O
or O
unstable O
pre O
- O
existing O
medical B-chronic_disease
, O
psychiatric B-chronic_disease
, O
or O
other O
condition O
that O
could O
interfere O
with O
subject O
's O
safety O
, O
provision O
of O
informed O
consent O
, O
or O
compliance O
to O
study O
procedures O

implants O
of O
levonorgestrel B-treatment

poorly O
controlled O
hypertension B-chronic_disease
( O
defined O
as O
systolic B-clinical_variable
blood I-clinical_variable
pressure I-clinical_variable
( I-clinical_variable
sbp I-clinical_variable
) I-clinical_variable

within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
beginning O
study B-treatment
treatment I-treatment

creatinine B-clinical_variable
clearance I-clinical_variable
or O
glomerular B-clinical_variable
filtration I-clinical_variable
rate I-clinical_variable
( I-clinical_variable
gfr I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
/ I-lower_bound
1.73m^2 I-lower_bound

pregnant B-pregnancy
at O
the O
time O
of O
evaluation O

signs O
and O
/ O
or O
symptoms O
attributable O
to O
the O
eosinophilia B-chronic_disease

prior O
disease O
progression O
on O
docetaxel B-treatment
or O
paclitaxel B-treatment
in O
metastatic B-treatment
setting I-treatment

female B-gender
participants I-gender
who O
are O
pregnant B-pregnancy
or O
breastfeeding O
will O
be O
excluded O
from O
the O
study O

patients O
with O
history O
of O
mds B-cancer
transformed O
to O
aml B-cancer
are O
eligible O
regardless O
of O
their O
prior B-treatment
therapy I-treatment
for O
mds O
provided O

liver O
function O
( O
bilirubin B-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
, O
ast B-clinical_variable
and O
/ O
or O
alt B-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound
) O

age B-age
< O
@NUMBER B-upper_bound
years I-upper_bound
at O
the O
time O
of O
enrollment O

moderate O
high O
risk O
: O
stage B-cancer
ct3 I-cancer
and O
gleason B-clinical_variable
@NUMBER O
and O
any O
prostate B-clinical_variable
- I-clinical_variable
specific I-clinical_variable
antigen I-clinical_variable

age B-age
and O
performance O
status O
, O
arm O
a O

arm O
c O
: O
evidence O
of O
progressive O
or O
recurrent O
gct B-cancer
( O
measurable O
or O
non O
- O
measurable O
) O
following O
one O
or O
more O
cisplatin O
- O
based O
chemotherapy B-treatment

arm O
d O
: O
certain O
cns B-cancer
tumor I-cancer
patients O
who O
can O
only O
undergo O
one O
transplant B-treatment

hematologic B-chronic_disease
: O
anc B-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound
, O
platelets B-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm3 I-lower_bound

lansky B-clinical_variable
play I-clinical_variable
score I-clinical_variable
≥ O
@NUMBER B-lower_bound
for O
patients O
≤ O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

one B-lower_bound
or O
more O
unfavorable O
prognostic O
features O
for O
achieving O
a O
cr O
with O
conventional B-treatment
- I-treatment
dose I-treatment
chemotherapy I-treatment

organ O
function O
, O
arm O
c O
( O
to O
begin O
ti B-treatment
chemotherapy I-treatment
) O

patients O
that O
are O
@NUMBER B-lower_bound
@NUMBER B-lower_bound
@NUMBER O
@NUMBER B-upper_bound
months I-upper_bound
of O
age B-age
with O
inss B-clinical_variable
stage I-clinical_variable
@NUMBER I-clinical_variable
and O
all O
@NUMBER O
favorable O
biologic O
features O
( O
ie O
, O
non- O
amplified O
mycn O
, O
favorable O
pathology O
, O
and O
dna B-clinical_variable
index I-clinical_variable
> O
@NUMBER O
) O

any O
known O
allergy O
to O
any B-allergy_name
component I-allergy_name
of I-allergy_name
the I-allergy_name
delivery I-allergy_name
vehicle I-allergy_name

clinical O
and O
molecular O
diagnosis O
of O
retinitis B-chronic_disease
pigmentosa I-chronic_disease
associated O
with O
usher B-chronic_disease
syndrome I-chronic_disease
type I-chronic_disease
@NUMBER I-chronic_disease
b I-chronic_disease

men B-gender
or O
women B-gender
who O
do O
not B-contraception_consent
agree I-contraception_consent
to I-contraception_consent
use I-contraception_consent
barrier I-contraception_consent
contraception I-contraception_consent
as O
specified O
in O
the O
inclusion O
criteria O

agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
an I-contraception_consent
effective I-contraception_consent
form I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
such O
as O
the O
contraceptive O
pill O
or O
intra O
uterine O
device O
for O
at O
least O
three B-lower_bound
months I-lower_bound
following O
sar421869 B-treatment
administration O

congenital B-chronic_disease
cyanotic I-chronic_disease
heart I-chronic_disease
defects I-chronic_disease

fractional B-clinical_variable
inspired I-clinical_variable
oxygen I-clinical_variable
concentration I-clinical_variable
( I-clinical_variable
fio2 I-clinical_variable
) I-clinical_variable
> O
@NUMBER B-lower_bound

uncuffed B-treatment
endotracheal I-treatment
tube I-treatment
( I-treatment
ett I-treatment
) I-treatment

estimated O
survival O
of O
less O
than O
one B-upper_bound
year I-upper_bound

must O
have O
an O
identified O
caregiver O
who O
is O
willing O
and O
able O
to O
oversee O
the O
training O
practice O
during O
the O
intervention O
period O
( O
ie O
, O
for O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
weeks I-upper_bound
starting O
approximately O
@NUMBER B-upper_bound
months I-upper_bound
after O
completion O
of O
crt B-treatment
) O

for O
women B-gender
, O
not B-pregnancy
pregnant I-pregnancy
as O
determined O
by O
pregnancy B-pregnancy
screening O
, O
nor O
breast O
feeding O
, O
and O
using B-contraception_consent
acceptable I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
methods I-contraception_consent

life O
- O
time O
consumption O
of O
at O
least O
@NUMBER B-lower_bound
cigarettes O

male B-gender
smokers O

smoke O
more O
frequently O
than O
once O
a O
week O
and O
≤ O
@NUMBER B-upper_bound
cpd I-upper_bound

cohort O
@NUMBER O
a O
will O
have O
participants O
with O
no O
prior B-treatment
lapatinib I-treatment
therapy I-treatment

cohort O
@NUMBER O
c O
will O
have O
participants O
will O
have O
progressive O
brain B-treatment
metastases I-treatment
and O
prior B-treatment
t I-treatment
- I-treatment
dm1 I-treatment

in O
cohort O
@NUMBER O
, O
eligible O
patients O
will O
include O
those O
who O
have O
cns B-chronic_disease
disease I-chronic_disease
that O
is O
amenable O
for O
surgery B-treatment
( O
typically O
< O
@NUMBER B-upper_bound
brain B-clinical_variable
metastases I-clinical_variable
and O
with O
planned O
resection O
by O
neurosurgery B-treatment
) O

it O
is O
anticipated O
that O
some O
patients O
may O
have O
multiple O
progressive O
cns O
lesions O
, O
one O
or O
several O
of O
which O
are O
treated O
with O
srs B-treatment
or O
surgery B-treatment
with O
residual O
untreated O
lesions O
remaining O

over O
- O
expression O
by O
immunohistochemistry B-clinical_variable
( I-clinical_variable
ihc I-clinical_variable
) I-clinical_variable
with O
score O
of O
3 O
+ O
( O
in O
> O
@NUMBER B-lower_bound
% I-lower_bound
of O
invasive O
tumor B-cancer
cells O
) O

patients O
who O
are O
receiving O
any O
cancer B-treatment
- I-treatment
directed I-treatment
concurrent I-treatment
therapy I-treatment
, O
such O
as O
concurrent O
chemotherapy B-treatment
, O
radiotherapy B-treatment
, O
or O
hormonal B-treatment
therapy I-treatment
while O
on O
study O
. O
concurrent O
treatment B-treatment
with O
bisphosphonates B-treatment
and O
denosumab B-treatment
is O
allowed O
for O
bony O
metastases B-cancer
but O
should O
be O
started O
before O
the O
first O
dose O
of O
neratinib B-treatment

patients O
with O
a O
negative O
or O
equivocal O
overall O
result O
( O
fish B-clinical_variable
ratio O
of O
< O
@NUMBER B-upper_bound
@NUMBER B-lower_bound
or O
≤ O
@NUMBER B-upper_bound
her2 B-clinical_variable
gene O
copies O
per O
nucleus O
) O
and O
ihc B-clinical_variable
staining O
scores O
of O
@NUMBER O
, O
1 O
+ O
, O
2 B-upper_bound
+ I-upper_bound
are O
not O
eligible O
for O
enrollment O

patients O
without O
pathologic O
or O
cytologic O
confirmation O
of O
metastatic B-cancer
disease I-cancer
should O
have O
unequivocal O
evidence O
of O
metastasis B-cancer
by O
physical O
exam O
or O
radiologic B-treatment
study I-treatment

patients O
with O
more O
than O
@NUMBER B-lower_bound
sites O
of O
extrahepatic B-cancer
disease I-cancer
( O
including O
nodes O
and O
pulmonary O
nodules O
) O

be O
receiving O
any O
investigational O
drug O
( O
a O
drug O
other O
than O
treprostinil B-treatment
administered O
under O
an O
ind O
) O
or O
participating O
in O
any O
other B-treatment
investigational I-treatment
study I-treatment
, O
with O
the O
exception O
of O
alemtuzumab B-treatment
( I-treatment
campath I-treatment
) I-treatment

be O
receiving O
any O
non O
- O
standard O
immunosuppression B-treatment
protocol O
or O
other O
non O
- O
standard O
treatment O
that O
could O
affect O
interpretation O
of O
the O
study O
results O

those O
currently O
receiving O
treatment O
for O
portopulmonary B-chronic_disease
hypertension I-chronic_disease

baseline O
hemoglobin B-clinical_variable
less O
than O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound
in O
women B-gender
men B-gender
and O
less O
than O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound
in O
men O

untreated O
proliferative O
diabetic B-chronic_disease
retinopathy I-chronic_disease

previous B-treatment
head I-treatment
and I-treatment
neck I-treatment
surgery I-treatment
that O
would O
preclude O
transoral B-treatment
/ I-treatment
robotic I-treatment
procedures I-treatment

female B-gender
patients I-gender
must O
be O
willing B-contraception_consent
to I-contraception_consent
use I-contraception_consent
two I-contraception_consent
adequate I-contraception_consent
barrier I-contraception_consent
methods I-contraception_consent
of I-contraception_consent
contraception I-contraception_consent
to O
prevent O
pregnancy B-pregnancy

i.q B-clinical_variable
. O
< O
@NUMBER B-upper_bound

a O
phe B-clinical_variable
> O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
at O
any O
time O

additional O
laboratory O
requirements O
anc B-clinical_variable
≥ O
@NUMBER B-lower_bound
x I-lower_bound
@NUMBER I-lower_bound
/ I-lower_bound
l I-lower_bound
hgb B-clinical_variable
≥ O
@NUMBER B-lower_bound
g I-lower_bound
/ I-lower_bound
dl I-lower_bound
( O
transfusion B-treatment
permitted O
) O
platelet B-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
x I-lower_bound
@NUMBER I-lower_bound
/ I-lower_bound
l I-lower_bound

fcbp O
must O
have O
a O
negative B-pregnancy
serum I-pregnancy
or I-pregnancy
urine I-pregnancy
pregnancy I-pregnancy
test O
and O
agree B-contraception_consent
to I-contraception_consent
birth I-contraception_consent
control I-contraception_consent

pts O
with O
primary B-cancer
systemic I-cancer
amyloidosis I-cancer

significant O
neuropathy B-chronic_disease
( O
grade B-chronic_disease
@NUMBER I-chronic_disease
, O
grade B-chronic_disease
@NUMBER I-chronic_disease
, O
or O
grade B-chronic_disease
@NUMBER I-chronic_disease
with O
pain O
) O
at O
the O
time O
of O
the O
first O
dose O
and O
/ O
or O
within O
@NUMBER B-upper_bound
days I-upper_bound
before O
enrollment O

a O
familial O
haploidentical B-treatment
donor O
without O
homozygous B-chronic_disease
sickle I-chronic_disease
cell I-chronic_disease
disease I-chronic_disease

clinically O
significant O
neurologic O
event O
( O
stroke B-chronic_disease
) O
or O
any O
neurologic B-clinical_variable
deficit I-clinical_variable
lasting O
> O
@NUMBER B-lower_bound
hours I-lower_bound
that O
is O
accompanied O
by O
an O
infarct O
on O
cerebral B-treatment
mri I-treatment

conditions O
that O
, O
in O
the O
opinion O
of O
the O
study O
team O
, O
may O
impact O
the O
immunomodulatory O
protocol O
potentially O
exposing O
the O
recipient O
to O
an O
unacceptable O
risk O
under O
immunosuppressive B-treatment
treatment I-treatment

inherited O
peripheral B-chronic_disease
neuropathy I-chronic_disease

personally O
identifiable O
tattoo O
( O
i.e. O
, O
donor O
name O
) O
on O
potential B-treatment
transplant I-treatment

recent O
( O
≥ O
@NUMBER B-lower_bound
months I-lower_bound
) O
or O
remote O
( O
i.e. O
, O
several O
decades O
) O
unilateral O
or O
bilateral B-chronic_disease
upper I-chronic_disease
limb I-chronic_disease
loss I-chronic_disease
( O
below O
the O
shoulder O
) O
desiring O
limb B-treatment
transplantation I-treatment

diagnosis O
other O
than O
multiple B-cancer
myeloma I-cancer

fvc B-clinical_variable
, O
fev1 B-clinical_variable
or O
dlco B-clinical_variable
< O
@NUMBER B-upper_bound
% I-upper_bound
of O
predicted O
and O
/ O
or O
receiving O
supplementary O
continuous O
oxygen O

melanoma B-cancer
in I-cancer
situ I-cancer
or O
thyroid B-cancer
carcinoma I-cancer

inability O
to O
lie O
flat O
for O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
minutes I-upper_bound
( O
the O
anticipated O
amount O
of O
time O
to O
complete O
the O
mri O
procedure O
) O

inability B-contraception_consent
to I-contraception_consent
give I-contraception_consent
informed I-contraception_consent
consent I-contraception_consent

pericardial B-clinical_variable
effusion I-clinical_variable
> O
@NUMBER B-lower_bound
cm I-lower_bound
on O
cardiac B-treatment
mri I-treatment
unless O
successful O
pericardiocentesis B-treatment
has O
been O
performed O

patients O
with O
severe B-chronic_disease
kidney I-chronic_disease
dysfunction I-chronic_disease

no O
evidence O
for O
androgen B-chronic_disease
excess I-chronic_disease
( O
hirsutism B-chronic_disease
or O
acne B-chronic_disease
) O

not O
breastfeeding O
or O
pregnant B-pregnancy

history O
or O
presence O
of O
underlying O
condition O
that O
could O
cause O
delayed O
puberty O
( O
chronic B-chronic_disease
illness I-chronic_disease
, O
weight B-chronic_disease
loss I-chronic_disease
, O
abnormal O
cranial O
magnetic B-treatment
resonance I-treatment
imaging I-treatment
( I-treatment
mri I-treatment
) I-treatment
) O

high B-treatment
- I-treatment
dose I-treatment
chemotherapy I-treatment
or O
external B-treatment
beam I-treatment
radiation I-treatment
therapy I-treatment
to I-treatment
lung I-treatment
, I-treatment
liver I-treatment
, I-treatment
or I-treatment
kidneys I-treatment
> O
@NUMBER B-lower_bound
gy I-lower_bound
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
prior B-treatment
to I-treatment
therapeutic I-treatment
@NUMBER I-treatment
y I-treatment
- I-treatment
ibritumomab I-treatment
tiuxetan I-treatment
dose I-treatment

prior B-treatment
allogeneic I-treatment
bone I-treatment
marrow I-treatment
transplant I-treatment
or O
double B-treatment
umbilical I-treatment
cord I-treatment
blood I-treatment
transplantation I-treatment

high O
risk O
acute B-cancer
myelogenous I-cancer
leukemia I-cancer
or O
high O
risk O
myelodysplastic B-cancer
syndrome I-cancer
status O
post O
allogeneic B-treatment
bone I-treatment
marrow I-treatment
transplant I-treatment

not O
able O
to O
swallow O
the O
lenalidomide B-treatment
capsule O
as O
a O
whole O

total O
bilirubin B-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound

kps B-clinical_variable
or O
lansky B-clinical_variable
score I-clinical_variable
> O
or O
= O
to O
@NUMBER B-lower_bound

new B-clinical_variable
york I-clinical_variable
heart I-clinical_variable
association I-clinical_variable
( I-clinical_variable
nyha I-clinical_variable
) I-clinical_variable
stage B-lower_bound
iii I-lower_bound
or O
iv B-upper_bound
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease

preceding O
and O
/ O
or O
ongoing O
organ B-chronic_disease
dysfunction I-chronic_disease
or O
other O
co O
- O
morbidity O
including O
but O
not O
limited O
to O
uncontrolled B-chronic_disease
infection I-chronic_disease
that O
would O
impair O
the O
patient O
's O
ability O
to O
endure O
known O
side O
effects O
of O
cytokine B-chronic_disease
release I-chronic_disease
syndrome I-chronic_disease
or O
neurological O
toxicity O

consumption O
of O
alcohol O
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
dosing O
or O
during O
the O
study O

( O
> O
@NUMBER B-lower_bound
th I-lower_bound
bmi B-bmi
% O
) O

mild O
elevations B-clinical_variable
may O
be O
seen O
in O
overweight O
girls O
, O
so O
elevations O
< O
@NUMBER B-upper_bound
times I-upper_bound
the I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
will O
be O
accepted O
in O
this O
group O

evidence O
of O
alcohol O
, O
drug O
abuse O
or O
other O
relevant O
neuropsychiatric B-chronic_disease
condition I-chronic_disease
such O
as O
psychotic B-chronic_disease
illness I-chronic_disease
or O
severe B-chronic_disease
depression I-chronic_disease

subjects O
with O
a O
mildly O
low B-clinical_variable
hematocrit I-clinical_variable
( O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
% I-upper_bound
) O
will O
be O
asked O
to O
take O
iron O
in O
the O
form O
of O
ferrous B-treatment
gluconate I-treatment
for O
up O
to O
@NUMBER B-upper_bound
days I-upper_bound

pregnant B-pregnancy
( O
self O
reported O
) O

inclusive O
of O
chemothearpy B-treatment

contraindication O
to O
use O
of O
cpm B-treatment
or O
regional B-treatment
brachial I-treatment
plexus I-treatment
block I-treatment
, O
such O
as O
bleeding B-chronic_disease
diathesis I-chronic_disease
, O
use O
of O
anticoagulants B-treatment
or O
severe O
restriction O
in O
shoulder O
range O
of O
movement O

must O
be O
willing O
to O
take O
effective O
antiretroviral B-treatment
therapy I-treatment
, O
if O
indicated O

no O
prior B-treatment
therapy I-treatment
for O
mcl B-cancer
, O
except O
< O
@NUMBER B-upper_bound
week I-upper_bound
of O
steroid B-treatment
therapy I-treatment
for O
symptom O
control O

mild O
visual B-chronic_disease
function I-chronic_disease
loss I-chronic_disease
, O
defined O
as O
grades O
@NUMBER B-lower_bound
@NUMBER O
or O
@NUMBER B-upper_bound
on O
the O
humphrey B-clinical_variable
visual I-clinical_variable
field I-clinical_variable
analyzer I-clinical_variable
sita I-clinical_variable
standard I-clinical_variable
@NUMBER I-clinical_variable
test I-clinical_variable
grading I-clinical_variable
scale I-clinical_variable
( O
table O
@NUMBER O
) O
at O
presentation O
and O
a O
worsening O
to O
moderate O
or O
greater O
visual O
function O
loss O
, O
defined O
as O
grades O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
, O
after O
@NUMBER B-lower_bound
month I-lower_bound
of O
treatment B-treatment
and O
/ O
or O
medication B-treatment
intolerance O

other O
neurological B-chronic_disease
problems I-chronic_disease
, O
such O
as O
neurofibromatosis B-chronic_disease
, O
lead O
poisoning O
, O
non B-chronic_disease
- I-chronic_disease
febrile I-chronic_disease
seizure I-chronic_disease
disorder I-chronic_disease
, O
or O
tuberous B-chronic_disease
sclerosis I-chronic_disease

participant O
must O
be O
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
months I-upper_bound
of O
age B-age

participant O
must O
be O
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
months O
of O
age B-age

any O
patient O
with O
hematologic B-chronic_disease
or O
oncologic O
diagnosis O
in O
which O
allogeneic B-treatment
hsct I-treatment
is O
thought O
to O
be O
beneficial O
, O
and O
in O
whom O
front O
- O
line O
therapy B-treatment
has O
already O
been O
applied O

hodgkin B-cancer
or O
indolent B-cancer
non I-cancer
- I-cancer
hodgkin I-cancer
's I-cancer
lymphoma I-cancer
with O
chemosensitive B-cancer
disease I-cancer

mds B-cancer
( I-cancer
myelodysplastic I-cancer
syndrome I-cancer
) I-cancer
, O
specific O
subtypes O
of O
ra B-chronic_disease
( I-chronic_disease
refractory I-chronic_disease
anemia I-chronic_disease
) I-chronic_disease
or O
rars B-chronic_disease
( I-chronic_disease
refractory I-chronic_disease
anemia I-chronic_disease
with I-chronic_disease
ringed I-chronic_disease
sideroblasts I-chronic_disease
) I-chronic_disease
subtypes O

patients O
treated O
on O
this O
protocol O
will O
be O
without O
morphological O
evidence O
of O
disease O
( O
complete B-treatment
remission I-treatment
or O
cr B-treatment
) O
, O
or O
if O
the O
patient O
has O
evidence O
of O
disease O
, O
the O
patient O
must O
have O
had O
at O
least O
a O
good O
partial O
response O
( O
pr O
) O
to O
the O
most O
recent B-treatment
therapy I-treatment
and O
the O
disease O
must O
be O
chemoresponsive O

l B-chronic_disease
- I-chronic_disease
transposition I-chronic_disease
of I-chronic_disease
the I-chronic_disease
great I-chronic_disease
arteries I-chronic_disease

patient O
with O
active B-chronic_disease
heart I-chronic_disease
disease I-chronic_disease

pregnant B-pregnancy
or O
breast O
- O
feeding O
women B-gender
are O
excluded O

visual B-clinical_variable
acuity I-clinical_variable
of O
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
in O
both O
eyes O
at O
the O
time O
of O
screening O
visit O

visual B-clinical_variable
acuity I-clinical_variable
≤ O
@NUMBER B-upper_bound
/ I-upper_bound
@NUMBER I-upper_bound
in O
the O
worst O
eye O

between O
@NUMBER B-lower_bound
years I-lower_bound
and O
@NUMBER B-upper_bound
years I-upper_bound
old O

fvc B-clinical_variable
, O
fev1 B-clinical_variable
, O
or O
dlco B-clinical_variable
< O
@NUMBER B-upper_bound
% I-upper_bound
of O
predicted O
and O
/ O
or O
receiving O
supplementary B-treatment
continuous I-treatment
oxygen I-treatment

recovery O
from O
all O
hematologic B-chronic_disease
and O
non B-chronic_disease
- I-chronic_disease
hematology I-chronic_disease
toxicities I-chronic_disease
from O
previous O
therapies B-treatment

chronic B-chronic_disease
myelogenous I-chronic_disease
leukemia I-chronic_disease

other O
myeloproliferative B-cancer
disorder I-cancer

has O
a O
pacemaker O
or O
other O
internal O
medical O
device O
, O
or O
reports O
being O
pregnant B-pregnancy
( O
pcs O
study O
) O

orthopedic B-chronic_disease
, O
neurologic B-chronic_disease
, O
or O
musculoskeletal B-chronic_disease
disability I-chronic_disease
that O
would O
interfere O
with O
the O
functional O
task O
of O
standing O
on O
a O
weight O
scale O
( O
pre O
- O
pilot O
phase O
, O
arm O
@NUMBER O
) O

> O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

weight B-clinical_variable
< O
@NUMBER B-upper_bound
kg I-upper_bound
for O
cord B-treatment
blood I-treatment
transplantation I-treatment

extensive O
liver B-cancer
tumor I-cancer
burden I-cancer
, O
defined O
as O
more O
than O
@NUMBER B-lower_bound
% I-lower_bound
of O
the O
liver O

patient O
's O
will O
have O
no O
evidence O
of O
gross B-chronic_disease
vascular I-chronic_disease
invasion I-chronic_disease

any O
disease O
or O
condition O
that O
contraindicates O
the O
use O
of O
the O
study O
medication B-treatment
/ O
treatment B-treatment
or O
places O
the O
patient O
at O
an O
unacceptable O
risk O
of O
experiencing O
treatment O
- O
related O
complications O

aged B-age
from O
@NUMBER B-lower_bound
to O
< O
@NUMBER B-upper_bound
years I-upper_bound
( O
at O
time O
of O
original O
diagnosis O
) O

any O
patient O
with O
a O
hematological B-chronic_disease
or O
oncological O
diagnosis O
in O
which O
allogeneic B-treatment
hematopoietic I-treatment
stem I-treatment
cell I-treatment
transplantation I-treatment
( I-treatment
hsct I-treatment
) I-treatment
is O
thought O
to O
be O
beneficial O

for O
patients O
with O
ra B-chronic_disease
or O
rars B-clinical_variable
or O
isolated B-chronic_disease
@NUMBER I-chronic_disease
q I-chronic_disease
- O
they O
can O
proceed O
to O
transplant B-treatment
without O
any O
treatment B-treatment

for O
patients O
with O
raeb-1 B-cancer
, O
rcmd+ B-cancer
/ I-cancer
-rs I-cancer
, O
or O
mds B-cancer
nos I-cancer
must O
have O
stable O
disease O
for O
@NUMBER B-upper_bound
months I-upper_bound
( O
as O
documented O
by O
serial O
bone O
marrow O
examinations O
) O
in O
the O
absence O
of O
any O
therapy B-treatment
but O
growth O
factors O
or O
transfusion O
support O
. O
patients O
who O
require O
treatment B-treatment
to O
control O
their O
disease O
must O
show O
chemo O
- O
responsiveness O

patients O
with O
life B-clinical_variable
expectancy I-clinical_variable
of O
< O
@NUMBER B-upper_bound
months I-upper_bound
for O
reasons O
other O
than O
their O
underlying O
hematological B-chronic_disease
/ O
oncological B-chronic_disease
disorder I-chronic_disease

baseline B-clinical_variable
pain I-clinical_variable
intensity I-clinical_variable
of O
at O
least O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
on O
average O
and O
pain O
report O
for O
at O
least O
@NUMBER B-lower_bound
% I-lower_bound
of O
days O

pulse B-clinical_variable
oximetry I-clinical_variable
of O
more O
than O
@NUMBER B-lower_bound
percent I-lower_bound
on O
room O
air O
in O
patients O
who O
previously O
received O
radiation B-treatment
therapy I-treatment

first O
relapse O
for O
indolent B-cancer
lymphoma I-cancer
after O
first B-treatment
line I-treatment
therapy I-treatment
for O
relapse O

with O
primary B-chronic_disease
refractory I-chronic_disease
disease I-chronic_disease
or O
persistent O
disease O
after O
first B-treatment
line I-treatment
therapy I-treatment
of O
relapse O

@NUMBER O
contrast O
- O
enhancing O
lesion O
on O
screening O
mri B-treatment
performed O
within O
one B-upper_bound
week I-upper_bound
of O
administration O
of O
mangafodipir B-treatment

previous O
venous O
ultrasound O
has O
been O
performed O
during O
the O
same O
pregnancy B-pregnancy

comorbid B-chronic_disease
illness I-chronic_disease
making O
@NUMBER O
year O
survival O
unlikely O

calcium B-clinical_variable
≥ O
lower O
limit O
of O
normal O
( O
≤ O
@NUMBER B-upper_bound
hours I-upper_bound
prior I-upper_bound
to O
treatment B-treatment
start O
. O
) O

history O
of O
allergic O
reactions O
attributed O
to O
compounds O
of O
similar O
chemical O
or O
biologic O
composition O
to O
panitumumab B-treatment

patients O
with O
history O
or O
known O
presence O
of O
primary B-cancer
cns I-cancer
tumors I-cancer
, O
seizures B-chronic_disease
not O
well O
controlled O
with O
standard O
medical B-treatment
therapy I-treatment
, O
or O
history O
of O
stroke B-chronic_disease
will O
also O
be O
excluded O

patient O
has O
any O
serious O
medical B-chronic_disease
problems I-chronic_disease
which O
may O
preclude O
receiving O
this O
type O
of O
treatment B-treatment

cd4 B-clinical_variable
plus O
cd45ra B-clinical_variable
+ O
lymphocytes B-clinical_variable
: O
absolute O
number O
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
percent I-upper_bound
of O
the O
lln B-clinical_variable
or O
t B-clinical_variable
- I-clinical_variable
cell I-clinical_variable
receptor I-clinical_variable
excision I-clinical_variable
circles I-clinical_variable
( I-clinical_variable
trecs I-clinical_variable
) I-clinical_variable
squared O
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
percent I-upper_bound
of O
normal O
for O
age B-age

skin B-chronic_disease
molluscum I-chronic_disease
contagiosum I-chronic_disease
molluscum B-chronic_disease
contagiosum O
or O
warts B-chronic_disease
( O
this O
criterion O
is O
satisfied O
if O
molluscum O
consists O
of O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
lesions O
or O
there O
are O
two B-lower_bound
or O
more O
lesions O
at O
each O
of O
two O
or O
more O
widely O
separated O
anatomic O
sites O
; O
or O
there O
are O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
warts O
at O
different O
anatomic O
sites O
at O
the O
same O
time O
; O
or O
the O
patient O
has O
both O
molluscum O
and O
warts O
) O

single O
dominant O
hand O
or O
multiple B-treatment
limb I-treatment
amputation I-treatment

respiratory B-chronic_disease
illness I-chronic_disease
of O
a O
bacterial B-chronic_disease
or O
viral B-chronic_disease
etiology I-chronic_disease
within O
@NUMBER B-upper_bound
days I-upper_bound
of O
mri B-treatment

intravitreal B-treatment
injections I-treatment
( O
including O
but O
not O
limited O
to O
anti B-treatment
- I-treatment
vascular I-treatment
endothelial I-treatment
growth I-treatment
factors I-treatment
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
baseline O

presence O
of O
known O
active O
or O
inactive O
toxoplasmosis B-chronic_disease
in O
either O
eye O

sufficient O
inflammation O
to O
require O
systemic B-treatment
treatment I-treatment
and O
, O
based O
on O
the O
investigator O
's O
decision O
, O
warrants O
intravitreal B-treatment
treatment I-treatment

combination O
of O
prednisone B-clinical_variable
≥ O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
day I-lower_bound
( O
or O
equivalent O
dose O
of O
another O
corticosteroid B-treatment
) O
and O
other O
systemic B-treatment
immunosuppressant I-treatment

able O
to O
provide O
informed O
consent O
in O
english B-language_fluency

patients O
who O
have O
received O
gemcitabine B-treatment
, O
oxaliplatin B-treatment
and O
/ O
or O
paclitaxel B-treatment

alt B-clinical_variable

healthy O
except O
for O
their O
tidm B-chronic_disease
and O
treated O
hypothyroidism B-chronic_disease

bilirubin B-clinical_variable
≤ O
@NUMBER B-upper_bound

uncontrolled O
hypertension B-chronic_disease
( O
> O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
mmhg I-lower_bound
despite O
optimal B-treatment
medical I-treatment
therapy I-treatment
) O

on O
histological O
examination O
, O
the O
tumor B-cancer
must O
be O
ductal B-cancer
carcinoma I-cancer
in I-cancer
situ I-cancer
( I-cancer
dcis I-cancer
) I-cancer
or O
invasive O
adenocarcinoma B-cancer
of I-cancer
the I-cancer
breast I-cancer

diagnosis O
of O
acute O
thrombophlebitis B-chronic_disease
( O
in O
last B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
) O

diagnosis O
of O
pulmonary B-chronic_disease
embolism I-chronic_disease
or O
deep B-chronic_disease
vein I-chronic_disease
thrombosis I-chronic_disease
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

women O
of O
child O
- O
bearing O
potential O
must B-pregnancy
not I-pregnancy
be I-pregnancy
pregnant I-pregnancy
or O
become B-pregnancy
pregnant I-pregnancy
during O
the O
@NUMBER B-upper_bound
week I-upper_bound
study O

ecog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
@NUMBER B-lower_bound
, O
@NUMBER O
or O
@NUMBER B-upper_bound

< O
@NUMBER B-upper_bound
pack I-upper_bound
yr I-upper_bound
smoking O
history O

platelets B-clinical_variable
≥ O
@NUMBER B-lower_bound
cells I-lower_bound
/ I-lower_bound
mm^3 I-lower_bound

patients O
must O
be O
free O
of O
distant B-cancer
metastases I-cancer
based O
upon O
the O
following O
minimum O
diagnostic O
workup O

age B-age
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
at O
enrollment O

certain O
exceptions O
are O
permitted O
, O
including O
topical B-treatment
medications I-treatment
, O
vitamins B-treatment
, O
and O
hormonal B-treatment
contraceptives I-treatment

prepubertal O
( O
tanner O
stage O
i O
breasts O
in O
girls B-gender
, O
or O
testicular B-clinical_variable
volumes I-clinical_variable
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
ml I-upper_bound
in O
boys B-gender
) O

recent O
( O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound
) O
use O
of O
drugs O
that O
alter O
glucose O
metabolism O
( O
e.g O
. O
metformin B-treatment
) O

alter O
gastric B-clinical_variable
ph I-clinical_variable
( O
e.g O
. O
proton B-treatment
pump I-treatment
inhibitors I-treatment
) O

age B-age
between O
birth O
and O
@NUMBER B-upper_bound
years I-upper_bound

nyha B-clinical_variable
class B-chronic_disease
iv I-chronic_disease
heart I-chronic_disease
failure I-chronic_disease

age B-age
between O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound

antibiotics B-treatment
in O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

have O
collagen B-chronic_disease
- I-chronic_disease
vascular I-chronic_disease
disease I-chronic_disease

pregnancy B-pregnancy
if O
applicable O

patients O
with O
chronic B-chronic_disease
immunosuppression I-chronic_disease
( O
such O
as O
hiv B-chronic_disease
/ O
aids B-chronic_disease
) O

serum B-clinical_variable
bilirubin I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
mg I-lower_bound
/ I-lower_bound
dl I-lower_bound
, O
transaminases B-clinical_variable
greater O
than O
@NUMBER B-lower_bound
times I-lower_bound
the O
upper B-clinical_variable
limit I-clinical_variable
of I-clinical_variable
normal I-clinical_variable

weight B-clinical_variable
> O
@NUMBER B-lower_bound
kg I-lower_bound

subjects O
are O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

the O
older O
adult O
must O
speak B-language_fluency
english I-language_fluency
and O
be O
able B-technology_access
to I-technology_access
be I-technology_access
contacted I-technology_access
by I-technology_access
telephone I-technology_access
( O
to O
obtain O
pre O
- O
study O
information O
and O
to O
remind O
the O
participant O
about O
the O
study O
appointment O
and O
confirm O
that O
he O
/ O
she O
is O
in O
a O
normal O
state O
of O
health O
on O
the O
day O
of O
the O
study O
) O

illicit O
drug O
use O
during O
pregnancy B-pregnancy

concurrent O
treatment B-treatment
or O
medications B-treatment
( O
must O
be O
off O
for O
at O
least O
@NUMBER B-lower_bound
week I-lower_bound
) O

documented O
negative O
serum O
βhcg O
for O
female B-gender
patients I-gender
who O
are O
post O
- O
menarchal O

patients O
must O
be O
≥ O
@NUMBER B-lower_bound
months I-lower_bound
and O
< O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age
at O
the O
time O
of O
study O
registration O

renal O
: O
serum B-clinical_variable
creatinine I-clinical_variable
based O
on O
age B-age
or O
creatinine B-clinical_variable
clearance I-clinical_variable
or O
radioisotope B-clinical_variable
gfr I-clinical_variable
> O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
/ I-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
m² I-lower_bound

planned O
aicd B-treatment
or O
crt B-treatment

bilirubin B-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
normal I-upper_bound

patients O
with O
tumor B-cancer
in I-cancer
the I-cancer
parametria I-cancer
, O
pelvic B-cancer
lymph I-cancer
nodes I-cancer
or O
any O
other O
extra B-cancer
uterine I-cancer
site I-cancer
or O
with O
positive O
surgical O
margins O

age B-age
> O
@NUMBER B-lower_bound
year I-lower_bound

lactating O
females B-gender
may O
not O
participate O
unless O
they O
have O
agreed O
not O
to O
breastfeed O
a O
child O
while O
on O
this O
study O

patients O
must O
be O
newly O
diagnosed O
with O
histologically O
confirmed O
intracranial B-cancer
ependymoma I-cancer
; O
patients O
with O
classic O
ependymoma B-cancer
( I-cancer
who I-cancer
ii I-cancer
) I-cancer
or O
anaplastic B-cancer
ependymoma I-cancer
( I-cancer
who I-cancer
iii I-cancer
) I-cancer
are O
eligible O
, O
as O
are O
various O
subtypes O
described O
as O
clear O
cell O
, O
papillary O
, O
cellular O
or O
a O
combination O
of O
the O
above O

having O
a O
vestibular B-chronic_disease
or O
seizure B-chronic_disease
disorder I-chronic_disease

known O
pregnancy B-pregnancy

evidence O
of O
infection B-chronic_disease
with O
hiv B-chronic_disease
, O
hepatitis B-chronic_disease
b I-chronic_disease
or O
hepatitis B-chronic_disease
c I-chronic_disease

recipients O
of O
unrelated O
donor O
transplants B-treatment
from O
a O
national O
marrow O
donor O
program O
( O
nmdp O
) O
center O
must O
sign O
a O
release O
of O
information O
form O
to O
authorize O
nmdp O
transfer O
of O
information O
to O
the O
nih O

birth B-clinical_variable
weight I-clinical_variable
less O
than O
@NUMBER B-upper_bound
grams I-upper_bound

intraperitoneal O
ports O
may O
be O
placed O
during O
or O
at O
any O
time O
separate O
from O
surgical B-treatment
debulking I-treatment

patients O
must O
have O
adequate O
renal O
function O
prior O
to O
chemotherapy B-treatment
defined O
as O
serum B-clinical_variable
creatinine I-clinical_variable
creatinine B-clinical_variable
≤ O
@NUMBER O
mg O
/ O
dl O
or O
creatinine B-clinical_variable
clearance I-clinical_variable
≥ O
@NUMBER O
@NUMBER B-lower_bound
ml.min I-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
m² I-lower_bound
for O
patients O
with O
creatinine O
levels O
above O
@NUMBER O
mg O
/ O
dl O

the O
patient O
should O
not O
have O
any O
serious O
medical O
of O
psychiatric B-chronic_disease
illness I-chronic_disease
that O
would O
prevent O
either O
the O
giving O
of O
informed O
consent O
or O
the O
receipt O
of O
treatment O

platelet B-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm³ I-lower_bound

at O
least O
@NUMBER B-lower_bound
prior O
courses O
of O
purine O
analog O

creatinine B-clinical_variable
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
or O
creatinine B-clinical_variable
clearance I-clinical_variable
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
ml I-lower_bound

enlarging B-clinical_variable
lymph I-clinical_variable
nodes I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
cm I-lower_bound

presence O
of O
active O
untreated O
infection B-chronic_disease

symptomatic O
splenomegaly B-chronic_disease

the O
patient O
may O
have O
any O
required O
vaccination B-treatment
/ O
booster B-treatment
administered O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
the O
initiation O
of O
study B-treatment
treatment I-treatment

agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
an I-contraception_consent
acceptable I-contraception_consent
method I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
during O
treatment B-treatment
and O
for O
twelve O
months O
after O
completion O
of O
treatment O

anc B-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
ul I-lower_bound

history O
of O
allergic O
reactions O
attributed O
to O
compounds O
of O
similar O
chemical O
or O
biologic O
composition O
to O
lenalidomide B-allergy_name
( O
including O
thalidomide B-allergy_name
) O
or O
melphalan B-allergy_name

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound

evidence O
of O
distant B-cancer
metastases I-cancer
( I-cancer
m1 I-cancer
) I-cancer

gleason B-clinical_variable
sum I-clinical_variable
< O
or O
= O
@NUMBER B-upper_bound

radical B-treatment
surgery I-treatment
for O
carcinoma B-cancer
of I-cancer
the I-cancer
prostate I-cancer
, O
prior B-treatment
pelvic I-treatment
radiation I-treatment
, O
pelvic B-treatment
surgical I-treatment
clips I-treatment
or O
other O
metallic O
foreign O
bodies O

patients O
who O
have O
received O
any O
prior B-treatment
cytotoxic I-treatment
chemotherapy I-treatment
or O
biologics B-treatment
for O
sex B-cancer
cord I-cancer
- I-cancer
stromal I-cancer
tumors I-cancer
( I-cancer
scsts I-cancer
) I-cancer

patients O
with O
a O
history O
of O
hypersensitivity O
reactions O
to O
prior B-allergy_name
chemotherapy I-allergy_name
administered O
for O
previous O
cancer B-cancer
diagnoses O
are O
eligible O
to O
participate O
in O
the O
study O
, O
unless O
the O
hypersensitivity O
reaction O
consisted O
of O
anaphylaxis B-chronic_disease
not O
amenable O
to O
desensitization B-treatment

recovery O
from O
effects O
of O
recent B-treatment
surgery I-treatment
, O
radiotherapy B-treatment
, O
or O
chemotherapy B-treatment

cisplatin B-cancer
- I-cancer
refractory I-cancer
, O
unresectable O
germ B-cancer
cell I-cancer
tumors I-cancer
( O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
enrollment O
slots O
) O

for O
subjects O
without O
liver B-cancer
metastases I-cancer
: O
alanine B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
and O
aspartate B-clinical_variable
aminotransferase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

the O
subject O
is O
known O
to O
be O
positive O
for O
the O
human B-chronic_disease
immunodeficiency I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
hiv I-chronic_disease
) I-chronic_disease

a1c B-clinical_variable
> O
@NUMBER B-lower_bound

current O
smokers O
( O
defined O
as O
smoked O
within O
the O
last O
year O
) O
or O
a O
former B-clinical_variable
smoker I-clinical_variable
with I-clinical_variable
a I-clinical_variable
history I-clinical_variable
of O
> O
@NUMBER B-lower_bound
pack I-lower_bound
years I-lower_bound

child O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound

positive O
urine O
culture O
resistant O
to O
preoperative B-treatment
oral I-treatment
antibiotic I-treatment
therapy I-treatment

previous O
adverse O
reaction O
to O
anesthesia B-allergy_name

screening O
labs O
obtained O
less O
than B-upper_bound
@NUMBER I-upper_bound
days I-upper_bound
prior I-upper_bound
to O
mdc O
injection O
meeting O

serum B-clinical_variable
creatinine I-clinical_variable
in O
normal O
range O
for O
age B-age

patients O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age
with O
≥ O
@NUMBER B-lower_bound
% I-lower_bound
tbsa O

any O
active O
clinically O
significant O
disease O
( O
e.g. O
, O
pancreatitis B-chronic_disease
, O
cardiac B-chronic_disease
dysfunction I-chronic_disease
) O
or O
findings O
of O
medical O
history O
, O
laboratory O
or O
physical O
examination O
that O
, O
in O
the O
investigator O
's O
opinion O
, O
would O
compromise O
the O
participant O
's O
safety O
during O
treatment B-treatment
with O
etr B-treatment

evidence O
of O
intolerance O
or O
toxicity O
associated O
with O
cyclosporine B-treatment
treatment I-treatment
of O
any O
duration O
including O
irreversible O
azotemia B-chronic_disease
, O
liver B-chronic_disease
dysfunction I-chronic_disease
or O
hypertension B-chronic_disease

albinism B-chronic_disease

ecog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
score I-clinical_variable
of O
@NUMBER B-upper_bound
or O
less O

failed O
standard B-treatment
therapies I-treatment
to O
prevent O
progression O
of O
liver B-chronic_disease
disease I-chronic_disease
( O
actigal O
, O
cyclic O
parenteral O
nutrition O
, O
avoidance O
of O
overfeeding O
, O
reduction O
/ O
removal O
of O
copper O
from O
parenteral O
nutrition O
if O
elevated O
my O
laboratory O
analysis O
, O
advancement O
of O
enteral O
feeds O
) O

history O
of O
hip B-treatment
replacement I-treatment

prostate B-cancer
cancer I-cancer
treated O
primarily O
with O
open B-treatment
, O
laparoscopic B-treatment
or O
robotically B-treatment
assisted I-treatment
prostatectomy I-treatment

clinical O
diagnosis O
of O
whims B-chronic_disease
and O
documented O
severe O
infection B-chronic_disease

active O
angina B-chronic_disease
pectoris I-chronic_disease
or O
ny B-clinical_variable
heart I-clinical_variable
association I-clinical_variable
class B-lower_bound
iii I-lower_bound
- O
iv B-upper_bound

active B-chronic_disease
serious I-chronic_disease
infection I-chronic_disease

ecog B-clinical_variable
performance I-clinical_variable
status I-clinical_variable
> O
@NUMBER B-lower_bound

platelet B-clinical_variable
count I-clinical_variable
< O
@NUMBER B-upper_bound
/ I-upper_bound
mm3 I-upper_bound
or O
history O
of O
platelet B-chronic_disease
count I-chronic_disease
abnormality I-chronic_disease
or I-chronic_disease
dysfunction I-chronic_disease

subjects O
on O
bisphosphonate B-treatment
therapy I-treatment
therapy B-treatment
or O
denosumab B-treatment
must O
be O
on O
a O
stable O
dose O
and O
must O
have O
started O
therapy O
> O
@NUMBER B-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
protocol B-treatment
therapy I-treatment

the O
subject O
has O
a O
systemic B-chronic_disease
or I-chronic_disease
metabolic I-chronic_disease
disorder I-chronic_disease
leading O
to O
progressive B-chronic_disease
bone I-chronic_disease
deterioration I-chronic_disease
that O
the O
surgeon O
feels O
would O
affect O
the O
overall O
outcome O
of O
the O
study O

cml B-cancer
: O
active O
blast B-cancer
crisis I-cancer

uncontrolled B-chronic_disease
infections I-chronic_disease
, O
defined O
as O
positive O
blood O
cultures O

patients O
with O
breast B-cancer
cancer I-cancer
diagnosis O
during O
pregnancy B-pregnancy
( O
women B-gender
who O
could O
bear O
children O
must O
have O
a O
negative B-pregnancy
pregnancy I-pregnancy
test O
before O
beginning O
this O
study O
) O

patients O
with O
renal B-chronic_disease
insufficiency I-chronic_disease
( O
serum B-clinical_variable
cr I-clinical_variable
> O
@NUMBER B-lower_bound
) O
due O
to O
the O
danger O
of O
nephrogenic B-chronic_disease
systemic I-chronic_disease
sclerosis I-chronic_disease
with O
the O
administration O
of O
gadolinium B-treatment

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
old O

bmi B-bmi
between O
@NUMBER B-lower_bound
th I-lower_bound
- O
@NUMBER B-upper_bound
th I-upper_bound
percentiles I-upper_bound
for O
age B-age

absence O
of O
menses O
for O
> O
three B-lower_bound
months I-lower_bound
( I-lower_bound
@NUMBER I-lower_bound
) I-lower_bound
within O
a O
period O
of O
oligomenorrhea B-chronic_disease
( O
cycle B-clinical_variable
length I-clinical_variable
> O
six B-lower_bound
weeks I-lower_bound
) O
for O
> O
six B-lower_bound
months I-lower_bound
, O
or O
absence O
of O
menarche O
at O
> O
@NUMBER B-lower_bound
years I-lower_bound

a O
previous O
diagnosis O
of O
diabetes B-chronic_disease

a O
total B-clinical_variable
testosterone I-clinical_variable
> O
@NUMBER B-lower_bound
ng I-lower_bound
/ I-lower_bound
dl I-lower_bound
in O
women B-gender
with O
pcos B-chronic_disease
( O
which O
suggests O
the O
possibility O
of O
a O
virilizing O
neoplasm B-cancer
) O
( O
confirmed O
on O
repeat O
) O

a O
hemoglobin B-clinical_variable
a1c I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound

a O
personal O
history O
of O
breast B-cancer
, O
ovarian B-cancer
, O
or O
endometrial B-cancer
cancer I-cancer

need O
for O
emergent B-clinical_variable
cabg I-clinical_variable

any O
patient O
or O
tumor B-cancer
/ O
anatomical O
factors O
that O
may O
prevent O
brachytherapy B-treatment
apparatus O
from O
being O
properly O
and O
safely O
inserted O
and O
positioned O
and O
from O
radiation B-treatment
therapy I-treatment
being O
administered O
per O
abs O
guidelines O

stratum O
@NUMBER O
: O
patient O
must O
have O
thalassemia B-chronic_disease
receiving O
an O
unrelated O
donor O
transplant B-treatment
with O
bone O
marrow O
or O
umbilical O
cord O
blood O
stem O
cells O

donor O
: O
females B-gender
with O
a O
positive B-pregnancy
pregnancy I-pregnancy
test O

receiving O
another O
experimental B-treatment
drug I-treatment
within O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
initiation O
of O
conditioning O
( O
day O
@NUMBER O
) O
unless O
approved O
by O
the O
pi O

healthy O
postmenopausal O
women B-gender

patients O
with O
a O
macroprolactinoma B-chronic_disease
confirmed O
on O
mri B-clinical_variable
imaging O

for O
women B-gender
, O
at O
time O
of O
screening O
negative B-pregnancy
hcg I-pregnancy
pregnancy I-pregnancy
test O

no O
illicit O
drug O
use O
or O
excessive O
alcohol O
consumption O
( O
< O
@NUMBER B-upper_bound
drinks I-upper_bound
/ I-upper_bound
week I-upper_bound
) O

no O
illicit O
drug O
use O
or O
excessive O
alcohol O
consumption O
( O
< O
@NUMBER B-upper_bound
drinks I-upper_bound
/ I-upper_bound
week I-upper_bound
) O

contraindication O
to O
haploidentical B-treatment
hct I-treatment
as O
defined O
by O
the O
investigator O

infections B-chronic_disease
requiring O
administration O
of O
ganciclovir B-treatment

left B-clinical_variable
ventricular I-clinical_variable
ejection I-clinical_variable
fraction I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound

history O
of O
allergy O
to O
klh B-allergy_name
, O
qs-21 B-allergy_name
, O
opt-821 B-allergy_name
, O
or O
glucan B-allergy_name

patients O
with O
grade B-upper_bound
@NUMBER I-upper_bound
toxicities I-upper_bound
or O
less O
using O
the O
common O
toxicity O
criteria O
( O
version O
@NUMBER O
) O
developed O
by O
the O
national O
cancer O
institute O
of O
the O
usa O
( O
ctcae O
v3.0 O
) O
related O
to O
cardiac O
, O
neurological O
, O
pulmonary O
, O
renal O
, O
hepatic O
or O
gastrointestinal O
function O
as O
determined O
by O
blood O
tests O
or O
physical O
exam O

chemotherapy B-treatment
is O
not O
administered O
prior O
to O
, O
during O
, O
and O
for O
≥ O
@NUMBER B-lower_bound
days I-lower_bound
after O
completion O
of O
radiotherapy B-treatment
( O
for O
patients O
receiving O
brachytherapy B-treatment
boost I-treatment
) O

has O
undergone O
lumpectomy B-treatment
or O
mastectomy B-treatment
and O
either O
sentinel B-treatment
node I-treatment
biopsy I-treatment
or O
axillary B-treatment
dissection I-treatment
( O
if O
invasive B-cancer
carcinoma I-cancer
is O
present O
) O

no O
other O
malignancy B-cancer
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
years I-upper_bound
except O
for O
nonmelanoma B-cancer
skin I-cancer
cancer I-cancer
( O
the O
disease O
- O
free O
interval O
from O
any O
prior O
malignancy O
must O
be O
continuous O
) O

@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age

active O
participation O
in O
other O
stroke B-chronic_disease
recovery O
trials O
testing O
experimental O
interventions O

more O
than O
@NUMBER B-lower_bound
stroke B-chronic_disease

total B-clinical_variable
bilirubin I-clinical_variable
≤ O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
unless O
hemolysis B-chronic_disease
or O
gilbert B-chronic_disease
's I-chronic_disease
disease I-chronic_disease

uncontrolled O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
or O
angina B-chronic_disease

age B-age
< O
@NUMBER B-upper_bound
with O
prior O
and O
subtotal O
resection O
or O
biopsy B-treatment
( O
i.e. O
, O
anything O
less O
than O
gross O
total O
resection O
) O

newly O
diagnosed O
and O
≤ O
@NUMBER B-upper_bound
months I-upper_bound
from O
surgical O
diagnosis O

at O
least O
@NUMBER B-lower_bound
/ I-lower_bound
@NUMBER I-lower_bound
rd I-lower_bound
of O
the O
liver B-treatment
parenchyma I-treatment
herniated O
into O
the O
thoracic O
cavity O

high O
risk O
for O
fetal B-chronic_disease
hemophilia I-chronic_disease

uterine B-chronic_disease
anomaly I-chronic_disease
( O
e.g. O
, O
large O
fibroid B-cancer
tumor I-cancer
) O

significant O
health O
impairment O
, O
including O
renal B-chronic_disease
disease I-chronic_disease

use O
of O
pacemaker B-treatment

known O
sensitivity O
to O
3,4-diaminopyridine B-allergy_name

ages B-age
@NUMBER B-lower_bound
to O
@NUMBER B-upper_bound
years I-upper_bound
old O

use O
of O
medications B-treatment
( O
other O
than O
oral B-treatment
hypoglycemic I-treatment
agents I-treatment
, O
hormonal B-treatment
contraceptives I-treatment
and O
medications O
taken O
only O
on O
an O
as O
- O
needed O
basis O
) O

patients O
who O
receive O
> O
@NUMBER B-lower_bound
hours I-lower_bound
of O
therapy B-treatment
from O
a O
mental O
health O
specialist O
during O
the O
study O
will O
not O
be O
included O
in O
the O
final O
analysis O

focal B-chronic_disease
neurological I-chronic_disease
deficits I-chronic_disease
that O
may O
, O
or O
may O
not O
, O
be O
transient O
( O
acrm O
, O
@NUMBER O
) O

age B-age
: O
participants O
must O
be O
@NUMBER B-upper_bound
years I-upper_bound
of O
age B-age
or O
younger O

bulky O
mediastinal B-chronic_disease
adenopathy I-chronic_disease

defined O
as O
stage B-cancer
ib I-cancer

more O
than O
@NUMBER B-lower_bound
met O
pet B-treatment
scans I-treatment
within O
the O
previous B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

absolute B-clinical_variable
granulocyte I-clinical_variable
count I-clinical_variable
≥ O
@NUMBER B-lower_bound
/ I-lower_bound
mm³ I-lower_bound

chemotherapy B-treatment
must O
have O
been O
completed O
( O
i.e O
. O
last O
dose O
received O
) O
a O
minimum O
of O
@NUMBER B-lower_bound
days I-lower_bound
and O
a O
maximum O
of O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
registration O

no O
concurrent B-treatment
anticancer I-treatment
treatment I-treatment
including O
chemotherapy B-treatment
, O
biological B-treatment
, O
or O
targeted B-treatment
agents I-treatment

evidence O
of O
distant B-cancer
metastases I-cancer
m1 I-cancer

previous O
chemotherapy B-treatment
or O
pelvic B-treatment
radiation I-treatment
therapy I-treatment

up O
to O
one O
cycle O
of O
prior B-treatment
induction I-treatment
therapy I-treatment
induction B-treatment
therapy I-treatment
will O
be O
permitted O
to O
include O
patients O
in O
whom O
presence O
of O
good O
- O
risk O
cytogenetics O
was O
initially O
missed O
; O
if O
the O
patient O
is O
in O
remission O
from O
induction O
therapy O
, O
he O
/ O
she O
will O
receive O
post B-treatment
- I-treatment
remission I-treatment
therapy I-treatment
; O
if O
the O
patient O
is O
not O
in O
remission O
then O
he O
/ O
she O
will O
receive O
induction O
therapy O

any O
previous O
use O
of O
arvs B-treatment
with O
the O
exception O
of O
single O
dose O
nvp B-treatment
( O
cohort O
@NUMBER O
and O
cohort O
@NUMBER O
) O
or O
up O
to O
@NUMBER B-upper_bound
weeks I-upper_bound
of O
azt B-treatment
( O
cohort O
@NUMBER O
only O
) O
to O
prevent O
mother O
- O
to O
- O
child O
transmission O
( O
mtct O
) O

patients O
who O
meet O
the O
following O
criteria O
; O
a O
) O
cohort O
@NUMBER O
: O
patients O
aged B-age
greater O
than O
or O
equal O
to O
( O
≥ O
) O
@NUMBER B-lower_bound
to O
less O
than O
( O
< O
) O
@NUMBER B-upper_bound
years I-upper_bound
, O
weight B-clinical_variable
is O
≥ O
@NUMBER B-lower_bound
kilogram I-lower_bound
( I-lower_bound
kg I-lower_bound
) I-lower_bound
, O
b O
) O
cohort O
@NUMBER O
; O
aged O
≥ O
@NUMBER B-lower_bound
to O
< O
@NUMBER B-upper_bound
years I-upper_bound
, O
weight O
is O
≥ O
@NUMBER B-lower_bound
kg I-lower_bound

history O
of O
acute B-chronic_disease
myocardial I-chronic_disease
infarction I-chronic_disease
or O
cerebrovascular B-chronic_disease
accident I-chronic_disease
within O
the O
past B-upper_bound
@NUMBER I-upper_bound
months I-upper_bound

no O
history O
of O
severe O
allergy O
including O
eczema B-allergy_name
or O
other O
exfoliative B-chronic_disease
skin I-chronic_disease
disorder I-chronic_disease

psoriasis B-chronic_disease

sever O
acneiform B-chronic_disease
rash I-chronic_disease

traumatic B-chronic_disease
or I-chronic_disease
pruritic I-chronic_disease
skin I-chronic_disease
conditions I-chronic_disease

alcohol O
( O
more O
than O
@NUMBER B-lower_bound
drinks O
per O
day O
) O

holes O
in O
the O
skull O
made O
by O
trauma B-chronic_disease
or O
surgery B-treatment

gleason B-clinical_variable
grade I-clinical_variable
of O
3 B-upper_bound
+ I-upper_bound
4 I-upper_bound
or O
3 B-lower_bound
+ I-lower_bound
3 I-lower_bound

the O
patient O
has O
a O
history O
of O
retinitis B-chronic_disease
pigmentosa I-chronic_disease
or O
severe B-chronic_disease
vision I-chronic_disease
loss I-chronic_disease

the O
patient O
has O
planned O
pre B-treatment
or I-treatment
post I-treatment
operative I-treatment
radiation I-treatment
therapy I-treatment

patients O
must O
have O
adequate O
pulmonary B-clinical_variable
function I-clinical_variable
studies I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound
of O
predicted O
on O
mechanical O
aspects O
( O
fev1 B-clinical_variable
, O
fvc B-clinical_variable
, O
etc O
) O
and O
diffusion B-clinical_variable
capacity I-clinical_variable
( I-clinical_variable
dlco I-clinical_variable
) I-clinical_variable
> O
@NUMBER O
% O
of O
predicted O

prior O
malignancy B-cancer
is O
acceptable O
provided O
there O
has O
been O
no O
evidence O
of O
disease O
within O
the O
three B-upper_bound
- I-upper_bound
year I-upper_bound
interval O

bisphosphonates B-treatment
and O
localized B-treatment
radiation I-treatment

ages B-age
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
years I-lower_bound
and O
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
years I-upper_bound

at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
since O
prior O
palliative B-treatment
radiotherapy I-treatment

patients O
with O
symptoms O
of O
coronary B-chronic_disease
artery I-chronic_disease
disease I-chronic_disease
, O
cardiac B-chronic_disease
arrhythmias I-chronic_disease
or O
an O
abnormal B-treatment
thallium I-treatment
stress I-treatment
test O
must O
be O
evaluated O
and O
cleared O
by O
cardiology O
prior O
to O
enrollment O

lymphoblastic B-cancer
lymphoma I-cancer
, O
burkitt B-cancer
's I-cancer
lymphoma I-cancer
, O
and O
other O
high B-cancer
- I-cancer
grade I-cancer
non I-cancer
- I-cancer
hodgkin I-cancer
lymphoma I-cancer
( I-cancer
nhl I-cancer
) I-cancer
after O
initial B-treatment
therapy I-treatment
if O
stage B-lower_bound
i I-lower_bound
stage B-lower_bound
iii I-lower_bound
ii B-upper_bound
i O
/ O
iv B-upper_bound
in O
first O
partial O
response O
( O
pr1 O
) O
or O
after O
progression O
if O
stage O
i O
/ O
ii O
< O
@NUMBER B-upper_bound
year I-upper_bound

patients O
≤ O
@NUMBER B-upper_bound
years I-upper_bound

patients O
in O
whom O
adequate O
marrow O
/ O
biopsy B-treatment
specimens O
can O
not O
be O
obtained O
to O
determine O
remission O
status O
by O
morphologic O
assessment O
, O
but O
have O
fulfilled O
criteria O
of O
remission O
by O
flow B-treatment
cytometry I-treatment
, O
recovery O
of O
peripheral O
blood O
counts O
with O
no O
circulating O
blasts O
, O
and O
/ O
or O
normal O
cytogenetics O
( O
if O
applicable O
) O
may O
still O
be O
eligible O
; O
reasonable O
attempts O
must O
be O
made O
to O
obtain O
an O
adequate O
specimen O
for O
morphologic O
assessment O
, O
including O
possible O
repeat O
procedures O
; O
these O
patients O
must O
be O
discussed O
with O
the O
principal O
investigator O
ann O
dahlberg O
prior O
to O
enrollment O

patients O
with O
clinical O
or O
laboratory O
evidence O
of O
liver B-chronic_disease
disease I-chronic_disease
will O
be O
evaluated O
for O
the O
cause O
of O
liver O
disease O
, O
its O
clinical O
severity O
in O
terms O
of O
liver O
function O
, O
histology O
, O
and O
the O
degree O
of O
portal B-chronic_disease
hypertension I-chronic_disease

the O
ucb B-chronic_disease
graft I-chronic_disease
is O
matched O
at O
@NUMBER O
human O
leukocyte O
antigen O
( O
hla O
) O
-a O
, O
b O
, O
drb1 O
antigens O
with O
the O
recipient O
; O
this O
may O
include O
@NUMBER O
antigen O
mismatches O
at O
the O
a O
or O
b O
or O
drb1 O
loci O

flow B-treatment
cytometry I-treatment
in O
a O
representative O
bone O
marrow O
sample O
with O
cellularity B-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound
for O
age B-age

patients O
persistently O
aplastic O
for O
greater O
than O
one B-lower_bound
month I-lower_bound
since O
completing O
last O
chemotherapy B-treatment
are O
also O
eligible O
with O
pi O
approval O

human B-chronic_disease
t I-chronic_disease
- I-chronic_disease
cell I-chronic_disease
lymphotropic I-chronic_disease
virus I-chronic_disease
( I-chronic_disease
htlv I-chronic_disease
) I-chronic_disease
-1-associated I-chronic_disease
myelopathy I-chronic_disease
( I-chronic_disease
ham I-chronic_disease
) I-chronic_disease
/ O
tropical B-chronic_disease
spastic I-chronic_disease
paraparesis I-chronic_disease
( I-chronic_disease
tsp I-chronic_disease
) I-chronic_disease

lambert B-chronic_disease
- I-chronic_disease
eaton I-chronic_disease
myasthenic I-chronic_disease
syndrome I-chronic_disease

myasthenia B-chronic_disease
gravis I-chronic_disease

willing O
to O
undergo O
multiple O
apheresis B-treatment
procedures O
( O
except O
donors O
< O
@NUMBER B-upper_bound
years I-upper_bound
who O
will O
undergo O
bone O
marrow O
harvests O
) O

ast B-clinical_variable
( O
sgot B-clinical_variable
) O
or O
alt B-clinical_variable
( O
sgpt B-clinical_variable
) O
≤ O
@NUMBER B-upper_bound
x I-upper_bound
uln I-upper_bound

platelets B-clinical_variable
≥ O
@NUMBER B-lower_bound
k I-lower_bound
/ I-lower_bound
mcl I-lower_bound

women B-gender
of O
childbearing O
age B-age
will O
be O
counseled O
to O
use O
birth O
control O
while O
on O
this O
study O

an O
aspartate B-clinical_variable
transaminase I-clinical_variable
( I-clinical_variable
ast I-clinical_variable
) I-clinical_variable
or O
a O
lanine B-clinical_variable
transaminase I-clinical_variable
( I-clinical_variable
alt I-clinical_variable
) I-clinical_variable
level I-clinical_variable
more O
than O
@NUMBER B-lower_bound
times I-lower_bound
the I-lower_bound
upper I-lower_bound
limit I-lower_bound
of I-lower_bound
normal I-lower_bound

daily O
or O
regular O
use O
of O
drugs O
known O
to O
inhibit O
or O
induce O
enzymes O
that O
metabolize O
alcohol O
in O
the O
4-week B-upper_bound
period I-upper_bound
prior I-upper_bound
to O
assessment O

history O
of O
significant O
withdrawal O
symptoms O
or O
presence O
of O
clinically O
significant O
withdrawal O
symptoms O
( O
clinical B-clinical_variable
institute I-clinical_variable
withdrawal I-clinical_variable
assessment I-clinical_variable
( I-clinical_variable
ciwa I-clinical_variable
) I-clinical_variable
score I-clinical_variable
> O
@NUMBER B-lower_bound
) O
at O
screening O

participants O
must O
be O
able O
and O
willing O
to O
refrain O
from O
consuming O
alcohol O
@NUMBER B-upper_bound
hours I-upper_bound
prior I-upper_bound
to O
each O
alcohol O
self O
- O
administration O
session O

positive O
hepatitis B-chronic_disease
a I-chronic_disease
, I-chronic_disease
b I-chronic_disease
antigen I-chronic_disease
or I-chronic_disease
c I-chronic_disease
or O
hiv B-chronic_disease
test O
at O
screening O

pregnancy B-pregnancy
or O
intention O
to O
become B-pregnancy
pregnant I-pregnancy
for O
women B-gender

patients O
must O
not O
have O
received O
irradiation B-treatment
for O
the O
four B-upper_bound
weeks I-upper_bound
prior I-upper_bound
to O
removal O
of O
the O
tumor B-cancer
and O
no O
previously O
irradiated O
tumor O
deposits O
may O
be O
used O
for O
tumor O
lysate O
in O
the O
development O
of O
the O
dendritic B-treatment
cell I-treatment
vaccine I-treatment

women B-gender
of O
child O
- O
bearing O
potential O
must O
agree B-contraception_consent
to I-contraception_consent
use I-contraception_consent
adequate I-contraception_consent
contraception I-contraception_consent
( O
hormonal B-contraception_consent
or O
barrier B-contraception_consent
method I-contraception_consent
of I-contraception_consent
birth I-contraception_consent
control I-contraception_consent
; O
abstinence B-contraception_consent
) O
prior O
to O
study O
entry O
and O
for O
the O
duration O
of O
study O
participation O

requirements O
for O
vaccine B-treatment
therapy I-treatment
initiation O

allergy O
to O
propofol B-allergy_name
, O
soybean B-allergy_name
oil I-allergy_name
, O
egg B-allergy_name
lecithin I-allergy_name
or O
glycerol B-allergy_name

smoking O
( O
greater O
than O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
cigarettes O
per O
day O
) O

uncontrolled O
hyperlipidemia B-chronic_disease
or O
hypertension B-chronic_disease

mechanical B-treatment
tricuspid I-treatment
valve I-treatment
, O
known O
vascular B-chronic_disease
access I-chronic_disease
problems I-chronic_disease
, O
active O
sepsis B-chronic_disease
, O
etc O

able O
to O
receive O
concurrent O
prophylactic B-treatment
anticoagulation I-treatment
therapy I-treatment
( O
e.g. O
, O
low O
- O
dose O
aspirin B-treatment
[ O
@NUMBER O
mg O
] O
daily O
or O
an O
alternative O
prophylaxis B-treatment
[ O
e.g. O
, O
warfarin B-treatment
or O
low B-treatment
molecular I-treatment
weight I-treatment
heparin I-treatment
] O
) O

measurable B-clinical_variable
disease I-clinical_variable
, O
defined O
as O
≥ O
@NUMBER B-lower_bound
lesion I-lower_bound
≥ O
@NUMBER B-lower_bound
cm I-lower_bound
in O
one O
diameter O
, O
as O
detected O
by O
ct B-treatment
scan I-treatment
or O
pet B-treatment
- I-treatment
ct I-treatment
scan I-treatment
( O
pet B-treatment
/ I-treatment
ct I-treatment
fusion I-treatment
) O

no O
known O
hiv B-chronic_disease
positivity O

women B-gender
with O
known O
pregnancy B-pregnancy

age B-age
requirement O
≥ O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

patients O
must O
have O
measurable O
disease O
, O
which O
includes O
lesions O
that O
can O
be O
accurately O
measured O
in O
at O
least O
one B-lower_bound
dimension O
( O
longest O
diameter O
to O
be O
recorded O
) O
as O
≥ O
@NUMBER B-lower_bound
cm I-lower_bound
with O
conventional B-treatment
techniques I-treatment
or O
≥ O
@NUMBER B-lower_bound
cm I-lower_bound
by O
spiral B-treatment
ct I-treatment
scan I-treatment

registration O
to O
calgb B-treatment
@NUMBER I-treatment
must O
take O
place O
within O
@NUMBER B-lower_bound
- O
@NUMBER B-upper_bound
days I-upper_bound
after O
the O
start O
of O
the O
non O
- O
protocol O
therapy B-treatment

children O
under O
the O
age B-age
of O
two B-upper_bound

patients O
can O
also O
be O
deemed O
not O
eligible O
for O
transplant B-treatment
because O
of O
specific O
organ O
toxicity O

acute B-cancer
myelogenous I-cancer
leukemia I-cancer
( I-cancer
aml I-cancer
) I-cancer
aml B-cancer
) O
or O
history O
of O
aml O

hepatic O
: O
no O
clinical O
evidence O
of O
hepatic B-chronic_disease
failure I-chronic_disease
( O
e.g O
. O
coagulopathy B-chronic_disease
, O
ascites B-chronic_disease
) O

hgb B-clinical_variable
< O
@NUMBER B-upper_bound
g I-upper_bound
/ I-upper_bound
dl I-upper_bound

malignant B-cancer
solid I-cancer
tumor I-cancer
( O
e.g O
. O
squamous B-cancer
cell I-cancer
carcinoma I-cancer
of I-cancer
the I-cancer
head I-cancer
/ I-cancer
neck I-cancer
/ I-cancer
cervix I-cancer
) O
within O
@NUMBER B-upper_bound
years I-upper_bound
of O
hct B-treatment

electrophysiology O
study O
performed O
without O
sedation O
or O
anesthesia B-treatment

evidence O
of O
cushing B-chronic_disease
's I-chronic_disease
syndrome I-chronic_disease
by O
history O
or O
physical O
exam O

subjects O
will O
be O
healthy O
women B-gender

obstructive B-clinical_variable
cad I-clinical_variable
≥ O
@NUMBER B-lower_bound
% I-lower_bound
luminal I-lower_bound
diameter I-lower_bound
stenosis O
in O
≥ O
@NUMBER B-lower_bound
epicardial I-lower_bound
coronary I-lower_bound
artery I-lower_bound

undergoing O
pcti B-treatment
for O
coronary B-chronic_disease
artery I-chronic_disease
disease I-chronic_disease

≥ O
@NUMBER B-lower_bound
years I-lower_bound
old O
or O
less O
than O
@NUMBER B-upper_bound
years I-upper_bound
old O

patients O
in O
cr B-chronic_disease
after O
≤ O
@NUMBER B-upper_bound
courses O
are O
also O
eligible O

complete O
workup O
staging O
should O
be O
performed O
prior O
to O
initiation O
of O
therapy B-treatment
to O
rule O
- O
out O
presence O
of O
metastatic B-cancer
disease I-cancer

patients O
must O
not O
have O
received O
neoadjuvant B-treatment
chemotherapy I-treatment
for O
the O
present O
recurrent O
disease O

hiv B-chronic_disease
or O
hepatitis B-chronic_disease
c I-chronic_disease
positive O
status O

subjects O
on O
insulin B-treatment
, O
metformin B-treatment
or O
sulfonylureas B-treatment
can O
participate O
in O
the O
study O
, O
provided O
that O
minimal O
changes O
are O
made O
to O
the O
doses O
during O
the O
study O

life B-clinical_variable
expectancy I-clinical_variable
: O
greater O
than O
@NUMBER B-lower_bound
weeks I-lower_bound

no O
history O
of O
severe O
prior O
or O
ongoing O
chronic B-chronic_disease
liver I-chronic_disease
disease I-chronic_disease

wbc B-clinical_variable
> O
@NUMBER B-lower_bound
x I-lower_bound
10 I-lower_bound
^ I-lower_bound
9 I-lower_bound
/ I-lower_bound
l I-lower_bound
with O
an O
anc B-clinical_variable
> O
@NUMBER B-lower_bound
x I-lower_bound
10 I-lower_bound
^ I-lower_bound
9 I-lower_bound
/ I-lower_bound
l I-lower_bound
and O
off O
g B-treatment
- I-treatment
csf I-treatment
for O
@NUMBER B-upper_bound
days I-upper_bound

decompensated O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease

medications O
that O
could O
interfere O
with O
autonomic B-clinical_variable
testing I-clinical_variable

with O
a O
single O
serum O
sample O
demonstrating O
low O
estradiol O
( O
estrogen O
) O
in O
association O
with O
low O
or O
inappropriately O
normal O
gonadotropin B-treatment
levels O

ability O
and O
willingness O
to O
come O
to O
clinical O
center O
for O
follow O
- O
up O
appointments O
and O
at O
the O
time O
of O
development O
of O
symptoms O
/ O
signs O
suggestive O
of O
oral O
gvhd B-chronic_disease

women B-gender
and O
minors O
with O
acquired O
hypogonadotropic B-chronic_disease
hypogonadism I-chronic_disease
will O
have O
a O
history O
of O
hypothalamic B-cancer
or O
pituitary B-cancer
tumor I-cancer
treated O
with O
surgery B-treatment
alone O
or O
in O
combination O
with O
radiotherapy B-treatment
or O
a O
history O
of O
hypothalamic B-treatment
irradiation I-treatment
as O
adjunctive B-treatment
therapy I-treatment
for O
leukemia B-cancer
or O
craniofacial B-cancer
neoplasms I-cancer

donor B-clinical_variable
: O
< O
@NUMBER B-upper_bound
months I-upper_bound
old O
and O
> O
@NUMBER B-lower_bound
years I-lower_bound
old O

donor O
: O
related O
donors O
who O
are O
identical O
for O
one O
hla B-clinical_variable
haplotype I-clinical_variable

fanconi B-chronic_disease
anemia I-chronic_disease

if O
unable O
to O
obtain O
ejection B-clinical_variable
fraction I-clinical_variable
, O
shortening B-clinical_variable
fraction I-clinical_variable
< O
@NUMBER B-upper_bound
% I-upper_bound
) O

matched O
sibling O
donor O
( O
hla B-clinical_variable
@NUMBER O
/ O
@NUMBER O
) O
, O
if O
available O
, O
or O
a O
unrelated O
partially O
hla O
matched O
single O
unit O
based O
on O
the O
following O
priority O

by O
molecular B-treatment
techniques I-treatment
( I-treatment
pcr I-treatment
or I-treatment
fish I-treatment
) I-treatment
or O
conventional B-treatment
cytogenetics I-treatment
( I-treatment
g I-treatment
- I-treatment
banding I-treatment
) I-treatment

chromosome B-clinical_variable
@NUMBER B-lower_bound
, O
@NUMBER O
, O
or O
@NUMBER B-upper_bound
abnormalities O

hypodiploid B-cancer
; O
t O
( O
@NUMBER O
; O
@NUMBER O
) O

has O
had O
prior B-treatment
b I-treatment
- I-treatment
raf I-treatment
or O
mek B-treatment
targeted I-treatment
therapy I-treatment
within O
@NUMBER B-upper_bound
days I-upper_bound
prior I-upper_bound
to O
the O
start O
of O
the O
lymphodepletion B-treatment
regimen I-treatment
( O
cohort O
a O
and O
cohort O
b O
) O

patients O
of O
both O
genders O
must O
practice B-contraception_consent
birth I-contraception_consent
control I-contraception_consent
for O
four B-upper_bound
months I-upper_bound
after I-upper_bound
receiving O
the O
preparative O
regimen O
. O
( O
turnstile O
ii O
- O
chemotherapy B-treatment
/ O
cell B-treatment
infusion I-treatment
- O
inclusion O
criteria O
) O

patients O
with O
vp B-treatment
shunts I-treatment
must O
have O
vp O
shunts O
with O
on O
/ O
off O
valves O
and O
must O
be O
expected O
to O
tolerate O
vp B-treatment
shunt I-treatment
valve I-treatment
off O
for O
more O
than O
@NUMBER B-upper_bound
hours I-upper_bound
patients O
who O
have O
received O
cns B-treatment
irradiation I-treatment
, O
including O
whole B-treatment
brain I-treatment
radiation I-treatment
or O
stereotactic B-treatment
radiosurgery I-treatment
, O
are O
eligible O
, O
if O
they O
are O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
post O
cns B-treatment
- I-treatment
irradiation I-treatment
( O
cohort O
d O
) O
patients O
who O
are O
currently O
being O
treated O
with O
it B-clinical_variable
il-2 I-clinical_variable
for O
lmd B-cancer
are O
eligible O
. O
no O
wash O
out O
period O
is O
required O
. O
( O
cohort O
d O
) O

patients O
with O
rapidly O
advancing O
parenchymal O
brain B-cancer
metastases I-cancer
( O
cohort O
d O
) O

serum B-clinical_variable
alt I-clinical_variable
less O
than O
three B-upper_bound
times I-upper_bound
the I-upper_bound
upper I-upper_bound
limit I-upper_bound
of I-upper_bound
normal I-upper_bound
. O
( O
turnstile O
ii O
- O
chemotherapy B-treatment
/ O
cell B-treatment
infusion I-treatment
- O
inclusion O
criteria O
) O

serum B-clinical_variable
creatinine I-clinical_variable
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
. O
( O
turnstile O
ii O
- O
chemotherapy B-treatment
/ O
cell B-treatment
infusion I-treatment
-inclusion O
criteria O
) O

cluster B-clinical_variable
of I-clinical_variable
differentiation I-clinical_variable
@NUMBER I-clinical_variable
( I-clinical_variable
cd20 I-clinical_variable
) I-clinical_variable
positive O

spinal B-treatment
block I-treatment
, O
are O
unsafe O
to O
undergo O
bbbd B-treatment
chemotherapy I-treatment
and O
are O
not O
eligible O

lack O
of O
platelet B-clinical_variable
response O
to O
aspirin B-treatment
or O
clopidogrel B-treatment

patients O
requiring O
isolated O
aortic B-treatment
valve I-treatment
replacement I-treatment
( I-treatment
avr I-treatment
) I-treatment
, O
or O
isolated O
mitral B-treatment
valve I-treatment
replacement I-treatment
( I-treatment
mvr I-treatment
) I-treatment

no O
neurological B-chronic_disease
disorders I-chronic_disease
and O
no O
history O
of O
concussion B-chronic_disease
with O
a O
black O
- O
out O
that O
lasted O
> O
@NUMBER B-lower_bound
minutes I-lower_bound

no O
vaccines B-treatment
for O
at O
least O
@NUMBER B-lower_bound
weeks I-lower_bound
prior I-lower_bound
to O
baseline O
blood O
draw O
( O
including O
the O
flu O
shot O
) O

biallelic B-cancer
brca2 I-cancer
mutations I-cancer

prior O
to O
evidence O
of O
vaccine B-treatment
clearance O

upper B-treatment
urinary I-treatment
tract I-treatment
endoscopic I-treatment
or I-treatment
perc I-treatment
procedure I-treatment
for I-treatment
kidney I-treatment
stones I-treatment
removal I-treatment

cardiac B-clinical_variable
: I-clinical_variable
ejection I-clinical_variable
fraction I-clinical_variable
> O
@NUMBER B-lower_bound
% I-lower_bound

patients O
with O
a O
history O
of O
uncontrolled O
seizures B-chronic_disease

tia B-chronic_disease
or O
stroke B-chronic_disease
in O
the O
last B-upper_bound
@NUMBER I-upper_bound
month I-upper_bound

untreated O
, O
uncontrolled O
sleep B-chronic_disease
apnea I-chronic_disease

active B-chronic_disease
serious I-chronic_disease
infections I-chronic_disease
not O
controlled O
by O
antibiotics B-treatment

any O
abnormality O
that O
would O
be O
scored O
as O
nci O
ctc O
grade O
iv O
toxicity O
that O
is O
unrelated O
to O
hiv B-chronic_disease
, O
its O
treatment O
, O
or O
to O
mcd B-chronic_disease
that O
would O
preclude O
protocol O
treatment O
and O
/ O
or O
observation O
only O

circulating B-clinical_variable
leptin I-clinical_variable
levels I-clinical_variable
< O
@NUMBER B-upper_bound
ng I-upper_bound
/ I-upper_bound
ml I-upper_bound
in O
females B-gender
males B-gender
and O
< O
@NUMBER B-upper_bound
ng I-upper_bound
/ I-upper_bound
ml I-upper_bound
in O
males O
as O
measured O
by O
linco O
assay O
from O
serum O
samples O
after O
an O
overnight O
fast O

in O
our O
experience O
with O
the O
younger O
children O
, O
we O
find O
that O
their O
participation O
in O
serial O
blood O
tests O
and O
mri O
scans O
improves O
greatly O
when O
they O
are O
at O
least O
@NUMBER B-lower_bound
years I-lower_bound
of O
age B-age

we O
would O
not O
want O
to O
treat O
a O
young O
child O
experiencing O
chronic O
hypoglycemia B-chronic_disease

known O
gastroparesis B-chronic_disease

severe O
diabetic B-chronic_disease
neuropathy I-chronic_disease

d816v O
kit O
- O
positive O
systemic O
mastocytosi B-treatment
mastocytosis B-chronic_disease

presence O
of O
greater O
than O
or O
equal O
to O
@NUMBER B-lower_bound
of O
the O
following O
laboratory O
criteria O
suggestive O
of O
a O
myeloid B-chronic_disease
disorder I-chronic_disease

pregnant B-pregnancy
women B-gender
with O
evidence O
of O
toxoplasma B-chronic_disease
infection I-chronic_disease
by O
clinical O
observation O
and O
amniotic O
fluid O
sampling O

female B-gender
patients I-gender
who O
are O
pregnant B-pregnancy
or O
lactating O
are O
not O
eligible O
to O
receive O
treatment O
but O
can O
be O
followed O
for O
natural O
history O

dysfunction O
not O
due O
to O
tumor B-cancer
involvement O
will O
not O
be O
eligible O
to O
receive O
da B-treatment
- I-treatment
epoch I-treatment
- I-treatment
r I-treatment
chemotherapy I-treatment

history O
of O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
will O
not O
be O
eligible O
to O
receive O

no O
active O
symptomatic O
ischemic B-chronic_disease
heart I-chronic_disease
disease I-chronic_disease
, O
myocardial B-chronic_disease
infarction I-chronic_disease
or O
congestive B-chronic_disease
heart I-chronic_disease
failure I-chronic_disease
within O
the O
past O
year O

in O
adults O
: O
serum B-clinical_variable
creatinine I-clinical_variable
less O
than O
or O
equal O
to O
@NUMBER B-upper_bound
mg I-upper_bound
/ I-upper_bound
dl I-upper_bound
or O
creatinine B-clinical_variable
clearance I-clinical_variable
greater O
than O
@NUMBER B-lower_bound
ml I-lower_bound
/ I-lower_bound
min I-lower_bound

